Scientific Programme

Transcription

www.eccmid-icc2011.org
27th
21st
Milan, Italy
7–10 May 2011
ECCMID
ICC
Final Programme
European Congress of
Clinical Microbiology
and Infectious Diseases
International Congress
of Chemotherapy
Visceral leishmaniasis:
an endemic disease with
global impact
An integrated symposium at the 21st European
Congress of Clinical Microbiology and Infectious
Diseases (ECCMID) and 27th International
Congress of Chemotherapy (ICC), Milan, Italy
Monday 9 May 2011, 09.00–11.00
Lecture Hall – White 2
Co-Chairs
O Lortholary (Paris, France)
R N Davidson (London, United Kingdom)
Prevalence, therapeutic need and effect of visceral
leishmaniasis in developing countries
J Alvar (Geneva, Switzerland)
The latest evidence from large scale clinical trials
S Sundar (Varanasi, India)
Visceral leishmaniasis – the European experience
J-P Gangneux (Rennes, France)
Organised and funded by Gilead Sciences Europe Ltd.
Leishmania is not an approved indication
for Liposomal Amphotericin B in Italy
Date of preparation: March 2011
131/IHQ/11-01/NM/1042h
© 2011 Gilead Sciences
Introduction
Final Programme of the
21st ECCMID / 27th ICC in Milan, Italy, 7–10 May 2011
Important Addresses
Table of Contents
Address during the Congress
21st ECCMID / 27th ICC
Milano Convention Centre – MIC
Viale Eginardo, 20149 Milan, Italy
Phone: +39 024 34 23 640, Fax: +39 024 34 23 642
Important Addresses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Welcome Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Congress Venue Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Congress President
Prof Andrea Novelli
University of Florence, Department of Pharmacology
Viale Pieraccini 6, 50139 Florence, Italy
Phone: +39 055 42 71 310, Fax: +39 055 42 71 280
Email: andrea.novelli@unifi.it
Awards, Fellowships, Travel Grants . . . . . . . . . . . . . . . . . . . . . . 15
Scientific Secretariat
c/o ESCMID Executive Office
P.O. Box, 4002 Basel, Switzerland
Phone: +41 61 686 77 99, Fax: +41 61 686 77 98
Email: info@eccmid-icc2011.org
Administrative Secretariat
c/o Congrex Switzerland Ltd.
Phone: +41 61 686 77 11, Fax: +41 61 686 77 88
Email: basel@congrex.com
Accommodation
Congrex Travel Ltd.
Phone: +41 61 690 94 11, Fax: +41 61 690 94 14
Email: eccmid-icc.hotel@congrex.com
Flight Bookings
Congrex Travel Ltd.
Phone: +41 61 560 75 60, Fax: +41 61 690 92 14
Email: eccmid-icc.flights@congrex.com
1
3
5
6
8
Scientific Programme Overview . . . . . . . . . . . . . . . . . . . . . . . . .
Introduction to the Scientific Programme . . . . . . . . . . . . . . . .
Instructions for Authors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ESCMID Study Group and other Business Meetings . . . . . . . .
ISC Working Group and other Business Meetings . . . . . . . . . .
32
37
39
40
42
Saturday, 7 May 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sunday, 8 May 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Monday, 9 May 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tuesday, 10 May 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43
55
67
82
Poster Sessions
Saturday, 7 May 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Sunday, 8 May 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Monday, 9 May 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Tuesday, 10 May 2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
List of Chairpersons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
List of Authors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
Industrial Exhibition Overview . . . . . . . . . . . . . . . . . . . . . . . . . . 230
List of Exhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233
Exhibitors’ Guide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267
Social / Cultural Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271
Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271
Milan City Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276
Future Congresses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278
Local Agency
O.I.C. Srl
Viale G. Matteotti 7, 50121 Florence, Italy
Phone: +39 055 50 351, Fax: +39 055 50 01 912
Email: eccmid-icc@oic.it
Imprint:
21st ECCMID / 27th ICC Final Programme
Publisher:
c/o Congrex Switzerland Ltd.
P.O. Box
4002 Basel, Switzerland
Phone +41 61 686 77 11
Fax +41 61 686 77 88
basel@congrex.com
Design / concept:
Flux Design Studios
www.fluxdesign.ch
Layout / print:
Interrepro AG
www.interrepro.ch
Subject to programme
changes without notice
21st ECCMID / 27th ICC / Milan Final Programme
1
Advanced Solutions in
Microbial Identification
Innovative technologies tailored to best meet your clinical needs.
We invite you to visit us at our booth no. 121
to learn more about our products
www.abbott.com
The Organising Committee expresses its thanks and appreciation
to all who have generously contributed to the success of the
21st European Congress of Clinical Microbiology and Infectious
Diseases and the 27th International Congress of Chemotherapy:
Platinum Medal Sponsor
Pfizer
Gold Medal Sponsor
Astellas Pharma Europe
Silver Medal Sponsors
Abbott
AstraZeneca
BD Diagnostics
bioMérieux
Bruker Daltonik
Cepheid
Gilead Sciences Europe
GlaxoSmithKline Biologicals
Janssen
Luminex Europe
MSD
Novartis Pharma
Siemens Healthcare
Additional Sponsors
Bio-Rad
Gen-Probe
Optimer Pharmaceuticals
Introduction
Acknowledgements
The ECCMID-ICC Programme Committee is proud to
acknowledge the scientific input from the following
organisations in setting up joint workshops and symposia:
API, Asociación Panamamericana de Infectología
Infectious disease with liver involvement – an update (page 83)
ASM, the Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC)
Antimicrobial peptides – update for infectious disease physicians
(page 48)
EAPCRI, European Aspergillus PCR Initiative
Educational Workshop 17: Just when you thought it was safe to
go back in the water: leisure-associated water-borne infections
(page 46)
ECMM, European Confederation of Medical Mycology
Educational Workshop 2: Fungi in the respiratory tract &
antifungal stewardship (page 43)
ESICM, European Society of Intensive Care Medicine
How to decrease resistance in the ICU (page 48)
ERS, European Respiratory Society
GRACE Educational Workshop 2: Fungi in the respiratory tract &
antifungal stewardship (page 43)
IDSA, Infectious Disease Society of America
Clinical Grand Rounds (page 83)
ISF, International Sepsis Forum
ISF Symposium and Presentation of International Sepsis Forum
Award (page 51)
ISHAM, International Society for Human and Animal Mycology
Educational Workshop 17: Just when you thought it was safe to
go back in the water: leisure-associated water-borne infections
(page 46)
3
Who can really help me grow?
Only Siemens has the innovative solutions your lab needs
to reach the top and the vision to keep you there.
Planning for your future starts with choosing the right diagnostics partner today. Siemens provides comprehensive and
customizable solutions so laboratorians and clinicians can improve productivity every day. And, with a 130-year tradition
of innovation, you can trust Siemens to stay on the leading edge of emerging trends and technologies, so together we
can set a new standard in patient care for years to come. www.siemens.com/diagnostics
Answers for life.
A91DX-9105-A1-4A00
© 2010 Siemens Healthcare Diagnostics Inc. All rights reserved.
Introduction
Welcome Address
Dear Colleagues and Friends,
It is a great pleasure and privilege to welcome you to Milan, Italy, on behalf of ESCMID and ISC and to the
21st ECCMID / 27th ICC, the second joint meeting of both organising societies. As the result of what seems like a
Renaissance mathematical cabala, both ESCMID and ISC held their 12th congresses in Italy, ESCMID 9 years ago
in spring 2002 in Milan and the ISC 30 years ago in summer 1981 in Florence. For the second time we experience
a joint ECCMID/ICC congress. In these years ECCMID has steadily grown in importance while ICC has become a
classic worldwide biennial meeting for antimicrobial chemotherapy since 1961.
We are pleased to offer you an excellent scientific programme, running over four days, with stimulating keynote
lectures and symposia on parallel tracks with the involvement of a high number of internationally-renowned
experts. The programme provides an unique opportunity for debate, discussion and the exchange of important
ideas and information in the fields of clinical microbiology, antimicrobial chemotherapy and infectious diseases.
In addition, your contributions were highly welcomed and are presented in oral sessions or poster exhibitions
that undoubtedly increase the knowledge of the latest scientific developments in these fields. Many great
scientists and experts from all over the world are taking part in this important joint meeting, where both clinical
and experimental research are showcased.
The Milano Convention Centre (MIC), located right in the centre of town, has been recently completely renewed and
is an even more attractive venue to meet old friends and to establish new and interesting contacts. The warm
hospitality of this northern Italian city undoubtedly enhances the enjoyment of your stay. Milan is a sprawling
metropolis, but most of its attractions are concentrated in the city centre, between the Duomo (cathedral) and the
Castello Sforzesco. Milan is renowned throughout the world for its fine arts, grand music and, of course, it is one
of the most important fashion capitals. Immediately north of the Duomo, you may find not only the Brera Art
Galleries but also fashionable shopping avenues where you can sample all the different aspects of this important
European city.
We hope that this second joint meeting becomes a reference model for the exchange of scientific information in
the future. We wish you a fruitful meeting and a pleasant stay in Milan!
Andrea Novelli
Teresita Mazzei
21st ECCMID / 27th ICC President ISC President
Giuseppe Cornaglia
ESCMID President
Jordi Vila
ECCMID / ICC Programme Director
5
Congress Venue Overview
6
Lecture Halls
Meeting Rooms
Exhibition
Various Service Areas
7
Introduction
Congress Venue Overview
Committees
Organising Committee
Giuseppe Cornaglia (Verona, IT), ESCMID President
Fiona M. MacKenzie (Aberdeen, UK), ISC Executive Director
Teresita Mazzei (Florence, IT), ISC President
Andrea Novelli (Florence, IT), 21st ECCMID / 27th ICC President
Jordi Vila (Barcelona, ES), ECCMID/ICC Programme Director
Evelina Tacconelli (Rome, IT)
ESCMID Professional Affairs Officer
Infectious Disease
ESCMID Executive Committee
Giuseppe Cornaglia (Verona, IT)
ESCMID President
Jordi Vila (Barcelona, ES)
ECCMID/ICC Programme Director
Murat Akova (Ankara, TR)
ESCMID Education Officer
Gunnar Kahlmeter (Växjö, SE)
ESCMID President-elect and
Secretary General
Jonathan Cohen (Brighton, UK)
22nd ECCMID President
Winfried V. Kern (Freiburg, DE)
ESCMID Treasurer
Didier Raoult (Marseille, FR)
CMI Editor-in-Chief
Elisabeth Nagy (Szeged, HU)
ESCMID Professional Affairs Officer
Robert C. Read (Sheffield, UK)
ESCMID Scientific Affairs Officer
8
ESCMID Ad hoc Executive Committee Members
Andrea Novelli (Florence, IT)
21st ECCMID / 27th ICC President
ISC Executive Committee
Teresita Mazzei (Florence, IT)
ISC President
Fiona M. MacKenzie (Aberdeen, UK)
ISC Executive Director
Alasdair M. Geddes (Solihull, UK)
IJAA Editor-in-Chief
Tetsuro Matsumoto (Kitakyoushu, JP)
ISC Executive Director
Ian M. Gould (Aberdeen, UK)
Secretary General
Enrico Mini (Florence, IT)
Chair Cancer Section
Andy Hoepelman (Utrecht, NL)
Kurt G. Naber (Straubing, DE)
Immediate Past President
Po-Ren Hsueh (Taipei, TW)
Treasurer
21st ECCMID / 27th ICC President
Shigeru Kohno (Nagasaki, JP)
Vice-President
David Paterson (Brisbane, AU)
Andre Lomar (Sao Paulo, BR)
Malik Peiris (Hong Kong, HK)
Chair Virology Section
9
Introduction
Committees
Roche. Delivering on the promise of medical value
by enabling better patient treatment decisions
#UVJGYQTNFNGCFGTKPKPXKVTQFKCIPQUVKEU4QEJGQ‫ڃ‬GTUCDTQCF
portfolio of instruments and assays for the screening, diagnosis, and
prevention of infectious diseases.
For more information,
see us at Booth #125
ROCHE is a trademark of Roche.
© 2011 Roche Molecular Systems, Inc. All rights reserved.
Raul Raz (Afula, IL)
Raphael Saginur (Ottawa, CA)
Francesco Scaglione (Milan, IT)
Wing-Hong Seto (Hong Kong, HK)
Pramod Shah (Frankfurt, DE)
Fred C. Tenover (Sunnyvale, US)
ECCMID-ICC Programme Committee
Jordi Vila (Barcelona, ES), ECCMID/ICC Programme Director
Fausto Baldanti (Pavia, IT)
Peter Chiodini (London, UK)
Silvano Esposito (Naples, IT)
Javier Garau (Barcelona, ES)
Marek Gniadkowski (Warsaw, PL)
Gilbert Greub (Lausanne, CH)
Stephan Harbarth (Geneva, CH)
Gunnar Kahlmeter (Vaxjo, SE)
Winfried V. Kern (Freiburg, DE)
Marc Lecuit (Paris, FR)
Fiona M. MacKenzie (Aberdeen, UK)
Patricia Muñoz (Madrid, ES)
Eskild Petersen (Aarhus, DK)
Mario Poljak (Ljubljana, SI)
Stefania Stefani (Catania, IT)
Fred C. Tenover (Sunnyvale, US)
Johan Van Eldere (Leuven, BE)
Claudio Viscoli (Genoa, IT)
Katsunori Yanagihara (Nagasaki, JP)
ESCMID Education Subcommittee
Murat Akova (Ankara, TR), Chair
Roberto Cauda (Rome, IT)
Jorge Garbino (Geneva, CH)
Souha Kanj (Beirut, LB)
Cornelia Lass-Flörl (Innsbruck, AT)
Patrice Nordmann (Paris, FR)
Tibor Pal (Al Ain, AE)
Mical Paul (Petah Tikva, IL)
Anna Skiada (Athens, GR)
11
Introduction
Committees
ESCMID Scientific Affairs Subcommittee
Robert C. Read (Sheffield, UK), Chair
Maiken C. Arendrup (Copenhagen, DK)
Yehuda Carmeli (Tel Aviv, IL)
Birgitta Evengård (Umeå, SE)
Jan A.J.W. Kluytmans (Breda, NL)
Hakan Leblebicioglu (Samsun, TR)
Jesus Rodriguez-Baño (Seville, ES)
Paul Savelkoul (Amsterdam, NL)
Harald Seifert (Cologne, DE)
ESCMID Professional Affairs Subcommittee
Elisabeth Nagy (Szeged, HU), Chair, CM
Evelina Tacconelli (Rome, IT), Chair, ID
Bridget Atkins (Oxford, UK)
Arta Olga Balode (Riga, LV)
Nick J. Beeching (Liverpool, UK)
Nur Benzonana (Istanbul, TR)
Emmanuelle Cambau (Paris, FR)
Giulia De Angelis (Rome, IT)
John Edward Degener (Smalle, NL)
Matthew E. Falagas (Athens, GR)
Hilary Humphreys (Dublin, IE)
Piotr Kochan (Cracow, PL)
Laetitia M. Kortbeek (Bilthoven, NL)
Truls Michael Leegaard (Lørenskog, NO)
Endre Ludwig (Budapest, HU)
Mario Umberto Mondelli (Pavia, IT)
Nicola Petrosillo (Rome, IT)
Arjana Tambic Andrasevic (Zagreb, HR)
Andrej Trampuz (Lausanne, CH)
Andrew J. Ullmann (Mainz, DE)
Nathalie Van Burgel (Leiden, NL)
Jos Willem Maarten Van Der Meer (Nijmegen, NL)
Alkiviadis C. Vatopoulos (Athens, GR)
ESCMID Publication Subcommittee
Giuseppe Cornaglia (Verona, IT), Chair
Verity Emmans (Oxford, UK)
ESCMID Awards Subcommittee
Giuseppe Cornaglia (Verona, IT), Chair
Parity Commission
Elisabeth Nagy (Szeged, HU), Chair
Evelina Tacconelli (Rome, IT), Chair
Nur Benzonana (Istanbul, TR)
Laetitia M. Kortbeek (Bilthoven, NL)
12
ISC Hamao Umezawa Memorial Award Advisory Board
and Committee
T. Mazzei (Florence, IT)
W. Craig (Madison, US)
A. Geddes (Solihull, UK)
I.M. Gould (Aberdeen, UK)
C. Kunin (Columbus, US)
A. Nomoto (Osaka, JP)
S. Omura (Tokyo, JP)
A. Ronald (Manitoba, CA)
ISC Executive Committee
ISC Tom Bergan Memorial Award Committee
P.R. Hsueh (Taipei, TW)
F.M. MacKenzie (Aberdeen, UK)
A. Novelli (Florence, IT)
ISC John David Williams Memorial Award Committee
T. Matsumoto (Kitakyoushu, JP)
ISC Masaaki Ohkashi Award Committee
Members of the ISC UTI Commission
ISC Young Investigator Travel Awards Committee
A. Novelli (Florence, IT)
ISC / Inter American Society of Chemotherapy (IASC)
Awards Committee
R. Feld (Toronto, CA)
R. Sidwell (Logan, US)
ISC Publication / Communication Committee: IJAA
A. Geddes (Solihull, UK)
Introduction
ESCMID Study Groups
Anaerobic Infections (ESGAI)
www.escmid.org/esgai
nagye@mlab.szote.u-szeged.hu
Helicobacter (EHSG)
www.escmid.org/ehsg
Colm O’Morain (Dublin, IE)
gastroenterology@amnch.ie
Antibiotic Policies (ESGAP)
www.escmid.org/esgap
Dilip Nathwani (Dundee, UK)
dilip.nathwani@nhs.net
Implant-Associated Infections (ESGIAI)
www.escmid.org/esgiai
andrej.trampuz@chuv.ch
Antimicrobial Resistance Surveillance (ESGARS)
www.escmid.org/esgars
giuseppe.cornaglia@univr.it
Infections in Compromised Hosts (ESGICH)
www.escmid.org/esgich
claudio.viscoli@unige.it
Biofilms (ESGB)
www.escmid.org/esgb
Niels Høiby (Copenhagen, DK)
hoiby@hoibyniels.dk
Lyme Borreliosis (ESGBOR)
www.escmid.org/esgbor
Gerold Stanek (Vienna, AT)
gerold.stanek@meduniwien.ac.at
Clinical Parasitology (ESGCP)
www.escmid.org/esgcp
Birgitta Evengård (Umeå, SE)
birgitta.evengard@climi.umu.se
Meningitis (EMESG)
www.escmid.org/emesg
Stephen Leib (Berne, CH)
stephen.leib@ifik.unibe.ch
Clostridium difficile (ESGCD)
www.escmid.org/esgcd
Ed J. Kuijper (Leiden, NL)
e.j.kuijper@lumc.nl
Molecular Diagnostics (ESGMD)
www.escmid.org/esgmd
Paul Savelkoul (Amsterdam, NL)
p.savelkoul@vumc.nl
Coxiella, Anaplasma, Rickettsia and Bartonella (ESCAR)
www.escmid.org/escar
Achilleas Gikas (Heraklion, GR)
gikas@med.uoc.gr
Mycobacterial Infections (ESGMYC)
www.escmid.org/esgmyc
emmanuelle.cambau@lrb.aphp.fr
Epidemiological Markers (ESGEM)
www.escmid.org/esgem
Sara Haeggman (Solna, SE)
sara.haeggman@smi.se
Nosocomial Infections (ESGNI)
www.escmid.org/esgni
Barry D. Cookson (London, UK)
barry.cookson@hpa.org.uk
Food- and Water-borne Infections (EFWISG)
www.escmid.org/efwisg
Kevin Kerr (Harrogate, UK)
kevin.kerr@hdft.nhs.uk
PK/PD of Anti-Infectives (EPASG)
www.escmid.org/epasg
Ursula Theuretzbacher (Vienna, AT)
utheuretzbacher@cefaia.com
Fungal Infection (EFISG)
www.escmid.org/efisg
Manuel Cuenca-Estrella (Madrid, ES)
mcuenca-estrella@isciii.es
Viral Hepatitis (ESGVH)
www.escmid.org/esgvh
Dominique Salmon-Ceron (Paris, FR)
dominique.salmon@cch.aphp.fr
13
Committees
ISC Sections and Working Groups
Cancer Section
www.ischemo.org/02_Section_Cancer
Enrico Mini (Florence, IT)
enrico.mini@unifi.it
Fungal Infections
www.ischemo.org/02_WG_FungalInfections
Jorge Garbino (Geneva, CH)
jgarbino@bluewin.ch
Virology Section
www.ischemo.org/02_Sections_Virology
Malik Peiris (Hong Kong, HK)
malik@hkucc.hku.hk
Human-Animal Interface in Antimicrobial Resistance (HAIR)
www.ischemo.org/02_WG_HAIR
Erika Vlieghe (Antwerp, BE)
evlieghe@itg.be
Antimicrobials of the Future
www.ischemo.org/02_WG_AntimicrobialsFuture
Paul M. Tulkens (Brussels, BE)
tulkens@facm.ucl.ac.be
Infections in Catastrophic Areas
www.ischemo.org/02_WG_ICA
Vladimir Krcmery (Bratislava, SK)
vladimir.krcmery@szu.sk
Antimicrobial Stewardship
www.ischemo.org/02_WG_MRSA_AntimicrobialStewardship
Jim Hutchinson (New Foundland, CA);
Gabriel Levy Hara (Buenos Aires, AG)
jimhutchinson60@gmail.com
Infections in the ICU
www.ischemo.org/02_WG_ICU
Jean Carlet (Paris, FR)
jcarlet@hpsj.fr
Antiseptics
Axel Kramer (Greifswald, DE)
kramer@uni-greifswald.de
MRSA
www.ischemo.org/02_WG_MRSA
Henri A. Verbrugh (Rotterdam, NL)
h.a.verbrugh@erasmusmc.nl
Bone, Skin and Soft Tissue Infections (SSTIs)
www.ischemo.org/02_WG_BonesSkin
silvanoesposito@libero.it
Pharmacokinetics / Pharmacodynamics
www.ischemo.org/02_WG_Pharmacokinetics
francesco.scaglione@unimi.it
Collateral Effects of Anti-infectives
www.ischemo.org/02_WG_CollateralEfectsAnti-Infectives
Mihai Nechifor (Lasi, RO)
mihai.nechifor@farmac-s.umfiasi.ro
Streptococcal Infections
www.ischemo.org/02_WG_Streptococcal
hsporen@ntu.edu.tw
Community Aquired Pneumonia (CAP)
Shigeru Kohno (Nahasaki, JP)
s-kohno@nagasaki-u.ac.jp
Urinary Tract Infections
www.ischemo.org/02_WG_Urinary
kurt@nabers.de
Controlling Antimicrobial Resistance
www.ischemo.org/02_WG_CAR
whseto@ha.org.hk
Device Related Infections and Biofilm
www.ischemo.org/02_WG_BRI
Shigeru Kamiya (Tokyo, JP)
skamiya@ks.kyorin-u.ac.jp
Endocarditis and Bloodstream Infections (BSI)
www.ischemo.org/02_WG_Endocarditis
Evangelos J. Giamarellos-Bourboulis (Athens, GR)
giamarel@ath.forthnet.gr
14
Zoonoses
www.ischemo.org/02_WG_Zoonoses
Georgios Pappas (Ioannina, GR)
gpele@otenet.gr
Awards, Grants and Fellowships 2011
Rino Rappuoli
Born 1952 in Siena, Italy; Global Head Vaccines Research,
Novartis Vaccines & Diagnostics, Siena, Italy.
In the past decade Rino Rappuoli has become one of
the major experts in vaccines and vaccinology unanimously recognised worldwide. Thanks to his contributions and original thinking, he has changed the way vaccines are made and the way they are conceived in the
research arena, and he had a great impact on the public
health perspective. His contributions in the field of vaccinology encompass broad areas. He characterised the
non-toxic mutant of diphtheria toxin (referred to as
CRM197) that is now utilised as a carrier molecule for
many efficacious conjugate vaccines, such as those
against pneumococci, Haemophilus, meningococci, etc.
His original work paved the way to the genetic detoxification of bacterial toxins which led to the development of
a novel vaccine against pertussis and to development of
a family of strong mucosal adjuvants based on Escherichia coli heat-labile enterotoxin. He first conceived
and applied the notion of reverse vaccinology, based on
the systematic mining of microbial genomes. This novel
experimental approach has allowed the development of
a vaccine against group B meningococci which is showing now its efficacy in clinical studies in very young children. This new methodology is now being successfully
applied to the development of vaccines to other bacteria,
such as group A and B streptococci, pneumococci, etc.
Last but not least, his work on the development of novel
adjuvant allowed the registration of the first oil-in-water
adjuvant (MF59) for human use with an influenza vaccine. This work represented the basis for the development of efficacious vaccines against pandemic influenza, both of avian and of swine origin.
Final Programme
Awards
ESCMID Award for Excellence
in Clinical Microbiology
In addition to his active involvement in the private sector, he has always been actively involved in aspects related to development of vaccines for developing countries. For several years Rino Rappuoli served in and
chaired various committees, including the Global Alliance for Vaccines and Immunization (GAVI), dealing with
vaccine development. More recently, he was instrumental in the creation in 2008 of the Novartis Vaccines Institutes for Global Health (NVGH), whose mission is the
development of vaccines against neglected diseases.
Rino Rappuoli is the author/co-author of more than
500 scientific publications, the majority in peer-reviewed
journals. He has edited more than twelve books in various fields of vaccinology.
The excellence of his work has been recognised by a
long series of international awards, such as the Paul Ehrlich and Ludwig Darmstaedter Prize in 1991, the European Federation of the Pharmaceutical Industries Association Award in 1992, the Arima Award for Applied Microbiology in 2002, the Gold Medal Award by the President
of the Italian Republic in 2005, the Miami Nature Biotechnology Winter Symposium Special Achievement
Award in 2007, the Albert B. Sabin Gold Medal Award in
2007, among others. In addition, in 2005 he was elected
as a full member to the National Academy of Sciences of
the USA.
Rino Rappuoli will be presented the ESCMID Excellence Award by Giuseppe Cornaglia, ESCMID President
and Chairman of the Awards Subcommittee, on Sunday,
8 May 2011. During the ceremony he will give his award
lecture: ‘Vaccines, medicine and public health in the XXI
century’.
15
ECCMID-ICC 2011
Experience BD Diagnostics –
from lab efficiency to clinical responsiveness
Monday, 9th May Lecture Hall: Amber 1
09.00 – 11:00
INTEGRATED SYMPOSIUM
The efficient laboratory –
an ideal partner in clinical practice
Chair: Prof. G.M. Rossolini, Siena, Italy
Prof. J. van Eldere, Leuven, Belgium
/// Streamlining the microbiology lab for improved
diagnostic utility
Prof. A. Simon, UCL ST Luc Brussels, Belgium
/// Saving time in sepsis diagnostics – MALDI-TOF MS
for identification of bacteria and yeasts from
positive blood cultures
Prof. S. Schubert, Ludwig-Maximilians-Universität (LMU) Munich, Germany
/// Monitoring of bone and joint samples with last
generation automated blood culture systems:
faster and better
Dr. M. Rottman and Dr. A. Dinh, Hôpital Raymond-Poincaré, Paris, France
/// New emerging resistances: challenges and
implications for efficient diagnosis and effective
treatment in critical patients
Prof. G.M. Rossolini, Azienda Ospedaliera Universitaria Senese, Siena, Italy;
Dr. G. Tulli, Nuevo Ospedale San Giovanni di Dio, Florence, Italy
Please join us for
coffee and pastries
coffee
outside the lecture
lecture hall
as of 08:30.
Experience innovative technologies, premium education and passionate people.
Visit BD Diagnostics.
Awards
ESCMID Young Investigator Awards for Research in Clinical
Microbiology and Infectious Diseases
Surbhi Malhotra-Kumar
Born 1972 in Sirsa, India; PhD, Senior Research Fellow at
the Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium, in recognition of her outstanding achievements in
bridging the gap between basic and ecologic research
and in trying to link antibiotic use to the emergence and
persistence of antibiotic resistance.
Surbhi Malhotra-Kumar will be presented her award
during the ESCMID Young Investigator Awards Session
on Tuesday, 10 May 2011. During the session, she will
give a talk on ‘Changing perspectives on antibiotic therapy: from proving the obvious to exploring innovative
strategies’.
Research Interests
Surbhi Malhotra-Kumar completed her Masters in Medical Microbiology in 1998, Masters in Molecular Biology
in 2003; and a PhD in Medical Microbiology in 2005 under the supervision of Herman Goossens. The research
of Surbhi Malhotra-Kumar has focused on the molecular
epidemiology and genetics of resistance to common
groups of antimicrobials in oral streptococci. Applying
molecular biological techniques on oro-pharyngeal
streptococcal flora in healthy individuals as a model,
she demonstrated that antibiotic use is the single most
important driver of antibiotic-resistance in vivo, that
antibiotics belonging to the same class can differ widely in resistance gene selection, and that differences in
predominance of certain resistance genes in geographically distinct areas might be linked to the preferential
use of specific antibiotic subclasses. Her current research interests include studying the impact of antibiotic use on the naso-oro-pharyngeal and intestinal
microbiome, mechanisms of biofilm formation, animal
models of infection, and developing rapid diagnostic assays for pathogens causing community-acquired and
nosocomial infections.
Annelies Zinkernagel
Born 1972 in Basel, Switzerland, Attending Senior Physician, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland, in recognition of her impact on our understanding of critical
aspects of the interaction between streptococci and
staphylococci and the host innate immune system.
Annelies Zinkernagel will be presented her award
during the ESCMID Young Investigator Awards Session
on Tuesday, 10 May 2011. During the session, she will
give a talk titled ‘Know your enemy – Group A streptococcal virulence factors’.
Research Interests
Annelies Zinkernagel completed her training in Internal
Medicine (2002) and Infectious Diseases in 2005 at
the University Hospital of Zurich, Switzerland, followed
by a PhD in 2009 and postdoctoral fellowship in the
laboratory of Victor Nizet in San Diego, California, USA.
There she studied group A streptococcal virulence factors and how these allow the bacteria to evade the
host’s innate immune system. Currently she combines
her clinical and laboratory expertise and works as an attending infectious disease specialist at the University
Hospital of Zurich, Switzerland, where she also leads an
independent research group. Her translational research
focuses on understanding bacterial virulence factors
and corresponding innate immune response pathways.
Improved knowledge on host pathogen interaction may
allow to develop novel treatment options that can either
neutralize the bacterial virulence factors or boost the
host defense and improve outcome in patients suffering from infectious diseases.
The Young Investigator Awards
are sponsored by Pfizer.
21st
ECCMID
/ 27th ICC /2Milan Final Programme
Final
Programme
17
GLAXOSMITHKLINE INTEGRATED SYMPOSIUM
21 ST EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES (ECCMID) &
27 TH INTERNATIONAL CONGRESS OF CHEMOTHERAPY (ICC)
Milan, Italy
Bacterial invasive and non-invasive diseases:
aetiology, epidemiology,
treatment implications, prevention
and surveillance
S a turda y 7 t h Ma y 2 0 1 1
16. 30 - 1 8 . 3 0
Chair
Prof. Andrea Novelli
University of Florence, Italy
M ila n C o ng re s s Centre,
Le c ture H a ll A m ber 4
Co-chair
16.30
18.30
Welcome and introduction
(Italy)
Are dual infections myth or reality? The example of otitis media
Prof. Ron Dagan
(Israel)
Evolving resistance in respiratory pathogens and its implications
Prof.
Johan Van Eldere
(Belgium)
Potential benefit of integrating vaccination in clinical guidelines to
optimize antibiotic use
Prof. Paola Marchisio
(Italy)
The need for improved surveillance of invasive bacterial disease
Dr Mary Slack
(United Kingdom)
Question and answer session
All faculty
Symposium close
Graphic Design: visible.be (7303) BIO/SYN/0013/11 Production March 2011, Wavre, Belgium
Prof. Johan Van Eldere
UZ Leuven, Laboratory Medicine,
Leuven, Belgium
Awards
ESCMID Excellence Training
Awardees 2011
Hilmir Asgeirsson, Huddinge, Sweden
The recipient studied medicine at the Faculty of Medicine of the University of Iceland from September 1999 to June 2005. After his intern year
he worked three months as a volunteer in Ethiopia. From January 2007
to January 2010 he did his residency in internal medicine at Landspitali
University Hospital, Reykjavik, Iceland. During this time he was involved
in epidemiological research on S. aureus bacteraemia resulting in published articles and poster presentations at international conferences.
He has also published papers in other sub-specialities of internal medicine and has been involved in teaching clinical skills to medical students.
Since February 2010 he has continued his training in infectious diseases at the Department of Infectious Diseases of the Karolinska University Hospital in Sweden. Most recently, he participated in the SwedishEthiopian Course in Tropical Infectious Diseases 2010-2011 and has
become a member of a competence group on tropical infections at the
Karolinska University Hospital. He is expected to finish his training in
December 2012.
Final Programme
Axel Hamprecht, Cologne, Germany
During his medical studies he developed a keen interest in infectious
diseases and tropical medicine and did internships in Botswana and at
the WHO in Geneva. He pursued medical training in France, Switzerland
and the UK and later completed his MD thesis at the Institute for Medical Microbiology of the Charité, Berlin. After his clinical term, Axel became a trainee in microbiology at the Institute for Medical Microbiology,
Immunology and Hygiene of the University Hospital Cologne.
Having a strong interest in mycology, he received further training in
this field at the Pasteur Institute in Paris. He established an intense cooperation with colleagues in the department of infectious diseases at
Cologne and mycologists in different European countries, resulting in
different mycological projects. He also works in the Clinic of Travel Medicine and in a joint project with a hospital in Ivory Coast. He is very involved in the teaching of medical students and gives lectures and
courses in microbiology and mycology. Currently, he is in the final year
of his training in microbiology.
19
Valentina Mazzocato, Rome, Italy
She started her studies at the ‘La Sapienza’ University and from the beginning has carried out extracurricular activities focused on social medicine: She collaborated with SISM (Italian Secretariat Medicine Students) and joined the Caritas (Catholic Charity) voluntary programme
for medicine students working at Caritas Immigrant Ambulatory. For her
thesis work, she carried out research on the Immigrant Ambulatory at
the ‘Umberto I Hospital’. In 2004 Valentina Mazzocato was enrolled in
the SISM Research Exchange Programme in Hospital Sao Rafael, Brazil
as a trainee student to improve her medicine competence in a tropical
environment. In 2010 she participated in an Observership in Ankara at
the Department of Infectious Diseases, Hacettepe University and Numune State Education and Research Hospital.
Currently she is employed as a resident doctor at ‘Gemelli Hospital’ in
Rome, in the infectious diseases and ambulatory units, where she also
participates in projects and networking activities between her department disciplines and related specialties as well as in student groups
and social campaigns for STD prevention. Her interests are on studies
about ARV adherence, vaccinations, tuberculosis and clinical ultrasound.
20
Djin-Ye Oh, Berlin, Germany
She is currently training in pediatrics at Tufts Medical Center in Boston,
USA. This training is in addition to her Microbiology training at Charité
University Medical Center in Berlin, Germany. Her multifaceted teaching
approach integrates basic science, laboratory medicine and clinical
medicine. Her research experience includes studies on the molecular
epidemiology of RNA viruses (Robert Koch-Institute, Germany), analyses on the impact of innate immune system genetic variation on RNA
viral diseases (Charité University Medical Center) and the use of adjuvant for potential neonatal vaccines (Children’s Hospital Boston / Harvard Medical School). She has initiated and coordinated several collaborations between basic science labs and clinical research groups.
Her clinical training and research efforts have strengthened her conviction that academic research and clinical medicine should exist as mutually supportive entities in the common service of promoting the human
welfare. Therefore, she envisions an academic career that consistently
integrates her scientific knowledge and laboratory skills with clinical
experience.
Final Programme
4
Awards
ISF Sepsis Award
Fuad Iraqi
Born on March 1st, 1961 in Tira City, Israel; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, in recognition of his excellent abstract submitted for
presentation at the 21st ECCMID / 27th ICC 2011.
He will give a short oral presentation titled ‘The collaborative cross
mouse genetic reference population as novel tool for dissecting host
susceptibility to infectious diseases’ at the Sepsis Forum on Saturday,
7 May 2011.
Research Interests
Fuad Iraqi is a molecular geneticist who has worked for the last four
years at the Tel-Aviv University. His research is focused on understanding diseases' etiology and host susceptibility to infectious and chronic
diseases including; Klebsiella pneumonia, Aspergillus fumigatus periodontitis, type-2 diabetes and modifiers for colon cancer. In addition he
is working on a project for identifying the host genetic factors influencing immune response cell lineages in peripheral blood in the naive population, aiming to using this information in a predictive genetics approach. Following his graduation from the Hebrew University in
Jerusalem in 1989, he worked for two years at the Hospital for Sick Children in Toronto, Canada, two more years at Michigan State University,
USA, before working for thirteen years with ILRI in Nairobi, Kenya on
mapping genes associated with host susceptibility to trypanosomiasis,
gastrointestinal nematodes and malaria in target species and a mouse
model.
Final Programme
21
ESCMID Research Grants 2011
The following ESCMID members have
received a Research Grant in 2011 for
the indicated project.
Alain Bizzini
Institute of Microbiology,
University Hospital
Center Lausanne,
Lausanne, Switzerland
Project: Study of the
emergence and evolution
of antibiotic heteroresistance
by microcalorimetry in
an experimental model of
foreign-body infection
Matthijs Christian Brouwer
Department of Neurology,
Center of Infection
and Immunity Amsterdam,
Academic Medical
Centre, University of
Amsterdam, The Netherlands
Project: The plasminogen
system in bacterial
meningitis
Helen Louisa Leavis
Medical Microbiology,
UMC Utrecht,
Utrecht, The Netherlands
Project: Pathogenesis
of Enterococcus faecium
biofilm formation
Dafne Bongiorno
Department of Microbiology,
University of Catania,
Catania, Italy
Alessandra Bragonzi
San Raffaele
Scientific Institute,
Milano, Italy
Project: Non-mutational
resistance to linezolid:
characterisation of the
plasmid-mediated
methyltransferase cfr gene
Project: Tracking down
virulence of Pseudomonas aeruginosa during
chronic infection
Paola Brun
Department of Histology,
Microbiology and Medical
Biotechnologies, University
of Padua, Padua, Italy
Sergio Filipe
Academic and Projects Office,
Instituto de Tecnologia
Quimica e Biologica,
Oeiras, Portugal
Project: Molecular
mechanisms of neurotropic
virus-mediated neuropathies
in the gut
Project: Identification
of bacterial cell wall
components that interfere
with peptidoglycan
recognition by the host
Paolo Miotto
Emerging Bacterial Pathogens
Unit, Division of Immunology,
Transplantation and
Infectious Diseases,
Fondazione Centro
San Raffaele del Monte Tabor,
Milan, Italy
Mariana Pinho
Academic and Projects Office,
Instituto de Tecnologia
Quimica e Biologica,
Oeiras, Portugal
Project: The role of small
RNAs in the stress
response of Mycobacterium
tuberculosis
22
Project: Study of the realtime response of individual
Staphylococcus aureus
cells to the presence of cell
wall active antibiotics
Final Programme
6
Awards
ESCMID Research Grants 2011(cont.)
Andreas Reisner
Biomedical Science,
University of Applied Sciences,
Graz, Austria
Thamarai Schneiders
Centre for Infection
and Immunity,
Queen’s University Belfast,
Belfast, United Kingdom
Project: Prevalence and spread
of bacterial silver resistance
Project: The frontline
defense: sRNA-mediated
mechanisms in antibiotic
resistance
Pierre Smeesters
Bacterial Genetics and
Physiology Laboratory,
Free University of Brussels,
Gosselies, Belgium
Eveline Snelders
Radboud University Nijmegen
Medical Center,
Nijmegen, The Netherlands
Project: Host-pathogen
interactions in a highly
necrotising group A
Streptococcus isolate
Project: The tandem
repeat as a resistance
mechanism in human and
plant pathogenic fungi
Andrew James Stewardson
Infection Control Program,
University of Geneva Hospitals,
Geneva, Switzerland
Ronald van Rij
Radboud University Nijmegen
Medical Centre,
Project: The household microbiome: a prospective observational study investigating
household clustering of oral and
intestinal microbiota and the
impact of oral antibiotic exposure
Project: A high-throughput
screen to identify
small molecule inhibitors
of Dengue virus
Final Programme
Roy Sleator
Biological Sciences, Cork
Institute of Technology,
Cork, Ireland
Project: Development of
a novel immunoprophylaxis
strategy for controlling
Campylobacter jejuni
Rita Sobral
Laboratory of Molecular
Genetics, Instituto
de Tecnologia Quimica
e Biologica,
Oeiras, Portugal
Project: The association
of extracellular DNA to
the Staphylococcus
aureus surface: roles and
mechanisms
Nicolas Veziris
Laboratoire de bactériologie,
UPMC, Paris, France
Project: In vivo evaluation
of the benefit of adding
moxifloxacin to drug
regimens used against
extensively drug-resistant
tuberculosis
23
ESCMID Training Fellowships 2011
Vincent Cattoir
Department of Microbiology,
Hôpital Côte de Nacre, Caen, France
Maria Chiara Di Luca
Laboratory of Microbiology,
School of Biosciences and Biotechnology,
University of Camerino, Camerino, Italy
Corine Geurts van Kessel
Department of Medical Microbiology and
Infectious Diseases, Erasmus MC Rotterdam,
Rotterdam, The Netherlands
Project: Clinical and molecular microbiology
of group A Streptococcus
Project: A clinical fellowship in tropical
infectious diseases in Bangladesh
Host: James M. Musser, The Methodist Hospital
Research Institute, Department of Pathology
and Laboratory Medicine, Houston, USA
Host: Hubert Ph. Endtz, Department of Tropical
Bacteriology and Director Laboratory Sciences
Division, ICDDR'B, Dhaka, Bangladesh
Ioana Sabina Macovei
Laboratory of Anaerobic Bacteria,
Cantacuzino Institute, Bucharest, Romania
Joseph Meletiadis
Laboratory of Clinical Microbiology,
Attikon University Hospital, Athens, Greece
Ioana Raluca Mihailescu
National Institute of Infectious Diseases
‘Prof. Dr. Matei Bals’, Bucharest, Romania
Project: Clostridium difficile and CDAD –
laboratory typing methods and molecular
epidemiology
Project: Experimental model for studying
combination therapy against azole-resistant
Aspergillus fumigatus isolates
Project: Antimicrobial activity against
vancomycin-resistant enterococci (VRE)
biofilms in experimental implant-associated
infections
Host: Emilio Bouza, Department of Clinical
Microbiology and Infectious Diseases,
Hospital General Universitario
Gregorio Marañón, University of Madrid, Spain
Host: Paul E. Verweij, Department of Medical
Microbiology, Radboud University Nijmegen
Medical Center, Nijmegen Institute for Infection,
Inflammation and Immunity,
Project: Systems approach towards understanding post-transcriptional regulation
of expression of Pseudomonas aeruginosa
genes important for pathogenesis
Host: Stephen Lory, Harvard Medical School,
Department of Microbiology and Molecular
Genetics, Boston, USA
Host: Andrej Trampuz, Department of Infectious
Diseases, University Hospital Lausanne,
Department of Infectious Diseases – Septic
Surgical Unit, Lausanne, Switzerland
Neven Papic
Department of Viral Hepatitis,
University Hospital for Infectious Diseases,
Zagreb, Croatia
Project: Discovery of host antiviral genes
regulating hepatitis C replication
Host: Curt Hagedorn, Division of Gastroenterology, Hepatology and Nutrition,
University of Utah School of Medicine and
Huntsman Cancer Institute, Salt Lake City, USA
24
Final Programme
8
IISC
SC H
Honorary
onorary M
Membership
embership
TThis
his is
is the
the hhighest
ighest aaward
ward ggiven
iven by
by the
the ISC
ISC ffor
or outstanding
outstanding
ccontributions
ontributions iinn the
the field
field ooff cchemotherapy.
hemotherapy.
ISC
Honorary
who
ho hhave
ave bbrought
rought
ISC H
onorary Membership
Membership iiss cconferred
onferred uupon
pon ppersons
ersons w
outstanding
in 2011,
2011,
outstanding contributions
contributions to
to chemotherapy.
chemotherapy. The
The awardees
awardees in
in
in conjunction
conjunction with
with the
the 27th
27th ICC,
ICC, are:
are:
PProfessor
rofessor SStuart
tuar t B.
B. Levy
Lev y
oStuart B.
B. Levy
Levy w
ho iiss Professor
Professor ooff M
The
who
MoThe 2011
2011 awardee
awardee is
is Professor
Professor Stuart
the
and of
of M
edicine aand
nd D
irector ooff the
lecular
Microbiology
Medicine
Director
lecular Biology
Biology aand
nd M
icrobiology and
and D
rug Resistance
Resistance at
at Tufts
Tufts University
Centre
Drug
Centre for
for Adaptation
Adaptation Genetics
Genetics and
University
School
School of
of Medicine.
Medicine.
reFor
For about
about 40
40 years,
years, Professor
Professor Levy
Levy has
has combined
combined bbasic
asic science
science research
at uunderndersearch with
with public
public health
health initiatives
initiatives and
and education
education aimed
aimed at
standing
resiststanding appropriate
appropriate use
use of
of antibiotics
antibiotics and
and curbing
curbing antibiotic
antibiotic resistance.
drug
ance. A number
number of
of seminal
seminal fifindings
ndings include
include his
his discovery
discovery of
of active
active drug
efflux
mechanism
he ddisisefflux aass a m
echanism for
for aantibiotic
ntibiotic (tetracycline)
(tetracycline) rresistance;
esistance; tthe
covery
multiple
ecovery ooff the
the cchromosomal
hromosomal rregulatory
egulatory llocus
ocus ffor
or m
ultiple aantibiotic
ntibiotic rresistance
of the
the
sistance (mar
(mar locus)
locus) and
and virulence;
virulence; the
the first
first demonstration
demonstration of
transfer
and
transfer of
of resistance
resistance genes
genes and
and resistant
resistant bacteria
bacteria among
among animals
animals and
people;
people; and
and discovery
discovery of
of the
the major
major target
target for
for triclosan
triclosan (a
(a commonlycommonlyused
His
isease
used bbiocide).
iocide). H
is sstudies
tudies hhave
ave iinfluenced
nfluenced efforts
effor ts iinn iinfectious
nfectious ddisease
research
and proproresearch and
and public
public health
health policy
policy worldwide
worldwide to
to increase
increase public
public and
fessional
use of
of
fessional awareness
awareness of
of antibiotic
antibiotic resistance
resistance and
and of
of the
the proper
proper use
antibiotics.
antibiotics.
His
widely-cited
H
is w
idely-cited 1992/2002
1992/2002 bbook
ook The
The Antibiotic
Antibiotic Paradox:
Paradox: How
How MiraMiracle
Drugs
Miracle
many
cle D
rugs aare
re Destroying
Destroying the
the M
any llananiracle hhas
as bbeen
een ttranslated
ranslated into
into m
guages.
guages.
1981,
Use
IInn 1
981, PProfessor
rofessor Levy
Levy cco-founded
o-founded tthe
he AAlliance
lliance ffor
or PPrudent
rudent U
se ooff
Antibiotics
Antibiotics ((APUA)
APUA) uusing
sing nnetworks,
etworks, ccountry-wide
ountry-wide chapters
chapters ((currently
currently
65),
65), aand
nd iindividuals
ndividuals ttoo ffoster
oster prudent
prudent aantibiotic
ntibiotic uuse
se aand
nd sstrategies
trategies ttoo
curtail
cur tail antibiotic
antibiotic rresistance.
esistance.
The
The Award
Award is
is provided
provided by
by the
the Microbial
Microbial Chemistry
Chemistry
Research
Research Foundation
Foundation of
of Japan
Japan in
in honour
honour of
of the
the late
late
PProfessor
rofessor Umezawa.
Umezawa.
The ISC
ISC Hamao
Hamao Umezawa
The
Umezawa Memorial
Memorial Award
Award Lecture
Lecture
will be
be presented
presented on
will
on SSunday,
unday, 8 May
May 2011
2011
at 14.30
14.30 in
in Lecture
Lecture Hall
at
Hall White
White 3 and
and is
is titled:
titled:
Antibiotic rresistance:
esistance: back
back to
to the
the bigger
bigger circle
circle
Antibiotic
M
Final Programmee
PProfessor
rofessor Fernando
Fernando Baquero
Baquero
Fernando
Fernando Baquero
Baquero is
is Research
Research Professor
Professor
in
Biomedical
in Bacterial
Bacterial Evolution
Evolution at
at the
the B
iomedical
Research
Research Foundation
Foundation aand
nd Department
Depar tment ooff
Microbiology
Ramon
Microbiology of
of tthe
he R
amon y CCajal
ajal UniverUniversity
sity Hospital,
Hospital, Madrid.
Madrid.
Hee has
made
major
H
has m
ade m
ajor ccontributions
ontributions ttoo
antimicrobial
antimicrobial chemotherapy
chemotherapy oover
ver many
many
yyears
ears rresulting
esulting ((at
at the
the last
last count)
count) in
in 360
360
scientific papers
papers cited
cited iinn PPubMed.
scientific
ubMed.
His
H
is rresearch
esearch iinterests
nterests are
are wide-rangwide-rangiing
ng aand
nd iinclude
nclude tthe
he bbiochemistry,
iochemistry, genetgenetiics,
cs, population
population biology,
biology, eecology
cology and
and evoevollution
ution ooff aantimicrobial
ntimicrobial rresistance
esistance aand
nd
bacterial
bacterial virulence.
virulence.
Professor JJavier
Professor
avier G
Garau
arau
Javier
Javier Garau
Garau iiss Associate
Associate PProfessor
rofessor of
of
Medicine
Medicine in
in the
the University
University of
of Barcelona,
Barcelona,
Spain
Head
Spain and
and H
ead of
of the
the Department
Department of
of
Medicine
Mutua
Hospital.
Medicine tthe
he M
utua de
de Terrassa
Terrassa H
ospital.
Hee has
H
has made
made iimportant
mportant ccontributions
ontributions
to
to antimicrobial
antimicrobial therapy,
therapy, especially
especially in
in the
the
area
area of
of rrespiratory
espiratory ttract
ract iinfections
nfections in
in
which
w
hich he
he iiss a world
world authority.
authority.
Professor
Professor Garau
Garau played
played a major
major part
part in
in
tthe
he success
success ooff tthe
he European
European Society
Society ooff
Microbiology
CClinical
linical M
icrobiology and
and Infectious
Infectious DisDiseeases,
ases, pparticularly
articularly iinn hhis
is rrole
ole as
as EEducaducattion
ion Officer
Officer and
and President.
President.
Professor H
Professor
Helen
elen G
Giamarellou
iamarellou
Helen
Helen Giamarellou
Giamarellou is
is a distinguished
distinguished
Greek
who
Greek infectious
infectious ddiseases
iseases pphysician
hysician w
ho
has
has made
made important
impor tant contributions
contributions ttoo anantimicrobial
timicrobial cchemotherapy
hemotherapy both
both iinn rreesearch
search aand
nd iinn tthe
he ttraining
raining ooff yyoung
oung pphyhysicians
sicians and
and microbiologists.
microbiologists.
She
She has
has served
ser ved on
on the
the Boards
Boards of
of nanational
tional and
and international
international societies
societies and
and
also
Boards
also tthe
he Editorial
Editorial B
oards sseveral
everal prestigprestigious
ious journals.
journals. Her
Her research
research interests
interests aare
re
wide-ranging
wide-ranging and
and iinclude
nclude llaboratory
aboratory
studies
studies oonn antibacterial
antibacterial agents
agents both
both in
in
vitro
vitro and
and in
in animal
animal models,
models, and
and also
also cliniclinical
cal trials
trials in
in humans.
humans. They
They have
have resulted
resulted
in
in the
the publication
publication of
of over
over 1’000
1’000 papers
papers iinn
scientific
scientific journals.
journals.
25
Awards
IISC
SC H
Hamao
amao U
Umezawa
mezawa M
Memorial
emorial AAward
ward
IISC
SC Meritorious
Meritorious M
Membership
embership
IISC
SC M
eritorious M
embership is cconferred
onferred uupon
pon ppersons
ersons wh
ave
Meritorious
Membership
whoo hhave
SC.
eextraordinarily
xtraordinarily ccontributed
ontributed tto,
o, an
upported, tthe
he aim
he IISC.
andd ssupported,
aimss ooff tthe
TThe
he aawardees
wardees in 2
011, in cconjunction
onjunction wi
th tthe
he 2
7th IC
C, are
2011,
with
27th
ICC,
are::
PProfessor
rofessor AAndrea
ndrea Novelli
Novelli
Professor Andrea
Andrea N
ovelli has
has served
ser ved oonn
Professor
Novelli
the ISC
ISC Executive
Executive Committee
Committee as
as both
both
the
FFESCI
ESCI President
President and
and President
President ooff tthe
he
2
7th ICC
ICC / 2
1st EECCMID.
CCMID.
27th
21st
ISC
ISC Yen
Yen Award
Award sponsored
sponsored bbyy tthe
he
TTaiwan
aiwan SSociety
ociety ooff Microbiology
Microbiology
D
Dr.r. D
David
avid LLivermore
i vermore
TThe
he aaward
ward iiss ffor
or aann ooutstanding
utstanding rresearchesearcheerr iinn tthe
he fifield
eld ooff iinfectious
nfectious D
iseases, CCliniDiseases,
liniccal
al M
icrobiology, aand
nd AAntimicrobial
ntimicrobial ChemMicrobiology,
Chemootherapy
therapy w
ho hhas
as m
ade ssignificant
who
made
ignificant
ccontributions
ontributions ttoo ccollaborative
ollaborative w
work
ork in
in TTaiaiw
an. TThis
his yyear’s
ear ’s w
inner iiss D
avid LiverLiverwan.
winner
Dr.r. D
David
m
ore, D
irector ooff tthe
he AAntibiotic
ntibiotic ResistResistmore,
Director
aance
nce M
onitoring & R
eference LLaboratory
aboratory
Monitoring
Reference
(ARMRL
ARMRL)),, H
HPA
PA CCentre
entre ffor
or IInfections,
nfections, LLondon.
ondon.
Professor
Professor Victor
Victor Lim
Lim
Professor Victor
Victor Lim
Lim served
ser ved on
on tthe
he ISC
ISC EExxProfessor
eecutive
cutive CCommittee
ommittee iinn hhis
is ccapacity
apacity aass
PPresident
resident ooff tthe
he W
estern PPacific
acific SSociety
ociety
Western
ooff Chemotherapy.
Chemotherapy.
ISC IInter
ISC
nter American
American Society
S ociety
ooff Chemotherapy
Chemotherapy (IASC)
(IA SC) Award
Award
Nishith
Nishith Mewada
Mewada
The
The recipient
recipient of
of the
the IASC
IASC aaward
ward is Nishith
Nishith
Mewada
was
1986
MumMewada who
who w
as bborn
orn iinn 1
986 iinn M
umbai,
Hee cu
currently
works
bai, IIndia.
ndia. H
rrently w
orks aass a reresearch
Department
search assistant
assistant at
at the
the D
epar tment ooff
Internal
ayne SState
Internal Medicine,
Medicine, W
Wayne
tate UUniversity,
niversity,
M
ichigan, UUSS.
Michigan,
Nishith and
and his
his co-workers
co-workers will
will
Nishith
present the
the ffollowing
ollowing work
work dduring
uring the
the
present
ccongress:
ongress: ‘‘Significance
Significance ooff TTroponin-I
roponin-I vvalalue iinn iinfective
nfective eendocarditis’.
ndocarditis’.
ue
This award
award has
This
has been sponsored by tthe
he Tai
TTaiwan
aiwan
Society of
of M
icrobiology in memory ooff PProfessor
rofessor
Society
Microbiology
Chi-Zhong Yen
Yen (1888
(1888 – 1
974). In addi
tion ttoo
Chi-Zhong
1974).
addition
Professor YYen
tensive experienc
he
en’s ex
Professor
Yen’s
extensive
experiencee in tthe
prevention ooff inf
ases and in medic
al
fec
ectious dise
prevention
infectious
diseases
medical
education, he gat
hered ttogether
ogether exper
ts in tthe
he
education,
gathered
experts
try
fields of
of medicine
ulture, scienc
fields
medicine,, agric
agriculture,
sciencee and indus
industry
ounded tthe
he Chine
se SSociety
ociety ooff M
icrobiology.
and ffounded
ounde
Chinese
Microbiology.
26
Final
a Programmee
1
Daniel Athanazio
Daniel was born in 1977 in Salvador, Brazil and is a Professor of Pathology in the
Federal University of Bahia, Salvador,
Brazil where his research focuses on
leptospirosis.
Daniel and his co-workers will present
the following work during the congress:
‘Experimental leptospiral infection in
transgenic / mutant mice: attenuated nephritis in indicible nitric oxide synthase
(iNOS) knock-out C57BL/6 mice and pulmonary haemorrhages in SCID CB17 and
recombinase activating gene Rag-1
knock-out C57BL/6 mice’.
James Elston
James was born in 1977 in Kings Lynn,
UK and currently works as a Specialist
Registrar in Health Protection / Public
Health in North Yorkshire whilst studying
for an MSc in Public Health.
James and his co-workers will present
the following during the congress: ‘Pneumococcal vaccination and invasive pneumococcal disease in East Yorkshire, UK’.
Małgorzata Bodaszewska-Lubas
Małgorzata was born in 1981 in Krosno,
Poland. She is currently a PhD student at
the Jagiellonian University Medical College, Cracow looking at Group B Streptococci isolated from invasive infections
and carriers.
Małgorzata and her co-workers will
present their work during the congress
entitled: ‘Dependence of Group B Streptococci adherence on serotypes and alphalike protein genes’.
Ivan N. Ivanov
Ivan was born in 1978 in Sofia, Bulgaria.
He gained his PhD in 2010 and currently
works at the Reference Centre for Diagnosis and Control of Nosocomial Infections,
Sofia, Bulgaria.
Ivan and his co-workers will present
their work during the congress entitled:
‘Allele-specific-real-time PCR for costeffective canonical SNP genotyping of
Bacillus anthracis’.
Eirini Christaki
Eirini was born in 1977 in Thessaloniki,
Greece and combines practicing medicine with studying for a PhD at the Aristotle University of Thessaloniki on the
pathophysiology of sepsis.
Eirini and her co-workers will present
the following during the congress: ‘Interalpha inhibitor proteins exhibit antiviral
activity against influenza strains in vitro’.
Olga Lastovetska
Olga was born in 1987 in Chernivtsky,
Ukraine and is currently studying for her
Master of Science Degree in Laboratory
Medicine and pathobiology at the University of Toronto, Canada.
Olga and her co-workers will present
the following work during the congress:
‘Surveillance of extended-spectrum cephalosporin- and carbapenem – resistance in Escherichia coli from the Greater
Toronto Area, Ontario, Canada.
Final Programme
27
Awards
ISC Young Investigator Travel Awards
ISC African Network Grants
28
Oladipo A. Aboderin
Oladipo was born in Ifewara, Nigeria and
practices as a consultant clinical microbiologist at the Obafemi Awolowo University teaching hospitals complex and a
senior lecturer at the Obafemi Awolowo
University, both in Ile-Ife, southwest Nigeria.
Oladipo is Principle Investigator in the
project ‘Antibiotic stewardship at the
Obafemi Awolowo University teaching
hospitals complex’ and has initiated the
measurement of antimicrobial use and
resistance in his hospital.
Marie-France Phoba
Marie-France was born in Kinshasa, Democratic Republic of the Congo (RDC) and
is training as a Clinical Microbiologist at
the University Hospital of Kinshasa.
Marie-France is involved in a network
for the surveillance of bacteraemia, and
the surveillance of antimicrobial resistance and will shortly embark on a study
looking at the microbiological aspects of
meningitis in RDC.
Samuel M. Kariuki
Sam was born in Kericho, Kenya and
works as a Chief Research Officer in Kenya Medical Research Institute.
For the last 15 years Sam has been
engaged in work on surveillance and
monitoring antimicrobial resistance
among key Gram negative pathogens,
and also using various molecular tools to
understand the epidemiology of antimicrobial resistant infections.
Yilkal Asfaw
Yilkal was born in Gojam, Ethiopia and is a
veterinarian by profession and is currently Dean of the Faculty of Veterinary
Medicine, Addis Ababa University.
Yilkal is involved in research investigating the epidemiology and treatment of
infectious diseases in livestock as well
as antimicrobial use and resistance in
livestock infectious diseases in Ethiopia.
Final Programme
1
Cees van Nieuwkoop
The winner of the Masaaki Ohkoshi
Award 2011 is Cees van Nieuwkoop (Leiden, NL) and his group for the following
seven publications during 2009 – 2010
on febrile urinary tract infections:
1. van Nieuwkoop C et al.
BJU Int. 2010;105:1689 – 95.
BMC Infect Dis. 2009;9:131.
Clin Infect Dis. 2010;50:e69 – 72.
2010;51:1266 – 72.
Crit Care. 2010;14:R206.
[Epub ahead of print]
J Infect 2010; 60:114 – 21.
7. van der Starre WE et al.
Antimicrob Chemother.
2010 Dec 1. [Epub ahead of print]
The Masaaki Ohkoshi Award was founded in 1995 for
the best clinical study on the subject of urinary
tract infections published during a two-year period.
The first three awards were sponsored by
Professor Masaaki Ohkoshi and all subsequent
awards have been sponsored by the Japanese
UTI Committee. These awards have been given at every
ICC since 1995.
ISC Tom Bergan and John David Williams
Memorial Awards
Funmilola Abidemi Ayeni
Funmilola was born in Nigeria and will
present the abstract: ‘Evaluation of the
potential of Weissella confusa and Lactobacillus paracasei isolated from Nigerian
traditional dairy fermented foods and
cows’ intestines’.
Devendra H. Dusane
Devendra was born in India and will
present the following abstract on behalf
of his co-workers: ‘A novel glycolipid biosurfactant from marine Serratia marcescens disrupts pathogenic Candida albicans BH and Pseudomonas aeruginosa
PA01 biofilms’.
Wichai Santimaleeworagun
Wichai is from Thailand and will present
the following abstract on behalf of his coworkers: ‘Molecular epidemiology of
Clostridium difficile and prevalence of
the NAP-1 strain among patients admitted to a general and a private hospital in
Houston, Texas, US’.
Professor Tom Bergan served the ISC as President
(1997 – 2001), Secretary-General (1989 – 1997) and
Executive Member (1985 – 1989). His significant
contributions included spearheading the establishment of the official ISC journal.
Professor John David Williams served the ISC as
Associate Secretary (1977 – 1978), Secretary-General
(1979 – 1989) and President (1989 – 1993). He was
the first Editor-in-Chief of the ISC journal, International
Journal of Antimicrobial Chemotherapy.
Final Programme
29
Awards
ISC Masaaki Ohkoshi Award
Awards, Fellowships, Travel Grants 2011
Travel Grant (€500) and Free Registration
The ECCMID-ICC travel grant programme is sponsored by ESCMID
and ISC and were awarded to those with an outstanding abstract.
Free Registration
Free registrations are sponsored by ESCMID and ISC and were
conditional upon acceptance of a high-quality abstract.
Akinloye, Oluwabukola Margaret (Ogun State, NG)
Ammerlaan, Heidi (Utrecht, NL)
Berry, Lisa (London, UK)
Blyth, Christopher (Perth, AU)
Börjesson, Stefan (Uppsala, SE)
Cottell, Jennifer (Birmingham, UK)
Deeny, Sarah (London, UK)
Desai, Darshana (London, UK)
Diana, Michele (Lausanne, CH)
Dominguez-Herrera, Juan (Seville, ES)
Eustace, Andrew (Birmingham, UK)
Faria, Nuno Alexandre (Oeiras, PT)
Ferreira, Luis (Lisbon, PT)
Gadsby, Naomi (Edinburgh, UK)
Gan, Yuki (Hong Kong, HK)
Grandgirard, Denis (Berne, CH)
Hamprecht, Axel (Cologne, DE)
Hensgens, Marjolein (Leiden, NL)
Hofer, Sandra (Berne, CH)
Hornsey, Michael (London, UK)
Jensen, Rasmus Hare (Copenhagen, DK)
Komp Lindgren, Patricia (Uppsala, SE)
Lenz, Ryan (Calgary, CA)
Luchs, Adriana (Sao Paulo, BR)
Manzoor, Susan (Birmingham, UK)
Mihailescu, Ioana Raluca (Bucharest, RO)
Platteel, Tamara Nadine (Utrecht, NL)
Quinteira, Sandra Maria (Vila Nova Famalicao, PT)
Rolo, Joana (Oeiras, PT)
Ruiz del Castillo, Belén (Santander, ES)
Ruiz-Garbajosa, Patricia (Madrid, ES)
Santos, Ana Catarina (Lisbon, PT)
Sherry, Leighann (Glasgow, UK)
Smani, Younes (Seville, ES)
Snelders, Eveline (Nijmegen, NL)
Stevens, Vanessa (Buffalo, US)
Szabados, Florian (Bochum, DE)
Tedim, Ana P. (Madrid, ES)
van Mansfeld, Rosa (Utrecht, NL)
Van Meensel, Britt (Aarschot, BE)
Vlek, Anneloes (Utrecht, NL)
Yu Mi, Wi (Changwon-si, KR)
Zander, Esther (Cologne, DE)
Zapasnik, Anna (Warsaw, PL)
Afanasev, Maxim (Irkutsk, RU)
Amri, Manel (Algiers, DZ)
Baietto, Lorena (Turin, IT)
Barbier, Mariette (Palma de Mallorca, ES)
Barchitta, Martina (Catania, IT)
Baugh, Stephanie (Birmingham, UK)
Beato, Sílvia (Lisbon, PT)
Biernat, Monika Maria (Wroclaw, PL)
Campoli, Paolo (Montreal, CA)
Cartman, Stephen (Nottingham, UK)
Cataldo, Maria Adriana (Rome, IT)
Chang, Fang Yu (Kuei Shan Hsiang, TW)
El Chakhtoura, Nadim (Beirut, LB)
Evans, Jason (Birmingham, UK)
Ferguson, Patricia (Blacktown, AU)
Fomichev, Mikhail (Tallinn, EE)
Freitas, Francisco (Viseu, PT)
Gazin, Muriel (Wilrijk, BE)
Gharsa, Haythem (Logroño, ES)
Giannella, Maddalena (Madrid, ES)
Giomerzis, Nikolaos (Patras, GR)
Gogou, Vasiliki (Volos, GR)
Goldenberg, Simon (London, UK)
Gómez-Sanz, Elena (Logroño, ES)
Green, Laura (Wellington, NZ)
Guglielmetti, Lorenzo (Verona, IT)
Hiba, Vered (Holon, IL)
Howard, Susan (Manchester, UK)
Howard, Julia Catriona (London, UK)
Ikonomidis, Alexandros (Larissa, GR)
Ildiko, Pecsi (Budapest, HU)
Islam, Mohammad Aminul (Dhaka, BD)
Jain, Anu (London, UK)
Jamrozy, Dorota (New Haw, UK)
Joo, Eun-jeong (Seoul, KR)
Kampschreur, Linda (Utrecht, NL)
Kanji, Jamil (Edmonton, CA)
Khanafer, Nagham (Lyon, FR)
Kiratisin, Pattarachai (Bangkok, TH)
Kirbs, Claudia (Halle, DE)
Kochan, Piotr (Cracow, PL)
Kontsevaya, Irina (Samara, RU)
Kreder, Sabrina (Gießen, DE)
Krizova, Lenka (Prague, CZ)
Labrou, Maria (Giannouli, GR)
Lopez Martinez, Maria (Logroño, ES)
Lozano Fernandez, Carmen (Logroño, ES)
Machado, Diana (Lisbon, PT)
Manukian, Gregor (New Orleans, US)
Martín-Peña, Almudena (Seville, ES)
Mavridou, Eleftheria (Nijmegen, NL)
Mendes, Elisa (Sao Paulo, BR)
Mignone, Federica (Turin, IT)
Miragaia, Maria (Oeiras, PT)
Navarro-Laredo, Jose Luis (Madrid, ES)
30
Nielsen, Xiaohui Chen (Slagelse, DK)
Novais, Carla (Sra. da Hora-Matosinhos, PT)
Oostdijk, Evelien Ali Neeltje (Utrecht, NL)
Persijn, Lies (Oostakker, BE)
Pfeifer, Yvonne (Wernigerode, DE)
Pinho, Marcos Daniel (Lisbon, PT)
Pitart Ferre, Cristina (Barcelona, ES)
Porres-Osante, Nerea (Logroño, ES)
Rahal, Elias (Beirut, LB)
Ramos, André (Lisbon, PT)
Retamar Gentil, Pilar (Seville, ES)
Ripoll Gonzalez, Aida (Madrid, ES)
Rock, Clare (Dublin, IE)
Rodrigues, Liliana (Lisbon, PT)
Rottier, Wouter (Utrecht, NL)
Rozemeijer, Wouter (Amsterdam, NL)
Ruiz de Alegria Puig, Carlos (Santander, ES)
Ruiz Ruiz, Elena (Logroño, ES)
Saberi Kashani, Samaneh (Tehran, IR)
Santos, Catia (Aveiro, PT)
Seputiene, Vaida (Vilnius, LT)
Shabir, Sahida (Birmingham, UK)
Shan, Adriana (Madrid, ES)
Sisco, Maria Carolina (Caracas, VE)
Skjot-Rasmussen, Line (Copenhagen, DK)
Somalo, Sergio (Logroño, ES)
Teh, Benjamin (Heidelberg, AU)
Teo, Jocelyn (Singapore, SG)
Tome Francisco, Ana Patricia (Lisbon, PT)
Trigo, Matilde (Pontevedra, ES)
Troughton, Judith (Belfast, UK)
van Mourik, Maaike S.M. (Utrecht, NL)
van Zoelen, Marieke A.D. (Utrecht, NL)
Varga, Zoltan Gabor (Szeged, HU)
Vejpongsa, Pimprapa (Bangkok, TH)
Vervoort, Jascha (Antwerp, BE)
Vila-Farres, Xavier (Barcelona, ES)
Voets, Guido Maarten (Utrecht, NL)
Wilmer, Amanda (Vancouver, CA)
Yeung, Man Kiu (Hong Kong, HK)
Zakikhany, Katherina (London, UK)
Zbinden, Andrea (Zurich, CH)
Zhang, Lei (Chengdu, CN)
Zong, Zhiyong (Chengdu, CN)
ESCMID Observerships
Improve your clinical and laboratory skills!
Get financial support to visit our Collaborative Centres
apply
now!
www.escmid.org /observerships
Awards
Awards, Fellowships, Travel Grants 2011
Scientific Programme Overview
Saturday, 7 May
07.00
Lecture Hall Gold Lecture Hall Red 1 Lecture Hall White 1
Lecture Hall White 2
P. 44
08.45–10.45
EW06:
Hand hygiene to control
HAI: what you still don’t
know interactive
P. 44
08.45–10.45
EW09:
Emerging diagnostic
methods in parasitology
P. 43
08.45–13.00
EW02:
Fungi in the
respiratory tract &
antifungal stewardship
11.00–13.00
EW13:
11.00–13.00
EW16:
Lecture Hall Amber 1 Lecture Hall Amber 2
08.00
09.00
10.00
interactive
P. 43
08.45-10.45
EW03:
The epidemiology and
clinical management
of MRSA infection
11.00–13.00
P. 46
EW14:
New challenges in the
management of viral
hepatitis interactive
11.00–13.00
P. 46
EW15:
Optimal management of
urinary tract infections
(UTI) and prostatitis
13.30–15.30
P. 48
Antimicrobial peptides –
update for infectious
disease physicians
13.30–15.30
P. 47
Clinical problems from
parasitology
13.30–15.30
P. 48
Molecular virology
16.30–18.30
P. 51
The role of PK/PD in
the treatment of severe
infections
16.30–18.30
08.45–10.45
P. 44
EW05:
Bacteraemia and sepsis
11.00
12.00
P. 45
Practical approaches to
infection control and treatment
of Clostridium difficile infection
interactive
13.00
13.30–15.30
P. 47
Surveillance of resistance
in M. tuberculosis and
potential impact of epidemiological cut-off values
14.00
15.00
P. 46
Presentation of the ESCMID
diagnostic & management
guideline for Candida
diseases 2011
13.15–18.45
TAE
Trainees Day
interactive
P. 47
16.00
16.30–18.30 P. 52
Antimicrobial
pharmacology: from
bench to bedside
17.00
18.00
16.30–18.30
P. 50
Infection control without
borders
P. 51
Emergence of virulent and
antibiotic-resistant bacterial
forms in the marine environment: a public health concern
16.30–18.30
P. 52
New antimicrobial drugs
in the pipeline
19.00
20.00
19.00–22.00 P. 271
Opening Ceremony
followed by
Welcome Reception
Sunday, 8 May
07.00
08.00
Lecture Hall Amber 1
07.45–08.45
P. 55
EUCAST disk diffusion test –
frequently asked questions
07.45–08.45
P. 55
Standardisation of molecular
diagnostics in virology
09.00
09.00–11.00
10.00
P. 58
The big question – are we staying ahead of antibiotic resistance in the hospital setting?
09.00–11.00
P. 57
Can we decrease
hospital-acquired infections
in "real" life?
09.00–11.00
P. 56
Genetics and epidemiology
of mobile resistance:
mobilome & resistome
09.00–11.00
P. 59
New challenges for
the infectious disease
laboratory
Siemens
09.00–11.00
P. 57
What is changing in
the invasive mycosis field?
11.30–12.30
P. 59
Prospects for the control of
neglected tropical diseases
11.30–12.30
P. 60
Antifungal drugs make me mad:
candins or azoles
11.30–12.30
P. 60
Amoeba as genitor of new
pathogenic microorganisms
11.30–12.30
P. 60
Biofilm: from pathogenesis
to preventive measures
11.00
12.00
11.30–12.30
Challenges in making a
TB vaccine
P. 59
13.00
12.45–14.15
ESCMID
European Council
14.00
15.00
14.30–15.30
P. 62
Experience from humanitarian
intervention in Haiti
14.30–15.30
P. 62
The year in infection control
14.30–15.30
P. 62
ISC Hamao Umezawa Award
Antibiotic resistance:
back to the bigger circle
14.30–15.30
Are probiotics growth
promoters in humans?
P. 62
14.30–15.30
P. 63
Molecular bacteriology: insight in
the virulence of Gram-positive
cocci
P. 66
16.00–18.00
Bad bugs need better drugs:
addressing the global
challenge
AstraZeneca
P. 64
16.00–18.00
European preparedness
and response to highly
infectious diseases
16.00–18.00
P. 64
The role of PK/PD for
choosing antifungal drugs
16.00–18.00
P. 66
Diagnosis of bloodstream
infections (BSI):
present and future
bioMérieux
16.00–18.00
P. 64
Antibiotic combination
interactions
16.00
17.00
18.00
18.15–19.30
ESCMID Assembly
of Members
19.00
20.00
Concert Sala Puccini at Conservatory of Milan
32
P. 40
Symposia
Meet-the-Expert Sessions and Educational Workshops
Keynote and Special Lectures
ESCMID and ISC Meetings
Oral and Poster Sessions
Social Events
Integrated Symposia organized by the Industry
TAE Trainees Day
Lecture Hall Brown 1
Lecture Hall Silver
Foyer & Exhibition
08.00
Registration
07.45–19.00
P. 43
08.45-10.45
EW04:
Infections in the immunocompromised
host – an update
08.45-10.45
EW07:
Update in zoonotic
infections
P. 44
11.00–13.00
P. 47
EW18:
Regulation of efflux pumps
of bacteria by non-antibiotics
11.00–13.00
EW17:
P. 46
08.45-10.45
EW08:
Resistance to antituberculous drugs
P. 44
08.45-10.45
EW10:
Rapid detection of
resistance
P. 45
P. 43
08.45-13.00
EW01:
Antimicrobial susceptibility
testing
07.00
Exhibition
12.00–18.45
09.00
Posters
12.00–19.00
10.00
11.00
13.30–15.30
P. 49
Hospital antibiotic use:
causing or coping with
multi-drug resistance?
11.00–13.00
P. 45
EW12:
Know your own local antibiotic susceptibility data
interactive
12.00
13.00
13.30–15.30
P. 50
Emerging trends in the
management of invasive
fungal infections
MSD
13.30–15.30
P. 48
How to decrease
resistance in the ICU
13.30–15.30
P. 48
New models for
microbiology lab services
14.00
15.00
Session I:I
Poster Session
Poster
15.30–16.30
15.30–16.30
16.30–18.30
P. 54
Spotlight on C. difficile
infections – revealing the
‘silent risk’
Astellas Pharma Europe/Optimer
16.30–18.30
P. 54
Bacterial invasive and noninvasive diseases: aetiology,
epidemiology, treatment
implications, prevention and
surveillance GSK
Programme Overview
13.30–15.30
P. 48
Rare in the North, frequent
in the South: infections
from the Mediterranean
Basin
Just when you thought it was
safe to go back into the water:
leisure-associated water-borne
infections
11.00–13.00
P. 45
EW11:
Molecular detection of
antimicrobial resistance
16.30–18.30
P. 51
ISF symposium and
presentation of the
International Sepsis
Forum Award
16.30–18.30
P. 53
ESBLs from the
environment to the clinic
50
PP..32
16.30–18.30
P. 51
New diagnostic methods
for invasive fungal
infections
16.00
17.00
18.00
19.00
20.00
07.45–08.45
PK/PD for non-experts
P. 55
09.00–11.00
P. 56
New aspects of antimicrobial
treatment of anaerobic
infections
11.30–12.30
P. 61
Antimicrobial activity of different
antibiotics or in combination
against MDR Gram-negative rods
14.30–15.30
Genetics of NDM-1
P. 63
07.45–08.45
P. 55
Zoonoses for the non-initiated:
when to suspect them, how to
diagnose them, how to treat them
07.45–08.45
P. 55
MALDI-TOF identification
(fungi, bacteria, viruses, cell
cultures)
07.45–08.45
09.00–11.00
09.00–11.00
P. 56
Q fever: a major threat
in Europe
P. 59
09.00–11.00
New updates on the
management of MRSA
nosocomial infection
Pfizer
09.00–11.00
P. 56
Opportunistic infections
in solid organ transplant
recipients
11.30–12.30
P. 60
Pro vs Con:guideline vs clincial
practice-driven strategies in treating severe infectious diseases
11.30–12.30
P. 60
The year in infectious diseases
11.30–12.30
P. 60
The disease and death of
Enrico Caruso, Italian tenor
P. 59
Current and future perspective in
clinical diagnosis of viral, bacterial,
parasites and fungal pathogens
using a unique multiplexing
technology Luminex
11.30–12.30
P. 60
Viral resistance testing –
where are we?
Lecture Hall Silver
P. 55
Making research and reporting better using
the ORION statement to design or evaluate
infection control intervention studies and
outbreak reports
Foyer & Exhibition
07.00
Registration
07.15–18.15
08.00
Exhibition
10.00–18.30
09.00
Posters
09.00–18.00
10.00
11.00
14.30–15.30
P. 62
Metagenomics and detection
of new viruses
14.30–15.30
Eradication of malaria
P. 63
P. 65
16.00–18.00
Mycobacterial disease to
Epi and beyond
16.00–18.00
P. 66
Bad bugs, which drugs?
Superior potency for better
outcomes in Gram-positive
infections Novartis
14.30–15.30
P. 63
Antifungal management
strategies
14.30–15.30
P. 62
ESCMID Excellence Award –
Vaccines, medicine and public
health in the XXI century
16.00–18.00
P. 66
Pneumococcal disease
in adults: a remaining
challenge
Pfizer
16.00–18.00
P. 64
The future of hospital
antibiotic stewardship –
what should we achieve
by 2020?
12.00
Poster Session II
12.30–13.30
P. 61
Poster Session III
13.30–14.30
P. 62
13.00
14.00
15.00
16.00
P. 64
16.00–18.00
Influenza H1N1 pandemic
and complications
17.00
18.00
19.00
20.00
33
Scientific Programme Overview
Monday, 9 May
07.00
07.45–08.45
P. 67
Controversies in antiparasitic
chemotherapy
08.00
07.45–08.45
P. 67
Current issues on the detection
of carbapenem-resistant
Gram-negative bacteria
07.45–08.45
P. 67
Surgical site infections, how can
we prevent them, an evidence
based approach
07.45–08.45
P. 67
Impossible-to-treat
Gram-negative infections
09.00
09.00–11.00
10.00
11.00
12.00
09.00–11.00
P. 68
Clinical and microbiological
update on antibioticresistant P. aeruginosa
09.00–11.00
P. 71
The efficient laboratory –
an ideal partner in clinical
practice
BD Diagnostics
09.00–11.00
P. 69
Tracking antibiotic –
resistance in Gram-positive
cocci
09.00–11.00
P. 69
Paediatrics infections:
preclinical and clinical data
Janssen
09.00–11.00
P. 70
Visceral leishmaniasis:
an endemic disease with
global impact
11.30–12.30
P. 73
MALDI-TOF:
is it as good as we hoped?
11.30–12.30
P. 73
CA-MRSA: what is going on
with CA-MRSA?
11.30–12.30
P. 71
150 years Semmelweis'
publication on hand hygiene –
historical perspective
11.30–12.30
P. 74
Epidemiology of antimicrobial
resistance
11.30–12.30
P. 71
Influenza: the reward year of
the new H1N1
11.30–12.30
Lyme borreliosis,
toxoplasmosis
P. 74
P. 76
14.30–15.30
Quality control: is it needed?
P. 76
14.30–15.30
Infections and human genetic
susceptibility
P. 76
14.30–15.30
Man-made bacteria – making
new bacteria: possibilities, ethical
considerations, problems
P. 77
14.30–15.30
Mycobacterium tuberculosis
14.30–15.30
Cellular and molecular
immunology
14.30–15.30
P. 76
16. 00–18.00
16.00–18.00
P. 81
Impact of molecular
diagnostics on public health
and patient care
Cepheid
16.00-18.00
P. 77
New insights in the role of
the commensal flora
16.00–18.00
P. 81
Embedding MALDI-TOF
mass spectrometry in
an open microbiology
landscape Bruker
16.00–18.00
P. 78
Virology
(non-HIV / non-hepatitis)
16.00–18.00
P. 78
Under your skin:
skin manifestations
of parasitic diseases
07.45–08.45
P. 82
Polymyxins: olds becomes new
07.45–08.45
P. 82
Infection prevention and
diagnostics in critically ill
patients in the ICU
P. 70
The growing challenges
of multi-drug-resistant (MDR)
Gram-negatives: what is your
strategy now?
13.00
14.00
15.00
P. 77
Recent advances in the pathogenesis
of Cytomegalovirus (CMV) and
Epstein-Barr virus (EBV)
16.00
17.00
18.00
P. 81
Decision points in the management
of invasive Candida infections:
Navigating the choices for optimal
patient care
19.00
20.00
Tuesday, 10 May
07.00
08.00
09.00
10.00
09.00–11.00
Studying infectious
diseases in vivo
P. 84
09.00–11.00
P. 83
Bridging the gap of innovation - what we all could do
09.00–11.00
P. 83
Clinical Grand Rounds
09.00–11.00
P. 85
Antifungals: in vitro and
in vivo activity, pharmacokinetics and resistance
09.00–11.00
P. 87
Tuberculosis:
tests and diagnosis
Abbott
09.00–11.00
P. 83
Infectious disease with liver
involvement - an update
11.30–12.30
RNAi and viral infections
11.30–12.30
P. 00
87
Enterococci
Interventions
– where
in the are
usewe now?
of antimicrobials
11.30–12.30
P. 87
Update on the new guidelines
11.30–12.30
P. 88
Microbial pathogenesis,
pathophysiology of infections
diseases
11.30–12.30
P. 88
Acinetobacter baumannii:
current situation
11.00
12.00
11.30–12.30
P. 87
ESCMID Young Investigator
Award
P. 87
13.00
14.00
P. 89
13.30-15.30
Late presenters in Europe
15.00
16.00
17.00
18.00
19.00
20.00
34
13.30–15.30
Controlling MRSA
P. 89
13.30–15.30
P. 89
Milestones in antimicrobial
chemotherapy during the
past 50 years!
Symposia
Meet-the-Expert Sessions and Educational Workshops
Keynote and Special Lectures
ESCMID and ISC Meetings
Oral and Poster Sessions
Social Events
Integrated Symposia organized by the Industry
07.45–08.45
P. 67
Infection control for neutropenic
cancer patients
09.00–11.00
P. 68
Pathogenesis of Chlamydia
infections
Lecture Hall Silver
07.45–08.45
P. 67
Zygomycosis:
an emerging fungal infection
09.00–11.00
P. 68
Antimicrobial stewardship
works – why isn't it widely
practiced?
09.00–11.00
P. 71
Update on the management
of fungal infections
Pfizer
Foyer & Exhibition
07.00
08.00
Registration
07.30–18.15
09.00–11.00
P. 68
Next generation sequencing
and clinical microbiology
09.00
Exhibition
10.00–18.30
10.00
Posters
09.00–18.00
11.00
P. 74
11.30–12.30
P. 71
New molecular diagnostics for
parasitic diseases
11.30–12.30
P. 71
Hospitalised CAP – penicillin/
doxy vs. FQ or Ceph3/macrolide?
11.30–12.30
P.73
The year in clinical microbiology
12.00
Poster Session IV
12.30–13.30
Poster Session V
13.30–14.30
14.30– 15.30
P. 76
14.30–15.30
P. 76
Information technology and global
surveillance of infectious diseases
Clinical management of urinary
tract infections
16.00–18.00
P. 79
Pneumococcal infections
and vaccine
16.00–18.00
P. 78
Infection control methods
for cancer patients
undergoing treatment
P. 76
14.30–15.30
Vancomycin and staphylococci –
is it as bad as the say?
14.30–15.30
P. 81
16.00-18.00
Management of complicated
infections in the 21st
century: current and future
approaches Pfizer
16.00–18.00
P. 78
Infective endocarditis:
lights and shadows
P. 75
P. 75
12.30–14.30
P. 39
ISC Council Meeting
Room Yellow 3
Programme Overview
11.30–12.30
HIV/AIDS
13.00
14.00
P. 77
New Delhi metallo-beta-lactamase
(NDM) producers; the emergence of
MDR bacteria of global concern
15.00
16.00
17.00
18.00
18.00–20.00
ISC 50th Anniversary
Foyer Lecture Hall Gold
19.00
20.00
Lecture Hall Silver
07.45–08.45
P. 82
Tropical mycoses: emerging
IFIs in Europe ?
07.45–08.45
P. 82
Vertical and horizontal infection
control: pros and cons
07.45–08.45
P. 82
Interferon-gamma release
assays in TB diagnosis
07.45–08.45
P. 82
Laboratory identification of betalactamases in Gram-negative
strains with multiple enzymes
Registration
07.30–16.00
09.00–11.00
P. 85
Travel medicine:
tropical and parasitic
diseases
09.00–11.00
C. difficile news
09.00–11.00
P. 83
71
Antimicrobial-resistant
bacteria in food and potable
water: a recipe for disaster?
09.00–11.00
Exhibition
10.00–13.30
11.30–12.30
P. 88
Mycoplasma genitalium: the new
Chlamydia? From epidemiology
to clinical diagnostics Bio-Rad
P. 86
11.30–12.30
P. 87
Do you know the concept
of anti-anaerobic quinolones?
P. 84
Genetic predisposition and
the outcome of infection: time
to include genetic polymorphisms in routine diagnostic
work-up?
Foyer & Exhibition
P. 89
08.00
09.00
10.00
Posters
09.00–15.00
11.00
11.30–12.30
P. 87
Invasive fungal infections
in our hospitals today
12.00
Poster Session VI
12.30–13.30
13.30–15.30
Imaging infection
07.00
P. 90
13.30–15.30
Resistant superbugs:
a comparative analysis of
Asia versus Europe
13.30–15.30
P. 90
Risk factors other than
neutropenia for developing
infection in immunosuppressed patients
P. 89
13.00
14.00
15.00
16.00
17.00
18.00
19.00
20.00
35
Inserat
Introduction to the Scientific Programme
Educational Workshops
At the beginning of ECCMID / ICC on Saturday morning, 7 May 2011,
from 08.45–10.45, 08.45–13.00 and 11.00–13.00 several educational workshops will take place. They are organised in cooperation
with ESCMID Study Groups, ISC Working Groups and other organisations. Participation in the educational workshops is free of
charge; however, delegates must register in advance as places are
limited. If you are not yet registered and would like to attend,
please go to the “New Registration” counters in the registration
area onsite.
Meet-the-Expert Sessions
Sunday through Tuesday, the day will start at 07.45 with up to
six Meet-the-Expert Sessions led by experts in their field. These
sessions count on active participation of the audience. After a
short presentation, the expert will open the session for discussion.
Coffee will be offered.
TAE Trainees Day
On Saturday, 7 May 2011, 13.15–18.45, the Trainee Association
of ESCMID (TAE) organises the first European Trainees Day, a day
of teaching dedicated to the unique needs of trainees. During this
session various topics in CM and ID will be discussed in a highly
interactive way between trainees and experienced CM and ID
specialists. A second and equally important aim of the day is to
give trainees an opportunity to meet and network with each other.
Participation is free of charge; however, delegates must register in
advance as places are limited. If you are not yet registered and
would like to attend, please go to the “New Registration” counters
in the registration area onsite.
Keynote and Award Lectures
Sunday through Tuesday at 11.30 and 14.30, lectures of 60 minutes
will be given by opinion leaders in their fields as well as by the
winner of the ISC Award and the ESCMID Award for Excellence 2011.
Symposia
From 09.00–11.00, from 11.30–12.30, from 14.30–15.30 and
from 16.00–18.00 each day, parallel symposia will convene
renowned speakers from Europe and other continents who
will cover a wide range of recent developments in their field. On
Tuesday, 10 May 2011, the last round of symposia takes place
from 13.30–15.30. A number of symposia are arranged in cooperation with ESCMID Study Groups and ISC Working Groups;
some symposia are jointly organised with other societies or
organisations.
Symposia arranged by the industry are organised in close cooperation with the ECCMID / ICC Programme Committee. They are an
integral part of the scientific programme (Integrated Symposia).
Oral Sessions
During the same time slots as the above-mentioned symposia,
you will also find sessions composed of abstracts selected for oral
presentation, which are indicated by the prefix "O" in front of the
programme numbers. The presenting author is indicated with an
asterisk (*).
Poster Sessions
Most of the accepted abstracts are scheduled for poster presentation from Saturday through Tuesday. The selection was based on
a blind review by at least three experts in each field. The posters
are displayed in Hall B of the convention centre. The poster area
is open to all participants on Saturday from 12.00–19.00, on
Sunday and Monday from 08.00–18.00 and on Tuesday from
08.00–16.00. Please note that posters are exchanged on a daily
basis. Poster authors must be present at their posters for
discussion during their poster session (see page 39 for details).
The presenting author is indicated by an asterisk (*). Posters
submitted prior to the congress for inclusion in the online poster
library can be viewed on PCs next to the poster desk during
the entire congress or on the congress website. Scan this tag to
access the online library or visit the congress website.
Get the free mobile app at
http://gettag.mobi
Publication Only
Due to a large response to the call for abstracts, the Programme
Committee had to restrict the number of abstracts for presentation
during the meeting. Abstracts of this category are not included in
the Final Programme but are published in the online library to
Clinical Microbiology and Infection (CMI), and on the congress
website. Scan this tag to access the online library or visit the
congress website.
http://gettag.mobi
37
Programme Overview
CME Credits – now online
ESCMID and ISC are seeking accreditation by the European Accreditation Council for Continuing Medical Education (EACCME) to provide
CME credits for medical specialists. EACCME is an institution of the
European Union of Medical Specialists (UEMS, www.uems.net).
EACCME credits are recognised as Physician’s Recognition Awards
by the American Medical Association. To claim CME credits log in on
the congress website (www.eccmid-icc2011.org), link CME. After
completing the questionnaire, you can print the certificate indicating
the CME credits.
For the Italian CME accredition please refer to page 267.
21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
and 27th International Congress of Chemotherapy (ICC)
Milan Convention Centre (MIC), Milan, Italy
7 - 10 May 2011
Sponsored integrated symposia
New Updates on the Management
of MRSA Nosocomial Infections
Date : Sunday, May 8th 2011
Time : 09:00 - 11:00
Location : Lecture Hall Brown 2
Chairman : R. Masterton (Ayrshire and Arran, UK)
Co-chairman : T. Mazzei (Florence, Italy)
Update on the Management of Fungal Infections
Date : Monday, May 9th 2011
Time : 09:00 - 11:00
Chairman : L. Pagano (Rome, Italy)
Co-chairman : C. Lass-Flörl (Innsbruck, Austria)
Management of Complicated Infections
in the 21st Century: Current and Future Approaches
Date : Monday, 9th May 2011
Time : 16:00 - 18:00
Chairman : L. Peterson (Chicago, USA)
Co-chairman : C. Wenisch (Vienna, Austria)
EU .AB.2011.30
EU .ECAL TA.2011. 16
Instructions for Authors
The following prefixes have been used throughout the
programme:
E = Meet-the-Expert Session
K = Keynote Lecture
S = Symposium
O = Oral Session
P = Poster Session
Audiovisual Equipment / Speakers’ Service Centre (SSC)
The Speakers’ Service Centre (SSC) is centrally located on the
mezzanine level of the Milano Convention Centre (please refer to
the overview on page 6). Presentations can be checked on PCs in
the SSC.
All lecture halls are equipped with a PC and a digital projector
for PowerPoint presentations only. Presentations must be handed
in using a CD-ROM, a zip drive, a memory stick or your personal
laptop at least one hour before your lecture.
Please allow enough time for a thorough check of the presentation
and the transfer of the data to the presentation system by the staff.
Publication/Online Library
All accepted abstracts are published in the online library to Clinical
Microbiology and Infection (CMI), the official journal of ESCMID, and
on the congress website. Scan this tag to access the online library
or visit the congress website.
http://gettag.mobi
Poster Sessions
Saturday, 7 May 2011
12.00 – 13.00 h
Poster Mounting
15.30 – 16.30 h
Poster Presentation I (P553 – P820)
17.00 – 18.00 h
Poster Removal
Sunday, 8 May 2011
08.00 – 09.00 h
Poster Mounting
12.30 – 13.30 h
Poster Presentation II (P821 – P1108)
13.30 – 14.30 h
Poster Presentation III (P1109 – P1388)
17.00 – 18.15 h
Poster Removal
Monday, 9 May 2011
08.00 – 09.00 h
Poster Mounting
12.30 – 13.30 h
Poster Presentation IV (P1389 – P1665)
13.30 – 14.30 h
Poster Presentation V (P1666 – P1956)
17.00 – 18.15 h
Poster Removal
Tuesday, 10 May 2011
08.00 – 09.00 h
Poster Mounting
12.30 – 13.30 h
Poster Presentation VI (P1957 – P2248)
15.00 – 16.00 h
Poster Removal
Posters will be displayed for one full day only. The presence of the
authors during the given presentation times is a MUST. The times
set for poster mounting and removal must be considered.
All posters left hanging beyond the given removal times will be
disposed of.
39
Programme Overview
Online Meeting Planner during the 21st ECCMID / 27th ICC
The final scientific programme including all accepted abstracts is
available at the congress website www.eccmid-icc2011.org. Go to
the link «Scientific Programme» to compose your personalised
programme of lectures. You can use the search function to find
keywords, speakers and chairpersons.
ESCMID Study Group and other Business Meetings
Friday, 6 May 2011
Monday, 9 May 2011
09.00 – 13.00
08.00 – 12.00
Executive Committee Meeting
Starhotel Rosa Grand
09.00 – 11.00
11.30 – 13.30
15.00 – 16.30
16.30 – 17.30
15.30 – 16.30
17.30 – 18.30
18.00 – 19.00
Publication Subcommittee Meeting
Meeting Room Office 4
ECCMID/ICC Press Conference
Press Conference Room
CMI Associate Editor Meeting
CMI Associate Editor and Scientific Committee
Meeting
Meeting Room Blue 1
ESCMID Study Group for Anaerobic
Infections (ESGAI)
Meeting Room Red 2
CMI Happy Hour
Meeting Room Yellow 3
ESCMID Study Group for Epidemiological
Markers (ESGEM)
09.00 – 10.00
12.45 – 14.15
12.45 – 14.15
15.00 – 18.00
18.15 – 19.45
18.15 – 19.15
18.15 – 19.15
18.15 – 19.15
18.15 – 19.15
Sunday, 8 May 2011
18.15 – 19.15
12.30 – 13.30
12.30 – 13.30
12.30 – 13.30
12.30 – 13.30
12.30 – 13.30
12.30 – 13.30
12.30 – 13.30
12.45 – 14.15
13.30 – 15.30
18.15 – 19.30
ESCMID Fungal Infection Study Group (EFISG)
Meeting Room Amber 1
ESCMID Food- and Water-borne Infections
Study Group (EFWISG)
Meeting Room Blue 1
ESCMID PK/PD of Anti-Infectives Study Group
(EPASG)
ESCMID Study Group for Coxiella, Anaplasma,
Rickettsia and Bartonella (ESCAR)
ESCMID Study Group for Biofilms (ESGB)
Meeting Room Blue 2
ESCMID Study Group for Mycobacterial
Infections (ESGMYC)
ESCMID Study Group for Viral Hepatitis
(ESGVH)
ESCMID European Council Meeting
Education Subcommittee Meeting
Meeting Room Red 2
ESCMID Assembly of Members
18.15 – 19.15
18.15 – 19.15
18.15 – 19.15
18.15 – 19.15
18.15 – 19.45
18.15 – 20.15
Trainee Association of ESCMID
Steering Committtee Meeting
Meeting Room Suite 3
ESCMID Study Group for Antimicrobial
Resistance Surveillance (ESGARS)
EUCAST General Committee Meeting
Meeting Room Blue 2
ECCMID Sponsor Meeting
Scientific Affairs Meeting
Meeting Room Red 1
EUCAST AFST Meeting
ESCMID Helicobacter Study Group (EHSG)
Meeting Room Red 2
ESCMID Meningitis Study Group (EMESG)
ESCMID Study Group for Antibiotic Policies
(ESGAP)
ESCMID Study Group for Lyme Borreliosis
(ESGBOR)
Meeting Room Red 1
ESCMID Study Group for Clinical Parasitology
(ESGCP)
ESCMID Study Group for Implant-Associated
Infections (ESGIAI)
Meeting Room Blue 2
ESCMID Study Group for Infections
in Compromised Hosts (ESGICH)
ESCMID Study Group for Molecular
Diagnostics (ESGMD)
ESCMID Study Group for Nosocomial
Infections (ESGNI)
Professional Affairs Subcommittee Meeting
ESCMID Study Group for Clostridium difficile
(ESGCD)
Meeting Room Blue 1
11.30 – 13.30
13.00 – 20.00
Parity Commission Meeting
EUCAST Steering Committee Meeting
Wednesday, 11 May 2011
07.30 – 16.00
40
EUCAST Steering Committee Meeting
EUCAST at ECCMID/ICC 2011
Education and science
EUCAST – help desk and committee meeting
Saturday, 7 May to Tuesday, 10 May 2011, all day
08.45 – 13.00
13.30 – 15.30
Educational Workshop 1:
Antimicrobial Susceptibility Testing
Lecture Hall Silver
Symposium (EUCAST-ESGARS):
Surveillance of resistance in M. tuberculosis
and potential impact of epidemiological
cut-off values
EUCAST booth (next to ESCMID booth):
for any EUCAST enquiries or technical
questions
Balcony
ESCMID Study Group Corner:
EUCAST poster on activities in past year
Programme Overview
Monday, 9 May 2011
Sunday, 8 May 2011
12.45 – 14.15
07.45 – 08.45
Meet-the-Expert: EUCAST disk diffusion test –
frequently asked questions
18.15 – 19.45
EUCAST General Committee Meeting:
Annual meeting open to all
Meeting Room Blue 2
EUCAST AFST Meeting
Monday, 9 May 2011
14.30 – 15.30
Symposium: Vancomycin and
staphylococci – is it as bad as they say?
13.00 – 20.00
EUCAST Stearing Committee Meeting
07.30 – 16.00
EUCAST Stearing Committee Meeting
Posters from EUCAST
Hall B
P 746
P 747
P748
P 749
P 751
P 750
P 752
P 753
15.30 – 16.30
Correlation between EUCAST disk diffusion and the standardised broth microdilution method
EUCAST MIC breakpoints and inhibition zone diameter correlates for staphylococci
Screening for beta-lactam resistance in Streptococcus viridans group with the EUCAST disk diffusion method
EUCAST proposed new MIC breakpoints for Moraxella catarrhalis and corresponding zone diameter breakpoints
Inhibition zone diameter distributions and MIC correlates for Pasteurella multocida on the EUCAST MH-F media
Methicillin resistance in Staphylococcus spp. Validation of CLSI and EUCAST disk diffusion screen using cefoxitin
Comparison of two disk diffusion-based screening methods for detection and classification of beta-lactam
resistance in Haemophilus influenzae
The EUCAST Mueller-Hinton fastidious agar for antimicrobial susceptibility testing of anaerobic bacteria?
41
ISC Working Group and other Business Meetings
Friday, 6 May 2011
Monday, 9 May 2011
12.00 – 18.00
08.00 – 09.00
ISC Executive Committee Meeting
09.00 – 10.00
17.00 – 19.00
10.00 – 11.00
ISC Working Group Urinary Tract Infections
Sunday, 8 May 2011
07.00 – 08.00
08.00 – 09.00
09.00 – 10.00
10.00 – 11.00
11.00 – 12.00
12.00 – 13.00
12.00 – 14.00
13.00 – 14.00
14.00 – 15.00
42
ISC Working Group Antiseptics
ISC Working Group Antimicrobials of the Future
General Meeting of ISC Working Groups
ISC Working Group MRSA
ISC Working Group Zoonoses
ISC Working Group Intensive Care and Sepsis
IJAA Editorial Board Meeting
ISC Working Group Infections in
Catastrophic Areas
ISC Working Group Fungal Infections
11.00 – 12.00
12.30 – 14.30
13.00 – 14.00
14.00 – 15.00
15.00 – 16.30
16.30 – 18.00
ISC Working Group Collateral Effects
of Anti-infectives
ISC Working Group Streptococcal Infections
ISC Working Group Controlling Antimicrobial
Resistance
ISC Working Group Pharmacokinetics /
Pharmacodynamics
ISC Council Meeting
Room Yellow 3
ISC Working Group Immunisations and
Vaccines
ISC Working Group Bone, Skin and Soft
Tissue Infections (SSTIs)
ISC Working Group Antimicrobial Stewardship
ISC Working Group Endocarditis
07.30 – 09.00
ISC Executive Committee Meeting
Saturday, 7 May
Participation in the Educational Workshops is free of charge,
yet delegates must register
(if you have not pre-registered, please go to the “New Registration”
counters)
Lecture Hall Educational Workshop 1
Silver Antimicrobial susceptibility testing
08:45 – 13:00 Convenors: Gunnar Kahlmeter (Växjö, SE);
Derek Brown (Peterborough, UK)
EUCAST definitions
A MIC is a MIC is a MIC – isn’t it?
Gunnar Kahlmeter (Växjö, SE)
PK/PD tools for breakpoints definition
Johan Mouton (Nijmegen, NL)
Clinical outcomes and breakpoints definition:
when is the evidence enough?
Alasdair MacGowan (Bristol, UK)
Rationale for new or revised EUCAST clinical
breakpoints
What is new in EUCAST expert rules?
Rafael Cantón (Madrid, ES)
Arranged with the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)
White 3 Fungi in the respiratory tract & antifungal
08:45 – 13:00 stewardship
Convenors: Cornelia Lass-Flörl (Innsbruck, AT);
Roger Finch (Nottingham, UK)
Detection of Candida: a marker of chronic
disease?
Riina Richardson (Manchester, UK)
Sensitisation to fungi: allergic bronchopulmonary aspergillosis (ABPA)
Tobias Welte (Hannover, DE)
Antifungal stewardship for Aspergillus
Malcolm Richardson (Manchester, UK)
Antifungal stewardship for other fungal
pathogens
Arranged with the ESCMID Fungal Infections
Study Group (EFISG), the European Confederation
of Medical Mycology (ECMM) and the EU-funded
project Genomics to Combat Resistance against
Antibiotics in Community-acquired LRTI in
Europe (GRACE)
Amber 2 The epidemiology and clinical management
08:45 – 10:45 of MRSA infection
Convenors: Teresita Mazzei (Florence, IT);
Educational Workshops
Current topics of resistance
Kazuhiro Tateda (Tokyo, JP)
What is CA-MRSA?
The prophylaxis and treatment of MRSA
infections
F. Kate Gould (Newcastle, UK)
Development of new antimicrobial agents
against MRSA
Amber 3 Infections in the immunocompromised host –
08:45 – 10:45 an update
Convenor: George Petrikkos (Athens, GR)
Bacterial infections in the immunocompromised
host: an update
George Petrikkos (Athens, GR)
Immunisation in the immunocompromised host
Sotirios Tsiodras (Athens, GR)
Invasive pulmonary aspergillosis – therapeutic
options
William Hope (Manchester, UK)
Infection in the solid organ transplant
recipient: a clinical update
Antifungal stewardship for Candida
Maiken C. Arendrup (Copenhagen, DK)
Fungal infections in the immunocompromised
host: therapeutic strategies and guidelines
Oscar Marchetti (Paris, FR)
21st ECCMID / 27th ICC / Milan
Final Programme
43
Saturday, 7 May
Amber 1 Bacteraemia and sepsis
08:45 – 10:45 Convenor: Evangelos J. Giamarellos-Bourboulis
(Athens, GR)
Amber 4 Update in zoonotic infections
08:45 – 10:45 Convenor: Georgios Pappas (Ioannina, GR)
A patient admitted with hypotension
Evangelos J. Giamarellos-Bourboulis (Athens, GR)
Chagas disease imported in Europe and North
America
Alfonso Rodriguez-Morales (Caracas, VE)
Is bacteraemia always a septic condition?
Ralph Corey (Durham, US)
Leptospirosis
Antonio Cascio (Messina, IT)
How to choose the correct antibiotics
Jos van der Meer (Nijmegen, NL)
Leishmaniasis
Luciano Nigro (Catania, IT)
The need for immunomodulation
Steven Opal (Providence, US)
Foodborne zoonoses
Christopher Parry (Liverpool, UK)
Sepsis in out-patients
Pierre-François Laterre (Brussels, BE)
Arranged with the ISC Working Group on Zoonoses
Arranged with the ISC Working Group on
Bloodstream Infections
White 1 Hand hygiene to control HAI:
08:45 – 10:45 what you still don’t know
Convenors: Markus Dettenkofer (Freiburg, DE);
Andreas F. Widmer (Basel, CH)
Hand hygiene: what you should know
Didier Pittet (Geneva, CH)
How to choose your product for hand hygiene?
Markus Dettenkofer (Freiburg, DE)
Hand hygiene technique: why you should care!
Andreas F. Widmer (Basel, CH)
Hand hygiene in hospitals: European activities
and the role of the ECDC
Marc Struelens (Stockholm, SE)
Arranged with the ESCMID Study Group for
Nosocomial Infections (ESGNI)
Brown 1 Resistance to anti-tuberculous drugs
08:45 – 10:45 Convenor: Emanuelle Cambau (Paris, FR)
Susceptibility testing of M. tuberculosis
strains
Is molecular testing an alternative to drug
resistance testing?
Francis Drobniewski (London, UK)
Surveillance of resistance in tuberculosis
Andrei Dadu (Copenhagen, DK)
Susceptibility to second line drugs
Thomas Schön (Kalmar, SE)
Antimicrobial Resistance Surveillance (ESGARS)
White 2 Emerging diagnostic methods in parasitology
08:45 – 10:45 Convenors: Titia Kortbeek (Bilthoven, NL);
Miriam J. Álvarez-Martinez
(Barcelona, ES)
Intestinal parasites: microscopy, antigen
detection or PCR
Titia Kortbeek (Bilthoven, NL)
Leishmania: culture vs. PCR and differences in
typing systems (PCR – zymodemes)
Gabriele Schönian (Berlin, DE)
Malaria: rapid testing, Giemsa staining and
molecular diagnostics
44
Final Programme
Saturday, 7 May
Arranged with the ESCMID Study Group
for Clinical Parasitology (ESGCP)
Brown 2 Rapid detection of resistance
08:45 – 10:45 Convenors: Fred Tenover (Sunnyvale, US);
Gaby Pfyffer (Lucerne, CH)
Rapid detection of resistance in blood cultures
Fred Tenover (Sunnyvale, US)
Direct detection of resistance in respiratory
samples
Emilia Cercenado (Madrid, ES)
Brown 2 Know your own local antibiotic susceptibility
11:00 – 13:00 data
Convenors: Ian M. Gould (Aberdeen, UK);
USA
Sylvain DeLisle (Baltimore, US)
Scandinavia
Niels Frimodt-Møller (Copenhagen, DK)
ViResiST
Jose Maria Lopez Lozano (Alicante, ES)
Asia
Antimicrobial Resistance
Rapid detection of resistant organisms with
MALDI-TOF
Elisabeth Nagy on behalf of ESGAI
Rapid detection of multidrug resistant
tuberculosis
Brown 1 Molecular detection of antimicrobial resistance
11:00 – 13:00 Convenors: Patrice Nordmann (Paris, FR);
Neil Woodford (London, UK)
Molecular mechanisms behind ESBL
Detection of carbapenemases: molecular/
phenotypic approaches
Role of transposons and integrons
Gian Maria Rossolini (Siena, IT)
Vancomycin-resistant enterococci
Wolfgang Witte (Wernigerode, DE)
White 1 Practical approaches to infection control and
11:00 – 13:00 treatment of Clostridium difficile infection
Convenor: Emilio Bouza (Madrid, ES)
Hand hygiene in the era of increasing
Clostridium difficile infection
Katherine Ellingson (Atlanta, US)
Should we test Clostridium difficile for
antimicrobial resistance?
Paola Mastrantonio (Rome, IT)
Treatment of Clostridium difficile infection:
what is new?
Emilio Bouza (Madrid, ES)
New aspects of prevention of Clostridium
difficile infection
Petra Gastmeier (Berlin, DE)
Clostridium difficile (ESGCD)
Molecular Diagnostics (ESGMD)
Final Programme
45
Evaluation of diagnostic tools for T.cruzi
Miriam J. Álvarez-Martinez (Barcelona, ES)
Saturday, 7 May
Amber 1 New challenges in the management of
11:00 – 13:00 viral hepatitis
Convenor: Andy Hoepelman (Utrecht, NL)
White 2 Presentation of the ESCMID diagnostic &
11:00 – 13:00 management guideline for Candida diseases 2011
Convenors: Andrew J. Ullmann (Mainz, DE);
Manuel Cuenca Estrella (Madrid, ES)
Therapeutic options for HCV therapy nonresponders
Philippe Sogni (Paris, FR)
Development of the guideline
Management of HCV – challenges for the future
Will Irving (Nottingham, UK)
Diagnostic procedures
Manuel Cuenca Estrella (Madrid, ES)
Current treatment paradigms for hepatitis B
therapy
Pietro Lampertico (Milan, IT)
Treatment in HIV/AIDS
Olivier Lortholary (Paris, FR)
Management of HIV/HCV coinfection –
clinical cases
Arranged with the ESCMID Study Group for Viral
Hepatitis (ESGVH)
Treatment in ICU and others
Oliver A. Cornely (Cologne, DE)
Treatment in Haematology/Oncology
Treatment in paediatrics
Emmanuel Roilides (Thessaloniki, GR)
Arranged with the ESCMID Fungal Infection
Study Group (EFISG)
Amber 2 Optimal management of urinary tract infections
11:00 – 13:00 (UTI) and prostatitis
Convenors: Kurt G. Naber (Straubing, DE);
Tetsuro Matsumoto (Kitakyushu, JP)
Emerging resistance campaign of uropathogens:
winners and losers
Ryoichi Hamasuna (Kitakyushu, JP)
Uncomplicated UTI – are international
guidelines meaningful?
Florian ME Wagenlehner (Straubing, DE)
Catheter-associated UTI – many guidelines,
no solution?
Peter Tenke (Budapest, HU)
Acute prostatitis – how to prevent and manage
chronic infection?
Yong-Hyun Cho (Seoul, KR)
Urinary Tract Infections and Asian Association
of UTI/STD
Amber 4 Just when you thought it was safe to go back
11:00 – 13:00 into the water: leisure-associated water-borne
infections
Convenors: Paul Hunter (Norwich, UK);
Maria José Figueras (Reus, ES)
What's lurking in the lake; what's skulking in
the sea? Microbiology of leisure-associated
water-borne infections
Paul Hunter (Norwich, UK)
Infections following recreational use of water:
the clinician's perspective
Nicholas Beeching (Liverpool, UK)
Green nails and hot feet: Pseudomonas
aeruginosa – a versatile water-borne pathogen
Tim Inglis (Nedlands, AU)
Being wary in the water: preventing
leisure-associated water-borne infections
Arranged with the ESCMID Food- and Waterborne Infections Study Group (EFWISG)
46
Final Programme
Saturday, 7 May
Regulation of efflux pumps of Salmonella
Laura Piddock (Birmingham, UK)
Efflux pumps and progression of antibiotic
resistance
Séamus Fanning (Dublin, IE)
Evaluation of efflux pumps of bacteria by a
semi-automated real-time method
Leonard Amaral (Lisbon, PT)
Modulation of membrane permeability:
an efficient response to stress
Jean-Marie Pages (Marseille, FR)
Official Symposia
Lecture Hall Surveillance of resistance in M. tuberculosis
White 1 and potential impact of epidemiological cut-off
13:30 – 15:30 values
Chairpersons: Giovanni Fadda (Rome, IT);
S6
13:30 The critical concentration is important
Girts Skenders (Stopinu, LV)
S7
14:00 The critical proportion is important
S8
14:30 Molecular tools for surveillance of resistance
in TB
Francis Drobniewski (London, UK)
S9
15:00 Epidemiological cut-off values in M. tuberculosis –
Potential impact on breakpoints
Christian Giske (Stockholm, SE)
Arranged with the ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)
and the European Committee on Antimicrobial
Susceptibility Testing (EUCAST)
Trainees Day
Lecture Hall Trainees Day: a time for trainees to share their
White 2 knowledge under the supervision of seniors
13:15 – 18:45 Chairpersons: Nathalie van Burgel (Leiden, NL);
Nicola Petrosillo (Rome, IT)
Opening remarks
A review of clinical and microbiological practice
in Europe for trainees
1
2
13:30 The case of community-acquired pneumonia CAP
– ID
Gavin Barlow (Nottingham, UK)
14:00 The case of community-acquired pneumonia CAP
– CM
Arjana Tambic-Andrasevic (Zagreb, HR)
Panel discussion
Lecture Hall Clinical problems from parasitology
Amber 1 Chairpersons: Peter Chiodini (London, UK);
Alessandro Bertoloni (Florence, IT)
13:30 – 15:30
S10
13:30 Severe malaria
Eskild Petersen (Aarhus, DK)
S11
14:00 Cutaneous leishmaniasis
Francisco Vega Lopez (London, UK)
S12
14:30 Strongyloides hyperinfestation
Francesco Castelli(Brescia, IT)
S13
15:00 African trypanosomiasis
Jan Clerinx (Antwerp, BE)
Coffee Break
A review of clinical and microbiological
practice in Europe for trainees
3
15:45 The case of device-associated infections – CM
4
16:15 The case of device-associated infections – ID
Panel discussion
Coffee break
Research and publication skills
5
17:45 How to critically appraise a paper
Robert Read (Sheffield, UK)
Closing remarks
Final Programme
47
Amber 3 Regulation of efflux pumps of bacteria by
11:00 – 13:00 non-antibiotics
Convenor: Leonard Amaral (Lisbon, PT)
Saturday, 7 May
Lecture Hall Antimicrobial peptides – update for infectious
White 3 disease physicians
13:30 – 15:30 Chairpersons: Jordi Vila (Barcelona, ES);
David Hooper (Boston, US)
Lecture Hall New models for microbiology lab services
Silver Chairpersons: Juan Picazo (Madrid, ES);
13:30 – 15:30
Johan Van Eldere (Leuven, BE)
S26
13:30 Challenges and opportunities for clinical
microbiology
Ellen Jo Baron (Sunnyvale, US)
14:00 Antimicrobial peptides in the lung
Pieter Hiemstra (Haarlem, NL)
S27
14:00 Core labs and point-of-care microbiology labs
Michel Drancourt (Marseille, FR)
S16
14:30 Antimicrobial peptides in the intestinal tract
Jan Wehkamp (Stuttgart, DE)
S28
S17
15:00 Antimicrobial peptides and urogenital tract
infection
Alexander M. Cole (Orlando, US)
14:30 Fully automated microbiology labs:
an inevitable evolution?
Ed Ijzerman (Haarlem, NL)
S29
15:00 The evolving role of the clinical microbiologists
Hilary Humphreys (Dublin, IE)
S14
13:30 The human skin, AMPs, infection and inflammation
Michael Otto (Bethesda, US)
S15
Arranged with the Interscience Conference on
Antimicrobial Agents and Chemotherapy
(ICAAC) and ESCMID
Oral Sessions
Lecture Hall Rare in the North, frequent in the South:
Amber 3 infections from the Mediterranean Basin
13:30 – 15:30 Chairpersons: Erdal Akalin (Istanbul, TR);
S18
13:30 Brucellosis
S19
14:00 Cystic hydatidosis
Enrico Brunetti (Pavia, IT)
S20
14:30 Visceral leishmaniasis
Yusuf Ozbel (Izmir, TR)
S21
O30
13:30 Cytokine gene polymorphism and its association
with Epstein-Barr virus infection outcome in
paediatric liver transplant recipients
B. Kasztelewicz*, I. Jankowska, J. Pawlowska,
J. Teisseyre, P. Kalicinski, M. Pronicki,
K. Dzierzanowska-Fangrat (Warsaw, PL)
O31
13:42 Cytokine gene polymorphism and congenital
cytomegalovirus infection
B. Kasztelewicz, J. Czech-Kowalska,
M. Bartoszewska-Kornacka, J. Romanska-Kita,
G. Biaszczyk, D. Dzierzanowska,
K. Dzierzanowska-Fangrat* (Warsaw, PL)
O32
13:54 Quantitation of human herpesvirus -6 and -7
DNAs in different blood fractions from blood
donors
A. Gautheret-Dejean*, B. Géraudie, M. Charrier,
D. Heurté, M. Desmonet, M-A. Bartoletti,
P. Bonnafous, C. Penasse, H. Agut (Paris, FR)
O33
14:06 Simultaneous detection of influenza A and
its subtypes (H1, H3, 2009 H1N1), influenza
B, and RSV A and B in respiratory specimens
on an automated, random access, molecular
platform
B. Buchan, N. Anderson, P. Jannetto, N. Ledeboer*
(Milwaukee, US)
15:00 Toscana virus infections
Remi Charrel (Marseille, FR)
Lecture Hall How to decrease resistance in the ICU
Brown 2 Chairpersons: Massimo Antonelli (Rome, IT);
13:30 – 15:30
S22
13:30 Predicting MDR pathogens: risk factors and
laboratory approach
S23
14:00 The de-escalation approach
Helen Giamarellou (Athens, GR)
S24
14:30 The challenge of shortening therapy
Jean Chastre (Paris, FR)
S25
15:00 The reality of infection control in the ICU
Georgeous Dimopoulos (Athens, GR)
Arranged with the European Society of
Intensive Care Medicine (ESICM)
48
Lecture Hall Molecular virology
Amber 2 Chairpersons: Fausto Baldanti (Pavia, IT);
13:30 – 15:30
Final Programme
O34
14:18 Detection of drug-resistant hepatitis B virus
mutant strains using ultradeep pyrosequencing
in patients with chronic hepatitis B
S.Y. Ko*, H.B. Oh, C.W. Park, J.E. Lee (Seoul, KR)
O35
14:30 Real-time Epstein-Barr virus PCR for the
diagnosis of primary EBV infection
C. Gartzonika, E. Kapsali*, N. Zotos, E. Priavali,
H. Sakkas, D. Papamichail, E. Papapetrou,
A. Mavridis, S. Levidiotou (Ioannina, GR)
O36
14:42 Nucleotide variation of Dengue virus serotype
2 during viral persistence after acute infection
in adults
M. Sriprapun*, C. Laosakul, S. Krajiw,
K. Arunyingmongkol, P. Siriyasatien, W. Kulwichit
(Bangkok, TH)
O37
14:54 Genetic diversity of Crimean-Congo
haemorrhagic fever viruses in Turkey
A.T. Kalaycioglu*, R. Durmaz, A. Özkul, Y. Uyar,
G. Korukluoglu, M. Ertek (Ankara, TR)
O38
15:06 Characterisation of HIV-1 genetic diversity
in established and recent infections among
intravenous drug users from Lisbon, Portugal
A.P. Francisco*, R. Coutinho, R. Silva, E. Paixão,
A.F. Silva, E. Pádua (Lisbon, PT)
O39
15:18 New microfluidic platforms for the simultaneous
detection of pathogens using TaqMan®
probe-based real-time PCR
A. Ferlinz*, L. Healy, K. Warrington, J. Sherlock,
J. Fryer, L. Young, A. Gottleib
(Berlin, DE; Potters Bar, Manchester, UK)
O42
13:54 The ECDC pilot Point-Prevalence Survey of
healthcare-associated infections and
antimicrobial use: antimicrobial use analysis
P. Zarb*, A. Muller, B. Coignard, J. Griskeviciene,
K. Weist, S. Hopkins, M. Goossens,
S. Vaerenberg, B. Catry, V. Vankerckhoven,
H. Goossens, C. Suetens on behalf of the
ECDC-PPS Study Group
O43
14:06 Initial antibiotic treatment patterns and
failure rates among hospitalised patients
with complicated skin and skin structure
infections: a 4-year review within an
integrated US healthcare system
R. Adamson*, S. Amara, X. Huang
(South Plainfield, Jersey City, US)
O44
14:18 Development of national prescribing indicators
for antimicrobials to support reduction in
J. Sneddon, D. Nathwani*, A. Patton,
W. Malcolm, E. Watson on behalf of the Scottish
Antimicrobial Prescribing Group
O45
14:30 Nephrotoxicity of continuous infusion of
vancomycin in critically ill patients
H. Spapen*, K. Janssen van Doorn,
W. Verbrugghe, R. Jacobs, N. Dobbeleir,
M. Diltoer, P. Honoré, P. Jorens
(Brussels, Edegem, BE)
O46
14:42 Continuous versus intermittent infusion of
vancomycin: the eternal diatribe
M.A. Cataldo*, E. Grilli, M. Musso, E. Tacconelli,
N. Petrosillo (Rome, IT)
O47
14:54 Are surgeons the only common denominator
between Clostridium difficile infections, surgical
site infections and poor compliance to antibiotic
prophylaxis in surgery guidance?
E. Byrne*, S. El-Sheikha, D. Fernandes, Z. Morad,
A. Shafiq, A. Hakeem-Habeeb, I. Sadasivam,
E. Tingi, D. D'Silva, M. Przybylo, A. Guleri
(Blackpool, UK)
O48
15:06 Procalcitonin-guided antibiotic stewardship in
lower respiratory tract infections. A real-life
international multicentre quality surveillance
(ProREAL)
W.C. Albrich*, F. Dusemund, B. Bucher, S. Meyer,
R. Thomann, F. Kühn, M. Sprenger, D. Amin,
P. Hausfater, P. Schuetz, B. Müller for the ProREAL
study team
O49
15:18 Hospital antimicrobial consumption pattern
in the era of multidrug-resistant bacteria
E. Iosifidis*, S. Boukouvala, V. Barbarousi,
C. Antachopoulos, E. Roilides (Thessaloniki, GR)
Lecture Hall Hospital antibiotic use: causing or coping with
Amber 4 multi-drug resistance?
13:30 – 15:30 Chairpersons: Nur Benzonana (Istanbul, TR);
Rossitza Vatcheva-Dobrevska
(Sofia, BG)
O40
13:30 Clinical impact of unsolicited post-prescription
antibiotic review in surgical and medical
wards: a randomised controlled trial
P. Lesprit*, C. Landelle, F. Hémery,
C. Brun-Buisson (Créteil, FR)
O41
13:42 Amikacin and tobramycin for Pseudomonas
aeruginosa and Acinetobacter baumannii
complex according to PK/PD and microbiological
breakpoints: is there a difference to revise
antibiotic policies?
F. Cardoso*, S. Gomes, E. Alves, C. Cardoso,
A. Ferreira (Rio de Janeiro, BR)
Final Programme
49
Saturday, 7 May
Saturday, 7 May
Integrated Symposium
Poster Session I
Lecture Hall Emerging trends in the management of invasive
Brown 1 fungal infections
13:30 – 15:30 MSD chair: Giuseppe Cornaglia (Verona, IT);
ESCMID/ISC chair: Po-Ren Hsueh (Taipei, TW)
Presence of authors: 15:30 – 16:30
Welcome and opening remarks
Giuseppe Cornaglia (Verona, IT); Po-Ren Hsueh
(Tapei, TW)
S54
S55
S56
Susceptibility and resistance: what does it
mean and why should it matter?
Michael Pfalle, Maiken Cavling Arendrup
(Iowa, US; Copenhagen, DK)
My daily clinical practice: a multidisciplinary
approach to the management of invasive
fungal infection in the ICU
Eckhard Müller (Herne, DE)
My daily clinical practice: a multidisciplinary
approach to the management of invasive
fungal infection in patients with haemotological
malignancy
Andrew Ullmann (Mainz, DE)
Panel discussion
Faculty
Closing remarks
Topics
P553 – P577
P578 – P585
P586 – P593
P594 – P601
P602 – P612
P613 – P636
P637 – P644
P645 –
P655 –
P677 –
P694 –
P654
P676
P693
P700
P701 – P716
P717 – P729
P730 – P745
P746 – P778
P779 – P794
P795 – P820
AMR in Gram-negatives
Helicobacter pylori infections:
from diagnosis to pathogenesis
Diagnosis of gastrointestinal infections
ESBL and AmpC in Enterobacteriaceae and
A. baumannii
Mechanisms of carbapenem-resistance in
Enterobacteriaceae and P. aeruginosa
Genetics of antimicrobial resistance
Molecular detection of antibiotic resistance
among Gram-negative bacteria
Epidemiology of NDM-1
ESBL: a growing problem
Carbapenem resistance in Enterobacteriaceae
Detection of beta-lactamases in
Gram-negative rods
Acinetobacter baumannii
Porins and efflux pumps are good friends
K. pneumoniae: the worst threat amongst
Enterobacteriaceae?
Antimicrobial susceptibility testing
Antimicrobial pharmacodynamics
Antimicrobial pharmacokinetics
Integrated symposium arranged by
MSD
Official Symposia
Lecture Hall Infection control without borders
White 1 Chairpersons: Margreet Vos (Rotterdam, NL);
16:30 – 18:30
50
Final Programme
S57
16:30 The EuRegio experience of successful
cross-border infection control (NL-D)
Alex W. Friedrich (Münster, DE)
S58
17:00 The WHO experience:
worldwide "clean care is safer care"
Benedetta Allegranzi (Geneva, CH)
S59
17:30 International transfer of patients and MDRO
control
Bruno Coignard (Paris, FR)
S60
18:00 What can we learn from each other in infection
control – EU versus USA experience?
Saturday, 7 May
S61
S62
S63
S64
16:30 Mobile genetic elements transferring
virulence and antibiotic resistance genes
among marine bacteria
Manuel Lemos (Santiago de Compostela, ES)
17:00 Pathogenic effects of marine Vibrio strains
on human cells
Maria del Mar Lleo (Verona, IT)
17:30 Fish farms: potential role as reservoirs of
antibiotic resistant bacteria and resistance
genes
David Verner-Jeffreys (Weymouth, UK)
18:00 Monitoring and modeling the microbiological
quality of water and shellfish
Monique Pommepuy (Plouzane, FR)
Lecture Hall ISF Symposium and presentation of the
Brown 1 International Sepsis Forum Award
16:30 – 18:30 Sepsis: update on pathogenesis, diagnosis
and therapy
Chairpersons: Thierry Calandra (Lausanne, CH);
Tom van der Poll (Amsterdam, NL)
S69
16:30 The collaborative cross mouse genetic reference
population as novel tool for dissecting host
susceptibility to infectious diseases
F. Iraqi*, K. Vered, I. Ofek, B. Yalcin, C. Durrant,
R. Mott (Tel-Aviv, IL; Oxford, UK)
S70
16:50 Pathophysiology: damage-associated
molecular patterns
Tom van der Poll (Amsterdam, NL)
S71
17:15 Diagnosis of sepsis: microbes versus
biomarkers?
Thierry Calandra (Lausanne, CH)
S72
17:40 The current status of MD2-TLR4 inhibitors in
the treatment of sepsis
Steven Opal (Providence, US)
S73
18:05 Is there a rationale to use immunostimulation
to counteract the altered immune status of
sepsis and SIRS patients?
Jean-Marc Cavaillon (Paris, FR)
Lecture Hall The role of PK/PD in the treatment of severe
White 3 infections
16:30 – 18:30 Chairpersons: George L. Drusano (Albany, US);
Emilia Cercenado (Madrid, ES)
S65
16:30 MRSA, enterococci, Pseudomonas aeruginosa
and Acinetobacter sp.: where are we going
with resistance patterns?
S66
17:00 PK/PD differences among old and new
glycopeptides and new anti Gram-positive
compounds
Alexander Firsov (Moscow, RU)
Lecture Hall New diagnostic methods for invasive fungal
Silver infections
16:30 – 18:30 Chairpersons: Jacques Bille (Lausanne, CH);
Maurizio Sanguinetti (Rome, IT)
S74
16:30 Non-culture based diagnosis of invasive
aspergillosis
S67
17:30 PK/PD and anti Gram-negative compounds:
which is the exact role?
S75
17:00 Latest developments in molecular detection
of outbreaks
Corné Klaassen (Nijmegen, NL)
S68
18:00 Do we need new compounds?
George Drusano (Albany, US)
S76
17:30 Rapid detection of Candida species and
resistance from blood cultures
Jesús Guinea Ortega (Madrid, ES)
S77
18:00 Old pathogens, new species: the role of the
new taxonomy
Andy Borman (Utrecht, NL)
Pharmacokinetics/Pharmacodynamics
Final Programme
51
Lecture Hall Emergence of virulent and antibiotic-resistant
Amber 1 bacterial forms in the marine environment:
16:30 – 18:30 a public health concern
Chairpersons: Luisa Peixe (Porto, PT);
Saturday, 7 May
Oral Sessions
O85
17:54 Outpatient and inpatient parenteral antibiotic
therapy with daptomycin in a large non-interventional study: reducing total therapy costs
A. Gonzalez-Ruiz*, Z. Dailiana,
P. Gargalianos-Kakolyris, V.J. González-Ramallo,
R.A. Seaton, V. Prisco, M. Heep, K. Bouylout,
Y. Yin, R.L. Chaves (Kent, UK; Larissa, Athens, GR;
Madrid, ES; Glasgow, UK; Salerno, IT; Basel, CH;
East Hanover, US)
Lecture Hall Antimicrobial pharmacology: from bench to
Red 1 bedside
16:30 – 18:30 Chairpersons: Elisa Bertazzoni-Minelli (Verona, IT);
Françoise Van Bambeke
(Brussels, BE)
O78
16:30 Comparative analysis of the potential of
polymyxin B and gentamicin to cause apoptosis
and necrosis in cultured renal LLC-PK1 cells:
concentration-dependent studies with incubated
and electroporated cells
M-P. Mingeot-Leclercq*, P. Tulkens (Brussels, BE)
O86
18:06 Colistin minimum plasma concentration is
an independent risk factor for nephrotoxicity
L. Sorlí*, S. Luque, S. Grau, N. Berenguer,
H. Knobel, F. Alvarez-Lerma, M. Montero,
I. Rodriguez, C. Segura, J.P. Horcajada
(Barcelona, ES)
O79
16:42 Time-kill effect of levofloxacin against multidrugresistant Pseudomonas aeruginosa isolated
from patients with ventilator-associated
pneumonia
A. Savva, M. Mouktaroudi, D. Carrer, A. Safarika,
E.J. Giamarellos-Bourboulis* (Athens, GR)
O87
O80
16:54 Staphylococcal resistance studies using
susceptible organisms supplemented with
their resistant mutants: linezolid and rifampin
combinations simulated in an in vitro dynamic
model
A. Firsov*, M. Smirnova, E. Strukova, Y. Portnoy,
S. Zinner (Moscow, RU; Cambridge, US)
18:18 Factors influencing pharmacokinetics of
prophylactic posaconazole oral solution in
patients with acute myeloid leukaemia or
myelodysplastic syndrome
J. Vehreschild, C. Müller, F. Farowski,
M.J. Vehreschild, O.A. Cornely*, U. Fuhr,
K.-A. Kreuzer, M. Hallek, V. Kohl (Cologne, DE)
Lecture Hall New antimicrobial drugs in the pipeline
Amber 2 Chairpersons: Atef Shibl (Riyadh, SA);
16:30 – 18:30
Elisabeth Presterl (Vienna, AT)
O81
17:06 Evaluation of ceftaroline activity versus
daptomycin (DAP) against DAP non-susceptible
methicillin-resistant Staphylococcus aureus
strains in an in-vitro pharmacokinetic/
pharmacodynamic model
M. Steed, C. Vidaillac*, M. Rybak (Detroit, US)
O88
16:30 Development of bacteriophage cocktails
for the management of nosocomial and
community-acquired methicillin-resistant
S. Morales*, G. Mearns, C. Fernandes, B. Hudson,
J. Iredell, A. Smithyman (Sydney, AU)
O82
17:18 Pharmakocinetics of daptomycin in patients
with Gram-positive infections receiving
different dosage regimens
M. Falcone*, M.I. Cassetta, A. Russo, A. Lappa,
S. Fallani, L. Tritapepe, D. Gabriella, V. Vullo,
M. Venditti, A. Novelli (Rome, Florence, IT)
O89
16:42 A novel silver colloid: assessment of
antibacterial activity
R.A. Dixon*, M. Baron (Lincoln, UK)
O90
16:54 Effect of novel antibacterial GSK2251052 on
mammalian mitochondrial protein synthesis
P. Chan*, T. Cecconie, T. Mandal, D. Cooper,
D. Holmes, P. DeMarsh (Collegeville, US)
O91
17:06 Carbohydrate-derived fulvic acid is a novel
antifungal product
L. Sherry*, C. Murray, B. Jones, C. Williams,
G. Ramage (Glasgow, UK)
O92
17:18 A novel chimeric lysin shows superiority
to mupirocin for skin decolonisation of
antibiotic-resistant (MRSA) and sensitive
(MSSA) Staphylococcus aureus
M. Pastagia*, C. Euler, V. Fischetti (New York, US)
O83
O84
52
17:30 Clinical dose finding of sitafloxacin (DU-6859a)
= pharmacokinetic/pharmacodynamic analysis
in patients with community-acquired respiratory
tract infections
Y. Tanigawara*, S. Kohno (Tokyo, Nagasaki, JP)
17:42 Clinical dose finding of sitafloxacin (DU-6859a):
pharmacokinetic/pharmacodynamic analysis
from two clinical trial results for communityacquired respiratory tract infections
S. Kohno (Nagasaki, JP)
Final Programme
O93
17:30 Completely novel protein synthesis inhibitors
demonstrate efficacy in three mouse models
of infection
A. Marra*, E. Bortolon, D. Molstad, Y. Wu, H. Jing,
E.M. Duffy (New Haven, US)
O94
17:42 Efficacy of the novel metallo-enzyme inhibitor
VT-1129 in combination with amphotericin B
for cryptococcal meningitis
N.P. Wiederhold*, L.K. Najvar, W.J. Hoekstra,
R.J. Schotzinger, W.R. Moore, E. Garvey,
R. Bocanegra, W. Kirkpatrick, T.F. Patterson
(San Antonio, Morrisville, US)
O95
17:54 A phase 1 trial to evaluate the safety
and pharmacokinetics of single doses of
intravenous solithromycin (CEM-101) in
healthy adult subjects
J. Schranz*, K. Clark, A. Marion, G. Ghibellini,
P. Fernandes (Chapel Hill, Omaha, Research
Triangle Park, US)
O96
18:06 TP-2758 is a novel oral tetracycline targeting
complicated urinary tract infections and
pyelonephritis
J. Sutcliffe*, Y. Deng, M. Ronn, X. Xiao
(Watertown, US)
O97
18:18 Investigation of potential mechanisms underlying transient paraesthesia associated with
PMX30063 administration in human subjects
R. Scott*, J. Arezzo, B. Korczak (Radnor, Bronx, US)
Lecture Hall ESBLs from the environment to the clinic
Brown 2 Chairpersons: Mikhail Edelstein (Smolensk, RU);
16:30 – 18:30
Waleria Hryniewicz (Warsaw, PL)
O98
16:30 Does the change in the EUCAST ESBL expert
rules help the patient?
M. Hoeck, B. Wiedemann* for the EPICENTER
Network
O99
16:42 The adjusted attributable mortality of extendedspectrum beta-lactamase-producing Enterobacteriaceae bacteraemia: a meta-analysis
W.C. Rottier*, H. Ammerlaan, M.J. Bonten
(Utrecht, NL)
O100
16:54 Extended-spectrum beta-lactamase-producing
Escherichia coli bloodstream infections
upon hospital admission (ESBL-EC/BSI-UHA):
molecular epidemiology and virulence traits
S. Navon-Venezia*, D. Karfunkel, D. Frienkel-Krispin,
T. Kotlovsky, I. Chmelnitsky, Y. Carmeli
on behalf of MOSAR and SATURN study groups
O101
17:06 Characterisation of extended-spectrum
beta-lactamase-producing Escherichia coli
from clinical patients, chicken meat and
domestic animals
Y. Ishii*, M. Eto, H. Esaki, T. Saga, S. Harada,
A. Yoshizumi, K. Tateda, M. Kuroda, S. Igimi,
A. Rambach, K. Yamaguchi (Tokyo, JP; Paris, FR)
O102
17:18 Prevalence of ESBL-producing Enterobacteriaceae (ESBL-E) in raw vegetables
E.A. Reuland*, N. al Naiemi, M.C. Rijnsburger,
P.H. Savelkoul, C.M. Vandenbroucke-Grauls
(Amsterdam, Enschede, NL)
O103
17:30 Prevalence and characterisation of extendedspectrum-beta-lactamase producing Escherichia
coli isolates in healthy volunteers in Tunisia
R. Ben Sallem*, K. Ben Slama, A. Jouini, N. Klibi,
V. Estepa, Y. Sáenz, A. Boudabous, C. Torres
(Tunis, TN; Logroño, ES)
O104
17:42 High faecal carriage rates of CTX-M ESBLproducing Escherichia coli in the Birmingham
area: implications of global origin
A. Eustace, N. Wickramasinghe, L. Xu, T. Saluja,
S. Shabir, P. Hawkey* (Birmingham, UK)
O105
17:54 Tracking the presence of class 1 integrons
in Gram-negative bacteria collected from
surfaces and biological samples in Hospital
Infante D. Pedro, Aveiro, central Portugal
C. Santos, C. Lima, E. Ramalheira, T. Caetano,
S. Mendo* (Aveiro, PT)
O106 18:06 Clonal group 025b-ST131 accounts for
more than 90% of clinical isolates of CTX-M
producing E. coli from residents of 26 nursing
homes in one region
C. Ludden, F. Boyle, B. Hanahoe, M. Lyons,
M. Cormican*, D. Morris (Galway, IE)
O107
18:18 Klebsiella pneumoniae sequence types
originally associated with specific ESBLs
might act as substrates for recently emerged
metallo-beta-lactamases or KPC enzymes
A. Valverde*, P. Ruiz-Garbajosa, T. Curiao, M. Tato,
D. Gijón, F. Baquero, T.M. Coque, R. Cantón
(Madrid, ES)
Final Programme
53
Saturday, 7 May
Saturday, 7 May
Integrated Symposia
Lecture Hall Spotlight on C. difficile infections – revealing
Amber 3 the ‘silent’ risk
16:30 – 18:30 Astellas/Optimer chair: Carl Erik Nord
(Stockholm, SE);
ESCMID/ISC chair: Paola Mastrantonio (Rome, IT)
Carl Erik Nord (Stockholm, SE);
S108
Evolving epidemiology of C. difficile across
Europe – the ‘silent’ killer
Ed Kuijper (Leiden, NL)
S109
The impact of C. difficile infections –
understanding the risks for recurrence
Oliver A. Cornely (Cologne, DE)
S110
A global perspective on management of CDI –
what do guidelines tell us?
Mark Wilcox (Leeds, UK)
S111
Addressing the unmet needs for patients at
risk of CDI
Stuart Johnson (Maywood, US)
Panel
Meeting summary
Carl Erik Nord (Stockholm, SE)
Integrated symposium organised by
Astellas Pharma Europe / Optimer
54
Final Programme
Lecture Hall Bacterial invasive and non-invasive diseases:
Amber 4 aetiology, epidemiology, treatment implications,
16:30 – 18:30 prevention and surveillance
GSK chair: Andrea Novelli (Florence, IT);
ESCMID/ISC chair: Johan Van Eldere (Leuven, BE)
S112
Are dual infections myth or reality?
The example of otitis media
Ron Dagan (Beer Sheva, IL)
S113
Evolving resistance in respiratory pathogens
and its implications
Johan van Eldere (Leuven, BE)
S114
Potential benefit of integrating vaccination in
clinical guidelines to optimise antibiotic use
Paola Marchisio (Milan, IT)
S115
The need for improved surveillance of invasive
bacterial disease
Mary Slack (Oxford, UK)
All faculty
GlaxoSmithKline
Sunday, 8 May
Lecture Hall EUCAST disk diffusion test – frequently asked
Amber 1 questions
07:45 – 08:45 Experts: Gunnar Kahlmeter (Växjö, SE);
Derek Brown (Peterborough, UK);
Erika Matuschek (Växjö, SE)
E116
Lecture Hall Zoonoses for the non-initiated:
Amber 4 when to suspect them, how to diagnose them,
07:45 – 08:45 how to treat them
Experts: Antonio Cascio (Messina, IT);
E119
Objectives
• To give a brief overview of the EUCAST disk
diffusion technique and how it was developed
• To explain the format of the EUCAST frequently
asked questions section on the website
• To discuss some of the questions frequently
asked by laboratories implementing the
EUCAST disk diffusion technique
Objectives
• To identify epidemiologic risk factors for
zoonotic diseases that would be important
points in history
• To identify clinical symptoms indicative of
a zoonotic disease
• To provide a clinical approach to the major
syndromes caused by a zoonotic disease
• To outline therapeutic dilemmas and
controversies for major zoonotic infectious
entities
Lecture Hall Standardisation of molecular diagnostics
Amber 2 in virology
07:45 – 08:45 Experts: Mario Poljak (Ljubljana, SI);
Philip Minor (South Mimms, UK)
E117
E120
Objectives
• To present the process for development of
international standard materials for molecular
diagnostics, illustrated by CMV
• To present ongoing work to develop working
reagents for inclusion in molecular diagnostic
assays on a routine basis
• To present experience in the use of different
external quality control systems
• To present views on the ideal control
Lecture Hall PK/PD for non-experts
Amber 3 Experts: Johan Mouton (Nijmegen, NL);
07:45 – 08:45
Federico Pea (Udine, IT)
E118
Lecture Hall MALDI-TOF identification (fungi, bacteria,
Brown 1 viruses, cell cultures)
07:45 – 08:45 Experts: Michel Drancourt (Marseille, FR);
Jacques Bille (Lausanne, CH)
Objectives
• To understand the essentials of PK/PD: pharmacokinetics, susceptibility and outcome
• To differentiate classes of antibiotics based
on pharmacodynamic effects
• To provide examples of dosing regimens
based on PK/PD
• To use PK/PD to optimise dosing regimens
Objectives
• To review the performance of MALDI-TOF
for the identification of bacteria in a routine
laboratory, with an emphasis on the gaps
• To review the performance of MALDI-TOF for
the direct identification from blood cultures
and urines
• To analyse the performance of MALDI-TOF for the
identification of yeasts and filamentous fungi
• To discuss the potential of MALDI-TOF for other
applications in clinical microbiology: microbial
typing, detection of toxins and resistance
mechanisms, identification of viruses and
cell lines
Lecture Hall Making research and reporting better using
Brown 2 the ORION statement to design or evaluate
07:45 – 08:45 infection control intervention studies and
outbreak reports
Experts: Barry Cookson (London, UK);
Sheldon Stone (London, UK)
E121
Objectives
• To write a high quality conference/journal
abstract
• To provide a framework to help them referee
a conference abstract
• To decide which conference oral/poster
presentations to see
• To decide which full journal articles to read
Final Programme
55
Sunday, 8 May
Official Symposia
Lecture Hall Q fever: a major threat in Europe
Brown 1 Chairpersons: Philippe Brouqui (Marseille, FR);
Jan Jelrik Oosterheert (Utrecht, NL)
09:00 – 11:00
Lecture Hall Genetics and epidemiology of mobile
White 3 resistance: mobilome and resistome
09:00 – 11:00 Chairpersons: Helen Leavis (Utrecht, NL);
Marek Gniadkowski (Warsaw, PL)
S122
09:00 SCCmec elements in staphylococci – origins,
evolution and dissemination
Herminia de Lencastre (Lisbon, PT)
S123
09:30 Mobile genetic elements behind resistance in
streptococci
Patrick Trieu-Cuot (Paris, FR)
S124
S125
10:00 Transposable elements in mobilisation and
spread of resistance genes in Gram-negatives
Timothy R. Walsh (Cardiff, UK)
09:00 Q fever in the Netherlands: epidemiology of
the largest ongoing European outbreak
Wim van der Hoek (Bilthoven, NL)
S131
09:30 Q fever in animals: epidemiology, diseases in
animals and zoonotic risk
Annie Rodolakis (Nouzilly, FR) on behalf of the
ESCMID Study Group for Coxiella, Anaplasma,
Rickettsia and Bartonella (ESCAR)
S132
10:00 Q fever: Prevention and treatment issues
during an outbreak
Alphons Horrevorts (Nijmegen, NL)
S133
10:30 Coxiella burnetii: lessons from genomics
10:30 Resistance plasmid families in Enterobacteriaceae
Alessandra Carattoli (Rome, IT)
Lecture Hall New aspects of antimicrobial treatment of
Amber 3 anaerobic infections
09:00 – 11:00 Chairpersons: Elisabeth Nagy (Szeged, HU);
David R. Snydman (Boston, US)
S126
09:00 Clinical failures in the antimicrobial treatment
of anaerobic infections
David R. Snydman (Boston, US)
S127
09:30 Antimicrobial resistance in Clostridium difficile
S128
10:00 Bacteroides, Prevotella and Porphyromonas
are becoming more resistant to antimicrobial
agents
Elisabeth Nagy (Szeged, HU) on behalf of ESGAI
S129
10:30 New approaches to treat anaerobic infections
Carl Erik Nord (Stockholm, SE)
Arranged with ESCMID Study Group for Anaerobic
Infections (ESGAI)
56
S130
Final Programme
Coxiella, Anaplasma, Rickettsia and Bartonella
(ESCAR)
Lecture Hall Opportunistic infections in solid organ
Silver transplant recipients
09:00 – 11:00 Chairpersons: Dominique Salmon (Paris, FR);
Guido Antonelli (Rome, IT)
S134
09:00 Human cytomegalorvirus infection in
transplant recipients
Paolo Grossi (Varese, IT)
S135
09:30 Respiratory viruses in transplant recipients
Laurent Kaiser (Geneva, CH)
S136
10:00 Polyomavirus infection in kidney transplant
recipients
Hans H. Hirsch (Basel, CH)
S137
10:30 Epstein-Barr virus (EBV) adoptive immunotherapy in transplant recipients
Helen Heslop (Houston, US)
Sunday, 8 May
Lecture Hall Can we decrease hospital-acquired infections
White 2 in ''real'' life?
09:00 – 11:00 Chairpersons: Leonard Leibovici (Petah Tikva, IL);
Krassimir Metodiev (Varna, BG)
O146
10:36 Low environmental contamination of rooms in
ESBL-positive patients
R.J. Piso*, E. Grui, U. Schibli, M. Bühlmann,
S. Bassetti (Olten, Aarau, CH)
O147
10:48 Model-based cost-effectiveness evaluation
of methicillin-resistant Staphylococcus
aureus screening and control in general
medical hospital wards
J.V. Robotham*, N. Graves, B. Cookson, J. Wilson,
A.G. Barnett, C. Worby, B.S. Cooper
(London, UK; Brisbane, AU; Bangkok, TH)
O138 09:00 Understaffing, overcrowding, inappropriate
nurse-to-ventilated patient ratio and nosocomial
infections – which parameter reflects deficits
best?
F. Schwab, P. Gastmeier, C. Geffers, E. Meyer*
(Berlin, DE)
O139
09:12 Selection of qacA carriage in MRSA clonal
complex 22 but not 30 during a successful
infection control programme incorporating
chlorhexidine-based decolonisation
R. Batra, E. Halligan, P. Cliff, J. Otter,
J. Edgeworth* (London, UK)
O140
09:24 First global survey on hand-hygiene
compliance before patient contact –
results from 47 countries
B. Allegranzi*, H. Sax, F. Eggimann, L. Pievaroli,
H. Attar, N. Colaizzi, C. Kilpatrick, D. Pittet
(Geneva, CH)
O141
09:36 A comparison of the microbiological efficacy
of hydrogen peroxide vapour and ultraviolet
light processes for room decontamination
N.L. Havill*, J. Boyce (New Haven, US)
O142 09:48 State-wide admission prevalence screening in
Saarland, Germany (MRSAarNetz)
C. Petit, B. Biechele* (Homburg, DE)
O143
10:00 Long-term maintenance of very low incidence
of nosocomial multidrug-resistant pathogens
in a tertiary hospital in Spain
J. Rodríguez-Baño*, L. García, L. López-Cerero,
C. Lupión, M. Alex, C. González, M. del Toro,
J. López-Méndez, E. Ramírez, M. Muniain,
A. Pascual (Seville, ES)
O144
10:12 What is the optimal period for measuring
hand-hygiene compliance? Are longer periods
any better than 20-minute periods?
S. Stone*, C. Fuller, S. Michie, A. Charlett
(London, UK)
O145
10:24 Control measures for preventing the spread
of vancomycin-resistant enterococci in
hospitals: where is the evidence?
M.A. Cataldo*, G. De Angelis, C. De Waure,
S. Venturiello, G. La Torre, R. Cauda, Y. Carmeli,
E. Tacconelli (Rome, IT; Tel Aviv, IL)
Lecture Hall What is changing in the invasive mycosis field?
Amber 2 Chairpersons: Mickaeli Aoun (Brussels, BE);
09:00 – 11:00
Johann Maertens (Leiden, BE)
O148 09:00 Six-year prospective candidaemia survey from
the fungal infection network of Switzerland
(FUNGINOS) – Candida species distribution
and antifungal susceptibility according to
recent EUCAST and old vs. new CLSI clinical
breakpoints
C.E. Orasch*, O. Marchetti, C. Durussel, C. Guyaz,
M. Ochsner, J. Bille and the Microbiological and
Clinical FUNGINOS Investigators
O149
09:12 Epidemiology of filamentous fungi in cystic
fibrosis patients in the Netherlands
P. Terpstra*, M. v. Westreenen, P. Croughs,
P. Verweij, R. Brimicombe, J. Yntema, C.H. Klaassen,
P. Merkus, J. Meis (Nijmegen, Rotterdam,
Maastricht, The Hague, NL)
O150
09:24 Improved clinical diagnosis of invasive
Candida infections in patients undergoing
cardiac surgery
C. Kratzer*, S. Tobudic, A. Lassnigg, A. Schiferer,
H. Fischer, W. Graninger, N. Kreischitz,
B. Steinlechner, E. Presterl (Vienna, AT)
O151
09:00 Analysis of aetiology of invasive fungal
infections using a panfungal PCR-based
method in tissue biopsies with proven
infection
M. Cuenca-Estrella*, M.J. Buitrago,
L. Bernal-Martinez, A. Gomez-Lopez,
J.L. Rodriguez-Tudela (Majadahonda, ES)
Final Programme
57
Oral Sessions
Sunday, 8 May
O152 09:36 Comparison of a commercial Aspergillus
real-time PCR assay with galactomannan
testing of BAL fluid for the diagnosis of
invasive pulmonary aspergillosis in lung
M. Luong, C. Clancy*, M. Wissel, K. Grantham,
S. Kleiboeker, E. Kwak, F. Silveira, Y. Toyoda,
R. Shields, S. Reddy, T. Walsh, M. Nguyen
(Pittsburgh, Kansas City, New York, US)
O153
O154
O155
09:48 A phase IV, open-label study evaluating efficacy
and safety of intravenous anidulafungin followed
by oral azole for the treatment of candidaemia/
invasive candidiasis in US/Korean patients
J. Vazquez*, A. Reboli, P. Pappas, T.F. Patterson,
J. Reinhardt, P. Chin-Hong, E. Tobin, D. Kett,
P. Biswas, R. Swanson (Detroit, Camden,
Birmingham, San Antonio, Newark,
San Francisco, New York, Miami, US)
10:00 Survey of antifungal combination therapy
for treatment of proven or probable invasive
fungal diseases in Italian haematological
centres. The Seifem-Combo Study
(NCT 00906633)
A. Candoni*, M. Caira, S. Cesaro, A. Busca,
M. Giacchino, R. Fanci, G. Specchia, A. Nosari,
A. Bonini, C. Cattaneo, L. Melillo, P. Musto,
M. Offidani, J. Peccatori, N. Vianelli, G. Milone,
R. Scimè, A. Venditti, L. Pagano on behalf of
SEIFEM Group (Sorveglianza Epidemiologica
Infezioni Fungine Nelle Emopatie Maligne), Italy.
10:12 Mortality due to invasive fungal infections
is low in lung transplant recipients receiving
voriconazole prophylaxis
C. Clancy*, U. Celik, A. Vadnerkar, M. Nguyen
(Pittsburgh, US)
O156
10:24 Impact of posaconazole prophylaxis on fungal
colonisation and invasive fungal infections:
a prospective study
A. Scemla*, M. Lafaurie, C. Lacroix, E. Raffoux,
P. Ribaud, S. Touratier, J.-M. Molina (Paris, FR)
O157
10:36 Stewardship in antifungals. How much do
prescribing physicians know?
M. Valerio*, P. Muñoz, E. Zamora, M. Salcedo,
E. Verde, A. Bustinza, J. Peral, J. Gayoso,
C. Menarguez, J. Hortal, I. Márquez,
L. Fernández-Quero, B. Pinilla, E. Vilalta,
E. Bouza on behalf of the COMIC (Collaboration
in Mycoses) Study Group
58
Final Programme
Integrated Symposia
Lecture Hall The Big Question – are we staying ahead of
White 1 antibiotic resistance in the hospital setting?
09:00 – 11:00 Astellas chair: Javier Garau (Barcelona, ES)
ESCMID/ISC chair: Marc Lecuit (Paris, FR)
S158
Understanding the risks for the critically
ill patient
S159
Navigating the evolving landscape of Grampositive resistance in Europe from a patient
perspective
Miguel Sánchez García (Madrid, ES)
S160
The role of the microbiologist in clinical
decision making
Juan Picazo (Madrid, ES)
S161
Current strategies for managing serious
Gram-positive infections
Matteo Bassetti (Genoa, IT)
S162
Optimising patient outcomes – fast forward
to the future of treating serious Gram-positive
infections
Summary
Sunday, 8 May
Lecture Hall New updates on the management of MRSA
Brown 2 nosocomial infection
09:00 – 11:00 Pfizer chair: Robert Masterton (Ayr, UK);
ESCMID/ISC chair: Teresita Mazzei (Florence, IT)
S163
Gram-negative resistance: new beta-lactamases
and testing methods for detection
David Wareham (London, UK)
S164
New advances in virological monitoring of
herpes viruses in solid organ transplantation
Tiziana Lazzarotto (Bologna, IT)
S171
IV to oral switch and early discharge from
the hospital
Matthew Dryden (Winchester, UK)
S165
HBsAg mutants in routine diagnostic:
impact and consequence
Jens Verheyen (Cologne, DE)
S172
S166
The critical role of the laboratory in the
management of infectious disease
Katherine Soreng (Los Angeles, US)
Nosocomial pneumonia: an enduring
challenges for the physician. Is vancomycin
still the gold standard?
Robert Masterton (Ayr, UK)
S173
Update on guidelines for the treatment
of MRSA nosocomial pneumonia
Hartmut Lode (Berlin, DE)
S174
New evidence in the treatment of MRSA
pneumonia: results from a new randomised
clinical trial
Siemens Healthcare
Robert Masterton, Teresita Mazzei
(Kilmarnock, UK; Florence, IT)
Lecture Hall Current and future perspectives in clinical
Amber 4 diagnosis of viral, bacterial, parasites and
09:00 – 11:00 fungal pathogens using a unique multiplexing
technology
Luminex chair: Eugene Halligan (London, UK);
ESCMID/ISC chair: Raúl Ortiz de Lejarazu
(Valladolid, ES)
S167
S168
Challenges and new developments in diagnosing
gastro-enteritis using multiplex PCR
Eric Claas (Leiden, NL)
Multiplexing a necessary strategy for
diagnoses of gastro-enteritis and other
infections
Jonas Blomberg (Uppsala, SE)
S169
New technology challenges for old diseases
Rolf Kaiser (Cologne, DE)
S170
A novel liquid suspension based assay for
rapid identification of fungi
Arun Balajee (Atlanta, US)
Integrated symposium arranged by Luminex
Lecture Hall New challenges for the infectious disease
Amber 1 laboratory
09:00 – 11:00 Siemens chair: Katherine Soreng (Los Angeles, US);
ESCMID/ISC chair: Fausto Baldanti (Pavia, IT)
Q&A session with panel discussion
Closing remarks
Integrated symposium organised by Pfizer
Keynote Lectures
Lecture Hall Challenges in making a TB vaccine
White 1 Chairperson: Daniele Cirillo (Milan, IT)
11:30 – 12:30
K175
Joel Ernst (New York, US)
Lecture Hall Prospects for the control of neglected tropical
White 2 diseases
11:30 – 12:30 Chairperson: Zeno Bisoffi (Verona, IT)
K176
David Molyneux (Liverpool, UK)
Final Programme
59
Sunday, 8 May
Lecture Hall Amoeba as genitor of new pathogenic
Amber 1 microorganisms
11:30 – 12:30 Chairperson: Gilbert Greub (Lausanne, CH)
K177
Lecture Hall The disease and death of Enrico Caruso,
Silver Italian tenor
11:30 – 12:30 Chairperson: Alasdair Geddes (Birmingham, UK)
K178
Lecture Hall Pro versus Con: guideline vs. clinical practiceBrown 1 driven strategies in treating severe infectious
11:30 – 12:30 diseases
Chairpersons: Silvano Esposito (Naples, IT);
S183
11:30 Guidelines are essential for treatment and
diagnosis
Erdal Akalin (Istanbul, TR)
S184
12:00 Nothing can replace clinical judgement
Ben de Pauw (Nijmegen, NL)
Lecture Hall The year in infectious diseases
Brown 2 Chairperson: Ercole Concia (Verona, IT)
11:30 – 12:30
S185
11:30 The year in infectious diseases (1)
S186
12:00 The year in infectious diseases (2)
Official Symposia
Lecture Hall Antifungal drugs make me mad:
White 3 candins or azoles
11:30 – 12:30 Chairpersons: Mario Venditti (Rome, IT);
Andrew Ullmann (Mainz, DE)
S179
11:30 Candins
Bart-Jan Kullberg (Nijmegen, NL)
S180
12:00 Azoles
John Rex (London, UK)
Oral Sessions
Lecture Hall Biofilm: from pathogenesis to preventive
Amber 2 measures
11:30 – 12:30 Chairpersons: Helen Leavis (Utrecht, NL);
O187
11:30 Modelling of controlled biofilm infection using
rats with totally implantable port access
intravenous catheter
A. Chauhan*, D. Lebeaux, I. Kriegel, B. Decante,
J.-M. Ghigo, C. Beloin
(Paris, Le Plessis Robinson, FR)
O188
11:42 Multidrug-resistance efflux pumps are required
for biofilm formation of Salmonella enterica
serovar typhimurium
S. Baugh*, M.A. Webber (Birmingham, UK)
O189
11:54 Lysogenic phages promote pneumococcal
biofilm development
M. Carrolo, M.J. Frias, F.R. Pinto, J. Melo-Cristino,
M. Ramirez* (Lisbon, PT)
Lecture Hall Viral resistance testing – where are we?
Amber 4 Chairpersons: Giovanni Di Perri (Turin IT);
11:30 – 12:30
Christelle Desnues (Marseille, FR)
S181
11:30 European HIV Drug Resistance Guidelines –
update
Anne-Mieke Vandamme (Leuven, BE)
S182
12:00 Hepatitis B viral resistance testing
Jean-Michel Pawlotsky (Paris, FR)
60
Final Programme
Sunday, 8 May
O191
12:06 HWP1 gene polymorphism in Candida albicans
isolates from bloodstream infections:
a possible role in biofilm formation?
E. Borghi*, C. Biassoni, L. Cappelletti, R. Sciota,
D. Cirasola, L. Vizzini, C.F. Orsi, G. Morace (Milan, IT)
Poster Session II
12:18 Characterisation of accumulation-associated
protein interaction partners involved in
Staphylococcus epidermidis biofilm formation
M. Michel, C. Burdelski, R. Decker, G. Franke,
M. Christner, H. Rohde* (Hamburg, DE)
Topics
P821 – P854
P855 – P895
P896 – P901
P902 – P919
Lecture Hall Antimicrobial activity of different antibiotics
Amber 3 alone or in combination against MDR Gram11:30 – 12:30 negative rods
Chairpersons: Derek Brown (Peterborough, UK);
Carmen Torres (Logrono, ES)
O192
11:30 The effect of NaCl on carbapenem susceptibility
in Acinetobacter baumannii
E. Zander*, H. Seifert, P.G. Higgins (Cologne, DE)
O193
11:42 In vitro activity of doripenem in combination
with polymyxin against multidrug-resistant
J. Teo*, T. Lim, W. Lee, S. Sasikala, D.Q. Chia,
L.Y. Hsu, T.T. Tan, A.L. Kwa (Singapore, SG)
O194
11:54 Antimicrobial activity of telavancin combined
with low-dose colistin versus multidrugresistant strains of Acinetobacter baumannii
M. Hornsey*, N. Gordon, L. Phee, C. Longshaw,
D. Wareham (London, Staines, UK)
O195
12:06 Activity of polymyxin B and rifampin against
Acinetobacter baumannii in suspension and
biofilm
C. Speil, R. Rzepka, N. Khardori* (Springfield, US)
O196
12:18 The in vitro antimicrobial effect of colistin
alone and in combination, against clinical
isolates of multidrug-resistant Pseudomonas
aeruginosa
F. M Zali*, L. Thabet, C. André, V. Dubois,
F. Mégraud, C. Quentin (Bordeaux, FR; Tunis, TN)
P920 – P935
P936 – P942
P943 – P957
P958 – P974
P975 – P984
P985 – P989
P990 – P1029
P1030 – P1041
P1042 – P1048
P1049 – P1067
P1068 – P1074
P1075 – P1096
P1097 – P1108
MRSA: trend, surveillance, genetic characterisation
Travel medicine: tropical and parasitic diseases
MRSA in animals
Molecular tools for Staphylococcus aureus:
from epidemiology to diagnosis
Enterococci
Coagulase-negative staphylococci
AMR in Gram-positives
Pneumococci
Streptococci: from diagnosis to pathogenesis
AMR in fastidious micro-organisms
Emerging infectious diseases
Detection of resistance in Gram-positive bacteria
Antimicrobial resistance
New insights in mechanisms of resistance in
Experimental treatments in vivo
Miscellaneous infections
Miscellaneous antimicrobial resistance
Final Programme
61
O190
Sunday, 8 May
Poster Session III
Keynote Lectures
Lecture Hall Antibiotic resistance: back to the bigger circle
White 3 Chairperson: Fernando Baquero (Madrid, ES)
14:30 – 15:30
Topics
P1109 – P1113 Reporting nosocomial infections – Where are we?
P1114 – P1118 Risk factors for nosocomial infections:
how many are modifiable?
P1119 – P1128 Tigecycline
P1129 – P1152 New antimicrobials in vitro activity
P1153 – P1159 New non-conventional antimicrobials (no drugs)
P1160 – P1168 New targets for new antimicrobials
P1169 – P1176 Antimicrobial activity of different antibiotics
alone or in combination against MDR Gramnegative rods
P1177 – P1184 Carbapenems
P1185 – P1189 Quinolones
P1190 – P1199 H1N1
P1200 – P1212 HAI and environmental contamination
P1213 – P1231 Nosocomial infection
P1232 – P1243 Outbreaks
P1244 – P1254 MRSA – colonisation and screening
P1255 – P1273 Measuring and influencing community
antibiotic use
P1274 – P1299 Antibiotic use, stewardship and resistance in
the hospital: optimising outcomes
P1300 – P1314 Surveillance systems
P1315 – P1339 Infection control
P1340 – P1378 Epidemiology of antimicrobial resistance
P1379 – P1388 Hand hygiene
K198
Stuart B. Levy (Boston, US)
Presentation of the
ISC Hamao Umezawa
Memorial Award
Lecture Hall Metagenomics and detection of new viruses
Amber 4 Chairperson: Massimo Clementi (Milan, IT)
14:30 – 15:30
K199
Christelle Desnues (Marseille, FR)
Lecture Hall Experience from humanitarian intervention
White 1 in Haiti
14:30 – 15:30 Chairperson: tbc
K200
Renaud Piarroux (Marseille, FR)
Award Lecture
Official Symposia
Lecture Hall ESCMID Excellence Award lecture
Silver Chairperson: Giuseppe Cornaglia (Verona, IT)
14:30 – 15:30
K197
Vaccines, medicine and public
health in the XXI century
Rino Rappuoli (Siena, IT)
Lecture Hall The year in infection control
White 2 Chairperson: Andreas F. Widmer (Basel, CH)
14:30 – 15:30
S202
14:30 The year in infection control (1)
Marc J. Bonten (Utrecht, NL)
S203
15:00 The year in infection control (2)
Lecture Hall Are probiotics growth promoters in humans?
Amber 1 Chairpersons: Eduard Stange (Stuttgart, DE);
14:30 – 15:30
Gianfranco Donelli (Rome, IT)
62
Final Programme
S204
14:30 No
Yolanda Sanz (Valencia, ES)
S205
15:00 Yes
Sunday, 8 May
S206
14:30 Global perspectives and policies
Marcel Tanner (Basel, CH)
S207
15:00 Vaccines
Pedro Alonso (Barcelona, ES)
Lecture Hall Antifungal management strategies
Brown 2 Chairpersons: Peter Donnelly (Nijmegen, NL);
14:30 – 15:30
John Rex (London, UK)
S208
14:30 The ICU patient
Thierry Calandra (Lausanne, CH)
S209
15:00 The haematological patient
Johan Maertens (Leiden, NL)
Oral Sessions
Lecture Hall Molecular bacteriology: insight in the virulence
Amber 2 of Gram-positive cocci
14:30– 15:30 Chairpersons: Annalisa Pantosti (Rome, IT);
François Vandenech (Lyon, FR)
O210
O211
O212
14:30 The contribution of bacterial virulence to
the clinical course of Staphylococcus aureus
bloodstream infection
S. McNicholas*, A. FeTalento, J. O'Gorman,
M. Hannon, M. Lynch, A. Shore, D. Coleman,
H. Humphreys, D. Fitzgerald-Hughes (Dublin, IE)
14:42 Correlation between bacterial DNA load and
severity of disease in S. aureus bacteraemia
W. Rozemeijer*, A.E. Nieman, R.P.H. Peters,
J. Kluytmans, P.H. Savelkoul, R.P. Schade
(Amsterdam, NL; Tzaneen, ZA)
O213
15:06 Invasive infections caused by a novel species
within the Streptococcus mitis group
A. Zbinden*, N.J. Müller, P.E. Tarr, P.M. Keller,
G.V. Bloemberg (Zurich, Basel, CH)
O214
15:18 Fitness cost of widely disseminated conjugative
plasmids carrying Tn1546-vanA among
Enterococcus faecium and Enterococcus
faecalis
A.P. Tedim*, A.R. Freitas, F. Baquero, T.M. Coque
(Madrid, ES; Oporto, PT)
Lecture Hall Genetics of NDM-1
Amber 3 Chairpersons: Laurent Poirel (Paris, FR);
14:30 – 15:30
Timothy R. Walsh (Cardiff, UK)
O215
14:30 Complete DNA sequence of blaNDM-1 gene
cassette integrated into the chromosome
of Acinetobacter baumannii
Y. Pfeifer, E. Zander, S. Göttig, K.P. Hunfeld,
H. Seifert, P.G. Higgins*
(Wernigerode, Cologne, Frankfurt, DE)
O216
14:42 Diversity of genetic structures at the origin
of acquisition and expression of the blaNDM-1
carbapenemase gene
L. Poirel*, R. Bonnin, L. Villa, A. Carattoli,
P. Nordmann (Le Kremlin-Bicêtre, FR; Rome, IT)
O217
14:54 Whole genome sequencing of NDM-1-producing
Escherichia coli: focus on antibiotic resistance
L. Poirel*, R. Bonnin, P. Nordmann
(Le Kremlin-Bicêtre, FR)
O218
15:06 Spread of blaNDM-1 gene identified in
enterobacterial isolates in Switzerland:
a molecular analysis
L. Poirel*, J. Schrenzel, A. Cherkaoui, S. Bernabeu,
P. Nordmann (Le Kremlin-Bicêtre, FR; Geneva, CH)
O219
15:18 A novel ICE mobilising DHA-1 in NDM-1 harbouring
clinical isolates of E. coli and Klebsiella
C. Mata, J. Weeks, T. Walsh, M. Toleman*
(Barcelona, ES; Cardiff, UK)
14:54 The distribution of enterotoxin and immune
evasion cluster genes among Staphylococcus
aureus isolates causing bloodstream infection
S. McNicholas, A. FeTalento, J. O'Gorman,
M. Hannon, M. Lynch, A. Shore, D. Coleman,
H. Humphreys, D. Fitzgerald-Hughes* (Dublin, IE)
Final Programme
63
Lecture Hall Eradication of malaria
Brown 1 Chairpersons: Colin Sutherland (London, UK);
14:30 – 15:30
Giovanni Di Perri (Turin, IT)
Sunday, 8 May
Official Symposia
Lecture Hall European preparedness and response to
White 2 highly infectious diseases
16:00 – 18:00 Chairpersons: Mauro Moroni (Milan, IT);
S220
16:00 How will the 21st century outbreak look like?
Barbara Bannister (London, UK)
S221
16:30 Networking approach in the face of highly
infectious diseases
Giuseppe Ippolito (Rome, IT)
S222
17:00 Management of highly pathogenic infectious
diseases in Europe – a EUNID recommendation
Philippe Brouqui (Marseille, FR)
S223
17:30 The role of ECDC in preparedness and
response to highly infectious diseases
Denis Coulombier (Stockholm, SE)
Lecture Hall The role of PK/PD for choosing antifungal drugs
White 3 Chairpersons: Andrea Novelli (Florence, IT);
16:00 – 18:00
S224
16:00 In vitro antifungal activity: importance and limits
Giulia Morace (Milan, IT)
S225
16:30 PK/PD of antifungal drugs: do we have
sufficient knowledge?
S226
17:00 Therapeutic drug monitoring and antifungal
drugs: where are we today?
Oscar Marchetti (Lausanne, CH)
S227
17:30 Combination therapy: do PK/PD concepts apply?
Lecture Hall The future of hospital antibiotic stewardship –
Silver What should we achieve by 2020?
16:00 – 18:00 Chairpersons: Leonardo Pagani (Bolzano, IT);
Lance Peterson (Chicago, US)
S232
16:00 Computerised decision support systems
Karin Thursky (Melbourne, AU)
S233
16:30 Interactive E-learning
S234
17:00 Rapid DNA-based tests
Surbhi Malhotra-Kumar (Antwerp, BE)
S235
17:30 Biomarkers: anything beyond PCT?
Miriam Christ-Crain (Basel, CH)
Oral Sessions
Lecture Hall Influenza H1N1 pandemic and complications
Amber 3 Chairpersons: Laurent Kaiser (Geneva, CH);
16:00 – 18:00
Jake Dunning (London, UK)
O236 16:00 Aetiology of community-acquired pneumonia
in the adult and the H1N1 influenza pandemic
A. San Gil*, A. Robles, V. Pascual, E. Calbo,
E. Viladot, S. Benet, B. Barreiro, E. Cuchi, J. Torres,
L. Canales, J. De Marcos, J. Perez, J. Garau
(Barcelona, ES)
O237
16:12 Vaccination against pandemic influenza
A/H1N1(2009) among healthcare workers:
lessons for the next pandemic
A. Azap*, G. Yilmaz-Bozkurt, M. Bayrak,
G. Aksoy, N. Bagid, A. Bayat, A. Bozkurt, B. Çakir,
F. Temel, S. Tezcan (Ankara, TR)
O238
16:24 The impact of European vaccination policies
on seasonal influenza vaccination coverage
rates in the elderly
P.R. Blank*, M. Schwenkglenks, T.D. Szucs
(Zurich, Basel, CH)
O239
16:36 Influenza vaccination of healthcare workers:
a case-control study of its effect on
laboratory-confirmed, hospital-acquired
influenza among patients
T. Bénet*, C. Régis, N. Voirin, O. Robert, B. Lina,
S. Cronenberger, P. Vanhems (Lyon, FR)
O240
16:48 Assessment of the frequency of emergence
of oseltamivir resistance in influenza A during
therapy
T. Barkham*, K.P. Toh, M.L. Goh, W.Y. Tang,
Y.S. Leo, M. Inoue (Singapore, SG)
arranged with the ISC Working Group on
Pharmacokinetics/Pharmacodynamics
Lecture Hall Antibiotic combination interactions
Amber 2 Chairpersons: Jon Cohen (Brighton, UK);
16:00 – 18:00
S228
16:00 When two is better than one
Jordi Rello (Barcelona, ES)
S229
16:30 When no clues indicate amelioration by
combination therapy
S230
17:00 Quantitative assessment and mathematical
modelling
Vincent Tam (Houston, US)
S231
17:30 Antibiotic combination in the critical patient
Pierluigi Viale (Bologna, IT)
64
Final Programme
O241
17:00 Hospitalised patients with pandemic influenza
A/H1N1 virus infection had similar outcomes
independently of hospital characteristics
M. Gutierrez-Cuadra, J.L. Gonzalez,
P. Rodriguez-Cundin, C. Fariñas-Alvarez ,
J.A. Parra, V. Sanjuan, A. Arnaiz, M. Carrrascosa,
G. Santiago, J.D. García-Palomo, M.C. Fariñas*
(Santander, Torrelavega, Laredo, ES)
O242
17:12 How many lives were saved during the A/H1N1
pandemic in 2010 in Europe?
R.N. Charrel*, H. Richet, D. Raoult (Marseille, FR)
O243
17:24 Pandemic influenza A/H1N1 vaccine in solid
organ transplant recipients: immunogenicity
outcomes after whole virus vaccination
H. Lagler*, J. Leitner, S. Tobudic, G. Andrés Gualdoni,
S. Rödler, S. Rockenschaub, P. Jaksch,
M. Redelberger-Fritz, T. Popow-Kraupp,
H. Burgmann (Vienna, AT)
O244
O245
17:36 Immunogenicity, efficacy, and safety of the
pandemic influenza A/H1N1 vaccine in solid
organ transplant recipients
E. Cordero, A. Perez-Ordoñez*, T. Aydillo,
J. Pachón, J. Torre-Cisneros, J. Gavaldá,
A. Gasch, R. Lara, C. Segura, E. Cabral, O. Len,
P. Perez-Romero the Novel Influenza A(H1N1)
Study Group of the Spanish Network for
Research in Infectious Diseases (REIPI)
17:48 Immunogenicity and evaluation of antibodies
persistence of a single-shot of 2009 pandemic
influenza vaccine in HIV-infected and HIVuninfected subjects living in a residential
drug-rehabilitation community
E. Pariani*, A. Boschini, A. Amendola, R. Poletti,
M. Begnini, G. Cecconi, A. Zanetti (Milan, Rimini, IT)
Lecture Hall Mycobacterial disease to Epi and beyond
Amber 4 Chairpersons: Mircea Ioan Popa (Bucharest, RO);
16:00 – 18:00
Po-Ren Hsueh (Taipei City, TW)
O246 16:00 Extensively drug-resistant tuberculosis at a
tuberculosis specialised hospital in Shanghai,
China: clinical characteristics and treatment
outcomes
S. Tang*, Q. Zhang, J. Yu, Y. Liu, W. Sha, H. Sun,
L. Fan, J. Gu, X. Hao, L. Yao, H. Xiao (Shanghai, CN)
O247
16:12 Pulmonary and extrapulmonary infections
caused by non-tuberculous mycobacteria:
report of 31 years in a tertiary hospital,
Madrid, Spain
G. Gabilondo*, M.A. Meseguer, R. del Campo,
P. Martin-Davila, J. Fortun, E. Navas, L. Ros,
R. Cantón, E. Gomez-Mampaso (Madrid, ES)
O248
16:24 Novel small RNAs in Mycobacterium
tuberculosis: experimental genome-wide
discovery and computational target prediction
P. Miotto*, A. Ambrosi, D. Pellin, D. Veiga, F. Forti,
G. Balazsi, M.L. Gennaro, C. Di Serio, D. Cirillo
(Milan, IT; Houston, Newark, US)
O249
16:36 Clinical characteristics and treatment
outcomes of tuberculosis in hospitals of
two large cities in Thailand
W. Manosuthi*, K. Kawkitinarong,
G. Suwanpimolkul, C. Chokbumrungsuk,
T. Jirawattanapisal, K. Ruxrungtham,
S. Akksilp (Nonthaburi, Bangkok, TH)
O250
16:48 Optimisation of follow-up samples for patients
with pulmonary tuberculosis
M. Alfa*, K. Manickam, J. Karlowsky, H. Adam,
C. Harrop, A. Rendina (Winnipeg, CA)
O251
17:00 Population differences in immune responses
following BCG vaccination in different African
settings
J.R. Fitchett*, M.K. Lalor, A. Ben-Smith, A. Crampin,
P. Fine, M.O. Ota, S. Burl, K.L. Flanagan,
H.M. Dockrell
(London, UK; Karonga District, MW; Fajara, GM)
O252
17:12 Paradoxical worsening in the treatment of
tuberculosis after discontinuation of anti-TNF
in patients with inflammatory diseases
C. Rivoisy*, A. Bourgarit, O. Fain, X. Mariette,
N. De Castro, F. Tubach, D. Salmon Ceron
(Paris, Bondy, Le Kremlin-Bicêtre, FR)
O253
17:24 IGRAs on paper – specific diagnosis of latent
TB sent via mail
M. Ruhwald*, I. Latorre, J. Diez, J. Maldonado,
I. Mialdea, P. Ravn, J. Dominguez, M.G. Aabye
(Copenhagen, DK; Barcelona, Badalona,
Valencia, ES)
O254
17:36 Rapid detection and susceptibility testing of
Mycobacterium abscessus by microcalorimetry
N. Boillat Blanco*, U. Furustrand, K. Jaton,
A. Trampuz (Lausanne, CH)
O255
17:48 In vitro, ex vivo and in vivo studies indicate
that the neuroleptic thioridazine cures
multidrug-resistant tuberculosis
L. Amaral*, E. Abbate, M. Boeree, S. Gillespie,
R. Thanacoody, Z. Udwadia, J. van Ingen,
D. van Soolingen, M. Viveiros
(Lisbon, PT; Buenos Aires, AR; Nijmegen, NL;
London, Newcastle-upon-Tyne, UK;
Mumbai, IN; Bilthoven, NL)
Final Programme
65
Sunday, 8 May
Sunday, 8 May
Integrated Symposia
Lecture Hall Bad bugs need better drugs: addressing the
White 1 global challenge
16:00 – 18:00 AstraZeneca chair: Antoni Torres (Barcelona, ES)
ESCMID/ISC chair: Christian Giske (Stockholm, SE)
Antoni Torres, Christian Giske (Barcelona, ES;
Stockholm, SE)
S256
16:05 Resistance: what’s our means of ESKAPE?
Matthew Dryden (Winchester, UK)
S257
16:25 Get it right first time: optimal management
of infections in an era of increasing resistance:
Focus on complicated skin and soft tissue
infections
Peter Kujath (Lübeck, DE)
Lecture Hall Bad bugs, which drugs? Superior potency for
Brown 1 better outcomes in Gram-positive infections
16:00 – 18:00 Novartis chair: Paolo Grossi (Milan, IT)
ESCMID/ISC chair: Harald Seifert (Cologne, DE)
Introduction
Paolo Grossi, (Milan, IT)
S264
Applied microbiology: the importance of
potency
David M. Livermore (London, UK)
S265
Hit hard, hit early to improve outcomes in
Gram-positive bacteraemias
Alex Soriano (Barcelona, ES)
S266
Challenges of treating cSSTIs, biofilms and
secondary complications
Matteo Bassetti (Genoa, IT)
Panel discussion and closure
Harald Seifert (Cologne, DE)
16:45 Focus on community-acquired bacterial
pneumonia
S258
17:05 Is just enough, good enough? Challenges
faced in the search for added value
S259
17:25 The search for new tools: the R&D challenge
John Rex (Boston, US)
Integrated symposium arranged by Novartis
Lecture Hall Pneumococcal disease in adults:
Brown 2 a remaining challenge
16:00 – 18:00 Pfizer chair: Murat Akova (Ankara, TR)
ESCMID/ISC chair: Nicola Petrosillo (Rome, IT)
17:45 Panel Q&A
Integrated symposium organised by
AstraZeneca
Lecture Hall Diagnosis of bloodstream infections (BSI):
Amber 1 present and future
16:00 – 18:00 bioMérieux chair: Emmanuelle Cambau (Paris, FR)
ESCMID/ISC chair: Jos van der Meer (Nijmegen, NL)
S260
Sepsis: a clinical challenge
Pierre-François Laterre (Brussels, BE)
S261
Blood culture collection: how can best
practices impact diagnosis?
S262
What role for biomarkers in BSI management?
S263
Will new diagnostic solutions help meet the
challenges of sepsis?
bioMérieux
66
Final Programme
Murat Akova, Nicola Petrosillo (Ankara, TR; Rome, IT)
S267
Pneumococcal disease in adults:
an open challenge
S268
Diagnosis of pneumococcal disease and CAP
aetiology: an underestimated disease
Mary Slack (Oxford, UK)
S269
Understanding the adult immune response to
vaccination
Beharzine Combadière (Paris, FR)
Closing remarks
Integrated symposium arranged by Pfizer
Monday, 9 May
Lecture Hall Controversies in antiparasitic chemotherapy
White 2 Experts: Eskild Petersen (Aarhus, DK);
07:45 – 08:45
Thomas Junghanss (Heidelberg, DE)
E270
Objectives
• To define indications for artemisinin-based
antimalarial (combination) treatment
What is new after SEAQUAMAT and AQUAMAT,
the two milestones in assessing the impact
of parenteral artesunate on mortality in patients with severe malaria?
What are the implications for treating severe
malaria in Europe?
• To define indications for the four treatment
modalities of cystic echinococcosis, including
albendazole
What is the evidence base for treating CE with
albendazole? Who benefits from this treatment? What are the risks? What are the alternatives?
• To define indications for chemotherapy for
congenital toxoplasmosis
When is treatment needed and what drugs do
we have?
For how long should we treat, and what is the
evidence that treatment prevent later relapses?
• To define the use of nitazoxanide
Nitazoxanide has effect on helminthes and
protozoa in particular cryptosporidia. When to
use nitazoxanide?
Effect on Giardia resistant to other drugs?
Potential side effects?
Lecture Hall Surgical site infections, how can we prevent
Amber 2 them, an evidence based approach
07:45 – 08:45 Experts: Souha Kanj (Beirut, LB);
E272
Lecture Hall Impossible-to-treat Gram-negative infections
Amber 3 Experts: Yehuda Carmeli (Tel Aviv, IL);
07:45 – 08:45
Matthew Falagas (Athens, GR)
E273
Lecture Hall Current issues on the detection of
Amber 1 carbapenem-resistant Gram-negative bacteria
07:45 – 08:45 Experts: Stefania Stefani (Catania, IT);
Athanassios Tsakris (Athens, GR)
Objectives
• To review mechanisms of carbapenem
resistance and the clinical importance to
detect major types of carbapenemases
• To discuss selection criteria of bacterial
isolates and current problems in the
detection of carbapenemases
• To review methods for phenotypic detection
of different types of carbapenemases
• To highlight the need of appropriate methods
for screening carriers of carbapenemases
and evaluate the current experience
Objectives
• To highlight the difficult-to-treat Gramnegative bacterial infections
• To present data on their attributable mortality
• To review the available treatment options
• To evaluate modern therapeutic strategies
including aerosolised antibiotics
• To discuss advantages and disadvantages
for emerging therapeutic approaches based
on PK/PD data
Lecture Hall Infection control for neutropenic cancer
Amber 4 patients
07:45 – 08:45 Experts: Jean Klastersky (Brussels, BE);
E274
E271
Objectives
• To describe the burden of surgical site
infections (SSI) on patients’ outcome
• To identify the risk factors predisposing to SSI
• To describe steps to minimise the risk of SSI
(endogenous and exogenous)
• To define examples of how health-care
workers can intervene to lower the rates
of infections
Objectives
• To discuss the implications of current evidence
on air quality control and barrier isolation
• To define indications for antibiotic prophylaxis
in the era of multidrug resistant bacteria
• To discuss the evidence on neutropenic
diet and future research design
Lecture Hall Zygomycosis: an emerging fungal infection
Brown 2 Experts: George Petrikkos (Athens, GR);
07:45 – 08:45
Arunaloke Chakrabarti (Chandigarh, IN)
E275
Objectives
• To present an update of the global epidemiology
of mucormycosis
• To review the clinical presentation and
highlight the new clinical type (renal)
• To outline recent advances in pathogenesis
of the disease
• To underline the main problems regarding
diagnosis of the disease and provide
recommendations regarding its treatment
Final Programme
67
Monday, 9 May
Official Symposia
S286
10:00 Use of next generation sequencing in
epidemiology
Lori Snyder (Edgbaston, UK)
Lecture Hall Pathogenesis of Chlamydia infections
Amber 4 Chairpersons: Carlo Contini (Ferrara, IT);
09:00 – 11:00
Johannes Hegemann
(Düsseldorf, DE)
S287
10:30 Possible use of next generation sequencing in
routine clinical microbiology
Maria R. Capobianchi (Rome, IT)
S276
S277
S278
S279
09:00 Adhesion: a crucial step for chlamydial
virulence
Johannes Hegemann (Düsseldorf, DE)
09:30 Subversion of the structure and function
of the Golgi of the host cell by Chlamydia
trachomatis
Thomas F. Meyer (Berlin, DE)
10:00 Pathogenesis and evolution of Chlamydia:
lessons from genomics of novel chlamydiae
10:30 Immunogenetics: why do not all women
become infertile following chlamydial
infection?
Servaas Morré (Amsterdam, NL)
Oral Sessions
Lecture Hall Clinical and microbiological update on
White 3 antibiotic-resistant P. aeruginosa
09:00 – 11:00 Chairpersons: Marek Gniadkowski (Warsaw, PL);
O288 09:00 Pseudomonas aeruginosa carbapenem
resistance mechanisms in Spain: impact
on the activity of imipenem, meropenem,
and doripenem
E. Riera*, G. Cabot, C. Juan, M. García-Castillo,
R. del Campo, R. Cantón, A. Oliver
(Palma de Mallorca, Madrid, ES)
O289
Lecture Hall Antimicrobial stewardship works –
Brown 1 Why isn't it widely practiced?
09:00 – 11:00 Chairpersons: Dilip Nathwani (Dundee, UK);
Jesús Rodriguez-Baño (Sevilla, ES)
S280 09:00 Antimicrobial stewardship: Where we are?
World initiatives inventory
Gabriel Levy Hara (Buenos Aires, AR)
S281
09:30 Successful strategies and campaigns to
improve outpatient antibiotic usage
S282
10:00 The antibiotic paradox; are new antibiotics
the answer?
Jim Hutchinson (Victoria, CA)
S283
10:30 Why is stewardship not widely practiced?
Lecture Hall Next generation sequencing and clinical
Silver microbiology
09:00 – 11:00 Chairpersons: Giovanni Fadda (Rome, IT);
S284
09:00 Next generation DNA sequencing techniques
Wilhelm Ansorge (Lausanne, CH)
S285
09:30 Use of next generation sequencing in
microbiological research (pathogenesis)
Lars Engstrand (Stockholm, SE)
68
Final Programme
09:12 IMP-29, a novel metallo-beta-lactamase in
Pseudomonas aeruginosa
K. Jeannot*, M. Robert Nicoud, P. Plésiat
(Besançon, FR)
O290 09:24 Carbapenem-resistant Pseudomonas
aeruginosa after short exposure to
therapeutic concentrations of ertapenem
S.J. Vainio*, M.L. Schepens, A. Wilhelm,
C.M. Vandenbroucke-Grauls, J.L. Murk,
Y.J. Debets-Ossenkopp (Amsterdam, NL)
O291 09:36 Exposure of Pseudomonas aeruginosa to subMIC concentrations of chlorhexidine leads
to increased resistance, marked phenotypic
changes, overexpression of MexG, and crossresistance to antipseudomonal antibiotics
Q. Tan, T. Nguyen*, F. Bilocq, D. De Vos, J. Pirnay,
P. Cornelis, F. Van Bambeke, P. Tulkens (Brussels, BE)
O292 09:48 Levofloxacin-doripenem combination prevents
emergence of resistance among Pseudomonas
aeruginosa expressing mechanisms of resistance
impacting susceptibility to one or both drugs
in the combination
P. Lister (Omaha, US)
O293 10:00 Linear increasing of resistance rates to
nine antibiotics of Pseudomonas aeruginosa
strains within a nosocomial outbreak
J.L. Navarro*, A. Somodevilla, M. Espínola,
N. Arenal, M.J. Moreno, T. Alarcón, M. López-Brea
(Madrid, ES)
Monday, 9 May
10:12 Antibiotic resistance trends of Pseudomonas
aeruginosa and Acinetobacter spp. isolates at
a teaching hospital in Istanbul, 2004–2010
S. Senbayrak Akcay, A. Inan*, S. Aksaray,
S. Cevan, M. Kücükercan (Istanbul, TR)
O295
10:24 Characterisation of resistance mechanisms in
clinical isolates of Pseudomonas aeruginosa
with reduced susceptibility to carbapenems
M. Íñigo*, A. Ocampo-Sosa, G. Martínez de Tejada,
M. Fernández-Alonso, E. Román, J. Leiva,
L. Martínez-Martínez (Pamplona, Santander, ES)
O296 10:36 Wide dispersion of ST175 clone despite a
high-genetic diversity of carbapenemnon-susceptible Pseudomonas aeruginosa
clinical strains from 16 Spanish hospitals
M. Garcia-Castillo*, R. del Campo, M. Morosini,
E. Riera, G. Cabot, A. Oliver, R. Cantón
(Madrid, Palma de Mallorca, ES)
O297
10:48 Comparison of chromogenic and selective
media for the detection of Staphylococcus
aureus and Pseudomonas aeruginosa in
respiratory samples from cystic fibrosis
patients
A. Nobre Machado*, C. Nonhoff, S. Roisin,
A. Vergison, F. Van Bambeke, N. Legros, G. Hay,
P. Buidin, C. Thiroux, O. Denis (Brussels, BE)
Lecture Hall Tracking antibiotic-resistance in GramAmber 2 positive cocci
09:00 – 11:00 Chairpersons: Angelo Pan (Cremona, IT);
Heidi Ammerlaan (Utrecht, NL)
O298 09:00 Colonisation and transmission of resistant
bacteria in 13 European intensive care units
L.P. Derde*, M.J. Dautzenberg, P.J. van Duijn,
C. Brun-Buisson, M.J. Bonten on behalf of
MOSAR research consortium
O299
09:12 Emergence and evolution of heteroresistant
vancomycin intermediate Staphylococcus
aureus in a single hospital over a 12-year period
S.J. van Hal*, T. Barbagiannakos, J. Mercer,
D. Chen, I.B. Gosbell, D.L. Paterson (Sydney, AU)
O300 09:24 Tracking antibiotic resistance along the Silk
Road
S. Quinteira, C. Novais*, P. Antunes, J. Campos,
A.R. Freitas, A. Abdukadir, N. Monteiro, L. Peixe
(Vila Nova de Famalicão, Porto, PT; Urumqi, CN)
O301 09:36 Spread of vancomycin-resistance among
Enterococcus faecalis: the influence of pAD1
and Inc18-plasmids (1987–2005)
A.R. Freitas, P. Ruiz-Garbajosa, M.V. Francia,
C. Novais, M.J. Zervos, S. Donabedian, L. Peixe,
F. Baquero, T.M. Coque* (Porto, PT; Madrid,
Santander, ES; Detroit, US)
O302 09:48 Emergence of MRSA ST130 in humans
C. Cuny*, F. Layer, W. Witte (Wernigerode, DE)
O303 10:00 High prevalence of EMRSA-15 in Portuguese
public buses: a worrisome finding
M. Aires-de-Sousa*, R.R. Simões, T. Conceição,
F. Antunes, P. Martins da Costa, H. de Lencastre
(Lisbon, Porto, Oeiras, PT; New York, US)
O304
10:12 Epidemiology of invasive group A streptococci
in Canada from 2000–2009
J.N. Kanji*, M. Lovgren, D.E. Low, L. Hoang,
A. Bougault, P. Van Caeseele, G.B. Horsman,
G.J. Tyrrell (Edmonton, Toronto, Vancouver,
Sainte-Anne-de-Bellevue, Winnipeg, Regina, CA)
O305
10:24 Prevalence and molecular characteristics
of MRSA colonisation among adult patients
visiting emergency department in a medical
centre in northern Taiwan
S.-Y. Lu, F.-Y. Chang*, C.-C. Cheng, K.-D. Lee,
Y.-C. Huang (Kuei Shan Hsiang, TW)
O306 10:36 A case-control study comparing infections due
Staphylococcus aureus with Panton-Valentine
leucocidin (PVL) to those without PVL
P. Boan*, J. Pearson, G. Coombs, C.H. Heath,
H.L. Tan, K. Christiansen, J.O. Robinson (Perth, AU)
O307 10:48 Confounding in determining attributable
mortality of methicillin-resistant Staphylococcus
aureus bacteraemia: a meta-analytical approach
H. Ammerlaan*, M.J. Bonten (Utrecht, NL)
Lecture Hall Paediatric infections: preclinical and
Amber 3 clinical data
09:00 – 11:00 Chairpersons: Susanna Esposito (Milan, IT);
Carlos Rodrigo (Badalona, ES)
O308 09:00 Viral respiratory tract infection in preschool
children: the burden and impact of co-infection
Z. Wake, N. Conway, S. Williams, A. Keil, D. Smith,
P. Richmond, C. Blyth* on behalf of the WAIVE
study
O309
09:12 Influence of the respiratory virus species
and multiple viral infections on bronchiolitis
severity in hospitalised infants
L. Andreoletti*, A. Huguenin, F. Renois, D. Talmud,
L. Moutte, M. Abely, F. Carrat, N. Leveque
(Reims, Paris, FR)
Final Programme
69
O294
Monday, 9 May
O310
O311
O312
O313
O314
O315
O316
O317
09:24 Group C rotavirus infection and VP6 diversity
in children, Brazil 2007–2010: monitoring
a potential impact of rotavirus vaccination
programme
A. Luchs*, S. Morillo, C. Oliveira, M. Timenetsky
(São Paulo, BR)
09:36 Congenital CMV infection: clinical outcome
according to the serological status of the
mother
A. Naessens*, I. Foulon, A. Vorsselmans,
A. Jansen, M. Leyder, W. Foulon (Brussels, BE)
09:48 DEVANI UK clinical screening study for maternal
carriage of Streptococcus agalactiae
B. Afshar*, A. Vickers, K. Morton, E. Demertzi,
I. Hassan, S. Stock, J. Telford, G. Orefici,
A. Efstratiou (London, Guildford, Manchester,
Edinburgh, UK; Siena, Rome, IT)
10:00 Retrospective study of Staphylococcus
aureus bacteraemia in an Irish neonatal
intensive care unit: epidemiology, risk
factors and management
K.J. O' Connell*, K. Grundy, T. Clarke,
M. Cafferkey (Dublin, IE)
Integrated Symposia
Lecture Hall The growing challenges of multi-drug resistant
White 1 (MDR) Gram-negatives: what is your strategy
09:00 – 11:00 now?
Janssen chair: Helen Giamarellou (Athens, GR)
ESCMID/ISC chair: Rafael Cantón (Madrid, ES)
S318
The growing challenges of multi-drug resistant
(MDR) Gram negatives
Helen Giamarellou (Athens, GR)
S319
Optimising beta-lactams by maximizing PK/PD
(part I)
S320
Optimising beta-lactams by reducing
resistance development (part II)
Luis Martinez-Martinez (Santander, ES)
S321
Clinical strategies to tackle Gram-negative
infections
Discussion and questions
10:12 The prevalence of Helicobacter pylori cagA,
vacA, iceA, babA genotypes in Polish children
with gastroduodenal diseases: impact on
histology
M.M. Biernat*, B. Iwanczak, M. Rzeszutko,
J. Grabinska, P. Biernat, G. Gosciniak (Wroclaw, PL)
10:24 Outcome of prenatal toxoplasmosis:
retrospective analysis for effectiveness of
pyrimethamine/sulfadiazine therapy during
pregnancy
A. Hruzik, H. Hlobil, U. Groß*
(Göttingen, Sindelfingen, DE)
10:36 Clinical presentation and management of deep
neck infections in an Italian cohort of children
and adolescents
F. Mignone*, C. Bertaina, S. Garazzino, C. Scolfaro,
I. Raffaldi, F. Peradotto, C. Gabiano, P.A. Tovo
(Turin, IT)
10:48 Improving clinical quality and patient safety
in cystic fibrosis paediatric patients. First
multidisciplinary clinical audit at a large
district hospital of northwest England
R. Sharma*, E. Chang, S. See, A. Guleri
(Blackpool, Blackburn, UK)
Janssen
Lecture Hall Visceral leishmaniasis: an endemic disease
White 2 with global impact
09:00 – 11:00 Gilead chair: Olivier Lortholary (Paris, FR)
ESCMID/ISC chair: Robert N. Davidson (London, UK)
09:00 Welcome
Introduction
Robert N. Davidson (London, UK)
S322
09:15 Prevalence, therapeutic need and effect of
visceral leishmaniasis in developing countries
Jorge Alvar (Geneva, CH)
S323
09:45 The latest evidence from large scale clinical
trials
Shyam Sundar (Varanasi, IN)
S324
10:15 Visceral leishmaniasis – the European experience
Jean-Pierre Gangneux (Rennes, FR)
10:45 Panel discussion and Q&A session
10:55 Closing remarks
70
Final Programme
Monday, 9 May
S325
Streamlining the microbiology lab for improved
diagnostic utility
Anne Simon (Louvain, BE)
S326
Saving time in sepsis diagnostics – MALDI-TOF
MS for identification of bacteria and yeasts
from positive blood cultures
Sören Schubert (Munich, DE)
S327
Monitoring of bone and joint samples with last
generation automated blood culture systems:
faster and better
Martin Rothman, Aurélien Dinh (Paris, FR)
S328
New emerging resistances: challenges and
implications for efficient diagnosis and
effective treatment in critical patients
Gian Maria Rossolini, G. Tulli (Siena, Florence, IT)
BD Diagnostics
Keynote Lectures
Lecture Hall 150 years Semmelweis' publication on hand
White 3 hygiene – a historical perspective
11:30 – 12:30 Chairperson: Wolfgang Graninger (Vienna, AT)
K334
Official Symposia
Lecture Hall Influenza, the reward year of the new H1N1
Amber 2 Chairperson: Fausto Baldanti (Pavia, IT)
11:30 – 12:30
S335
11:30 Two world wide studies Flu1 and Flu2
Jens D. Lundgren (Copenhagen, DK)
S336
12:00 UK experience of serious H1N1 and
B influenza this winter
Jake Dunning (London, UK)
Lecture Hall Update on the management of fungal infections
Brown 2 Pfizer chair: Livio Pagano (Rome, IT)
09:00 – 11:00 ESCMID/ISC chair: Cornelia Lass-Flörl (Innsbruck, AT)
Livio Pagano, Cornelia Lass-Flörl
(Rome, IT; Innsbruck, AT)
S329
Invasive fungal infections from diagnosis to
treatment
Raoul Herbrecht (Strasbourg, FR)
S330
Is pre-emptive therapy a realistic approach?
Peter J. Donnelly (Nijmegen, NL)
S331
Treatment of invasive aspergillosis in haematological patients: from clinical trials to reallife
Livio Pagano (Rome, IT)
S332
Fungal infections in the ICU: invasive candidiasis
Markus. Ruhnke (Berlin, DE)
S333
Fungal infections in the ICU: invasive aspergillosis
Dirk Vogelaers (Ghent, BE)
Lecture Hall New molecular diagnostics for parasitic
Brown 1 diseases
11:30 – 12:30 Chairpersons: Titia Kortbeek (Bilthoven, NL);
François Peyron (Lyon, FR)
S337
11:30 Molecular versus microscopic diagnosis of
faecal parasites; the pros and cons
Lisette van Lieshout (Leiden, NL)
S338
12:00 Molecular diagnosis of blood and tissue
protozoa; time to discard the microscope
Colin Sutherland (London, UK)
Lecture Hall Hospitalised CAP – penicillin/doxy versus FQ or
Brown 2 Ceph3/macrolide?
11:30 – 12:30 Chairpersons: Shigeru Kohno (Nagasaki, JP);
Roger Finch (Nottingham, UK)
S339
11:30 Penicillin + [doxy or macrolide]
Thomas Gottlieb (Concord, AU)
S340
12:00 Pro FQ or Ceph3/macrolide?
Francesco Blasi (Milan, IT)
Closing remarks
Livio Pagano (Rome, IT)
Lecture Hall The efficient laboratory – an ideal partner in
Amber 1 clinical practice
09:00 – 11:00 BD-Diagnostics chair: Gian Maria Rossolini (Siena, IT)
ESCMID/ISC chair: Johan van Eldere (Leuven, BE)
Integrated symposium organised by Pfizer
Final Programme
71
Membership makes
you part of
a community
– Sign up for
ESCMID
Membership
Good reasons to join us:
• Subscription to the monthly issues and
supplements of Clinical Microbiology and
Infection (CMI), in print and /or online
• Registration discounts for ECCMID,
ESCMID Summer School and other scientific and educational events organised
or endorsed by ESCMID
• Receipt of ESCMID Newsletter by email
and ESCMID Yearbook by post
• Option to subscribe to several European
journals at a preferential rate
• Access to ESCMID member-only
webpages, including the Membership
Directory and Online Lecture Library
• Eligibility for ESCMID Training Fellowships,
Research Grants and Observerships
• Right to vote and actively participate in
shaping the Society
Apply for ESCMID Membership
Visit our website and join us now!
www.escmid.org/membership
Monday, 9 May
Lecture Hall The year in clinical microbiology
Silver Chairperson: Giuseppe Nicoletti (Catania, IT)
11:30 – 12:30
Lecture Hall CA-MRSA – What is going on with CA-MRSA?
White 2 Chairpersons: Heidi Ammerlaan (Utrecht, NL);
11:30 – 12:30
Gavin Barlow (Cottingham, UK)
S341
11:30 The year in clinical microbiology (1)
S342
12:00 The year in clinical microbiology (2)
Fred Tenover (Sunnyvale, US)
O348 11:30 High genetic diversity of communityassociated Staphylococcus aureus in Europe
J. Rolo*, M. Miragaia, A. Turlej, J. Empel,
O. Bouchami, N.A. Faria, A. Tavares,
W. Hryniewicz, A.C. Fluit, H. de Lencastre
and the CONCORD Working group
Oral Sessions
Lecture Hall MALDI-TOF: is it as good as we hoped
White 1 Chairpersons: Katja Seme (Ljubljana, SI);
11:30 – 12:30
Michel Drancourt (Marseille, FR)
O343 11:30 MALDI-TOF identification from BacTAlert blood
cultures in Cambridge, UK
M.J. Ellington*, N. Bentley, S. Pai, T. Gouliouris,
J. Greatorex, N.M. Brown, S.H. Aliyu
(Cambridge, UK)
O344 11:42 Clinical impact of direct matrix-assisted
laser desorption ionisation time-of-flight
mass spectrometry analysis on positive
blood cultures
A.L. Vlek*, M.J. Bonten, E. Boel (Utrecht, NL)
O345
11:54 MALDI-TOF mass spectrometry ID of bacteria
directly from cerebrospinal fluid – what you
see is what you get
J.V. Bjørnholt*, S.M. Nilsen, I. Noorland,
M. Wigemyr, C.H. Løken, F. Müller, A. Ingebretsen
(Oslo, Nordbyhagen, NO)
O346 12:06 Preliminary results from a comparison of two
matrix-assisted laser desorption ionisation–
time-of-flight mass spectrometry (MALDI-TOF)
systems with 16S rRNA gene sequencing for
identification of anaerobic bacteria to the
species level
U.S. Justesen*, A. Holm, E. Knudsen,
L.B. Andersen, T.G. Jensen, M. Kemp, M. Skov,
B. Gahrn-Hansen, J.K. Møller (Odense, Vejle, DK)
O347
12:18 Rapid detection of Salmonella by selective
enrichment and mass spectrometry based on
MALDI Biotyper
U. Weller, K. Sparbier, C. Boogen, M. Kostrzewa*
(Cologne, Bremen, DE)
11:42 Changing trends in the epidemiology of PVLMRSA in England
A.M. Kearns*, M. Ganner, L. Hicks, I. McCormick
Smith, R. Hill, B. Pichon, M.J. Ellington,
B. Cookson (London, UK)
O350 11:54 High prevalence of hospital-associated
Staphylococcus aureus epidemic clones in the
community in Portugal: evidence for blurring
of community/hospital boundaries
A. Tavares*, M. Miragaia, R. Mato, J. Rolo,
J. Melo-Cristino, L.M. Lito, F. Martins,
E. Gonçalves, G. Ribeiro, L. Boaventura,
J. Amorim , R. Campainha, A. Fonseca,
M. Guimarães, M. Gonçalves, A.M. Costa,
J. Mairos, S. Francisco, M.A. Guimarães,
C. Lameiras, M. Ribeiro, L. Branco, D. Tuna,
A. Faustino, M.T. Vaz, M. Gião, P. Paixão, C. Febra,
M.A. Read, M.J. Soares, M.J. Nunes, A. Coutinho,
M. Carvalho, T. Sardinha, L. Sancho, G. Sousa,
P. Correia, R.M. Barros, C. Gouveia, M. Pinto,
M.J. Brito, I. Daniel, G.C. Ferreira, A. Morais,
I. Valadares, H. de Lencastre
(Oeiras, Lisbon, Coimbra, Santo Tirso, Cascais,
Porto, Braga, Portimão, Matosinhos, Évora,
Amadora, PT; New York, US)
O351
12:06 Rise of USA300 hospitalisations in the US
during 2004–2008
R.M. Mera*, J.A. Suaya, H.A. Madsen,
P.F. O'Hara, L.A. Miller
(Durham, Philadelphia, Upper Providence, US)
O352
12:18 Prevalence of Panton-Valentine leukocidin
in methicillin-susceptible and -resistant
Staphylococcus aureus from Australia and
New Zealand, 2009
J. Stepnell, J. Bell, P. Andersson, J. Turnidge*
(North Adelaide, AU)
Final Programme
73
O349
Monday, 9 May
Lecture Hall Epidemiology of antimicrobial resistance
Amber 1 Chairpersons: Luisa Peixe (Porto, PT);
Lorena Abadia-Patino (Cumana, VE)
11:30 – 12:30
O353 11:30 High prevalence of ESBL-producing Escherichia
coli in chicken meat imported into Sweden
S. Börjesson*, M. Egervärn, M. Finn, I. Tillander,
C. Wiberg, S. Englund (Uppsala, SE)
O354
O355
11:42 High prevalence of ESBL-producing Enterobacteriaceae carriage in Dutch patients
visiting their general practitioner
E.A. Reuland*, N. al Naiemi, J.S. Kalpoe,
M.C. Rijnsburger, S.A. Raadsen,
I. Ligtenberg-Burgman, P.H. Savelkoul,
C.M. Vandenbroucke-Grauls
(Amsterdam, Enschede, NL)
11:54 Complex epidemiology of KPC-producing
Enterobacteriaceae in a university hospital
in Madrid (Spain) after an outburst of KPC3producing Klebsiella pneumoniae
P. Ruiz-Garbajosa*, T. Curiao, M. Tato, M. Morosini,
F. Baquero, T.M. Coque, R. Cantón (Madrid, ES)
O356 12:06 Epidemiology of invasive disease due to
serotype 6A and 6C Streptococcus pneumoniae
from 2002 to 2009 in France
C. Janoir, A. Lepoutre, S. Grondin, S. Simon,
L. Gutmann, E. Varon and The French Regional
Observatories of Pneumococcus (ORP) network
O357
12:18 Group B streptococcal neonatal infection in
the Barcelona area: 18-year surveillance
E. Martins*, M. Gimenez, M. Sierra, M. Lite,
J. Melo-Cristino, M. Ramirez on behalf of the
microbiologist group for the study of vertical
transmission infections from the catalan society
for clinical microbiology and infectious diseases
Lecture Hall Lyme borreliosis, toxoplasmosis
Amber 3 Chairpersons: Gabriela Loredana Popa
11:30 – 12:30
(Bucharest, RO);
Birgitta Evengård (Umea, SE)
O358 11:30 Direct detection of early Lyme borreliosis
from whole blood
M. Eshoo*, C. Crowder, M. Rounds, H. Mathews,
M. Soloski, A. Schwarzwalder, S. Schutzer,
J. Aucott (Carlsbad, Baltimore, Newark, US)
O359
74
11:42 Survey of pathogens in nymphal ticks from
the Czech Republic
C. Crowder, M. Rounds, H. Matthews, V. Honig,
L. Grubhoffer, B. Luft, M. Eshoo*
(Carlsbad, US; Prague, CZ; Stony Brook, US)
Final Programme
O360 11:54 Toxoplasma seroprevalence studies: what are
we looking at?
L.M. Kortbeek*, A. Hofhuis, P. Teunis (Bilthoven, NL)
O361
12:06 How to detect significant changes in Borrelia
burgdorferi antibody reactivity in a follow-up
sample
R.B. Dessau (Naestved, DK)
O362
12:18 Childhood neuroborreliosis does not lead to
long-term cognitive disturbances
H. Schmidt*, K. Drenck, J. Wiefek, J. Blocher,
K. Rostasy, N. von Steinbüchel, H. Eiffert,
K. Brockmann (Göttingen, DE; Innsbruck, AT)
Lecture Hall HIV/AIDS
Amber 4 Chairpersons: Roberto Cauda (Rome, IT);
11:30 – 12:30
O363 11:30 Genotypic (V3 sequencing) determination
of co-receptor usage in HIV-infected patients
carrying non-B subtypes
N. Chueca*, M. Alvarez, V. Guillot, J. López-Bueno,
M.D. Merida, A. Peña, A. B. Lozano, J. HernándezQuero, F. Garcia for the CoRAO
O364 11:42 Fine epitope specificity of circulating autoantibodies to endogenous erythropoietin,
in HIV-1 infected patients, reveals molecular
mimicry with HIV-1 p17 Gag protein: a potential
pathogenetic mechanism for HIV-1-related
anaemia
A. Tsiakalos*, I. Routsias, T. Kordossis, A. Tzioufas,
H. Moutsopoulos, N. Sipsas (Athens, GR)
O365 11:54 The role of hepatitis B virus co-infection in
immunologic progression among patients with
primary human immunodeficiency virus type
1 infection in an area of hyperendemicity for
HBV infection
M. Tsai*, Y. Lo, H. Sun, W. Sheng, W. Liu, C. Hsieh,
C. Hung, S.C. Chang (Taipei, TW)
O366 12:06 Prevalence of high-risk genotypes human
papillomavirus in anal samples with cytological
changes from homosexual patients attending
in a tertiary hospital, Madrid
G. Gabilondo*, B. Romero, T. Hellin, J. Chacon,
I. Sanz, M. Mateos (Madrid, ES)
O367
12:18 High rate of adverse events and serious
adverse events after antiretroviral therapy
initiation in a resource-limited setting:
preliminary data from a prospective study
S. Kiertiburanakul*, N. Rajatanavin,
A. Charoenyingwattana, A. Rojanawiwat,
W. Wangsomboonsiri, W. Manosuthi,
P. Kantipong, A. Apisarnthanarak, W. Chantratita,
S. Sungkanuparph (Bangkok, Nonthaburi,
Nakornsawan, Chiang Rai, Pratumthani, TH)
Poster Session IV
Poster Session V
Topics
P1389 – P1403
P1404 – P1407
P1408 – P1414
P1415 – P1424
P1425 – P1438
Topics
P1666 – P1670 Gram-negative bacteria: molecular detection of
P1671 – P1675 Bacteriology highlights
P1676 – P1682 Sample collection
P1683 – P1702 Molecular diagnosis of urogenital infections
P1703 – P1734 The power of typing
P1735 – P1739 Molecular tools for the diagnosis of
culture-negative infections
P1740 – P1781 Microbial pathogenesis – miscellaneous
P1782 – P1786 Pathophysiology of infectious diseases, in vivo
P1787 – P1791 Molecular point-of-care tests
P1792 – P1809 Lab automation
P1810 – P1817 Mobile genetic elements
P1818 – P1821 New species and unusual pathogens:
usefulness of molecular tools for bacterial
identification
P1822 – P1844 MALDI-TOF
P1845 – P1864 Biofilm: diagnostic approaches to therapeutic
measures
P1865 – P1883 Molecular virology
P1884 – P1915 Molecular diagnostics
P1916 – P1923 From molecular diagnosis to molecular
epidemiology
P1924 – P1928 Molecular diagnosis of respiratory tract
infections – upper and lower
P1929 – P1937 Molecular diagnosis on culture-negative
infections
P1938 – P1956 Molecular mycology
P1439 – P1446
P1447 – P1464
P1465 – P1495
P1496 – P1499
P1500 – P1504
P1505 – P1527
P1528 – P1533
P1534 – P1552
P1553 – P1570
P1571 – P1586
P1587 –
P1602 –
P1611 –
P1616 –
P1626 –
P1633 –
P1654 –
P1658 –
P1601
P1610
P1615
P1625
P1632
P1653
P1657
P1665
Urinary tract infections
Diagnosis of syphilis
Diagnosis of parasitic infections
Serological diagnosis of infections
Immunology, immunopathogenesis and
vaccinology
Vaccines – miscellaneous
Miscellaneous
Bloodstream infections
Influenza miscellaneous
Assessing antimicrobial therapy in animals
New antimicrobials: preclinical and
clinical studies
New antimicrobials: phase 2-3 studies
Clinical trials with antibacterials
Paediatric infections: preclinical and
clinical data
Community-acquired pneumonia and its
complications
Bacteraemia, sepsis and endocarditis
Respiratory pathogens
Biomarkers for infections
Blood cultures and diagnosis of sepsis
Diagnosis of foreign body infections
Skin soft tissue infections
Prosthetic joint infections
Nosocomial pneumonia
Final Programme
75
Monday, 9 May
Monday, 9 May
Keynote Lectures
Lecture Hall Man-made bacteria – making new bacteria:
White 3 possibilities, ethical considerations, problems
14:30 – 15:30 Chairperson: Patrick Trieu-Cout (Paris, FR)
K368
S374
14:30 Recent advances in the pathogenesis of CMV
infection
Stipan Jonjic (Rijeka, HR)
S375
15:00 Recent advances in the pathogenesis of EBV
infection
Janos Minarovits (Budapest, HU)
Sanjay Vashee (Rockville, US)
Lecture Hall Information technology and global surveillance
Amber 4 of infectious diseases
14:30 – 15:30 Chairperson: Evangelista Sagnelli (Caserta, IT)
K369
Lecture Hall Recent advances in the pathogenesis of
Amber 3 cytomegalovirus (CMV) and Epstein-Barr
14:30 – 15:30 virus (EBV)
Chairpersons: William Irving (Nottingham, UK);
Fausto Baldanti (Pavia, IT)
David L. Buckeridge (Montreal, CA)
Lecture Hall Clinical management of urinary tract infections
Brown 1 Chairpersons: Peter Tenke (Budapest, HU);
14:30 – 15:30
Matteo Bassetti ( Genoa, IT)
S376
14:30 An update of complicated urinary tract
infections
S377
15:00 How to treat acute pyelonephritis
Tetsuro Matsumoto (Kitakyoushu, JP)
Official Symposia
Lecture Hall Quality control: is it needed?
White 1 Chairpersons: Jacques Schrenzel (Geneva, CH);
14:30 – 15:30
Maria R. Capobianchi (Rome, IT)
Lecture Hall Vancomycin and staphylococci – Is it as bad
Brown 2 as they say?
14:30 – 15:30 Chairpersons: Robert Moellering (Boston, US);
Francesco Menichetti (Pisa, IT)
S370
14:30 Quality control in molecular diagnostics
Anton M. van Loon (Utrecht, NL)
S378
14:30 Pro
Alasdair MacGowan (Bristol, UK)
S371
15:00 Quality control in MALDI-TOF
S379
15:00 Con
Alex Soriano (Barcelona, ES)
Lecture Hall Infections and human genetic susceptibility
White 2 Chairpersons: Massimo Clementi (Milan, IT);
14:30 – 15:30
Thomas Wex (Magdeburg, DE)
S372
14:30 Where are we?
Oresetta Zuffardi (Pavia, IT)
S373
15:00 Where are we going?
Anne Puel (Paris, FR)
76
Final Programme
Monday, 9 May
S380
14:30 Worldwide spread of NDM producers;
from clinics to genetics
S381
15:00 NDM producers in the UK as the example of
rapid invasion of a European country
Oral Sessions
Lecture Hall Mycobacterium tuberculosis
Amber 1 Chairpersons: Mircea Ioan Popa (Bucharest, RO);
14:30 – 15:30
Giovanni Delogu (Sassari, IT)
O382 14:30 Drug-resistant Mycobacterium tuberculosis
in Taiwan, 2003–2008
R. Jou*, T.F. Wang, C.Y. Yu (Taipei, TW)
O383
14:42 Drug-resistant tuberculosis among foreignborn persons in Italy
A. Mustazzolu, G. Piccaro, M. Pardini, P. Filippini,
F. Giannoni, E. Borroni, P. Miotto, D. Cirillo,
L. Fattorini* and the TB-CCM Study Group
O384 14:54 Six-year laboratory data report on drugresistant tuberculosis in Lisbon health region,
Portugal
J. Perdigão, R. Macedo, C. Silva, C. Pinto,
C. Furtado, L. Brum, I. Portugal* (Lisbon, PT)
O385 15:06 High-resolution melting analysis for rapid
detection of rifampicin resistance in
Mycobacterium tuberculosis clinical isolates
M. Nica*, A. Dascalu, T. Biolan, E. Turcu,
E. Ceausu, P. Calistru, I. Apostol, T. Hainisteanu,
O. Moldovan (Bucharest, RO)
O386
15:18 Inhibiting the beta-lactamase of
Mycobacterium tuberculosis (Mtb)
with novel Boronate-Transitional-StateAnalogs (BATSAs)
S.G. Kurz*, C.R. Bethel, L.W. Tremblay,
J.S. Blanchard, E. Caselli, F. Prati, R.A. Bonomo
(Cleveland, New York, US; Modena, IT)
Lecture Hall Cellular and molecular immunology
Amber 2 Chairpersons: Marike Van Zoelen (Utrecht, NL);
14:30 – 15:30
O387 14:30 Characterising pandemic H1N1 crossreactive influenza cytokine and T-lymphocyte
responses induced by seasonal intranasal
live-attenuated influenza vaccine
Y. Keynan*, A. Meyers, M. Kimani, J. Kimani,
F. Plummer, T. Ball, K. Fowke (Winnipeg, CA;
Nairobi, KE)
O388 14:42 Mannose-binding lectin concentrations and
infections in haemato-oncology patients:
preliminary results
L. Berry*, M.M. Ceesay, H. Sikondari, A. Pagliuca,
J. Wade, M. Smith (London, UK)
O389 14:54 Pseudomonas aeruginosa vs. the innate
immune system: understanding bacterial
response to macrophage engulfment
L.K. Green*, A.C. La Flamme, D.F. Ackerley
(Wellington, NZ)
O390 15:06 Cytokine response of Th17 and oral lactobacilli
in chronic periodontitis
A.K. Szkaradkiewicz*, T.M. Karpinski,
M. Wyganowska-Swiatkowska, A. Zeidler
(Poznan, PL)
O391
15:18 Increased expression of CD11A and CD45
and TH2 predominant immune response in
isolated coronary artery ectasia patients
A. Adiloglu*, A. Ocal, T. Tas, S. Onal, S. Kapan,
B. Aridogan (Ankara, Isparta, TR)
Official Symposia
Lecture Hall New insights in the role of the commensal flora
White 3 Chairperson: Yolanda Sanz (Valencia, ES);
16:00 – 18:00
Fernando Baquero (Madrid, ES)
S392
16:00 The role of the commensal intestinal flora in
inflammatory bowel diseases
Eduard F. Stange (Stuttgart, DE)
S393
16:30 Do nutrient-gut-microbiota interactions play
a role in human obesity and type 2 diabetes?
Michaela Diamant (Amsterdam, NL)
S394
17:00 The “Microflora Hypothesis” of allergic
diseases
Maria Jenmalm (Linkoping, SE)
S395
17:30 The intestinal flora as reservoir of known and
unknown resistance genes
Fernando Baquero (Madrid, ES)
Final Programme
77
Lecture Hall New Delhi metallo-beta-lactamase (NDM)
Silver producers; the emergence of MDR bacteria of
14:30 – 15:30 global concern
Chairpersons: Giuseppe Cornaglia (Verona, IT);
Jordi Vila (Barcelona, ES)
Monday, 9 May
Lecture Hall Under your skin: skin manifestations of
Amber 3 parasitic diseases
16:00 – 18:00 Chairpersons: Enrico Brunetti (Pavia, IT);
Thomas Junghanss (Heidelberg, DE)
S396
16:00 Skin manifestations of parasitic diseases:
what you should know, how to diagnose
François Peyron (Lyon, FR)
S397
16:30 Photodynamic therapy in cutaneous
leishmaniasis
Eric van der Snoek (Rotterdam, NL)
S398
17:00 Toxocariasis in patients with skin disorders
Carmen-Michaela Cretu (Bucharest, RO)
S399
17:30 Maggot debridement therapy
Gwendolyn Cazander (The Hague, NL)
Oral sessions
Lecture Hall Virology (non-HIV/non-hepatitis)
Amber 2 Chairpersons: Pasquale Ferrante (Milan, IT);
16:00 – 18:00
José Maria Aguado-Garcia
(Madrid, ES)
O408 16:00 Upsurge of human enterovirus 68 infections
in patients with severe respiratory tract
infections
J.C. Rahamat-Langendoen*, R. Borger,
A. Riezebos-Brilman, A. Brandenburg,
E.H. Schölvinck, H.G. Niesters
(Groningen, Leeuwarden, NL)
O409
16:12 Occurrence and characteristic of viral
agents in respiratory tract infection in
Nigerian children
O.M. Akinloye*, E. Rönkkö, C. Savolainen-Kopra,
T. Ziegler, M. Deji-Agboola, B. Iwalokun,
A. Oluwadun, M. Roivainen, F. Adu, T. Hovi
(Ago-Iwoye, NG; Helsinki, FI; Ibadan, NG)
O410
16:24 Clinical impact of HSV-1 detection in the
lower respiratory tract from hospitalised adult
patients
C. Costa*, A. Saldan, F. Sidoti, S. Gambarino,
M. Terlizzi, S. Astegiano, A. Curtoni, M. Bergallo,
R. Cavallo (Turin, IT)
O411
16:36 PMOplus™ antisense oligomers protect
nonhuman primates against Ebolavirus and
Marburgvirus
T. Warren, A. Shurtleff, J. Wells, N. Garza,
L. Dong, D. Mourich, S. Crumley, P. Iversen*,
S. Bavari (Fredrick, Bothell, US)
O412
16:48 The role of WU and KI viruses: pathogens
or passengers?
A. Riezebos-Brilman, R. Xue, J.C. RahamatLangendoen*, T. Schuurman, H.G. Niesters
(Groningen, NL)
O413
17:00 Asymptomatic Crimean-Congo haemorrhagic
fever infection in endemic regions
I. Koksal*, G. Yilmaz, F. Aksoy, S. Erensoy,
H. Aydin (Trabzon, TR)
O414
17:12 Prevalence of the newly described human
enterovirus 109 in infants with acute
respiratory disease in Italy
A. Piazza*, M. Debiaggi, F. Canducci,
E.R. Ceresola, M. Sampaolo, R. Brerra,
M. Clementi (Pavia, Milan, IT)
Lecture Hall Infection control methods for cancer patients
Brown 1 undergoing treatment
16:00 – 18:00 Chairpersons: Winfried V. Kern (Freiburg, DE);
Angelo Pan (Cremona, IT)
S400
16:00 Prospective: logic and implementation over
the years
Jean Klastersky (Brussels, BE)
S401
16:30 Practice and guidelines in Europe
Catherine Cordonnier (Créteil, FR)
S402
17:00 The base of evidence
S403
17:30 Infection control measures for prevention of
fungal infections in neutropenic patients
Petra Gastmeier (Berlin, DE)
Lecture Hall Infective endocarditis: lights and shadows
Silver Chairpersons: Javier Garau (Barcelona, ES);
16:00 – 18:00
Mario Venditti (Rome, IT)
S404
16:00 The changing epidemiology
Riccardo Utili (Naples, IT)
S405
16:30 Guidelines on antimicrobial prophylaxis:
evidences and controversies
Xavier Duval (Paris, FR)
S406
17:00 Culture-negative endocarditis: a diagnostic
conundrum
Pierre-Edouard Fournier (Marseille, FR)
S407
17:30 When the surgeon is needed
Carlos A. Mestres (Barcelona, ES)
78
Final Programme
Monday, 9 May
O416
O417
17:24 Different rates of spontaneous clearance of
HPV infections in anal and cervical lesions
P. Ravanini*, E. Omodeo-Zorini, F. Fila, S. Costantino,
A. Godino, V. Ilaria, L. Krizmancic, L. Servino,
C.M. Antonacci, F. Pagano, R. Beretta, G. Orlando,
M. Bandi, A.M. Nicosia, M.G. Crobu
(Galliate, Milan, Biella, Novara, IT)
17:36 Rhinovirus-induced basic fibroblast growth
factor release from bronchial epithelial cells
mediates airway remodelling features
C.L. Skevaki*, S. Psarras, E. Volonaki,
H. Pratsinis, I.S. Spyridaki, M. Gaga, V. Georgiou,
S. Vittorakis, A.G. Telcian, P. Maggina, D. Kletsas,
D. Gourgiotis, D.A. Kafetzis, S.L. Johnston,
A. Tsakris, N.G. Papadopoulos
(Athens, GR; London, UK)
17:48 Outcome of pregnant patients post-VZIG
J. Troughton*, L. Duffy, J. Devlin, P. Coyle
(Belfast, UK)
O422 16:48 Activity of ceftaroline against serotyped
Streptococcus pneumoniae isolates from
Europe (2007–2008)
I. Morrissey*, A. Leakey, J. Ambler
(Fordham, UK; Waltham, US)
O423
17:00 The associated mortality of invasive
pneumococcal disease – Why are we not
vaccinating?
C. Rock*, J. Fitzgerald, C. Sadlier, A. Brown,
S. Kelly, C. Dowling, C. Bergin (Dublin, IE)
O424
17:12 Epidemiology of community-acquired
pneumonia requiring hospitalisation
after introduction of the conjugated
pneumococcal vaccine in Switzerland
B. Betsch, K. Mühlemann* (Berne, CH)
O425
17:24 Immunogenicity and safety of a 13-valent
pneumococcal conjugate vaccine in adults
70 years of age and older previously
vaccinated with 23-valent pneumococcal
polysaccharide vaccine
L. Jackson*, A. Gurtman, K. Rice, K. Pauksens,
R. Greenberg, T. Jones, D. Jayawardene, J. Love,
D. Scott, E. Emini, W. Gruber, B. Schmoele-Thoma
(Seattle, Pearl River, Minneapolis, US; Uppsala,
SE; Lexington, Collegeville, US; Munich, DE)
O426
17:36 Immunogenicity and safety of a 13-valent
pneumococcal conjugate vaccine in
pneumococcal vaccine naïve adults,
50–64 years of age
L. Jackson*, A. Gurtman, M. van Cleeff,
K. Jansen, D. Jayawardene, C. Devlin, D. Scott,
E. Emini, W. Gruber, B. Schmoele-Thoma (Seattle,
Pearl River, Cary, Collegeville, US; Munich, DE)
O427
17:48 Pneumococcal vaccination and invasive
pneumococcal disease in East Yorkshire, UK
J. Elston*, A. Newton, J. Meigh, V. Allgar,
M. Porter, T. Allison, G. Richardson, R. Meigh,
G. Barlow (Hull, York, Willerby, East Yorkshire, UK)
Lecture Hall Pneumococcal infections and vaccine
Amber 4 Chairpersons: Adalyat Abdullayev (Baku, AZ);
16:00 – 18:00
Delfino Legnani (Milan, IT)
O418
16:00 High rates of multidrug-resistant
Streptococcus pneumoniae in Europe.
Pneumococcal activity profile from GLOBAL
6 surveillance (2009–2010)
C. Pillar*, J. Deane, D.F. Sahm (Chantilly, US)
O419
16:12 Antimicrobial resistance of S. pneumonia in
Russia: ten-year (1999–2009) prospective
study PEHASus
R. Kozlov*, O. Sivaya, N. Ivanchik
for the PEHASus project group
O420
16:24 Decrease in antibiotic resistance of
Streptococcus pneumoniae between 2003
and 2009 in France and changes in serotype
distribution: ongoing survey of the French
Pneumococcus Network
A. Gravet*, M. Kempf, A. Lepoutre, M.C. Ploy,
E. Varon on behalf of the French Regional
Pneumococcal Observatories (ORP) Network
O421
16:36 Invasive pneumococcal disease:
serotypes and antimicrobial susceptibility
in adult patients from Madrid
A. Correa*, C. De las Cuevas, A. Guiu,
M. Lopez-Brea, J. Sanz (Madrid, ES)
Final Programme
79
O415
Monday, 9 May
Lecture Hall Decision points in the management of
White 1 invasive Candida infections: Navigating the
16:00 – 18:00 choices for optimal patient care
Astellas chair: Claudio Viscoli (Genoa, IT)
ESCMID/ISC chair: Manuel Cuenca-Estrella
(Madrid, ES)
Lecture Hall Embedding MALDI-TOF mass spectrometry in
Amber 1 an open microbiology landscape
16:00 – 18:00 Bruker Daltonik chair: Markus Kostrzewa
(Bremen, DE)
ESCMID/ISC chair: Elisabeth Nagy (Szeged, HU)
S435
MALDI Biotyper: past, present and future
Markus Kostrzewa (Bremen, DE)
S436
MALDI Identification combined with
accelerated AST
Caroline Visser (Amsterdam, NL)
S437
Efficient embedding of MALDI-based ID
into AST and blood culture workflows
Marlies Höck (Berlin, DE)
S438
Rapid identification of bacteria from
patients with cystic fibrosis
Mark Wilks (London, UK)
S428
Susceptibility, breakpoints, and resistance
to antifungals among Candida species –
where are we in 2011?
Maiken Cavling Arendrup (Copenhagen, DK)
S429
Early, effective treatment of Candida
infections – implications for patient,
physician and hospital
S430
Not all Candida infections are the same –
choosing the right solution for each patient:
clinical challenges
Maiken Cavling Arendrup, Manuel Cuenca-Estrella,
Paolo Manzoni, Robert Masterton, Patricia Muñoz,
Claudio Viscoli (Copenhagen, DK; Madrid, ES;
Turin, IT; Ayr, UK; Madrid, ES; Genoa, IT)
Bruker Daltonik
Lecture Hall Management of complicated infections in the
Brown 2 21st century: current and future approaches
16:00 – 18:00 Pfizer chair: Lance Peterson (Chicago, US)
ESCMID/ISC chair: Jesus Rodriguez-Baño (Seville, ES)
Summary
16:00 Welcome and introduction
Lecture Hall Impact of molecular diagnostics on public
White 2 health and patient care
16:00 – 18:00 Cepheid chair: Fred Tenover (Sunnyvale, US)
ESCMID/ISC chair: Gilbert Greub (Lausanne, CH)
S431
16:00 Bringing high tech tuberculosis diagnostics
to low tech settings
Catherina Boehme (Geneva, CH)
S432
16:30 Diagnosis of Clostridium difficile infection:
a light at the end of the tunnel
Ferric Fang (Seattle, US)
S433
17:00 Chlamydia infections: confronting the silent
scourge
Henrik Westh (Hvidovre, DK)
S434
17:30 Rapid detection of sepsis
Jacques Schrenzel (Geneva, CH)
S439
16:10 European epidemiology of multi-resistant
hospital pathogens
David Livermore (London, UK)
S440
16:30 Understanding Pharmakokinetics/Pharmacodynamics in managing complex patients
S441
16:50 Principles for the management of complicated
intra-abdominal infections: from theory to
clinical practice
Christian Eckmann (Dresden, DE)
S442
17:10 Appropriate antimicrobial treatment in
complicated intra-abdominal infections:
which are the real life challenges?
Christoph Wenisch (Vienna, AT)
17:30 Q&A session with panel discussion
17:55 Closing remarks
Integrated symposium arranged by Pfizer
Integrated symposium arranged by Cepheid
Final Programme
81
Integrated Symposia
Tuesday, 10 May
Lecture Hall Polymyxins: old becomes new
Amber 2 Experts: Lisa Saiman (New York, US);
07:45 – 08:45
Francesco Menichetti (Pisa, IT)
E443
E446
Objectives
• To describe the mechanism of action of colistin
• To analyse clinical study designs for colistin
in cystic fibrosis and non-CF patients
• To provide examples for the complexity of
in vitro susceptibility and synergy studies
involving colistin
• The risk for the emergence of resistance
to colistin and the ways to prevent this
(combination therapy?)
• Different view on daily dose related to the
PK/PD profile
Lecture Hall Infection prevention and diagnostics in
Amber 3 critically ill patients in the ICU
07:45 – 08:45 Experts: Massimo Antonelli (Rome, IT);
E444
Lecture Hall Vertical and horizontal infection control:
Brown 1 pros and cons
07:45 – 08:45 Experts: Margreet Vos (Rotterdam, NL);
Maria Luisa Moro (Bologna, IT)
Lecture Hall Interferon-gamma release assays in TB
Brown 2 diagnosis
07:45 – 08:45
Expert: Roland Diel (Hannover, DE)
E447
Objectives
• attributable mortality of VAP
• diagnosis of VAP
• prevention of VAP (non-antibiotics)
• topical antibiotics to prevent VAP
(SDD and SOD)
Lecture Hall Tropical mycoses: emerging IFIs in Europe?
Amber 4 Experts: Olivier Lortholary (Paris, FR);
07:45 – 08:45
Jacques Meis (Nijmegen, NL)
E445
Objectives
• To identify the epidemiology of travel related
IFI in Europe
• To provide clinic al cases of imported IFI
in both immunocompetent and immunocompromised hosts
• To recognise emerging risk factors for
endemic mycoses
• To realise that endemic fungi can reactivate
late after travel in endemic areas
Arranged with the ESCMID Fungal Infection
Study Group (EFISG)
Objectives
• To understand the differences among
horizontal and vertical infection control
approaches
• To take into account the setting
(epidemiological characteristics, dynamics
of transmission, prevention possibilities,
resources available) when deciding for a
vertical approach
• To discuss horizontal and vertical approaches
with three examples (MRSA, ESBL,
Acinetobacter)
Objectives
• To describe the current evidence on the
accuracy of IGRAs in detecting latent TB
infection
• To gain a better understanding of the role of
IGRAs when considering preventive therapy
• To underscore the advantages of IGRA testing
in immunocompromised patients
• To discuss the topics on which further
research is required
Expert: Christoph Lange (Borstel, DE)
Objectives
• Interferon-gamma release assays for
detecting active TB
Lecture Hall Laboratory identification of beta-lactamases
Silver in Gram-negative strains with multiple enzymes
07:45 – 08:45 Experts: David Livermore (London, UK);
Gian Maria Rossolini (Siena, IT)
E448
Objectives
• To identify which antibiograms suggest the
presence of multiple beta-lactamases
• To know the phenotypic tests to confirm the
presence of multiple enzymes
• To know which genetic tests to apply and when
• To know what to send to a reference lab
.
82
Final Programme
Tuesday, 10 May
Lecture Hall Bridging the gap of innovation – what we
White 2 all could do
09:00 – 11:00 Chairpersons: Roger Finch (Nottingham, UK);
Lecture Hall Infectious disease with liver involvement –
Amber 3 an update
09:00 – 11:00 Chairpersons: Shigeru Kohno (Nagasaki, JP);
Sergio Cimerman (Sao Paolo, BR)
S454
09:00 Hepatitis B treatment. Current guidelines in
Latin America and variability in access to
treatment
Eduardo Savio (Montevideo, UY)
S455
09:30 Political processes for the global need
for effective antibiotics – moving towards
concerted action
Otto Cars (Uppsala, SE)
09:30 Update on Leptospirosis: how to diagnose
and therapeutic options
S456
10:00 Hepatic dysfunction in dengue, yellow fever
and malaria
Raul Isturiz (Caracas, VE)
S451
10:00 New ways of using old and coming antibiotics
Johan Mouton (Nijmegen, NL)
S457
10:30 Diagnosis and treatment of liver abscesses
Maximo Brito (Chicago, US)
S452
10:30 Improving usage by guidelines – the European
experience
Paul Tulkens (Brussels, BE)
S449 09:00 Antibacterial pipelines – what to expect
in the future
Ursula Theuretzbacher (Vienna, AT)
S450
Arranged with the ESCMID PK/PD of AntiInfectives Study Group (EPASG) and the
ISC Working Group on Antimicrobials of
the Future
Lecture Hall Clinical Grand Rounds
White 3 Chairperson: Robert Read (Sheffield, UK)
09:00 – 11:00
S453
Clinical Grand Rounds
Six cases will be presented to experienced
professors of infectious disease, who will
then discuss the differential diagnosis and
management plan. All cases have been carefully
selected for their instructive qualities and
topicality, and will be presented by Fellows
from major infectious disease centres in Europe
and beyond.
Expert Facutly:
Joel Ernst (New York, US)
Barbara Bannister (London, UK)
Jos van der Meer (Nijmegen, NL)
Arranged with the Asociaciòn Panamericana de
Infectología (API)
Lecture Hall Antimicrobial-resistant bacteria in food and
Brown 2 potable water: a recipe for disaster?
09:00 – 11:00 Chairpersons: Carmen Torres (Logroño, ES);
Tom Inglis (Nedlands, AU)
S458
09:00 Antibiotic-resistant bacteria in food:
from farm to fork
Luisa Peixe (Porto, PT)
S459
09:30 Antibiotic-resistant bacteria in potable water:
tapping into the problem
Martin Cormican (Galway, IE)
S460
10:00 Chewing it over: the clinical and public
health relevance of antibiotic-resistant
bacteria in food
Anna-Pelagia Magiorakos (Stockholm, SE)
S461
10:30 Reining in resistance: what role for organic
farming methods?
John Threlfall (London, UK)
Arranged with the ESCMID Food- and
Water-borne Infections Study Group (EFWISG)
Case presenters:
Ariela Levcovich (Petach Tikva, IL)
Laura Prtack (Sheffield, UK)
Kalisvar Marimuthu (Singapore, SG)
Valentina Mazzotta (Rome, IT)
Flaminia Olearo (Rome, IT)
Maya El Sin (Beirut, LB)
Final Programme
83
Official Symposia
Tuesday, 10 May
Lecture Hall Genetic predisposition and the outcome of
Silver infection: time to include genetic
09:00 – 11:00 polymorphisms in routine diagnostic work-up?
Chairpersons: Diederik van der Beek
(Amsterdam, NL);
Colin Sutherland (London, UK)
S462
09:00 Host genetics, predisposition and outcome
in meningococcal disease
Diederik van de Beek (Amsterdam, NL)
S463
09:30 Genetics of susceptibility to Plasmodium
falciparum
David Modiano (Rome, IT)
S464
10:00 Genetic dissection of host resistance
to Mycobacterium tuberculosis
Stefan Kaufmann (Berlin, DE)
S465
10:30 Helicobacter pylori infection, host genetics
and gastric cancer
Thomas Wex (Magdeburg, DE)
Oral Sessions
Lecture Hall Studying infectious diseases in vivo
White 1 Chairpersons: Marike Van Zoelen (Utrecht, NL);
09:00 – 11:00
Joan Gavalda (Barcelona, ES)
O466 09:00 Experimental leptospiral infection in
transgenic/mutant mice: attenuated
nephritis in inducible nitric oxide synthase
knock-out C57BL/6 mice and pulmonary
haemorrhages in SCID CB17 and recombinase
activating gene Rag-1 knock-out C57BL/6
mice
D. Athanazio*, M. Bandeira, C.S. Santos,
E.C. Azevedo, A.D. Chagas Jr, L.M. Soares,
S. Marchi, J.O. Macedo, C.L. da Silva,
A.J. McBride, F.W. McBride, M.G. Reis (Salvador, BR)
O467
09:12 Bacterial translocation is the major driver
to death in experimental multiple organ
dysfunction
K. Louis*, A. Kotsaki, A. Alexis, J. van der Meer,
M. Netea, E.J. Giamarellos-Bourboulis
(Athens, GR; Nijmegen, NL)
O468 09:24 A model of tick-borne encephalitis in rats
infected with Langat virus
C. Maffioli, D. Grandgirard, O. Engler, S. Leib*
(Berne, Spiez, CH)
84
Final Programme
O469 09:36 Dengue fever, Dengue haemorrhagic fever,
Dengue shock syndrome modelled in the
ferret, Mustela putorius furo
T. Voss*, J. Barbercheck, R. Brocato, M. Chen,
R. Cross, C. Garry, T. Hartley, D. Minor,
G. Manukian, B. Kaplan, D. Mourich, S. Naveen,
P. Iversen (New Orleans, Bothell, US)
O470 09:48 Brain inflammation in a new mouse model for
meningococcal meningitis
T. Davidsen, C. Castellanos, D. Frydenlund,
E. Antal, S.A. Frye, O.P. Ottersen, T. Tønjum*
(Oslo, NO)
O471
10:00 Demyelination in murine cerebral malaria is
reversed by neuroprotective erythropoietin
treatment
C. Hempel, C. Jendresen, P. Hyttel, T. Staalsø,
J.R. Nyengaard, J.A. Kurtzhals*
(Copenhagen, Aarhus, DK)
O472
10:12 Grafted neuronal stem/progenitor cells
differentiate and functionally integrate at the
site of pneumococcal-induced hippocampal
brain injury in vitro
S. Hofer*, V. Magloire, J. Streit, S. Leib (Berne, CH)
O473
10:24 Host response during Pseudomonas
aeruginosa adaptation to cystic fibrosis lung
C. Cigana, N.I. Lorè, S. Schwager, M. Juhas,
L. Eberl, A. Bragonzi* (Milan, IT; Zurich, CH)
O474
10:36 In vitro and in vivo reduced fitness and
virulence in ciprofloxacin-resistant
Y. Smani*, R. López-Rojas, J. DomínguezHerrera, F. Docobo-Pérez, S. Marti, J. Vila,
J. Pachón (Seville, Barcelona, ES)
O475
10:48 Relationship between the gut microbiota and
obesity in children and adolescents
V. Vankerckhoven*, L. Bervoets,
K. Van Hoorenbeeck, C. Lammens, S. Chapelle,
C. Vael, K. Desager, H. Goossens
(Antwerp, Hasselt, BE)
Tuesday, 10 May
O476 09:00 EUCAST susceptibility testing of Candida
species to echinocandins: improved
separation between wild type isolates and
fks mutants by supplementation of BSA to
the test medium
M. Cavling Arendrup*, S. Park, J.L. RodriguezTudela, W. Hope, C. Lass-Flörl, P.J. Donnelly,
M. Cuenca-Estrella, D.S. Perlin
(Copenhagen, DK; Newark, US; Madrid, ES;
Manchester, UK; Insbruck, AT; Nijmegen, NL)
O477
O478
09:12 Comparison of in vitro fungicidal activities
of echinocandins against C. albicans in
different peritoneal dialysis fluids
S. Tobudic*, H. Schranz, C. Kratzer, W. Poeppl,
09:24 Prospective surveillance of azole-resistance
in Aspergillus fumigatus in the Netherlands
J.W. van der Linden, E. Snelders, G.A. Kampinga,
B.J. Rijnders, E. Mattsson, Y.J. Debets-Ossenkopp,
E. Kuijper, F.H. van Tiel, W. Melchers, P. Verweij*
(Nijmegen, Groningen, Rotterdam, Utrecht,
Amsterdam, Leiden, Maastricht, NL)
O479 09:36 In vitro secondary azole resistance in
A. fumigatus isolates does not necessarily
involve mutations in the cyp51A gene
P. Escribano, S. Recio, T. Peláez, A. Simón,
E. Bouza, J. Guinea* (Madrid, ES)
O480 09:48 Multidrug resistance transporter genes play
a potential role in Aspergillus fumigatus azole
resistance
R. Rajendran*, R. Wotherspoon, E. McCulloch,
B. Jones, C. Williams, M. Bromley, P. Bowyer,
G. Ramage (Glasgow, UK)
O481
10:00 Azole-resistance in Aspergillus fumigatus:
collateral damage of fungicide use?
E. Snelders*, S.M. Camps, A. Karawajczyk,
C.H. Klaassen, G.H. Kema, W. Melchers,
P. Verweij (Nijmegen, Wageningen, NL)
O482
10:12 Caspofungin exposure in patients with
haematological malignancies is a risk factor
for fungaemia due to decreased susceptible
Candida spp.: a case-control study in Paris
E. Blanchard*, O. Lortholary, M. Desnos-Ollivier,
F. Dromer, D. Guillemot (Paris, FR)
O483
10:24 Efficacy of anidulafungin and caspofungin
against a caspofungin-resistant isolate of
Candida albicans in a murine model
K.V. Clemons, M. Martinez, V. Chen,
M.E. Johansen, D.A. Stevens* (San Jose, US)
O484 10:36 In vitro posaconazole pharmacokinetics
P. Campoli*, R. Robitaille, M. Laverdiere,
D. Sheppard (Montreal, CA)
O485 10:48 Pharmacokinetics and pharmacodynamics of
micafungin, anidulafungin and caspofungin
for disseminated candidiasis due to Candida
glabrata
S.J. Howard*, J. Slater, A. Sharp, J. Goodwin,
L. Gregson, A. Alastruey-Izquierdo,
D.S. Perlin, P. Warn, W. Hope
(Manchester, UK; New Jersey, US)
Lecture Hall Travel medicine: tropical and parasitic diseases
Amber 4 Chairpersons: Carmen Cretu (Bucharest, RO);
09:00 – 11:00
Miriam J. Álvarez-Martinez
(Barcelona, ES)
O486 09:00 Dientamoeba fragilis DNA detected in eggs of
Enterobius vermicularis by conventional and
real-time PCR
D. Röser*, J. Carlsgart, P. Nejsum, H.V. Nielsen,
C. Stensvold (Copenhagen, DK)
O487
09:12 Long-term sonographic follow-up of inactive
echinococcal cysts of the liver
L. Piccoli*, F. Tamarozzi, C. Filice, E. Brunetti
(Pavia, IT)
O488 09:24 The United Kingdom National External
Quality Assessment Service (UKNEQAS)
for parasitology: will the participants
never learn?
M. Manser*, A. Saez, P. Chiodini (London, UK)
O489 09:36 Discordance with World Health Organization
2009 admission criteria in outpatient confirmed
adult Dengue patients in Singapore
V. Gan*, T.L. Thein, F. Dimatatac, D. Lye, Y.S. Leo
(Singapore, SG)
O490 09:48 Adventure tourism and schistosomiasis:
serology and clinical findings in a group
of Danish students after white-water rafting
in Uganda
D. Röser*, S. Bjerrum, M. Helleberg, L. Abel,
H.V. Nielsen, K. David, S. Thybo
(Copenhagen, Nakskov, DK)
Final Programme
85
Lecture Hall Antifungals: in vitro and in vivo activity,
Amber 1 pharmacokinetics and resistance
09:00 – 11:00 Chairpersons: Francesco Barchiesi (Milan, IT);
Tuesday, 10 May
O491 10:00 Multilocus sequence typing of Blastocystis
sp. subtype 3
C. Stensvold*, C.G. Clark (Copenhagen, DK;
London, UK)
O492
O493
10:12 Anti-Wolbachia antibodies and acute
lymphadenopathy in lymphatic filariasis
E.M. Salvana*, K. Gentil, A. Hise, E. Pearlman,
F. Hazlett, J. Kazura (Manila, PH; Cleveland, US)
10:24 Protection against diarrhoea and fever
without localising signs associated with
asymptomatic Giardia lamblia infection is
lost with multi-nutrient supplementation:
a prospective study among rural Tanzanian
children
T.G. Mank*, J. Veenemans, R. Olomi, J. Wielders,
H. Savelkoul, H. Verhoef (Haarlem, Wageningen,
NL; Moshi, TZ; Amersfoort, NL; London, UK)
O494 10:36 The occurrence of Demodex spp. in
blepharitis patients and healthy people a
3-year observational study
M.M. Biernat*, J. Rusiecka-Ziólkowska,
J. Grabinska, E. Piatkowska, I. Helemejko,
A. Kania, G. Gosciniak (Wroclaw, PL)
O495 10:48 Mitochondrial phylogenetic analysis
of Portuguese samples of Echinococcus
granulosus
S. Beato*, R. Parreira, M. Calado, M.A. Grácio
(Lisbon, PT)
Lecture Hall C. difficile news
Brown 1 Chairpersons: Ed J. Kuijper (Leiden, NL);
09:00 – 11:00
Stephanie Dancer (Glasgow, UK)
O496 09:00 Differential risk of Clostridium difficile
infection with Proton pump inhibitor use by
level of antibiotic exposure
V. Stevens*, G. Dumyati, J. Brown,
E. van Wijngaarden (Buffalo, Rochester, US)
O497
09:12 The changing epidemiology before, during and
after an outbreak of CD027 in Denmark
B. Olesen*, K.E. Olsen, R.L. Andersen,
D.S. Hansen, M. Thorpdal, S. Bacci, B.G. Bruun
(Hillerød, Copenhagen, DK)
O498 09:24 Community versus healthcare-associated
Clostridium difficile infection: a surveillancebased study
N. Khanafer*, T. Benet, P. Vanhems (Lyon, FR)
86
Final Programme
O499 09:36 Investigation of outcome in cases of
Clostridium difficile infection due to isolates
with reduced susceptibility to metronidazole
J. Purdell, W. Fawley, J. Freeman, M. Wilcox*
(Leeds, UK)
O500 09:48 Success of a national service, Clostridium
difficile Ribotyping Network for England &
N. Ireland (CDRN), to help control epidemic
strains and incidence of C. difficile infection
M. Wilcox*, W. Fawley, M. Shemko, P. Coen,
A. Birtles, E. Bolton, M. Curran, S. Green,
D. Fairley, K. Hardy, P. Hawkey, P. Hawtin,
J. Magee, B. Patel, A. Sails, N. Shetty, E. Walpole,
M. Wren on behalf of the Clostridium difficile
Ribotyping Network for England & N. Ireland
(CDRN)
O501
10:00 Does C. difficile infection per se or other
factors lead to death in severe disease
J. Leitner*, D. Schmid, H. Kuo, F. Allerberger,
P. Tesik, V. Michl, C. Wenisch (Vienna, AT)
O502
10:12 A national enhanced DNA fingerprinting
service to investigate potential C. difficile
infection case clusters sharing the same
ribotype
M. Wilcox*, W. Fawley on behalf of the
Clostridium difficile Ribotyping Network
for England and N. Ireland (CDRN)
O503
10:24 Time-interval of increased risk for Clostridium
difficile infection after exposure to antibiotics
M.P. Hensgens*, A. Goorhuis, O.M. Dekkers,
E. Kuijper (Leiden, NL)
O504 10:36 Immunosuppression and the risk of death,
cure rates and disease recurrence among
patients with Clostridium difficile infection
Y. Golan*, K. Mullane, T. Louie, M. Miller,
K. Weiss, A. Lentnek, Y. Kean, Y.K. Shue,
S. Gorbach (Boston, Chicago, US; Calgary,
Montreal, CA; Georgia, San Diego, US)
Tuesday, 10 May
Official Symposia
Lecture Hall Tuberculosis: tests and diagnosis
Amber 2 Abbott chair: Enrico Tortoli (Milan, IT);
09:00 – 11:00 ESCMID/ISC chair: Vincent Jarlier (Paris, FR)
Lecture Hall RNAi and viral infections
White 2 Chairperson: Thomas Meyer (Berlin, DE)
11:30 – 12:30
S511
09:05 TB diagnosis: current technology and future
opportunities
Enrico Tortoli (Milan, IT)
11:30 Whole genome RNAi screen and novel
antiviral targets
Thomas Meyer (Berlin, DE)
S512
12:00 RNAi as a therapeutic approach against viruses
Judy Lieberman (Boston, US)
S506 09:40 Development of a biosafe, automated assay
for MTB detection
Gregor Leckie (Maidenhead, UK)
S507
10:15 Diagnosing drug resistant TB
Barry Kreiswirth (Newark, US)
10:50 Panel discussion and questions
Integrated symposium arranged by Abbott
Lecture Hall Enterococci – Where are we now?
White 3 Chairpersons: Marek Gniadkowski (Warsaw, PL);
11:30 – 12:30
S513
11:30 Current epidemiology of vancomycinresistant enterococci in Europe
Guido Werner (Wernigerode, DE)
S514
12:00 What do we learn about enterococci from
genomic studies?
Rob J. Willems (Utrecht, NL)
Keynote Lectures
Lecture Hall ESCMID Young Investigator Award lectures
White 1 Chairperson: Robert Read (Sheffield, UK)
11:30 – 12:30
K508 11:30 Know your enemy – group A
streptococcal virulence factors
Annelies Zinkernagel (Zurich, CH)
K509 12:00 Changing perspectives on antibiotic therapy: from proving the
obvious to exploring innovative
strategies
Surbhi Malhotra-Kumar
(Antwerp, BE)
Lecture Hall Invasive fungal infections in our hospitals today
Brown 2 Chairperson: Maiken C. Arendrup
11:30 – 12:30
(Copenhagen, DK)
K510
S505
09:00 Introduction
Lecture Hall Update on the new guidelines
Amber 1 Chairpersons: Erdal Akalin (Istanbul, TR);
11:30 – 12:30
S515
11:30 Treatment of acute uncomplicated cystitis
and pyelonephritis in women: international
guideline 2010
Bjorn Wullt (Lund, SE)
S516
12:00 The management of adult lower respiratory
tract infections
Mark Woodhead (Manchester, UK)
Lecture Hall Do you know the concept of anti-anaerobic
Brown 1 quinolones?
11:30 – 12:30 Chairpersons: Tetsuro Matsumoto
(Kitakyoushu, JP);
Luis Martinez-Martinez
(Santander, ES)
S517
11:30 Overview on anaerobic fluoroquinolones
David Hooper (Boston, US)
S518
12:00 Clinical significance of anti-anaerobic
quinolones in VAT and VAP
Hiroshige Mikamo (Aichi, JP)
Arranged with the Japanese Society for
Chemotherapy
Final Programme
87
Tuesday, 10 May
Oral Sessions
Lecture Hall Acinetobacter baumannii: current situation
Amber 3 Chairpersons: Harald Seifert (Cologne, DE);
German Bou (La Coruna, ES)
11:30 – 12:30
Lecture Hall Microbial pathogenesis, pathophysiology of
Amber 2 infections diseases
11:30 – 12:30 Chairpersons: Johannes Hegemann
(Düsseldorf, DE);
Philippe Morillion (Lausanne, CH)
O519
11:30 Relative fitness of tigecycline-susceptible
versus resistant isolates of Acinetobacter
baumannii recovered from a single patient
M. Hornsey*, N. Woodford, D.W. Wareham
(London, UK)
O520 11:42 Hospital- and community-acquired methicillin-resistant Staphylococcus aureus differ
greatly in their ability toinvade bone cells,
persist intracellularly and induce cell damage
J.P. Rasigade*, S. Trouillet, Y. Lhoste, T. Ferry,
S. Tigaud, J. Etienne, F. Vandenesch, F. Laurent
(Lyon, FR)
O521
11:54 Immunological and molecular mechanisms
induced in an in vitro model of co-culture of
Helicobacter pylori and dendritic cells
A. Hocès De La Guardia, C. Staedel, I. Kaafarany,
A. Clément, P. Blanco, F. Mégraud, P. Lehours*
(Bordeaux, FR)
O524
11:30 Trends in antimicrobial resistance in
Acinetobacter spp. from the European
TEST programme
M. Hackel, D. Hoban, R. Badal, S. Bouchillon,
B. Johnson, J. Johnson, S. Hawser*, M. Dowzicky
(Schaumburg, US; Epalinges, CH; Collegeville, US)
O525
11:42 Molecular epidemiology of Acinetobacter
baumannii in Germany, 2005–2009
X. Schleicher*, P.G. Higgins, H. Wisplinghoff,
D. Stefanik, M. Kresken, H. Seifert
(Cologne, Rheinbach, DE)
O526 11:54 Aminoglycoside resistance and distribution
of resistance genes in sporadic and outbreak
strains of Acinetobacter baumannii isolated
in Abu Dhabi
T. Pal*, A. Gazawi, A. Sonnevend, M. Ibrahim,
S.E. Belal, M. Al-Haj (Al Ain, AE)
O527 12:06 Ceftazidime-resistance in Acinetobacter
baumannii of clonal complex 92 in Korea
Y. Lee*, Y. Kim, I.K. Bae, S.H. Jeong, K. Lee
(Seoul, KR)
O528
O522 12:06 MicroRNA expression profile in human
macrophages infected with Mycobacterium
tuberculosis
L. Furci*, E. Schena, P. Miotto, P. Mantegani,
D. Cirillo (Milan, IT)
O523
12:18 Toll-like receptor 4 polymorphism Asp299Gly
and its association with nasopharyngeal
colonisation of Moraxella catarrhalis in
Finnish infants
J. Vuononvirta*, L. Toivonen, L. Lindholm,
J. Mertsola, V. Peltola, Q. He (Turku, FI)
12:18 Endemic multidrug-resistant Acinetobacter
baumannii from animal specimens in German
veterinary clinics
S. Kreder*, E. Prenger-Berninghoff, R. Weiss,
T. van der Reijden, P. van den Broek, G. Baljer,
L. Dijkshoorn (Gießen, DE; Leiden, NL)
Lecture Hall Mycoplasma genitalium: the new Chlamydia?
Amber 4 From epidemiology to clinical diagnostics
11:30 – 12:30 Bio-Rad chair: C. Bébéar (Bordeaux, FR)
ESCMID/ISC chair: tbc
S528a
Epidemiology of Mycoplasma genitalium –
evidence for the need to detect and treat
Lisa E. Manhart (Seattle, US)
S528b
Mycoplasma genitalium treatment – not as
simple as we thought
Jorgen Skov Jensen (Copenhagen, DK)
S528c
Evaluation of a triplex real-time PCR assay
for simultaneous detection of Chlamydia
trachomatis, Neisseria gonorrhoeae and
Mycoplasma genitalium in urogenital samples
Cécile Bébéar (Bordeaux, FR)
Integrated symposium arranged by Bio-Rad
88
Final Programme
Tuesday, 10 May
Poster Session VI
Lecture Hall Controlling MRSA
White 3 Chairpersons: Andreas F. Widmer (Basel, CH);
13:30 – 15:30
Heidi Ammerlaan (Utrecht, NL)
Topics
P1957 – P1961 Clinical management challenges in hepatitis in
an era of changing treatment options
P1962 – P1976 Clostridium difficile
P1977 – P1995 Diagnosis of C. difficile infections
P1996 – P2020 Mycobacterial disease: diagnosis
P2021 – P2024 Advances in mycobacterial culture
P2025 – P2029 Antimicrobial activity against mycobacteria
P2030 – P2046 Mycobacterial disease, pathogenesis and
epidemiology
P2047 – P2053 Molecular diagnosis of mycobacterial infections
P2054 – P2061 Lyme borreliosis, toxoplasmosis
P2062 – P2067 Sexually transmitted diseases
P2068 – P2071 Acute diarrhea
P2072 – P2083 Solid organ transplant infections
P2084 – P2094 Infections in the immunocompromised host
P2095 – P2103 Molecular diagnosis of invasive fungal
infections: has the era of empirical antifungals
come to an end?
P2104 – P2139 Fungal infections: epidemiology, molecular
bases and management
P2140 – P2153 Systemic antifungals: in vitro and in vivo data
P2154 – P2164 Diagnosis of viral infections
P2165 – P2194 HIV/AIDS
P2195 – P2215 Virology: non HIV/non hepatitis
P2216 – P2237 Viral hepatitis
P2238 – P2248 Infection in cancer patients
S533
13:30 Routine admission screening or risk
assessment?
Jacqueline Reilly (Glasgow, UK)
S534
14:00 MRSA carriage – methods of detection
Peter Hawkey (Birmingham, UK)
S535
14:30 Measures to be taken: hand hygiene,
isolation, hospital cleaning
Benedetta Allegranzi (Geneva, CH)
S536
15:00 Is it cost-effective?
Arranged with the ISC Working Group on MRSA
and the Scottish Microbiology Association
(SMA)
Lecture Hall Milestones in antimicrobial chemotherapy
Amber 1 during the past 50 years!
13:30 – 15:30 Chairperson: Wing-Hong Seto (Hong Kong, HK)
S537
13:30 Penicillins
Alasdair Geddes (Birmingham, UK)
S538
14:00 Cephalosporins
Ragnar S. Norrby (Solna, SE)
S539
14:30 Aminoglycosides
Robert L. Moellering (Boston, US)
S540
15:00 From sulphonamides to fluoroquinolones
Axel Dalhoff (Wuppertal, DE)
Official Symposia
Lecture Hall Late presenters in Europe
White 2 Chairpersons: Cristina Mussini (Modena, IT);
13:30 – 15:30
Caroline Sabin (London, UK)
Lecture Hall Imaging infection
Brown 1 Chairpersons: Dominique Salmon (Paris, FR);
13:30 – 15:30
S529
13:30 Epidemiology of late presenters in Europe
(Euro-CDC)
Caroline Sabin (London, UK)
S541
13:30 Imaging human infections (Ultrasound,
CT-scan, MRI, PET)
Claus Peter Heussel (Mainz, DE)
S530
14:00 Advances in the microbiological diagnosis
of opportunistic infections in AIDS patients
Miriam J. Álvarez-Martinez (Barcelona, ES)
S542
14:00 Imaging microbes in vivo
Agneta Richter-Dahlfors (Stockholm, SE)
S543
S531
14:30 When to start anti-retroviral therapy in
patients with opportunistic infections
Cristina Mussini (Modena, IT)
14:30 Dynamic imaging (bioluminescence,
two-photon imaging)
Chris Contag (Stanford, US)
S544
S532
15:00 Risk factors, immunopathology and
management of IRIS
Paola Cinque (Milan, IT)
15:00 Ultraresolutive imaging (FRAP, STORM,
electron microscopy, tomography)
Jost Enninga (Paris, FR)
Final Programme
89
Tuesday, 10 May
Lecture Hall Resistant superbugs: a comparative analysis
Brown 2 of Asia versus Europe
13:30 – 15:30 Chairpersons: Patrice Nordmann (Paris, FR);
Roman Kozlov (Smolensk, RU)
Lecture Hall Risk factors other than neutropenia for
Silver developing infection in immunosuppressed
13:30 – 15:30 patients
Chairperson: Mickael Aoun (Brussels, BE)
S546
13:30 MRSA, VISA and VRSA
S549
S547
14:00 ESBLs and carbapenemases
David Livermore (London, UK)
13:30 Toll-like receptors polymorphisms and fungal
infections
Luigina Romani (Perugia, IT)
S550
14:30 Quinolone resistance in Gram-negative bacilli
Minggui Wang (Shanghai, CN)
14:00 Complement and fungal infections
S551
14:30 Mannose-binding lectin and bacterial
infections in patients with haematological
cancer
Mickael Aoun (Brussels, BE)
S552
15:00 Severe graft-versus-host disease (GVHD) and
infection in allogeneic stem cell recipients
Herman Einsele (Würzburg, DE)
S548
S545
15:00 In vitro resistance and in vivo efficacy
EESCMID
SCMID Parity
Parity CCommission
ommission
FFurther
ur ther iinformation:
nformation:
www.escmid.org/parity
w
ww.escmid.org/parity or
or
pa
rity@escmid.org
parity@escmid.org
90
Final Programme
Poster Sessions
Saturday, 7 May
P553
AMR in Gram-negatives
Prevalence and molecular epidemiology of
infections caused by extended-spectrum and
plasmid-mediated AmpC beta-lactamase
producing Gram-negative bacteria in hospital
and community settings in Bosnia and
Herzegovina
S. Uzunovic;-Kamberovic, A. Ibrahimagic*,
B. Bedenic, A. Ibrahimagic, F. Kamberovic, T. Ille,
S. Sivec, Ž. Žagar (Zenica, Travnik, Zenica, BA;
Zagreb, HR; Ljubljana, SI; Belgrade, RS)
P554
High rates of multidrug resistance among
Gram-negative pathogens in Europe. Results
from GLOBAL 6 Surveillance (2009–2010)
C. Pillar*, J. Deane, D.F. Sahm (Chantilly, US)
P555
Antimicrobial resistance of Citrobacter spp.,
Enterobacter spp. and Klebsiella spp. strains
isolated from meat samples
P. Gousia, E. Economou, H. Sakkas,
S. Levidiotou*, C. Papadopoulou (Ioannina, GR)
P556
Comparative antibacterial activity against
E. coli from paediatric patients in North
America and Europe: 2006–2009
D. Hoban, S. Bouchillon, M. Hackel*, B. Johnson,
R. Badal, J. Johnson, S. Hawser, M. Dowzicky
P557
Increase of polymicrobial infections and
multi-resistant pathogens causing prosthetic
joint infections
S. Petersdorf*, T. Hoppe, A. Hoerauf,
G. Pagenstert, D. Wirtz, M. Wimmer, S. Gravius
(Bonn, DE; Basel, CH)
P558
Emerging quinolone resistance in typhoid
outbreaks caused by haplotype H58 in Kenya
S. Kariuki*, G. Revathi, R. Kingsley, K. Holt,
G. Dougan (Nairobi, KE; Cambridge, UK)
P559
Multilocus sequence typing of IncN plasmids
A. García-Fernández*, L. Villa, A. Moodley,
H. Hasman, V. Miriagou, L. Guardabassi,
A. Carattoli (Rome, IT; Frederiksberg, Lyngby, DK;
Athens, GR)
P560
The ecology of major resistance plasmids in
E. coli
J. Ellem, Z. Zong, S. Partridge, J. Iredell*
(Sydney, AU)
P561
Who are the carriers of multi-resistant
bacteria in the community? A one-year
prospective study in France
J. Caillon*, S. Thibaut, N. Foucher, S. Allorent,
G. Grandjean, F. Ollivier, F. Ballereau (Nantes, FR)
P562
Epidemiology of plasmid-mediated quinolone
resistance determinants in bacterial isolates
from animals and food with co-resistance to
several antibiotics
E. Ferreira, A.P. Francisco, D. Jones-Dias*,
V. Manageiro, M. Caniça (Lisbon, PT)
P563
Colistin therapy for multidrug-resistant
Gram-negative infection: clinical outcome
and risk factors
Y. Jun*, H.J. Choi (Seoul, KR)
P564
Vibrio cholerae O1 Ogawa, a major aetiological
agent of diarrhoeal disease outbreak in
Western Nepal
B.R. Adhikari*, G. Shakya, S. Shrestha,
B. Upadhyay, K. Kc (Kathmandu, NP)
P565
Antimicrobial susceptibility trends of
Enterobacteriaceae from intra-abdominal
infections in Europe: SMART 2002–2010
R. Badal*, S. Hawser, S. Bouchillon, D. Hoban,
M. Hackel, A. Johnson (Schaumburg, US;
Epalinges, CH)
P566
Comparison of antimicrobial susceptibility
of Escherichia coli from intra-abdominal
and urinary tract infections in Europe:
SMART 2009–2010
R. Badal*, D. Hoban, S. Hawser, S. Bouchillon,
M. Hackel, A. Johnson (Schaumburg, US;
Epalinges, CH)
P567
A 3-year study of Stenotrophomonas
maltophilia clinical isolates in a tertiary
hospital. Emergence of sulfamethoxazole/
trimethoprim resistance
A. Stylianakis*, S. Tsiplakou, V. Papaioannou,
P. Thomaidis, A. Panagopoulou, C. Karra,
A. Koutsoukou (Athens, GR)
P568
Serotypes, antibiotic resistance, and class 1
integrons in Salmonella isolates from
paediatric cases of enteritis in Tehran, Iran
R. Ranjbar*, G.M. Giammanco, S. Farshad,
P. Owlia, A. Aleo, N. Jonaidi, M. Izadi,
N. Sadeghifard, C. Mammina (Tehran, IR;
Palermo, IT; Shiraz, IR; Ilam, IR)
P569
AAC(3)-II is the major aminoglycosidemodification enzyme in China, which leading
to the obvious partial cross-resistance in
Escherichia coli to agents
Y. Xiao*, Y. Hu (Hangzhou, Beijing, CN)
P570
Surveillance of nosocomial and communityacquired enteric pathogens shed in equine
faeces and analysis of risk factors
associated with antibiotic resistant E. coli
M. Ahmed* (Tripoli, LY)
Final Programme
Posters
15:30 – 16:30
91
Poster Sessions
Saturday, 7 May
P571
Prevalence of carbapenem-resistant
Enterobacteriaceae and carbapenem-resistant
Pseudomonas aeruginosa and Acinetobacter
baumannii in routine ESBL surveillance
samples
M. Pirs*, A. Andlovic, T. Cerar, T. Furlan,
J. Guzej, K. Seme (Ljubljana, SI)
P572
Evaluation of a new gradient-diffusion
system for MIC determination with
Gram-negative pathogens
V. Conte, M.M. D'Andrea, T. Giani, G.M. Rossolini*
(Siena, IT)
P573
In vitro activity of piperacillin-tazobactam
and comparators against P. aeruginosa in
countries of Eastern Europe, 2006–2010
S. Lob, S. Bouchillon, R. Badal, D. Hoban*,
S. Hawser, M. Hackel, M. Dowzicky
P574
Surveillance of antimicrobial susceptibility
of Pseudomonas aeruginosa isolates from
a central hospital in central Portugal:
7 years of evolution or involution?
S.G. Pereira*, H. Oliveira, L. Albuquerque,
R. Leitão, O. Cardoso on behalf of the Center
for Pharmaceutical Studies
P575
Resistance rates of Pseudomonas aeruginosa
clinical isolates in a tertiary hospital
S. Tsiplakou, A. Stylianakis, V. Papaioannou,
P. Thomaidis, E. Chatziandreou, C. Karra,
A. Koutsoukou* (Athens, GR)
P576
Activity of colistin against European
P. aeruginosa from the TEST Study: 2009 – 2010
M. Hackel, D. Hoban*, B. Johnson, S. Bouchillon,
J. Johnson, S. Hawser, M. Dowzicky
P577
Population structure of clinical and
environmental Pseudomonas aeruginosa
isolates from five Mediterranean countries
M. Maatallah, A. Bakhrouf, C. Giske*
(Monastir, TN; Stockholm, SE)
15:30 – 16:30
92
Helicobacter pylori infections: from diagnosis
to pathogenesis
P578
Can Helicobacter pylori reside in the human
oral cavity?
A. Al-Ahmad*, A. Kürschner, A. Wittmer,
E. Hellwig, M. Kist, B. Waidner (Freiburg, DE)
P579
Assessment of peroxisome proliferatoractivated receptor-gamma polymorphisms in
Helicobacter pylori infected patients
H. Goudarzi* (Tehran, IR)
Final Programme
P580
Detection of H. pylori and clarithromycin
and/or fluoroquinolone resistance in gastric
biopsies by Genotype® HelicoDR
T. Alarcon*, A. Somodevilla, S. Agudo,
P. Urruzuno, M.J. Martinez, M. Lopez-Brea
(Madrid, ES)
P581
Cytokine levels in serum of patients with
gastric pathologic infected with Helicobacter
pylori cagA negative and cagA positive
D. Ortiz Princz*, O. Rodríguez, M. Cavazza
(Caracas, VE)
P582
Prevalence and distribution of virulence
factor jhp0562 and jhp0563 genes among
Spanish Helicobacter pylori clinical isolates
Á. Somodevilla*, T. Alarcón, E. Aznar,
M.J. Martínez, M. López-Brea (Madrid, ES)
P583
Molecular characterisation of Helicobacter
pylori associated to different gastric
pathology in adult Moroccan population:
prospective study
S. Alaoui, B. Bennani, M. Mahmoud*, M. Lahbabi,
D. Benajah, M. El Abkari, A. Ibrahimi, H. Belghiti,
A. Amarti, K. El Ghazi, C. Nejjari, A. Souleimani
(Fez, MA)
P584
Prevalence of virulence factor HomB among
Spanish Helicobacter pylori clinical isolates
Á. Somodevilla*, T. Alarcón, M. Espínola,
P. Urruzuno, M. López-Brea (Madrid, ES)
P585
Mice immune responses to UreB332-HpaA,
a recombinant fusion protein from Helicobacter
pylori
B. Hajikhani*, S. Najar Peerayeh,
H. Soleimanjahi, Z. Hassan (Tehran, IR)
15:30 – 16:30
Diagnosis of gastrointestinal infections
P586
Prospective application of the Luminex
xTAG®-GPP multiplex PCR in diagnosing
infectious gastroenteritis
E. Wessels, L. Rusman, M. van Bussel, L. Lan,
D. Himsworth, E. Claas* (Leiden, NL; Toronto, CA)
P587
Screening for enteropathogenic Escherichia
coli by an eight-plex PCR of nucleic acids
extracted directly from human stools using
the NorDiag Bullet stool DNA kit
J.K. Møller*, B. Kolmos, M.H. Dahl,
L. Pødenphant, D. Ørnskov (Vejle, DK)
P588
Microarray-based detection of virulence
genes in verotoxic Escherichia coli strains
isolated from human, cattle and food in
Poland
A. Januszkiewicz*, J. Szych, J. Osek,
W. Rastawicki (Warsaw, Pulawy, PL)
Poster Sessions
Saturday, 7 May
Evaluation of a new multiplex PCR as a tool
for the identification of Campylobacter
species in bacterial gastroenteritis
M.A. Lucien*, M. Boissinot, A. Huletsky,
D. Boudreau, M.C. Helie, M.G. Bergeron
(Quebec City, CA)
P590
Contrast-enhanced sonography for the
diagnosis and therapy of liver abscesses
R. Chiavaroli*, P. Grima, L. Gillini (Galatina, IT)
P591
Distribution of Salmonella enteritidis and
Salmonella typhimurium phage types in
Slovakia
L. Majtánová, V. Majtán* (Bratislava, SK)
P592
Comparison of two different Rappaport
broths for the detection of Salmonella in
faecal specimens from patients with
gastroenteritis
L. Conter*, R. Vaiani, R. Botrugno, M. Reboldi,
S. Missorini, R. Colombo (Brescia, IT)
P593
Isolation of the emerging food-borne
pathogen Arcobacter from human stool
K. Houf*, S. Drieghe, A. Van den Abeele
(Merelbeke, Ghent, BE)
15:30 – 16:30
P594
P595
P596
P597
ESBL and AmpC in Enterobacteriaceae and
A. baumannii
Acquisition of carbapenem resistance in
multi-resistant Klebsiella pneumoniae
strains harbouring blactx-m-15, qnrs1 and
aac(6’)-Ib-cr genes
E. Ruiz*, A. Ocampo-Sosa, A. Rezusta, M. Revillo,
E. Román, C. Torres, L. Martínez-Martínez
(La Rioja, Santander, Zaragoza, ES)
Molecular characterisation of extendedspectrum beta-lactamase CTX-M-15 carrying
Escherichia coli isolates from cattle
J.-Y. Madec*, A. Gourguechon, E. Saras,
M. Haenni (Lyon, FR)
Genetic characterisation of CTX-M producing
Proteus mirabilis and Morganella morganii
clinical strains with association of resistance
genes in Tunisia
S. Mahrouki, M. Ben-Moussa, O. Belhadj,
M. Perilli*, G. Amicosante (Tunis, Monfleury, TN;
L'Aquila, IT)
Biochemical characterisation of TEM-107
extended-spectrum beta-lactamase with an
additional Arg164His substitution compared
to TEM-52
K. Lee, J. Yum, D. Yong, S.H. Jeong,
J.D. Docquier, G.M. Rossolini, Y. Chong*
(Seoul, Busan, KR; Siena, IT)
P598
Cephalosporin and clavulanic acid resistance
mechanisms in Escherichia coli isolates from
cattle in Portugal
C. Pomba*, F. Loução, N. Couto, M. Delgado,
J. Duarte Correia (Lisbon, PT)
P599
Genetic characterisation of an extendedspectrum AmpC-cephalosporinase with
hydrolysing activity against fourthgeneration cephalosporins in a clinical
isolate of Enterobacter aerogenes selected in
vivo
J.M. Rodríguez-Martínez*, P. Fernández,
F. Fernández-Cuenca, P. Diaz de Alba, A. Briales,
Á. Pascual (Seville, ES)
P600
Evaluation of phenotypic methods for the
detection of AmpC beta-lactamase producers and
their differentiation from extended-spectrum
beta-lactamases in Enterobacteriaceae
E.C. Coyle*, J. Kavanagh, D. Keating, K. Schaffer
(Dublin, IE)
P601
Role of IS30 in the expression of the blaADC
gene in Acinetobacter baumannii
B. Lopes, A. Hamouda, S. Amyes* (Edinburgh, UK)
15:30 – 16:30
Mechanisms of carbapenem-resistance in
Enterobacteriaceae and P. aeruginosa
P602
Investigation of carbapenem resistance
in Klebsiella pneumoniae isolates from
St. James's hospital, Dublin, Ireland
C. Roche* (Dublin, IE)
P603
Lack of 37kDa outer membrane protein in
Klebsiella pneumoniae associated with
decreased susceptibility to imipenem in
Japan
T. Sho*, T. Muratani, R. Hamasuna, H. Yakushiji,
M. Honda, T. Kobayashi, N. Fujimoto,
T. Matsumoto (Kitakyushu, JP)
P604
KdgM a novel porin associated to carbapenem
resistance in Klebsiella pneumoniae
L. Garcia-Sureda*, A. Doménech-Sánchez,
C. Juan, S. Albertí (Palma, ES)
P605
Accumulation of carbapenemase-producing
Gram-negative bacteria in a single patient
linked to the acquisition of multiple
carbapenemase-producing strains and to the
in vivo transfer of a plasmid encoding VIM-1
L. Drieux*, N. Bourgeois-Nicolaos,
J. Cremniter, C. Lawrence, E. Macheras,
V. Jarlier, F. Doucet-Populaire, W. Sougakoff
(Paris, Boulogne-Billancourt, Garches, FR)
Final Programme
Posters
P589
93
Poster Sessions
Saturday, 7 May
Characterisation of Acinetobacter baumannii
isolates causing infections in animals
A. Endimiani*, K.M. Hujer, A.M. Hujer,
I. Bertschy, A. Rossano, C. Koch, V. Gerber,
T. Francey, R.A. Bonomo, V. Perreten
(Bern, CH; Cleveland, US)
P616
Emergence of OXA-48-producing enterobacterial
isolates in France, with multiple importations
from Turkey and North Africa
L. Poirel*, N. Fortineau, P. Nordmann
Genotypic evaluation of a collection of
Cfr-producing staphylococcal clinical isolates
from the SENTRY Antimicrobial Surveillance
Program.
R. Mendes*, L. Deshpande, M. Castanheira,
R. Jones (North Liberty, US)
P617
X-ray crystal structure of the Acinetobacter
baumannii OXA-24/40 Class D
carbapenemase inhibited by NXL104
J.D. Docquier*, M. Benvenuti, J.M. Bruneau,
G.M. Rossolini, S. Mangani, C. Miossec, M.T. Black
(Siena, IT; Romainville, FR)
Prevalence of Tn6060-like transposons,
harboured in a pathogenicity island in
E. Martinez*, A. Ingold, P. Roy Chowdhury,
J. Merlino, C. Marquez, H. Stokes
(Sydney, AU; Montevideo, UY)
P618
Provisional report of an association between
the carbapenemase KPC and the pandemic
clone E. coli 025b:ST131
I. Condon, C. Ludden, M. Corcoran, N. O'Connell,
M. Cormican*, T. Boo, D. Morris
(Limerick, Galway, IE)
P619
High incidence of horizontal transfer of
ampicillin resistance (pbp5) among CC17
Enterococcus faecium
C. Novais*, R. Escada, A.R. Freitas, E. Silveira,
T.M. Coque, L. Peixe (Porto, PT; Madrid, ES)
P620
Diversity of animal and human Tn1546Enterococcus faecium isolates belonging to
CC9 and CC17 (ST78)
M. López*, A.P. Tedim, F. Baquero, C. Torres,
T.M. Coque (Logroño, Madrid, ES)
P621
Quantitation of bacteria in gastric biopsy
specimen from patients with gastrointestinal
disorders: relationship between counts and
23S rRNA point mutations
M. Kargar*, S. Ghorbani-Dalini, A. Doosti,
N. Souod, P. Abbasi (Jahrom, Shahrekord, IR)
P622
Prevalence and molecular characterisation
of extended-spectrum beta-lactamaseproducing Escherichia coli in Moroccan
community
A. Barguigua, K. Zerouali, M. Talmi, F. El Otmani,
M. Timinouni* (Casablanca, El Jadida, MA)
P623
Mutations on the quinolone-resistant
determining regions in gyrA or parC gene
of Mycoplasma genitalium
R. Hamasuna*, M. Matsumoto, T. Sho,
N. Fujimoto, T. Matsumoto, J.S. Jensen
(Kitakyushu, JP; Copenhagen, DK)
First detection of blaIMI-2 gene in a clinical
Escherichia coli strain
B. Rojo-Bezares*, C. Martín, C. Torres, Y. Sáenz
(Logroño, ES)
P607
Emergence of OXA-181 carbapenemaseproducing Enterobacteriaceae
L. Poirel*, E. Lafeuille, S. Bernabeu, P. Nordmann
P608
P609
P610
Evaluation of a commercial microarray
to detect carbapenemase-producing
Enterobacteriaceae
N. Woodford* (London, UK)
P611
Identification of OXA-198, a novel carbapenemhydrolysing class D beta-lactamase, in
F. El Garch*, P. Bogaerts, C. Bebrone,
Y. Glupczynski (Yvoir, Liège, BE)
P612
Characterisation of OprD in Pseudomonas
aeruginosa clinical strains showing high
and intermediate levels of resistance to
imipenem and meropenem
A. Ocampo-Sosa*, C. Rodríguez, G. Cabot,
E. Roman, F. Tubau, M. Macia, B. Moya,
L. Zamorano, C. Suarez, C. Peña, A. Oliver,
L. Martinez-Martinez (Santander, Palma de
Mallorca, Barcelona, ES)
15:30 – 16:30
94
P615
P606
Genetics of antimicrobial resistance
P613
Association of 16S rRNA methylases and
NDM-1 in isolates from Indian hospitals
collected in 2006–2007
M. Castanheira*, L. Deshpande, R. Mendes,
R. Jones (North Liberty, US)
P614
IMP-18-producing Klebsiella oxytoca,
increasing genetic diversity of metallo-betalactamases in Mexican hospitals
M. Castanheira*, L. Deshpande, R. Morfin-Otero,
E. Rodriguez-Noriega, R. Jones
(North Liberty, US; Guadalajara, MX)
Final Programme
Poster Sessions
Saturday, 7 May
P624
Association of virulence markers and
antimicrobial susceptibility in Escherichia
coli clinical isolates
V. Calhau*, T. Lin, G. Ribeiro, N. Mendonça,
G. Da Silva (Coimbra, PT; Ann Arbor, US)
P633
Rapid detection system consisting of
multiplex PCR and melting curve analysis
to amplify and identify blaTEM, blaSHV and
blaCTX-M genes in a single reaction
M. Chroma*, M. Kolar (Olomouc, CZ)
P625
Mutations in the dihydropteroate synthase
gene in Pneumocystis jirovecii isolates from
children in Cape Town
S. Kumar, L. Ah Tow, C.M. Samuel, B. Morrow,
M. Zampoli, H.J. Zar, A.C. Whitelaw* (Cape Town, ZA)
P634
The oqxAB gene complex is present in all
Klebsiella pneumoniae clinical isolates
J. Yuan, X. Xu, Q. Guo, X. Ye, M. Wang*
(Shanghai, CN)
P635
P626
Characterisation of the penA mosaic gene
in Neisseria gonorrhoeae strains with
decreased susceptibility to cephalosporins
in Amsterdam, Netherlands
R. Heymans*, S.M. Bruisten, H.J. de Vries,
A.P. van Dam (Amsterdam, NL)
Genetic basis of expanded-spectrum
cephalosporin resistance in Salmonella from
food animals detected by the Italian
Veterinary Monitoring System (ITAVARM)
A. Franco*, F. Feltrin, V. Donati, R. Amoruso,
R. Lorenzetti, S. Tagliabue, M. D'Incau, A. Lettini,
A. Battisti (Rome, Brescia, Legnaro, IT)
P627
abaR3-like genomic resistance islands
are associated with Acinetobacter baumannii
strains of European clone I
L. Krizova*, L. Dijkshoorn, A. Nemec
(Prague, CZ; Leiden, NL)
P636
P628
CTX-M sequence types, plasmid replicon
types, antimicrobial resistance genes and
virulence genes in Escherichia coli isolates
from cattle, chickens and turkeys in Great
Britain
L.P. Randall*, M. Toszeghy, H. Wearing,
R. Horton, G. Wu, R.H. Davies, N. Coldham,
C.J. Teale (New Haw, UK)
Identification of Inc plasmids types and its
association with plasmid-mediated quinolone
resistance and extended-spectrum betalactamases determinants carried by
Escherichia coli clinical strains
V. Calhau*, M. Fois, G. Ribeiro, N. Mendonça,
G. Da Silva (Coimbra, PT)
P630
P631
P632
Comparison of genetic characteristics
between Acinetobacter baumannii and
Acinetobacter genomospecies 3 and 13TU
isolated from Tae-jeon, Korea
S.H. Koo*, K. Kwon, G. Sung on behalf of the
Korean Soceity of Clinical Microbilogist
Genetics basis of antimicrobial resistance in
clinical multidrug-resistant strains of
Salmonella typhimurium, southern Italy
M. Legretto, F. Nuccio, R. Monno*, A. Pupillo,
A. Dionisi, D. De Vito, C. Pazzani (Bari, Rome, IT)
Point mutations associated with antibiotic
resistance and clonal relatedness of
Pseudomonas aeruginosa clinical isolates
M. Straut*, S. Dinu, M. Surdeanu (Bucuresti, RO)
Molecular characteristics of extendedspectrum beta-lactamase-producing
Escherichia coli in Japan: emergence of CTXM-15 in Japanese clinical isolates of E. coli
ST131
H. Yano*, K. Hitoshi, Y. Hirakata, K. Arai, S. Endo,
H. Kanamori, M. Ogawa, M. Shimojima,
N. Ishibashi, T. Aoyagi, M. Hatta, M. Yamada,
K. Nishimaki, K. Tokuda, M. Kitagawa,
H. Kunishima, M. Kaku (Sendai, Kawagoe, JP)
Molecular detection of antibiotic resistance
among Gram-negative bacteria
P637
Characterisation of carbapenemases in
multidrug-resistant Acinetobacter baumannii
isolates from intensive care units
A. Uskudar Guclu*, A. Kilic, A.G. Gozen,
O. Bedir, A. Basustaoglu (Ankara, TR)
P638
Evaluation of a low-density microarray
for the identification of ESBL, AmpC and
carbapenemase-producing Enterobacteriaceae
U. Eigner*, D. Bertsch, K. Moskorz, M. Holfelder
(Heidelberg, DE)
P639
Diversity of gene cassette promoters
in antibiotic-resistant bacteria from
wastewater environments
A. Moura, T. Jové*, M.C. Ploy, I. Henriques,
A. Correia (Aveiro, PT; Limoges, FR)
P640
Evaluation of a commercial miniaturised DNA
microarray for detection of beta-lactamase
genes in Gram-negative bacteria
M. Gazin*, J. Vervoort, L. Bryssinck, C. Lammens,
M. Gniadkowski, H. Goossens, S. Malhotra-Kumar
on behalf of the MOSAR WP2 and SATURN WP1
study groups
Final Programme
95
Posters
P629
15:30 – 16:30
Poster Sessions
Saturday, 7 May
P641
P642
P643
P644
15:30 – 16:30
P645
P646
Development of a real-time multiplex
PCR assay for the detection of plasmidmediated AmpC beta-lactamases directly
from blood cultures
G.L. Vanstone*, L. Ramzi, B.M. Charalambous,
I. Balakrishnan (London, UK)
Long-term evolution of hyper-mutable
strains increases the mutational cost of
M.C. Turrientes*, A. Ripoll, M.R. Baquero,
R. Cantón, F. Baquero, J.C. Galán (Madrid, ES)
Rapid molecular detection of carbapenemaseproducers in Enterobacteriaceae including
the newly described NDM-1 carbapenemase
(TEST 2009 – 2010)
C. Lascols*, M. Hackel, S. Hawser, R. Badal,
S. Bouchillon, D. Hoban, M. Dowzicky
P650
First documented New Delhi metallo-betalactamase 1 (NDM-1) cases in Switzerland
C. Fankhauser*, A. Cherkaoui, G. Renzi,
J. Schrenzel, S. Harbarth (Geneva, CH)
P651
Characterisation of the first NDM-1 producing
Enterobacteriaceae in Belgium
P. Bogaerts*, W. Bouchahrouf, A. Deplano,
R. Rezende, C. Berhin, O. Denis, Y. Glupczynski
(Yvoir, Brussels, BE)
P652
NDM-1 in Israel, evidence of travelling and
carriage of carbapenem-resistant organisms
M. Castanheira*, L. Deshpande, G. Smollan,
R. Mendes, R. Jones, D. Ben-David, M. Hindiyeh,
S. Gefen-Halevi, N. Keller (North Liberty, US;
Tel-Hashomer, IL)
P653
Nosocomial transmission of NDM-1-producing
Klebsiella pneumoniae in a tertiary care
hospital, United Arab Emirates
A. Sonnevend*, T. Pal, R. Hashmey,
M.B. Hamadeh, M. Al-Haj, N. Akawi, A. Gazawi,
A. Javad (Al Ain, AE)
P654
Diversity of sequence types and serotypes
among invasive isolates of Klebsiella
pneumoniae years 2007–2009, isolated at
a tertiary university hospital in Sweden
M. Andersson*, M. Kabir, A. Iversen, C. Giske
(Stockholm, SE)
Epidemiology of NDM-1
Emergence of New Delhi metallo-beta-lactamase
(NDM-1)-producing Enterobacteriaceae in Austria
A.J. Grisold*, G. Zarfel, M. Hönigl, T. Valentin,
H.J. Salzer, E. Leitner, R. Krause (Graz, AT)
Characterisation of the first NDM-1 metallo
beta-lactamase producing Escherichia coli
isolates from an Italian hospital
T. Giani, M.M. D'Andrea, F. Arena, V. Conte,
C. Venturelli, P. Bresciani, F. Rumpianesi,
F. Narni, G.M. Rossolini* (Siena, Modena, IT)
P647
Emergence and epidemiology of New Delhi
metallo-beta-lactamase 1–producing
Klebsiella pneumoniae in a Korean tertiary
care hospital
M.N. Kim*, S.H. Park, D. Ahn, M. Lee (Seoul, KR)
P648
Klebsiella pneumoniae harbouring NDM-1
metallo-beta-lactamase isolated in Croatia
A. Mazzariol*, Z. Bosnjak, P. Ballarini, A. Budimir,
B. Bedenic, S. Kalenic, G. Cornaglia
(Verona, IT; Zagreb, HR)
P649
96
Multiplex polymerase chain reactions
for extended-spectrum beta-lactamases,
AmpC beta-lactamases and carbapenemases
G.M. Voets*, A.C. Fluit, J. Scharringa,
J.W. Cohen Stuart, M. Leverstein-van Hall
on behalf of the ESBL National Surveillance
Working Group
First description of an Escherichia coli strain
producing NDM-1 carbapenemase in Spain
M.M. Solé*, C. Pitart, P. Salvador, L. Muñoz,
I. Oliveira, J. Gascón, I. Roca, A. Fàbrega,
F. Marco, J. Vila (Barcelona, ES)
Final Programme
15:30 – 16:30
ESBL: a growing problem
P655
Dissemination of Salmonella enterica serovar
enteritidis sequence type 11 producing
CTX-M-15 extended-spectrum beta-lactamase
in Korea
I.K. Bae*, Y. Kim, S.H. Jeong, C. Lee, K. Lee
(Seoul, Daegu, KR)
P656
Susceptibility and incidence of extendedspectrum beta-lactamase producing
Escherichia coli and Klebsiella pneumoniae
in intra-abdominal infections globally:
SMART 2009–2010
R. Badal*, S. Hawser, S. Bouchillon, D. Hoban,
M. Hackel, A. Johnson
(Schaumburg, US; Epalinges, CH)
P657
Temporal trends of Enterobacteriaceae with
resistance to higher generation cephalosporins
in Switzerland, 2004 to 2010
A. Kronenberg*, K. Mühlemann (Berne, CH)
Poster Sessions
P658
Country-wide prevalence of ESBL-producing
Enterobacteriaceae in 2009
D.S. Hansen*, F. Hansen, H. Schumacher,
K. Schønning, S.G.K. Hansen, K. Fuursted,
T. Højbjerg, H.K. Johansen, J.K. Møller,
B.H. Kallesøe, M. Arpi, E. Dzajic, B. Røder,
O. Heltberg, A.M. Hammerum, N. Frimodt-Møller
(Hillerød, Copenhagen, Herning, Hvidovre,
Odense, Århus, Aalborg, Vejle, Viborg,
Herlev, Esbjerg, Slagelse, Næstved, DK)
P659
Clinical, epidemiological and microbiological
features of urinary tract infections caused
by ESBL-producing Enterobacteriaceae in
hospitalised patients
A. Toumi*, Y. Kadri, H. Ben Abdallah, S. Noomen,
M. Chakroun, M. Mastouri (Monastir, TN)
P660
Escherichia coli and Klebsiella pneumoniae
ESBL genotype distribution in Denmark:
CTX-M-15 prevails countrywide, also in
hospital epidemics
R.F. Leihof, D.S. Hansen, F. Hansen, H. Schumacher,
S.G. Kjær Hansen, K. Fuursted, T. Højbjerg,
H.K. Johansen, J.K. Møller, J. Prag, M. Arpi,
E. Dzajic, B. Røder, O. Heltberg, A.M. Hammerum*,
N. Frimodt-Møller (Copenhagen, Hillerød,
Herning, Odense, Aarhus, Aalborg, Vejle,
Viborg, Herlev, Esbjerg, Slagelse, Næstved, DK)
P661
Prevalence of beta-lactamase enzymes in
bacteria from inanimate surfaces in Hospital
Infante D. Pedro, Aveiro, central Portugal
C. Santos, R. Diaz, E. Ramalheira, T. Caetano,
S. Mendo* (Aveiro, PT)
P662
Emergence of third-generation cephalosporinresistant Escherichia coli from bloodstream
infections in Denmark: this is due to both
clonal and non-clonal spread of CTX-M-15
F. Hansen*, C. Lester, S.S. Olsen, O. Heltberg,
U.S. Justesen, T. Højbjerg, J. Knudsen,
A.M. Hammerum (Copenhagen, Næstved,
Odense, Aalborg, Hvidovre, DK)
P663
P664
Significant increase in antimicrobial
co-resistance among extended-spectrum
beta-lactamase-producing Escherichia
coli urinary isolates in Spain (2005–2009)
I. Rodriguez-Avial*, C. Rodríguez-Avial,
E. Hernandez, J. Picazo (Madrid, ES)
Studying the urinary reservoir of extendedspectrum beta-lactamase-producing
Enterobacteriaceae in a teaching hospital
S. Le Fournis, C. Prouteau, F. Kowalczyk,
M. Joly-Guillou, M. Eveillard* (Angers, FR)
P665
Risk factors and outcome of bacteraemia due
to cefotaxime-resistant Enterobacteriaceae
in a Japanese university hospital
Y. Matsumura*, K. Yasuma, M. Yamamoto,
A. Matsushima, M. Nagao, Y. Ito, S. Takakura,
S. Ichiyama (Kyoto, JP)
P666
Risk factors for and laboratory detection time
of ESBLs
A. Khan*, C.J. Collins, M. Morris Downes,
D. Williams, H. Humphreys (Dublin, IE)
P667
Alarming rates of fluoroquinolone resistance
in CTX-M-15 harbouring Enterobacteriaceae
recovered from patients with hospitalassociated diarrhoea
J. Vervoort*, M. Gazin, M. Kazma, T. Kotlovsky,
C. Lammens, Y. Carmeli, H. Goossens,
S. Malhotra-Kumar on behalf of the SATURN
WP1 and MOSAR WP2 study groups
P668
Molecular survey of beta-lactamases
conferring third-generation cephalosporin
resistance in Enterobacteriaceae from the
Netherlands
G.M. Voets*, T.N. Platteel, J.W. Cohen Stuart,
J. Scharringa, C.M. Schapendonk, M.J. Bonten,
A.C. Fluit, M. Leverstein-van Hall on behalf of
the ESBL National Surveillance Working Group
P669
Real-time PCR typing of CTX-M and SHV family
genes of extended-spectrum beta-lactamaseproducing Enterobacteriaceae clinical
isolates from Vilnius University Hospital
Santariskiu Clinics, Lithuania
A. Macioniene, S. Kiveryte, Z. Kucinskiene,
J. Gulbinovic, L. Griskevicius, A. Jakubauskas*
(Vilnius, LT)
P670
Monomicrobial bacteraemia caused by
extended-spectrum beta-lactamase-producing
Escherichia coli: predictors of mortality and
potential role of ertapenem
U.I. Wu*, H.M. Chang, W.C. Chen, C.S. Yang,
J. Wang, F.C. Hu, S.C. Chang, Y.C. Chen
(Taipei City, Taichung, TW)
P671
Molecular characterisation of Escherichia
coli and Klebsiella pneumoniae producing
CTX-M-type extended-spectrum beta-lactamase
in Örebro County, Sweden
A. Önnberg*, P. Mölling, B. Söderquist
(Örebro, SE)
P672
The clinical risk factors and susceptibility to
fosfomycin in community-acquired urinary
tract infections caused by extendedspectrum beta-lactamase producing
Escherichia coli
A. Gokcay Canpolat, P. Zarakolu, D. Turgut,
S. Asioglu, M. Akova* (Ankara, TR)
Final Programme
97
Posters
Saturday, 7 May
Poster Sessions
Saturday, 7 May
P673
P674
P675
P676
15:30 – 16:30
P677
P678
P679
P680
98
Healthcare-associated and hospital-acquired
infections caused by Enterobacteriaceae
producing extended-spectrum beta-lactamases
in hospitalised patients: are there any
significant differences?
E. Tacconelli*, E. Mantengoli, C. Cadeddu,
L. Attala, A. Bartoloni, E. Bombana, G. Cologni,
A. Pan, R. Cauda, G.M. Rossolini (Rome, Siena,
Florence, Bergamo, Cremona, IT)
Multidrug-resistant chromosomal AmpCproducing Enterobacteriaceae isolates
carrying blaESBL, qnrB, aac-(6)-Ib-cr, and
armA
S. Sabtcheva*, T. Saga, T. Kantardjiev,
M. Kaku (Sofia, BG; Tokyo, JP; Sendai, JP)
Amplification of CTX-M-15-B2-ST131 and
emergence of A and D widespread clones
producing different ESBLs in Portuguese
hospitals
Â. Novais*, E. Machado, S. Amaral, T. Gonçalves,
R. Cantón, T.M. Coque, L. Peixe
(Porto, PT; Madrid, ES)
The occurrence of pandemic serotype ST131
in animal Escherichia coli in Slovakia
V. Kmet, Z. Drugdova, D. Ohlasova, M. Niks*
(Kosice, Bratislava, SK)
P681
Resistance of Enterobacteriaceae to
carbapenems in the University Hospital
Olomouc, Czech Republic
M. Htoutou Sedlakova*, V. Hanulik, M. Chroma,
K. Hricova, M. Senkyrikova, M. Kolar (Olomouc, CZ)
P682
Prevalence and molecular characterisation of
carbapenem-resistant Enterobacteriaceae
clinical isolates from a teaching hospital in
Shanghai, China
F. Hu*, S. Chen, X. Xu, W. Wu, Y. Liu, D. Zhu,
Y. Zhang (Shanghai, CN)
P683
A simple phenotypic algorithm for direct
and specific detection of KPC and MBL
carbapenemase-producing Enterobacteriaceae in rectal screening
O. Zarkotou, I. Kristo, A. Poulou, G. Chrysos,
K. Themeli-Digalaki, S. Pournaras*, A. Tsakris
(Athens, Larissa, Serres, GR)
P684
Molecular characterisation of multidrugresistant Enterobacteriaceae producing
carbapenemase OXA-48
Y. Pfeifer*, K. Schlatterer, E. Engelmann,
R.A. Schiller, S.-H. Cho, H.R. Frangenberg,
W. Witte (Wernigerode, Greifswald, Berlin, DE;
Seoul, KR; Lüdenscheid, DE)
P685
A study to identify risk factors for the
acquisition of carbapenemase-producing
Gram-negative organisms in a tertiary
hospital serving a major international airport
C. MacDonald*, S. Thomas, C. Thornhill
(Manchester, UK)
P686
Enterobacteriaceae producing VIM-1 metallobeta-lactamases in England – a project for a
EUPHEM fellow
K. Zakikhany*, R. Hill, R. Blackburn, J. Croall,
N. Woodford, R. Jarvis, D. Livermore, A. Efstratiou,
E. Sheridan (London, Chester, Merseyside, UK)
P687
Risk factors for carbapenem-resistant
Enterobacteriaceae carriage on admission to
a surgical unit and acquisition rate during
hospitalisation
G. Bouzala*, M. Psichogiou, L. Hadjihanas,
V. Sypsa, M. Grammaticou, D. Goukos, G. Daikos
(Athens, GR)
P688
Evaluation of the Dutch surveillance on carbapenemase producing Enterobacteriaceae
J. Muilwijk*, J.W. Cohen Stuart, N. van de Sande,
G. Voets, J. Scharringa, A.C. Fluit, M. Leversteinvan Hall (Bilthoven, Utrecht, NL)
P689
Carbapenemases in Enterobacteriaceae –
Report from the Austrian National Reference
Center
R. Hartl*, C. Luger, H. Kerschner, C. Müllner,
P. Apfalter (Linz, AT)
Carbapenem resistance in Enterobacteriaceae
Comparative in vitro activity of doripenem,
imipenem and meropenem against
contemporary Gram-negative pathogens from
Portugal, Saudi Arabia, South Africa and Turkey
J. Laeuffer*, P. Cidália, M. Cassettari,
I. Morrissey (Baar, CH; Porto, PT; Fordham, UK)
Global evaluation of meropenem nonsusceptible Enterobacteriaceae: 2006/07
versus 2009/10
S. Lob, S. Hawser*, R. Badal, S. Bouchillon,
D. Hoban, M. Hackel, M. Dowzicky
Lack of ertapenem “MIC creep” in E. coli:
data from SMART 2002 – 2010
R. Badal*, S. Lob, S. Bouchillon, M. Hackel,
D. Hoban, S. Hawser, A. Johnson
(Schaumburg, US; Epalinges, CH)
Surveillance of extended-spectrum
cephalosporin- and carbapenem- resistance
in Escherichia coli from the Greater Toronto
Area, Ontario, Canada
O. Lastovetska*, N. Tijet, A. McGeer, R. Melano
on behalf of the Toronto Invasive Bacterial
Network
Final Programme
Poster Sessions
Saturday, 7 May
P690
Carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa
strains in Finland
M. Österblad*, J. Kirveskari, P. Tissari,
K. Vuorenoja, M. Bergman, A. Hakanen,
S. Koskela, J. Jalava, M. Vaara (Turku, Helsinki, FI)
P699
Comparison of automated and phenotypic
methods for detection of extended-spectrum
beta-lactamases in a clinical microbiology
laboratory
S. Ferreira*, A. Paradela, S. Rocha, E. Ramalheira
(Aveiro, PT)
P691
Rapid emergence of carbapenemase-producing
Enterobacteriaceae isolates in Belgium
T.D. Huang*, P. Bogaerts, C. Berhin, B. Jans,
O. Denis, Y. Glupczynski (Yvoir, Brussels, BE)
P700
P692
Molecular epidemiology and mechanism of
carbapenem-resistant Enterobacteriaceae in
a West China hospital
T. Wang*, C. Tao, Y. Xie, H. Ning, D. Li, M. Kang,
L. Guo, H. Chen, H. Fan (Chengdu, CN)
Rapid strategy to detect colonisation by
KPC-producing Klebsiella pneumoniae during
an outbreak
C. Tascini*, F. Menichetti, T. Giani, G. Gemignani,
F. Arena, I. Ciullo, A. Leonildi, M.M. D'Andrea,
B. Casini, E. Tagliaferri, G. Privitera,
G.M. Rossolini (Pisa, Siena, IT)
P693
Eradication of carbapenem-resistant
Enterobacteriacea colonisation with nonabsorbable oral antibiotic treatment
I. Oren*, H. Sprecher, R. Finkelstein, S. Hadad,
N. Krivoy, T. Zuckerman (Haifa, IL)
P694
Detection of beta-lactamases in Gramnegative rods
Evaluation of a confirmatory test for
phenotypic detection of acquired AmpC
beta-lactamases
F. Freitas*, R. Silva, A. Novais, T.M. Coque,
R. Cantón, L. Peixe, E. Machado on behalf of
The Portuguese Resistance Study Group
P695
Detection and differentiation of broadspectrum beta-lactamases among
carbapenem-resistant Klebsiella pneumoniae
clinical isolates
A. Poulou*, F. Markou, S. Pournaras, E. Voulgari,
K. Ranellou, G. Vrioni, A. Tsakris
(Serres, Larissa, Athens, GR)
P696
Rapid detection of ESBL-producing
Enterobacteriacae with a new chromogenic
medium: Colorex Orientation/Colorex ESBL
P. Laudat*, C. Jouannet, V. Le floch, M. Deniau
(Tours, FR)
P697
P698
Phenotypic method for the detection
of metallo-beta-lactamases and KPC
carbapenemases in the same isolate of
Enterobacteriaceae
J.B. Casals*, M. Pandrup Duer-Jensen
(Roskilde, Rosco, DK)
Evaluation of Colorex C3Gr agar for the
detection of resistant Escherichia coli and
Klebsiella sp. rectal colonisation
C. Vermerien*, E. Mak, K.C. Katz (Toronto, CA)
P701
Acinetobacter baumanni in Italian hospitals:
results from a retrospective data analysis
from the Micronet Network laboratories
F. D Ancona*, A. Sisto, A. Raglio, M. Meledandri,
A. Rocchetti and the Micronet Network
participants
P702
Epidemiology of multidrug- and carbapenemresistant Acinetobacter baumannii in
Belgium: an emerging threat?
A. Verroken*, P. Bogaerts, T.D. Huang, A. Deplano,
C. Bauraing, O. Denis, Y. Glupczynski
(Yvoir, Brussels, BE)
P703
Strain diversity and antibiotic resistance
including carbapenem resistance in
Acinetobacter baumannii in Bulgarian
hospitals
R. Vatcheva-Dobrevska*, T. van der Reijden,
E. van Strijen, E. Keuleyan, H. Hitkova, E. Savov,
M. Lesseva, I. Ivanov, E. Dobreva, M. Grigorova,
A. Dimitrova, V. Tolekova, T. Yovcheva,
T. Kantardjiev, P. van den Broek, L. Dijkshoorn
(Sofia, BG; Leiden, NL; Pleven, Varna, Yambol,
V. Tirnovo, Targovishte, BG)
P704
Preliminary results of the multicentre study
on carbapenem resistance of Acinetobacter
baumannii in northern Croatia
B. Bedenic*, M. Vranic-Ladavac, A. Budimir,
V. Rezo-Vranjes, S. Sivec, D. Sijak, J. Vranes,
N. Beader, S. Kalenic, Z. Bosnjak
(Zagreb, Pula, HR)
P705
OXA-carbapenemase-producing multidrugresistant Acinetobacter baumannii isolates
from Sweden
N. Karah*, C. Giske, A. Sundsfjord, Ø. Samuelsen
(Tromsø, NO; Stockholm, SE)
Final Programme
99
Posters
15:30 – 16:30
15:30 – 16:30
Poster Sessions
Saturday, 7 May
P706
Molecular typing of multidrug-resistant
Acinetobacter baumannii from a tertiary care
university hospital in Lithuania
J. Povilonis*, V. Šeputiene, A. Vitkauskiene,
E. Sužiedeliene (Vilnius, Kaunas, LT)
P707
OXA-carbapenemase producing Acinetobacter
baumannii in tertiary care university hospital
in Lithuania
V. Seputiene*, A. Bogdaite, J. Povilonis,
R. Juškaite, A. Vitkauskiene, E. Sužiedeliene
(Vilnius, Kaunas, LT)
P708
Genetic basis of carbapenem resistance
of Acinetobacter baumannii in Belarus
Y. Gorbich*, I. Karpov, A. Martinovich
(Minsk, BY; Smolensk, RU)
P709
Resistance to antibiotics of Acinetobacter
spp. in Saint Petersburg, Russia
E.P. Barantsevich*, N.E. Barantsevich,
N.S. Kozlova, V.G. Goik (Saint-Petersburg, RU)
P710
Antibiotic resistance profile in hospital-acquired
multidrug-resistant Acinetobacter spp.
A. Büyük, F.F. Yilmaz-Köz*, S. Gül-Yurtsever,
M. Hosgör-Limoncu (Izmir, TR)
P711
P712
Prevalence of carbapenem-resistant
Acinetobacter baumannii isolated from
symptomatic patients in two hospitals in
Kuwait
N. Al-Sweih*, M. Al-Hubail, R. Joshi, V. Rotimi
(Kuwait, KW)
Analysis of multidrug-resistant Acinetobacter
baumannii clinical isolates
V. Kasinathan, T. Drake, Y. Wang* (Atlanta, US)
P713
Risk factors for acquisition of imipenemresistant Acinetobacter baumannii in Taiwan
H.Y. Lee*, R. Chang, L. Su, T.Y. Lin, C. Wu,
C.-H. Chiu (Taoyuan, TW)
P714
Molecular epidemiology of clinical
Acinetobacter baumannii isolates in a Korean
hospital
S.Y. Kim*, Y.J. Park, J.K. Yu, J.Y. Kim
(Suwon, Seoul, Daejeon, KR)
P715
Evaluation of a novel selective medium,
CHROMagar acinetobacter with KPC
supplement, for detection of multidrugresistant Acinetobacter baumannii from
clinical specimens in Japan
S. Kawakami*, M. Asahara, N. Matsunaga,
Y. Ono, T. Hurukawa, R. Kubo, M. Onozaki,
T. Nakano, T. Kaneko, T. Teramoto, Y. Miyazawa
(Tokyo, JP)
100 21st ECCMID / 27th ICC / Milan
Final Programme
P716
MDR Acinetobacter baumannii faecal
colonisation of nursing home residents of
northern Portugal
D. Gonçalves*, H. Ferreira (Porto, PT)
15:30 – 16:30
Porins and efflux pumps are good friends
P717
RNase-mediated post-transcriptional
regulation of gene ompA seems to be the
major mechanism of carbapenem
heteroresistance in A. baumannii
M. Samiotaki, M. Panopoulou, G. Panayotou,
A. Ikonomidis* (Athens, Alexandroupolis, GR)
P718
Effect of Sub-MIC concentrations of
biocides on the expression of genes coding
for efflux pumps and porins in Acinetobacter
baumannii ATCC 19606
F. Fernández-Cuenca*, M.C. Gómez-Sánchez,
F. Caballero, S. Ballesta, J. Vila, L. MartínezMartínez, G. Bou, J. Rodríguez-Baño, Á. Pascual
(Seville, Barcelona, Santander, La Coruña, ES)
P719
Effect of environmental factors on outer
membrane proteins expression and
antimicrobial susceptibility of multi-resistant
clinical isolates of Escherichia coli
B. Ruiz Del Castillo*, E. Román, L. MartínezMartínez (Santander, ES)
P720
Genome analysis of human multidrugresistant strain of Enterobacter aerogenes
S.M. Diene, C. Robert, A. El Filali, M. Henry,
S. Azza, D. Raoult, J.M. Rolain* (Marseille, FR)
P721
Exposure of Salmonella enterica serovar
typhimurium to high-level biocide challenge
can select for novel-mechanism, multidrugresistant mutants in a single step
R.N. Whitehead*, T.W. Overton, C.L. Kemp,
M.A. Webber (Birmingham, UK)
P722
Evaluation of quinolone resistance
determining region mutations and efflux
pump expression in Neisseria meningitidis
resistant to fluoroquinolones
M. Castanheira*, L. Deshpande, R. Jones,
D. Farrell (North Liberty, US)
P723
Phenotypic adaptation to isoniazid in
Mycobacterium tuberculosis: a pathway
to multidrug-resistant tuberculosis
D. Machado*, I. Couto, L. Rodrigues, L. Amaral,
M. Viveiros (Lisbon, PT)
P724
Contribution of efflux activity to isoniazid
resistance in Mycobacterium tuberculosis
complex
L. Rodrigues*, D. Machado, I. Couto, L. Amaral,
M. Viveiros (Lisbon, PT)
Poster Sessions
P725
Differential recognition of quinolones by
efflux pumps in Gram-positive
(Staphylococcus aureus, Streptococcus
pneumoniae) and Gram-negative
(Pseudomonas aeruginosa) bacteria
C. Vallet*, J. Buyck, F. El Garch, P. Tulkens,
F. Van Bambeke (Brussels, BE)
P733
Ertapenem-resistant Escherichia coli and
Klebsiella pneumoniae bacteraemia:
meropenem as an independent risk factor,
and potential efficacy of imipenem and
meropenem
K. Marimuthu*, T. Ng, D. Lye, T. Lim, T. Tan,
P. Krishnan, L. Ling, B. Ang, C. Teng (Singapore, SG)
P726
Rapid mutation of Staphylococcus aureus
norA efflux pump promoter after induction
with ciprofloxacin is associated with an
increased norA expression and an increased
ciprofloxacin MIC
P. Wolffs*, I. Spyckerelle, E. Beuken,
E. Stobberingh (Maastricht, NL)
P734
The epidemiology of carbapenemases and
extended-spectrum beta-lactamases among
nosocomial Klebsiella isolates
M. Dizbay*, H.S. Ozger, U. Gaygisiz,
O. Karasahin, G. Telli (Ankara, TR)
P735
Duration of colonisation with carbapenemresistant Klebsiella pneumoniae
D. Ben-David*, A. Barsist, I. Tal, Y. Maor, N. Keller,
G. Smollan, G. Rahav (Ramat-Gan, IL)
P736
Colistin-resistant Klebsiella pneumoniae in
a tertiary hospital: epidemiology and
investigation of resistance mechanisms
H. Moraitou, S. Papadopoulos*, I. Galani,
M. Makarona, A. Mavrommati, P. Zarkadas,
L. Kormali, I. Papazacharia (Athens, GR)
P737
KPC-producing Klebsiella pneumoniae
in a cohort of urinary tract infections:
clinical features, molecular epidemiology
and outcomes
O. Zarkotou*, K. Stamatiou, D. Voutsinas,
S. Pournaras, A. Tsakris, K. Themeli-Digalaki
(Athens, Larissa, GR)
P738
Spread of a plasmid-mediated carbapenem
hydrolysing OXA-48 beta-lactamase in
Klebsiella pneumoniae in a tertiary teaching
hospital, Spain
C. Pitart*, M.M. Solé, J. Vila, F. Marco
(Barcelona, ES)
P739
Clinical and epidemiological study of an
outbreak of KPC-producing Klebsiella
pneumoniae infection in Buenos Aires,
Argentina
E. Cordova, C. Rodriguez, F. Pasteran, N. Gomez,
M. Badia, V. Oviedo, M. Lespada* (Buenos Aires, AR)
P740
Analysis of Klebsiella pneumoniae strains
with non-enzymatic carbapenem resistance
isolated in the Czech Republic, Poland and
Russia
E. Chudackova*, T. Bergerova, H. Zemlickova,
M. Edelstein, M. Gniadkowski, J. Hrabak
(Plzen, Prague, CZ; Smolensk, RU; Warsaw, PL)
P741
DiversiLab analysis of a KPC-3-producing
Klebsiella pneumoniae outbreak in an Italian
surgery unit
A. Mazzariol*, G. Lo Cascio, P. Ballarini,
M. Ligozzi, F. Bercelli, R. Fontana, G. Cornaglia
(Verona, IT)
P727
P728
P729
Total genome sequencing of multidrug and
efflux pump inhibitor resistant Streptococcus
pneumoniae reveals new roles for genes in
PatAB-mediated antibiotic resistance
A. Baylay*, L.J. Piddock (Birmingham, UK)
Variability and inducibility of the mef(A)msr(D) region in erythromycin-resistant
Streptococcus pyogenes
L.A. Vitali*, M.C. Di Luca, V. Iebba, D. Petrelli,
I. Moltoni, W. Bahnan, M. Prenna, S. Ripa
(Camerino, Rome, IT)
Impact of inoculum on the antibacterial effect
of levofloxacin and moxifloxacin against
S. pneumoniae strains with defined resistance
mechanisms studied in an in vitro model of
infection
K.E. Bowker*, A.R. Noel, S. Tomaselli, H. Elliott,
A. MacGowan (Bristol, UK)
15:30 – 16:30
K. pneumoniae: the worst threat amongst
Enterobacteriaceae?
P730
Closely related carbapenem-resistant
K. pneumoniae from hospital inpatients
and community in Mid-West of Ireland
I. Condon, C. Ludden, M. Corcoran,
N. O'Connell, M. Cormican*, T. Boo, D. Morris
(Limerick, Galway, IE)
P731
Antimicrobial resistance in K. pneumoniae
in hospitalised and outpatients in Germany,
2009
I. Noll*, B. Schweickert, M. Feig, G. Krause,
T. Eckmanns (Berlin, DE)
P732
Antimicrobial susceptibility patterns
associated with European KPC producers
M. Hackel*, C. Lascols, S. Hawser, R. Badal,
D. Hoban, S. Bouchillon, B. Johnson, J. Johnson,
M. Dowzicky (Schaumburg, US; Epalinges, CH;
Collegeville, US)
Final Programme
101
Posters
Saturday, 7 May
Poster Sessions
Saturday, 7 May
P751
Inhibition zone diameter distributions and
MIC correlates for Pasteurella multocida on
the EUCAST MH-F media
C. Karlsson*, J. Åhman, E. Matuschek,
G. Kahlmeter (Växjö, SE)
P752
Comparison of two disk diffusion-based
screening methods for detection and
classification of beta-lactam resistance
in Haemophilus influenzae
D. Skaare*, I.L. Anthonisen, A. Hannisdal,
A. Jenkins, G. Kahlmeter, A. Lia, E. Matuschek,
Y. Tveten, B.-E. Kristiansen
(Tønsberg, Skien, NO; Växjö, SE)
In vivo transfer of OXA-48 during an outbreak
of Klebsiella pneumoniae with decreased
susceptibility to carbapenems
S. Göttig*, V.A. Kempf, T.A. Wichelhaus
(Frankfurt, DE)
P753
The EUCAST Mueller-Hinton fastidious agar
for antimicrobial susceptibility testing of
anaerobic bacteria?
U.S. Justesen*, E. Matuschek, G. Kahlmeter
(Odense C, DK; Växjö, SE)
First outbreak of OXA-48-positive carbapenemresistant Klebsiella pneumoniae isolates
in Western Europe, France
G. Cuzon*, J. Ouanich, H. Ahmed-Zaid, R. Gondret,
T. Naas, P. Nordmann (Le Kremlin-Bicêtre,
Villeneuve-Saint-Georges, FR)
P754
Feasibility of the E-test for susceptibility
testing of doripenem against Gram-negative
and Gram-positive bacteria using EUCAST
breakpoints
M. Kresken*, B. Körber-Irrgang on behalf
of the German Doripenem Study Group
P755
Usefulness of Microscan System panels
with EUCAST clinical breakpoints to evaluate
the antimicrobial susceptibility of betalactamase producing Gram-negative isolates
E. Nucleo*, G. Fugazza, M. Spalla, A. Piazza,
L. Pagani, R. Migliavacca (Pavia, IT)
P756
Automating selection of epidemiological
cut-off values using a dedicated software
tool: MicDat®
J. Turnidge*, J. Mouton, N. Punt
(North Adelaide, AU; Nijmegen, Maastricht, NL)
P757
Amoxicillin-clavulanic acid susceptibility
testing: fixed ratio versus fixed concentration
of clavulanic acid
T. Halaby*, N. AL Naiemi, T. van 't Klooster,
N. Koehorst, F. Heilmann (Enschede, NL)
P758
A rapid and functional assay for detection
of resistance against beta-lactam antibiotics
by MALDI-TOF mass spectrometry
K. Sparbier, U. Weller, S. Schubert, C. Boogen,
M. Kostrzewa* (Bremen, Cologne, Munich, DE)
P759
Screening and confirmation methods for
carbapenemases in Enterobacteriaceae
J.W. Cohen Stuart*, G. Voets, S. Voskuil,
J. Scharringa, A.C. Fluit, M. Leverstein-Van Hall
(Utrecht, NL)
P742
Nosocomial outbreak of Klebsiella
pneumoniae harbouring blaKPC-3 in France
subsequent to a patient transfer from Italy
G. Cuzon*, T. Naas, M. Demachy,
H. Ittah-Desmeulles, P. Nordmann
(Le Kremlin-Bicêtre, Meaux, FR)
P743
Early stage of dissemination of KPCproducing Enterobacteriaceae in Poland
(2008–2009)
A. Baraniak, A. Grabowska, R. Izdebski*,
J. Fiett, M. Herda, A. Bojarska, D. Zabicka,
G. Mlynarczyk, W. Hryniewicz, M. Gniadkowski
on behalf of the KPC-PL Study Group
P744
P745
15:30 – 16:30
P746
P747
P748
P749
P750
Antimicrobial susceptibility testing
Correlation between EUCAST disk diffusion
and the standardised broth microdilution
method
S. Bengtsson*, C. Bjelkenbrant, G. Kahlmeter
(Växjö, SE)
EUCAST MIC breakpoints and inhibition zone
diameter correlates for staphylococci
E. Matuschek*, J. Åhman, A. Petersen,
R. Skov, R. Jones, G. Kahlmeter
(Växjö, SE; Copenhagen, DK; Iowa, US)
Screening for beta-lactam resistance in
Streptococcus viridans group with the EUCAST
disk diffusion method
E. Matuschek*, J. Åhman, P. Littauer,
G. Kahlmeter (Växjö, SE; Hvidovre, DK)
EUCAST proposed new MIC breakpoints for
Moraxella catarrhalis and corresponding zone
diameter breakpoints
J. Åhman*, E. Matuschek, G. Kahlmeter
(Växjö, SE)
Methicillin resistance in Staphylococcus spp.
Validation of CLSI and EUCAST disk diffusion
screen using cefoxitin
J. Åhman*, E. Matuschek, R. Skov, G. Kahlmeter
(Växjö, SE; Copenhagen, DK)
Final Programme
Poster Sessions
Saturday, 7 May
Discrepancies in susceptibility testing of
KPC-producing Klebsiella pneumoniae using
Vitek2
E. Cavassin, E. Sakagami, A. Fogagnoli,
C. Santos, G. Von Konell, K. Macedo,
S. Sampaio, J. Sampaio* (Sao Paulo, BR)
P761
Evaluation of Alert™ PBP2a immunochromatographic assay for detection
of methicillin resistance in Staphylococcus
isolates
R. Selvarangan*, A. Nguyen, B. Doerge
(Kansas City, US)
P762
The effects of varying susceptibility test
parameters on TP-434 activity in vitro
C. Pillar, D.H. Sahm, T. Grossman*, J. Sutcliffe
(Chantilly, Watertown, US)
P763
A pragmatic approach to blood culture isolate
susceptibility testing and ID on the fast track:
direct E-test and MALDI-TOF mass
spectrometry
J.V. Bjørnholt*, P. Gaustad, A. Ingebretsen,
T.M. Leegaard (Oslo, Nordbyhagen, NO)
P764
P765
Performance of the Dutch national
phenotypic ESBL detection guideline in
clinical setting
T.N. Platteel*, J.W. Cohen Stuart, G.M. Voets,
J. Scharringa, A.J. de Neeling, N. van de Sande,
M.J. Bonten, A.C. Fluit, M. Leverstein- van Hall
on behalf of the ESBL National Surveillance
Working Group
Vancomycin susceptibility trends in MRSA
isolated from blood cultures in Aberdeen
Royal Infirmary from 2006–2010.
Is vancomycin "creep" method dependent?
B. Edwards*, K. Milne, I. Cook, I.M. Gould
(Aberdeen, UK)
P766
MALDI-TOF mass spectrometry: detection of
carbapenem resistance within one hour
I. Burckhardt*, S. Zimmermann (Heidelberg, DE)
P767
A novel flow cytometric method for
rapid detection of carbapenem-resistant
I. Faria-Ramos*, J. Santos-Antunes,
A.G. Rodrigues, C. Pina-Vaz (Porto, PT)
P768
Detection of carbapenemase enzymes
in clinical isolates of Pseudomonas
aeruginosa by Re-modified Hodge Test and
other phenotypic methods
S. Jain*, S. Rai, K.N. Prasad, T.N. Dhole,
A. Maurya (Lucknow, IN)
P769
Application of fluorescence in situ
hybridisation using peptide nucleic
acid probes in gastric samples for detection
of Helicobacter pylori clarithromycin
resistance
L. Cerqueira*, R. Fernandes, R. Ferreira,
F. Carneiro, M. Dinis-Ribeiro, C. Figueiredo,
C.W. Keevil, N.F. Azevedo, M. Vieira
(Braga, Porto, PT; Southampton, UK)
P770
Comparison of the PBP2a latex agglutination
assay, PBP2a rapid immunochromatographic
assay and chromogenic medium for identifying
directly from positive blood cultures
S. Hong, B. Son, K. Shin*
(Cheongwon, Cheongju, KR)
P771
A comparative study of antibiotic gradient
devices for the determination of tigecycline
minimum inhibitory concentration
S. Withey* (Basingstoke, UK)
P772
Comparison of Oxoid M.I.C. Evaluator®
Strips to CLSI broth microdilution method and
E-test® with selected antimicrobial agents
S.D. Munro*, C. Tau, N. Banaei, E.J. Baron,
A. Hsiung, M.A. Silvius (Palo Alto, Lenexa, US)
P773
Advantages and limitations of tigecycline
and fosfomycin disk diffusion method for
antimicrobial susceptibility testing in
multidrug-resistant strains, including KPC
producers
F. Pasteran*, C. Lucero, M. Rapoport,
L. Guerriero, I. Barreiro, E. Albornoz, O. Veliz,
A. Corso (Buenos Aires, AR)
P774
Study of MIC results obtained with
streptococci and pristinamycin using
a performance evaluation device
MicroScan MICroSTREP® plus panel
P. Schreckenberger, J. Tjhio, J. Hindler,
M. Lewinski, F. Sooudipour, M. Weinstein,
J. Rothberg, K. Roshak, J. O'Connor, H. Boyd,
B. Zimmer* (Maywood, Los Angeles,
New Brunswick, West Sacramento, US)
P775
Performance of the Vitek2 system for
detection of inducible clindamycin
resistance in staphylococci
M. Lee, Y. Hwang*, M.K. Kim, J. Hong
(Seoul, KR)
P776
A new reliable screening method for the
evaluation of VISA and hVISA strains by
“Vancomycin-Teicoplanin MIC Test Strip”
(Liofilchem Srl, Italy)
F. Campanile, D. Bongiorno, M. Perez, C. Scuderi,
G. Mongelli, L. Sessa, S. Stefani* (Catania, IT)
Final Programme
Posters
P760
103
Poster Sessions
Saturday, 7 May
P777
Evaluation of the MicroScan MICroSTREP
plus antimicrobial panel for testing betahaemolytic streptococci and viridans group
streptococci
Y. Uh*, I.H. Jang, K.S. Lee, S.D. Park, K.J. Yoon
(Wonju, KR)
P778
Comparison of different methods for
detection of methicillin resistance in a
challenge set of Staphylococcus aureus
isolates
C. Nonhoff*, P. Buidin, G. Hay, N. Legros,
C. Thiroux, M. Hallin, S. Roisin, O. Denis
(Brussels, BE)
15:30 – 16:30
P779
P780
Activities of moxifloxacin and ertapenem
against E. coli, E. cloacae, E. faecalis, and
B. fragilis in mono- and mixed cultures in an
in vitro pharmacokinetic/pharmacodynamic
model simulating human pancreas
concentration
S. Schubert*, A. Dalhoff (Kiel, DE)
P786
Pharmacodynamic effects of serum on in
vitro activities of echinocandins against
Aspergillus spp.
A. Elefanti*, R. Al-Saigh, L. Zerva, J. Meletiadis
(Athens, GR)
P787
Mutant prevention concentration values for
linezolid against contemporary methicillinresistant Staphylococcus aureus clinical
isolates with elevated MPC values to
vancomycin
J.M. Blondeau*, K. MacKenzie (Saskatoon, CA)
P788
The impact of pancreatic enzymes on the in
vitro activity of cefotaxime, ciprofloxacin,
meropenem and moxifloxacin against
organisms associated with intra-abdominal
infections
A. Malawski, M. Moser, J.M. Blondeau*
(Saskatoon, CA)
P789
Time-kill effect of doripenem against
multidrug-resistant pathogens for
ventilator-associated pneumonia
D. Carrer, A. Savva, M. Raftogiannis,
G. Damoraki, E.J. Giamarellos-Bourboulis*
(Athens, GR)
P790
Combined activity of MK-7655 and imipenem
against carbapenem-resistant Pseudomonas
aeruginosa
E.B. Hirsch*, K.R. Ledesma, K.T. Chang,
M.S. Schwartz, M.R. Motyl, V. Tam
(Houston, Rahway, US)
P791
Evaluation of a supratherapeutic dose
of intravenous ceftaroline fosamil on the
QTc interval
T. Riccobene*, D. Rank, L. Rekeda, L. Llorens,
D. Thye (Jersey City, Oakland, US)
P792
Evaluation of the effect of protein on the
antibacterial activity and pharmacodynamics
of ceftaroline
S. Schubert*, A. Dalhoff (Kiel, DE)
P793
Plasma concentrations and occurrence of
drug-related toxic effects in patients treated
with linezolid
G. Orlando*, E. Clementi, D. Cattaneo, L. Cordier,
S. Merli, C. Gulisano (Milan, IT)
Antimicrobial pharmacodynamics
Pharmacodynamic and pharmacogenomic
profiling of accessory gene regulator (agr)
expression in Staphylococcus aureus in
response to linezolid
B. Tsuji*, T. Brown, D. Brazeau, S. Lanke,
P. Holden, P. Kelchlin, A. Forrest (Buffalo, US)
Intracellular activity of fusidic acid against
clinical isolates of Staphylococcus aureus
of increasing MIC
S. Lemaire, D. Piérard, F. Van Bambeke,
P. Tulkens* (Brussels, BE)
P781
Activity of 9 antibiotics against intracellular
forms of S. pneumoniae
S. Lemaire*, P. Tulkens, F. Van Bambeke
(Brussels, BE)
P782
Comparative pharmacodynamics of
doripenem and ciprofloxacin with
Pseudomonas aeruginosa in an in vitro
dynamic model
S. Zinner*, D. Gilbert, Y. Portnoy, A. Firsov
(Cambridge, US; Moscow, RU)
P783
A pharmacokinetic-pharmacodynamic
investigation of MUT056399 against
Staphylococcus aureus in an in vitro PD
model
B. Tsuji*, S. Lanke, D. Ngo, C. Soulama-Mouze,
S. Fischer, A. Forrest (Buffalo, US; Paris, FR)
P784
P785
Colistin and doripenem combinations
demonstrate synergy and suppression of
resistance against Acinetobacter baumannii
at multiple inocula in an in vitro PK/PD model
A. Poudyal, H. Yu, K. Davis, C. Ku, R. Nightingale,
J. Jacob, B. Tsuji, J. Bulitta, A. Forrest, J. Li,
R. Nation* (Melbourne, AU; Buffalo, Albany, US)
Final Programme
Poster Sessions
Saturday, 7 May
15:30 – 16:30
P795
P796
Linezolid plasma levels in long-term
treatment of osteoarticular infections:
relationship with haematologic toxicity
N. Berenguer*, S. Luque, L. Sorli, L. Puig,
F. Álvarez-Lerma, J.P. Horcajada, S. Grau
(Barcelona, ES)
P803
Anidulafungin pharmacokinetic evaluation
in a cohort of patients
F.G. De Rosa, L. Baietto*, A. D'Avolio, D. Pasero,
S. Raviolo, S. Pace, C. Marra, V.M. Ranieri,
G. Di Perri (Turin, IT)
P804
Population pharmacokinetic study of
colistin in combined healthy volunteers
and patients with severe Gram-negative
multidrug-resistant infections
N. Grégoire, B. Mégarbane, P. Gobin, D. Balayn,
W. Couet*, O. Mimoz (Poitiers, Paris, FR)
P805
Population pharmacokinetics of doripenem
in Japanese subjects and Monte Carlo
simulation for patients with renal impairment
Y. Matsuo*, T. Ishibashi, R. Kubota, T. Wajima
(Osaka, JP)
P806
Lean body weight explains variability in
clearance and absorption rate constant
of linezolid in cystic fibrosis patients
A. Schaeftlein*, R. Keel, J.L. Kuti, C. Kloft
(Halle/Saale, DE; Hartford, US)
P807
Population pharmacokinetics of temocillin
in intensive care patients and Monte Carlo
simulations to evaluate resistance breakpoints
A.E. Muller*, P.F. Laterre, T. Dugernier,
X. Wittebole, N. Couwenbergh, P. Tulkens,
S. Carryn, J. Mouton (Rotterdam, NL; Brussels,
Manage, BE; Nijmegen, NL)
P808
Pharmacodynamics of three carbapenems
against drug-resistant Gram-negative
pathogens isolated from hospitalised
patients in Germany using Monte Carlo
simulation
M. Kresken*, B. Körber-Irrgang,
S. Decker-Burgard, D. Hafner
(Rheinbach, Neuss, Düsseldorf, DE)
P809
Population pharmacokinetics of peramivir
and dose adjustment for influenza patients
with renal impairment
T. Ishibashi*, T. Wajima, Y. Matsuo, A. Hollister,
S. Kohno, J. Shimada (Osaka, JP; Durham, US;
Nagasaki, Tokyo, JP)
P810
Usefulness of therapeutic drug monitoring
of posaconazole in haematological adult
patients
L. Baietto*, F.G. De Rosa, A. D'Avolio, E. Biasin,
F. Nesi, F. Saglio, C. Marra, S. Pace, G. Di Perri
(Turin, IT)
P811
Intra-ocular pharmacokinetics of doripenem
in rabbits
O. Semoun, S. Marchand, I. Lamarche, C. Adier,
N. Grégoire, L. Laroche, P. Goldschmidt, W. Couet*
(Paris, Poitiers, FR)
Antimicrobial pharmacokinetics
Antibacterial effect of ceftaroline against
MRSA and VISA strains studied in an in vitro
pharmacokinetic model of infection
A.R. Noel, S. Tomaselli, H. Elliott, K.E. Bowker,
A. MacGowan* (Bristol, UK)
Interspecies scaling for prediction of
human intravenous pharmacokinetics
of GSK2251052, a novel boron-based
antimicrobial against Gram-negative bacteria
L. Liu*, L.T. Zane, A. Wu, W. Bu, M.R. Alley,
V. Hernandez, H. Sexton, X.Q. Fan, L. Feng,
S. Baker, K. Maples, I. Heyman (Palo Alto, US)
P797
Pharmacokinetic variability of clarithromycin
is due to differences in CYP3A4 activity in
patients with cystic fibrosis – a reason for
treatment failure?
C.S. Dalbøge*, X.C,. Nielsen, K. Dalhoff,
M. Dunø, A. Buchard, J.W. Alffenaar, A.G. Jensen,
T. Pressler, N. Høiby, H.K. Johansen
(Copenhagen, Slagelse, DK; Groningen, NL)
P798
Minimal sampling colistin pharmacokinetics
in critically ill patients
P. Menna*, F. Battistoni, F. Crea, G. Minotti,
E. Salvatorelli, G. Dicuonzo (Rome, IT)
P799
Pharmacokinetics of daptomycin in critically
ill patients
B. Preiswerk*, A. Rudiger, J. Fehr, N. Corti
(Zurich, CH)
P800
Linezolid pharmacokinetics in children:
validation of a new method with dried blood
spots
A. Novelli*, M.I. Cassetta, S. Fallani, G. la Marca,
F. Villanelli, M. De Gaudio, L. Galli (Florence, IT)
P801
Monitoring plasma voriconazole levels may
be necessary to avoid sub-therapeutic levels
in lung transplant recipients
H. Lyster*, N. Leaver, A. Hall, A. Simon, M. Carby
(Harefield, UK)
P802
Caspofungin: is standard dosing optimal or
inadequate? Pharmacokinetic description in
a cohort of patients
F.G. De Rosa, L. Baietto*, A. D'Avolio, D. Pasero,
S. Raviolo, C. Marra, S. Pace, V.M. Ranieri,
G. Di Perri (Turin, IT)
Final Programme
Posters
P794
105
Poster Sessions
Saturday, 7 May
P812
Serum and urine concentrations of antibiotics
in patients implanted with gentamycin
and vancomycin PMMA spacers: data from
the first 50 patients (multi-centre study)
E. Bertazzoni Minelli*, A. Benini, T. Della Bora
(Verona, IT)
P813
Penetration of moxifloxacin into liver tissue
of patients undergoing liver resection
C. Justinger, O. Kollmar, M.G. Kees*, F. Kees,
M.K. Schilling (Homburg, Berlin, Regensburg, DE)
P814
Pharmacokinetic evaluation of colistin in
cerebrospinal fluid after endoventricular
administration of colistin methanesulfonate
at different regimens in patients with
multidrug-resistant CNS infections
M. Cusato*, R. Imberti, P. Villani, L. Carnevale,
G. Iotti, G. Accetta, M. Regazzi (Pavia, IT)
P815
Microdialysis study of metronidazole cerebral
distribution in patients with acute brain injury
D. Frasca, C. Dahyot-Fizelier, O. Mimoz,
B. Debaene, W. Couet*, S. Marchand (Poitiers, FR)
P816
Study on the penetration of levofloxacin into
the prostatic tissue
K. Takahashi*, S. Ishihara, T. Matsumoto
(Onga-gun, Minokamo, Kitakyushu, JP)
P817
Clinical long-term microdialysis study with
voriconazole in healthy volunteers
C. Kirbs*, F. Simmel, M. Zeitlinger, E. Lackner,
C. Rimmbach, C. Kloft (Halle, DE; Vienna, AT;
Greifswald, DE)
P818
Microdialysis for the study of ertapenem
muscle distribution and protein binding in
healthy volunteers
T. Loupec, L. Laksiri, C. Adier, P. Saulnier,
O. Mimoz, W. Couet*, S. Marchand (Poitiers, FR)
P819
Concentration of moxifloxacin in plasma
and tissue in morbidly obese patients
S. Weber, M.G. Kees*, F. Kees, T. Horbach
(Schwabach, Berlin, Regensburg, Erlangen, DE)
P820
Penetration of moxifloxacin into wound
tissue and wound exudate obtained during
topical negative pressure therapy
M. Sedigh, E. Polykandriotis, M. Jost, M.G. Kees,
F. Kees*, R.E. Horch
(Erlangen, Berlin, Regensburg, DE)
Final Programme
Poster Sessions
12:30 – 13:30
P821
P822
P823
P824
MRSA: trend, surveillance, genetic
characterisation
The emergence of novel and composite
SCCmec element types into Western
Australian community S. aureus
G. Coombs*, J. Pearson, S. Monecke,
F.G. O'Brien, K. Christiansen
(Perth, AU; Dresden, DE)
MRSA: different methods to predict
healthcare or community genotype
A. Charitakis*, C. Dimoulas, Z. Archontakis,
S. Kanaki, M. Kleisarchaki, S. Foyntoylakis,
A. Xydaki, V. Liakou (Heraklion, GR)
Evolving trends in treatment outcome
of S. aureus bacteraemia in Aberdeen
Royal Infirmary, 2006 – 2009
B. Edwards*, J. Abdel-Moneim, K. Girvan,
B. Cosgrove, G. Edwards, I.M. Gould
(Aberdeen, Glasgow, UK)
Genotypic characterisation of Staphylococcus
aureus isolates causing bacteraemia at
Tygerberg Hospital, Western Cape Province,
South Africa
H. Orth*, Z. Salaam-Dreyer, E. Makgotlho,
B. Sinha, E. Wasserman
(Cape Town, ZA; Würzburg, DE)
P825
MALDI-TOF mass spectrometry: a useful tool
for typing Staphylococcus aureus strains in
the context of cystic fibrosis
N. Murillo, F. Bittar, M. Reynaud-Gaubert,
J.C. Dubus, N. Stremler, D. Raoult, J.M. Rolain*
(Marseille, FR)
P826
Methicillin-resistant staphylococci in the
Republic of Belarus: results of the National
Surveillance System (2008 – 2010)
L. Titov, T. Ermakova, V. Gorbunov, F. Lebedev*,
I. Kazakov, S. Glazkova (Minsk, BY)
P827
P828
HA-MRSA epidemiology in an Italian
paediatric ICU: an outbreak caused by
the Southern Germany clone
P. Cocchi*, G. Taccetti, M. Tanganelli,
C. Braggion, M. de Martino, G. Fognani,
S. Campana (Florence, IT)
An interaction between clone type
and vancomycin MIC influences risk
of endocarditis associated with MRSA
C. Miller, O. Tosas, R. Batra, J. Otter,
G. French, J. Edgeworth* (London, UK)
P829
Genetic characterisation of early MRSA
isolates in England
B. Pichon*, M. Ganner, R. Hill, R. Ehricht,
B. Cookson, A.M. Kearns (London, UK; Jena, DE)
P830
Temporal trends in the incidence of
Staphylococcus aureus bacteraemia.
A multi-national population-based study
K. Laupland*, O. Lyytikainen, M. Søgaard,
K. Kennedy, J. Knudsen, C. Ostergaard,
H. Schonheyder for the International
Bacteremia Surveillance Collaborative
P831
The changing molecular epidemiology
aureus bacteraemia at a London teaching
hospital, 1999 – 2009
J.A. Otter*, J. Edgeworth, C. Miller, G. French
(Andover, UK)
P832
Mechanisms of adaptation of successful
methicillin-resistant Staphylococcus
aureus clones
R. Baldan*, F. Testa, P. Cichero, C. Ossi,
M. Moro, A. Biancardi, P. Nizzero, D. Cirillo
(Milan, IT)
P833
The risk factors of mortality for nosocomial
A. Bastug*, G.R. Yilmaz, B. Kayaaslan, H. Bodur
(Ankara, TR)
P834
BASALOMB: the Lombardy regional
Staphylococcus aureus bacteraemia
surveillance system, Italy
A. Pan*, M. Arghittu, V. Bettamio, P. Casella,
V. Cattolico, E. Costa, C. Farina, F. Franzetti,
M. Moro, G. Ortisi, A. Russo, E. Viganò
on behalf of the Lombardy Group of Technical
Assessment (GTA) for Surveillance from
Microbiological Data
P835
MRSA CC398 as an emerging cause of human
infections in Germany
R. Köck, A. Mellmann, A.W. Friedrich, K. Becker*
(Münster, DE)
P836
Persistent methicillin-resistant
Staphylococcus aureus bacteraemia: risk
factors analysis and clinical outcomes
Y.M. Wi*, K.R. Peck, S.S. Yoon, K.W. Lee,
J.M. Kim (Changwon-si, Seoul, KR)
P837
Distribution of the arginine catabolic mobile
element in staphylococci
S. Monecke*, D. Coleman, G. Coombs, E. Deasy,
R. Ehricht, M. Ip, A. Shore (Dresden, DE; Dublin, IE;
Perth, AU; Jena, DE; Hong Kong, HK)
Final Programme
107
Posters
Sunday, 8 May
Poster Sessions
Sunday, 8 May
P838
Is our hospital environment clean enough
for the containment of methicillin-resistant
Staphylococcus aureus?
Y. Gan*, M.K. Yeung, M. Chan, P.L. Ho
(Hong Kong, HK)
P839
First report of methicillin-resistant
Staphylococcus aureus Cordobes/Chilean
clone involved in nosocomial infections in
Brazil
A.P. Becker, C. Dias*, P.A. d'Azevedo
(Porto Alegre, BR)
P840
P841
P842
Molecular characterisation of methicillinresistant Staphylococcus aureus:
ST239 isolates collected over a 12-year
period in Hong Kong
S. Shabir*, M. Ip, K. Hardy, P. Hawkey
(Birmingham, UK; Shatin, HK)
Clinical features of Staphylococcus
aureus resistant to linezolid at the
Hospital Universitario Infanta Cristina,
Badajoz, Spain
E. Garduño*, M. Fajardo, S. Rodríguez-Garrido,
R. Hidalgo, N. Calvo Sanchez, N. GutiérrezZufiaurre (Badajoz, Salamanca, ES)
Community-acquired methicillin-resistant
Staphylococcus aureus in Spain: present
situation and evolution over the last 7 years
in a general hospital
E. Cercenado*, A. Vindel, M. Marín, B. Gama,
O. Cuevas, E. Bouza (Madrid, ES)
P843
Hospital-onset of “community-associated”
USA300 strain in Vancouver, Canada
A. Wilmer*, E. Lloyd-Smith, M. Romney,
L. Hoang, M. Hull, S. Champagne (Vancouver, CA)
P844
Epidemiology and antibiotic resistance of
MRSA isolated in Hospital Bologhine Ibn Ziri,
Algiers
W. Amhis*, Y. Beroual, N. Amrar, S. Benmesbah,
L. Benbetka, N. Sahel, W. Hamzi (Algiers, DZ)
P845
Clonal lineages of tetracycline-resistant
MRSA strains isolated in a Spanish hospital
during 2009. Detection of MRSA ST398
C. Lozano*, A. Rezusta, E. Gómez-Sanz ,
C. Colmenarejo, R. Báez, D. Benito, M. Revillo,
M. Zarazaga, C. Torres (Logroño, Zaragoza, ES)
P846
Clinical outcomes and risk factors for
mortality in patients with invasive infection
caused by ST72-MRSA-SCCmec type IV strains
in South Korea
E.J. Joo*, Y.E. Ha, J. Kim, S.J. Kang, S.Y. Park,
C.I. Kang, K.R. Peck, N. Lee, J.H. Song,
D.R. Chung (Seoul, KR)
Final Programme
P847
Comparison of mortality-associated
bacteraemia due to methicillin-resistant and
methicillin-susceptible Staphylococcus
aureus
M. Cameo, M. Palacian, M. Marco, C. Marne,
M. Aísa, A. Rezusta*, M. Revillo (Zaragoza, ES)
P848
Genetic lineages, virulence and antimicrobial
resistance mechanisms detected in methicillinresistant Staphylococcus aureus of blood
origin in a Spanish hospital
N. Porres-Osante*, J. Crettaz, C. Martin,
Y. Sáenz, C. Torres (Logroño, ES)
P849
Molecular analysis of Staphyloccus aureus
strains isolated in a newborns unit in 2010
I. Codita*, E.C. Dragulescu, B.E. Lixandru,
I.L. Coldea, S. Dinu (Bucharest, RO)
P850
Characterisation of oxacillin-susceptible
mecA-positive Staphylococcus aureus:
could this be a new type of MRSA?
S. Al Johani*, A. Al Awaji (Riyadh, SA)
P851
Hospital strains of methicillin-resistant
Staphylococcus aureus in Saint Petersburg,
Russia
A. Goncharov*, T. Suborova, V. Kolodzieva,
L. Zueva (Saint Petersburg, RU)
P852
Distribution of virulence factors and clonal
complexes in Staphylococcus aureus isolates
from nosocomial bloodstream infections
D. Jonas*, S. Rieg, C. Schneider, A.J. Kaasch,
H. Seifert, W.V. Kern (Freiburg, Cologne, DE)
P853
Methicillin-resistant Staphylococcus
aureus control in Italy: the ProSA study,
a questionnaire-based survey
A. Pan*, E. Bombana, G. Tura, C. Curti,
S. Lorenzotti, P. Mondello, M. Rosina,
L. Signorini, M. Vizio, V. Rigobello, A. Goglio
on behalf of SIMPIOS (the Italian Multidisciplinary Society for Prevention
of Health Care Associated Infections) and
ANIPIO (the Nurses National Association
for Prevention of Hospital Infections)
P854
MRSA-Surveillance in Germany:
first data from the Antibiotic Resistance
Surveillance System (ARS) and the
mandatory surveillance of MRSA in blood
and cerebrospinal fluid
B. Schweickert, I. Noll, M. Feig, H. Claus,
G. Krause, T. Eckmanns* (Berlin, DE)
Poster Sessions
Sunday, 8 May
Travel medicine: tropical and parasitic
diseases
P855
Liver dysfunction and its outcome in patients
with Dengue infection
S. Kumarasena, A. De Silva, R. Premaratna*,
J. de Silva (Ragama, LK)
P856
The effects of benznidazol treatment in
the autonomical and immunological response
in chronic Chagas disease
M. Llaguno*, M. Silva, V. Rodrigues, V. Silva,
D. Correa (Uberaba, BR)
P857
Severity of confirmed adult Dengue in
Singapore: comparison of World Health
Organization 1997 and 2009 criteria
V. Gan*, T.L. Thein, W.W. Lin, D. Lye, Y.S. Leo
(Singapore, SG)
P858
The utility of warning signs in predicting
Dengue severity in confirmed adult Dengue:
number needed to diagnose
V. Gan*, T.L. Thein, W.W. Lin, D. Lye, Y.S. Leo
(Singapore, SG)
P859
P860
P861
Echinococcus multilocularis in the
Netherlands: what about humans?
L.M. Kortbeek*, M. Harms, W. van Pelt,
J. van der Giessen, E. Pinelli Ortiz (Bilthoven, NL)
Burden of anaemia associated to
helminthiases: partial results from an
ongoing Venezuelan survey
J. Flores*, C. Navarro, M. Montero,
R. Nino-Incani, J. Cortez, S. Jiménez, M. Díaz,
D. Ortega, M. Cachare, L. Gómez, A. Marín,
E. Sanz, M. Gámez, Y. Sandoval, E. Villegas,
N. Briceño, N. Carrillo, E. Salazar-Labori,
V. González, M. Echeverría-Ortega, J. Mendoza,
C. Albano, G. Hidalgo, A. Rodriguez-Morales
(Caracas, VE)
The comparison of microscopy, antigen
detection and real-time polymerase chain
reaction tests for the diagnosis of
Pneumocystis jirovecii pneumonia:
evaluation of clinical parameters
S. Ozensoy Toz*, C. Gündüz, A. Tetik,
H. Pullukçu, M. Tasbakan, F. Bacakoglu,
M. Sezai Tasbakan, F. Gulen, A. Unver Yolasigmaz,
N. Turgay (Izmir, TR)
P862
Rich monotherpenic hydrocarbon plant
extracts as potential anti-protozoa agents:
effects of Juniperus oxycedrus (berries
and leaves extracts), alpha-pinene and
beta-myrcene on Giardia lamblia, Leishmania
infantum, L. tropica and L. major
M. Machado*, C. Cavaleiro, G. Santori,
A. Dinis, L. Salgueiro, M.C. Sousa
(Coimbra, PT; Rio de Janeiro, BR)
P863
Preparedness for malaria prevention in relief
camps for flood affectees – a cross-sectional
survey from Pakistan
B. Ahmed*, K. Nanji (Karachi, PK)
P864
Cryptosporidiosis in Iranian immunocompromised patients: prevalence,
molecular characteristics and risk factors
N. Jonaidi Jafari*, M. Izadi, M.R. Rezaiemanesh,
M. Fazel, M. Mohammad Jonaidi, R. Ranjbar
(Tehran, IR)
P865
Tropical infections in Coventry, UK
K. Lipas*, A. Illychysn, R. Gowda (Coventry, UK)
P866
Neurocysticercosis in Italy
M.T. Giordani*, R. Binazzi, F. Tamarozzi,
E. Brunetti (Vicenza, Bolzano, Pavia, IT)
P867
Loa Loa African eye worm: two cases
in a non-endemic country, Italy
G. Giuliani*, L. Chenal, M. De Filippis,
A. Tosoni, M. Corbellino, L. Galimberti,
S. Antinori, M.R. Gismondo (Milan, IT)
P868
Argas persicus Ethiopian soft ticks as
disease vectors
S. Cutler*, H. Adamu, A. Abdissa, T. Tolosa,
A. Gashaw (London, UK; Jimma, ET)
P869
Molecular investigation of Cryptosporidium
spp. using the TRAP-C2 gene
A. Keshavarz, N. Taghipour,
E. Nazemalhosseini-Mojarad*,
M. Rostami-Nejad, A. Haghighi, M. Zali
(Tehran, IR)
P870
Epidemiology of intestinal parasitosis in
eleven states of Venezuela: partial results
of an ongoing national survey
E. Salazar-Labori*, C. Navarro, M. Montero,
R. Nino-Incani, J. Cortez, S. Jiménez, M. Díaz,
D. Ortega, M. Cachare, L. Gómez, A. Marín,
E. Sanz, M. Gámez, Y. Sandoval, E. Villegas,
N. Briceño, N. Carrillo, J. Flores, V. González,
M. Echeverría-Ortega, C. Albano, G. Hidalgo,
A. Rodriguez-Morales (Caracas, VE)
P871
Splenic abscess due to Salmonella enteritidis
H. Çabadak*, A. Erbay, K. Karaman, S. Sen,
Y. Tezer Tekçe (Ankara, Yozgat, TR)
Final Programme
Posters
12:30 – 13:30
109
Poster Sessions
Sunday, 8 May
P872
A case of Alkhurma haemorrhagic
fever virus infection in an Italian traveller
returning from Egypt
F. Carletti*, C. Castilletti, A. Di Caro, M. Rosaria,
C. Nisii, F. Suter, M. Rizzi, A. Tebaldi, A. Goglio,
C. Passerini Tosi, G. Ippolito (Rome, IT)
P881
Occurrence and genotype characterisation
of Giardia lamblia in wolves (Canis lupus
L. 1758) from Portugal
M.C. Sousa*, M. Machado, A. Loureiro, A. Brás,
R. Godinho, H. Rio-Maior, F. Álvares, P.J. Esteves
(Coimbra, Porto, Viana do Castelo, PT)
P873
Two cases of visceral leishmaniasis
treated with a single-dose of liposomal
amphotericin B
F. Brillo*, G. Cattani, B. Del Pin, F. Bragantini,
M. Merelli, G. Villa, A. Pagotto, D. Pecori,
M. Gramiccia, A. Beltrame (Udine, Rome, IT)
P882
Detection of Acinetobacter sp. in human
lice from Ethiopia
M. Kempf*, E. Angelakis, A. Abdissa, G. Diatta,
J.F. Trape, D. Raoult (Marseille, FR; Jimma, ET)
P883
Performance of a multiplex PCR to identify
diarrhoeagenic Escherichia coli: experience
from a tropical medicine hospital
A. Palmeiro*, C. Toro, A. Amor, N. Iglesias,
P. Trevisi, M. Subirats, A. Olaiz, M. Baquero
(Madrid, ES)
P884
Disseminated Penicillium marneffei
infection in a non-HIV-infected woman
R. Plongla*, K. Asvametha, P. Leethong,
A. Chaindamporn, C. Saunkratay (Bangkok, TH)
P885
Occupational outbreak of tropical rat
mite (Ornithonyssus bacoti) dermatitis in
laboratory personnel, in southern Italy
(Apulia region)
M.A. Cafiero, D. Galante*, N. Cavaliere,
C. Nardella La Porta, M. Caiazzo, M. Lomuto
(Foggia, IT)
P886
Molecular analysis applied to mitochondrial
DNA from the family Planorbidae (Pulmonata:
Basommatophora) snails, potential
intermediate hosts of trematode
M. Calado, D. Correia, A. Afonso, P. Ferreira,
C. Ferreira, A. Pinto, I. Maurício, S. Beato*,
M.A. Grácio (Lisbon, PT)
P887
Ocular parasitosis: diagnosis and treatment
G.L. Popa*, C.M. Cretu, C. Chiotan, S. Cilievici,
F. Balta, S. Radulescu (Bucharest, RO)
P888
Visceral leishmaniasis in a patient on
haemodialysis
T. Exiara*, A. Konstantis, A. Risggits,
M. Kouroupi, E. Filippidou, L. Mporgi,
S. Saridou, S. Papanastasiou, L. Papazoglou,
D. Papadopoulou (Komotini, Alexandroupolis, GR)
P889
Development of new anti-Leishmania
drugs: activity of heterocyclic derivates,
pyrroles and porphyrin synthetic compounds
on L. infantum and L. tropica promastigotes
M.C. Sousa*, E. Bonifácio, J. Dias, J. Vitorino,
K. Silva, M. Machado, A. Sobral, A.T. Cabral
(Coimbra, PT)
P890
Increased level of interleukin-10 and
tumour necrosis factor-a associated with
severe scrub typhus
Y.S. Kim*, S.J. Park (Daejeon, KR)
P874
P875
P876
Fatal melioidosis diagnosed by mass
spectrometry in a tourist returning from
Martinique Island
L. Getaz, M. Abbas, L. Loutan, A. Iten, F. Simon,
A. Decosterd, R. Studer, P. Sudre, Y. Michel,
P. Merlani, S. Emonet* (Geneva, CH)
Cutaneous and visceral tropisms
of Leishmania tropica strains isolated in
Turkey in murine model
A. Özbilgin*, G. Culha, F. Yildiz Zeyrek,
S. Özensoy Töz, C. Gündüz, Ö. Kurt, F. Pratlong,
Y. Özbel (Manisa, Hatay, Sanliurfa, Izmir, TR;
Montpellier, FR)
Not just Lake Malawi. Katayama fever at
the Hospital of Tropical Diseases, London,
UK, over the last 12 years
S.A. Logan*, G. Nebbia, M. Armstrong, C. Whitty,
T. Doherty (London, UK)
P877
Laboratory diagnosis of malaria and
leishmaniasis: conventional or molecular
methods?
A. Calderaro*, C. Gorrini, S. Montecchini,
G. Piccolo, C. Chezzi (Parma, IT)
P878
Serological screening for Chagas disease in
Latin American pregnant women in Barcelona
South Metropolitan Area
E. Dopico, M. Aguilar*, E. Grenzner, L. Guerrero,
B. Allende, R. Navarro, J. Ros (Barcelona, ES)
P879
May immunochromatographic assay
allow accurate detection of antibodies
against Echinococcus granulosus?
G. Sonmez Tamer* (Kocaeli, TR)
P880
The pinworm: a Trojan horse for Dientamoeba
fragilis?
Ö. Kurt*, N. Turgay, A. Bart, S. Özensoy Töz,
N. Verhaar, T. van Gool (Manisa, Izmir, TR;
Amsterdam, NL)
Final Programme
Poster Sessions
Sunday, 8 May
Clinical and epidemiological peculiarities
of severe leptospirosis in Georgia
E. Vashakidze*, T. Megrelishvili, T. Khuchua,
T. Tkhilaishvili, P. Imnadze, N. Mamuchishvili
(Tbilisi, GE)
P892
Severe Mediterranean spotted fever
complicated by bilirubin nephropathy
M. Sonmezoglu*, G. Kantarci, O. Akin,
I. Dogan Ekici, G. Yilmaz Celik (Istanbul, TR)
P893
Two cases of Toscana virus meningitis
in Algarve, Portugal
A. Proenca*, R. Pereira, A. Mingo, M.J. Alves
(Faro, Lisbon, PT)
P894
Visceral leishmaniasis: a final diagnosis
of an intermittent febrile syndrome with
3 years of evolution. Case report
M. Ribeiro*, J. Louro, L. Riem (Barcelos, PT)
P895
12:30 – 13:30
P896
P897
Evaluation of therapeutic potential of
methanolic extract of stem bark of Acacia
nilotica (Linn) for the treatment of African
trypanosomiasis
E.O. Ogbadoyi*, M. Garba, A.Y. Kabir, J. Okogun
(Minna, Abuja, NG)
P900
High prevalence of methicillinresistant Staphylococcus aureus in pigs
and slaughterhouse workers
A. Morcillo*, B. Castro, J. González,
C. Rodríguez-Alvarez, M. Novo, A. Sierra,
A. Arias (La Laguna, ES)
P901
Diversity of rep-families in Staphylococcus
aureus of food, animal and human origin
C. Lozano*, L. Garcia-Migura, C. Aspiroz,
M. Zarazaga, C. Torres, F.M. Aarestrup
(Logroño, ES; Lyngby, DK; Zaragoza, ES)
12:30 – 13:30
Molecular tools for Staphylococus aureaus:
from epidemiology to diagnosis
P902
Presence of Panton-Valentine leukocidin,
toxin genes and Agr typing of methicillinresistant Staphylococcus aureus strains
isolated from bloodstream infections
at Hacettepe University Adult Hospital,
Ankara, Turkey
P. Zarakolu*, Z.C. Karahan, S. Unal (Ankara, TR)
P903
Identification of methicillin-resistant
staphylococci by PNA FISH directly
from positive blood cultures
A.K. Rasmussen*, H.K. Johansen,
B. Kummerfeldt, A. Mortensen, L. Bay,
H. Stender (Vedbaek, Copenhagen, DK)
P904
Genotypic and phenotypic methods for
detection of S. aureus, coagulase-negative
staphylococci and oxacillin resistance
B. Zaloudikova*, E. Nemcová, M. Stechová,
F. Ruzicka, V. Holá, P. Nemec, T. Freiberger
(Brno, CZ)
P905
Discrimination of staphylococci using an
rpoB-consensus PCR coupled with a
microarray hybridisation assay
S. Monecke*, P. Slickers, E. Müller, H. Hotzel,
R. Ehricht (Dresden, Jena, DE)
P906
Multicentre trial of the LightCycler®
MRSA advanced test, Xpert™ MRSA assay,
and MRSASelect™ directly plated culture
for detection of methicillin-resistant
Staphylococcus aureus in nasal swabs
R. Arcenas, S. Spadoni, F. Kiechle, K. Walker,
R. Fader, F. Perdreau-Remington, J. Osiecki,
O. Liesenfeld*, A. Rao (Hollywood, Hines, Temple,
San Francisco, Indianapolis, Pleasanton, US)
P907
Reduced delta-haemolysin activity and
agr-expression correlate with an hVISA/VISA
phenotype
V. Cafiso, T. Bertuccio, S. Purrello, D. Spina,
F. Campanile, D. Bongiorno, G. Blandino,
S. Stefani* (Catania, IT)
MRSA in animals
Occurrence and characteristics
aureus in pig farming in the Czech Republic
J. Bardon*, M. Kolar, R. Karpiskova,
H. Zemlickova, M. Fridrichova, P. Sauer,
Z. Stastkova, V. Hanulik
(Olomouc, Prague, Brno, CZ)
aureus isolated from swine and farm
workers in Spain
C. Potel-Alvarellos, L. Constenla-Carames,
A. Moreno-Flores, C. Lopez-Coton,
E. Comesaña-Da-Vila, L. Eiroa-De-La-Puente,
S. Perez-Castro, M. Alvarez-Fernandez*
(Vigo, Pontevedra, ES)
P898
Livestock-associated MRSA responsible
for human colonisation and infection in
a northern region of Italy
M. Monaco, M. Pedroni, A. Sanchini,
A. Bonomini, B. Milanesi, A. Pantosti*
(Rome, Manerbio, IT)
P899
Occurrence of methicillin-resistant
Staphylococcus aureus in dairy products
of Apulia region Italy
E. Crisetti*, A. Cataleta, T. Onni, M.A. Cafiero,
S. Tola, G. La Salandra (Foggia, Sassari, IT)
Final Programme
Posters
P891
111
Poster Sessions
Sunday, 8 May
P908
mecA expression in clinical MRSA strains
upon cefoxitin induction
T.Y. Wolff*, J. Lorenzen, T. Thomsen,
H.S. Andersen, A.K. Rasmussen,
B. Kummerfeldt, L. Bay (Aarhus, Aalborg,
Vedbæk, DK)
P909
MRSA PCR screening and optimisation
of laboratory services: an innovative way
for saving precious pennies in times of
financial turbulence in NHS
D. Singleton*, K. Chandler, S. Williams,
M. Przybylo, A. Guleri, J. CarterLindsay
(Blackpool, UK)
P910
Comparison of two molecular methods,
Xpert MRSA assay and MRSA Advanced Test,
for methicillin-resistant Staphylococcus
aureus nasal screening
P. Stano*, M. Avolio, R. De Rosa, M. Modolo,
A. Camporese (Pordenone, IT)
P911
Evaluation of the BD GeneOhm molecular
assays as a rapid screening tool for detection
aureus and vancomycin-resistant
enterococci in a tertiary hospital in Saudi
Arabia
H. Hassan*, M. Shorman (Dammam, SA)
P912
Development of a rapid and simple
isothermal molecular assay for the
qualitative detection of Staphylococcus
aureus and methicillin-resistant
Staphylococcus aureus directly from blood
culture on a non-instrumented platform
W. Tang, K. Cooper, T. Pack, N. Nasser,
T. Ranalli*, R. Lollar, H. Kong, T. Stenzel
(Beverly, San Diego, US)
P913
Evaluation of the impact of a rapid MRSA
point-ofcare test
K. Desai, N. Baker, N.P. Brenwald,
B. Oppenheim* (Birmingham, UK)
P914
Genotypic and phenotypic characteristics of
blood isolates with higher MIC (3 mg/L) of
vancomycin in Taiwan
W.Y. Wang , S.M. Tsao, Y.L. Lee, T.S. Chiueh,
J.J. Lu* (Taichung, Miao-Li, Taipei, TW)
P915
Detection of small colony variants
among methicillin-resistant Staphylococcus
aureus blood isolates
S. Yagci, B. Sancak, G. Hascelik* (Ankara, TR)
P916
Susceptibility patterns of S. aureus as
predictors of Panton-Valentine leukocidin
positivity
A. Hamprecht*, A.J. Kaasch, P. Wiegel, G. Plum
(Cologne, DE)
Final Programme
P917
Measuring S. aureus exotoxin concentrations
using protein microarrays with antibodies
generated by phage display
S. Monecke*, J. Buechler, R. Ehricht
(Dresden, DE; San Diego, US; Jena, DE)
P918
Extending rapid PCR screening to all
Staphylococcus aureus (MSSA and MRSA):
an innovative project at Blackpool Victoria
Teaching Hospital, UK
B. Lunt*, D. Singleton, J. Sycamore, S. Staff,
S. Williams, J. Carter Lindsay, R. Palmer,
A. Guleri (Blackpool, UK)
P919
Emergence and distribution
of Clostridium difficile PCR ribotype
027 in Hungarian hospitals
G. Terhes*, J. Sóki, K. Latkóczy, L. Szikra,
M. Konkoly-Thege, G. Princz, T. Nagy,
H. Osztie, E. Urbán
(Szeged, Budapest, Székesfehérvár, HU)
12:30 – 13:30
Enterococci
P920
Colonisation with vancomycin-resistant
Enterococcus faecium in a neonatal intensive
care unit in Greece
A. Liakopoulos*, E. Lebessi, A. Mavroidi,
A. Doudoulakis, E. Charachousou,
M. Papadimitriou, E. Petinaki
(Larissa, Athens, GR)
P921
High-level aminoglycoside resistance
in vancomycin-sensitive and -resistant
enterococci
B. Grabein, M. Hoeck, A. Toniolo, B. Wiedemann*
for the EPICENTER Network
P922
Focus and outcome for community-acquired
Enterococcus faecalis bacteraemia
M. Pinholt*, C.Ø. Andersen, M. Arpi, J. Knudsen
(Herlev, Hvidovre, DK)
P923
Increased prevalence of high-level
gentamycin resistance in invasive
Enterococcus faecium strains in Norway
is associated with hospital-adapted
genetic lineages carrying virulence
determinants and aac(6')-Ie-aph(2")-Ia
containing transferable megaplasmids
T. Pedersen, B. Langnes, K. Hegstad,
T.C. Rosvoll, B. Aasnæs, A.M. Hammerum,
C. Lester, G.S. Simonsen, A. Sundsfjord*
(Tromsø, NO; Copenhagen, DK)
Poster Sessions
Sunday, 8 May
The widespread VRE outbreak in Swedish
hospitals 2007–2009 was associated with
clonal E. faecium CC17 genogroup strains
harbouring several virulence traits and
transferable vanB pRUM-like repA plasmids
A. Sivertsen*, E.W. Lundblad, K.T. Wisell,
B. Liljequist, H. Billström, M. Ullberg, D. Heimer,
I. Sjögren, B. Aasnæs, A. Sundsfjord, K. Hegstad
(Tromso, NO; Stockholm, Huddinge, Halmstad,
Västerås, SE)
P925
Emergence of vancomycin-resistant
Enterococcus gallinarum strains carrying
acquired glycopeptide resistance
determinants in Stockholm, Sweden
H. Fang*, G. Hedin, A. Ohlsson, A. Kahsai,
M. Ullberg (Stockholm, SE)
P926
Prevalence and rep-PCR typing
of vancomycin-resistant enterococci
VanA-type recovered from sewage
in Austria
J. Posch*, H. Galler, D. Haas, G. Zarfel,
A. Melkes, G. Feierl, L. Masoud, A.J. Grisold,
E. Leitner, E. Marth, F.F. Reinthaler (Graz, AT)
P927
The vancomycin-resistant enterococci
in drinking water
T. Konstantinidis, I. Alexandropoulou,
M. Panopoulou*, E. Alepopoulou, A. Varelas,
A. Milona, T.C. Constantinidis
(Alexandrupolis, GR)
P928
P929
In vitro susceptibility of 104 vancomycinresistant Enterococcus faecium isolates
from clinical specimen against daptomycin,
linezolid and tigecycline
S. Lemmen*, S. Scheithauer, G. Haase,
H. Haefner (Aachen, DE)
Susceptibility of 234 clinical isolates
of vancomycin-resistant Enterococcus spp.
to teicoplanin, daptomycin, tigecycline,
doripenem and linezolid
M. Diab-El Schahawi*, C. Kratzer, A. Hirschl,
V. Dosch, E. Presterl, W. Graninger (Vienna, AT)
P930
Antimicrobial susceptibility of enterococci
and streptococci from United States hospitals:
a 9-year summary of the Daptomycin
Surveillance Program (2002 – 2010)
H. Sader*, P. Rhomberg, D. Farrell, R. Jones
(North Liberty, US)
P931
Evaluation of enterococcosel broth for
detection of vancomycin-resistant
Enterococcus at Royal North Shore Hospital
Sydney, Australia
L.A. Fernandes*, P.G. Huntington, C. Fernandes,
G. Kotsiou (St Leonards, AU)
P932
In vitro activity of linezolid and comparators
against Enterococcus phenotypes:
Europe, 2007 – 2010
D. Hoban*, B. Johnson, S. Hawser, R. Badal,
M. Hackel, S. Bouchillon, M. Dowzicky
P933
First detection of the trimethoprim resistance
gene dfrK in Enterococcus isolates
M. López*, K. Kadlec, S. Schwarz, C. Torres
(Logroño, ES; Neustadt-Mariensee, DE)
P934
Emergence of tigecycline and linezolid
resistance in a vancomycin-resistant isolate
of Enterococcus faecium
M. Hornsey*, D.W. Wareham, J.F. Turton,
K. Martin, R. Pike, M. David, D. Livermore,
N. Woodford (London, UK)
P935
Characterising vancomycin-resistant
Enterococcus strains with varying
daptomycin resistance developed in
an in vitro PK/PD model
M. Steed, C. Vidaillac*, R. Warren, P. Winterfield,
G. Kaatz, M. Rybak (Detroit, Madison, US)
12:30 – 13:30
P936
carrying mecA and other antibiotic resistance
genes among healthy volunteers in the UK
A. Endimiani*, I. Bertschy, J. Barford,
A. Shamaei-Tousi, A. Coates, B.J.F. Keijser,
M. Wilson, V. Perreten
(Berne, CH; London, UK; Zeist, NL)
P937
pseudintermedius from healthy dogs
in Spain: novel genotypic and phenotypic
characteristics of this emerging multiresistant pathogen
E. Gómez-Sanz*, C. Lozano, C. Aspiroz, C. Torres,
M. Zarazaga (Logroño, Zaragoza, ES)
P938
Dissimilar distribution of cassette
chromosome recombinase allotypes
among methicillin-susceptible
coagulase-negative staphylococci
M. Miragaia*, J. Rolo, O. Bouchami,
H. de Lencastre (Oeiras, PT; Tunis, TN;
New York, US)
P939
Prevalence of coagulase-positive
staphylococci and methicillin-resistant
coagulase-negative staphylococci in
healthy humans and their companion
animals: 6 cases of interspecies transmission
E. Gómez-Sanz*, C. Lozano, C. Aspiroz, C. Torres,
M. Zarazaga (Logroño, Zaragoza, ES)
Final Programme
113
Posters
P924
Poster Sessions
Sunday, 8 May
P940
High diversity of genetic backgrounds
and SCCmec carried by coagulase-negative
staphylococci from a single host
N.A. Faria*, D.C. Oliveira, M. Miragaia,
H. de Lencastre, H. Westh (Oeiras, Caparica, PT;
New York, US; Copenhagen, DK)
P949
Prostate-derived Propionibacterium
acnes isolates are sensitive to potentially
useful antibiotics
J. Olsson*, S. Davidsson, M. Unemo, P. Mölling,
S.-O. Andersson, O. Andrén, M. Sellin, B. Söderqvist,
F. Elgh (Umeå, Örebro, SE)
P941
Prevalence of mecA, clonal relation and
linezolid susceptibility of environmental
Staphylococcus epidermidis
M. Hercun, L. Radtke, J. Knobloch* (Lübeck, DE)
P950
P942
Rapid colonisation by methicillinresistant coagulase-negative staphylococci
of the nose upon hospitalisation
C. McMurray, K. Hardy, P. Hawkey*
(Birmingham, UK)
Determination of the postantibiotic and
postantibiotic sub-MIC effect of vancomycin
and daptomycin on Staphylococcus aureus
and Enterococcus faecalis by isothermal
microcalorimetry
C. Zalila, A. Trampuz, A. Bizzini* (Lausanne, CH)
P951
In vitro development of high-level resistant
Viridans group streptococci upon exposure
to daptomycin
R. Akins* (Shreveport, US)
P952
Linezolid resistance due to CFR in a
clinical isolate of methicillin-susceptible
J.P. Quinn*, G. Harrington, M.M. Lemmon, S. Bittner,
M. Huband, K.D. Ford (Groton, Battle Creek, US)
P953
Study of frequency of metallo beta-lactamase
among Pesudomonas aeruginosa strains
isolated in clinical samples in Ilam hospitals,
Iran
N. Sadeghifard*, S. Ghafouryan, R. Mohebi,
R. Ranjbar (Ilam, Tehran, IR)
P954
Microbiological characteristics of
clinically significant Gram-positive bacilli
from soft-tissue infections
S.Y. Ng*, J. Sim, L.C. Eng, T. Tan (Singapore, SG)
12:30 – 13:30
P943
P944
AMR in Gram-positives
Antimicrobial activity and spectrum
of daptomycin tested against Grampositive strains collected in European
hospitals: results from 7 years of
surveillance (2003 – 2009)
H. Sader*, D. Farrell, G. Moet, R. Jones
(North Liberty, US)
Fusidic acid activity and coverage of Grampositive pathogens associated with acute
bacterial skin and skin structure infections
in the USA (2008 – 2010)
R. Jones*, D. Farrell, H. Sader, M. Castanheira
(North Liberty, US)
P945
Antimicrobial activity of ceftaroline
tested against common pathogens causing
complicated skin and soft tissue infections
in European medical centres in 2009
P. Rhomberg, D. Farrell, R. Jones, H. Sader*
(North Liberty, US)
P955
Incidence and spread of multi-resistant
methicillin-susceptible Staphylococcus
aureus in southeastern Sweden
M. Lindqvist*, B. Isaksson, L. Nilsson,
A. Wistedt, S. Löfgren, A. Hällgren
(Linköping, Kalmar, Jönköping, SE)
P946
Analysis of linezolid in vitro activity
against Gram-positive species in Asia –
TEST 2004 – 2010
S. Lob, R. Badal, D. Hoban, J. Johnson*,
S. Bouchillon, M. Dowzicky
(Schaumburg, Collegeville, US)
P956
Streptococcus bovis infection:
a comparative study of epidemiology
and clinical manifestations between
biotypes I and II
R. Plongla*, C. Saunkratay, S. Ngamwongwan,
T. Chatsuwan (Bangkok, TH)
P947
Comparative in vitro potency of torezolid
(TR-700) and linezolid against key Grampositive pathogens of European origin
(2009 – 2010)
C. Pillar, D.F. Sahm, K. Bartizal*
(Chantilly, San Diego, US)
P957
P948
In vitro activity of telavancin and
comparators against Gram-positive bacteria
isolated from bloodstream infections
H. Seifert*, D. Stefanik, A.J. Kaasch (Cologne, DE)
Molecular characterisation of group B streptococci isolated from invasive neonatal infections
and colonised pregnant women in Greece
A. Mavroidi*, S. Vourli, L. Zachariadou,
K. Tsiveriotis, F. Kolonitsiou, A. Liakopoulos,
E. Papoutsidou, D. Kairis, M. Oeconomou,
L. Zerva, A. Pangalis, C. Koutsia-Carouzou,
E. Malli, A. Vasdeki, S. Xytsas, M. Panopoulou,
S. Kartali-Ktenidou, E.D. Anastassiou,
I. Spiliopoulou, E. Petinaki
(Larissa, Athens, Patras, Alexandroupolis, GR)
Final Programme
Poster Sessions
12:30 – 13:30
P958
P959
P960
Pneumococci
Pneumococcal serotype distribution in
invasive pneumococcal disease among
adults >50 years old in Belgium in 2009
J. Verhaegen*, W. De Backer, B. Delaere,
J. Flamaing, W. Peetermans, P. Van Damme,
K. Van Herck, Y. Van Laethem, F. Surmont
on behalf of the Adult IPD Study Group
Distribution of Streptococcus pneumoniae
serotype isolates from invasive disease in
Lombardy, northern Italy
M.L. Garlaschi*, L. Daprai, L. Cariani,
M.C. Garlaschi, G. Clarizia, M. D'Accico,
G. Defilippi, A. Biffi, R. Rubini, A. Pavan,
E. Torresani (Milan, IT)
Penicillin- and erythromycin-non-susceptible
Streptococcus pneumoniae serotypes in a
Greek paediatric population, 2005 – 2009:
replacement of 19F by 19A and 6A
I. Paraskakis, A. Pangalis, J. Papaparaskevas,
P.T. Tassios*, H. Kirikou, A. Charisiadou,
L.S. Tzouvelekis, N.J. Legakis, A.Z. Tsakris
(Athens, GR)
P961
Characteristics of invasive Streptococcus
pneumoniae samples
A. Infante*, M.V. Garcia, V. Odero, C. Arana,
I. Viciana, M.A. Sanchez (Malaga, ES)
P962
Serotype distribution and antimicrobial
susceptibility of Streptococcus pneumoniae
isolated from children with invasive
pneumococcal infections in Turkey
S. Nar Otgun, R. Durmaz*, A. Gozalan,
D. Guldemir, B. Acar, M. Ertek for the Invasive
Pneumococcal Diseases Study Group
P963
P964
P965
Temporal analysis of invasive pneumococcal
serotypes from patients attending a
university hospital in Brazil
S.R. dos Santos, E.H. Takagi, L.F. Passadore,
C.M. Fujii, M.B. Martinez* (Sao Paulo, BR)
Impact of pneumococcal vaccination in
preventing invasive pneumococcal disease
in Cantabria (Spain)
C. Fariñas-Alvarez*, M.A. Nuñez-Viejo,
L. Ansorena-Pool, F. Rojo, J.A. Sanz-Salanova,
J. Llorca, M.C. Fariñas (Santander, Laredo, ES)
Prognostic factors and mortality of invasive
pneumococcal disease in Cantabria (Spain)
C. Fariñas-Alvarez*, M.A. Nuñez-Viejo,
C. Fernandez-Mazarrasa, M.P. Roiz, I. De-Benito,
P. Mellado, J. Llorca, M.C. Fariñas (Torrelavega,
Santander, Laredo, ES)
P966
Utility of Pneumotest-Latex in serotyping
of Streptococcus pneumoniae directly in
clinical samples
A. Golebiewska*, A. Kuch, I. Wasko,
P. Ronkiewicz, M. Markowska, W. Hryniewicz,
A. Skoczynska (Warsaw, PL)
P967
Clinical and bacteriological efficacies of
sitafloxacin against community-acquired
pneumonia caused by Streptococcus
pneumoniae: a multicentre clinical trial
J. Fujita*, S. Kohno (Okinawa, Nagasaki, JP)
P968
FOCUS 1 and 2: Streptococcus pneumoniae
subset analyses from two phase III trials
of ceftaroline fosamil vs ceftriaxone in the
treatment of community-acquired pneumonia
P.B. Eckburg*, I. Critchley, H.D. Friedland,
L. Llorens, D. Thye (Oakland, US)
P969
Nasopharyngeal carriage of pneumococcal
and other respiratory bacteria in communitydwelling asymptomatic elderly
A.M. van Deursen*, M.R. van den Bergh,
E. Hak, R.H. Veenhoven, M.K. Sidhu, P. Zhao,
M.J. Bonten, E.A. Sanders (Utrecht, Groningen,
Hoofddorp, NL; Pearl River, US)
P970
A pilot study of serotype distribution and
antimicrobial resistance of nasopharyngeal
isolates of S. pneumoniae from healthy
toddlers in Evros, Greece
E. Mantadakis*, D. Themelidis, M. Panopoulou,
S. Maraki, E. Alepopoulou, S. Kartali,
A. Chatzimichael
(Alexandroupolis, Heraklion, GR)
P971
Evaluation of different techniques to detect
S. pneumoniae in hospitalised adults with
community-acquired pneumonia across
Europe
K. Loens*, A. Vanderstraeten, K. Bergs,
H. Goossens, M. Ieven (Antwerp, BE)
P972
The impact in Ireland of the 7-valent
pneumococcal conjugate vaccine on
invasive pneumococcal disease within
two years of its introduction
I. Vickers*, M. Fitzgerald, S. Murchan,
P. O'Lorcain, S. Cotter, D. O'Flanagan,
M. Cafferkey, H. Humphreys (Dublin, IE)
P973
Trends in serotypes causing invasive
pneumococcal disease in Canadian adults,
2000-2009
W. Rudnick*, A. McGeer, K. Green,
S. Pong-Porter, A. Plevneshi, M. Romilowych,
D.E. Low Canadian Bacterial Surveillance
Network
Final Programme
115
Posters
Sunday, 8 May
Poster Sessions
Sunday, 8 May
P974
12:30 – 13:30
P975
P976
Serotype-specific trends in population-based
surveillance for invasive and respiratory
pneumococcal disease in adults, Toronto,
2000–2009
K. Green*, W. Rudnick, D.E. Low, S. Pong-Porter,
A. Plevneshi, M. Romilowych, A. McGeer
on behalf of the Toronto Invasive Bacterial
Diseases Network
Can we distinguish Streptococcus
pneumoniae from other streptococci
in the mitis-group using the lytA gene?
A comparison of bacterial strains by
real-time PCR and phylogenetic analysis
T. Greve*, J.K. Møller (Skejby, Vejle, DK)
Chromosomal drug efflux pumps in
Streptococcus pneumoniae
N. Tocci*, A. Bidossi, M.L. Ciusa, F. Decorosi,
C. Viti, G. Pozzi, S. Ricci, M.R. Oggioni
(Siena, Firenze, IT)
Detection of group B streptococci
intrapartum using BD™ Max GBS assay
J.C. Nguyen Van*, E. Sauvanet, Y. Giovangrandi
(Paris, FR)
P978
The MutR transcriptional regulator
plays an important role in the virulence
of Streptococcus pyogenes
A.A. Zutkis*, S. Anbalagan, M.S. Chaussee,
A.V. Dmitriev (Saint-Petersburg, RU;
Vermillion, US)
P979
Streptococcus pneumoniae: a Multiplex-PCR
challenged by rough variants
R. Dargis, L. Lambertsen, M. Kemp,
J.J. Christensen* (Copenhagen, Odense,
Slagelse, DK)
P980
The streptokinase gene as a candidate
target for differentiation between
Streptococcus dysgalactiae subsp.
equisimilis causing infections in humans
and horses
S. Preziuso*, M. Pinho, A.R. Attili,
J. Melo-Cristino, M. Ramirez, V. Cuteri
(Matelica, IT; Lisbon, PT)
P982
Rapid detection of Streptococcus pyogenes
in peripheral medical centres.
A pilot custody assay
J.L. Ramos*, M.T. Fraile, M. Chanzá, N. Tormo,
A. Lurbe, C. Gimeno (Valencia, ES)
P984
Faster diagnosis by antigen detection for
group B Streptococcus carriage in pregnant
women
A. Raglio*, P. Serna Ortega, S. Rampello,
B. Pasini, M. Arosio, F. Vailati, A. Grigis,
A. Goglio (Bergamo, IT)
Streptococci: from diagnosis to pathogenesis
P977
P981
P983
Distribution of pathogenicity island XII
of group B streptococci
E. Kuleshevich*, A. Savicheva, A. Suvorov
(St. Petersburg, RU)
Non-haemolytic GBS on Granada medium:
there might be a solution for this problem!
S. Nickmans*, E. Verhoye, A. Boel,
K. Van Vaerenbergh, H. De Beenhouwer
(Aalst, BE)
Final Programme
12:30 – 13:30
AMR in fastidious micro-organisms
P985
Antimicrobial resistance in Helicobacter
pylori positive patients after therapy failure
and in Helicobacter pylori positive untreated
patients
L. Franzin*, C. Avanzini, V. Demarie, A. Ferrari,
A. Garripoli, P. Lerro, C. Barbera (Turin, IT)
P986
Resistance of Helicobacter pylori
to clarithromycin and metronidazole in
a tertiary hospital in the Netherlands
H.F. Wunderink*, P.E. Mourad-Baars,
K.E. Veldkamp (Leiden, NL)
P987
High incidence of ciprofloxacin-resistant
Neisseria gonorrhoeae in a tertiary hospital
in Madrid, Spain (2005 – 2010)
A. Burillo*, E. Cercenado, M. Marín, M. Rivera,
T. Vicente, E. Bouza (Madrid, ES)
P988
Cefixime resistance in Neisseria
gonorrhoeae isolates from 2006 to 2010:
correlation of MIC values with target gene
alterations, the Italian experience
A. Carannante, I. Dal Conte, V. Ghisetti,
S. Del Re, M. Cusini, L. Scioccati, G. Prignano,
G. Palamara, A. Di Carlo, V. Sambri, A. D'Antuono,
F. Cavrini, A. Matteelli, M. De Francesco,
A. Di Taranto, R. De Nittis, P. Stefanelli*
(Rome, Turin, Milan, Bologna, Brescia, Foggia, IT)
P989
Macrolide-resistant Mycoplasma pneumoniae
in Japan
N. Miyashita*, Y. Kawai, K. Ouchi (Kurashiki City, JP)
12:30 – 13:30
P990
Emerging infectious diseases
Clinical epidemiology and manifestations
of Campylobacter concisus
H.L. Nielsen*, T. Ejlertsen, J. Engberg, H. Nielsen
(Aalborg, Slagelse, DK)
Poster Sessions
P991
A study on Chikungunya virus infection
in north India
J. Agarwal*, S. Srivastava, S. Malik,
K.P. Singh, M. Singh (Lucknow, IN)
P992
The burden of invasive disease with non-b
Haemophilus influenzae serotypes in Alaska
and Northern Canada, 2000–2009
M. Bruce*, T. Zulz, S. Desai, J. Lourenco, S. Kitka,
D. Hurlburt, D. Bruden, K. Rudolph, C. Debyle,
R. Tsang (Anchorage, US; Ottawa; Winnipeg, CA)
P993
P994
P995
Tertiary care hospital candidaemia:
epidemiology and emerging species
C. Ruiz de Alegria Puig*, M.A. Ballesteros Sanz,
E. Román Paucar, J.L. Teja Barbero,
C. Fernández-Mazarrasa , L. Martínez-Martínez
(Santander, ES)
Clinical and molecular epidemiology of
emerging S. aureus ST398 strains associated
with bloodstream infections in France.
N.L. van der Mee-Marquet*, X. Bertrand,
P.Y. Donnio, A.-S. Valentin-Domelier, N. Girard,
R. Quentin on behalf of the Bloodstream
Infection Study Group of the Réseau des
Hygiénistes du Centre, RHC
Low prevalence of Coxiella burnetii
endocarditis in patients with a history
of valve surgery or cardiac valve prosthesis
in a Q-fever endemic area in the Netherlands
L.M. Kampschreur*, J.J. Oosterheert,
P.J. Lestrade, N.H. Renders, P. Elsman,
P.C. Wever (Utrecht, 's Hertogenbosch, NL)
P996
The initial presentation of soft tissue anthrax
D. Hamilton*, G. Jones (Dumfries, UK)
P997
Cryptosporidiosis in Kuwaiti children:
association of clinical characteristics with
Cryptosporidium species and subtypes
J. Iqbal*, P.R. Hira, N. Khalid (Safat, KW)
P998
Deep-brain stimulation hardware related
infection: an emerging infectious disease
F. Fily, C. Haegelen, P. Tattevin*,
S. Buffet-Bataillon, M. Revest, A. Cady,
P.Y. Donnio, H. Leroy, C. Arvieux, C. Michelet
(Rennes, FR)
P999
P1000
High-level gentamycin resistant
Enterococcus faecalis isolated from urinary
tract infections and poultry in close contact
with the patient
L. Poulsen*, M. Bisgaard, A. Dalsgaard, N. Son,
H. An, N. Trung (Frederiksberg, DK; Hanoi, VN)
Imported symptomatic Hantavirus infection
in three family members travelling from Cuba
F. Rovida*, E. Percivalle, A. Sarasini, G. Chichino,
F. Baldanti (Pavia, IT)
P1001
A severe H1N1 and Legionella co-infection
necessitating extracorporal membrane
oxygenation treatment
P. Pongratz*, G. Hinterholzer, F. Thaller,
M. Rosner, D. Schmid, C. Wenisch, H. Laferl,
J. Leitner (Vienna, AT)
P1002
Lymphogranuloma venereum variant
L2b-specific PCR: insertion used to close
an epidemiological gap
P. Verweij, A. Catsburg, S. Ouburg, A. Lombardi,
R. Heijmans, F. Dutly, R. Frei, S. Morré,
D. Goldenberger* (Amsterdam, NL; Milan, IT;
Zurich, Basel, CH)
P1003
Infective endocarditis caused by Nocardia
cyriacigeorgica, the first case reported
S. Nimitvilai*, N. Bumrungsri, A. Leelaporn,
N. Angkasekwinai, P. Koomanachai,
M. Chayakulkeeree (Bangkok, TH)
P1004
Q fever across the Dutch border in Limburg
province, Belgium
R. Naesens*, K. Magerman, I. Gyssens,
A. Leenders, J. Meekelenkamp, M. Van Esbroeck,
G. Coppens, E. Oris, J. Craeghs, I. Thoelen,
P. Gabriëls, M. Vandevelde, A.-M. Forier,
L. Waumans, R. Cartuyvels
(Hasselt, BE; ‘s-Hertogenbosch, NL; Antwerp,
Genk, Tongeren, Sint-Truiden, Maaseik-Bree, BE)
P1005
Prevalence of Borrelia burgdorferi sensu
lato, Anaplasma phagocytophilum, Rickettsia
spp. and Babesia spp. in ticks removed from
humans in the area of Belluno, Italy
L. Brugnera Muraro, A. Tessari*, G. Del Giudice,
G. Piccolin, M. Battistel, E. Modolo, G. Bertiato
(Belluno, IT)
P1006
Intracellular growth and survival of Vibrio
cholerae in human macrophages
H. Abd* (Stockholm, SE)
P1007
Clinical and epidemiological features of
Chikungunya fever in returning travellers
P. Papineni*, M. Armstrong, T. Doherty
(London, UK)
P1008
Crimean-Congo haemorrhagic fever: six-year
experience of a secondary care hospital in
the epidemic region
C. Kader*, A. Erbay, S. Bakir Özbey
(Kastamonu, Yozgat, TR)
P1009
All-cause mortality among hospitalised
CDI patients is associated with PCR-ribotype
027 but independent of the presence
of binary toxin
M.P. Hensgens*, A. Goorhuis, O.M. Dekkers,
E. Kuijper (Leiden, NL)
Final Programme
117
Posters
Sunday, 8 May
Poster Sessions
Sunday, 8 May
P1010
P1011
P1012
Dutch patients, retail chicken meat
and poultry share the same ESBL genes,
plasmids and strains
M. Leverstein - van Hall*, C.M. Dierikx,
J.W. Cohen Stuart, G.M. Voets,
T.M. van den Munckhof, A. van Essen-Zandbergen,
T.N. Platteel, A.C. Fluit, N. van der Sande,
J. Scharringa, M.J. Bonten, D. Mevius
on behalf of the ESBL national surveillance
working group
Characteristics of microsporidial keratoconjunctivitis in an eastern Indian cohort:
a case series
S. Saha*, A. Khetan, D. Banerjee, J. Sengupta
(Midnapore West, Kolkata, IN)
Rapid recognition of Clostridium difficile
PCR ribotypes 027 and 078 using MALDI-TOF
mass spectrometry
C.W. Knetsch, J. Corver, E. Kuijper* (Leiden, NL)
P1019
Using real-time PCR for detection of Yersinia
pestis in field samples from Mountain Altai
natural focus of plague
M. Afanas’ev*, E. Chipanin, V. Shestakov,
A. Denisov, L. Fomina, A. Ostyak, S. Balakhonov
(Irkutsk, RU)
P1020
Coinfection of ticks with Borrelia burgdorferi
sensu lato and Rickettsia spp. in densely
populated areas of the Po River valley
M. Pajoro*, S. Epis, F. Comandatore,
M. Montagna, N. Vicari, M. Fabbi, D. Pistone,
P. Marone, C. Bandi (Pavia, Milan, IT)
P1021
Clonal distribution of Streptococcus
pneumoniae serotype 19A isolated in
Malaysian hospitals
R. Md. Yasin*, K.N. Mohd Khalid, R. Issa,
N. Ahmad (Kuala Lumpur, MY)
P1022
Pacemaker-related endocarditis:
clinical features and microbiological
spectrum of 43 consecutive cases
T. Exiara*, A. Konstantis, A. Risggits,
A. Kalpaka, M. Kouroupi, E. Gidaris, L. Mporgi,
S. Papanastasiou, L. Papazoglou
(Komotini, Thessaloniki, Alexandroupolis, GR)
P1023
H1N1 influenza pandemic from June 2010
to November 2010 at a single nodal centre
in Hyderabad, India
F. Mohammad*, R. Paul, L. Nutankalva,
S. Narreddy (Hyderabad, IN)
P1024
Serologic evidence of tick-borne aetiologies
in Bulgaria
E. Taseva*, T. Gladnishka, I. Trifonova,
V. Ivanova, I. Christova, R. Refaat, E. Mohareb
(Sofia, BG; Cairo, EG)
P1013
Invasive disease caused by Haemophilus
influenzae serotypes e and f in England and
Wales
A. Vickers*, C. Crawford, D. Litt, S. Ladhani,
M. Slack (London, UK)
P1014
Emergence of uncommon EMM types of
Streptococcus pyogenes among adult
patients in southern Taiwan
C. Chiang-Ni, A.B. Wu, C.C. Liu, K.T. Chen,
Y.S. Lin, W.J. Chuang, H.Y. Fang, J.J. Wu*
(Tainan, TW)
P1015
Phylogenetic and virulence analysis
of tick-borne encephalitis virus field isolates
from Switzerland
C.M. Beuret* (Spiez, CH)
P1016
Comparative genetic characterisation
of human and animal isolates of methicillinresistant Staphylococcus aureus ST398
D. Jamrozy*, M. Sharma, M. Fielder, A.F. Kelly,
P. Butaye, R. Ehricht, S. Monecke, N. Coldham
(New Haw, London, UK; Brussels, BE; Jena,
Dresden, DE)
P1025
Strong relationship between total thiol
status and thrombocytopenia in patients with
Crimean-Congo haemorrhagic fever
R. Guner, M.A. Tasyaran*, S. Keske,
I. Hasanoglu, D. Yapar, A. Kaya Kalem,
T. Arslan Gulen, S. Isikoglu, S. Neselioglu,
O. Erel (Ankara, TR)
P1017
Essentiality of dUTPase mediated by its
Mycobacterium-specific structural motif
identifies a novel TB drug target
I. Pecsi*, R. Hirmondo, A.C. Brown, A. Lopata,
T. Parish, V.G. Beata, J. Toth (Budapest, HU;
London, UK)
P1026
P1018
West Nile fever outbreak in humans in
northern Greece
D. Karabaxoglou*, A. Karabournidis,
G. Kagkalou, E. Vassiliadou, F. Kamaria,
D. Chrysagis, A. Bakas, A. Kansouzidou
(Thessaloniki, GR)
Diagnosis of a case of Plasmodium vivax
malaria in Aragón, Northern Spain.
This is the first autochthonous case since its
eradication in 1964
M. Ferrero*, P. Mairal, E. Latorre, A. Puy,
J. Lucientes, J.M. Rubio
(Huesca, Zaragoza, Madrid, ES)
P1027
Tularaemia outbreak in central Anatolia
A. Ulu Kilic*, E. Tutuncu, Y. Gurbuz, S. Kilic,
G. Cicek Senturk, G. Gulen, F. Sezen, I. Sencan
(Ankara, TR)
Final Programme
Poster Sessions
Sunday, 8 May
Short-course high-dose rifaximin rescue
treatment in CDI – a single-centre experience
T. Marcello*, K. Schreiter, N. Schultheis, C. Hechler,
I. Raila, M. Lindner, A. Bethke, T. Grünewald
(Leipzig, DE)
P1029
Pyosalpinx and pelvic pain due to Brucella
melitensis
A. Poulou*, F. Markou, G. Vrioni, A. Tsakris
(Serres, Athens, GR)
12:30 – 13:30
Retrospective evaluation of Brilliance VRE®
and VRESelect® Chromogenic agars
for detection of vancomycin-resistant
enterococci using a diverse isolate collection
B.M. Willey*, K. Prayitno, P. Gnanasuntharam,
P. Gnanasuntharam, T. Fung, L. Louie, P. Lo,
K. Wong, T. Mazzulli, S.M. Poutanen (Toronto, CA)
P1038
External quality assessment of culturebased detection of methicillin-resistant
Staphylococcus aureus by a network
of European laboratories
M. Gazin*, C. Lammens, M. Ieven, H. Goossens,
S. Malhotra-Kumar on behalf of the MOSAR WP2
study team
P1039
Improved sensitivity and reduction in
MRSA surveillance costs by using MRSA-B
enrichment broth
C. Lee*, C. Rutherford, J. Korver (Hamilton, CA)
P1040
Validation of new BinaxNow Staphylococcus
aureus and PBP2a tests performed directly
from blood cultures
J. Montgomery* (Melbourne, AU)
P1041
Detection of oxacillin resistance of S. aureus
by whole cell matrix assisted laser
desorption time of flight mass spectrometry:
the time has not yet come
F. Szabados*, M. Kaase, A. Anders, S. Gatermann
(Bochum, DE)
Detection of resistance in Gram-positive
bacteria
P1030
Validation of the new inducible clindamycin
resistance test on Vitek2 cards for
staphylococci (AST-P610)
B. Van Meensel*, M. Lontie (Louvain, BE)
P1031
Assessment of heteroresistance to
vancomycin and other antibiotics by broth
macrodilution in Staphylococcus aureus
strains
F.F. Arhin*, I. Sarmiento, G. Moeck
(Ville Saint Laurent, CA)
P1032
Evaluation of a rapid detection method
for methicillin-resistant coagulasenegative staphylococci, the Clearview®
Exact PBP2a test
E. De Witte, M. Ieven* (Edegem, BE)
P1033
Multicentre validation of the Clearview®
Exact PBP2a test
B. Van Meensel *, J. Frans, W. Laffut,
D. Van Kerkhoven, A. Lemmens,
J. Van Schaeren, E. De Laere
(Louvain, Bonheiden, Lier, Sint-Truiden,
Mechelen, Antwerp, Roeselare-Menen, BE)
P1034
Evaluation of CHROMagar MRSA agar
(E&O) and brilliance MRSA 2 agar
(Thermo Fisher Scientific)
D. Bangura* (Salisbury, UK)
P1035
Methicillin-resistant Staphylococcus aureus
screening using Brilliance MRSA 2 Agar
C. Sander*, W. Kalka-Moll, E. Scopes
(Mönchengladbach, DE; Basingstoke, UK)
P1036
P1037
Prospective evaluation of Brilliance VRE®
and VRESelect® Chromogenic Agars
for detection of vancomycin-resistant
enterococci from surveillance specimens
B.M. Willey*, L. Louie, P. Gnanasuntharam,
T. Fung, C. Watt, P. Gnanasuntharam,
C. Vermeiren, G. Ricci, P. Lo, K. Wong, A. Simor,
A. McGeer, T. Mazzulli, S.M. Poutanen
(Toronto, CA)
12:30 – 13:30
Posters
P1028
Antimicrobial resistance
P1042
Antimicrobial resistance of H. pylori
in Smolensk, Russia
N. Dekhnich, E. Kostykova, A. Punin, A. Alimov,
N. Ivanchik, R. Kozlov* (Smolensk, RU)
P1043
Resistance and virulence characterisation
of CTX-M15 and KPC-3 Klebsiella pneumoniae
clinical isolates
C. Caneiras, F. Calisto, A. Narciso, S. Arriaga,
J. Melo Cristino, A. Duarte* (Lisbon, PT)
P1044
In vitro assessment of the core/shell/
extra-shell nanosystem influence on the
antibiofilm effect of usnic acid
C. Saviuc*, A. Grumezescu, M.C. Chifiriuc,
L. Dascalu, M. Popa, A. Cotar, A. Holban,
C. Bleotu, E. Oprea, D. Mihaiescu, V. Lazar
(Bucharest, RO)
P1045
Major genetic plasticity found in NDM-1
plasmids grown under different conditions
S. Agouri*, J. Weeks, T. Walsh, M. Toleman
(Cardiff, UK)
Final Programme
119
Poster Sessions
Sunday, 8 May
P1046
P1047
P1048
12:30 – 13:30
Carbapenemase-2 producing Klebsiella
pneumoniae transmission in an Italian
university hospital
M. Rossi*, G. Migliorino, E. Motta, G. Foti,
F. Morini, G. Giltri, E. Viganò, R. Fumagalli,
A. Gori (Monza, IT)
A significant impact on the rate of
ESBL-producing Klebsiella pneumoniae
by changing the antibiotic policy and
consumption
J. Knudsen*, S.E. Andersen
for the Bispebjerg Intervention Group
Chromosome-encoded extendedspectrum class A beta-lactamase MIN-1 from
Minibacterium massiliensis
B. Bercot*, P. Nordmann, M. Drancourt,
L. Poirel (Le Kremlin Bicetre, Marseille, FR)
Loss of activity of the GdpP protein leads
to beta-lactam tolerance in Staphylococcus
aureus
J. Griffiths*, A.J. O'Neill (Leeds, UK)
P1050
A novel mechanism of reduced susceptibility
to vancomycin in Staphylococcus aureus
A.Y. Peleg*, D. Cameron, D. Ward, R. Moellering,
G.M. Eliopoulos (Melbourne, AU; Boston, US)
Structural insights into fusidic acid
resistance mediated by FusB-type proteins
in Staphylococcus aureus
G. Cox*, G.S. Thompson, H.T. Jenkins,
S.W. Homans, T.A. Edwards, A.J. O'Neill
(Leeds, UK)
P1052
Linezolid decreases exotoxin expression
in Staphylococcus aureus by early
repressing agr, sarA and SAE regulators
O. Dumitrescu*, F. Forey, M. Bes,
F. Vandenesch, J. Etienne, G. Lina (Lyon, FR)
P1053
The effect of ermTR gene in isogenic
conditions on erythromycin and lincomycin
susceptibilities of S. aureus RN4220
E. Oryasin*, B. Bozdogan (Aydin, TR)
P1054
Ultrastructural cell wall characteristics of
clinical gentamycin-resistant Staphylococcus
aureus isolates
K. Fukutsuji*, S. Yamada, T. Harada
(Kurashiki, JP)
P1055
Correlation of consumption and resistance
in Staphylococcus aureus in Lebanon
Z. Daoud*, M. Hajjar, E. Salem, E. Azar, C. Afif
(Beirut, LB)
P1057
Susceptibility of S. aureus from inpatient
vs outpatient settings – a global analysis
2009 – 2010
S. Lob, D. Hoban, S. Bouchillon, R. Badal*,
M. Hackel, J. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
P1058
Susceptibilities of antibiotics with activity
against methicillin-resistant Staphylococcus
aureus from 2004 – 2008
T. Crawford*, L. Danziger, K. Rodvold, W. Janda
(Chicago, US)
P1059
Antimicrobial susceptibility phenotypes
of vancomycin intermediate Staphylococcus
aureus isolates
R. Craven*, C. Doern, C. Burnham, C. Weber,
S. Metzger, W.M. Dunne
(St. Louis, Dallas, Denver, US)
P1060
Present situation of antimicrobial resistance
of Staphylococcus in Spain (2010): seventh
nationwide prevalence study and emerging
resistance to linezolid
E. Cercenado*, O. Cuevas, B. Gama, A. Vindel,
M. Marín, E. Bouza on behalf of the
Staphylococcus Study Group
P1061
Thioridazine increases susceptibility
to oxacillin in methicillin-sensitive
K. Jacobsen*, M. Bonde, H. Kolmos,
B. Kallipolitis, J.K. Klitgaard (Odense, DK)
P1062
Secondary metabolites from lichens:
drug interaction of usnic acid, lobaric
acid and protolichesterinic acid with
antibiotics against MRSA clinical isolates
G. Celenza*, B. Segatore, D. Setacci, P. Bellio,
F. Brisdelli, V. Petitto, M. Perilli, M. Nicoletti,
G. Amicosante (l'Aquila, Rome, IT)
P1063
Genetic analysis of bacteriophages encoding
virulence factors among methicillin-resistant
Staphylococcus aureus isolated from clinical,
animal and environmental samples in Iran
F. Rahimi*, M. Bouzari, M. Katouli, M. Pourshafie
(Isfahan, IR; Queensland, AU; Tehran, IR)
P1064
Comparision of MIC values of vancomycin,
teicoplanin, linezolid and daptomycin in
strains between 2007–2010
B. Dinc, A. Tezer-Tekçe*, S. Yagci, H. Cabadak,
H. Kilic, S. Sen (Ankara, TR)
New insights on mechanisms of resistance in
P1049
P1051
P1056
Antimicrobial activity of daptomycin
tested against S. aureus collected from
osteoarticular infections
H. Sader*, D. Farrell, R. Jones (North Liberty, US)
Final Programme
Poster Sessions
Sunday, 8 May
Multisite evaluation of the daptomycin
Neo-Sensitab prediffusion method against
20 S. aureus
L. Koeth*, B. Katz, P. Bradford, J. Dallow,
R. Skov (Westlake, Lexington, Cambridge, US;
Fordham, UK; Copenhagen, DK)
P1066
An in vitro multisite study of vancomycin
and daptomycin MIC results and tolerance
of contemporary Staphylococcus aureus
from Spain
L. Koeth*, E. Cercenado, F. Marco, C. Pitart,
F. Linares, E. Perez-Trallero, R. Cantón,
J.L. Perez Saenz (Westlake, US; Madrid,
Barcelona, San Sebastián, Mallorca, ES)
P1067
12:30 – 13:30
P1068
P1069
P1070
Influence of telavancin sub-minimum
inhibitory concentration on methicillinresistant Staphylococcus aureus virulence
factor expression
C. Teles*, C. Gemmell, S. Lang
(Glasgow, St Andrews, UK)
P1073
Efficacy of high doses of daptomycin
in combination with cloxacillin in an
experimental foreign-body infection by
C. Garrigós*, O. Murillo, J. Lora-Tamayo,
M. Vivas, F. Tubau, R. Verdaguer, X. Cabo,
C. Cabellos, J. Ariza (Barcelona, ES)
P1074
Comparative efficacy of omadacycline
(PTK796) in a lethal Streptococcus
pneumoniae and Staphylococcus aureus
pneumonia model
R.G. Leahy, B. Hanley, A. Macone, M. Draper*,
S. Tanaka (Boston, US)
12:30 – 13:30
P1075
Invasive pneumococcal disease in adults,
Poland, 2006 – 2009
A. Skoczynska*, A. Kuch, A. Golebiewska,
I. Wasko, W. Hryniewicz (Warsaw, PL)
P1076
Incidence estimate of invasive pneumococcal
disease in Belgium in 2009 using the capturerecapture method
K. Van Herck*, T. Braeckman, P. Van Damme,
J. Verhaegen, F. Surmont
(Ghent, Antwerp, Louvain, Brussels, BE)
P1077
Evolution of meningococcal disease
incidence on Navarre's population
(north of Spain)
D. Morales, F.J. Gil, M. Herranz, A. Barricarte,
J. Castilla, E. Bernaola* (Pamplona, Estella, ES)
P1078
Increase of invasive meningococcal disease
caused by serogroup Y in Finland, 2010
M. Toropainen, A. Vainio, L. Saarinen, H. Käyhty,
M. Kuusi, A. Virolainen* (Helsinki, FI)
P1079
Epidemiological characteristics of Q- fever in
Vojvodina Province, Serbia, from 1985 to 2009
J. Djekic*, G. Cosic, M. Petrovic (Novi Sad, RS)
P1080
Seroprevalence of whooping cough among
Danish adults
T. Dalby*, A. Linneberg, K. Krogfelt
(Copenhagen, Glostrup, DK)
P1081
Review of tetanus cases in England and Wales,
1984–2007. Does administration of tetanus
immunoglobulin and prior vaccination status
influence outcome?
J. Howard*, K. Wagner, J. White, N. Crowcroft
(London, UK; Toronto, CA)
P1082
Epidemiological survey of diabetic foot
infections in Lisbon
J.J. Mendes*, L. Prata, C. Vilela, J. Neves,
N. Candeias, P. Cavaco Silva, J. Melo Cristino
(Lisbon, PT)
Experimental treatments in vivo
Ceftobiprole efficacy in vitro on PantonValentine leukocidin production and in vivo in
a rabbit community-associated methicillinresistant Staphylococcus aureus osteomyelitis
model
A. Saleh Mghir, A. Dinh, O. Dumitrescu,
G. Lina, Y. Boutrad, F. Vandenesch, J. Etienne,
A.C. Crémieux* (Garches, Lyon, FR)
Efficacy of daptomycin versus vancomycin in
an experimental model of foreign body
infection by biofilm producer Staphylococcus
epidermidis
J. Domínguez-Herrera*, F. Docobo-Pérez,
R. López-Rójas, C. Pichardo, J. Pachón
(Seville, ES)
Meropenem treatment of experimental
thigh infections caused by meropenemheteroresistant Acinetobacter baumannii
clinical isolates
G. Michail*, E. Neou, A. Tsakris, S. Pournaras
(Larissa, Athens, GR)
P1071
In vivo activity of 22beta-hydroxyoleanonic
acid, against Streptococcus pneumoniae in
a mouse model
M. Sharma*, A. Rakhi, M. Janlav
(Waknaghat, IN; Ulaanbaatar, MN)
P1072
Evaluation of combinational antimicrobial
treatment using rifampicin and gentamicin
for Escherichia coli O157:H7 in vitro and
in vivo in BALB/c mice
E.A. Rahal*, N. Kazzi, A.M. Abdelnoor,
G.M. Matar (Beirut, LB)
Miscellaneous infections
Final Programme
121
Posters
P1065
Poster Sessions
Sunday, 8 May
P1083
Rectal carriage and pyogenic liver abscess
associated CPS genotyping of Klebsiella
pneumoniae in asymptomatic diabetic
patients in Taiwan
P.R. Hsueh, C. Liao, Y. Huang, J. Wang, C.Y. Liu*
(Taipei, TW)
P1084
Fever of unknown origin: a retrospective
study of 52 cases with evaluation of the
diagnostic utility of PET/CT
T. Ingemann*, C. Roed, L.S. Knudsen, P. Skinhøj,
S. Nielsen (Copenhagen, DK)
P1085
Risk factors and outcome of treatment in
patients with psoas abscesses
A. Kara*, M.C. Kizilarslanoglu, S. Alp, M. Akova
(Ankara, TR)
P1086
Clinical features and outcome of
cardiovascular implantable electronic
device infections due to staphylococci
K. Le*, M. Sohail, P. Friedman, D. Uslan,
S. Cha, D. Hayes, W. Wilson, J. Steckelberg,
L. Baddour (Rochester, Los Angeles, US)
P1087
P1088
Mortality risk factors in patients with
prosthetic vascular graft infection:
a prospective cohort study
L. Legout*, P. Dhelia, B. Sarraz-Bournet,
P. Devos, M. Caillaux, F. Wallet, Y. Yazdanpanah,
E. Senneville, O. Leroy (Tourcoing, Lille, FR)
Spread of Corynebacterium diphtheriae
in Ukraine during post-epidemic period
T. Chumachenko*, A. Podavalenko,
T. Glushkevich (Kharkiv, Kiev, UA)
P1089
Measles among healthcare workers in Bulgaria
R. Komitova*, A. Kunchev, Z. Mihneva
(Plovdiv, Sofia, BG)
P1090
Transient bradycardia in patients with
Crimean-Congo haemorrhagic fever infection
S. Erol*, Z. Ozkurt, K. Ozden, M. Parlak
(Erzurum, TR)
P1091
Evaluation of cutaneous anthrax patients in
eastern Anatolia, Turkey
K. Ozden, Z. Ozkurt, S. Erol*, M.H. Uyanik,
M. Parlak (Erzurum, TR)
P1092
P1093
Epidemiology and clinical aspects of murine
typhus in central Tunisia
A. Toumi*, A. Aouam, C. Loussaief, H. Ben Brahim,
F. Ben Romdhane, M. Chakroun (Monastir, TN)
A nosocomial outbreak of red mite
(Dermanyssus gallinae) dermatitis in Italy
D. Galante*, M. Lomuto, G. Totaro, G. Mancini,
C. Nardella La Porta, M.A. Cafiero (Foggia, IT)
Final Programme
P1094
Increased incidence of invasive
meningococcal disease in Switzerland
due to serogroup Y strains: a molecular
characterisation
B. Ninet*, R. Born, J. Schrenzel (Geneva, CH)
P1095
Epidemiologic study of bacterial gastroenteritis in Greek children (2003 – 2009)
G. Kalogeras, N. Palaiologou, K. Giannakopoulou,
F. Antonopoulou, P. Xenos, M. Papadimitriou,
D. Hatzaki, E. Vetouli, E. Lebessi* (Athens, GR)
P1096
Communicable diseases among Roma
population in selected district of Slovakia,
1997 – 2006
K. Rimarova *, M. Feckova , M. Rimar
(Kosice, Bardejov, Bratislava, SK)
12:30 – 13:30
Miscellaneous antimicrobial resistance
P1097
Susceptibility to antibacterial agents
in Germany amongst ocular isolates,
2004 – 2009: results of two laboratory
surveillance studies
M. Kresken*, B. Körber-Irrgang on behalf
of the German Ophthalmologic Study Group
P1098
Detection of antibiotic residues in pork
and chicken meat using the STAR test
M. Liousia, P. Gousia, E. Economou, H. Sakkas,
S. Levidiotou*, C. Papadopoulou (Ioannina, GR)
P1099
Surveillance of Aspergillus section Nigri
in a general hospital during two decades
T. Pelaez*, B. Gama, P. Lopez Roa,
A. Espinel-Ingroff, P. Gijon, P. Escribano,
L. Alcala, J. Guinea, P. Muñoz, E. Bouza
(Madrid, ES; Richmond, US)
P1100
Twelve years of resistance monitoring
in Salmonella from healthy chickens in two
EU regions
A. de Jong*, C. Ludwig, B. Stephan
(Leverkusen, DE)
P1101
Susceptibility to enrofloxacin of major
bacterial pathogens from dogs and cats
in four EU countries
A. de Jong*, J.C. Dörner, C. Ludwig, A.T. Feßler,
S. Schwarz, B. Stephan
(Leverkusen, Neustadt-Mariensee, DE)
P1102
Phenotypic and molecular-genetic
characterisation of antimicrobial resistance
of Neisseria meningitidis isolates from
Belarus
S. Glazkova*, F. Lebedev, L. Titov (Minsk, BY)
Poster Sessions
Sunday, 8 May
Routine susceptibility testing: selection
bias, sensitivity, specificity, and performance
related to MIC
R. Reynolds*, R. Hope, K. Maher
on behalf of BSAC Working Party on Resistance
Surveillance
P1105
Does the long-term use of a triclosan
toothpaste lead to resistant organisms?
M.P. Cullinan*, P.S. Bird, N.C. Heng, G.J. Seymour
(Dunedin, NZ; Brisbane, AU)
P1106
Antibiotic susceptibility pattern
of nosocomial and community-acquired
Clostridium difficile in Hungary
G. Terhes*, J. Sóki, K. Latkóczy, L. Szikra,
M. Konkoly-Thege, G. Princz, T. Nagy,
H. Osztie, E. Urbán (Szeged, Budapest,
Székesfehérvár, HU)
P1107
Antibiotic susceptibility, class I integrons
and sporulation activity of Clostridium
difficile strains from antibiotic-associated
diarrhoea patients in two different years
in Estonia and Norway
S. Kõljalg, J. Stsepetova*, I. Smidt, I. Löhr,
K. Truusalu, P. Naaber, E. Sepp (Tartu, EE)
P1108
13:30 – 14:30
Trends in antimicrobial resistance of
Pseudomonas aeruginosa (2001 – 2010)
J.J. Garcia Irure, C. Ezpeleta Baquedano*,
I. Tordoya Titichoca, C. Fernandez Jauregui,
E. Fernandez Vizan, A. Ganuza (Pamplona, ES)
Reporting nosocomial infections –
Where are we?
P1109
Comprehensive reporting of nosocomial
infection incidences
N. Grambauer*, M. Schumacher, M. Dettenkofer,
D. Luft, J. Beyersmann (Freiburg, DE)
P1110
The concordance of European (HELICS/IPSE)
and US (CDC/NHSN) definitions for
healthcare-associated infections
S. Hansen*, D. Sohr, C. Geffers, P. Astagneau,
A. Blacky, W. Koller, I. Morales, M.L. Moro,
M. Palomar, E. Szilagyi, C. Suetens, P. Gastmeier
(Berlin, DE; Paris, FR; Vienna, AT; Brussels, BE;
Bologna, IT; Barcelona, ES; Budapest, HU;
Stockholm, SE)
P1111
The ECDC Pilot Point-Prevalence Survey of
healthcare-associated infections and
antimicrobial use: main results
C. Suetens*, A. Muller, B. Coignard,
J. Griskeviciene, S. Hopkins, K. Weist,
M. Goossens, S. Vaerenberg, B. Catry,
V. Vankerckhoven, H. Goossens, P. Zarb
on behalf of the ECDC-pPPS Study Group
P1112
Reducing nosocomial infections in
neutropenic patients through participation
in the multicentre surveillance project
ONKO-KISS
D. Luft*, F. Schwab, R. Babikir, H. Bertz,
W.V. Kern, A.F. Widmer, M. Dettenkofer
and the ONKO-KISS study group
P1113
Epidemiological trends of emerging
organisms and antimicrobial resistance
in Italian ICUs: risk-adjusted rates from
the SPIN-UTI project
A. Agodi*, F. Auxilia, M. Barchitta, S. Brusaferro,
D. D'Alessandro, M.T. Montagna, C. Pasquarella,
E. Righi, S. Tardivo, V. Torregrossa, I. Mura
and the GISIO, Italian Study Group of Hospital
Hygiene
13:30 – 14:30
Risk factors for nosocomial infections:
how many are modifiable?
P1114
Identification of widespread seasonal
variations in the occurrence of healthcareassociated infections: role of climatic
and host factors
H. Richet*, D. Raoult (Marseille, FR)
P1115
Identifying and exploring core group dynamics
in healthcare-associated methicillin-resistant
Staphylococcus aureus transmission
S.R. Deeny*, J.V. Robotham, B. Cookson,
D.R. Jenkins, B.S. Cooper
(London, Leicester, UK; Bangkok, TH)
P1116
Colistin resistance in Gram-negative
bacteria during prophylactic colistin use
in intensive care units
E.A. Oostdijk*, M. Leverstein-van Hall,
J. Muilwijk, J. Kesecioglu, M.J. Bonten
(Utrecht, NL)
P1117
Nosocomial infections in critically ill
patients: when should multidrug-resistant
Pseudomonas aeruginosa be suspected?
L. Dalfino*, A. Mosca, N. Brienza, M. Spada,
S. Coppolecchia, G. Miragliotta, R. Giuliani,
F. Bruno (Bari, IT)
P1118
Assessing risk factors for acquiring extendedspectrum beta-lactamase-producing Gramnegative infections in long-term care facilities:
a case-control study
E. Tacconelli*, E. Mantengoli, C. Cadeddu,
E. Cunietti, F. Luzzaro, R. Cauda, G.M. Rossolini,
M. Tinelli (Rome, Siena, Lodi, Lecco, IT)
Final Programme
123
Posters
P1104
Poster Sessions
Sunday, 8 May
13:30 – 14:30
P1128
Tigecycline
P1119
Susceptibility profiles of most common Polish
probiotics to daptomycin and tigecycline
P. Kochan*, A. Drzewiecki, K. Wajda-Drzewiecka,
T. Gosiewski, K. Pakosz, P. Heczko
(Cracow, Katowice, PL)
P1120
Trends in antimicrobial susceptibility
in European Gram-positive anaerobes:
the Tigecycline European Surveillance Trial,
2007 – 2010
M. Hackel, R. Badal, S. Bouchillon, B. Johnson,
D. Hoban, S. Hawser*, M. Dowzicky
P1121
Dalbavancin surveillance results
for European Gram-positive species in
a contemporary (2006–2009) sample
of 23,825 strains
R. Jones*, D. Farrell, H. Sader
(North Liberty, US)
P1130
Dalbavancin activity and spectrum
evaluated against a contemporary
(2007 – 2009) worldwide collection
of staphylococci (62,590 strains)
R. Jones*, H. Sader, R. Mendes, D. Farrell
(North Liberty, US)
P1131
Assessment of oritavancin activity
tested against beta-haemolytic streptococci
responsible for skin and skin structure
infections in Europe (2008 – 2010)
R. Mendes*, H. Sader, D. Farrell, R. Jones
(North Liberty, US)
P1132
Analysis of oritavancin activity tested against
a challenge set of Staphylococcus aureus
from Europe (2008 – 2010)
R. Mendes*, H. Sader, D. Farrell, R. Jones
(North Liberty, US)
P1133
In vitro activity of tigecycline against
multidrug-resistant Klebsiella pneumoniae
isolates
V. Papaioannou, S. Tsiplakou, A. Stylianakis,
E. Chatziandreou, K. Ntetsika, N. Zalavras,
A. Koutsoukou* (Athens, GR)
Activity of a novel cyclic lipopeptide,
CB-183,315 against Gram-positive aerobic
and anaerobic enteric isolates, including
vancomycin-resistant enterococci and
C. difficile strains with elevated MICs to
metronidazole, vancomycin and fluorquinolones
D.R. Snydman*, N.V. Jacobus, L.A. McDermott
(Massachusetts, US)
P1134
Comparison of tigecycline activity tested
against multidrug-resistant bacteria isolated
from European medical centres in two time
periods: 2003 – 2005 and 2008 – 2010
H. Sader*, D. Farrell, P. Rhomberg, R. Jones
(North Liberty, US)
Potency of radezolid (RX-1741) and torezolid
(DA-7157) tested against a collection of
linezolid-non-susceptible strains with
genetically defined resistance mechanisms
D. Farrell*, R. Mendes, H. Sader, R. Jones
(North Liberty, US)
P1135
The investigation of antimicrobial activity
of 5 heterocyclic compounds against some
clinical isolates of oral streptococci
G. Bancescu*, M. Radu-Popescu, A. Bancescu,
A. Neagu, M. Nica, A. Dascalu, I. Nistor,
S-F. Barbuceanu (Bucharest, RO)
Activity of tigecycline and five comparators
against recent Gram-negative anaerobes
in Europe – the Tigecycline European
Surveillance Trial
M. Hackel, S. Bouchillon, B. Johnson*, D. Hoban,
M. Renteria, J. Johnson, R. Badal, S. Hawser,
M. Dowzicky (Schaumburg, US; Epalinges, CH;
Collegeville, US)
In vitro activity of tigecycline against clinical
isolates from a large tertiary care institution
L. von Müller*, M. Herrmann (Homburg/Saar, DE)
P1123
Tigecycline susceptibility trends in Germany
among Gram-positive and Gram-negative
pathogens recovered from wounds,
the peritoneal cavity and blood
M. Kresken*, K. Becker, H. Seifert,
B. Körber-Irrgang, C. von Eiff, P.-A. Löschmann
on behalf of the German Tigecycline Study Group
P1125
P1126
P1127
New antimicrobials in vitro activity
P1129
P1122
P1124
13:30 – 14:30
Comparative MIC and MPC results for
tigecycline repeatedly tested against
American Type Culture Collection
control strains: suggested MPC quality
control value ranges
J.M. Blondeau*, C. Hesje, S.D. Borsos,
L.D. Blondeau, B.J. Blondeau (Saskatoon, CA)
In vitro activity of tigecycline and
comparators against Enterococcus faecalis
and Enterococcus faecium isolates collected
in Germany
F.-J. Schmitz* (Minden, DE)
In vitro activity of tigecycline against
non-clonal Stenotrophomonas maltophilia
isolates from serious infection sites
J. Steinmann*, J. Buer, P.M. Rath (Essen, DE)
Final Programme
Poster Sessions
P1136
Antimicrobial activity of solithromycin
(CEM-101), a novel fluoroketolide, tested
against isolates collected in Europe during
2010 surveillance
D. Biedenbach, H. Sader, R. Jones, D. Farrell*
(North Liberty, US)
P1137
Activity of JNJ-Q2, a new fluoroquinolone,
tested against contemporary (2010)
European pathogens isolated from patients
with community-acquired bacterial
pneumonia
D. Farrell*, L. Liverman, P. Rhomberg, R. Jones
(North Liberty, Morrisville, US)
P1138
Activity of JNJ-Q2, a new fluoroquinolone,
tested against contemporary (2010)
European pathogens isolated from patients
with acute bacterial skin and skin-structure
infections
D. Farrell*, L. Liverman, P. Rhomberg, R. Jones
(North Liberty, Morrisville, US)
P1139
Activity of finafloxacin, a fluroquinolone
with enhanced activity at acid pH, against
intracellular Legionella pneumophila:
comparison with azithromycin,
clarithromycin, telithromycin, ciprofloxacin
and moxifloxacin
S. Lemaire*, P. Tulkens, F. Van Bambeke
(Brussels, BE)
P1140
The activity of ozenoxacin (GF-001001-00)
against atypical bacteria
I. Morrissey, K. Maher*, C. Tarragó, A. Guglietta
(Fordham, UK; Barcelona, ES)
P1141
In vitro activity of omadacycline (PTK796)
in broth plus lung surfactant or human serum
A. Macone, J. Donatelli, M. Draper*, S. Tanaka
(Boston, US)
P1142
In vitro activity of TP-2758 against panels
of recent bacterial clinical isolates
T. Grossman*, W. O'Brien, C. Fyfe, C. Sun,
W. Zhang, J. Sutcliffe (Watertown, US)
P1143
P1144
E-101, a novel first-in-class topical antiinfective, has potent activity against clinical
isolates of important pathogens in Europe
collected from 2008 – 2010
C. Pillar*, G.A. Denys, P. O'Hanley,
J.T. Stephens, jr., D.F. Sahm
(Chantilly, Indianapolis, Little Rock, US)
E-101, a novel first-in-class topical antiinfective, maintains a high degree of potency
in vitro against problematic resistant clinical
pathogens (ESKAPE pathogens)
C. Pillar*, G.A. Denys, P. O'Hanley,
J.T. Stephens, Jr., D.F. Sahm
(Chantilly, Indianapolis, Little Rock, US)
P1145
Antibacterial activity of nanosized TiO2
against Escherichia coli
M. Sredkova*, A. Stoyanova, H. Hitkova,
R. Iordanova, Y. Dimitriev,
A. Bachvarova-Nedelcheva (Pleven, Sofia, BG)
P1146
Activity of the novel sulfactam BAL30072,
alone and in combination with meropenem,
against Enterobacteriaceae harbouring the
NDM-1 beta-lactamase
T. Walsh*, J. Weeks, M. Toleman, W. Stubbings,
M. Page, M. Jones (Brisbane, AU; Cardiff, UK;
Basel, CH)
P1147
Activity of ACHN-490 against MDR
clinical isolates of Klebsiella pneumoniae,
Escherichia coli and Enterobacter spp.
from Athens, Greece
I. Galani*, M. Souli, G. Daikos, Z. Chrysouli,
G. Poulakou, M. Psichogiou, T. Panayea,
A. Argyropoulou , I. Stefanou, G. Plakias,
H. Giamarellou, G. Petrikkos (Athens, GR)
P1148
ACHN-490 as a potential addition to the
antimicrobial armamentarium in ICUs
with high levels of resistant organisms
T. Kotlovsky*, S. Navon-Venezia, L. Keren,
Y. Carmeli (Tel Aviv, IL)
P1149
The novel broad-spectrum fluorocycline
TP-434 is active against MDR Gram-negative
pathogens
C. Fyfe, T. Grossman*, W. O'Brien, C. Achorn,
J. Sutcliffe (Watertown, US)
P1150
In vitro bactericidal and anti-biofilm activity
of bovine myeloid antimicrobial peptides
against multidrug-resistant bacteria from
patients with cystic fibrosis
G. Di Bonaventura*, A. Pompilio, V. Crocetta,
S. Pomponio, V. Di Vincenzo, M. Scocchi,
G. Gherardi, E. Fiscarelli, G. Dicuonzo, R. Gennaro
(Chieti, Trieste, Rome, IT)
P1151
Activity of POL7001 against Pseudomonas
aeruginosa isolates from cystic fibrosis
patients
A. Bragonzi*, C. Cigana, F. Bernardini,
M. Paroni, S. DeMarco, P. Misson, N. Schmitt,
K. Dembowsky, D. Obrecht
(Milan, IT; Allschwil, CH)
P1152
The biology of environmental bacteriophages
lytic to multidrug-resistant Klebsiella strains
A. Kesik-Szeloch*, Z. Drulis-Kawa, J. Kassner,
B. Weber-Dabrowska (Wroclaw, PL)
Final Programme
125
Posters
Sunday, 8 May
Poster Sessions
Sunday, 8 May
13:30 – 14:30
P1153
New non-conventional antimicrobials
(no drugs)
In vitro activity of wine compounds
(resveratrol, methyl gallate and other
phenolic compounds) against Helicobacter
pylori clinical isolates
T. Alarcon*, S. Rodrigo, A.J. Martinez-Rodriguez,
A.V. Carrascosa, M. Lopez-Brea (Madrid, ES)
P1154
Fruit and vegetable extracts as source for
anti-adhesion agents against oral bacteria
M. Stauder, D. Steinberg, M. Daglia, A. Papetti,
G. Gazzani, E.I. Weiss, C. Pruzzo, I. Ofek*
(Genoa, IT; Jerusalem, IL; Pavia, IT; Tel Aviv, IL)
P1155
Evaluation of the probiotic potential of
Weissella confusa and Lactobacillus paracasei
strains isolated from Nigerian traditional
dairy fermented foods and cow’s intestines
F. Ayeni*, B. Sánchez, B. Adeniyi,
C. de los Reyes-Gavilána, A. Margolles,
P. Ruas-Madiedo (Bayelsa State, NG;
Villaviciosa, ES; Ibadan, NG)
P1156
Antimicrobial effect of methanolic extract
of ginger on Helicobacter pylori
N. Rahimifard*, L. Beitolahi, S. Shoeibi,
M. Rabiei, F. Bagheri, H. Hajimehdipoor
(Tehran, IR)
P1157
Photodynamic inactivation effect
of methylene blue on multidrug-resistant
bacteria isolated from chronic diabetic
foot ulcers
N. Kashef, G. Esmaeeli Djavid*,
G. Ravaei Sharif-Abadi (Tehran, IR)
P1158
Sterilisation efficacy of atmospheric plasma
sources for biomedical applications
R. Sadeq*, M. ElShaer, M. Mobasger, R. Sadeek,
M. Gohar, T. Abdel-Fattah (Zagazig, EG)
P1159
Antimicrobial effect of treated medical
textiles
A. Di Nauta*, R. Baldan, C. Romanò, L. Drago,
F. Elia, D. Cirillo (Milan, IT)
Final Programme
13:30 – 14:30
New targets for new antimicrobials
P1160
Quorum sensing inhibition by trifluoromethyl
ketones
Z.G. Varga*, E. Szegedi, M. Kawase, N. Motohashi,
J. Molnar
(Szeged, Budapest, HU; Ehime, Tokyo, JP)
P1161
Activity of PF-1 and PF-2, novel siderophore
conjugated beta-lactams, tested against
Enterobacteriaceae strains carrying emerging
resistance mechanisms
M. Castanheira, R. Jones, D. Farrell*, M. Huband,
J. Quinn, J. Mueller (North Liberty, US)
P1162
Antimicrobial activity of a novel programme
of protein synthesis inhibitors against
clinical isolates containing KPC and NDM-1
carbapenemases
J. DeVito*, J. Remy, A. Bhattacharjee, Z. Kanyo,
E.M. Duffy (New Haven, US)
P1163
Interactome for essential genes as a
prediction of antibacterial potency
B. Geller, P. Iversen* (Bothell, US)
P1164
Inhibiting the activity of the DNA gyrase
from E. coli
X. Vila-Farres*, J. Sanchez-Cespedes,
E. Giralt, J. Vila (Barcelona, ES)
P1165
Determination of the mechanism of
action of three novel chemical scaffolds
with broad-spectrum antibacterial
activity, including multidrug-resistant
F. Franceschi*, E. Skripkin, A. Bhattacharjee,
J. Remy, Z. Kanyo, E.M. Duffy (New Haven, US)
P1166
Three completely novel antibiotic scaffolds
for treating multidrug-resistant Gramnegative infections
Z. Kanyo*, A. Bhattacharjee, S. Chen, F. Collin,
J. Dalton, J. DeVito, M. DeVivo, J. Ippolito, R. Lou,
H. O'Dowd, J. Martynow, I.-H. Paik, J. Remy,
M. Scheideman, S. Sinishtaj, E. Skripkin, Y. Tang,
B. Wimberly, Y. Wu, E.M. Duffy (New Haven, US)
P1167
Antibacterial activity of C10 and C12 fatty
acids and their sucrose esters towards
Escherichia coli and Clostridium perfringens
E. Skrivanova*, M. Marounek, S. Prazakova
(Prague, CZ)
P1168
In vitro activity profile of PMX30063 against
recent clinical isolates of Gram-positive and
B. Korczak*, R. Scott (Radnor, US)
Poster Sessions
Sunday, 8 May
Antimicrobial activity of different antibiotics
alone or in combination against MDR Gramnegative rods
P1169
CLSI 2010 recommendations for
cephalosporin/Enterobacteriaceae
breakpoints. What changed?
Ö. Azap*, H. Arslan, F. Timurkaynak,
A. Yesilkaya (Ankara, TR)
P1170
Susceptibility to expanded-spectrum
cephalosporins among ESBL-producing
Klebsiella pneumoniae and Escherichia
coli clinical isolates according to the
new CLSI recommendations
I. Kristo, O. Zarkotou, A. Poulou, S. Pournaras*,
A. Tsakris (Larissa, Piraeus, Serres, Athens, GR)
P1171
P1172
The in vitro activity of ceftaroline against
isolates from the 2008 British Society for
Antimicrobial Chemotherapy Bacteraemia
Surveillance Programme
D. Biek, K. Krause, I. Critchley* (Oakland, US)
Expression analysis of DHA-1, AmpR, OmpK35
and OmpK36 genes in Klebsiella pneumoniae
and inoculum effect determination for
selected antibiotics
D. Hepnar, D. Cervena, E. Chudackova,
T. Bergerova, V. Studentova, H. Zemlickova,
J. Hrabak* (Plzen, Prague, CZ)
P1173
Fosfomycin susceptibility testing in
Enterobacteriaceae isolates producing
KPC-2, KPC-3, OXA-48 and VIM-1
carbapenemases
M. Kaase*, F. Szabados, A. Anders,
S. Gatermann (Bochum, DE)
P1174
Polymyxin heteroresistance in extremely
drug-resistant Acinetobacter baumannii
T. Tan*, C.C. Loh, M.Y. Chin, N. Syahidah,
S. Sasikala, T.P. Lim (Singapore, SG)
P1175
Synergy of fosfomycin with carbapenems,
colistin, netilmicin, and tigecycline against
MDR Klebsiella pneumoniae, Escherichia
coli, and Pseudomonas aeruginosa clinical
isolates
G. Samonis*, S. Maraki, D. Karageorgopoulos,
E. Vouloumanou, M. Falagas
(Heraklion, Athens, GR)
P1176
Antibiotic combinations for Klebsiella sp.
harbouring New Delhi Metallo-betalactamase-1 in Singapore
T.P. Lim*, J. Teo, W. Lee, S. Sasikala, D.Q. Chia,
T.Y. Tan, L.Y. Hsu, T.H. Koh, T. Tan, A.L. Kwa
(Singapore, SG)
13:30 – 14:30
Carbapenems
P1177
Minimum inhibitory concentrations
of meropenem and doripenem for
Pseudomonas aeruginosa from the UK
R. Hope*, A. Chaudhry, R. Adkin, A. Guleri,
S. Williams, R. Sharma, D. Livermore
(London, Blackpool, Blackburn, UK)
P1178
Activity of doripenem versus imipenem,
meropenem and ceftazidime in clinical
isolates of Pseudomonas aeruginosa and
Acinetobacter baumannii in Portugal
L. Sancho*, T. Sardinha, G. Sousa, F. Silva,
F. Matos (Amadora, PT)
P1179
Antimicrobial activity and spectrum
of doripenem against contemporary (2010)
clinical bacterial pathogens from Europe
D. Farrell*, G. Moet, H. Sader, R. Jones
(North Liberty, US)
P1180
In vitro activity of doripenem against
multidrug-resistant clinical strains
of Acinetobacter baumannii, Pseudomonas
aeruginosa and Klebsiella pneumoniae
N. Skarmoutsou*, M. Kehagia, D. Dimitriadi,
K. Stamoulos, I. Mintziras, M. Martsoukou,
E.M. Fakiri (Athens, GR)
P1181
In vitro antibacterial activity of doripenem
against multidrug-resistant Acinetobacter
baumannii isolates from adult intensive
care units
E. Protonotariou, S. Arampatzi*, O. Vasilaki,
F. Tsiapara, F. Frantzidou, E. Diza
(Thessaloniki, GR)
P1182
Comparative activity of doripenem, ertapenem
and imipenem against clinical isolates of
Klebsiella pneumoniae producing extendedspectrum beta-lactamases, plasmid- mediated
AmpC-type beta-lactamases or both, associated
or not with porin deficiency
M.C. Conejo, J.M. Rodríguez-Martínez*,
L. Serrano, Á. Pascual (Seville, ES)
P1183
Carbapenems alone or combined with
colistin are still bactericidal against clonal
VIM-1 beta-lactamase-producing-Klebsiella
pneumoniae epidemic strains
M. Morosini, A. Shan*, M. García-Castillo,
M. Tato, R. Cantón (Madrid, ES)
P1184
In vitro activity of the siderophore
sulfactam BAL30072 against meropenem
non-susceptible Acinetobacter baumannii
P.G. Higgins*, D. Stefanik, M. Page,
M. Hackel, H. Seifert
(Cologne, DE; Basel, CH; Schaumberg, US)
Final Programme
Posters
13:30 – 14:30
127
Poster Sessions
Sunday, 8 May
13:30 – 14:30
P1185
P1186
P1188
P1189
13:30 – 14:30
Quinolones
In vitro activity of delafloxacin against
European isolates of Staphylococcus
aureus from skin and soft tissue, respiratory,
urine and blood specimens
L. Lawrence*, C. Pillar, D.F. Sahm, E. Burak
(New Haven, Chantilly, US)
Antibacterial activity of the investigational
fluoroquinolone finafloxacin under different
pH conditions against Staphylococcus
aureus small-colony variants
E.A. Idelevich, A. Kriegeskorte, W. Stubbings,
B. Kahl, G. Peters, K. Becker* (Münster, Berlin, DE)
Comparative in vitro activity of sitafloxacin
and other fluoroquinolones against bacteria
isolated from patients with urinary tract
infections and lower respiratory tract infections
V. Thamlikitkul*, S. Tiengrim,
D. Phiboonbanakit, S. Thunyaharn,
W. Tantisiriwat, S. Santiwatanakul,
W. Susaengrat, N. Srisurat, A. Malithong,
P. Srisangchan (Bangkok, Khon-Kaen, TH)
Biofilm susceptibility of P. aeruginosa
isolated from patients with otitis media to
ciprodex, ciprofloxacin and N-acetylcysteine
M. Noble, V. Restelli, B. Westerberg, R. Rennie*,
L. Turnbull (Vancouver, Edmonton, CA)
H1N1
P1190
Bacterial co-infections in communityacquired pneumonia cases of 2009
pandemic influenza A/H1N1 in Spain
C. Cillóniz*, R. Menendez, S. Ewig, E. Polverino,
A. Gabarrus, M. Marcos, E. Moreno, J. Mensa,
A. Torres (Barcelona, Valencia, ES; Bochum, DE)
P1191
Comparative analysis of positive and
negative H1N1 hospitalised adult patients
during the influenza A pandemic in Mar del
Plata, Argentina
C. Miglioranza*, J. Corral, S. Aquilia, A. Ferro,
M. Hualde, G. Corral, A. Manzo, M. Rosati,
L. De labra, G. Loizaga, R. Garcia
(Mar del Plata, AR)
P1192
Prospective surveillance of 2009 pandemic
influenza A/H1N1 at a university hospital:
characteristics and factors associated with
severe disease
P. Cassier, N. Voirin, D. Lutringer, C. Payet,
M. Gourbil, T. Benet*, M. Nicolle, V. Escuret,
P. Vanhems (Lyon, FR)
Final Programme
P1193
Immunogenicity and safety of two doses
of AS03A-adjuvanted influenza A/H1N1 2009
vaccine in cancer patients on chemotherapy –
VACANCE study
P. Loulergue*, B. Rousseau, O. Mir, E. Viel,
A. Krivine, F. Goldwasser, A. de Gramont,
O. Launay, C. Tournigand (Paris, FR)
P1194
Knowledge, perception, attitude and
behaviour regarding influenza immunisation
in Lebanon
N. El Chakhtoura*, H. Hassouna, N. Sidani,
M. Yasmin, S. Kanj, Z. Kanafani (Beirut, LB)
P1195
Individual determinants of seasonal and
pandemic A/H1N1 influenza vaccination
among healthcare workers
F. Barbier*, F. Tubach, L. Biard, B. Mourvillier,
B. Le Corre, A. Macrez, C. Zanker, C. Najem,
B. Regnier, J. Lucet, M. Wolff, L. Bouadma
for the INFLUENCE-A study group
P1196
The benefit of early treatment with
oseltamivir in hospitalised patients with
documented 2009 influenza A/H1N1:
retrospective study
V. Hiba* (Tel Aviv, IL)
P1197
2009 H1N1 influenza infection in Korean
healthcare personnel
C.S. Lee*, J. Yeom, J.H. Lee, I.G. Bae, W.S. Oh,
C. Moon, K.H. Park, J.H. Lee, E.S. Kim, Y. Kwak,
B.N. Kim (JeonJu, Seoul, Jinju, Chuncheon,
Busan, Gwangju, Iksan, Goyang, KR)
P1198
A comparison of severity scores for
identifying adult patients with severe 2009
pandemic influenza A/H1N1 pneumonia
S.T. Heo, W.S. Oh*, C.S. Lee, S.W. Park, E.S. Kim,
J. Yeom, B.N. Kim, Y. Kwak, M.D. Oh, J.A. Hur,
A.C. Hur, Y.S. Park, I.G. Pai, H.B. Kim, J.H. Song,
K.S. Lee, S.R. Lee, S.J. Lee, J.H. Lee, H.Y. Kim,
Y.K. Kim, N.J. Kim on behalf of the Korean
Influenza Outcome Surveillance study group
P1199
Evaluation of different cell lines in the
isolation by the shell vial culture of pandemic
influenza A/H1N1 2009 from respiratory
samples
J. Reina*, C. Marinescu, C. Deniz
(Palma de Mallorca, ES)
13:30 – 14:30
P1200
HAI and environmental contamination
In vitro antimicrobial properties study of a
polyurethane foam that releases silver ions
J.M. Sahuquillo-Arce*, A. Iranzo Tatay,
M. Llácer Luna, Y. Sanchis Boix, J. Guitán
Deltell, E.M. González Barberá, J. Beltrán Heras,
M. Gobernado Serrano (Valencia, ES)
Poster Sessions
Sunday, 8 May
P1201
Optimised antibacterial measures against
E. coli O157:H7 and S. aureus
M. Raftari*, F. Azizi jalilian, S. Ghafouryan,
F. Abu Bakr (Putra, MY; Ilam, IR)
P1202
Multi-resistant bacterial colonisation
of reusable hospital tourniquets
A. Pinto*, T. Phan, G. Sala, E. Cheong,
S. Siarakas, T. Gottlieb (Sydney, AU)
P1203
Influence of temperature and chemical
decontamination on the prevalence
of Legionella pneumophila in hot water
C. Colombo*, G. Senn, A. Bürgel, C. Ruef
(Zurich, CH)
P1205
P1206
P1207
P1208
P1209
P1210
13:30 – 14:30
Risk of Pneumocystis transmission in an
endoscopy respiratory unit
R. Morilla*, J. Martín-Juan, V. Friaza,
M. Martinez-Risquez, E. Campano,
B. Romero-Romero , N. Respaldiza,
C. De la Horra, J.M. Varela, E. Calderón,
F.J. Medrano (Seville, ES)
Nosocomial infection
P1213
Reduction of healthcare-associated
infections after implementation of bundle
programmes in a tertiary care teaching
hospital in Saudi Arabia
W. Mazi*, D. Abdullah, G. Gasem, N. Helali,
A. Senok (Taif, Riyadh, SA)
P1214
Intestinal carriage of colistin resistant
Enterobacteriaceae during selective
decontamination of the digestive tract
E.A. Oostdijk*, A.M. De Smet, M. Leversteinvan Hall, M.J. Bonten (Utrecht, NL)
P1215
Eradication of extended-spectrum
beta-lactamases during selective digestive
tract decontamination
E.A. Oostdijk*, A.M. De Smet, M.J. Bonten
on behalf of the Dutch SOD-SDD trialists group
P1216
Screening of gastrointestinal carriage
of ESBL-producing Enterobacteriaceae in
neonates
É. Kenesei*, M. Szénási, M. Szabó, M. Pataki
(Budapest, HU)
P1217
Absence of Clostridium difficile stool
carriage in asymptomatic volunteers
M. Hell*, K. Sickau, G. Chmelizek, J.M. Kern,
M. Maass, S. Huhulescu, F. Allerberger
(Salzburg, Vienna, AT)
Risk factors for acquiring extended-spectrum
beta-lactamase producing Escherichia coli
infection from prior colonisation
T.M. Goulenok*, E. Bille, A. Ferroni, H. Lecuyer,
O. Join-Lambert, A. Kouatchet, X. Nassif,
J.-R. Zahar (Paris, FR)
P1218
Do silver-coated needleless intravascular
catheter connectors reduce microbial
contamination?
T.J. Karpanen*, A.L. Casey, P. Nightingale,
M. Cook, T.S. Elliott (Birmingham, UK)
Adequacy of antimicrobial therapy of
intra-abdominal infections: healthcareassociated versus community-acquired
V.M. Meijering, M.B. Ekkelenkamp,
D.W. de Lange* (Utrecht, NL)
P1219
Disproportionate increase from 2004 – 2008
in S. aureus associated US hospitalisation
rates in children
R.M. Mera*, J.A. Suaya, H.A. Madsen, F.P. O'Hara,
D.F. Sahm, L.A. Miller, C.A. Rodriguez (Durham,
Philadelphia, Upper Providence, Chantilly, US)
Impact of a single-room design on the
spread of multidrug-resistant bacteria in
an intensive care unit
T. Halaby*, R. de Wit, N. Al Naiemi
(Enschede, NL)
Objectively improving operating theatre
disinfection cleaning in 12 hospitals
P. Carling*, J. Po, J. Jeffferson, M. Parry
for the Healthcare Environmental Hygiene
Study Group
The in vitro activity of hydrogen peroxide
vapour against spores of epidemic strains
of Clostridium difficile strains
F. Barbut, S. Yezli, J.A. Otter*
(Paris, FR; Andover, UK)
Cross-transmission audit of environmental
surfaces, clinical equipment and patient:
who touches what?
S.J. Smith, V. Young, S.J. Dancer*, C. Robertson
(Glasgow, UK)
Disinfection of CVC catheters with
ultraviolet-C light
T. Begovic, T. Bjarnsholt, A. Nielsen, J. Bak*
(Roskilde, Copenhagen, DK)
Final Programme
Posters
P1204
P1212
129
Poster Sessions
Sunday, 8 May
P1220
Risk factors for and consequences
of nosocomial infections caused by
multidrug-resistant pathogens
E. Hajdu*, Z. Peto, G. Kitti, B. Renata,
M. Matuz, R. Benko, Z. Molnar (Szeged, HU)
P1228
Device-associated infection surveillance
in intensive care units of Duzce University
Hospital, 2008–2009, Turkey
M. Yildirim*, M.F. Geyik, D. Ozdemir,
A. Iskender, M. Erbas, A. Danis (Düzce, TR)
P1221
Antibiotic drug consumption and the
emergence and spread of antimicrobialresistant Klebsiella pneumoniae clones
in an intensive care unit
A. Quattrocchi*, M. Barchitta, G. Valenti,
L. Giaquinta, M.A. Romeo, A. Tsakris, A. Agodi
(Catania, IT; Greece, GR)
P1229
P1222
Is there a variation in microorganisms
causing healthcare-associated infections
in a tertiary care hospital? Analysis of five
years data
M.A. Yetkin, D. Kanyilmaz, P. Onguru, E. Akinci,
S. Eren, N. Avci, I. Cinarbas, F. Coskun Alaca,
N. Aksu, H. Bodur* (Ankara, TR)
Increase of patients co-colonised or coifected
with methicillin-resistant Staphylococcus
aureus, vancomycin-resistant Enterococcus
faecium or extended spectrum betalactamase-producing Enterobacteriaceae
E. Meyer*, R. Ziegler, F. Mattner, F. Schwab,
P. Gastmeier, M. Martin
(Berlin, Nuremberg, Cologne, Freiburg, DE)
P1230
Frequency of colonisation by multiresistant
organisms among patients hospitalised in
a geriatric ward: a one-year prospective
observational study
D. Schoevaerdts*, A. Verroken, M. Frennet,
J. Jamart, D. Huang, P. Bogaerts, C. Swine,
Y. Glupczynski (Yvoir, BE)
P1231
ICU – always the hotbed of resistance?
R. Reynolds*, K. Maher, R. Hope on behalf of
BSAC Working Party on Resistance Surveillance
P1223
P1224
P1225
Primary colonisation with coagulase-negative
staphylococci in hospitalised newborns
D. Knaack*, C. Härtel, J. Knobloch
(Lübeck, DE)
Retrospective analysis of nosocomial
infections in the intensive care unit
of a tertiary hospital in China during 2008
and 2010
Y. Chen*, Z.T. Yang, Z.Q. Che, T.S. Wang,
S.Y, Zhao, Y.J. Yang, C. Zhu, J.W. Shao,
W.J. Zhou, H.Q. Sheng, W. Xu, M. Zhong,
X.Y. Liu, F. Jing, E.Z. Chen, Y.M. Lu
(Shanghai, CN)
Clinical findings and risk factors in children
with imipenem-resistant Acinetobacter
infections: single-centre experience between
2004 and 2009 in Turkey
E.C. Dinleyici*, Z.Y. Yargic, A. Kiremitci,
G. Durmaz, N. Tekin, S. Sahin, F. Aydin,
A. Aydin, O. Bor (Eskisehir, TR)
P1226
Nosocomial infection incidence and risk
factors in elderly patients in intensive care
units
K. Ozdemir, M. Dizbay*, A. Dikmen (Ankara, TR)
P1227
Staying a step ahead of nosocomial infections:
an accurate predictive model using a novel
correlation matrix and simple linear regression
A. Karunakaran*, A. Arunachalam,
K. Sivagnanam, P. Srikanth
(Chennai, IN; Minneapolis, US)
Final Programme
13:30 – 14:30
Outbreaks
P1232
Molecular typing by pulsed-field gel
electrophoresis of an outbreak of multidrugcarbapenem-resistant Acinetobacter
baumannii bacteraemia in a haematology
department
E. Us*, A. Azap, H. Aslaner, S. Civriz-Bozdag,
A. Tekeli, I. Balik, H. Akan, G. Gürman (Ankara, TR)
P1233
Description of an outbreak of multi-resistant
Acinetobacter baumannii: clinical impact,
genotypic analysis and outcome
G. Migliorino*, E. Motta, S. Bramati, G. Foti,
M. Rossi, A. Bandera, E. Viganò, R. Fumagalli,
A. Gori (Monza, IT)
P1234
Outbreak of methicillin-resistant
Staphylococcus aureus in a neonatal
intensive care unit
L. Cariani*, G. Defilippi, R. Colombo,
M. Colosimo, L. Pugni, C. Parlato, P. Cavallerio,
F. Mosca, R. Serra, E. Torresani (Milan, Turin, IT)
P1235
Epidemiological characterisation of epidemic
and non-epidemic clones of Acinetobacter
baumannii: is surveillance of carriage in
intensive care units useful?
M. Barchitta*, G. Valenti, A. Quattrocchi,
M.A. Romeo, L. Giaquinta, C. Santangelo,
G. Castiglione, A. Agodi (Catania, IT)
Poster Sessions
Sunday, 8 May
Nosocomial pseudo-outbreak of XDR
Pseudomonas aeruginosa urinary tract
infections due to analytical contamination
in the laboratory
M. Hallin*, A. Deplano, S. Roisin, V. Boyart,
R. De Ryck, C. Nonhoff, O. Denis (Brussels, BE)
P1237
High-throughput molecular screening
aureus during a major nosocomial outbreak
caused by various genotypes
L. Roorda*, W. Hendriks, A. van der Zee,
J. Ossewaarde, J. Buitenwerf (Rotterdam, NL)
P1238
Outbreak of Pseudomonas (Flavimonas)
oryzihabitans bacteraemia in a neonatal
intensive care unit
H. Prifti *, D. Oikonomidou, O. Pappa,
K. Tryfinopoulou, K. Vatzeli , K. Karaiskos,
E. Kostis, A. Vatopoulos, K. Tzanetou
(Athens, GR)
P1239
MALDI-TOF mass spectrometry proteome
profiling for identification and typing of
multidrug-resistant Klebsiella pneumoniae
strains in a paediatric nosocomial outbreak
P. Bernaschi*, L. Putignani, F. Del Chierico,
B. Lucignano, S. Ranno, M. Argentieri,
L. Pansani, M. Ciofi degli Atti, G. Ciliento,
F. Locatelli, D. Menichella, M. Raponi (Rome, IT)
P1240
Consecutive outbreaks of Serratia
marcescens infections in a neonatal ICU
are due to the repeated introduction of new
clones
K. Tryfinopoulou*, O. Pappa, M. Polemis,
H. Prifti, K. Vatzeli, L. Ftika, H. Maltezou,
K. Tzanetou, A. Vatopoulos (Athens, GR)
P1241
Super spreader and nosocomial outbreaks
L. Danzmann, P. Gastmeier, R.P. Vonberg*
(Hanover, Berlin, DE)
P1242
A retrospective review of hospital MRSA
outbreaks: does UK15 cause increased
colonisation of healthcare workers?
J. Hart*, R. Lee, K. Christiansen, J.O. Robinson
(Perth, AU)
P1243
A systematic review of nosocomial
outbreaks caused by multidrug-resistant
E. Zhuchenko, K. Graf*, R.P. Vonberg
(Hanover, DE)
13:30 – 14:30
MRSA – colonisation and screening
P1244
Nasopharyngeal colonisation with
among incarcerated population in Avaré, Brazil
C.L. Witzel* (Botucatu, BR)
P1245
ESwab and Xpert MRSA/SA nasal assay
optimises collection to detection of
community-acquired MRSA in children
M. Onori*, L. Mancinelli, F. Gesualdo,
D. Menichella, C. Russo (Rome, IT)
P1246
Risk factors for methicillin-resistant
Staphylococcus aureus colonisation on
admission to rehabilitation medicine
A. Pan*, F. Antonioli, R. Lazzari, A. Patroni,
S. Garilli, F. Bernieri, P. Mangoni, C. Meinecke
(Cremona, Esine, Brescia, IT)
P1247
Prevalence and basal characteristics
of persistent and intermittent colonisation
aureus among residents living in long-term
care facilities
M.L. Martín-Ponce, J. Santos-Morano,
J.A. García-García*, C. Castro,
A. de Miguel-Albarreal, L.M. Martín-Rodríguez,
S. Vergara-López, A. Mateos-Gómez,
E. Bayoll-Serradilla, E. León-Jiménez,
J.M. Gómez-Mateos, J.E. Corzo-Delgado
(Seville, Osuna, ES)
P1248
Nasal carriage of methicillin-resistant
staphylococci among sick and healthy
horses in Portugal
N. Couto*, P. Tilley, J. Simões, J. Sales-Luís,
C. Pomba (Lisbon, PT)
P1249
Methicillin resistance, virulence factors and
genetic lineages of Staphylococcus aureus
isolates from nasal samples of healthy sheep
in Tunisia
H. Gharsa*, K. Ben Slama, C. Lozano,
E. Gómez-Sanz, N. Klibi, A. Jouini, M. Zarazaga,
A. Boudabous, C. Torres (Tunis, TN; Logroño, ES)
P1250
Effective screening for methicillin-resistant
Staphylococcus aureus on the basis of
hospital-specific risk factors
A. Bühling*, R. Tech, K. Mydlak, P. Thorausch,
F. Schwab, K. Schenke
(Cottbus, Berlin, Luckenwalde, DE)
P1251
Study of Staphylococcus aureus nasal
carriage in diabetic patients and non-diabetic
controls: preliminary results
C. Loupa*, A. Karaitianou-Velonaki, C. Chiotis,
G. Kouppari, D. Voyatzoglou, M. Lelekis
(Athens, GR)
Final Programme
131
Posters
P1236
Poster Sessions
Sunday, 8 May
P1252
Staphylococcus aureus colonisation and
recurrent furunculosis in young Greek adults:
the role of CA-MRSA
V. Sakka, P. Nikou*, L. Galani, A. Fragou,
I. Karaiskos, T. Panagea, S. Kanellaki,
G. Petrikkos, H. Giamarellou (Athens, GR)
P1253
External quality assessment scheme
for MRSA screening
E. Fagan*, S. Seaton, C. Walton (London, UK)
P1254
13:30 – 14:30
Estimating the effectiveness of isolation
and decolonisation measures in reducing
MRSA transmission in hospital general
wards: a model-based analysis
C. Worby*, J.V. Robotham, D. Jeyaratnam,
T. Kypraios, P. O'Neill, D. De Angelis,
G. French, B.S. Cooper (London, Nottingham,
Cambridge, UK; Bangkok, TH)
Surveillance of topical antibacterial usage
in primary care in Wales
M. Heginbothom* (Cardiff, UK)
P1256
More awareness of antibiotic risks and
benefits are needed amongst Polish
general public
B. Mazinska*, W. Hryniewicz (Warsaw, PL)
P1257
The impact of antibiotic education sessions
in primary care in the Republic of Ireland –
a case study
M. Murphy*, S. Byrne, C.B. Bradley (Cork, IE)
P1258
A national study of antimicrobial stewardship
structures and antimicrobial use in Irish
long-term care facilities
M.P. Cotter*, S. Donlon, F. Roche, H. Byrne,
F. Fitzpatrick (Dublin, Cork, IE)
P1259
Variation in outpatient antibiotic prescribing
J. Zweigner*, F. Schwab, E. Meyer, S. Ebert,
P. Gastmeier (Berlin, DE)
P1261
European Surveillance of Antimicrobial
Consumption (ESAC): disease-specific
quality indicators for outpatient antibiotic
prescribing
N. Adriaenssens, S. Coenen*, S. Tonkin-Crine,
T. Verheij, P. Little, H. Goossens
and the ESAC Ambulatory Care subprojec
P1263
Antibiotic consumption trends in the adult
population in Emilia-Romagna, Italy,
2003 – 2009
A. Pan*, R. Buttazzi, M. Marchi, C. Gagliotti,
D. Resi, M.L. Moro for the Antibiotic Use and
Resistance Surveillance Study Group of
Regione Emilia-Romagna
P1264
Impact of the H1N1 pandemic on antibiotic
consumption in the adult population
in Emilia-Romagna, Italy
A. Pan*, R. Buttazzi, M. Marchi, C. Gagliotti,
D. Resi, M.L. Moro on behalf of the Antibiotic
Use and Resistance Surveillance Study Group
of Regione Emilia-Romagna
P1265
Identifying determinants of antibiotic
use in Europe
P. Beutels*, C. Marais, N. Hens, A. Blommaert,
J. Cortinas Abrahantes, S. Coenen, A. Muller,
H. Goossens (Antwerp, Hasselt, BE)
P1266
Antibiotic prescribing for adults with acute
cough/LRTI: congruence with guidelines
C. Butler*, J. Wood, K. Hood, M.J. Kelly, T. Verheij,
P. Little, A. Torres, F. Blasi, T. Schaberg,
H. Goossens, J. Nuttall, S. Coenen (Cardiff, UK;
Utrecht, NL; Southampton, UK; Barcelona, ES;
Milan, IT; Rotenburg, DE; Antwerp, BE)
P1267
Severity assessment for lower respiratory
tract infections: potential use and validity
of CRB-65 in primary care
N.A. Francis*, J. Cals, C. Butler, K. Hood,
T. Verheij, P. Little, H. Goossens, S. Coenen
on behalf of the GRACE Project Group
P1268
Antimicrobial prescribing for urinary tract
infections in European nursing homes
K. Latour*, E. Broex, A. Muller, N. Drapier,
V. Vankerckhoven, R. Stroobants, H. Goossens,
B. Jans on behalf of the European Surveillance
of Antimicrobial Consumption (ESAC) Nursing
Home subproject group
P1269
Repeated point-prevalence surveys on
antimicrobial prescriptions in Finnish nursing
homes, 2009 – 10
M.-L Rummukainen*, O. Lyytikäinen,
T. Kärki, M. Kanerva, M. Haapasaari, J. Ollgren,
B. Jans, A. Muller, H. Goossens on behalf
of the European Surveillance of Antimicrobial
Consumption (ESAC) Nursing Home Subproject
Group
Measuring and influencing community
antibiotic use
P1255
P1260
P1262
How to improve parental knowledge and
awareness about antibiotics?
A unique Swedish Strama educational
programme in child health centres
B. Jönsson*, L. Ernstson, M. Erntell
(Halmstad, SE)
Improved compliance to antibiotic guidelines
in long-term care facilities in Region Västra
Götaland, Sweden
P. Ulleryd*, L. Karlsson, A. Arvidsson, R. Eklund,
M. Eriksson, L. Osbeck, M. Schewenius,
T. Wahlberg, S. Öberg (Region Västra Götaland,
Borås, Skövde, Uddevalla, Gothenburg, SE)
Final Programme
Poster Sessions
Sunday, 8 May
Antimicrobial consumption and stewardship
in nursing homes in European regions
B. Jans*, K. Latour, E. Broex, A. Muller,
N. Drapier, V. Vankerckhoven, R. Stroobants,
H. Goossens on behalf of the European
Surveillance of Antimicrobial Consumption
(ESAC) Nursing Home subproject group
P1279
Junior and senior residents’ knowledge and
perceptions about antimicrobial resistance
C. Navarro-San Francisco, J. Rodríguez-Baño,
J. Cobo, J.H. de Gea-García, S. Vañó,
F. Moreno-Ramos, M. del Toro, J. Morán-Barrios,
J.R. Paño-Pardo*
(Madrid, Seville, Murcia, Bilbao, ES)
P1271
European Surveillance of Antimicrobial
Consumption (ESAC): outpatient antibiotic
use in children and teenagers in Europe
A. Versporten*, S. Coenen, N. Adriaenssens,
H. Goossens on behalf of the ESAC Ambulatory
Care Project Group
P1280
Antibiotic management and early discharge
from hospital: an economic analysis
A.M. Gray*, M. Dryden, A. Charos
(Oxford, Winchester, Walton-on-the-Hill, UK)
P1281
Consequences of failure of initial antibiotic
therapy in complicated skin and skin
structure infections in US hospitals,
2000 – 2009
A. Berger, G. Oster, J. Edelsberg, K.T. LaPensee,
X. Huang*, D.J. Weber (Brookline, Jersey City,
Chapel Hill, US)
P1282
Audits and antibiotic advisors to control
antibiotic consumption and fluoroquinolones
use: a five-year survey in 74 French
hospitals, 2005 – 2009
C. Dumartin*, A.-M. Rogues, B. Amadeo,
M. Pefau, A.-G. Venier, P. Parneix, C. Maurain
(Bordeaux, FR)
P1283
Dynamic relationship between
fluoroquinolone use and emergence
of E. coli ESBL producers
J.M. López-Lozano*, N. Gonzalo Giménez,
F. Lajara-Marco, P. Campillos-Alonso
(Orihuela, ES)
P1284
Antibiotic prophylaxis in surgical procedures
in the Latium region, Italy
V. Puro, L.E. Ruscitti*, P. Piselli, L. Martini,
F. Ferraro, P. Villari, D. Orazi, A.L. Scanu,
S. Parrocchia, R. Saviano, G. Natalini,
A. Silvestri, G. Pagano, F. Cerquetani,
G. Sguazzini, A. Caterini, N. Petrosillo,
G. Ippolito on behalf of Centro Regionale
Infezioni Associate Pratiche Assistenziali –
Lazio. Coordinamento: INMI “L.Spallanzani”
Roma
P1285
Assessing stewardship programmes
as a potential determinant of antibiotic
management in European intensive care
units: a survey
G. De Angelis*, M. Cipriani, F. Di Muzio,
G. Restuccia, E. Milozzi, R. Cauda,
M. Antonelli, U. Frank, A. Brink-Huis,
M. Hulscher, E. Tacconelli
(Rome, IT; Freiburg, DE; Nijmegen, NL)
P1272
Comparative effects of the extended and
the immediate release formulations of
ciprofloxacin on normal human intestinal
microflora
M. Rashid, A. Weintraub, C.E. Nord*
(Stockholm, SE)
P1273
Effect of telavancin on the normal human
intestinal microflora
M. Rashid, A. Weintraub, C.E. Nord*
(Stockholm, SE)
13:30 – 14:30
Antibiotic use, stewardship and resistance
in the hospital: optimising outcomes
P1274
Results of Irish National point-prevalence
studies 2009 and 2010
D. Lambert*, M. Philbin, A. Oza
on behalf of the IAPG
P1275
The association between “guideline-adherent”
empirical treatment of community-acquired
pneumonia and mortality in the Netherlands
S.M. Huijts*, M.J. Bonten
on behalf of the CAP-diagnostics investigators
P1276
Adherence to antibiotic guidelines for
empirical treatment of pneumonia in the
Netherlands
S.M. Huijts*, M.J. Bonten
on behalf of the CAP-diagnostics investigators
P1277
Results of a counselling programme in
antibiotic treatment in an Andalusian hospital
A. del Arco Jiménez*, B. Tortajada Goitia,
J. de la Torre, J. Olalla Sierra, J. Prada Pardal,
M. Noureddine López, J. García Alegría
(Marbella, ES)
P1278
Antimicrobial consumption in VINCat
hospitals: stratified data by hospital size
S. Grau*, E. Fondevilla, M. Palomar, J. Valles,
M. Pujol, F. Gudiol on behalf of the VINCat
Program Group. Department of Health,
Catalonia, Spain
Final Programme
Posters
P1270
133
Poster Sessions
Sunday, 8 May
P1286
Comparison of inhaled and intravenous
colistin combined with tigecycline in
treatment of multidrug-resistant
Acinetobacter baumannii pneumonia
Y. Tezer Tekçe*, A. Erbay, H. Cabadak, S. Sen
(Ankara, Yozgat, TR)
P1287
Audit of antibiotic therapies in 66 cases
of endocarditis
E. Demonchy, E. Cua, P. Roger, P. Dellamonica,
C. Pulcini* (Nice, FR)
P1288
Integrated care pathway for management
of infective endocarditis – an innovative
multidisciplinary approach: clinical outcomes
and experience from the Lancashire cardiac
centre, UK
A. Guleri*, R. More, D. Roberts, J. Zacharias,
A. Tang, N. Waddington, M. Przybylo, T. Morris,
S. Rogers (Blackpool, UK)
P1289
P1290
P1291
P1292
P1293
Results from a non-interventional study:
daptomycin as empiric treatment of
Gram-positive infections
K.N. Malizos *, P. Gargalianos-Kakolyris,
A. Gonzalez-Ruiz, A. Cogo, A. Galloway,
A. Beiras-Fernandez, M. Heep, Y. Yin,
R.L. Chaves (Larissa, Athens, GR; Kent, UK;
Vicenza, IT; Newcastle upon Tyne, UK; Munich,
DE; Basel, CH; East Hanover, US)
Clinical response and nephrotoxicity
according to the trough serum vancomycin
concentration among patients with
bacteraemia
W. Choi, J. Noh, J. Huh, Y. Youn, J.Y. Song, J. Sohn,
H. Choeng, W. Kim, M.J. Kim, D.W. Park*
(Seoul, KR)
Superinfection during the treatment
of nosocomial infection with tigecycline
M.E. Jiménez-Mejias, E. García-Cabrera,
C. Martín-Gandul*, M.J. Gómez-Gómez,
M. Ruiz-Perez de Piapaón, M.V. Gil-Navarro,
E.R. Alfaro-Lara on behalf of the Spanish
Network for Research in Infectious Disease
Clinical and economic impact of rapid
microbiological information of the samples
more frequently processed in the Department
of Clinical Microbiology
A. Galar*, J. Leiva, M. Espinosa, F. Guillén-Grima,
J.R. Yuste (Pamplona, ES)
Forgotten antibiotics: an inventory in Europe,
US, Canada and Australia
C. Pulcini*, K. Bush, W. Craig, N. Frimodt-Möller,
L. Grayson, J. Mouton, J. Turnidge, S. Harbarth,
I. Gyssens on behalf of the ESCMID Study Group
on Antibiotic Policies (ESGAP)
Final Programme
P1294
Getting acquainted with aztreonam:
a six-month audit of use in a tertiary
referral hospital
K. Burns, S. Foley*, F. Fitzpatrick, E. Smyth
(Dublin, IE)
P1295
Drug content, powder characterisation
and particulate matter contamination in
imipenem/cilastatin powder for injections
from Asia region
J. Konsil*, S. Supattanapong, O. Apirakkan
(Khon Kaen, TH)
P1296
Multiple-dose pharmacokinetics
of anidulafungin during continuous
veno-venous haemofiltration
J. Leitner* (Vienna, AT)
P1297
A 3-year survey of antifungal therapy
results in febrile neutropenic patients
with haematological malignancies:
an analysis of 335 febrile episodes
F. Aksoy*, I. Koksal, G. Yilmaz, K. Aydin
(Trabzon, TR)
P1298
Early antibiotic use during pregnancy
changes the vaginal microflora near time
of birth
J. Stokholm*, S. Schjørring, L. Pedersen,
A.L. Bischoff, N. Følsgaard, C. Giwercman,
B. Chawes, K. Bønnelykke, A. Mølgaard,
J.S. Jensen, K. Krogfelt, H. Bisgaard
(Gentofte, Copenhagen, DK)
P1299
Nanosensors for antibiotic discovery and
therapeutic drug monitoring in real time
J. Ndieyira*, N. Kappeler, S. Logan,
R. McKendry, G. Aeppli (London, UK)
13:30 – 14:30
Surveillance systems
P1300
Results from the 2010 antimicrobial
susceptibility testing external quality
assessment exercise organised for
EARS-Net participants
N. Patel*, C. Walton, A. Laja, C. Gagliotti,
O. Heurer, D. Brown, V. James
(London, UK; Bologna, IT; Stockholm, SE;
Peterborough, UK)
P1301
Ten years of SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance
in German Intensive Care Units); 2001 – 2010
E. Meyer*, F. Schwab, P. Gastmeier (Berlin, DE)
Poster Sessions
P1302
ISIS-AR and ISISweb: a new surveillance
system for antimicrobial resistance
surveillance
N. van de Sande-Bruinsma*,
M. Leverstein-van Hall, E. Boel, G. Ruijs,
J. Alblas, S. Thijsen on behalf of ISIS-AR
participants
P1303
Antimicrobial resistance surveillance
for hospital- and community-acquired
strains from southwestern Romania
M. Licker*, L. Baditoiu, D. Muntean, R. Zugravu,
L. Dragomirescu, F. Horhat, C. Pilut, E. Hogea,
P. Deutsch, C. Macarie, M. Radulescu,
R. Moldovan (Timisoara, RO)
P1304
P1305
P1306
Japan Nosocomial Surveillance System
(JANIS), a national surveillance system
of antimicrobial resistance and nosocomial
infections in Japan
S. Suzuki*, K. Yamane, A. Tsutsui, T. Yamagishi,
Y. Arakawa (Tokyo, JP)
National antimicrobial resistance
alerts – an early warning and quality
assurance system
A.T. Eastaway*, J. Wilson, P. Webb, C. Wiuff
(Glasgow, UK)
Real-time local epidemiological data
through the internet as a management tool
for infections in the community
G.S. Simonsen*, T. Chomutare, L. Ilebrekke,
P.A. Bakkevoll, A. Sjøveian, J.G. Bellika
(Tromsø, NO)
P1307
Social media and infectious disease
surveillance: tweets indicate norovirus
outbreak at a university
E. Velasco, M. Krieck, L. Otrusina, F. Bazoche,
J. Linge, T. Eckmanns*, J. Dreesman
for the M-Eco Project
P1308
A validation study of the Korean Nosocomial
Infections Surveillance System
Y.K. Cho*, J.Y. Kim, S.-O. Lee, H.Y. Kim, Y.K. Kim,
Y. Kwak, E.S. Kim, H.B. Kim, M.S. Lee, J.S. Eom,
H.Y. Jin, J.Y. Lee, E.S. Park, S.Y. Jeong, S.R. Kim,
H.K. Hong for the Korean Nosocomial Infections
Surveillance System (KONIS)
P1309
The ECDC Pilot Point-Prevalence Survey
of healthcare-associated infections and
antimicrobial use: feasibility analysis
A. Muller*, C. Suetens, B. Coignard,
M. Goossens, S. Vaerenberg, B. Catry,
for the ECDC-PPS Study Group
P1310
The ECDC Pilot Point-Prevalence Survey
of healthcare-associated infections and
antimicrobial use: healthcare-associated
infection results
C. Suetens*, A. Muller, B. Coignard,
M. Goossens, B. Catry, S. Vaerenberg,
on behalf of the ECDC-pPPS Study Group
P1311
Active surveillance for methicillinresistant Staphylococcus aureus in intensive
care units: incidence density reduced to that
of general wards
B. Ang, A. Earnest, A. Chow, T. See, W. Ng,
B. Poh, D. Lye* (Singapore, SG)
P1312
Korean Nosocomial Infections Surveillance
System, Intensive Care Unit Module Report:
data summary from July 2009 through June
2010 and analysis of 4-year results
Y. Kwak*, Y.K. Cho, J.Y. Kim, H.Y. Kim, Y.K. Kim,
E.S. Kim, M.S. Lee, J.S. Eom, Y.S. Lee, E. Kim
(Goyang, Incheon, Wonju, Seoul, KR)
P1313
Assessment of European practices in
infection control. First results from PROHIBIT
M. Martin*, A. Conrad, W. Zingg, S. Hansen,
P. Gastmeier, D. Pittet, M. Dettenkofer
and the PROHIBIT consortium
P1314
A technical committee for epidemiological
surveillance from microbiology laboratories
data: an Italian five-year period experience
in Lombardy region
E. Costa*, A. Pan, M. Arghittu, V. Bettamio,
P. Casella, V. Cattolico, C. Farina, F. Franzetti,
M. Moro, G. Ortisi, A. Russo, E.F. Viganò
on behalf of the Lombardy Group of Technical
Assessment (GTA) for Surveillance from
Microbiological Data
13:30 – 14:30
Infection control
P1315
Prevalence and risk factors for carriage
aureus in 17 German hospitals: results
of a point-prevalence study in the rural
district Hannover
I.F. Chaberny, H.-B. Behrends, M.-E. Höpken,
B. Klingelbiel, U. Mai, E. Ott* (Hannover, DE)
P1316
Guidelines for infection control staff:
goals and reality in Germany
E.B. Kruse*, H. Gartmann, W. Gärtner,
S. Schulz-Stübner (Freiburg, DE)
Final Programme
135
Posters
Sunday, 8 May
Poster Sessions
Sunday, 8 May
P1317
Preliminary evaluation of an automated
detection tool for healthcare-associated
infections, based on screening natural
language medical reports
Y. Berrouane*, C. Hagège, Q. Gicquel,
I. Kergoulay, S. Pereira, D. Proux, S. Darmoni,
F. Segond, M.H. Metzger (Nice, Meylan, Lyon,
Rouen, Issy-les-Moulineaux, FR)
P1318
Surgical site infections after cardiac
surgery in Oslo, Norway
T. Tollefsen*, B. Andersen, Ø. Vengen (Oslo, NO)
P1319
Procedures for isolation and management
of patients with highly infectious diseases
in emergency departments: EuroNHID
(European Network for Highly Infectious
Diseases) data from 40 centres in
13 European countries
F.M. Fusco*, G. De Iaco, S. Schilling, H.R. Brodt,
P. Brouqui, H. Maltezou, B. Bannister,
G. Thomson, V. Puro, G. Ippolito
for the EuroNHID (European Network for
Highly Infectious Diseases) Study Group
P1320
Does infection control regulation lead to less
nosocomial infections? A comparison of
federal states in Germany with infection
control regulations and without
E. Meyer*, F. Schwab, C. Geffers, P. Gastmeier
(Berlin, DE)
P1321
Outbreak investigation because of neonatal
listeriosis cases in a Swiss maternity unit
C. Kahlert*, F. Limacher, W. Girardi, J. Bille,
M. Schlegel (St. Gallen, Grabs, Lausanne, CH)
P1322
Epidemiology of Serratia marcescens
colonisations and infections in a neonatal
intensive care unit
M. Papadimitriou*, K. Tryfinopoulou,
D. Kyriakou, A. Doudoulakakis, O. Pappa,
J. Kapetanakis, A. Vatopulos, E. Lebessi
(Athens, GR)
P1323
P1324
Infection control in daily practice:
improvement in prevention of catheterrelated bloodstream infections
with audit tools
S. Kostourou*, F. Veini, M. Samarkos,
K. Papanikolaou, V. Papastamopoulos,
I. Baraboutis, O. Paniara, A. Skoutelis
(Athens, GR)
Impact of an intervention based on
contact precautions in hospital-acquired
infections in a neonatal unit
I.F. Corrales*, J.A. Cortes, G. Troncoso,
M.I. Alvarez, G. Buitrago, M. Ibañez, A.L. Leal
(Bogotá, CO)
Final Programme
P1325
Perioperative antibiotic prophylaxis:
results of a second audit in 7 major hospitals
in North Italy
C. Tassan din*, C. Oltolini, P. Scarpellini,
G. Vighi, G. Barranco, V. Conti, G. Genduso
(Milan, Lecco, IT)
P1326
A one-stop shop real-time national decision
support system for infectious disease control
in England
C. Kara-Zaitri*, M. Schweiger
(Bradford, Leeds, UK)
P1327
Epidemiology of blood and body fluid
exposures among healthcare workers,
in a Greek tertiary hospital
F. Veini, S. Kostourou, M. Samarkos*,
E. Dokoutsidou, I. Baraboutis,
V. Papastamopoulos, O. Paniara,
A. Skoutelis (Athens, GR)
P1328
Transporting patients with highly infectious
diseases: a survey in 14 EU member states
S. Schilling*, H. Maltezou, F.M. Fusco,
H.R. Brodt, B. Bannister, P. Brouqui, V. Puro,
R. Gottschalk, G. Ippolito for the European
Network for Highly Infectious Diseases –
EuroNHID
P1329
Implementing peripheral vascular catheter
care bundle in a tertiary care hospital:
no room for complacency?
A.F. Talento, M. Morris-Downes, T. Thomas,
J. Walsh, E. Smyth, H. Humphreys,
F. Fitzpatrick* (Dublin, IE)
P1330
Multidrug-resistant organisms: concurrent
burden and implication on isolation
D. Kee, B. Ang, A. Chow, D. Lye* (Singapore, SG)
P1331
Development of an epidemiological tool to
assess the potential of spread of organisms
in rehabilitation centres
Y. Carmeli*, M. Kazma, E. Mordechai, A. Klein,
M. Hochman, R. Taya, M. Shakler, S. NavonVenezia, A. Raskin-segal, G. Rabinowitz,
Y. Lerman, J. Vidal-samso, A. Salvia, J. Salomon,
E. Isakov on behalf of the MOSAR-WP5
P1332
Outbreak of Burkholderia cenocepacia
bacteraemia in an intensive care unit:
an epidemiologic and molecular study
M. Katsiari*, Z. Roussou, A. Xydaki,
K. Tryfinopoulou, A. Vatopoulos, E. Platsouka,
A. Maguina (Athens, GR)
P1333
Infection control and MRSA in nursing
homes – the perspective of nursing
home staff
P. McClean*, C. Hughes, M. Tunney, D. Gilpin,
C. Parsons, N. Baldwin (Belfast, UK)
Poster Sessions
Sunday, 8 May
Development of a preparedness plan
to control the spread of carbapenemaseproducing Gram-negatives in a tertiary
hospital serving a major international airport
S. Thomas*, B. Isalska, C. Thornhill,
J. Turner-Gardner, D. Walter (Manchester, UK)
P1335
From IPSE to TRICE: evolution in Europe
of the state of the art of infection control
S. Brusaferro*, F. Coiz, B. Cookson, G. Privitera,
R. Gallagher, T. Cooper, J. Fabry, P. Hartemann,
S. Kalenic, W. Popp, K. Mannerquist, P. Viale,
C. Ruef, K. Weist, C. Varela Santos, C. Suetens
(Udine, IT; London, UK; Pisa, IT; Lyon, Nancy, FR;
Zagreb, HR; Essen, DE; Stockholm, SE;
Bologna, IT; Zurich, CH)
P1336
Respiratory isolation in HIV patients
with suspected pulmonary tuberculosis:
comparison of clinical predictive models
M. Carugati*, F. Zanini, C. Schiroli, F. Croce,
F. Franzetti (Milan, IT)
P1337
Evaluation of control measurement
procedures in the prevention of
carbapenemase-2 (KPC-2)–producing
Klebsiella pneumoniae nosocomial
transmission
M. Rossi*, G. Migliorino, E. Motta, S. Foresti,
S. Bramati, S. Malandrin, M. Vanenti,
P. Lanfranco, E.F. Viganò, A. Gori (Monza, IT)
P1338
P1339
13:30 – 14:30
P1340
Reducing the spread of Acinetobacter
baumannii and methicillin-resistant
Staphylococcus aureus on a burns unit
through the intervention of an infection
control bundle including hydrogen peroxide
vapour decontamination
F. Barbut, J. Pham, S. Yezli, M. Mimoun,
J.A. Otter* (Paris, FR; Andover, UK)
Effect of multimodal interventions and
healthcare-worker influenza vaccination
on reducing all-cause nosocomial pneumonia
in haematopoietic stem cell transplant
recipients
P. Ferguson*, N. Gilroy, T. Sloots, M. Nissen,
T. Sorrell (Blacktown, Sydney, Brisbane,
Westmead, AU)
Epidemiology of antimicrobial resistance
Emergence of novel blaKPC-12 and
blaKPC-13 variants in carbapenem
non-susceptible Enterobacter cloacae:
a first report of blaKPC gene in Thailand
T. Netikul, P. Kiratisin* (Bangkok, TH)
P1341
Plasmid-carried blaKPC-2 genes in
Enterobacteriaceae in Brazil
L.N. Andrade, T. Curiao, J.C. Ferreira,
J.M. Longo, E.C. Climaco, R. Martinez,
F. Bellissimo-Rodrigues, A. Basile-Filho,
M.A. Evaristo, F. Baquero, R. Cantón,
A.L. Darini*, T.M. Coque
(Ribeirao Preto, BR; Madrid, ES)
P1342
KPC-producing Klebsiella pneumoniae
from Rome, Italy
A. García-Fernández*, A. Giordano, L. Villa,
C. Venditti, M. Venditti, C. Mancini, A. Carattoli
(Rome, IT)
P1343
Dissemination of DHA-1 and CMY-2
beta-lactamases among Klebsiella spp. and
E. coli from Portuguese clinical settings
F. Freitas*, A. Novais, T. Gonçalves, S. Amaral,
R. Cantón, T.M. Coque, E. Machado, L. Peixe
on behalf of The Portuguese Resistance Study
Group
P1344
Emergence of VIM-1-carbapenemaseproducing Enterobacter cloacae isolates
in the Tyrol, Austria
I. Heller*, K. Grif, D. Orth-Höller (Innsbruck, AT)
P1345
Microarray analyses of Escherichia coli
isolates producing extended-spectrum
beta-lactamases from food, farm animals
and humans from the UK, the Netherlands
and Germany
G. Wu*, M. Mafura, J. Fenner, M. Woodward,
N. Coldham (Addlestone, UK)
P1346
Trends in annual prevalence of Escherichia
coli O25b/ST131 (ESBL producer and
non-producer), in a 6-year period in
southern Spain
M. Bellido, L. López-Cerero*, L. Serrano,
D. Navarro, J. Rodríguez-Baño, A. Pascual
(Seville, ES)
P1347
Multidrug-resistant NDM-1-producing
super-bugs in Bangladesh
M. Islam, P. Talukdar, A. Hoque, M. Huq, A. Nabi,
I. Azmi, D. Ahmed, K. Talukder, J. Hays,
A. Cravioto, H. Endtz*
(Dhaka, BD; Rotterdam, NL)
P1348
Surveillance of beta-lactamase production
in a recent sample of Klebsiella pneumoniae
isolated in Greek hospitals
C.C. Papagiannitsis*, K. Tryfinopoulou,
P. Giakkoupi, O. Pappa, M. Polemis,
E. Malamou-Lada, M. Orfanidou, S. Tsiplakou,
V. Papaioannou, H. Fakiri, K. Stamoulos, D. Kairis,
H. Papoutsidou, H. Katsifa, F. Kesidou,
E. Tsafaraki, A. Tsouri, E. Platsouka, Z. Roussou,
H. Kaitsa-Tsiopoulou, P. Kazila, E. Tzelepi, A.
Vatopoulos (Athens, Thessaloniki, Chania, GR)
Final Programme
Posters
P1334
137
Poster Sessions
Sunday, 8 May
P1349
High prevalence of clonally related
CMY-2-producing Escherichia coli in
poultry from Switzerland
A. Endimiani*, D. Kunz, V. Perreten (Berne, CH)
P1350
High frequency of the ST131-O25b pandemic
Escherichia coli clone among uropathogenic
isolates from companion animals and
humans in Portugal
N. Couto, L. Guerreiro, A. Belas, C. Leandro,
R. Barbosa, P. Cavaco-Silva, C. Pomba*
(Lisbon, PT)
P1351
P1352
P1353
P1354
P1355
P1356
Extended-spectrum cephalosporin resistance
and production of beta-lactamases in
Salmonella strains of different serovars in
Germany, 2005 – 2010
Y. Pfeifer*, S. Trüpschuch, R. Prager, W. Rabsch,
J.-S. Frick, W. Witte (Wernigerode, Tübingen, DE)
Persistence of ciprofloxacin- and ceftriaxoneresistant Salmonella enterica serotype
Choleraesuis and emergence of IncI1
resistance plasmids among ceftriaxoneresistant nontyphoid Salmonella in Taiwan
L. Su*, T.L. Wu, A.J. Kuo, J.H. Chia, H.-C. Li,
C.-L. Chen, C.-H. Chiu (Taoyuan, TW)
Turkey meat as a source of determinants
conferring plasmid-mediated quinolone
resistance in Salmonella
B. Guerra*, K. Thomas, J. Beutlich, L. Cavaco,
K. Veldman, R. Helmuth, A. Schroeter
(Berlin, DE)
Multidrug-resistant Salmonella clones
in slaughtered swine
E. Gomes Neves*, P. Antunes, A. Tavares,
P. Themudo, J.M. Correia da Costa, L. Peixe
(Porto, Vairão, Lisbon, PT)
High prevalence of plasmid-mediated
quinolone resistance among nalidixic acid
resistant, ciprofloxacin susceptible
Enterobacteriaceae isolated in a Greek
university hospital
A. Margaritis*, I. Galani, T. Panayea,
G. Petrikkos, M. Souli (Athens, GR)
Distribution of virulence determinants and
serotypes in relation to fluoroquinolone
resistance and the presence of blaCTX-M
among Klebsiella pneumoniae isolates
J. Chang*, S.B. Han, J.K. Yu, H. Chae, K. Park,
Y.J. Park (Seoul, KR)
Final Programme
P1357
Escherichia coli from human and avian
origin: detection of fluoroquinolonesresistance associated clonal groups
M. Giufrè, M. Accogli, C. Graziani, I. Luzzi,
M. Argentieri, A. Giammanco, A. Lettini, P. Pecile,
A. Raglio, M. Staffolani, G. Tosi, M. Cerquetti*
(Rome, Palermo, Legnaro, Padoa, Florence,
Bergamo, Macerata, Forlì, IT)
P1358
Spread of plasmid-mediated quinolone
resistance and pathogenic islands in
Escherichia coli isolated from water
N. Mendonça*, J. Ramalho, P. Vieira,
A. Tavares, P. Pereira, G. Da Silva
(Coimbra, Aveiro, Leiria, PT)
P1359
Occurrence of plasmid-mediated
quinolone resistance among bacteria
isolated in animals in Portugal
E. Ferreira, L. Clemente, D. Jones-Dias,
A.P. Francisco, V. Manageiro, P. Themudo,
T. Albuquerque, A. Amado, M. Caniça*
(Lisbon, PT)
P1360
Aminoglycoside resistance in Escherichia
coli in western Norway
P.C. Lindemann*, K. Risberg, H. Mylvaganam
(Bergen, NO)
P1361
Phenotypic and genotypic characterisation
of aminoglycoside resistance in Norwegian
clinical isolates of Escherichia coli and
Klebsiella spp.
B. Haldorsen*, K. Hegstad, G.S. Simonsen,
A. Sundsfjord, Ø. Samuelsen
on behalf of the Norwegian Study Group on
Aminoglycoside Resistance
P1362
Carbapenemase-producing Acinetobacter
spp. in Kyoto University Hospital, Japan:
the occurrence of metallo-beta-lactamases
M. Yamamoto*, K. Yasuma, Y. Matsumura,
A. Matsushima, M. Nagao, Y. Ito, S. Takakura,
S. Ichiyama (Kyoto, JP)
P1363
Evolution of Acinetobacter baumannii clonal
lineages in Greek hospitals over the last
15 years
V. Gogou*, M. Giannouli, E. Voulgari, R. Zarrilli,
A. Tsakris, S. Pournaras
(Larissa, GR; Naples, IT; Athens, GR)
P1364
Spread of imipenem-resistant Acinetobacter
baumannii of European clone II in western
China
C. He*, Y. Xie, H. Fan, M. Kang, C. Tao, R. Zhang,
Y. Hu, Z. Chen, L. Wang
(Chengdu, Hangzhou, Beijing, CN)
Poster Sessions
Sunday, 8 May
Retrospective analysis of carbapenemresistant Acinetobacter baumannii strains
in a tertiary hospital
M. Pirs*, T. Cerar, R. Kofol, M. Mueller Premru,
V. Krizan Hergouth, J. Ambrozic Avgustin,
K. Seme (Ljubljana, SI)
P1373
Penicillin non-susceptible pneumococcal
invasive clones circulating in Italy in the
vaccine era (2006 – 2010)
G. Gherardi*, F. D'Ambrosio, M. Del Grosso,
R. Camilli, D. Visaggio, G. Dicuonzo, A. Pantosti
(Rome, IT)
P1366
Phenotypic and molecular characterisation
of carbapenem-hydrolysing class D
beta-lactamase-producing Acinetobacter
baumannii isolated in Portugal
V. Manageiro*, D. Jones-Dias, E. Ferreira,
D. Louro, M. Caniça on behalf of the Antibiotic
Resistance Surveillance Program in Portugal
(ARSIP)
P1374
Emergence of a macrolide-resistant lineage
among invasive serotype 6C pneumococci
in Spain
D. Rolo, A. Fenoll, C. Ardanuy, L. Calatayud,
M. Cubero, J. Liñares* (Barcelona, Madrid, ES)
P1375
Phenomenal increase in fluoroquinolonenon-susceptibility among clinical group A
streptococci in Belgium during 2007 – 2010
L. Van Heirstraeten*, G. Leten, C. Lammens,
S. Malhotra-Kumar, H. Goossens
on behalf of the Belgian reference centre
for Group A Streptococcus
P1376
Unexpectedly high prevalence of spa
type t008, SCCmec type IV MRSA clone in
Russian paediatric hospitals
A. Romanov*, A. Dekhnich, M. Edelstein,
L. Kozlova, R. Kozlov (Smolensk, RU)
P1377
Clonal dissemination with particular
phenotypes of methicillin-resistant
Staphylococcus aureus isolates from
patients diagnosed with mastitis in
Central Taiwan
W.Y. Wang*, T.S. Chiueh, J.R. Sun, J.J. Lu
(Taichung, Taipei, TW)
P1378
Report from the National Surveillance
Program (2000–2009) of Enterococcus in
Cuba: phenotype and genotype studies
D. Quiñones Pérez*, D. Marrero, M. Abreu,
A. Llop, R. del Campo, R. Gómez Luz,
C. Rubio, P. Goñi, N. Kobayashi
(Havana City, Holguín, CU; Madrid, Zaragoza, ES;
Sapporo, JP)
P1367
Linezolid susceptibility in Europe for 2010:
ZAAPS Program (5,532 strains)
R. Jones*, J. Ross, H. Sader, D. Farrell,
R. Mendes (North Liberty, US)
P1368
Erythromycin resistance of clinical
isolates of Streptococcus pneumoniae
isolated over a thirty-year period in
Barcelona, Spain (1979 – 2008)
L. Calatayud, C. Ardanuy, F. Tubau,
M.A. Dominguez, I. Grau, R. Pallarés,
R. Martín, J. Liñares*
(Hospitalet de Llobregat, ES)
P1369
Serotype distribution of nasopharyngeal
pneumococci among children having acute
otitis media before the introduction of a
pneumococcal conjugate vaccination
programme
K. Vuorenoja*, L. Siira, A. Virolainen, J. Jalava,
P. Huovinen, P.A. Tähtinen, M.K. Laine, A. Ruohola
(Turku, Helsinki, FI)
P1370
Prior use of fluoroquinolones, fluoroquinolone
resistance and gyrA/parC mutations
in Streptococcus pneumoniae in Ontario
A. McGeer*, R. Melano, S. Patel, S. Drews,
K. Green, D.E. Low on behalf of the Canadian
Bacterial Surveillance Network
P1371
Invasive pneumococci in Italy: serotype
changes and antibiotic resistance after
pneumococcal conjugate vaccine
implementation
M. Del Grosso*, R. Camilli, F. D'Ambrosio,
M. Monaco, F. D'Ancona, G. Gherardi, A. Pantosti
(Rome, IT)
P1372
Prevalence and characteristics of
pneumococci colonising adults older than
60 years in Portugal: the PneumoEL project
S. Nunes*, S. Almeida, I. Valadares, S. Martins,
F. Breia, A. Brito-Avô, A. Morais, H. de Lencastre,
R. Sá-Leão (Oeiras, Montemor-o-Novo, PT;
New York, US)
13:30 – 14:30
Posters
P1365
Hand hygiene
P1379
"Hand-hygiene champion junior doctor
picks up the gauntlet": The hand hygiene
re-audit conducted by junior doctors in a
large district hospital of northwest England
M. Przybylo*, L. Moorhouse, A. Guleri
(Blackpool, UK)
P1380
Reliability testing of the WHO Hand
Hygiene Self-Assessment Framework
A. Stewardson*, B. Allegranzi, H. Attar,
T. Perneger, D. Pittet (Geneva, CH)
Final Programme
139
Poster Sessions
Sunday, 8 May
P1381
The Feedback Intervention Trial: a randomised
controlled trial to improve hand-hygiene
compliance in ITUs and acute elderly wards
in 16 hospitals
S. Stone*, C. Fuller, J. Savage, S. Besser,
S. Michie, J. MacAteer, A. Hayward, A. Charlett,
B. Cookson, M. Murray, G. Duckworth,
J. Roberts, L. Teare, A. Jeanes
(London, Chelmsford, UK)
P1382
Linear correlation between the compliance
with hand hygiene and glove using without
indication
M. Eveillard*, V. Guilloteau, B. Lefrancq,
A. Rabjeau, M. Pradelle, V. Bréjon, F. Raymond,
M. Joly-Guillou, P. Brunel (Angers, Nantes, FR)
P1383
Sustaining hand-hygiene compliance
following implementation of the World Health
Organization Hand Hygiene Improvement
Strategy in a tertiary hospital in Saudi Arabia
W. Mazi*, A. Senok, D. Abdullah, S. Al Khaldy
(Taif, Riyadh, SA)
P1384
The short-term and long-term effectiveness
of a multidisciplinary hand hygiene
improvement programme
M. Tromp*, A. Brink-Huis, I. de Guchteneire,
J. van der Meer, T. van Achterberg, M. Hulscher,
C. Bleeker-Rovers (Nijmegen, NL)
P1385
Hospital-wide evaluation of hand disinfectant
tolerability: is sufficient good enough?
B. Bertisch*, B. Schöbi, T. Lehmann, M. Schlegel
(St. Gallen, CH)
P1386
Increase of alcoholic hand disinfection
performance due to new touchless dispensers
S. Scheithauer*, H. Haefner, A. Koch, S. Lemmen
(Aachen, DE)
P1387
Beyond compliance with hand hygiene: watch
out for the WHO hand hygiene technique!
A.F. Widmer*, N. Frey, M. Dangel, M. Battegay,
S. Tschudin Sutter (Basel, CH)
P1388
Healthcare workers’ perceptions of a
programme inviting patients to report
staff hand-hygiene compliance
N. Farquet*, Y. Longtin, A. Gayet-Ageron,
H. Sax, T. Perneger, D. Pittet (Geneva, CH)
Final Programme
Poster Sessions
12:30 – 13:30
Urinary tract infections
P1389
Extended-spectrum beta-lactamase
producing urinary tract infection isolates
V. Skandami-Epitropaki*, M. Papadaki,
A. Xanthaki, A. Karaferi, E. Zampeta,
A. Tsiringa, M. Toutouza-Giotsa (Athens, GR)
P1390
Trends in antimicrobial susceptibility among
bacterial isolates from UTI of Japanese
hospitals participating in the Levofloxacin
Surveillance Group during 1994 – 2010
Y. Ishii*, A. Ohno, K. Tateda, K. Yamaguchi
(Tokyo, JP)
P1391
Clinical impact of fluoroquinolone
resistance in acute pyelonephritis caused
by Escherichia coli
S.J. Kang*, D.R. Chung, S.Y. Park, Y.E. Ha, E.J. Joo,
M.K. Joung, C.I. Kang, K.R. Peck, J.H. Song
(Seoul, KR)
P1392
Clinical predictors for the acquisition of
fluoroquinolone-resistant uropathogens
among patients with community-onset
complicated acute pyelonephritis
Y.K. Cho*, H. Pai, J. Kim, S. Wie, S. Lim, S.Y. Shin,
J.S. Yum, J.S. Lee, K.T. Kweon, H. Lee, H.J. Cheong,
S.H. Park, D.W. Park, S. Ryu, M. Chung
(Incheon, Seoul, Suwon, Jeju, Daegu, Busan, KR)
P1393
P1394
P1395
P1396
Fluoroquinolone resistance in communityacquired urinary tract infections
V. Skandami-Epitropaki*, E. Zampeta,
A. Tsiringa, A. Karaferi, M. Papadaki,
A. Xanthaki, M. Toutouza-Giotsa (Athens, GR)
Nationwide survey of community-acquired
lower urinary tract infections in primary care
D. Arman*, C. Agalar, M. Dizbay, O. Tunccan,
D.T. Keten, G. Aygun, O. Tunger, N. Demirturk,
D. Inan, C. Ozakin, Y. Bayindir, A. Akbulut,
M. Bakir, I. Koksal, M.A. Ozinel, N. Oztoprak,
E. Aktas, Y. Alpay on behalf of the Turkish
urinary infection study group
The emergence of antimicrobial resistance in
various urinary pathogens in Japan
K. Ishikawa* on behalf of the JSC Surveillance
Committee
Urinary pathogens in Greek children:
prevalence and antibiotic resistance trends
over a 5-year period (2005 – 2009)
D. Hatzaki*, E. Vetouli, G. Kalogeras,
N. Palaiologou, G. Antonaki, M. Matsas, E. Lebessi
(Athens, GR)
P1397
The changing pattern of antimicrobial
resistance within 42033 Escherichia
coli isolates from nosocomial, community,
and urology patient-specific urinary tract
infections, Dublin, 1999 – 2009
I.M. Cullen*, R.P. Manecksha, E. McCullogh,
S. Ahmad, R. Grainger, R. Flynn, T. McDermott,
J.A. Thornhill, J. Fennell, P. Murphy (Dublin, IE)
P1398
Aetiology and antibiotic susceptibility
of urinary tract infections in the elderly:
a cohort study
E. De Vecchi*, S. Sitia, R. Mattina, T. Luraschi,
S. Santinato, L. Drago (Milan, IT)
P1399
The influence of menopause on
the species and distribution of causative
bacteria isolated from patients with
acute uncomplicated cystitis and on
the sensitivity to antibacterial agents
T. Matsumoto*, R. Hamasuna, K. Ishikawa,
S. Takahashi, M. Yasuda, H. Hayami, K. Tanaka,
H. Kiyota, T. Muratani, K. Monden, S. Arakawa,
S. Yamamoto (Fukuoka, Toyoake, Sapporo,
Gifu, Kagoshima, Kobe, Jikei, Kyurin, Okayama,
Hyogo, JP)
P1400
Antimicrobial resistance of Escherichia coli
isolates collected from eight urology services
in the EU region Meuse-Rhine, 2009 – 2010
C. van der Donk*, T. Trienekens, E. De Brauwer,
S. Nys, I. Thoelen, W. Kalka-Moll, E. Stobberingh
(Maastricht, Venlo, Heerlen, NL; Hasselt,
Tongeren, BE; Mönchengladbach, DE)
P1401
How do we manage pre-operative quantified
bacteriuria by antimicrobial administration?
J. Hashimoto*, S. Takahashi, T. Uehara,
Y. Kurimura, T. Tsukamoto (Sapporo, JP)
P1402
A randomised clinical trial to evaluate
the preventive effect of cranberry juice
(UR65) for patients with recurrent
urinary tract infection
S. Takahashi*, R. Hamasuna, M. Yasuda,
S. Arakawa, K. Tanaka, K. Ishikawa, H. Kiyota,
H. Hayami, T. Matsumoto on behalf of the
Japanese UTI Research Group
P1403
Clinical and microbiological survey
of indwelling catheter
M. Tinelli*, A. Piatti, L. Pagani, F. Luzzaro,
R. D'Angelo, L. Trezzi, M. Di Stefano, R. Caprioli,
M. Gramegna, L. Zerbi (Sant'Angelo Lodigiano,
Milan, Pavia, Lecco, Bergamo, IT)
Final Programme
141
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
12:30 – 13:30
P1404
Diagnosis of syphilis
Comparison of three treponemal assays for
anti-Treponema pallidum antibodies detection
N. Calvo Sanchez, M.L. Fernández Rueda,
M.N. Gutiérrez Zufiaurre,
A.M. Blázquez de Castro, S. Muñoz Criado,
J.L. Muñoz Bellido* (Salamanca, ES)
P1405
Bioplex 2200, a new treponemic assay
to diagnose syphilis
J. Acosta*, L. Barrado, E. Viedma, A. Fuertes
(Madrid, ES)
P1406
Evaluation of the Liaison® Treponema screen
assay compared to ELISA and CLIA assays
D. Itzhaky*, H. Poran, O. Rozenberg, M. Barak,
G. Blumstein, O. Cooper (Kfar-Saba, Nesher,
Haifa, Abu Kabir, IL)
P1407
12:30 – 13:30
Evaluation of two automated chemiluminescence immunoassays, the Liaison
Treponema screen and the Architect Syphilis
TP, as screening tests for syphilis
N. Wellinghausen* (Ravensburg, DE)
Reliability of immunodiagnostic tests
for diagnosis of alveolar echinococcosis
Y.A. Öner*, G. Adas, H. Uysal, I. Özden,
S. Bayirlioglu (Istanbul, TR)
P1414
Comparison of two methods for detection
and quantification of leptospires in tissue
samples: immunofluorescence-based
leptospiral detection in imprint samples
versus real-time PCR
A.D. Chagas Jr*, C.L. da Silva, D. Athanazio,
C.S. Santos, C.D. Matos Silva, M.G. Reis,
F.W. McBride, A.J. McBride (Salvador, BR)
12:30 – 13:30
IgG avidity maturation with Liaison®
IgG avidity II assay for the diagnosis
of toxoplasmosis in pregnant women
F. Peyron*, J. Chevallier, C. Goy,
C. Garrigou, M. Wallon (Lyon, FR)
P1409
Performance of two rapid tests for the
diagnosis of malaria imported in travellers:
influence of anti-malarial prophylaxis
N. Iglesias*, A. Palmeiro, P. Trevisi, A. Olaiz,
C. Toro, M. Subirats, M. Baquero (Madrid, ES)
P1410
Rapid diagnosing test in malaria screening
P. Davoodian*, A. Daryanavard, R. Safari,
T. Eqbal Eftekhaari, M. Khalilzadeh, S. Fekri,
M. Mehranzadeh (Bandar-Abbas, IR)
P1411
Detection of malaria infection in blood
transfusion: a comparative study among
real-time PCR, rapid diagnostic test and
microscopy
G.R. Hassanpour*, H. Keshavarz, M. Mohebali,
H. Zeraati, E. Azizi, A. Raiisi (Tehran, IR)
Feconomics®: a simple, novel and fast
technique for stool concentration in the
parasitology laboratory
Ö. Kurt*, I. Akyar, S. Görgün, T. Kocagöz,
A. Özbilgin (Manisa, Istanbul, TR)
Final Programme
Serological diagnosis of infections
P1415
Performance of new ELISA IgG anti-Aspergillus
(Platelia Bio-rad) using recombinant proteins
M. Dautigny*, S. Le Cam, O. Cornet, T.D. Ly
(Ivry-sur-Seine, Lyon, FR)
P1416
Evaluation of a new immunochromatographic
assay for the detection of antibodies against
Francisella tularensis
A. Cubero-Ribas, T. Pardo, F. Menegotto,
S. González-Cabrero, P. Gutiérrez,
M.A. Bratos-Pérez, J.M. Delgado, A. Orduña*
(Valladolid, Santa Fe, ES)
P1417
Neuroborreliosis: detection of intrathecally
produced antibodies against Borrelia in
cerebrospinal fluid using the line blot
immunoassay Anti-Borrelia Euroline-RN-AT
W. Meyer*, T. Scheper, A. Ott, B. Kuehn,
S. Falke, L. Persson Rova, K. Steinhagen,
D. Eichhorst, W. Schlumberger, W. Stoecker
(Lübeck, DE; Karlskrona, SE)
P1418
Evaluation of serological tests and clinical
features in patients with culture-positive
brucellosis
A. Al Aska*, I. Al Orainey, A. Kambal,
M. Gad El Rab, M. Al Hedaithy, A. Al Anazi,
S. Al Sobaie, K. Halim, F. Buba, U. Yusuf,
N. Al Anazi (Riyadh, SA)
P1419
Dimeric OspCadv – advanced recombinant
OspC antigens for the sensitive and specific
detection of class IgM antibodies in early
stages of Borrelia infections
A. Ott*, L. Komorowski, C. Probst,
W. Schlumberger, W. Stoecker, T. Scheper,
W. Meyer (Lübeck, DE)
P1420
New liaison® automated immunoassays
for the detection of Mycoplasma pneumoniae
IgG and IgM antibodies in human serum/plasma
specimens
F. Capuano*, B. Grassi, L. Pallavicini, Z. Greenberg,
M. Lipson (Saluggia, IT; Ashdod, IL)
Diagnosis of parasitic infections
P1408
P1412
P1413
Poster Sessions
P1421
PCR versus serology for diagnosing
mycoplasma pneumoniae infection:
a systematic review and meta-analysis
L. Zhang, X.-J. Lv* (Chengdu City, CN)
P1422
Clinical potential of diagnostic methods for
the rapid diagnosis of Mycoplasma
pneumoniae pneumonia in adults
N. Miyashita*, Y. Kawai, K. Ouchi
(Kurashiki City, JP)
P1423
P1424
12:30 – 13:30
P1425
P1426
P1427
Cloning and expression of Helicobacter
pylori cagA C-domain for screening high-risk
populations through a Western blotting assay
M. Esmaili, F. Ebrahimzadeh*, Y. Talebkhan,
S. Saberi Kashani, Z. Karimi, S. Jahangiri,
P. Hassanpour, A. Oghalaie, A. Nahvijoo,
M. Mohagheghi, M. Eshagh Hosseini,
M. Mohammadi (Tehran, IR)
Helicobacter pylori CagA sero-reactivity
and serum pepsinogen levels in developing
gastric cancer screening approaches in
Iranian high-risk populations
Y. Talebkhan*, F. Ebrahimzadeh, M. Bababeik,
A. Farjaddoost, F. Fereidouni,A. Morakabati,
M. Eshagh Hosseini, M. Mohagheghi,
M. Mohammadi (Tehran, Qom, IR)
Immunology, immunopathogenesis and
vaccinology
Time-dependent effect of MBL, TLR2,
TLR4, FcgammaRIIA genes polymorphisms,
treatment and sepsis in invasive
pneumococcal disease mortality
E. García Cabrera, A. Díaz-Martin,
J. Garnacho-Montero*, R. Jiménez-Álvarez,
C. Garnacho-Montero, J. Revuelto-Rey,
J. Aznar for the Spanish Network for the
Research in Infectious Disease
Mannose-binding lectin inhibits
cytomegalovirus capture and transmission
by human primary monocyte-derived
dendritic cells
S.Q. Shang*, Y.H. Chen, R. Tao, H.J. Qiao,
W. Wu (Hangzhou, CN)
Mannose-binding lectin inhibits human
cytomegalovirus infection in human
embryonic pulmonary fibroblasts
W. Wu*, S.Q. Shang, R. Tao, Y.H. Chen, H.J. Qiao
(Hangzhou, CN)
P1428
Association of Toll-like receptor 4
(A896G, C1196T and G1199A) and CD14
(C-159T) polymorphisms with susceptibility
to brucellosis
M. Rasouli*, M. Kalani, S. Kiany, S. Asaei,
A. Moravej (Shiraz, IR)
P1429
IL-15 gene polymorphisms are associated
with resistance to visceral leishmaniasis
M. Rasouli*, S. Asaei, M. Choopanizadeh,
A. Moravej, M. Kalani, S. Kiany (Shiraz, IR)
P1430
The effects of Candida albicans cell
wall protein fractions on dendritic cell
maturation and cytokine secretion
profile by Th1 and Th2 in mice
M. Roudbary*, S. Roudbarmohammadi,
M. Bozorgmehr, S. Moazzeni (Tehran, IR)
P1431
IgG2 and IgG3 subclass response to
merozoite surface protein-2 and malaria
status
A. Khosravi*, E. Asadollahy (Ilam, IR)
P1432
Interleukin-33 induction is correlated with
an efficient hepatic granulomatous response
during experimental Leishmania donovani
visceral leishmaniasis
F. Robert-Gangneux*, O. Rostan, M. Rauch,
M. Samson, J.-P. Gangneux (Rennes, FR)
P1433
Oral intake of heat-killed Lactobacillus
pentosus strain b240 reduces incidence of
acute upper respiratory tract infection in the
elderly: a randomised, double-blind, placebocontrolled trial
M. Toba*, S. Shinkai, T. Saito, I. Sato, M. Tsubouchi,
K. Taira, T. Inamatsu, H. Yoshida, H. Amano,
Y. Fujiwara, N. Kohda (Otsu, Tokyo, JP)
P1434
Cellular immune responses in the ferret
(Mustela putorius furo): tools for
understanding the correlates
of protection and pathogenesis for
pandemic influenza and Dengue fever
G. Manukian*, S. Naveen, M. Chen, R. Cross,
C. Garry, B. Kaplan, G. Nichols, T. Voss
(New Orleans, US)
P1435
Increased activated and proliferating
T-cells in acute respiratory distress
syndrome with altered CD28 and CTLA-4
expression in humans
G. Kumar*, K. Risso, C. Marquette,
C. Sanfiorenzo, P. Dellamonica, P.M. Roger,
A. Bernard (Nice, FR)
Final Programme
143
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
P1437
Production of human beta-defensin-1
in the urinary tract and its correlation
to uncomplicated urinary tract infection
in women
K.L. Nielsen*, P.S. Andersen, N. Frimodt-Møller
(Copenhagen, DK)
P1438
AZD9773 is a novel selective anti-TNF-a
ovine polyclonal immune Fab
P. Newham*, A. Heier, F. Brennan, P. Ceuppens,
J. Growcott (Macclesfield, UK)
12:30 – 13:30
P1439
Safety of hepatitis B, pneumococcal,
and meningococcal vaccines in pregnancy:
evaluation of the published evidence
M. Makris, K. Polyzos, M. Mavros, S. Athanasiou,
P. Rafailidis*, M. Falagas (Athens, GR)
Process development of an affordable
bivalent conjugate vaccine against the two
major causes of enteric fever, Salmonella
typhi and Salmonella paratyphi A
S. Kothari*, J.A. Kim, N. Kothari, R. Carbis
(Seoul, KR)
P1441
Development of chimeric peptides based
on group B streptococcal surface proteins
as potential vaccine components
A. Lanskova, M. Samoilovich, I. Krutetskaya,
T. Gupalova, K. Grabovskaya, A. Suvorov*
(Saint-Petersburg, RU)
P1443
P1444
Safety and immunogenicity of an inactivated
pandemic H1N1 vaccine provided by the Thai
Ministry of Public Health as a routine public
health service
O. Kankawinpong, C. Sangsajja, A. Chonlapan,
W. Manosuthi*, V. Thientong, P. Noitung,
P. Puthavathana (Nonthaburi, Bangkok, TH)
P1446
Preclinical development of a bio-conjugate
vaccine against Staphylococcus aureus
disease
V. Gambillara*, J. Lee, K.A. Kelley, K. Shields,
M. Shields, C. Alaimo, D. Desgrandchamps,
G. Lipowsky, M. Kowarik, M. Wacker
(Schlieren, CH; Boston, US)
Vaccines – miscellaneous
P1440
P1442
P1445
Effectiveness versus efficacy of conjugated
pneumococcal vaccine: a systematic review
of randomised, controlled trials with metaanalysis examining absolute risk reduction
and relative risk
J. Puliyel*, J. Mathew, N. Vashisht, V. Sreenivas
(Delhi, Chandigarh, IN)
HPV vaccine awareness and willingness
of first-year students entering university
in western Turkey
R. Durusoy*, M. Yamazhan, M. Tasbakan,
I. Ergin, M. Aysin, H. Pullukçu, T. Yamazhan
(Izmir, TR)
Vaccine status of Streptococcus pneumoniae
evaluated with a 12 plex luminex based
method: comparison of data from a 6 plex
ELISA versus a 12 plex luminex method
B. Kantsø*, K. Krogfelt, C. Jørgensen
(Copenhagen, DK)
Final Programme
12:30 – 13:30
Miscellaneous
P1447
Chelation of nickel cations by the urinary
antimicrobial nitroxoline (5-nitro-8 hydroxyquinoline) inhibits urease activity
and stone formation in clinical isolates
of Proteus mirabilis
A. Sobke*, S. Sachse, C. Bär, C. Ranke,
E. Straube, W. Pfister (Jena, DE)
P1448
Uncovering the mechanism of action of the
phenothiazine, thioridazine, using Salmonella
typhimurium as a model bacterium
M.P. McCusker*, M.S. Martins, M. Viveiros,
L. Amaral, S. Fanning (Dublin, IE; Lisbon, PT)
P1449
Fluoroquinolones induce the expression
of smaqnr, a chromosome-encoded quinolone
resistant determinant, in Serratia marcescens
A. Briales, J.M. Rodríguez-Martínez*,
C. Velasco, Á. Pascual (Seville, ES)
P1450
The biological fitness cost and mutation
frequency associated with MDR development
P. Komp Lindgren*, O. Klockars, H. Seifert,
O. Cars (Uppsala, SE; Cologne, DE)
P1451
Effect of colistin exposure and growth
phase on the surface properties of live
Acinetobacter baumannii cells examined
by atomic force microscopy
R. Soon, R. Nation, M. Harper, B. Adler, J. Boyce,
R. Tan, J. Li*, I. Larson (Melbourne, AU)
P1452
Ribosomal mutations associated
with ketolide resistance in Haemophilus
influenzae found in the SENTRY
Antimicrobial Surveillance Program
D. Farrell*, L. Deshpande, R. Mendes, R. Jones
(North Liberty, US)
Poster Sessions
Monday, 9 May
Effect of E-101 solution and its oxidative
products on microbial ultrastructure changes
associated with microbicidal action
G.A. Denys*, M.P. Goheen, R.C. Allen, P. O'Hanley,
J.T. Stephens, Jr.
(Indianapolis, Omaha, Little Rock, US)
P1454
Antibacterial mode of action and resistance
studies with the silver cation (Ag+) in
C. Randall*, L. Oyama, J. Bostock,
I. Chopra, A.J. O'Neill (Leeds, UK)
P1455
P1456
Detection of lymphogranuloma venereum
based on the deletion in pmpH gene
may underestimate the extension of the
European outbreak
M. Rodriguez-Dominguez*, T. Puerta,
J.M. Gonzalez-Alba, B. Menéndez,
F.J. Gonzalez-Sainz, R. Cantón,
J. del Romero, J.C. Galán (Madrid, ES)
Pharmacoeconomic analysis of perioperative
antibiotic prophylaxis application in
Lombardy, Italy
P. Scarpellini*, G. Vighi, E. Spreafico, G. Barranco,
V. Conti, C. Tassan Din, G. Genduso
on behalf of the PAC Project Regional Group
P1462
Viral infections and analysis of circulating
immune complexes in patients with Nijmegen
breakage syndrome, a cancer-prone disease
with profound immunodeficiency
H. Gregorek, A. Zapasnik*, K.H. Chrzanowska,
B. Kasztelewicz, B. Pietrucha,
E. Heropolitanska-Pliszka,
K. Dzierzanowska-Fangrat (Warsaw, PL)
P1463
Studies on sepsis in haemodialysis patients
H. Iwabuchi*, T. Nakahara, M. Okamoto,
M. Asano, K. Oguchi, K. Tateda, K. Yamguchi
(Tokyo, JP)
P1464
Fluorine-18 fluoro-2-deoxy-D-glucose
positron emission tomography/computed
tomography (PET/CT) contributes to the
diagnosis and management of patients with
brucellar spondylodiscitis
S. Ioannou*, S. Chatziioannou,
S. Pneumatikos, N. Sipsas (Athens, GR)
12:30 – 13:30
Bloodstream infections
P1465
A randomised controlled trial on the clinical
significance of use of PCR for 16S ribosomal
DNA and sequencing in patients with
bacteraemia
C. Moser*, M. Bjørnsdottir, P. Rammer,
J. Lorenzen, T. Thomsen, P. Nielsen, N. Høiby,
T. Bjarnsholt (Copenhagen, Aarhus, Aalborg, DK)
P1457
Granulomatous diseases following
treatment with anti-TNF therapies
D. Ersozlu Bozkirli, T. Turunc*, A. Gorek Dilektasli,
E. Yucel (Adana, Ankara, TR)
P1458
Campylobacter bacteraemia:
a 10-year experience in a single centre
K. Hussein*, Y. Shachor Meyouhas,
A. Raz-Pasteur, I. Oren, R. Finkelstein,
I. Kassis (Haifa, IL)
P1466
A single-centre epidemiological study
of E. coli bacteraemia, antibiotic resistance,
and association with hospital exposure
C. Jeppesen*, A. Claxton, B. Muller-Pebody,
K. Henderson, E. Sheridan (London, UK)
P1459
Therapeutical approach and prognostic
factors in Listeria monocytogenes meningitis
I. Pelegrin*, A. Ribera, C. Suarez, M. Moragas,
R. Verdaguer, S. Martínez-Yelamos, F. Gudiol,
P.F. Viladrich, C. Cabellos
(L'Hospitalet de Llobregat, ES)
P1467
Predictors of bloodstream infection in
673 episodes of bacteraemia with
coagulase-negative staphylococci
L. Elzi*, N. Vögeli, M. Dangel, M. Battegay,
R. Frei, A.F. Widmer (Basel, CH)
P1468
P1460
Distinctive characteristics of pneumococcal
meningitis in cirrhotic patients
P. Pagliano*, V. Attanasio, M. Rossi, F. Fraganza,
N. Carannante, A. Pomicino, R. Di Sarno,
M. Conte, F. Faella (Naples, IT)
Bloodstream infection in patients with
kidney disease. Risk factors for poor
outcome and mortality
L. Rojas, P. Muñoz*, M. Kestler, D. Arroyo,
M. Rodríguez-Créixems, E. Verde, E. Bouza
(Madrid, ES)
P1461
Infections by Corynebacterium species in
immunocompromised and non-immunocompromised patients
I. Fernández-Natal*, J.A. Sáez-Nieto,
S. Valdezate-Ramos, R.H. Rodríguez-Pollán,
S. Lapeña , J.M. Guerra-Laso, F. Soriano García
(León, Madrid, ES)
P1469
Capsular types and genetic relatedness
of Klebsiella pneumoniae isolates causing
recurrent bloodstream infection
C.Y. Liu*, P.R. Hsueh, C. Liao, J. Wang, Y. Huang
(Taipei, TW)
Final Programme
145
Posters
P1453
Poster Sessions
Monday, 9 May
P1470
A 5-year retrospective review of BSI in a
national bone marrow transplantation unit
M. Fraher*, M. Kelleher, E. Conneally,
B. O'Connell (Dublin, IE)
P1471
Candidaemia in an intensive care unit:
epidemiology and predisponent risk-factors
C. Ruiz de Alegría Puig*, M.A. Ballesteros Sanz,
J.L. Teja Barbero, C. Fernández-Mazarrasa,
M. Gutiérrez Cuadra, L. Martínez-Martínez
(Santander, ES)
P1472
Can syndromic surveillance based on crude
mortality serve as a tool for monitoring
healthcare-associated bloodstream
infection?
H. Richet*, V. Loffeier, N. Cassir, D. Raoult
(Marseille, FR)
P1473
Bacterial bloodstream infections in
a newly constructed medical centre in
Saint Petersburg, Russia
N.E. Pestova, N.S. Rybkova (St. Petersburg, RU)
P1474
Coagulase-negative Staphylococcus
bacteraemia: a prospective study
of clinical and microbiological predictors
of true bacteraemia
A. Fernández-Rufete*, E. García-Vazquez,
J. Ruiz, A. Hernández-Torres, E. Moral-Escudero,
H. Albendin, J.A. Herrero, J. Gómez-Gómez,
L. Martinez-Lage, T. García-Lucas (Murcia, ES)
P1475
Comprehensive analysis of the impact
of empirical therapy in the mortality
of bloodstream infections
P. Retamar*, M. López-Prieto, M. Portillo,
C. Natera, E. Nuño, M. Herrero, A. Arco,
A. Muñoz, F. Téllez, M. Torres, A. Martin,
S. Pérez-Cortes, R. Moya, J.E. Corzo-Delgado,
L. Leónn, M.A. Martinez, J. Rodriguez-Baño
on behalf of SAEI-SAMPAC.
P1476
Clinical features and prognosis of bacteraemia
caused by Acinetobacter lwoffii
H. Tsai*, Y. Huang, C. Liao, P.R. Hsueh
(Taipei, TW)
P1477
Bloodstream infections due to ESBL-producing
Escherichia coli can be safely treated with
active beta-lactam/beta-lactam inhibitors
J. Rodríguez-Baño*, M. Navarro, P. Retamar,
E. Picón, L. López-Cerero, A. Pascual
(Seville, ES)
Final Programme
P1478
Trends of nosocomial bloodstream infection
incidence in a haematology department,
Edouard Herriot hospital, Lyon (France),
2004 – 2009: a surveillance-based study
C. Dell’Agostino, T. Bénet, D. Lutringer,
M. Michallet, M. Nicolle, P. Cassier, P. Vanhems*
(Lyon, FR)
P1479
Pathogenic profiles of bloodstream
infections in a West China hospital
C. He*, Y. Xie, M. Kang, C. Tao, B. Xie, H. Fan,
L. Wang (Chengdu, CN)
P1480
Few blood cultures – few infections?
P. Gastmeier*, F. Schwab, M. Behnke, C. Geffers
(Berlin, DE)
P1481
Influence of the timing of therapeutic
interventions on the outcome of catheterassociated Staphylococcus aureus
bacteraemia: is there a need for speed?
S.C. de Ruiter, P.M. Ellerbroek, D.J. Hetem,
A.G. Buiting, J. Kluytmans, S. Thijsen,
B.J. Vlaminckx, R.G. Wintermans, M.J. Bonten,
M.B. Ekkelenkamp* (Utrecht, Tilburg, Breda,
Nieuwegein, Roosendaal, NL)
P1482
Healthcare-associated versus hospitalacquired Staphylococcus aureus bacteraemia
H. Shaked*, M. Paul, J. Bishara (Petah Tikva, IL)
P1483
Impact of infectious diseases consultation
on outcome of methicillin-resistant
Staphylococcus aureus bacteraemia in a
tertiary care centre: a ten-year experience
F. Tissot*, T. Calandra, G. Prod'hom,
D.S. Blanc, G. Zanetti, G. Greub, L. Senn
(Lausanne, CH)
P1484
Clinical and molecular characterisation
of Staphylococcus aureus bloodstream
infections in a university hospital, Italy
F. Tordato*, E. Borghi, M. Cainarca, F. Crippa,
G. Morace, A. d'Arminio Monforte (Milan, IT)
P1485
Intensive care unit candidaemia:
a 2-year retrospective analysis in a Greek
tertiary-care hospital
V. Mamali*, G. Vrioni, M. Drogari-Apiranthitou,
A. Prekates, K. Themeli-Digalaki,
A. Mitroussia-Ziouva, A. Tsakris
(Piraeus, Athens, GR)
P1486
Epidemiology of candidaemia in an Italian
tertiary hospital during a 7-year period:
January 2004 – November 2010
A.M. Azzini, M. Cordioli*, G. Lo Cascio,
P. Sette, E. Concia (Verona, San Bonifacio, IT)
Poster Sessions
Monday, 9 May
Pre-exposure to antifungals as a risk factor
for fluconazole-non-susceptible Candida
species in hospitalised patients with
candidaemia
D. Shah*, R. Yau, J. Weston, T. Lasco, M. Salazar,
H. Palmer, K. Garey (Houston, San Antonio, US)
P1488
Sepsis in critically ill patients in Swedish
intensive care units
G. Fransson, L. Nilsson, A. Petropoulos,
S. Walther, H. Hanberger* on behalf of the
ICU-Strama and Swedish Intensive Care Registry
P1489
P1490
P1491
P1492
P1493
P1494
Risk factors of nosocomial bacteraemia
in intensive care units vary between
causative agents: results of a prospective
surveillance data from 2003 to 2006
N. Khanafer*, P. Vanhems (Lyon, FR)
Antimicrobial resistance in ICU-acquired
bacteraemias in 13 European intensive
care units
L.P. Derde, M.J. Dautzenberg, P.J. van Duijn*,
C. Brun-Buisson, M.J. Bonten
on behalf of the MOSAR research consortium
Bacteraemia and antibiotic resistance
of its pathogens reported in Greece between
2000 and 2009: trend analysis
M. Polemis*, K. Trifinopoulou, S. Chrisochoidou,
M. Panopoulou, E. Platsouka, K. Tzanetou,
V. Galanopoulou, E. Skouteli, C. Koutsia-Carouzou,
K. Poulopoulos, M. Anagnostopoulou, M. Toutouza,
K. Aveliodi, A. Pasxali, K. Dimarogona,
P. Karampogia, A. Petridis, A. Mavridis, E. Tsorlini,
E.M. Fakiri, S. Nikolaou, E. Kaitsa-Tsiopoulou,
G. Stamatopoulou, A. Vatopoulos
(Vari, Thessaloniki, Alexandroupolis, Athens,
Corfu, Ioannina, Xanthi, GR)
Resistance evolution in antibiotics of the
most prevalent Gram-negative bacteria
isolated from blood cultures in ICU patients
during eight years (2002 – 2009)
M. Orfanidou, M. Kamperogianni, E. Vagiakou*,
G. Ganteris, P. Afentoglou, A. Karabinis,
E. Malamou-Lada (Athens, GR)
Burden of resistance: mortality and hospital
stay attributable to antibiotic-resistant
Staphylococcus aureus and Escherichia coli
bacteraemias in Europe
M.E.A. de Kraker*, P.G. Davey, H. Grundmann
(Bilthoven, NL; Dundee, UK)
Empiric antibiotic therapy and multidrugresistant Gram-negative bloodstream
infections in critically ill patients:
does colonisation status make a difference?
A preliminary study
A. Mosca*, L. Dalfino, G. Tzakis, M. Spada,
S. Coppolecchia, F. Bruno, G. Miragliotta (Bari, IT)
P1495
12:30 – 13:30
Gram-negative bacterial bloodstream
infections: resistance patterns and risk
factors
A. Hristea, I. Olaru*, O. Dorobat, M. Nica, M. Ion,
V. Petcu, C. Tenea, I. Badicut, R. Moroti, V. Arama,
C. Popescu, A. Rafila, E. Ceausu (Bucharest, RO)
Influenza miscellaneous
P1496
Factors associated with death or ICU
admission due to pandemic 2009 influenza
A/H1N1 infection
A. Moradi*, P. Tabarsi, S.A. Nadji, M. Marjani,
P. Baghaei, D. Mansouri (Tehran, IR)
P1497
Two-site intradermal influenza vaccination
in elderly
S. Sibunruang* (Bangkok, TH)
P1498
Immunogenicity of whole virion pandemic
influenza H1N1 vaccine in HIV-infected
patients
H. Lagler*, K. Grabmeier-Pfistershammer,
V. Touzeau-Römer, S. Tobudic, J. Leitner,
G. Gualdoni, M. Redelberger-Fritz,
S. Neumüller-Guber, T. Popow-Kraupp,
A. Rieger, H. Burgmann (Vienna, AT)
P1499
Pandemic influenza on a military ship:
retrospective investigation of an influenza
A/H1N1pdm outbreak on an Italian military
ship cruising in the Mediterranean Sea,
May – September 2009
D. Lapa*, C. Castilletti, M. Tarabbo, P. Tommaselli,
R. Guarducci, G. Lucà, A. Emanuele, O. Zaccaria,
V. La Gioia, E. Girardi, M.R. Capobianchi,
G. Ippolito (Rome, Taranto, IT)
12:30 – 13:30
Assessing antimicrobial therapy in animals
P1500
Diffusion of ofloxacin in the endocarditis
vegetation assessed with synchrotron
radiation UV fluorescence microspectroscopy
E. Batard*, F. Jamme, S. Villette,
E. Montassier, G. Potel, M. Réfrégiers
(Nantes, Gif-sur-Yvette, Orléans, FR)
P1501
Bone tissue distribution of gentamycin and
vancomycin from polymethylmethacrylate
intramedullary nails in experimental
osteomyelitis model (MRSA infection)
E. Bertazzoni Minelli *, A. Benini,
T. Della Bora, M. Fini, G. Giavaresi, R. Giardino
(Verona, Bologna, IT)
Final Programme
147
Posters
P1487
Poster Sessions
Monday, 9 May
P1502
In vivo efficacy of ceftaroline in a methicillinresistant and PVL-producing Staphylococcus
aureus pneumonia rabbit model
D. Croisier-Bertin*, D. Biek, D. Hayez,
S. Rousseau, D. Labrousse, C. Badiou,
M. Dumitrescu, F. Vandenesch, G. Lina,
J. Etienne, L. Piroth, P. Chavanet
(Dijon, FR; Oakland, US; Lyon, FR)
P1503
Experimental infections caused by
oxacillin-susceptible mecA-positive
Staphylococcus aureus clinical isolates
treated by oxacillin versus vancomycin
G. Michail, M. Labrou*, C. Stathopoulos,
A. Tsakris, S. Pournaras (Larissa, Athens, GR)
P1504
Assessment of linezolid, vancomycin, and
rifampicin as monotherapy in comparison
with combination of linezolid/rifampicin and
vancomycin/rifampicin in the treatment
aureus acute osteomyelitis
C. Jacqueline*, G. Amador, C. Desessard,
V. Le Mabecque, A.F. Miegeville, J. Caillon,
G. Potel (Nantes, FR)
12:30 – 13:30
P1505
P1506
P1507
P1508
P1509
New antimicrobials: preclinical and clinical
studies
Efficacy of human simulated ceftaroline
exposures against phenotypically diverse
Staphylococcus aureus in a mouse thigh
model
R. Keel*, J. Crandon, D. Nicolau (Hartford, US)
Treatment of renal abscesses caused
by Staphylococcus aureus MW2, using
delafloxacin and moxifloxacin
Y. Ding*, R. Villet, J. Lee, D. Hooper (Boston, US)
Antisense phosphorodiamidate morpholino
oligomers inhibition of Burkholderia cepacia
complex
D. Greenberg, K. Marshall-Batty, P. Iversen*,
B. Geller (Dallas, Bothell, US)
Efficacy of a LRS inhibitor GSK2251052
against Enterobacteriaceae isolates using
a computer-controlled infusion system
to recreate human PK profiles in rats
C. Singley*, R. Page, J. Hoover, P. Elefante,
P. DeMarsh (Collegeville, US)
Broad-spectrum fluorocycline TP-434
has oral bioavailability in humans
A. Leighton*, I. Zupanets, N. Bezugla,
L. Plamondon, G. Macdonald, J. Sutcliffe
(San Francisco, US; Kharkov, UA; Watertown, US)
Final Programme
P1510
MUT056399: a single intravenous ascending
dose study in healthy human volunteers
C. Soulama-Mouzé*, A. Bryskier, D. Chassard,
S. Fischer (Paris, Rennes, FR)
P1511
Phosphorodiamidate morpholino
oligomer RNA therapeutics cross the bloodbrain barrier of healthy volunteers
S. Shrewsbury*, P. Iversen (Bothell, US)
P1512
The effect of H2 blockade and food
on the pharmacokinetics of GSK1322322
in healthy subjects
O.J. Naderer*, L.S. Jones, J.Z. Zhu,
M. Kurtinecz, E.F. Dumont
(Research Triangle Park, Upper Merrion, Upper
Providence, US)
P1513
Phase I study with the novel Pseudomonas
aeruginosa antibiotic POL7080 in healthy
volunteers
D. Wilbraham, S. DeMarco, A. Ograbek,
J. Agren, A. Wach, D. Obrecht, K. Dembowsky*
(London, UK; Allschwil, CH; Uppsala, SE)
P1514
PMX30063 – understanding neuronal
effects in multi dose-phase 1 clinical study
B. Korczak*, R. Echols, E. Walters
(Radnor, Easton, US)
P1515
A phase 1 trial to evaluate the tolerability,
safety and pharmacokinetics of multi-dose
intravenous regiments of PMX30063
B. Korczak*, E. McAllister (Radnor, US)
P1516
Assessment of the venous tolerability
of torezolid phosphate infused via a
peripheral catheter: a novel approach
K.A. Muñoz, P. Bien, P. Prokocimer*
(San Diego, US)
P1517
The effect of food on the oral bioavailability
of AFN-1252 in healthy human subjects
N. Kaplan*, B. Hafkin (Toronto, CA; Austin, US)
P1518
Pharmacokinetic and pharmacodynamic
modelling of the anti-staphylococcal activity
of AFN-1252 in humans
N. Kaplan*, J.R. Koup, B. Hafkin
(Toronto, CA; Ann Arbor, Austin, US)
P1519
Pharmacokinetics of CXA-101/tazobactam
in subjects with mild or moderate renal
impairment
E. Hershberger*, D. Benziger, L. Pheng,
M. Trinh, J. Marier, I. Friedland
(Lexington, US; Montreal, CA)
P1520
CXA-101/tazobactam probability of target
attainment using population pharmacokinetic
analysis
E. Hershberger*, M. Mouksassi, J. Steenbergen,
D. Benziger, F. Fenneteau, J. Marier, I. Friedland
(Lexington, US; Montreal, CA)
Poster Sessions
Monday, 9 May
Safety, tolerability, and pharmacokinetics
of a novel Gram-negative antimicrobial,
GSK2251052, in healthy subjects
L.T. Zane*, S. Shakib, R. Milne, L. Liu, S. Baker,
F.A. Heerinckx (Palo Alto, US; Adelaide, AU)
P1522
Antifungal activity of the Neosartorya
fischeri antifungal protein against
filamentous fungal isolates from clinical
sources
L. Kovács*, M. Virágh, M. Takó, T. Papp,
C. Vágvölgyi, L. Galgóczy (Szeged, HU)
P1523
In vitro susceptibility of Cryptococcus
neoformans preincubated with anti-Hsp90
to many antifungal agents
R. Alakeel* (Riyadh, SA)
P1524
BC-3781: evaluation of the CYP3A
interaction potential
U. Schmidt, W.W. Wicha, F. Obermayr*,
R. Novak, W. Prince (Vienna, AT)
P1525
Antimicrobial peptides with antiviral activity
against a novel bunyavirus
Q. Bian*, Y. Chi, Y. Li, X. Guo, Z. Shi, H. Wang
(Nanjing, CN)
P1526
Phosphorodiamidate morpholino
oligomer RNA therapeutics for neuroinvasive
infectous disease
S. Shewsbury*, P. Iversen (Bothell, US)
P1527
AVI-6006 for the treatment of Dengue viral
infections
P. Iversen*, S. Crumley, D. Mourich, S. Perry,
S. Shresta, T. Voss
(Bothell, LaJolla, New Orleans, US)
12:30 – 13:30
P1528
P1529
P1530
Dalbavancin versus linezolid for
acute bacterial infections of the skin:
a comparison of early and standard
outcome measures in study VER001-009
M. Dunne*, G. Talbot, A. Das (Morristown,
Philadelphia, San Francisco, US)
P1531
Integrated safety analysis of CANVAS
and FOCUS studies: randomised, doubleblinded, phase 3 studies of ceftaroline
versus comparators in complicated
skin and skin structure infection and
community-acquired bacterial pneumonia
D. Rank*, T. Baculik, P.B. Eckburg, A. Smith,
J. Laudano, H.D. Friedland (Oakland, US)
P1532
Efficacy and safety of ceftazidime/
NXL104 plus metronidazole vs. meropenem
in the treatment of complicated intraabdominal infections in hospitalised adults
C. Lucasti*, I. Popescu, M. Ramesh, J. Lipka,
C. Sable (Somers Point, US; Bucharest, RO;
Bangalore, IN; Wilmington, US)
P1533
Efficacy, safety and tolerability of ceftazidime/
NXL104 vs. imipenem cilastatin in the
treatment of complicated urinary tract
infections in hospitalised adults
J. Vazquez*, L.D. Gonzalez Patzan, J. Lipka,
C. Sable (Detroit, US; Guatemala City, GT;
Wilmington, US)
12:30 – 13:30
Characteristics of bacterial isolates
from a phase 2 study of oritavancin for
treatment of acute bacterial skin and
skin structure infections
F.F. Arhin*, I. Sarmiento, G. Moeck
(Ville Saint Laurent, CA)
Clinical trials with antibacterials
P1534
Linezolid and vancomycin in the treatment
of lower extremity complicated skin and skin
structure infections caused by methicillinresistant Staphylococcus aureus by vascular
disease status
T. Duane*, C. Thompson, L. Puzniak, D. Huang,
A. Reisman, J. Weigelt
(Richmond, Collegeville, Milwaukee, US)
P1535
The impact of linezolid versus vancomycin
treatment on the resolution of local signs
of inflammation of complicated skin and skin
structure infections caused by culture proven
A. Tice*, O. Equils, D. Huang, D. Stevens
(Honolulu, Collegeville, Boise, US)
P1536
Linezolid versus vancomycin in the treatment
of healthcare-associated pneumonia caused
by culture-proven methicillin-resistant
M. Bassetti*, D. Kett, S. Puttagunta, E. Scerpella,
P. Biswas, D. Huang
(Genoa, IT; Miami, Collegeville, US)
New antimicrobials: phase 2-3 studies
In a phase 2 complicated skin and soft
tissue infections trial, outcomes assessed
early in the course of therapy were
consistent with outcomes 10–17 days
after completing therapy with either
omadacycline (OMC; PTK796) or linezolid
H. Hait, R. Arbeit, D. Molnar, G.J. Noel*,
S.K. Tanaka (Boston, US)
Posters
P1521
Final Programme
149
Poster Sessions
Monday, 9 May
P1538
P1539
P1540
Evaluation of safety and tolerability
of daptomycin doses >=8 mg/kg/day:
results from 270 patients in the European
Cubicin® Outcomes Registry and
Experience (EU-COREsm)
R. Utili*, P. Dohmen, Z. Dailiana,
F. Nacinovich, B. Almirante, A. Galloway,
M. Heep, U. Trostmann, Y. Yin, R.L. Chaves
(Naples, IT; Berlin, DE; Larissa, GR; Buenos
Aires, AR; Barcelona, ES; Newcastle upon Tyne,
UK; Basel, CH; East Hanover, US)
Results from an observational study:
daptomycin is safe and well tolerated
in patients receiving haemodialysis
P. Nikolaidis*, A. Simon, S. Suefke, I. Lampreabe
Gaztelu, P. Dohmen, G. Petrikkos, A. Manzano
Ramírez, W. Jabs, A. Beiras-Fernandez,
M. Scialabba, M. Heep, Y. Yin, R.L. Chaves
(Thessaloniki, GR; Hannover, Lübeck, DE;
Bizcaia, ES; Berlin, DE; Athens, GR; Vitoria-Gasteiz,
ES; Munich, DE; Cefalù, IT; Basel, CH; East
Hanover, US)
Treatment of multi-resistant typhoid
fever with tigecycline: the first 10 cases
H. Laferl, P. Pongratz, G. Tucek, J. Leitner,
C. Wenisch* (Vienna, AT)
P1546
Single-dose doxycycline for the treatment
of Mediterranean spotted fever
A. Toumi*, A. Aouam, F. Ben Romdhane,
H. Ben Brahim, C. Loussaief, M. Chakroun
(Monastir, TN)
P1547
A randomised, placebo-controlled trial
of trimethoprim-sulfamethoxazole plus
doxycycline versus trimethoprimsulfamethoxazole alone for eradication
phase treatment of melioidosis
P. Chetchotisakd*, W. Chierakul, V. Chaowagul,
W. Susaenrat, S. Piphitaporn, J. Pilaikul,
P. Mootsikapun, S. Anunnatsiri,
D. Limmathurotsakul, B. Thinkhamrop,
N. Day, S. Peacock (Khon Kaen, Bangkok, Ubon
Ratchathani, Udon Thani, Mahasarakam, TH)
P1548
Moxifloxacin versus ceftriaxone in the
treatment of primary pyogenic liver abscess:
a prospective, randomized, open-labelled,
active-controlled trial
S.S.J. Lee*, K. Wu, Y. Ni, C. Sy, C. Kao, J. Chen,
Y. Wang, H. Tsai, S. Wann, Y.S. Chen
(Kaohsiung, TW)
P1549
Outcome of initial ciprofloxacin treatment
for bloodstream infections caused by
extended-spectrum beta-lactamase
producing E. coli and K. pneumoniae
J. Son*, J.H. Song, C.I. Kang, D.R. Chung,
K.R. Peck, K. Ko, J. Yeom, H. Ki, S.W. Kim,
H.H. Chang, S. Ryu, Y.S. Kim, S. Jung, S.S. Lee,
K.T. Kwon, H. Lee, C. Moon
on behalf of the Korean Network for Study
of Infectious Diseases (KONSID)
P1541
Tigecycline as a therapeutic option in
Stenotrophomonas maltophilia infections
Y. Tezer Tekçe*, A. Erbay, H. Çabadak, S. Sen
(Ankara, Yozgat, TR)
P1542
Effectiveness and safety of colistin therapy:
a study in a tertiary hospital in Korea
E.J. Choo*, M.H. Jeon, E.J. Lee, Y. Kwak
(Bucheon, Goyang, KR)
P1550
An observational, follow-up study in
a clinical cohort of Clostridium difficile
infection patients comparing three initial
treatment regimes
J. Leitner*, D. Schmid, H. Kuo, V. Michl,
F. Allerberger, C. Wenisch (Vienna, AT)
Efficacy and safety of 5-day therapy
with cefixime versus ciprofloxacin for
uncomplicated urinary tract infections in
women: randomised, controlled study
E. Dovgan*, V. Rafalskiy, V. Galkin, I. Malev
(Smolensk, RU)
P1551
Pivmecillinam in the treatment of ESBLproducing Escherichia coli
G. Schön*, K. Hedin, M. Sundqvist (Växjö, SE)
P1552
Comparative effectiveness of 1 dose versus
3 weekly doses of benzathine penicillin in
treatment of early syphilis in HIV-infected
patients
H. Wu*, C. Yang, Y. Lin, H.C. Lee, N. Lee, W. Ko,
W. Liu, C. Hung, S.C. Chang
(Taipei County, Taichung, Tainan, Taipei, TW)
P1543
P1544
P1545
A randomised, double-blind, placebocontrolled pilot study to assess the effect
of rifaximin “chaser” to prevent recurrent
diarrhoea in patients with Clostridium
difficile infection
K. Garey*, S. Ghantoji, D. Shah, M. Habib,
V. Arora, Z.D. Jiang, H. DuPont (Houston, US)
Comparison of doxycycline-streptomycin,
doxycycline-rifampin and ofloxacin-rifampin
in the treatment of human brucellosis
S. Hashemi*, L. Gachkar, F. Keramat, M.
Mamani, M. Hajilooi, A. Janbakhsh, M. Majzoobi,
H. Mahjub (Hamedan, Tehran, Kermanshah, IR)
Final Programme
Poster Sessions
Monday, 9 May
P1553
P1554
P1555
P1556
P1557
P1558
P1559
P1560
Paediatric infections: preclinical and clinical
data
The impact of HIV-1 infection on B-cell
subpopulations in children
C. Bertaina*, F. Mignone, S. Garazzino,
D. Montin, F. Licciardi, E. Ricotti, C. Calitri,
C. Gabiano, P.A. Tovo (Turin, IT)
Detection of both known and newly identified
viruses in children hospitalised for acute
respiratory infections
A. Zappa, M. Martinelli*, D. Dilillo, E. Galli,
F. Salvini, M. Giovannini, E. Riva, A. Amendola,
G. Zuccotti (Milan, IT)
Transmission of pertussis to 2 young infants:
identification of their mothers as the
potential source of infection
A. Zouari*, H. Smaoui, S. Bousnina, A. Kechrid
(Tunis, TN)
Pertussis cases in the paediatric department
of a university hospital
L. Oksuz*, N. Gurler, S. Hancerli Torun, A. Somer,
N. Salman (Istanbul, TR)
Serotype distribution of Streptococcus
pneumoniae isolated from Argentinian
paediatric patients
V. Reijtman, S. Fossati, C. Hérnandez,
P. Sommerfleck, P. Bernaldez, M. Litterio,
J. Pinheiro, H. Lopardo* (Buenos Aires, AR)
The dynamics of Streptococcus
pneumoniae nasopharyngeal carriage
in mothers and children of the Warao
Amerindians from Venezuela
M.C. Sisco*, I.A. Rivera-Olivero, B. Del Nogal,
P. Hermans, J. De Waard
(Caracas, VE; Nijmegen, NL)
Nasopharyngeal carriage of Streptococcus
pneumoniae in healthy Czech children:
implications for clinical practice
M. Trojanek, Z. Vancikova, M. Fridrichova,
H. Zemlickova*, J. Motlova, Z. Blechova,
J. Matejkova, N. Kocnarova, V. Maresova
(Prague, CZ)
Invasive pneumococcal disease in Austrian
children <5 years of age (2007 to 2009)
M. Paulke-Korinek*, B. Schmidle-Loss,
C. Seidl-Friedrich, A. Postl, B. Laaber,
H. Burgmann, P. Rendi-Wagner, H. Kollaritsch
(Vienna, AT; Tel Aviv, IL)
P1561
Determination of immunoglobulin E and
eosinophil cationic protein in children with
Mycoplasma pneumoniae infection
G. Antonaki, M. Matsas*, K. Giannakopoulou,
E. Lebessi, I. Paraskakis (Athens, GR)
P1562
Norovirus prevalence in “pathogen negative”
gastroenteritis in Peruvian children
F. Rivera, T. Ochoa, J. Ruiz*, A. Medina,
L. Ecker, A. Gil, L. Huicho, C. Lanata
(Lima, PE; Barcelona, ES)
P1563
Molecular versus traditional methods for
the detection of gastrointestinal pathogens
in children
M. Onori*, A. Grandin, L. Coltella, D. Valentini,
M. Argentieri, A. Villani, C. Russo (Rome, IT)
P1564
Prevalence of O122 genes in enteropathogenic Escherichia coli strains isolated
from Peruvian children
N. Piscoche *, C. Contreras, D. Durand,
J. Ruiz, T. Cleary, T. Ochoa
(Lima, PE; Barcelona, ES; Houston, US)
P1565
Community-acquired respiratory
tract infections during childhood
T. Guahardo, I. Grafakos, A. Kyratsa, H. Iliadou,
P. Giannopoulou, F. Lykou, P. Safioleas,
E. Trikka*, A. Voyatzi (Athens, GR)
P1566
Neonatal bacteraemia due to Pasteurella
bettyae
L. Moreno Parrado, J.J. Palomar Pérez,
L. Robles Fonseca, J. Lozano Serra*,
M.R. Vicente Romero, E. Riquelme Bravo,
M. Martínez Serrano, M.D. Crespo Sánchez
(Albacete, ES)
P1567
Complications of bacterial meningitis in
children
T. Habanec*, L. Homola, P. Mikolasek,
J. Pavelka, J. Helesic (Brno, CZ)
P1568
Risk factors associated with mucosal
colonisation by common Gram-negative
species and yeasts in the neonatal
intensive care unit
Ü. Parm*, T. Metsvaht, E. Sepp, M. Ilmoja,
H. Pisarev, M. Pauskar, I. Lutsar (Tartu, EE)
P1569
Reduced vancomycin susceptibility in
Staphylococcus capitis strains causing
late-onset sepsis in intensive care neonates
J.P. Rasigade*, C. Tellini, O. Raulin, M. Ben Saïd,
J.-C. Picaud, O. Claris, J. Etienne, F. Vandenesch,
S. Tigaud, F. Laurent (Lyon, FR)
Final Programme
Posters
12:30 – 13:30
151
Poster Sessions
Monday, 9 May
P1570
12:30 – 13:30
P1571
P1572
Fungaemia in paediatrics patients –
population characteristic, trends in
infection frequency, aetiological factors
and strain susceptibility. Epidemiological
study 2000 – 2009, Poland
E. Romanowska, P. Nadkowska,
K. Dzierzanowska-Fangrat*, D. Dzierzanowska,
M. Migdal, D. Perek, O. Gryniewicz, J. Ksiazyk,
J. Teisseyre (Warsaw, PL)
Community-acquired pneumonia and its
complications
Mycoplasma pneumoniae is not an important
cause of lower respiratory tract infections
in the European GRACE study: a combination
of methods is necessary for early detection
of cases
M. Ieven*, C. Lammens, K. Loens,
A. Vanderstraeten, D. Ursi, S. Dettlaff,
H. Goossens on behalf of the GRACE study group
Review of positive Chlamydia pneumoniae
PCR in a tertiary care centre over a ten-year
period (2001–2010)
L. Senn*, K. Jaton, J.W. Fitting, G. Greub
(Lausanne, CH)
P1573
Hospitalised community-acquired
pneumonia: role of atypical organisms
I. Edelstein*, A. Punin, O. Shelyakina,
A. Chagarjan, R. Kozlov (Smolensk, RU)
P1574
Doxycycline versus macrolides in combination
therapy for treatment of atypical
community-acquired pneumonia: outcomes
from ACAPS
B. Teh*, L. Grayson, P.D. Johnson, P. Charles
(Melbourne, AU)
P1575
The impact of Q fever on communityacquired pneumonia in Germany
K. Boden*, M. Schack, S. Sachse,
M. Baier, E. Straube (Jena, DE)
P1576
Spectrum of causative agents of communityacquired pneumonia in hospitalised adults
and their susceptibility to antimicrobials
S. Rachina*, E. Shal, R. Kozlov, N. Ivanchik,
O. Kretchikova (Smolensk, RU)
P1577
Statin use and hospitalisation with
pneumonia: population-based observational
study of risk and prognosis among 70,914
hospitalised pneumonia patients in Northern
Denmark
A.G. Nielsen*, R.B. Nielsen, A.H. Riis,
H.T. Sørensen, R.W. Thomsen (Aarhus, DK)
Final Programme
P1578
Management of community-acquired
pneumonia and capping Clostridium difficile
infections: are we falling at the CURB?
M. Paracha, M. Przybylo*, K. Polster, T. Adizie,
S. Staff, A. Guleri (Blackpool, UK)
P1579
Epidemiology, clinical features, and
outcomes of community-acquired pneumonia
in patients with diabetes mellitus
S. Di Yacovo*, C. Garcia-Vidal, I. Oriol, F. Gili,
J. Adamuz, D. Viasus, R. Verdaguer, F. Gudiol,
J. Carratalà (Barcelona, ES)
P1580
Clinical impact of combined viral and
bacterial infection in patients with
community-acquired pneumonia
N. Johansson*, M. Kalin, J. Hedlund
(Stockholm, SE)
P1581
The relative importance of respiratory
viruses in lower respiratory tract infections
in primary care
F. Coenjaerts*, C. Lammens, M. Viveen,
L. Tan, K. Loens, H. Goossens, M. Ieven,
A. van Loon, E. Claas
on behalf of the GRACE study group
P1582
Value of prognostic scores in predicting
mortality from community-acquired
pneumonia. A prospective comparison in
emergency departments
F. Tumietto, L. Scudeller, S. Tedeschi, R. Ferrari,
P. Viale* (Bologna, Pavia, IT)
P1583
The use of procalcitonin to guide antimicrobial
use for respiratory tract infections in
a district general hospital: a feasibility study
R. Scott, B. Sage, K. Cheah,
R. Vancheeswaran, D.J. Mack* (London, UK)
P1584
Practical use of urine antigens and
implementation of national recommendations
for the management of community-acquired
pneumonia (CAP): results from a retrospective
study on 214 CAP hospitalised by the
emergency department
C. Bastide, F. Borlot, G. Le Falher, J. Reny, A. Dao,
E. Mennesson, B. Simorre, E. Oziol*
(Béziers, FR)
P1585
Pneumonia treated in the internal medicine
department: a nationwide study in Spain
M. Giannella*, E. Bunsow, B. Pinilla,
J.A. Capdevila, J. Martinez Alarcon, P. Muñoz,
E. Bouza on behalf of the ENEMI Study Group
P1586
Incidence, length of stay, and prognosis
among patients hospitalised with thoracic
empyema: a Danish nationwide study,
1995 – 2009
R.W. Thomsen*, J.B. Kornum, R.B. Nielsen,
M. Søgaard, H. Schønheyder, H.T. Sørensen
(Aalborg, DK)
Poster Sessions
12:30 – 13:30
P1587
P1588
P1589
P1590
Bacteraemia, sepsis and endocarditis
Trends in the incidence of bloodstream
infections and sepsis management
organisation in Emilia-Romagna, Italy
A. Pan*, R. Buttazzi, C. Gagliotti, C. Capatti,
S. Giordani, M. Parenti, F. Pedna, D. Resi,
M. Sarti, C. Venturelli, M.L. Moro
on behalf of the Antibiotic Use and Resistance
Surveillance Study Group of Regione
Emilia-Romagna and LaSER Study Group
The impact of diabetes and poor glycaemic
control on risk of bacteraemia with
haemolytic streptococci groups A, B and G
in adults: a 15-year population-based casecontrol study
R.W. Thomsen*, A.H. Riis, S. Kjeldsen,
H.T. Sørensen, H. Schønheyder
(Aarhus, Aalborg, DK)
P1596
Significance of troponin-I value in infective
endocarditis
N. Mewada*, A. Mewada, D. Levine
(Detroit, Michigan, US)
P1597
The broadening spectrum of septic pulmonary
embolism: a retrospective review
D.N. Williams*, U. Goswami, J. Brenes
(Minneapolis, US)
P1598
Outcome and prognostic factors in patients
with community-acquired bacteraemic severe
sepsis or septic shock
Y.K. Yoon*, D.W. Park, S. Kwon, B. Chun, J. Sohn,
H.J. Cheong, J.Y. Choi, H.J. Choi, Y.H. Choi,
H.Y. Kim, J.S. Eom, S.I. Kim, Y.G. Song, K.R. Peck,
Y.S. Kim, J.M. Kim, M.J. Kim
on behalf of the Korean Sepsis Working Group
P1599
The role of imaging of the urinary tract in
patients with urosepsis
S.M. Sørensen*, H. Schønheyder, H. Nielsen
(Aalborg, DK)
P1600
Clinical significance of Staphylococcus
aureus bacteriuria in patients with S. aureus
bacteraemia
H. Asgeirsson*, M. Kristjansson, K. Kristinsson,
O. Gudlaugsson (Huddinge, SE; Reykjavik, IS)
Evaluating the importance of defining
healthcare-associated bloodstream
infections
R. Lenz*, J.R. Leal, D.L. Church, D.B. Gregson,
T. Ross, K. Laupland (Calgary, CA)
P1601
Risk factors of septic shock in patients with
bacteraemic acute pyelonephritis visiting
emergency room
J. Lee*, J. Cho, S. Shin (Iksan, KR)
Community-onset ESBL E. coli bacteraemias:
prevalence, risk factors and outcomes in a
London tertiary hospital
S. Reddy*, L. Phee, A. Sivaramakrishnan,
E. Hennessey, M. Millar (London, UK)
P1592
Laboratory predictors of mortality in
community-acquired Escherichia coli
C.J. Collins*, M. Kelleher, T.R. Rogers (Dublin, IE)
P1594
Abiotrophia endocarditis and bacteraemia –
an 8-year experience in a tertiary care centre
Y. Maor*, N. Belausov, D. Ben-David, G. Smollan,
N. Keller, G. Rahav (Ramat Gan, IL)
Delayed appropriate therapy in
Staphylococcus aureus bloodstream
infection does not influence outcome
A.J. Kaasch*, S. Rieg, J. Kütscher, T. Widmann,
C. Meyer, P. Kern, U. Haars, I. Hübner,
B. Sinha, F. Brunkhorst, W.V. Kern, H. Seifert
on behalf of the preSABATO study group
P1591
P1593
P1595
Clinical characteristics and outcome
of Haemophilus bacteraemia in the
post-vaccination era
S. Thønnings, C. Østergaard*
(Herlev, Hvidovre, DK)
Five cases of Campylobacter fetus infection
detected at a university hospital in Japan
A. Uehara*, M. Nakashima, M. Kadowaki,
Y. Uchida, N. Shimono, K. Akashi (Fukuoka, JP)
12:30 – 13:30
Respiratory pathogens
P1602
In vitro activity of antimicrobial agents
against Streptococcus pyogenes obtained
in four different regions of Turkey
H. Erdogan*, F. Can, M. Demirbilek, S. Colakoglu,
H. Turan, O. Azap, H. Arslan
(Antalya, Istanbul, Ankara, Adana, Konya, TR)
P1603
Susceptibility of respiratory pathogens
to less common agents
V. Daniels*, M. Wootton, L. Davis, R. Howe
(Cardiff, UK)
P1604
Nationwide surveillance of bacterial
pathogens isolated from patients with lower
respiratory infections in 2010 in Japan
A. Watanabe*, T. Matsumoto, A. Iwamoto,
K. Totsuka, N. Aoki, K. Yanagihara,
T. Matsumoto, M. Yagisawa, J. Sato,
K. Sunakawa, H. Hanaki (Tokyo, JP)
Final Programme
153
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
P1605
Antimicrobial resistance of respiratory
pathogens in Finland, 2005 – 2009
M. Bergman*, P. Huovinen, A. Hakanen
and the Finnish Study Group for Antimicrobial
Resistance (FiRe Network)
P1614
CSF lactate level in diagnosis of bacterial
meningitis following neurosurgical
intervention
A. Deveci, O. Acicbe, B. Avci, A. Ulus, F. Celik,
N. Tulek* (Samsun, Ankara, TR)
P1606
Risk factors for fluoroquinolone-resistant
Streptococcus pneumoniae bacteraemia
M.C. Isea Peña*, J. Esteban, R. Fernández
Roblas, J. Sanz, B. Ramos, M. Fernández
Guerrero (Madrid, ES)
P1615
P1607
Activity of ceftaroline and comparator
agents tested against organisms responsible
for community-acquired respiratory tract
infections in Europe (2009)
M. Castanheira*, P. Rhomberg, R. Jones,
H. Sader (North Liberty, US)
Prospective study of diagnostic and prognostic
significance of C-reactive protein in
cerebrospinal fluid in critically ill patients in
the intensive care unit
J. Nikolic*, A. Urosevic, A. Mitrovic, B. Milosevic,
O. Dulovic (Belgrade, RS)
P1608
Macrolide resistance in European isolates
of Streptococcus pneumoniae, 2009 – 2010
D. Hoban, M. Hackel, S. Bouchillon, J. Johnson*,
R. Badal, S. Hawser, M. Dowzicky
P1609
Trend of antimicrobial susceptibility among
bacterial isolates from RTI of Japanese
hospital participating in the levofloxacin
surveillance group during 1994–2010
Y. Keizo*, O. Akira, I. Yoshikazu, T. Kazuhiro
for the Levofloxacin Surveillance group
P1610
Serotype distribution and antimicrobial
susceptibility of IPD-causing Streptococcus
pneumoniae in the Comunidad Valenciana,
Spain during the winter of 2009–2010
C.M. Gant*, A.W. Rosingh, M. van der Heijden,
E. Cantón, M. Gobernado, F. González-Morán,
J.J. Bijlsma for the RedMiva
(Red Microbiología Valencia)
12:30 – 13:30
P1611
12:30 – 13:30
P1616
Predictive value of soluble urokinase
plasminogen activator factor in ventilatorassociated pneumonia and sepsis
A. Savva, C. Routsi, G. Dimopoulos,
A. Antonopoulou, M. Georgitsi,
E.J. Giamarellos-Bourboulis* (Athens, GR)
P1617
Panel or serial analyses of inflammatory
markers do not improve the prediction of
bacteraemia compared with a single
determination of procalcitonin
M. Tromp*, B. Lansdorp, C. Bleeker-Rovers,
J. Klein Gunnewiek, B. Kullberg, P. Pickkers
(Nijmegen, NL)
P1618
Evaluation of procalcitonin and sTREM-1
levels in early diagnosis and monitoring
of sepsis
H. Bayram, O. Tunger, M. Sakarya,
H. Yuceyar, C. Ulman, G. Dinc, C.B. Cetin*
(Manisa, TR)
P1619
Increasing yield and reducing contamination
rates of blood cultures: an audit at James
Paget University Hospital, January 2006 to
December 2007
T. Chinniah*, T. Elumogo
(Colombo, LK; Great Yarmouth, UK)
P1620
Transport time for blood culture bottles:
underlying factors and their consequences
V. Özenci*, M. Mildh, M. Ullberg (Stockholm, SE)
P1621
Differential time-to-positivity for the
diagnosis of catheter-related bloodstream
infection: do we need to obtain one or more
peripheral vein blood cultures?
M. Guembe*, M. Rodríguez-Créixems,
C. Sánchez, P. Martín-Rabadán, E. Bouza
(Madrid, ES)
Biomarkers for infections
Measurement of C-reactive protein velocity in
febrile bacterial infections and non-bacterial
febrile illnesses
D. Koutete*, E. Koukou, I. Pilios, C. Karagiannis,
S. Velakoulis, P. Tsiodra, S. Pagoni (Xolargos, GR)
P1612
CSF LDH estimation to differentiate pyogenic
and viral meningitis and its role in tuberculous
meningitis
T. John*, C. Ittycheria, J. George, C. Jacob,
A. Jacob, A. George (Kottayam, IN)
P1613
Establishing the optimal breakpoints
in cerebrospinal fluid cell counts for the
diagnosis of secondary meningitis
B. Hilvering, A. Huisman, P.A. Woerdeman,
M.J. Bonten, M.B. Ekkelenkamp* (Utrecht, NL)
Final Programme
Blood cultures and diagnosis of sepsis
Poster Sessions
Monday, 9 May
Bloodstream infections related to Gramnegative rods. Usefulness of the Vitek2C
System for direct identification and
susceptibility testing from positive BactAlert blood cultures
R. Soloaga*, J. Pidone, M. Mendez Aranibia,
M. Giovanakis, A. Sujemecki, C. Bondulich,
L. Guelfand, A. Margari, N. Carrion
(Buenos Aires, AR)
P1623
Comparison of three blood culture systems
(Bactec 9240, Bact/ALERT 3D, and Versatrek)
for blood cultures involving delayed vial entry
S.Y. Ng*, S. Teh, T. Tan (Singapore, SG)
P1624
Performance analysis of blood culture
and frequency of medically important
bacteria in 9 university hospitals in Korea
S. Kim*, J. Shin, N.Y. Lee, E. Kim, M.N. Kim
(Jinju, Busan, Seoul, KR)
P1625
P1630
Predictive value of surface cultures
in tunnelled haemodialysis catheter-related
bloodstream infections. Do they select
a low-risk population?
E. Bouza*, L. Rojas, M. Guembe, M. Marín,
F. Anaya, J. Luño, J. López, P. Muñoz
on behalf of the Colonized Catheter in
Hemodialysis (COCADI) Study Group
P1631
The role of Gram staining in the rapid
diagnosis of tunneled central venous
catheter colonisation
M. Guembe*, P. Martín-Rabadán,
A. Echenagusia, F. Camúñez,
G. Rodríguez Rosales, G. Simó,
M. Echenagusia, E. Bouza (Madrid, ES)
P1632
Is it possible to know whether candidaemia
is caused by catheter-related infection
without having to remove the catheter?
M. Rodríguez-Créixems*, L. Alcalá, P. Muñoz,
P. Martín-Rabadán, M. Guembe, E. Bouza
(Madrid, ES)
Nationwide survey of blood culture
performance in Korea, 2010
S. Kim*, J. Shin, M.N. Kim, N.Y. Lee
(Jinju, Busan, Ulsan, Seoul, KR)
12:30 – 13:30
12:30 – 13:30
Diagnosis of foreign body infections
P1626
C-reactive protein is not a clinically
useful predictor of outcome in prosthetic
joint infection
N. Gordon*, A. Berendt, I. Byren, B.L. Atkins,
P. Bejon (Oxford, UK)
P1627
Is prosthetic joint vortexing/sonication
effective in aseptic failure?
M. Fernandez-Sampedro*, C. Salas-Venero,
C. Fariñas-Alvarez, S. Plaza Garcia,
M.A. Alonso-Aguirre, M.B. Busta-Vallina,
F. Figols, J. Gomez-Roman,
L. Martinez-Martinez, M.C. Fariñas
(Santander, ES)
P1628
P1629
Improving the diagnosis of prosthetic
joint infection by prolonged culture of
periprosthetic tissues
A.L. Skovby*, N. Bjørslev, M. Andersen,
J.J. Hvolris, A. Friis-Møller
(Hvidovre, Bispebjerg, DK)
Three different ways of processing samples
from sonication. Which is the best to improve
diagnosis of infected orthopaedic devices?
E. Cuchi*, A. Matamala, D. Haro, L. Gómez,
G. Muñoz, S. Quintana, J. Perez, F. Anglés
(Terrassa, ES)
Skin soft tissue infections
P1633
Nosocomial infections, emerging MDR
pathogens and antibiotic prophylaxis in
cardiothoracic surgery: clinical surveillance
study at Lancashire cardiac centre, UK
K. Al-hadid*, L. Moorhouse, A. Guleri
(Blackpool, UK)
P1634
Perioperative statin for the prevention
of infectious complications in patients
who undergo neurosurgery
S. Shokouhi*, G. Sharifi, L. Gachkar,
A. Amirsardari, M. Samadian, A. Aliasgari
(Tehran, IR)
P1635
Risk factors affecting the incidence
of infection after orthopaedic surgery:
the role of chemoprophylaxis
A. Masgala*, E. Chronopoulos, G. Nikolopoulos,
J. Sourlas, E. Brilakis, S. Lallos, J. Lazarettos,
S. Soultanis, N. Efstathopoulos (Athens, GR)
P1636
Associations between operative site
microbial counts and procedure classification
in neurosurgery
I. Kourbeti*, S. Tsiodras, S. Maraki,
D. Karabetsos, C. Neophytou, M. Filippou,
A. Ioannou, A. Vakis
(Chalkida, Athens, Heraklion, GR)
P1637
Gram-negative bacillary meningitis in
post-neurosurgical patient associated
with high mortality
C. Moon*, J. Lee, J. Shin, M. Kim (Busan, KR)
Final Programme
155
Posters
P1622
Poster Sessions
Monday, 9 May
P1638
Risk factors for mesh-related infections
after hernia repair surgery: a meta-analysis
of cohort studies
M. Mavros*, S. Athanasiou, V. Alexiou,
P. Mitsikostas, G. Peppas, M. Falagas
(Athens, GR)
P1647
Surgical site infections after elective
craniotomy: a review of 362 procedures
performed in a four-year period (2006 – 2010)
I. Rodríguez-Pintó*, L. Sorli, G. Villalba, H. Knobel,
R. Güerri, M. Montero, E. Torres, E. Molas,
G. Conesa, J.P. Horcajada (Barcelona, ES)
P1639
External ventricular drain-related
ventriculomeningitis – a five-year,
single-centre survey
M. Hell*, M. Lunzer, C. Unterkoefler,
G. Forsthuber, M. Dollenz, M. Maass,
B. Richling (Salzburg, AT)
P1648
Analysis of risk factors for surgical site
infections after gastric surgery in the Korean
Nosocomial Infections Surveillance System
(KONIS)
E.S. Kim*, H.B. Kim, H.J. Choi, H.Y. Kim,
Y.K. Cho on behalf of KONIS
P1641
Hardware-related infections in patients
subjected to deep-brain stimulation
K. Chang*, A. San Gil, M. Varela, E. Calbo,
M. García-Bach, V. Pascual, J. Garau
(Terrassa, Barcelona, ES)
P1649
Using a data warehouse to predict rates
of external ventricular and lumbar drain-related
meningitis
M.S. van Mourik*, R.H. Groenwold,
A. Troelstra, M.J. Bonten (Utrecht, NL)
P1642
Surgical wound infections after median
sternotomy: clinical and microbiologic
preliminary results of a large multicentre
study in Italy
L. Scudeller, L. Soavi, E. Pistella, C. Santini*
on behalf of the GIS-INCARD
P1650
The surgeon as an independent risk factor
for surgical site infection
M. Hübner, M. Diana*, G. Zanetti, M.C. Eisenring,
N. Demartines, N. Troillet (Lausanne, Sion, CH)
P1651
Persistently bacteraemic infective endocarditis
V. Krcmery*, P. Kisac (Bratislava, SK)
P1652
Drainage days – an independent risk factor
for serious sternal wound infections after
cardiac surgery
S. Tschudin Sutter*, R. Meinke, H. Schuhmacher,
M. Dangel, O. Reuthebuch, F.S. Eckstein,
A.F. Widmer (Basel, CH)
P1653
Shifting sands: a multicentre survey
of changes in practices of antibiotic
prophylaxis in cardiac surgery across
cardiac centres in United Kingdom
S. Hosmane*, R. Williams, L. Moorhouse,
J. Moon, M. Przybylo, A. Guleri
(Plymouth, Blackpool, UK)
P1643
Procedure specific surgical site infection
rates in a tertiary care hospital in Turkey
R. Guner, I. Hasanoglu, S. Ascioglu, A. Kaya
Kalem, S. Keske, M.A. Tasyaran* (Ankara, TR)
P1644
Impact of post-discharge surveillance
on the incidence of surgical site infections
in cardiac surgery in a Swiss tertiary care
hospital
D.L. Braun*, R. Gaudenz, C. Ruef (Zurich, CH)
P1645
Incidence and risk factors for surgical
site infection in Latium, Italy
V. Puro*, F. Ferraro, L.E. Ruscitti, P. Piselli,
L. Martini, N. Petrosillo, G. Ippolito
on behalf of “Centro Regionale Infezioni
nella Pratica Assistenziale” (CRIPA)
P1646
Postoperative bacterial meningitis
after trans-sphenoidal surgery:
a retrospective study of 99 interventions
over a 10-year period
S. Giulieri*, D. Bervini, K. Darling,
A. Trampuz, R. Daniel (Lausanne, CH)
Final Programme
12:30 – 13:30
Prosthetic joint infections
P1654
Epidemiology and outcome after treatment
of prosthetic joint infections. Observational
study
T. Ascione*, M.D. Iannece, P. Rosario, P. Pagliano,
M. Conte, R. Rotondo, M. Mariconda,
C. Pempinello, S. Lepore, R. Pempinello
(Naples, IT)
P1655
Outcome of periprosthetic joint infection
caused by rifampin-resistant staphylococci
K. Eigenmann*, Y. Achermann, M. Clauss,
P. Rafeiner, L. Derksen, R. Nueesch,
C. Zellweger, M. Vogt, W. Zimmerli, A. Trampuz
(Zurich, Liestal, St. Gallen, Lucerne, Berne,
Baar, Lausanne, CH)
Poster Sessions
Monday, 9 May
Multicentre review of prosthetic joint
infections treatment and outcomes
T. Peel*, K. Buising, A. Cheng, P. Choong
(Melbourne, AU)
P1657
Gram-negative prosthetic joint infection
G. Muñoz-Gamito*, L. Gómez, A. Matamala,
D. Haro, E. Cuchí (Terrassa, ES)
P1665
13:30 – 14:30
12:30 – 13:30
P1658
P1659
Nosocomial pneumonia
Healthcare-associated pneumonia:
an attempt to refine the concept
M. Salvadó *, V. Pascual, E. Calbo, N. Freixas,
M. Riera, M. Xercavins, J. Garau
(Martorell, Terrassa, ES)
Ventilator-associated pneumonia rates
in three different intensive care units in a
tertiary care hospital
M.A. Yetkin, D. Karryilmaz, P. Onguru, E. Akinci,
A. But, F. Alaca Coskun, N. Aksu, H. Bodur*
(Ankara, TR)
P1660
Candida sp. colonisation could promote
antibiotic-resistant bacteria selection within
the airways of the patients with clinically
suspected ventilator-associated pneumonia
M. Hamet*, A. Pavon, S.D. Barbar, S. Prin,
J.P. Quenot, F. Dalle, P.E. Charles (Dijon, FR)
P1661
Hospital-acquired bacteraemic pneumonia
in non-ventilated patients
E. Espejo*, M. Andrés, J. Torviso, M.A. Morera,
R.M. Borrallo, J. Pérez, F. Bella (Terrassa, ES)
P1662
A study on aetiology and drug resistance
pattern of ventilator-associated pneumonia
in an Iranian 1.000-beds tertiary care
hospital
M. Rahbar*, H. Bahrami (Tehran, IR)
P1663
Hospital-acquired Klebsiella pneumonia
bacteraemia: risk factors for carbapenemresistance and predictor for mortality
K. Hussein*, A. Raz-Pasteur, A. Neuberger,
Y. Shachor Meyouhas, I. Oren, R. Finkelstein,
I. Kassis (Haifa, IL)
P1664
Ventilator-associated pneumonia due to
methicillin-resistant Staphylococcus aureus:
risk factors and outcome in a large general
hospital
E. Bouza, M. Giannella*, E. Bunsow, M. Torres,
P. Martin-Rabadan, P. Muñoz
on behalf of the Gregorio Marañón Task Force
for Pneumonia
Low incidence of multidrug-resistant
organisms in healthcare-associated
pneumonia requiring hospitalisation
C. Garcia-Vidal*, D. Viasus, J. Adamuz,
A. Roset, R. Verdaguer, J. Dorca, F. Gudiol,
J. Carratalà (Barcelona, ES)
Gram-negative bacteria: molecular detection
of antibiotic resistance
P1666
Real-time PCR for detection of NDM-1carbapenemase genes from stools
T. Naas*, A. Ergani, A. Carrer, P. Nordmann
P1667
The complete sequence of the F group
Plasmid p3452 from E. coli 345-2 carrying
silent antibiotic resistance genes
B. Humphrey, D. Walker, N.R. Thomson,
V.I. Enne* (London, Cambridge, UK)
P1668
Evaluation of an ESBL microarray as
a confirmation test for the presence
of extended-spectrum beta-lactamases
in the routine clinical setting
T.N. Platteel*, J.W. Cohen Stuart, G.M. Voets,
J. Scharringa, N. van de Sande, A.C. Fluit,
M. Leverstein-van Hall
on behalf of the ESBL working group
P1669
Multicentre evaluation of a new DNA
microarray for the detection of plasmidic
AmpC and NDM-1 genes in Enterobacteriaceae
P. Bogaerts*, A.M. Hujer, T. Naas,
R. Rezende, A. Endimiani, P. Nordmann,
R.A. Bonomo, Y. Glupczynski
(Yvoir, BE; Cleveland, US; Paris, FR)
P1670
Evaluation of a DNA microarray for the
rapid detection of extended-spectrum
beta-lactamases (TEM, SHV and CTX-M),
and carbapenemases KPC, OXA-48, VIM,
IMP, and NDM
T. Naas*, G. Cuzon, P. Bogaerts,
Y. Glupczynski, P. Nordmann
(Le Kremlin-Bicêtre, FR; Mont-Godinne, BE)
Final Programme
157
Posters
P1656
Poster Sessions
Monday, 9 May
13:30 – 14:30
P1671
P1672
P1673
P1674
P1675
13:30 – 14:30
P1676
P1677
P1678
P1679
Comparison of the Copan fecal swab to dry
containers for collection and transportation
of stool samples for detection of bacteria
causing gastrointestinal infections
A. Altieri, M.C. Bossa*, F. Capalbo, L. Di Traglia,
C. Fontana (Rome, IT)
P1680
IS-pro: fully automated molecular analysis
of the human intestinal microbiota
A.E. Budding*, M.E. Grasman,
A.A. van Bodegraven, P.H. Savelkoul
(Amsterdam, NL)
SL-Solution for pre-treatment of mucus-rich
respiratory specimens for culture and
molecular assays
M. Favaro, M. Pellicioni, C. Fontana* (Rome, IT)
P1681
Evolution of a high-prevalent clone
of Pseudomonas aeruginosa in a cystic
fibrosis patient during chronic infection
R. van Mansfeld*, M.J. Bonten, R.J. Willems
(Utrecht, NL)
Cryopreservation of Blastocystis:
significance of foetal calf serum
A. Özbilgin*, Ö. Kurt, T. Oyur, V.Ö. Ermis,
T. Tabak, E. Kal Cakmakliogullari, C. Stensvold
(Manisa, TR; Copenhagen, DK)
P1682
Preliminary evaluation of the HB&L system
for the microbiological screening of storage
liquids of preserved corneas at 31°C
D. Camposampiero*, S. Grandesso, E. Zanetti,
S. Mazzucato, M. Solinas, R. Bussolotto, M. Gion,
D. Ponzin (Venice, IT)
Bacteriology highlights
Bacteriophage and Helicobacter pylori:
an underestimated phenomenon
F. Vale, J. Guegueniat, S. Lacomme, E. Gontier,
A. Alves Matos, L. Engstrand, F. Mégraud,
P. Lehours* (Lisbon, PT; Bordeaux, FR;
Stockholm, SE)
Identification of a novel Brachyspira
species in human intestinal spirochaetosis
L.J. Westerman, H.V. Stel, M.E. Schipper,
L.J. Bakker, E. Boel*, J.H. van den Brande,
P.D. Siersema, J.G. Kusters
(Utrecht, Blaricum/Hilversum, NL)
Genotypic detection of rifampicin- and
isoniazid-resistant Mycobacterium
tuberculosis strains by the pyrosequencing
method
I. Hernández-Cáceres*, Ó. Díez-Gil,
J. Alcoba-Flórez (Santa Cruz de Tenerife, ES)
13:30 – 14:30
P1683
Diversity of human vaginal bacterial
communities in healthy women and bacterial
vaginosis
K. Wang , Z. Lv, J. Su* (Beijing, CN)
P1684
Diagnostic accuracy of molecular biology in
the diagnosis of syphilis: a meta-analysis
A. Gayet-Ageron*, S. Lautenschlager, B. Ninet,
T. Perneger, C. Combescure
(Geneva, Zurich, CH)
P1685
Evaluation of the Bio-rad Dx CT/NG/MG assay,
a new real-time PCR test for the simultaneous
detection of Chlamydia trachomatis, Neisseria
gonorrhoeae and Mycoplasma genitalium
P. Sednaoui*, N. Nassar, G. Allemelou, F. Castano,
L. Monfort (Paris, FR)
P1686
Duplex PCR for systematic simultaneous
detection of Chlamydia trachomatis and
Neisseria gonorrhoeae in clinical specimens:
the added value of a dual approach
K. Jaton*, R. Brouillet, G. Greub (Lausanne, CH)
P1687
Fully automated microfluidic PCR for the
detection of Chlamydia trachomatis with
the BD MAX™ instrument
L. Berlinger*, E. Sutter-Minder, K. Egli,
M. Altwegg (Lucerne, CH)
Sample collection
Detection of epidemiologically significant
organisms (ESO) from surveillance
specimens using pooled ESwabs compared
to swabs in Amies transport medium
B.M. Willey*, P. Gnanasuntharam, G. Nguyen,
B. Borgundvaag, W. Leung, M. Loftus,
R. Thanabalan, V. Porter, G. Small, I. Edwards,
P. Lo, K. Wong, Y. Wei, G. Mahli, A. McGeer,
S.M. Poutanen (Toronto, CA)
Stability of Bordetella pertussis and
Bordetella parapertussis in the ESwab
transport system for culture and PCR
K. Van Horn*, C. Audette (Cypress, US)
Preliminary evaluation of a Copan ESwab
system for lower respiratory tract samples
for microbiological culture
M. Avolio*, R. De Rosa, P. Stano, M. Modolo,
A. Camporese (Pordenone, IT)
Final Programme
Molecular diagnosis of urogenital infections
Poster Sessions
P1696
Evaluation of the Cobas® 4800 CT/NG test
using clinician and self-collected vaginal
swabs, cervical specimens in PreservCyt
Solution, and pharyngeal throat wash
specimens
D. Hardy, J. Pane, A. Sunhachawee,
E. Cervantes, R. Kotadia, S. Joshi, R. Puckett,
M. Watson, J. Cheung, O. Liesenfeld*,
M. Krevolin (Pleasanton, US)
P1697
Usefulness of Neisseria gonorrhoeae
systematic PCR detection on urogenital
specimens with the Abbott real-time
Chlamydia trachomatis/Neisseria
gonorrhoeae assay
J.M. Rousee*, C. Rieder-Monsch, T. Gueudet
(Strasbourg, FR)
Comparison of the VERSANT® CT/ GC DNA
assay and the APTIMA Combo 2® rRNA assay
for detection of Chlamydia trachomatis and
Neisseria gonorrhoeae in male urine
J.K. Møller* (Vejle, DK)
P1698
Comparison of three commercial molecular
assays for detection of Chlamydia
trachomatis and Neisseria gonorrhoeae
J. van de Bovenkamp*, J.W. Rossen,
C.M. van Herk, L.M. Raaijmakers,
R. Roymans, J.M. Verbakel, A.J. van den Brule
(Veldhoven, Tilburg, Eindhoven, NL)
Evaluation of the Siemens Versant® CT/GC
DNA 1.0 (kPCR) assay for detection of
Chlamydia trachomatis and Neisseria
gonorrhoeae
M. Bongaerts*, J. van de Bovenkamp,
S. Morré, M. Manders, E. Heddema
(Sittard-Geleen, Veldhoven, Amsterdam, NL)
P1699
Evaluation of the new Versant® kPCR
CT/GC DNA 1.0 assay for detecting Chlamydia
trachomatis compared to the Aptima
Combo 2 assay
M. Dautigny*, S. Merlin, C. Ronsin
(Ivry-sur-Seine, FR)
P1700
Chlamydia trachomatis and other bacteria
as aetiological agents to pelvic inflammatory
disease by 16S rRNA gene sequencing
B. Hammas*, C. Bjartling, K. Persson, H. Janson
(Malmö, SE)
P1701
Evaluation of the new Cobas 4800 CT/NG
test for detecting Chlamydia trachomatis
and Neisseria gonorrhoeae in urogenital
swabs and urine specimens
M. Parra, S. Bernal, N. Sivianes, L. Pérez,
I. Pueyo, E. Martín-Mazuelos, J.C. Palomares*
(Seville, ES)
P1702
Demonstrating the performance of a fully
integrated, low-cost, ultra-rapid PCR device
with true point-of-care applications
M. Green*, A. Larry, D. Shenton, D. Pearce
(Trowbridge, UK)
P1688
Vaginal swabs are the optimal sample
for screening women for chlamydial and
gonorrheal infection using the Roche
Cobas® 4800 system
B. Van Der Pol*, B. Body, M. Nye, C. Eisenhut,
S. Taylor, O. Liesenfeld (Bloomington, Burlington,
Indianapolis, New Orleans, Pleasanton, US)
P1689
Evaluation of Seeplex STD6 ACE detection kit
for the diagnosis of six sexually transmitted
pathogens
S.J. Lee*, C.H. Han (Suwon, Uijeongbu, KR)
P1690
P1691
P1692
Performance of the Bio-Rad Dx CT/NG/MG
assay for simultaneous detection of
Chlamydia trachomatis, Neisseria gonorrhoeae
and Mycoplasma genitalium in urogenital
samples
C. Le Roy, I. Le Hen, M. Clerc, V. Arfel,
F. Normandin, C. Bébéar*, B. de Barbeyrac
(Bordeaux, FR)
P1693
Evaluation of the platform cobas® 4800 CT/NG
test for detecting Chlamydia trachomatis in
urogenital samples
B. de Barbeyrac*, V. Mehats, M. Clerc, C. Le Roy,
C. Bébéar (Bordeaux, FR)
P1694
Evaluation of Versant® CT/GC DNA 1.0 assay
for the detection of Chlamydia trachomatis
and Neisseria gonorrhoeae in urine
specimens in selected STD patients
A. Marangoni*, C. Foschi, P. Nardini,
A. D'antuono, N. Banzola, A. Di Francesco,
R. Cevenini (Bologna, IT)
P1695
Molecular detection of Chlamydia
trachomatis and Neisseria gonorhoea in
(self)collected vaginal swabs and rectal
swabs with the Cobas 4800 system
P.H. Savelkoul*, L. Poort, S. Morré,
W. Ritmeester, H. van Krugten,
M.M. van de Pas, A. Beerens, J.W. Rossen
(Amsterdam, Tilburg, Groningen, NL)
Final Programme
159
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
13:30 – 14:30
P1703
P1704
P1705
P1706
P1707
P1708
P1709
P1710
P1711
Allele-specific real-time PCR for cost-effective
canonical SNP genotyping of Bacillus anthracis
I. Ivanov*, K. Marinov, E. Tsvetkova, R. Nenova,
R. Vatcheva-Dobrevska, E. Dobreva,
T. Kantardjiev (Sofia, BG)
P1712
New approaches to genotyping of clinically
relevant bacteria: typing of Escherichia coli
by single nucleotide polymorphism
pyrosequencing
N. Fernández-Romero*, M.P. Romero-Gómez,
M.R. Gómez-Gil, J. Mingorance (Madrid, ES)
P1713
Genetic diversity of invasive strains of
Neisseria meningitidis serogroup B before the
introduction of the new menB vaccine in Italy
C. Fazio*, A. Carannante, T. Sofia, A. Neri,
P. Mastrantonio, P. Stefanelli (Rome, IT)
P1714
Interlaboratory comparison of DiversiLab®
rep-PCR clustering against characterised
Acinetobacter baumannii isolates
P.G. Higgins*, A.M. Hujer, K.M. Hujer, R.A. Bonomo,
H. Seifert (Cologne, DE; Cleveland, US)
Using the Argus™ optical mapping system
to investigate a Salmonella enterica serovar
Saintpaul outbreak occurring in alfalfa
sprouts
E. Zentz*, A. Briska, S. Hinrichs, P. Iwen,
J. Henkhaus (Gaithersburg, Lincoln, US)
P1715
MLST types of vancomycin-resistant
Enterococcus faecium isolated from blood
samples in a university hospital in Konya,
Turkey
U. Arslan*, E. Demir, E. Oryasin, I. Tuncer,
D. Findik, B. Bozdogan (Konya, Aydin, TR)
Multilocus sequence typing characterisation
of Streptococcus dysgalactiae subsp.
equisimilis isolates from Portugal
M. Pinho*, M. Ramirez, J. Melo-Cristino
on behalf of the Portuguese group for the
study of streptococcal infections
P1716
Multilocus sequence typing used as
a tool to confirm the ability of susceptible
Helicobacter pylori strains to gain resistance
to clarithromycin during eradication therapy
S. Jeverica*, A. Ihan, B. Tepeš
(Ljubljana, Rogaška Slatina, SI)
Genetic lineages and plasmid profile
of extended-spectrum beta-lactamase
producing Escherichia coli isolates of food
and animal origin
S. Somalo*, Y. Sáenz, V. Estepa, S. Martínez,
L. Vinué, C. Torres (Logroño, ES)
P1717
Usefulness of SpectraCell RA Ramen
spectroscopy in tracking epidemic
methicillin-resistant Staphylococcus
aureus in Scotland
R.V. Goering*, M.R. Donnellan, E.K. Girvan,
A. Holmes, K.E. Templeton, G. Edwards
(Omaha, US; Glasgow, Edinburgh, UK)
P1718
Molecular characterisation of Clostridium
difficile clinical strains from Bulgarian
hospitals
E. Dobreva*, I. Ivanov, R. Vatcheva-Dobrevska,
K. Ivanova, M. Marina, T. Kantardjiev, E. Kuijper
(Sofia, BG; Leiden, NL)
P1719
Blastocystis sp. subtype 4 is common in
Blastocystis-positive patients presenting
with acute diarrhoea
C. Stensvold*, D.B. Christiansen, K.E. Olsen,
H.V. Nielsen (Copenhagen, DK)
The power of typing
Spa typing and multilocus variable-number
tandem-repeat analysis of methicillinresistant S. aureus in The Netherlands
G.N. Pluister, M. van Luit, T. Bosch, M.E. Heck*
(Bilthoven, NL)
Entamoeba dispar: genetic diversity
of clinical isolates-based on four tRNA
gene-linked short repeat loci
E. Nazemalhosseini-Mojarad*, A. Haghighi,
M. Alebouyeh, M. Zali (Tehran, IR)
Molecular characterisation of highpathogenicity Yersinia enterocolitica
bioserotype 1B/O8 clinical isolates
collected in Poland, 2009
K. Zacharczuk*, R. Gierczynski, J. Szych,
N. Rokosz, W. Rastawicki (Warsaw, PL)
Evaluation of the performance of the
Chlamydia trachomatis detection kit and
Ct Genotyping RHA kit compared to the Cobas
Amplicor CT/NG in SVS from females visiting
a STI clinic
L. van Dommelen*, A.A. Brink, F.H. van Tiel,
W.G. Quint, S. Morré, P. Wolffs, C.J. Hoebe
(Maastricht, Voorburg, Amsterdam, Geleen, NL)
Extended multilocus variable-number
tandem-repeat analysis of Clostridium
difficile
S. Manzoor*, H.E. Tanner, C. Marriott,
J.S. Brazier, K. Hardy, S. Platt, P. Hawkey
(Birmingham, Cardiff, London, UK)
Final Programme
Poster Sessions
P1720
Application of three different variable
number tandem repeat typing schemes on
Staphylococcus aureus within the east
and west Midlands
M. Lewis, K. Hardy, S. Shabir*, C. McMurray,
P. Hawkey (Birmingham, UK)
P1721
Evaluation of DiversiLab system performance
for typing of multi-resistant bacterial
pathogens
A. Deplano*, M. Hallin, R. De Ryck,
H. Rodriguez-Villalobos, M. Struelens,
O. Denis (Brussels, BE)
P1722
Molecular epidemiology of human listeriosis
in Andalucía, Spain
M.J. Torres, J.A. Lepe, J. Liró, J. Aznar*
(Seville, ES)
P1723
Comparison between automated rep-PCR
and MALDI-TOF for molecular typing of AmpCproducing Proteus mirabilis
M. Trevino*, D. Navarro, G. Barbeito, C. GarcíaRiestra, M.D. Peñalver, F. Pardo, M. Hernández,
M.T. Garea, B.J. Regueiro
(Santiago de Compostela, ES)
P1724
P1725
P1726
Epidemiological typing of Clostridium difficile
isolates from China
C. Marriott, S. Manzoor*, K. Hardy, L. Xu,
W.E. Liu, Z.J. Jian, Q. Gao, P. Hawkey
(Birmingham, UK; Changsha, CN)
Re-identification according to the new
taxonomy and genetic diversity
of streptococcus bovis causing bacteraemia
in the last 8 years
B. Romero*, M. Morosini, E. Loza,
M. Rodriguez-Baños, R. Cantón, R. del Campo
(Madrid, ES)
Speciation of Brachyspira, Brucella and
Mycoplasma species by MALDI-TOF
L.P. Randall*, L. Mappley, F. Lemma,
C. Churchward, R. Ayling, M. Fielder,
A. Whatmore, N. Coldham
(New Haw, Kingston Upon Thames, UK)
P1727
Molecular characterisation of methicillinresistant Staphylococcus pseudintermedius
of canine origin from central Italy
J. Kandhavelu, S. Preziuso, A.R. Attili,
J.S. Weese, V. Cuteri* (Matelica, IT; Guelph, CA)
P1728
Horizontal spread of highly resistant
Gram-negative rods – evaluation of the
Diversilab® typing method
I. Overdevest*, I. Willemsen, S. Elberts,
C. Verhulst, J. Kluytmans (Tilburg, Breda, NL)
P1729
Rapid typing of Listeria monocytogenes
by high-resolution melting curve analysis
of inlB
A. Pietzka*, A. Stöger, S. Huhulescu,
F. Allerberger, W. Ruppitsch (Vienna, AT)
P1730
Evaluation of a novel fluorescent amplified
fragment length polymorphism assay
and optical mapping to probe the genetic
diversity of Staphylococcus aureus
D. Desai*, M.J. Ellington, C. Arnold, M. Desai
(London, Cambridge, UK)
P1731
Correlation between blaOXA-51 variant
and DiversiLab® worldwide clonal lineages
E. Zander*, P.G. Higgins, H. Seifert (Cologne, DE)
P1732
Multilocus sequence typing of
Propionibacterium acnes with diverse origin
S. Davidsson*, B. Söderquist, F. Elgh, O. Andrén,
M. Unemo, P. Mölling (Örebro, Umeå, SE)
P1733
Changes in Clostridium difficile type
distribution: a national reference laboratory
perspective
S. Mentula*, S. Kotila, S. Ibrahem, O. Lyytikäinen,
J. Jalava, A. Virolainen (Helsinki, Turku, FI)
P1734
A population study on Chlamydia trachomatis
in adolescents in a high-incidence area in
north Norway reveals multiple new MLST
genotypes and the new Swedish mutant
(nvCT)
K. Gravningen*, L. Christerson, A. Ståhlsten,
G.S. Simonsen, K. Ödman, A.-S. Furberg,
B. Herrmann (Tromsø, NO; Uppsala, SE)
13:30 – 14:30
Molecular tools for the diagnosis
of culture-negative infections
P1735
Molecular pathogen detection
(16S rDNA-PCR/sequencing) in
culture-negative infections
O. Nolte*, F. Locher, H. Haag (Constance, DE)
P1736
Evaluation of real-time 16S rDNA PCR and
pyrosequencing for routine diagnostic
practice
N.J. Gadsby*, A. Onen, S.-A. Phillips, L. Tysall,
S. Breusch, H. Simpson, J. Dave, E. Czarniak,
K.E. Templeton (Edinburgh, UK)
P1737
A novel FISH test for rapid pathogen
identification in positive blood cultures
A. Makristathis*, S. Riss, M. Hirschl (Vienna, AT)
Final Programme
161
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
P1738
Detection of bacterial endocarditis by using
culture and culture-independent analysis
of cardiac biopsies
L. von Müller*, O. Wick, H.-J. Schäfers,
M. Herrmann (Homburg, DE)
P1748
Expression of virulence factors in Pseudomonas
aeruginosa strains from nosocomial pneumonia
and from non-infectious respiratory colonisation
processes
H. Sahly*, R. Podschun (Hamburg, Kiel, DE)
P1739
16S ribosomal RNA gene sequences from
cardiac valve tissue biopsies convey the
diagnosis of culture-negative endocarditis
M. Bjørnstad, F. Müller, I. Nordøy, A. Fiane,
O. Geiran, J. Svennevig, T. Tønjum* (Oslo, NO)
P1749
Alginate exopolysaccharide acts as a ligand
for P. aeruginosa invasion of lung epithelial
cells through its interaction with p63
M. Barbier*, I. Martínez-Ramos, S. Alberti
(Palma de Mallorca, ES)
P1750
In vivo gene expression and growth
conditions of Pseudomonas aeruginosa
in cystic fibrosis lungs
M. Macedo-Vinas, T. Köhler, D. Hocquet,
C. Amstutz, J. Dalphin, P. Pleasiat,
C. van Delden* (Geneva, CH; Besançon, FR)
P1751
Comparative evaluation of enterotoxin 2
encoding gene expression levels in Shigella
spp. and EIEC strains grown in the presence
of eukaryotic HeLa cells and artificial culture
media
V. Lazar*, M.C. Chifiriuc, S. Dinu, C. Szmal,
D. Cristea, I. Aldea, L. Dascalu, A.I. Cotar,
M. Popa, A. Holban, C. Bleotu (Bucharest, RO)
P1752
Virulence patterns of Pseudomonas
aeruginosa nosocomial strains associated
with different clinical infections
A.I. Cotar*, M.C. Chifiriuc, A. Holban, M. Popa,
O. Banu, V. Lazar (Bucharest, RO)
P1753
Interaction between oral streptococci and
two Prevotella species: an in vitro study
C.S. Stingu*, A.C. Rodloff (Leipzig, DE)
P1754
Prevalence of cytolethal distending toxin
(cdtABC) virulence gen in Campylobacter spp.
isolated from diarrhoeal and control cases in
Peruvian children under 2 years of age
A. Lluque, J. Ruiz*, A. Prada, T. Ochoa
(Lima, PE; Barcelona, ES)
P1755
Stool culture profile and long-term follow-up
of antibiotic associated haemorrhagic colitis
M. Yilmaz*, Y.A. Bilir, Y. Erzin, R. Ozturk, A.F. Celik
(Istanbul, TR)
P1756
Mechanical ventilation up regulates Toll-like
receptor 2 and activation of the lung by
bacterial lipopeptide
S.D. Barbar*, P.E. Charles, P. Tissières,
D. Croisier, J. Dufour, P. Chavanet, J. Pugin
(Dijon, FR; Geneva, CH)
13:30 – 14:30
P1740
P1741
Microbial pathogenesis – miscellaneous
Immunomodulatory effects of voriconazole
and caspofungin on human peripheral blood
mononuclear cells stimulated with Candida
albicans and Candida krusei
I. Fidan*, E. Yesilyurt, A. Kalkanci, S. Ozyegen
Aslan, N. Sahin, M.C. Ogan,M. Dizbay
(Ankara, TR)
Lipopolysaccharides O1 antigen and outer
membrane proteins contribute to virulence
and protective efficacy of O1 antisera in
Klebsiella pneumoniae
P.F. Hsieh, T.L. Lin, J. Wang* (Taipei, TW)
P1742
Isolation of genetic loci associated with
phagocytosis and virulence in Klebsiella
pneumoniae using a Dictyostelium model
Y.J. Pan, T.L. Lin, C.R. Hsu, J. Wang* (Taipei, TW)
P1743
Effect of endoplasmic reticulum stress
pathway on mycobacteria-induced cell death
Y. Lim, H.H. Choi, J.A. Choi, H.J. Kim, E. Jo,
J. Park, C. Song* (Daejeon, KR)
P1744
The role of aberrant tcdC sequences
in toxin production by Clostridium difficile
S.T. Cartman*, M.L. Kelly, S.A. Kuehne,
J.T. Heap, N.P. Minton (Nottingham, UK)
P1745
Analysis of cellular senescence induced
by lipopolysaccharide in pulmonary alveolar
epithelial cells
C. Kim*, S. Han, N. Ku, B. Chin, S. Jin, S. Jeong,
Y.G. Song, Y.K. Kim (Seoul, KR)
P1746
Virulence genes focG and agn43aCFT073
are related to mortality in Escherichia coli
bacteraemia
L. Skjøt-Rasmussen*, K. Ejrnæs, B. Lundgren,
A.M. Hammerum, N. Frimodt-Møller
(Copenhagen, DK)
P1747
Stenotrophomonas maltophilia phenotypic
properties of clinical relevance
M. Adamek* (Karlsruhe, DE)
Final Programme
Poster Sessions
Monday, 9 May
Virulence of Salmonella enterica serovar
Agona Pulse Field Type SAGOXB.0066,
cause of the 2008 European outbreak ex vivo studies
M.S. Martins*, M.P. McCusker, S. Fanning
(Dublin, IE)
P1758
Bacterial lipoprotein acylation is dispensable
for the pathophysiology of experimental
group B streptococcal meningitis
D. Grandgirard*, P. Henneke, P. Trieu-Cuot,
S. Leib (Berne, CH; Freiburg, DE; Paris, FR)
P1759
Characterisation of virulence factors and
antimicrobial resistance in Escherichia coli
strains causing pyelonephritis in children
J. Koren, K. Curova, M. Kmetova, L. Siegfried*,
L. Kovacs, H. Hupkova (Bratislava, Kosice, SK)
P1760
Pathogenic elements among staphylococci
isolated from bloodstream and prosthetic
devices-associated infections
N. Giormezis*, F. Kolonitsiou, A. Foka, E.
Drougka, G. Dimitriou, A. Spiliopoulou, E.D.
Anastassiou, I. Spiliopoulou (Patras, GR)
P1761
The role of monocyte derived VEGF in
hantavirus induced vascular leak
R. Cross*, T. Voss (New Orleans, US)
P1762
A role of triggering receptors expressed on
myeloid cells and the myeloid differentiation
factor 88 in Helicobacter pylori infection in
children
J. Michalkiewicz, A. Szaflarska, A. Helmin-Basa,
A. Marszalek, B. Kasztelewicz,
K. Dzierzanowska-Fangrat*
(Warsaw, Torun, PL)
P1763
P1764
Antibodies against a 20-kDa polysaccharide
of Staphylococcus epidermidis inhibit
adhesion and facilitate endocytosis to human
macrophages
A. Spiliopoulou, F. Kolonitsiou, I. Spiliopoulou,
N.K. Karamanos, D. Mack, E.D. Anastassiou*
(Patras, GR; Swansea, UK)
A new model to study microRNA modulation
in response to Mycobacterium tuberculosis
infection
E. Schena*, B. Gentner, P. Miotto, L. Sergi Sergi,
D. Cirillo, L. Furci (Milan, IT)
P1765
Early correlates between viral load and
host immune response in critical pandemic
influenza disease at ICU admission
R. Almansa, A. Antón, T. Pumarola,
J. Bermejo-Martin, P. Ramirez, D. Andaluz,
I. Martin-Loeches, P. Merino, L. Xu, L. Ran,
D. Banner, J. Eiros, L. Socias, A. Loza, E. Maravi,
M. Marcos, D. Kelvin, R. Ortiz de Lejarazu*
(Valladolid, Barcelona, Valencia, Tarragona, ES;
Toronto, CA; Palma de Mallorca, Seville,
Pamplona, ES)
P1766
Bacterial inoculum impact on the prognosis
of patients with Escherichia coli bacteraemia
L. Viñas Castillo* (Seville, ES)
P1767
Role of surface structures of an atypical
enteropathogenic Escherichia coli in
attachment and induction of IL-8 production
at early stages of intestinal cells infection in
vitro
S. Sampaio*, T.A. Gomes (São Paulo, BR)
P1768
Association of in vitro growth parameters
with in vivo virulence of Aspergillus fumigatus
based on a novel virulence index
E. Mavridou*, J. Meletiadis, P. Jancura, S. Abbas,
M. Cavling Arendrup, W. Melchers, J. Mouton,
P. Verweij (Nijmegen, NL; Athens, GR;
Copenhagen, DK)
P1769
May the brain parenchyma be influenced
in cutaneous anthrax patients without
central nervous system disorder?
A magnetic resonance spectroscopy study
Y. Bayindir*, A.K. Firat, U. Kayabas, A. Alkan,
F. Yetkin, H.M. Karakas (Malatya, TR)
P1770
The cutaneous interface as a key event in
Lyme borreliosis: study of different human
pathotypes in a murine model
A. Kern, E. Collin, C. Barthel, S.J. De Martino,
B. Jaulhac*, N. Boulanger (Strasbourg, FR)
P1771
Pseudomonas aeruginosa virulence
potential: comparison between clinical
isolates and pristine water isolates
obtained from a hydrotherapy facility
S.G. Pereira*, R. Leitão, O. Cardoso
(Coimbra, PT)
P1772
Chemokine secretion after stimulation with
Staphylococcus aureus is increased in
human neutrophil granulocytes from female
donors compared to male controls
F. Hitzenbichler*, W. Falk, P. Groß, B. Salzberger,
F. Hanses (Regensburg, DE)
Final Programme
Posters
P1757
163
Poster Sessions
Monday, 9 May
P1774
Dexamethasone reduces Staphylococcus
aureus-induced production of inflammatory
cytokines and matrix metalloproteases in
primary human chondrocytes and synovial
fibroblasts
F. Hanses*, I. Fink, S. Graessel, B. Salzberger,
M. Fleck (Regensburg, DE)
P1783
Induction of streptococcal experimental
endocarditis by cumulative low-grade
bacteraemia mimicking spontaneous
bacteraemia in humans
T.R. Veloso, M. Amiguet, M. Giddey,
J. Vouillamoz, V. Rousson, P. Moreillon,
J.M. Entenza* (Lausanne, CH)
P1775
Relationship between Bordetella pertussis
and chronic obstructive pulmonary disease
S. Hashemi*, E. Nadi, M. Hajilooi, M. Seif-Rebiei,
A. Samaei (Hamedan, IR)
P1785
P1776
Altered protein secretion of Chlamydia
trachomatis in persistently infected human
endocervical epithelial cells
J. Wang*, A.J. Quayle, L. Buckner, K. Frohich,
L. Shen (Beijing, CN; New Orleans, US)
Role of Candida albicans and Pseudomonas
aeruginosa direct interaction in the
protective effect of C. albicans colonisation
on P. aeruginosa-induced lung injury
J.B. Mear*, E. Kipnis, H. Tiesset, S. Jawahara,
C. Rouyer, F. Vuotto, D. Poulain, K. Faure,
B. Guery (Lille, FR)
P1786
Evaluation of bacterial colonisation
of biomaterials and its effect on TNF-A,-B
defensin-2 and Il-10 expression in tissues,
in vivo study, after 2- and 4-week exposure
in rabbit tissues
A. Reinis*, M. Pilmane, J. Kroica, J. Vetra,
A. Stunda, L. Berzina-Cimdina, V. Kuznecova,
D. Rostoka (Riga, LV)
P1777
Screening of nuclear targeting proteins in
Acinetobacter baumannii and their pathologic
effects on host cells
J.C. Lee*, D.C. Moon, M. Gurung, J.H. Lee, S. Jun,
J.S. Jin, B. Kim (Daegu, KR)
P1778
Effect of avian influenza A/H5N1 infection
on human cellular microRNA profile –
identification of gene regulatory pathways
leading to adverse clinical outcome
P. Chan*, W. Lam, K. To (Shatin, HK)
P1779
P1780
P1781
13:30 – 14:30
P1782
Dependence of group B streptococci
adherence on serotypes and alpha-like
protein genes
M. Bodaszewska-Lubas*, M. Brzychczy-Wloch,
T. Gosiewski, P. Adamski, M. Strus, P. Heczko
(Cracow, PL)
The Sov protein of the Porphyromonas
gingivalis secretion system functions
as an independent virulence factor
S. Shashkova*, J. Koziel, K. Maresz,
I. Thogersen, J. Enghild, Y. Guo, J. Potempa
(Cracow, PL; Aarhus, DK; Louisville, US)
Impact of different peritoneal dialysis fluids
on bacterial and yeast growth of common
pathogens
S. Tobudic*, C. Kratzer, H. Schranz, W. Poeppl,
13:30 – 14:30
P1787
Clinical and economic impact of GBS
intrapartum screening using molecular
diagnosis
N. El Helali*, Y. Giovangrandi, M.D. Kitzis,
M. Bobin, J. Fresson (Paris, Nancy, FR)
P1788
Quick and accurate diagnosis of toxinogenic
C. difficile combining Techlab C. diff Quik Chek
Complete and GeneXpert C. difficile RT-PCR
P. Vandecandelaere*, R. Joseph, C. De Ridder
(Ypres, BE)
P1789
Evaluation of the Xpert MRSA/SA® SSTI RT-PCR
assay for rapid detection of staphylococcal
osteoarticular infections
F. Laurent, V. Blanc-Pattin, J. M. Gandois,
A.M. Freydiere, N. Mehdi, S. Boisset, R. Guinand,
E. Chanard, A. de Ladoucette, D. Benzaquen,
A. Dubouix-Bourandy* (Lyon, L'Union, FR)
P1790
Detection of MRSA by GeneXpert:
poor sensitivity of throat specimens
compared to nose and groin specimens
D.S. Blanc*, L. Senn, G. Zanetti (Lausanne, CH)
P1791
Is VRE screening by Xpert™ vanA/vanB
PCR superior to selective culture on chromID™
VRE indicator agar?
H. Peltroche-Llacsahuanga*, G. Haase
(Aachen, DE)
Pathophysiology of infectious diseases, in vivo
Can Salmonella cure cancer?
Insights on a novel antitumoural mutant
I.A. Campos Damiani*, M.H. de Moraes,
A. dos Santos Moraes, A. Farias, L.M. Santos,
M. Brocchi (Campinas, BR)
Final Programme
Molecular point-of-care tests
Poster Sessions
Monday, 9 May
Lab automation
P1792
Automating the bacteriology laboratory
N. Bentley* (Cambridge, UK)
P1793
Experience with KIESTRA's Total Lab
Automation solution to meet the challenge
of universal MRSA screening for Lister
Hospital, a large UK district general hospital
G. Humphrey, C. Malone, H. Gough,
F.M. Awadel-Kariem* (Stevenage, UK)
P1794
Design of a new microbiology laboratory
based on Lean Six Sigma principles
J.P. Brochet*, J.M. Cassorla, H. Palumbo
(Le Haillan, Lyon, FR)
P1795
Efficiency of an automated streaking system
for bacteriological diagnostics
J. Knobloch* (Luebeck, DE)
P1796
Lean Six Sigma methods as a core asset
of the microbiology lab
J.M. Rousee*, T. Gueudet, C. Rieder-Monsch,
J.M. Cassorla, H. Palumbo
(Strasbourg, Montoison, Marcy-L'Etoile, FR)
P1797
Is liquid microbiology by the WASP® reliable?
M.E. Bierma*, J.M. van Bree, M.J. van de Ven,
T.C. Liebregts, N.L. Arents (Veldhoven, NL)
P1798
Automation in routine bacteriology –
experience with the WASP inoculation robot
O. Nolte*, H. Haag, M. Kommerell,
S. Brunner-Zillikens (Constance, DE)
P1799
P1800
Use of a sputum dipper and sputum
liquifying solution to process sputum
specimens prior to inoculation with
the Copan WASP instrument
P. Bourbeau*, F. Tomashefski, M. Tomcavage,
R. Wywadis (Danville, US)
WASP, a Walk Away Specimen Processor
enables accuracy and cost benefits
managing multiple specimens on a single
culture plate
G. Catalano*, M. Savarese, R. Botrugno,
S. Castriciano (Brescia, IT)
P1801
Reproducibility and quality of the InoqulA
M. Kleefstra*, C. Visser, M. van der Kaap
(Drachten, Amsterdam, NL)
P1802
Evaluation of the UriSwab® as a tool
to diagnose urinary tract infections
N.L. Arents*, U. Bayir, M. Förster, A.R. Jansz
(Veldhoven, NL)
P1803
The utilisation of the bacterial mode on
UF 1000i for the screening of urine samples
submitted to a microbiology laboratory
for culture
J. Jurankova*, J. Protivinsky (Brno, CZ)
P1804
Automated microscope and flow cytometer
to screen bacteriuria: a comparison
M. Trevino*, P. Areses-Elizalde, D. Navarro,
D. Peñalver-Barral, A. García-Zabarte,
C. García-Riestra (Santiago de Compostela, ES)
P1805
Comparison between UF-1000i (Sysmex)
flow cytometer and bacterial culture in rapid
diagnosis of urinary tract infection
I. Caola*, P. Lanzafame, R. Predazzer, A. Amari,
A. Rigoni (Trento, IT)
P1806
Screening for urinary tract infection in children:
evaluation of diagnostic performance and
optimal cut-off for Sysmex UF1000i flow
cytometer
R. De Rosa*, S. Grosso, M. Avolio, M. Modolo,
P. Stano, A. Camporese (Pordenone, IT)
P1807
Evaluation of automated microbiology
identification systems: comparison
of the Sensititre Aris® and Vitek® 2 when
testing Gram-positive and -negative
pathogens
S. Swoboda, B. Olson, T. Novicki, S. Shukla,
J. Meece, T. Fritsche* (Marshfield, US)
P1808
Efficiency of an automated Gram-staining
system for bacteriological diagnostics
J. Knobloch* (Lübeck, DE)
P1809
Evaluation of the Vitek2 ANC card for
the identification of clinical isolates
of anaerobic bacteria
E.H. Lee*, J. Degener, G.W. Welling, A. Veloo
(Groningen, NL)
13:30 – 14:30
Posters
13:30 – 14:30
Mobile genetic elements
P1810
The small resistance plasmid p9123
is widespread among enteric pathogens
and enhances their fitness
C.S. Wong, L.M. Hall, V.I. Enne*
(Bristol, London, UK)
P1811
Complete sequences of two 'untypable'
plasmids carrying blaCTX-M-1 group genes
S. Partridge*, J. Ellem, Z. Zong, S. Tetu,
I. Paulsen, J. Iredell (Sydney, AU; Chengdu, CN)
Final Programme
165
Poster Sessions
Monday, 9 May
P1812
Plasmid-mediated antimicrobial resistance:
characterising extended-spectrum betalactamases in Escherichia coli isolated from
cattle
C. Boinett*, M. Anjum, L. Villa, A. van Essen,
M. Woodward (Surrey, UK; Rome, IT; Lelystad, NL)
P1813
Genetic environments of aac(6’)-Ib-cr
and qnrs1 genes and plasmid content in
Enterobacteriaceae
E. Ruiz*, R. Rocha, M. Zarazaga, C. Torres,
G. Arlet (La Rioja, ES; Puebla, MX; Paris, FR)
P1814
Novel gene cassettes and integrons in
environmental antibiotic-resistant bacteria
A. Moura*, C. Pereira, I. Henriques, A. Correia
(Aveiro, PT)
P1815
Presence of mobile genetic elements
carrying virulence and antibiotic resistance
genes in non-pathogenic Vibrio strains
M. Gennari*, V. Ghidini, M. Tafi, M. Lleò
(Verona, IT)
P1816
P1817
13:30 – 14:30
P1818
The Repository of Antibiotic-resistance
Cassettes – an online database of gene
cassettes found in mobile resistance
integrons and a web-based application for
annotation of DNA sequences containing
these cassettes
S. Partridge*, G. Tsafnat (Sydney, AU)
Mobile genetic elements: a comparative
study of their presence in bacteria from
inanimate surfaces in Hospital Infante D. Pedro,
Aveiro, central Portugal, in 2005 and 2008
C. Santos*, R. Diaz, E. Ramalheira,
T. Caetano, S. Mendo (Aveiro, PT)
P1819
Application of DNA sequence analysis
of 16S-23S intergenic spacer region
for species identification of strains belonging
to the genera Abiotrophia, Aerococcus,
Facklamia, Gemella, Globicatella,
Granulicatella, Leuconostoc, and Rothia
X.C. Nielsen*, R. Dargis, M. Hammer,
A. Hesselbjerg, L. Hannecke, U.S. Justesen,
M. Kemp, J.J. Christensen
(Slagelse, Copenhagen, Næstved, Odense, DK)
1821
Combined DVC-FISH method for in situ
detection of viable Arcobacter butzleri cells
M.A. Artigot, A. González*, Y. Moreno, M.A. Ferrús
(Valencia, ES)
13:30 – 14:30
P1822
Faster microbial identification with MALDI-TOF
mass spectrometry and digital imaging:
a pilot study
N. Mutters, C. Hodiamont*, C. Visser
(Heidelberg, DE; Amsterdam, NL)
P1823
Tapping the potential of intact cell mass
spectrometry with a combined data analytical
approach
M. Wittwer*, J. Heim, M. Schaer, N. Schuerch
(Spiez, CH)
P1824
Methods for the immediate identification
of bacteria in charcoal-containing
BacT/ALERT® blood cultures by MALDI-TOF
mass spectrometry
J.D. Walsh*, J.M. Hyman (Durham, US)
P1825
Improved method for the immediate
identification of pathogens in BacT/ALERT®
standard aerobic blood cultures by
MALDI-TOF mass spectrometry
J.M. Hyman, J.D. Walsh* (Durham, US)
P1826
Use of MALDI-TOF technology for the rapid
microbiological diagnosis from blood samples
A. Peña*, R. Camacho, V. Guillot,
J.A. Perez-Lopez, M. Alvarez, F. Garcia Garcia,
J. Roman, T. Escobar, F. Garcia (Granada, ES)
P1827
Comparison of two MALDI-TOF mass
spectrometry instruments in a routine
microbiological laboratory
E. Leitner*, M. Keimel, B. Heiling, S. Grabner,
G. Feierl, W. Buzina, A.J. Grisold, L. Masoud,
U. Wagner-Eibel, M. Gehrer, E. Marth (Graz, AT)
P1828
MALDI-TOF in diagnosis of fungal infections
A. Iranzo Tatay*, J. Frasquet Artés, G. Fagundez
Machiain, M. Gobernado Serrano (Valencia, ES)
New species and unusual pathogens:
usefulness of molecular tools for bacterial
identification
A quantitative assessment of Borrelia and
Bartonella DNA and tick-borne encephalitis
virus RNA in Ixodes persulcatus Schulze ticks
collected in Chelyabinsk region of Russia
A. Grishechkin*, A. Kon'kova-Reidman,
O. Morozova (Moscow, Chelyabinsk, RU)
Final Programme
MALDI-TOF
Poster Sessions
P1829
Replacement of classical non-automated
methods by MALDI-TOF mass spectrometry
for routine identification of bacteria and
yeasts
G. Coppens*, K. Martens, G. De Sutter,
J. Heyligen, E. Oris (Genk, BE)
P1830
Improvement of identification of anaerobes
by MALDI-TOF mass spectrometry analysis
M. Marschal*, U. Schumacher, I. Autenrieth
(Tübingen, DE)
P1831
Identification of clinically relevant
anaerobic bacteria using two different
MALDI-TOF mass spectrometry methods
M. Knoester*, A. Veloo, J. Degener, E. Kuijper
(Leiden, Groningen, NL)
P1832
Excellent identification of coagulasenegative staphylococci using MALDI-TOF
despite a rough procedure
J. Åhman, A.-K. Gustafsson, M. Bergman
Jungström, L. Serrander, M. Sundqvist*
(Växjö, Karlskrona, Linköping, SE)
P1833
Evaluation of MALDI-TOF mass spectrometry
to identify Corynebacterium spp.
P.M. Juiz*, C. Salas, C. García de la Fuente,
J. Agüero, C. Pitart, F. Marco, M. Almela,
L. Martínez-Martínez, J. Vila
(Barcelona, Santander, ES)
P1834
P1835
MALDI-TOF mass spectrometry-based
analysis for identification of CF Burkholderia
strains and validation of phylogenetic tree by
triple-locus sequence typing
C. Vogne*, G. Prod'Hom, K. Jaton, G. Greub
(Lausanne, CH)
Candida identification with direct smear
and ethanol-formic acid extraction methods
of MALDI-TOF: comparison with Vitek2
E. Kalogeropoulou*, G. Vrioni, W. Solbach,
A. Tsakris, J. Knobloch
(Chaidari, Athens, GR; Lübeck, DE)
P1836
Prediction of carbapenem resistance in
Bacteroides fragilis by MALDI-TOF mass
spectrometry analysis
I. Wybo, A. De Bel, O. Soetens, F. Echahidi,
K. Vandoorslaer, M. Van Cauwenbergh,
D. Pierard* (Brussels, BE)
P1837
Comparision of Vitek2, Phoenix, and MALDITOF for the identification of Acinetobacter
species
N. Karah, R. Smyth, B. Haldorsen, A. Sundsfjord,
Ø. Samuelsen* (Tromsø, NO; Växjö, SE)
P1838
Identification of Acinetobacter calcoaceticusAcinetobacter baumannii complex strains by
MALDI-TOF mass spectrometry
P. Espinal*, I. Roca, J. Vila (Barcelona, ES)
P1839
Identification of non-tuberculous
mycobacteria by MALDI-TOF mass
spectrometry fingerprinting
A.J. Buss*, M. Timke, M. Kostrzewa
(Groningen, NL; Bremen, DE)
P1840
Challenges when applying MALDI-TOF
mass spectrometry as a diagnostic tool for
the identification of dermatophytes
R. Jensen*, D. Nielsen, M. Cavling Arendrup
(Copenhagen, DK)
P1841
Rapid identification of bacteria and fungi
from positive blood cultures by MALDI-TOF
proteome profiling
F. Del Chierico, S. Ranno, B. Lucignano,
M. D'Urbano, S. Tredici, P. Bernaschi, L. Putignani*,
D. Menichella (Rome, IT)
P1842
Direct identification of microorganisms
from the bioMérieux BacT/Alert blood culture
system by MALDI-TOF is possible
J.D. Haigh*, D. Ball, M. Eydmann, M. Millar,
M. Wilks (London, UK)
P1843
Streptococcus identification using proteomic,
metabolic and molecular biologic approaches
M. Risch, T. Leibundgut, U. Nydegger*,
D. Radjenovic, L. Risch (Liebefeld, CH)
P1844
Discrepancies in Gram-positive cocci
identification when comparing conventional
tests and mass spectrometry
A. Iranzo Tatay*, J.L. Lopez Hontangas,
M. Gobernado Serrano (Valencia, ES)
13:30 – 14:30
Biofilm: diagnostic approaches to therapeutic
measures
P1845
Evaluation of colonisation of pacemakers
and defibrillators from strains that produce
biofilm and their study with atomic force
microscopy
S. Arampatzi*, G. Giannoglou, E. Protonotariou,
S. Logothetidis, S. Paraskevaidis, V. Vasilikos,
I. Styliadis, E. Diza (Thessaloniki, GR)
P1846
Evaluation of biofilm formation on coronary
angiography catheters and their study with
atomic force microscopy
S. Arampatzi*, G. Giannoglou, E. Protonotariou,
S. Logothetidis, Y. Chatzizisis, S. Hatzimiltiadis,
I. Styliadis, E. Diza (Thessaloniki, GR)
Final Programme
167
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
P1847
Visualisation of microbial biofilm on
explanted central venous catheters by
two-photon laser scanning microscopy
F. Tessarolo*, I. Caola, M. Lorenzato,
F. Piccoli, G. Nollo, P. Caciagli (Trento, IT)
P1848
The effects of ferulic and gallic acids on
motility and biofilm control of pathogenic
bacteria
A. Borges*, M.J. Saavedra, M. Simões
(Vila Real, Porto, PT)
P1849
P1850
P1851
P1852
P1853
P1854
P1855
Characterisation of bacterial cells recovered
from biofilms formed on orthopaedic metal
components used in surgical implants
E.L. Pizzolitto*, C.A.L. Santos, F.F. Campos
Junior, A.C. Bernardi, T.P. Leivas, K.E. Kojima,
A.C. Pizzolitto (Araraquara, Sao Paulo, BR)
Isolation of genes involved in biofilm
formation of a Klebsiella pneumoniae
strain causing pyogenic liver abscess
M.C. Wu*, T.L. Lin, P.F. Hsieh, H.C. Yang
(Taipei, TW)
Molecular genotyping, adhesion and biofilm
formation in methicillin-resistant
Staphylococcus aureus clinical strains
G. Gherardi, S. Pomponio, D. Visaggio,
A. Pompilio, G. Dicuonzo, S. Angeletti*,
R. Creti, L. Baldassarri, G. Di Bonaventura
(Rome, Chieti, IT)
Comparison of various antimicrobial agents
as catheter lock solutions in an in vitro model
of coagulase-negative staphylococcal biofilm
A. Peña, R. Gálvez, C. Tomás-Jiménez,
D. Parra, J. Hernández-Quero, J. Parra-Ruiz*
(Granada, Murcia, Oviedo, ES)
Application of Escherichia coli biofilm
supported on clinoptilolite for biosorption
of cadmium from aqueous solution
A. Maleki*, E. Kalantar, B. Davari, A. Mahvi
(Sanandaj, Tehran, IR)
Phenolic antioxidants that target the
staphylococcal membrane may have
potential as biofilm-eradicating agents
N. Ooi*, I. Chopra, J. Cove, A. Eady, A.J. O'Neill
(Leeds, Bradford, UK)
Multidrug-resistant Acinetobacter baumannii
and Pseudomonas aeruginosa biofilm
formation and the destruction activity of
macrolide antibiotics
S. Fujimura*, H. Takane, Y. Nakano, A. Watanabe
(Sendai, JP)
Final Programme
P1856
Improved antibiotic activity against
Pseudomonas aeruginosa biofilms using a
novel surface active lamellar body mimetic
LMS-611
R. Rajendran*, C. Williams, E. McCulloch,
G. MacGregor, S. Bicknell, G. Park, G. Ramage
(Glasgow, UK)
P1857
Activity of daptomycin, levofloxacin,
clindamycin and rifampicin against
Propionibacterium acnes in planktonic
and biofilm state
U. Furustrand*, W. Zimmerli, A. Trampuz
(Lausanne, Liestal, CH)
P1858
Ciprofloxacin or linezolid in combination
with rifampicin is effective against
Enterococcus faecalis in biofilm
A. Holmberg*, M. Mörgelin, M. Rasmussen
(Lund, SE)
P1859
The evaluation of lethal photosensitisation
for decontamination of implant surfaces
in the treatment of peri-implantitis in
patients of Paschoal Dantas Dental College,
Sao Paulo, Brazil
E. Costa*, C. Costa, F.P. Varolli, M.F. Rodrigues,
D. Cassiri (Sao Paulo, BR)
P1860
Antibiofilm activities of bismuth-thiol-biocides
on bacteria isolated from urinary catheter
surfaces
G. Rahmany*, A. Abdi Ali, P. Mohammadi
(Tehran, IR)
P1861
Biofilm communities on urinary tract catheters
V. Hola*, F. Ruzicka (Brno, CZ)
P1862
Coral-associated bacteria as a novel source
for antibiofilm and quorum quenching agents
D. Bakkiyaraj*, C. Siva Sankar, S. Karutha
Pandian (Karaikudi, IN)
P1863
Fluconazole susceptibility, oxidative stress
response and production of extracellular
hydrolases in Candida glabrata clinical isolates
N. Berila, P. Hyrossova, J. Subik* (Bratislava, SK)
P1864
A novel glycolipid biosurfactant from marine
Serratia marcescens disrupts pathogenic
Candida albicans BH and Pseudomonas
aeruginosa PAO1 biofilms
D. Dusane*, V. Pawar, Y. Nancharaiah,
V. Venugopalan, A.R. Kumar, S. Zinjarde
(Pune, Chennai, IN)
Poster Sessions
13:30 – 14:30
P1865
P1866
P1867
P1868
Molecular virology
RT-PCR microarray detection of viral
respiratory pathogens in acute exacerbations
of COPD in France
F. Renois*, J. Perotin, G. Deslee, F. Lebargy,
L. Andreoletti (Reims, FR)
Laboratory investigation of the Greek
measles 2010 outbreak
A. Melidou*, G. Gioula, V. Pogka, M. Exindari,
A. Moutoussi, D. Sgouras, K. Papadakos,
D. Chatzidimitriou, D. Karabaxoglou, A. Mentis,
N. Malisiovas (Thessaloniki, Athens, GR)
Respiratory viruses involved in acute
respiratory infections in a Greek paediatric
population during the winter period of the
years 2005 – 2008
V. Pogka*, A. Kossivakis, M. Giannaki,
A. Moutousi, D. Sgouras, T. Panagiotopoulos,
M. Theodoridou, V. Syriopoulou, A. Mentis
(Athens, GR)
In-house real-time PCRs are more sensitive
than RespiFinder Plus TwoStep, and xTAG RVP
for detection of respiratory viruses in
nasopharyngeal flocked swabs from adult
patients with lower respiratory tract infections
K. Loens*, A. Vanderstraeten, C. Lammens,
H. Goossens, F. Coenjaerts, E. Claas, A. van Loon,
M. Ieven on behalf of the GRACE study group
P1869
Rapid killing of influenza virus and RNA
preservation from samples held at elevated
temperatures for extended periods
L.T. Daum*, S.A. Worthy, Y.W. Choi, G.W. Fischer
(San Antonio, Columbus, US)
P1870
Genomic extraction methods for detection
of viral respiratory infections
M. de Oña*, P. Capón, L. Garrido, M.E. Alvarez,
J. Boga, S. Melón (Oviedo, ES)
P1871
P1872
Human rhinovirus species occurrence among
adults with respiratory tract infection and
asymptomatic individuals during two
consecutive winter seasons
K. Zlateva*, S. van Nieuwkoop, F. Coenjaerts,
N. Farzad, T. Verheij, P. Little, M. Ieven, E. Claas
on behalf of the GRACE Study Group
Comparison of the Abbott real-time highrisk HPV with Genomica HPV clinical array
for the detection of human papillomavirus
genotypes
C. Sias*, A.R. Garbuglia, D. Lapa, F. Del Nonno,
S. Belladonna, G. de Cunto, F.R. Pulvirenti,
M.R. Capobianchi (Rome, IT)
P1873
Human papillomavirus typing in a cohort
of 200 women in Greece
C. Trigoni*, A. Chrysagi, D. Chrysagi,
J. Stamatiou, D. Karakalpakis, E. Charvalos
for the IASO group
P1874
Implementation validation of the Qiagen
Artus HCV RT-PCR assay on the Rotorgene
6000 platform
G. Duson, B. Van Meensel, A. Smismans,
I. Verstreken, J. Frans* (Bonheiden, BE)
P1875
Comparison of BD ProbeTec™ HSVQ^x assays,
ELVIS viral culture system, and TaqMan
real-time HSV PCR assays in herpes simplex
virus detection of external anogenital lesions
M. Huang*, L. Corey, B. Van Der Pol, E. Hook,
B. Body, M. Nye, S. Taylor, M. Martens, P. Fine,
S. Ginde, J. LeBed, L. Mena, T. Warren
(Seattle, Indianapolis, Birmingham,
Burlington, New Orleans, Tulsa, Houston,
Denver, Philadelphia, Jackson, Portland, US)
P1876
Performance characteristics of GeneXpert
FluA PCR in comparison with real-time PCR
in the current H1N1 influenza A pandemic
S. Al Johani* (Riyadh, SA)
P1877
Evaluation of AdvanSure HPV screening
real-time PCR, Abbott real-time high-risk HPV
test, and Hybrid Capture 2 HPV DNA test for
the detection of human papillomavirus
Y. Hwang*, M. Lee (Seoul, KR)
P1878
Quantification of CMV DNA in plasma by
real-time PCR for monitoring allogeneic stem
cell transplant recipients
L. Cardeñoso, A. Somodevilla*, A. Palmeiro,
A. Garcia-Noblejas, A. Figuera, R. de la Cámara
(Madrid, ES)
P1879
Evaluation of the extractor of nucleic
acids incorporated in the Versant kPCR
molecular system to use with the Trugene
HIV-1 genotyping kit in plasma samples
with viral loads <1000 copies/ml
F. Fernández-Cuenca*, F.J. Vázquez-Barbero,
M.J. Ríos, J. Rodríguez-Baño, Á. Pascual
(Seville, ES)
P1880
Quantitative real-time PCR with automated
viral DNA extraction for diagnosis and
monitoring of cytomegalovirus in allogeneic
bone marrow transplant recipients
K. Liopeta*, O. Dimitrakopoulos, M. Liga,
A. Spyridonidis, E.D. Anastassiou, F. Paliogianni
(Patra, GR)
P1881
Could conjunctival swabs be useful
to diagnose herpetic keratitis?
L. Barrado*, E. Perez-Blazquez, M. Suarez,
J.R. Otero, L. Folgueira (Madrid, ES)
Final Programme
169
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
P1882
P1883
13:30 – 14:30
P1884
P1885
P1886
P1887
P1888
P1889
P1890
The impact of thermocycler variability
on IVD CE kit validation
M. Span* (Landgraaf, NL)
P1891
Evaluation of automated DNA extraction
devices for sepsis diagnostics
S. Laakso*, M. Mäki (Helsinki, FI)
P1892
Molecular versus conventional diagnosis
of intestinal parasitoses
A. Calderaro*, C. Gorrini, S. Montecchini,
G. Piccolo, C. Chezzi (Parma, IT)
P1893
Use of PCR on urine samples for the diagnosis
of toxoplasmosis after allogeneic stem cell
transplantation
V. Suybeng, H. Labussière, M. Wallon,
M. Rabodonirina, F. Peyron* (Lyon, FR)
P1894
Two multiplexed nucleic acid tests for the
detection of viral and bacterial pathogens
in cerebrospinal fluid
A. Zoldowski*, S. McBride, F. Merante,
H. Zhang, N. Krunic (Toronto, CA)
P1895
Evaluation of a multiplex nucleic acid test for
the detection of gastrointestinal pathogens
in faecal samples
C. Öhrmalm*, S. Yaghoubian, L. Leyva,
H. Zhang, J. Blomberg (Uppsala, SE; Toronto, CA)
P1896
Development of a rapid method for Proteus
spp. detection in urine by peptide nucleic
acid fluorescence in situ hybridisation (PNA)
C. Almeida*, N.F. Azevedo, J. Bento, M.J. Vieira,
C.W. Keevil (Braga, Porto, PT; Southampton, UK)
P1897
Comparison of six differentiation methods
for identification of coagulase-negative
staphylococci
A.J. Loonen*, A.R. Jansz, J.N. Bergland,
P. Wolffs, A.J. van den Brule
(Eindhoven, Maastricht, NL)
Evaluation of the QIAsymphony® DSP
pathogen complex system: mid-throughput
automation for diagnostic sample extraction
T. Hanselle*, S. Hammerschmidt, Y. Kasper,
C. Kupfer, K. Lindebaum, M. Otte,
M. Sprenger-Haussels (Hilden, DE)
P1898
Evaluation of PrimeStore® molecular
transport medium for use in the diagnosis
of TB
N.A. Ismail*, A. Dreyer, S.V. Omar, L.T. Daum,
G. Fischer, P.B. Fourie, A.A. Hoosen
(Pretoria, ZA; Bethesda, US)
Non-culture diagnosis of neonatal sepsis
caused by Streptococcus agalactiae
A. De Zoysa*, A. Vickers, K. Edwards, S. Gharbia,
A. Underwood, A. Bedford Russell, P. Heath,
E. Galiza, I. Storey, A. Efstratiou
(London, Birmingham, UK)
P1899
Performance of Gen-Probe’s Aptima
Combo 2® Assay on the Panther™ system
C. Clark, M. Archer, J. Gilker, M. Hunsicker,
S. Lang*, T. Le-Nguyen, C. Motta, C. Nguyen,
J.K. Pham, T. Trsic, M. Vi, L. Villegas, B. Vinluan,
C. Vu, A. Williams, A. Worlock (San Diego, US)
Molecular-genetic heterogeneity of tick-borne
encephalitis virus in Transbaikalie region
E. Sidorova*, E. Andaev, T. Borisova, A. Trukhina,
L. Karan, V. Pogodina, N. Kalyasnikova,
O. Nagibina, S. Balakhonov (Irkutsk, RU)
Investigation of potential relationship
between BKV with kidney and bladder
cancers
Y. Bulut*, E. Ethem, N. Akpolat, F. Aker,
Z.A. Toraman, A. Seyrek (Elazig, Istanbul, TR)
Molecular diagnostics
A new method to inactivate genes on large
conjugative plasmids for investigation of
their biological function
J.L. Cottell*, M.A. Webber, L.J. Piddock
(Birmingham, UK)
Evaluation of a novel non-enzymatic method
for enrichment of pathogen DNA from whole
blood
A.J. Loonen, B. van Meerbergen, S. Neerken,
R. Penterman, I. Dobbelaer, K. Schmidt,
P. van de Wiel, A.J. van den Brule*
(Eindhoven, NL)
Development of a rapid, fully automated
method for selective isolation of bacterial
and fungal DNA from large volumes of whole
blood
S. Neerken*, R. Penterman, B. van Meerbergen,
I. Dobbelaer, K. Schmidt, P. van de Wiel
(Eindhoven, NL)
Liquor protein profiling for the diagnostics
of acute bacterial meningitis using MALDI-TOF
mass spectrometry and ClinProt technology
L. Ikryannikova*, E. Ilina, E. Klimova, N. Yuschuk,
M. Kostrzewa, V. Govorun
(Moscow, RU; Bremen, DE)
Final Programme
Poster Sessions
P1900
Performance of Gen-Probe’s Aptima®
Assays for Chlamydia trachomatis and
Neisseria gonorrhoeae on the Panther™
system
C. Clark, M. Archer, J. Gilker, M. Hunsicker,
S. Lang*, T. Le-Nguyen, C. Motta, C. Nguyen,
J.K. Pham, T. Trsic, M. Vi, L. Villegas, B. Vinluan,
C. Vu, A. Williams, A. Worlock (San Diego, US)
P1901
A novel, automated DNA extraction method
from cervical SurePath® specimens
C. Kupfer*, K. Lindebaum, C. Papadopoulos,
J. Giles, T. Hanselle, M. Sprenger-Haussels
(Hilden, DE; Gaithersburg, US)
P1902
Variability of ompC and ompF porin genes
in multi-resistant clinical isolates of E. coli
B. Ruiz del Castillo*, E. Roman, G. Moncalian,
L. Martinez-Martinez (Santander, ES)
P1903
Cloning, soluble expression and immunoreactivity of HIV-1 CRF35_AD p24 protein
in fusion with HP-thioredoxin from an
Iranian clinical isolate
M. Farajollahi*, Z. Sharifi, F. Gorgipor
(Tehran, IR)
P1904
Campylobacter jejuni cmeA/B transcription
in poultry and human
M. Dzieciol*, M. Wagner, I. Hein (Vienna, AT)
P1905
The impact of rapid identification with
PNA FISH® of selected bacteria and yeasts
from blood cultures on antibiotic treatment
and clinical advice: a cross-sectional study
of 123 episodes of bacteraemia in 118 patients
S.H. Hartzen*, H. Colding
(Hillerød, Copenhagen, DK)
P1906
P1907
Characterisation of probiotic and
antioxidative properties of Nisin A producer
L. lactis LL27 strain
D. Kaya Ozdogan, N. Akkoc*, P. Sanlibaba,
M. Akcelik (Ankara, TR)
CagA status and VacA subtypes of Helicobacter
pylori in relation to gastrointestinal
complications in Iranian population
S. Saberi*, M. Douraghi, F. Ebrahimzadeh,
Y. Talebkhan, S. Jahangiri, P. Hassanpour,
N. Mohajerani, E. Mostafavi, N. Rakhshani,
M. Mohagheghi, M. Eshagh Hosseini,
M. Mohammadi (Tehran, IR)
P1908
The association of MDR1 gene C3435T
polymorphism with CMV reactivation
in patients with multiple myeloma
N. Gorovenko*, N. Kostyukova, S. Vydyborets,
S. Kyryachenko, L. Gorenko, V. Mazurik,
O. Popova, Z. Rossokha (Kiev, UA)
P1909
Integrated DNA extraction and purification
on an automated microfluidic lab-on-chip
from bacterial pathogens causing
community-acquired lower respiratory
tract infections
L. Van Heirstraeten*, T. Roeser, P. Spang,
B. Nieto, M. Camps, B. Landgraf, C. Schwind,
K. Drese, M. Ritzi-Lehnert, H. Goossens,
S. Malhotra-Kumar on behalf of the TheraEDGE
(European Commission, 7th Framework
Programme) WP 2, 3 and 5 study groups
P1910
Reduction of workload of microbial
gastroenteritis diagnostics by molecular
pre-screening
W.A. van der Reijden*, C. Nguyen, T.G. Mank,
R. Jansen (Haarlem, NL)
P1911
Evaluation of the PNA FISH® technology
for yeast identification directly from positive
blood cultures. An Italian experience
C. Farina*, S. Andreoni, C. Bonetti, P. Casella,
M. Conte, P. Fazii, G. Lombardi, F. Luzzaro,
E. Manso, P. Marone, C. Morazzoni, M. Passera,
S. Perin, A. Rocchetti, S. Sanna, E. Viganò
on behalf of the Medical Mycology CommitteeAssociazione Microbiologi Clinici Italiani (AMCLI)
P1912
Comparison of culture with two different
qPCR assays for detection of rectovaginal
carriage of Streptococcus agalactiae
N. El Aila*, I. Tency, G. Claeys, H. Verstraelen,
P. Deschaght, E. Decat, G. Santiago, P. Cools,
M. Temmerman, M. Vaneechoutte (Ghent, BE)
P1913
Rapid identification of yeasts by PNA-FISH
in patients with candidaemia
S. van den Tempel, V. Özenci, L. Klingspor,
M. Ullberg* (Stockholm, SE)
P1914
Clinical consequences of using PNA-FISH
U.S. Jensen*, J. Knudsen (Copenhagen, DK)
P1915
Integration of affordable molecular
detection of beta-lactamase genes with the
CDS disc diffusion method of antibiotic
susceptibility testing
I.W. Carter*, J. Pham, S.M. Bell (Sydney, AU)
Final Programme
171
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
13:30 – 14:30
From molecular diagnosis to molecular
epidemiology
P1916
Full automation of nucleic acid extraction
with the dual STARlet (Hamilton)-MagNAPure
96 (Roche) system: a preliminary experience
K. Jaton*, R. Brouillet (Lausanne, CH)
P1917
Recognition of positive urine samples
by using a real-time PCR-based semiquantitative breakpoint
W.L. Hansen*, C. van der Donk, E. Stobberingh,
P. Wolffs (Maastricht, NL)
P1918
P1919
P1920
P1921
Description of an unusual N. meningitidis
isolate containing and expressing
N. gonorrhoeae-specific 16S rDNA sequences
M. Walcher*, M. Montgomery-Fullerton,
R. Skvoretz, V. Jonas, S. Brentano
(San Diego, US)
Multicentre evaluation of PNA-FISH
test for species identification of selected
Gram-negative bacilli, Gram-positive
cocci and yeasts from blood cultures
A. Raglio, C. Venturelli, D. Barbarini, A. Grosini,
E. Carretto*, P. Marone, F. Rumpianesi,
P. Serna Ortega, M. Passera, A. Goglio
(Bergamo, Modena, Pavia, IT)
Escherichia coli of the phylogenetic group
B2 from patients with inflammatory bowel
disease compared with uropathogenic B2
isolates
H. Mirsepasi*, J. Engberg, K. Krogfelt,
A. Friis-Møller, I. Nordgaard-Lassen, S. Wildt,
A. Petersen (Copenhagen, Hvidovre, DK)
Evaluation of the new GNR Traffic Light™
PNA FISH® fluorescence in situ hybridisation
probes for rapid same-day identification
of Gram-negative rods from positive blood
culture bottles
L. Leerbeck*, D.S. Hansen (Hillerød, DK)
13:30 – 14:30
Molecular diagnosis of respiratory tract
infections – Upper and lower
P1924
Molecular differentiation of H. influenzae
and non-haemolytic H. haemolyticus in
bronchoalveolar lavage fluids of children
with lower respiratory tract infections
I. Leroux-Roels*, I. De Schutter, F. Crokaert,
C. Heymans, J. Debruyne, J. Bouckaert,
O. Soetens, D. Piérard (Brussels, BE)
P1925
Diagnostic utility of BinaxNow for detection
of S. pneumoniae among children with
suspected IPD
J. Picazo, J. Ruiz Contreras, E. Ríos*,
E. Culebras, I. Rodriguez-Avial, C. Betriu,
C. Mendez on behalf of Heracles Study Group
P1926
Implementation validation of a real-time
Mycoplasma pneumoniae assay (Diagenode)
on the Rotorgene 6000 platform
G. Duson, B. Van Meensel, A. Smismans,
I. Verstreken, J. Frans* (Bonheiden, BE)
P1927
Detection rates of Haemophilus influenzae,
Streptococcus pneumoniae, Moraxella
catarrhalis in children with otitis media with
effusion and comparison of the results
obtained by culture and PCR
M. Baysallar*, A. Uskudar Guclu, S. Yetiser,
A. Kilic, C. Acikel (Ankara, TR)
P1928
Weak mutators within first positive
Pseudomonas aeruginosa isolates recovered
from bronchial secretions of cystic fibrosis
patients
A. Fernandez-Olmos*, L. Garcia-Garcia,
M.C. Turrientes, F. Baquero, J.C. Galán, R. Cantón
(Madrid, ES)
13:30 – 14:30
Molecular diagnosis on culture-negative
infections
P1922
Diversity of emerging Acinetobacter species
in a tertiary university hospital in northern
Spain
R. Cayô*, M.E. Cano, J. Calvo, L. Martínez-Martínez
(Santander, ES)
P1929
Identification of bacteria by sequencing
in routine laboratory practice
N.E. Pestova, M.O. Lubkina, E.V. Schlyakhto
(St. Petersburg, RU)
P1923
Molecular epidemiology and clonal
evolution of Brucella melitensis in Spain
S. González Cabrero, F. Menegotto, A. Cubero
Ribas, W. Cuervo, V. de Santiago, M.P. Gutiérrez
Rodríguez, A. Orduña, M.A. Bratos Pérez*
(Valladolid, ES)
P1930
Implementation of a novel multiple-target
real-time assay into a clinical microbiology
laboratory
L. Thomas*, T. Olma, J. Iredell
(New South Wales, AU)
P1931
Molecular-based methods for identification
of microbiological aetiologies of bacteraemia
T.Y. Wolff*, C. Moser, T. Bjarnsholt, N. Høiby,
J. Lorenzen, P. Nielsen, T. Thomsen (Aarhus,
Copenhagen, Aalborg, DK)
Final Programme
Poster Sessions
P1932
16S rDNA sequence analysis as supplement
to traditional blood culturing for improved
detection of pathogens in diagnostic setting
E. van Zanten*, A.V. Möller, A.M. Kooistra-Smid
(Groningen, NL)
P1933
Molecular diagnosis of bacterial endocarditis
by 16S rDNA broad-range PCR and sequencing
directly from valvular tissue with vegetations
K. Ohkusu*, T. Ezaki (Gifu, JP)
P1934
Multiplex PCR in sonication fluid of removed
implants for diagnosis of prosthetic joint
infection
M.E. Portillo*, S. Diaz, A. Alier, M.L. Sorli,
S. Martinez, N. Sandoval, L. Puig, J.P. Horcajada,
M. Salvadó (Barcelona, ES)
P1935
Application of PCR, FISH and culture
methods in rapid detection of bacterial joint
fluid infection
M. Bulanda*, T. Gosiewski, A. Chmielarczyk,
D. Romaniszyn (Cracow, PL)
P1936
P1937
13:30 – 14:30
Molecular characterisation of the viable
bacterial content of ascitic fluid from patients
with cirrhosis
G.B. Rogers*, P. Marsh, L. Fraser, J. Collins,
K.D. Bruce, M. Wright
(London, Southampton, UK)
Contribution of molecular methods to
diagnostics of prosthetic joint infections
T. Freiberger*, B. Zaloudikova, J. Novak,
M. Filipovic, J. Jurankova, E. Nemcova,
M. Stechova (Brno, CZ)
P1941
Comparison of MycAssay™ Aspergillus
test with galactomannan detection in
bronchoalveolar lavage fluid samples of
haematological and ICU patients
R. Torelli, B. Posteraro, E. De Carolis,
G. De Pascale, M. Caira, G. Bello, M. Antonelli,
L. Pagano, G. Fadda, M. Sanguinetti* (Rome, IT)
P1942
Evaluation of MycAssay™ Aspergillus
molecular diagnostic test and automated
EZ1 DNA extraction for detecting Aspergillus
spp. DNA in bronchoalveolar samples
of patients with risk factors for pulmonary
invasive aspergillosis
E. Roselló*, M. Culebras, J. de Gracia, G. Codina,
A. Alvarez, I. Ruiz, C. Figueras, A. Moreno,
A. Torrent, C. Díaz de Heredia, A. Andreu
(Barcelona, ES)
P1943
CandidaFinder: an innovative multiplex
diagnostics for the detection of Candida spp.
G. Dingemans, Y. Ozog, R. Boesten,
C.H. Klaassen, M. Reijans*, J. Meis,
M. Vaneechoutte, T. Boekhout, G. Simons
(Maastricht, Utrecht, Nijmegen, NL; Ghent, BE)
P1944
Candida mesorugosa sp. nov., a novel yeast
species similar to Candida rugosa, isolated
from clinical samples in Brazil
G.M. Chaves, G.R. Terçarioli, A.C. Padovan*,
R.C. Rosas, A.S. Melo, A.L. Colombo
(Natal, Sao Paulo, BR)
P1945
Resolution of C. albicans identification
discrepancies using a C. dubliniensis
specific PNA probe
S. Stevens*, J. Shepard, H. Stender,
M. Fiandaca, K. Oliveira
(Woburn, US; Vedbaek, DK)
P1946
Rapid discrimination between Candida
glabrata, Candida nivariensis and Candida
bracarensis using a simple-plex PCR
A. Enache-Angoulvant*, J. Guitard,
F. Grenouillet, C. Fairhead, C. Hennequin
(Le Kremlin-Bicêtre, Paris, Besançon, Orsay, FR)
P1947
Molecular investigation of Fusarium
isolates from keratomycosis
C.S. Shobana, L. Galgóczy*, M. Homa,
L. Kredics, K. Panneerselvam, R. Rajendran,
V. Narendran, C. Vágvölgyi, P. Manikandan
(Coimbatore, IN; Szeged, HU)
P1948
MALDI-TOF mass spectrometry proteome
profiling for identification of clinically
relevant moulds
L. Putignani*, F. Del Chierico, E. Fiscarelli,
M. Onori, L. Mancinelli, G. Ricciotti, T. Franchin,
A. Pompilio, L. Dimiziani, C. Russo, A. Urbani,
D. Menichella (Rome, Chieti, IT)
Molecular mycology
P1938
Aetiology of invasive fungal infections:
results of a two-centre study in tissue
biopsies from patients with proven infection
M.J. Buitrago*, A. Ballen, J. Garcia-Rodriguez,
L. Bernal-Martinez, A. Garcia-Reyne, M. Prieto,
J.M. Aguado, M. Cuenca-Estrella
(Majadahonda, Madrid, ES)
P1939
Development of an inhalation model
of invasive pulmonary aspergillosis
by Aspergillus fumigatus for evaluating
the efficacy of detection of non-invasive
markers for early diagnosis of infection
Z. Khan*, A. Al-Shaikh, S. Ahmad (Safat, KW)
P1940
Metabolomics of Scedosporium and
Aspergillus by mass spectrometry
V. Havlicek*, M. Sulc, K. Peslova, M. Volny,
P. Novak, J.-P. Bouchara, M. Strohalm
(Prague, CZ; Angers, FR)
Final Programme
173
Posters
Monday, 9 May
Poster Sessions
Monday, 9 May
174
P1949
Fast and sensitive detection of the mycotoxin
gliotoxin and related compounds during
human aspergillosis
M. Domingo, J. Pardo, L. Roc, M. Palacian,
C. Colmenarejo, J. Meis, N. Peyman-Fard,
M. Revillo, E. Galvez, A. Rezusta*
(Zaragoza, ES; Nijmegen, NL)
P1950
Usefulness of the 1,3-beta-D-glucan and
antibody germ tube C. albicans for early
diagnosis of invasive candidiasis in
non-neutropenic critically ill adult patients
C. Castro*, A. Ubeda, T. González, P. Saavedra,
J. Córdoba, A. Loza, S. Ruiz-Santana,
E. Martín-Mazuelos for the CAVA II Study Group
P1951
Diversity of proteome profiles in neutropenic
patients developing versus not developing
invasive pulmonary aspergillosis
F. Dalle*, C. Truntzer, D. Pecqueur, A. Jeannin,
S. Chabri, D. Caillot, R. Herbrecht,
V. Letscher-Bru, P. Ducoroy, A. Bonnin
(Dijon, Strasbourg, FR)
P1952
Detection of galactomannan in serum and
isolates of Fusarium species from patients
with proven invasive Fusarium infection
M.P. Roiz*, M.S. Garcia, J. Agüero,
C. Ruiz de Alegria, I.C. Perez del Molino Bernal,
L. Martínez-Martínez (Santander, ES)
P1953
Laboratory diagnosis of invasive
aspergillosis in haematological patients:
comparison between galactomannan,
1,3-beta-D-glucan and Aspergillus IgG test
L. Persijn*, E. Steel, G. Claeys, A. Piette,
S. Blot, K. Vandewoude, P. Depuydt, D. Benoit,
L. Noens, D. Vogelaers, E. Padalko (Ghent, BE)
P1954
A clinical evaluation of two novel PCR-based
analyses for the diagnosis of
dermatophytosis in skin and hair
R. Jensen*, M. Cavling Arendrup
(Copenhagen, DK)
P1955
The effect of antifungal treatments on
laboratory diagnostic assays for invasive
fungal infections
E. McCulloch*, G. Ramage, R. Rajendran,
D. Lappin, B. Jones, P. Warn, R. Shrief,
W. Kirkpatrick, T.F. Patterson, C. William
(Glasgow, Manchester, UK; San Antonio, US)
P1956
Clinical relevance of a positive PCR
assay to diagnose Pneumocystis pneumonia
in immunocompromised patients
F. Robert-Gangneux*, M. Revest, P. Tattevin,
C. Guiguen, J.-P. Gangneux (Rennes, FR)
Final Programme
Poster Sessions
12:30 – 13:30
P1957
P1958
Clinical management challenges in hepatitis
in an era of changing treatment options
Hepatitis C virus genetic and amino acid
diversity within NS3 protease from 302
chronically-infected patients who never
received NS3 protease inhibitors in Marseille,
southeastern France
P. Colson*, A. Motte, N. Tivoli, C. Tamalet,
R. Gérolami (Marseille, FR)
IL28B-gen polymorphic variants as
pharmacogenetic markers of HCV treatment
response in HIV-infected patients
J. Guardiola*, J. Martin, K. Lamarca, C. Pacho,
I. Fernández, C. Cabeza, M. Sambeat,
A. Fontanet, J. Muñoz, E. Martin, J. Salazar,
J. Cadafalch, M. Baiget, P. Domingo
on behalf of the Sant Pau Pharmacogenomic
HCV-HIV Study Group
P1959
Fulminant hepatitis E in southeastern France
P. Colson*, F. Raissouni, P. Borentain,
A. Le Goffic, J. Hardwigsen, C. Nafati,
Y.-P. Le Treut, R. Gérolami (Marseille, FR)
P1960
Seroepidemiology of hepatitis virus
infections among men who have sex with
men aged between 18 to 40 years in Taiwan
Y. Tseng*, W. Liu, C. Hsieh, P. Wu, C. Wu,
H. Sun, C. Hung (Taipei, TW)
P1961
12:30 – 13:30
P1962
P1963
P1964
Impact of the use of epoetin beta on
sustained virological response in patients
with hepatitis C virus treated with pegylated
interferon alfa-2a plus ribavirin
F. Lunel-Fabiani, D. Larrey, I. Fouchard-Hubert,
M.T Dao, P. Mélin, L. D'alteroche, P. Veillon*
(Angers, Montpellier, Caen, Saint-Dizier, Tours, FR)
P1965
Epidemiologic study of Clostridium difficile
culture positive cases using repetitivesequence based PCR fingerprinting and
PCR-ribotyping in 3 tertiary care hospitals
in Korea from 2004 to 2010
B. Shin*, S. Mun (Seoul, KR)
P1966
Molecular epidemiology of Clostridium
difficile at a medical centre in Taiwan:
an increasing prevalence of toxin A-positive
and toxin B-positive strains
J.H. Chia*, T.L. Wu, H.C. Lai, L. Su, A.J. Kuo,
C.F. Sun (Taoyuan, TW)
P1967
Surveillance analysis of C. difficile genotyps
demonstrates decreasing frequencies of
027 infections in a tertiary care hospital
L. von Müller*, K. Speck, M. Herrmann
(Homburg/Saar, DE)
P1968
Clostridium difficile recurrence, alcohol
consumption, and the effect of fidaxomicin
vs vancomycin
Y. Golan*, T. Louie, K. Weiss, K. Mullane,
Y. Kean, A. Lentnek, S. Gorbach, M. Miller
(Boston, US; Calgary, Montreal, CA; Chicago,
San Diego, Georgia, US)
P1969
Molecular epidemiology of Clostridium
difficile and prevalence of the NAP-1 strain
among patients admitted to a general and a
private hospital in Houston, Texas, USA
W. Santimaleeworagun*, J. Christensen,
V. Singh, D. Shah, K.T. Chang, V. Tam, K. Garey
(Nakhon Pathom, TH; Houston, US)
P1970
C. difficile in patients with chronic heart
failure
N.A. Bylova*, G.P. Arutyunov, L.I. Kafarskaya
(Moscow, RU)
P1971
Demographic and clinical characteristics
of patients with Clostridium difficile
associated diarrhoea: a retrospective study
B. Chazan*, N. Teitler, H. Edelstein, R. Raz
(Afula, IL)
P1972
Detection of Clostridium difficile PCR
ribotype 027 from hospitalised patients
in Sydney, Australia
P.G. Huntington*, A.A. Darbar, G. Kotsiou
(St Leonards, AU)
P1973
Microbial factors in recurrent Clostridium
difficile infections in Stockholm, 2010
A. Weintraub, C. Jorup-Rönström, S. Sandell,
K. Ellström, M. Rashid, Y. Chen, C.E. Nord*
(Stockholm, SE)
Clostridium difficile
Clostridium difficile in Dutch animals:
presence, characteristics and comparison
with human isolates
M.G. Koene*, D. Mevius, J.A. Wagenaar,
C. Harmanus, M.P. Hensgens, E. Kuijper
(Lelystad, Utrecht, Leiden, NL)
Validation of the time and temperature
relationships of HSG (95) 18, for an extended
panel of multi-resistant healthcare infectionassociated bacteria
J. Holton*, N. Lakdawalla (London, UK)
Survival of Clostridium difficile on bed linen
after processing in a commercial continuous
batch (tunnel) washer according to HSG(95)18
N. Lakdawalla, R. Morris, J. Holton* (London, UK)
Final Programme
175
Posters
Tuesday, 10 May
Poster Sessions
Tuesday, 10 May
P1974
Retrospective study of the epidemiology
of Clostridium difficile infection in a district
general hospital in United Kingdom
N. Virgincar*, S. Iyer, L. Downing, A. Stacey
(Reading, UK)
P1975
Molecular characterisation and antimicrobial
susceptibility in clinical isolates of Clostridium
difficile in a university hospital, Split, Croatia
A. Novak*, P. Spigaglia, M. Tonkic, I. Goic Barisic,
F. Barbanti, V. Punda-Polic (Split, HR; Rome, IT)
P1976
12:30 – 13:30
Risk factors for recurrence of Clostridium
difficile infection: impact of stool vancomycinresistant enterococci colonisation
H.K. Choi*, S.J. Lee, K. Kim, S.H. Lee, Y.S. Park
(Yangsan, Busan, Ilsan, KR)
Analytical comparison of the BD GenOhm
Cdiff assay to the Ridascreen C. difficile
toxin A/B ELISA for detection of C. difficile
associated disease
I. Müller*, O. Coste, K. Schmidt, K.P. Hunfeld
(Frankfurt/Main, DE)
P1978
Development of a multiplexed LATE-PCR
assay for Clostridium difficile identification
and characterisation
S. Goldenberg*, K. Pierce, H. Khan, R. Mistry,
J. Lewington, L. Wangh, G. French (London, UK;
Waltham, US; Watford, UK)
P1979
Development of a novel multiplexed molecular
assay for detection of the tcdA and tcdB
genes in pathogenic Clostridium difficile
using room temperature stable reagents
N. Nasser*, H. Liang, V. Armendarez, T. Ott,
T. Pack, R. Lollar, T. Ranalli, T. Stenzel
(San Diego, US)
P1981
Low variability of the surface layer proteins
between two high virulent Clostridium
difficile PCR-ribotypes
P. Spigaglia*, F. Barbanti, C. Galeotti,
M. Scarselli, J. Van Broeck, P. Mastrantonio
(Rome, Siena, IT; Brussels, BE)
P1983
Evaluation of the RIDA™Gene Clostridium
difficile and toxin A/B for molecular detection
of toxigenic Clostridium difficile in diarrhoeal
faeces
S. Petersdorf, H. Britt, D. Martens*, A. Simons,
T. Hoppe (Bonn, Cologne, Darmstadt, DE)
P1984
Evaluation of new real-time PCR assay using
stool specimens compared with conventional
real-time PCR assay, toxigenic culture and
enzyme immunoassay for rapid diagnosis of
B. Shin*, S. Mun (Seoul, KR)
P1985
Evaluation of a real-time PCR assay
and conventional methods for the detection
of toxigenic Clostridium difficile in stool
samples
M. Turan, B. Levent*, T. Demir, H. Bayrak,
R. Gulesen, M. Akgeyik, B. Esen
(Ankara, Kirsehir, Mersin, TR)
P1986
Correlation between Clostridium difficile
toxin genes and the direct toxin detection
assay results
L. Lindholm*, M. Kalluinen, E. Eerola,
O. Meurman, A. Virolainen, J. Jalava
(Turku, Helsinki, FI)
P1987
A new player on the market for detection
of Clostridium difficile?
K. Floré* (Bruges, BE)
P1988
Evaluation of three real-time PCR-methods
for the detection of C. difficile in stool specimens
I. Fenner*, U. Eigner, C. Lensing, H. Petersen,
A. Veldenzer, U. Wild, M. Holfelder
(Hamburg, Heidelberg, DE)
P1989
External quality assessment for laboratory
detection of Clostridium difficile
C. Walton*, E. Fagan, A. Marwaha (London, UK)
P1990
Evaluation of a novel loop-mediated
amplification system (Illumi-pro10™ Meridian
Bioscience Inc.), glutamate dehydrogenase
(Meridian and TechLab) and a rapid
immunoassay, Tox A/B Quik Chek (TechLab)
for the detection of C. difficile toxin
F. Yazdani*, D. Gnanarajah, Y. Hussain
(Derby, UK)
Diagnosis of C. difficile infections
P1977
P1980
P1982
Development of a rapid and simple isothermal
molecular assay for the qualitative detection
of Clostridium difficile from faecal specimens
in a non-instrumented platform with room
temperature stable reagents
W. Tang, M. Wilson, K. McCarthy, T. Pack, N. Nasser,
T. Ranalli*, R. Lollar, H. Kong, T. Stenzel
(Beverly, San Diego, US)
Loop-mediated isothermal amplification
technique for routine detection of Clostridium
difficile
V. Zidaric, N. Oresic, M. Rupnik* (Maribor, SI)
Final Programme
Poster Sessions
P1991
Evaluation of culture methods for isolation
of Clostridium difficile and comparison of
phenotypic identification with identification
by 16S ribosomal DNA sequencing and
matrix-assisted laser desorption ionisation –
time-of-flight mass spectrometry
A. Jain*, C. Pope, M. Wilks, M. Pond, J. Haigh,
T. Planche (London, UK)
P1999
Performance of the GenoType® MTBDRplus
assay for detection of Mycobacterium
tuberculosis drug resistance in routine
settings: a multicentre study
S. Mironova, I. Kontsevaya*, E. Pimkina,
V. Nikolayevskyy, G. Skenders, T. Kummik,
Y. Balabanova, F. Drobniewski (Samara, RU;
Vilnius, LT; London, UK; Riga, LV; Tartu, EE)
P1992
Lack of impact of strain type on detection
of Clostridium difficile using PCR and
glutamate dehydrogenase
S. Goldenberg*, M. Gumba, A. Hall, A. Patel,
G. French (London, UK)
P2000
P1993
Evaluation of five methods for rapid detection
of Clostridium difficile in diarrhoeal stool
samples from paediatric patients
C. Burnham*, D. Tasler, R. Craven,
L.F. Westblade, W.M. Dunne (Saint Louis, US)
Clinical utility of immunochromatographic
assay based on mouse monoclonal antiMPT64 antibody for simple and rapid
discrimination between M. tuberculosis
complex and non-tuberculous mycobacteria
in clinical isolates of extrapulmonary
tuberculosis
A. Maurya*, S. Kant, V. Nag, R. Kushwaha,
S. Jain, T.N. Dhole (Lucknow, IN)
P2001
Experience and consequences of using
improved methods for the diagnosis of
S. Goldenberg*, N. Price, D. Tucker, P. Wade,
G. French (London, UK)
Ambiguous Quantiferon-TB gold test results
in Swiss healthcare workers: analysis of
IL-2/IFN-g ratios
D. Mayor*, A. Berger, P. Bittel, P. Iseli,
F. Suter-Riniker, T. Bodmer (Berne, CH)
P2002
MALDI-TOF Biotyper assay to test potential
drug susceptibility of non-tuberculous
mycobacteria: the case of Mycobacterium
avium and clarithromycin resistance
L. Mancinelli*, L. Coltella, E. Tortoli,
D. Menichella, C. Russo (Rome, Florence, IT)
P2003
Use of the genotype Mycobacterium assay for
rapid identification of non-tuberculous
mycobacteria in routine clinical laboratory
F. Kontos, D. Mavromanolakis, M. Zande,
G. Kosmadakis, A. Manidaki, Z. Gitti* (Athens, GR)
P2004
Lymphocyte subpopulations phenotyping
in active tuberculosis: association with
Quantiferon-TB gold in-tube® assay and
radiological/microbiological markers of
severe disease
L. Guglielmetti*, M. Conti, R. Valentinotti,
A. Cazzadori, A. Vella, R. Ortolani, F. Boccafoglio,
E. Concia (Verona, Trento, IT)
P2005
Direct detection of multiple drug-resistant
Mycobacterium tuberculosis in clinical
specimens using real-time PCR, multiplex
allele-specific PCR and PCR-sequencing
W. Yam*, G. Siu, V. Cheng, P.L. Ho
(Hong Kong, HK)
P2006
Introduction of 24-loci MIRU-VNTR typing
in a region-wide scheme considerably
reduces the number of cases requiring
epidemiological investigation
J.T. Evans*, A.L. Gibson, S. Khanom,
C. Overton-Lewis, S. Gardiner, E.G. Smith,
P. Hawkey (Birmingham, UK)
P1994
P1995
12:30 – 13:30
P1996
P1997
P1998
Frozen human foreskin fibroblasts provide a
convenient alternative to conventional cell
lines for diagnosis of Clostridium difficile by
cell cytotoxicity assay
N.K. Tan*, C. Pope, T. Planche (London, UK)
Mycobacterial disease: diagnosis
Evaluation of a new molecular oligochromatographic assay for direct mycobacterial
detection in human respiratory clinical
specimens
M.J. Martínez-Lirola*, P. Mendoza López,
A. Fernández-Sánchez, I. Toro-Peinado,
M.P. Bermúdez-Ruiz , B. Palop-Borrás
on behalf of the IndalTB group
Evaluation of the new GenoType MTBDRsl®
assay for rapid detection of resistance
in Mycobacterium tuberculosis isolates
in a low-incidence community
F. Kontos, M. Zande, D. Mavromanolakis,
S. Bazigos, A. Manidaki, Z. Gitti* (Heraklion, GR)
Could negative T Spot-TB exclude an active
tuberculosis suspect?
M. Arosio, G. Bargiggia, M. Rizzi, V. Ravasio,
P. Serna Ortega, F. Moioli, L. Trezzi, A. Raglio*,
A. Goglio (Bergamo, IT)
Final Programme
177
Posters
Tuesday, 10 May
Poster Sessions
Tuesday, 10 May
P2007
Evaluation of Gene Xpert® MTB/RIF system
for the direct detection of rifampicinresistant Mycobacterium tuberculosis
from pulmonary and extrapulmonary
specimens in the National Tuberculosis
Reference Laboratory in Kuwait
E. Mokaddas*, S. Haneef, H. Saad Eldeen
(Dasma, KW)
P2008
Detection of Mycobacterium tuberculosis
complex by RT-PCR in non-respiratory clinical
specimens in Health Department 9, Valencia
(Spain)
M.R. Guna*, N. Tormo, L. Villamayor, A. Jimenez,
M.T. Fraile, M.D. Ocete, M. Chanzá, C. Gimeno
(Valencia, ES)
P2009
New DNA microarray platform for detection
of MDR Mycobacterium tuberculosis and
of drug-resistant malaria
A.M. Cabibbe*, P. Miotto, E. Lazzeri,
J. Mugasa, F. Santoro, V. Nikolayevskyy,
L. Ranford-Cartwright, G. Pozzi, S. Niemann,
F. Drobniewski, D. Cirillo
and the TM-REST Consortium (EU-FP7 project)
P2010
P2013
P2014
P2015
P2016
Evaluation of GeneXPERT MTB/RIF assay in
respiratory and non-respiratory specimens
for the rapid detection of Mycobacterium
tuberculosis
Z. Archontakis, C. Dimoulas, A. Charitakis*,
S. Kanaki, S. Foyntoylakis, E. Michailellis,
K. Thymaki, V. Liakou (Herakleion, GR)
Clinical evaluation of the GenoType MTBDRsl
for the rapid diagnosis of second-line
resistance in Mycobacterium tuberculosis
I. Festoso*, P. Mantegani, P. Miotto, A.M. Cabibbe,
I. Valente, E. Borroni, D. Cirillo (Milan, IT)
Evaluation of GeneXpert MTB/RIF assay
for the diagnosis of tuberculosis and rapid
detection of rifampin resistance in clinical
specimens
A. Nazli*, C. Cavusoglu (Izmir, TR)
Specificity of urine PCR in diagnosing
tuberculosis
M. Jamshidi*, A. Nejatizadeh, P. Davoodian,
S. Zaare, H. Vahdat, T. Eqbal eftekhaari,
M. Baqer shiroodi, H. Dadvand, F. Fakhar
(Tehran, Bandar Abbas, IR)
Evaluation of an induced sputum service
for diagnosis of pulmonary tuberculosis
P. Papineni*, R. Lever, A. Bello, J. Aspinall,
M. Brown (London, UK)
Final Programme
P2017
Use of Quantiferon-TB gold assay for
tuberculosis in immunocompromised
patients
M. Fomichev*, K. Levina, N. Fomicheva
(Tallinn, EE)
P2018
Multicentre laboratory validation of the
colorimetric redox indicator assay for the
rapid detection of extensively drug-resistant
Mycobacterium tuberculosis
A. Martin*, F. Paasch, S. Docx, K. Fissette,
B. Imperiale, W. Ribon, L. Gonzalez, W. Werngren,
A. Engstrom, G. Skenders, P. Jureen, S. Hoffner,
P. Del Portillo, N. Morcillo, J.C. Palomino
(Antwerp, BE; Buenos Aires, AR; Bogota, CO;
Solna, SE; Riga, LV)
P2019
Prevalence of drug-resistant tuberculous
meningitis in real-time PCR-proven patients
from Southern China: a retrospective
study based on the commercial molecular
line probe assays
D. Lina*, W. Lanlan, Y. Binwu (Chendu, CN)
P2020
Incubation of whole blood at 39°C augments
IP-10 and IFN-gamma responses to
M. tuberculosis antigens
M.G. Aabye*, P. Ravn, I.S. Johansen, M. Ruhwald
(Copenhagen, Odense, DK)
12:30 – 13:30
Advances in mycobacterial culture
P2021
Selective use of automated liquid
mycobacterial culture in an area
of low tuberculosis incidence
J. Greig* (Plymouth, UK)
P2022
Enrichment of Mycobacterium spp. in sodium
metasilicate solution
S. Das* (Kolkata, IN)
P2023
Bead-based specimen concentration for
mycobacterial culture
S. Mitarai*, H. Yamada, K. Mizuno,
K. Chikamatsu, A. Aono, T. Sugamoto,
R. Karinaga, T. Hatano (Kiyose, Matsudo, JP)
P2024
Evaluation of a rapid identification test for
Mycobacterium tuberculosis complex on
mycobacteria growth indicator tube
S. Van den Wijngaert*, G. Stas, W. Chaker,
A. Dediste (Brussels, BE)
Poster Sessions
12:30 – 13:30
P2025
Antimicrobial activity against mycobacteria
Synergism of linezolid, levofloxacin and
amikacin combination against multidrugresistant and drug-susceptible isolates of
M. tuberculosis
E. Rey*, G. Tudó, J. González-Martín
(Barcelona, ES)
P2026
Activity of drugs against Mycobacterium
tuberculosis under hypoxic plus acidic
conditions
G. Piccaro, F. Giannoni, P. Filippini, L. Fattorini*
(Rome, IT)
P2027
Antimicrobial susceptibility testing of rapidly
growing mycobacteria by microdilution
C. Cavusoglu*, T. Gurpinar, T. Ecemis
(Izmir, Manisa, TR)
P2028
Antibiotic susceptibility testing of
Mycobacterium avium subspecies
under iron starvation
R. Kopinc*, M. Ocepek, A. Lapanje (Ljubljana, SI)
P2029
Change in first-line anti-tuberculosis drug
susceptibility trends of Mycobacterium
tuberculosis clinical isolates over a period
(30 years)
A. Alberte-Castiñeiras*, M. Dominguez-Gil
Gonzalez, M. Gonzalez-Sagrado,
P. Pérez-Pascual (Valladolid, ES)
12:30 – 13:30
Mycobacterial disease, pathogenesis and
epidemiology
P2030
Epidemiology and clinical significance
of non-tuberculous mycobacteria isolated
from pulmonary specimens
E. Braun*, H. Sprecher, S. Davidson, I. Kassis
(Haifa, IL)
P2031
P2032
Multifocal tuberculous vertebral osteomyelitis:
a re-emerging infection
E. Arosemena*, M. Varela, V. Pascual, E. Calbo,
C. Corbella, E. Ayats, E. Cuchí, J. Garau
(Terrassa, ES)
Risk factors of mortality among MDR-TB
patients in Iran: 2002 – 2009
P. Tabarsi*, P. Baghaei, M. Marjani, M. Shamai,
J. Soroush, M. Seyed javadi, M. Masjedi (Tehran,
IR)
P2033
Variations in the occurrence of specific
rpoB mutations in rifampicin-resistant
Mycobacterium tuberculosis strains isolated
from patients of different ethnic groups
in Kuwait
S. Ahmad*, N. Al-Mutairi, E. Mokaddas
(Safat, KW)
P2034
Genetic analysis of the host-pathogen
interaction in tuberculosis (“TB-EURO-GEN”)
study – progress and current tuberculosis
epidemiology
O. Ignatyeva*, I. Kontsevaya, Y. Balabanova,
V. Nikolaevskyy, S. Mironova, A. Kovalev,
A. Isaeva, Y. Chinkova, A. Rybkina, A. Kritskyy,
D. Gromova, M. Korobova, A. Shakhmistova,
N. Malomanova, I. Fedorin, S. Nejentsev,
R. Horstmann, S. Hoffner, F. Drobniewski
(Samara, RU; London, UK; Cambridge, UK;
Hamburg, DE; Solna, SE)
P2035
Molecular epidemiology of multidrugresistant (MDR) Mycobacterium tuberculosis
revealed by genotype MTBDR assays in
southern China
L. Zhang*, L. Duo, X. Lu, Y. Xie, X. Song, M. Kang,
B. Ying, L. Wang (Chengdu, CN)
P2036
Multidrug resistance profiles of pulmonary
tuberculosis in Georgia
N. Tadumadze*, N. Bablishvili, N. Shubladze,
N. Lomtadze, M. Akhalaia, R. Aspindzelashvili,
M. Gegia (Tbilisi, GE)
P2037
Detection of gene mutations causing
antibiotic resistance in Mycobacterium
tuberculosis complex by an array
T. Chan*, H. Huang, R. Jou, Y. Yang, P. Lu,
S. Huang, T. Chang
(Tainan, Taipei, Kaohsiung, TW)
P2038
Combinations of TNF alpha/IL-10
polymorphisms affect active tuberculosis
development in Tunisia
W. Ben Selma, A. Ferjani, H. Harizi, M. Marzouk,
I. Ben Kahla, J. Boukadida* (Sousse, TN)
P2039
Host-pathogen relationship in tuberculosis:
association between the genetic diversity
of M. tuberculosis strains and the disease
presentation in the State of Antioquia,
Colombia
J.M. Hernandez Sarmiento*, E.M. Zapata,
V. Gomez, G.I. Mejia, N. Correa, M. Martinez,
J. Robledo (Medellin, CO)
Final Programme
179
Posters
Tuesday, 10 May
Poster Sessions
Tuesday, 10 May
P2040
The presence of viable Mycobacterium
tuberculosis in tissue specimens of lung
surgery patients
N. Shubladze*, S. Vashakidze, S. Gogishvili,
L. Kupreishvili, M. Pochkhua, I. Kalandadze
(Tbilisi, GE)
P2048
Isothermal target and probe amplification
method for the identification of
Mycobacterium tuberculosis complex from
broth cultures
M. Hur*, H. Moon, H. Kim, J.Y. Kim, Y. Yun
(Seoul, KR)
P2041
Mycobacterium tuberculosis replicates
in human fibroblasts and interferes with
their antigen presentation capacity
S. Mariotti*, V. Sargentini, M. Pardini,
M. De Spirito, M.C. Gagliardi, M. Fraziano,
R. Nisini (Rome, IT)
P2049
Removal of PCR inhibitors in a real-time PCR
of Mycobacterium tuberculosis
H.S. Kim*, Y.K. Lee, J.S. Kim, H.Y. Yoon, W. Song,
H.J. Kang, K.M. Lee (Anyang, KR)
P2050
Comparative evaluation of GeneXpert
MTB/RIF assay and Gen-Probe amplified
Mycobacterium tuberculosis direct test
for detection of Mycobacterium tuberculosis
complex in smear-negative respiratory
specimens
J.S. Lin*, C. Lin, R. Hsiao, L. Shih
(Changhua, TW)
P2051
Detection of dnaA and dnaN reagents for
identification Beijing strains of Mycobacterium
tuberculosis in pulmonary tuberculosis
patients with culture-positive specimens
S. Jahani Sherafat*, H. Goudarzi, E. Mirsamadi
(Tehran, IR)
P2052
Detection and differentiation of M. tuberculosis
and non-tuberculous mycobacteria by
real-time PCR on the BD MAX system targeting
a region upstream of the 65 kDa heat-shock
protein gene
K. Egli*, C. Casanova, T. Bodmer, M. Altwegg
(Lucerne, Berne, CH)
P2053
Comparison of Advansure MDR-TB Genoblot
assay kit with Genotype HMDRTBplus and
conventional drug susceptibility test
S.B. Han*, J.K. Yu, K. Park, G.D. Lee, Y. Kim,
Y.J. Park (Seoul, KR)
P2042
Mycobacterium abscessus soft tissue
infection in a murine model: fast infection
clearance but long lasting pro-inflammatory
cytokine production
A. D'Alessandro*, A. Rodríguez, D. Aguilar,
Y. Tovar, D. Mata, R. Hernández-Pando,
J. de Waard (Caracas, VE; Mexico City, MX)
P2043
Cutaneous infections of Mycobacterium
marinum in human aquarists and tracing
of its possible sources
M. Slany*, M. Bodnarova, P. Jezek, V. Fiserova,
J. Stork, I. Pavlik (Brno, Prague, Pribram, CZ)
P2044
Mycobacterium abscessus in cystic fibrosis:
what does it all mean?
J.T. Evans*, N. Ratnaraja, S. Gardiner, P. Hawkey,
E.G. Smith (Birmingham, UK)
P2045
Updated meta-analysis on genetic
predisposition of four variants at NRAMP1
(SLC11A1) gene to tuberculosis
D. Li*, C. Tao, X. Hu, M.N Zou, T. Wang, H. Ning,
B. Ying (Chengdu, CN)
P2046
Outcome of Port Health referrals for new
entrant screening for tuberculosis in the
United Kingdom
M. Healy, M.M. Raza* (Milton Keynes, UK)
12:30 – 13:30
12:30 – 13:30
P2047
Molecular diagnosis of mycobacterial
infections
First report of molecular detection of
fluoroquinolone resistance-associated gyrA
mutations in multidrug-resistant clinical
Mycobacterium tuberculosis isolates in
Kuwait
E. Mokaddas*, N. Al-Mutairi, S. Ahmad
(Dasma, Jabrya, KW)
Final Programme
Lyme borreliosis, toxoplasmosis
P2054
German Investigation of Lyme Borreliosis:
Evaluation of Therapeutic and Diagnostic
Cost (GILEAD)
M. Freitag, I. Müller, G. Poggensee,
E. Scharnetzki, J. Gensichen, K.P. Hunfeld*
(Jena, Frankfurt/Main, Berlin, Hamburg, DE)
P2055
Primary toxoplasmosis in pregnancy –
results of a multidisciplinary approach
K. Schreiter*, U. Dietz, A. Reich, I. Raila,
E. Robel-Tillich, M. Borte, F. Gebauer, S. Glasow,
H.-J. Gottwald, C. Springer, C. Klein, A. Pöge,
B.R. Ruf, T. Grünewald (Leipzig, DE)
Poster Sessions
Tuesday, 10 May
Unusual case of early stage Lyme borreliosis
presenting as acute anicteric hepatitis with
splenomegaly
J. Nikolic*, N. Popovic, S. Stojakovic,
G. Stevanovic, M. Pavlovic (Belgrade, RS)
P2057
An unusual presentation of neuroborreliosis
J. Cortez*, M. Shamasna, J. Nunes, C. Valente,
F. Pissarra (Coimbra, PT)
P2058
Correlation between clinical manifestation
and reactive Borrelia antigens in patients
with Lyme disease
T. Gladnishka, E. Taseva*, I. Trifonova,
V. Ivanova, I. Christova (Sofia, BG)
P2059
Congenital toxoplasmosis in the health area
of Pontevedra, Spain
M. Trigo*, A. Pallarés, V. Pulián, P. Álvarez,
A. Moreno-Flores, M. García-Campello
(Pontevedra, ES)
P2060
Susceptibility to Toxoplasma gondii infection
in women of childbearing age: a two-year
study (2009–2010)
N. Terzi, A. Charalabopoulou*, A. Papanagiotou,
A. Bliamou, H. Chrysopoulou, D. Togas,
T. Brouchos, K. Tzanetou (Athens, GR)
P2061
Multiparametric serological diagnosis
in congenital toxoplasmosis
C.M. Costanzo*, C. Franchina, C.I. Palermo,
R. Russo, D. Zappala, G. Scalia (Catania, IT)
12:30 – 13:30
Sexually transmitted diseases
P2062
Prevalence of and factors associated with
sexually transmitted diseases in clients
seeking anonymous counselling and testing
at a university hospital in Taiwan
P. Wu*, C. Wu, W. Liu, C. Hsieh, C. Hung
(Taipei, TW)
P2063
Epidemiological study of occurrence of
urogenital chlamydial infection in women
from Slovakia
L. Cisláková*, M. Halánová, J. Mikulová,
Z. Szovenyiová, P. Jarcuška (Košice, SK)
P2064
P2065
Chlamydia trachomatis infection among
women in Italy: data from a laboratory-based
sentinel surveillance system
M.C. Salfa*, V. Regine, M. Raimondo, L. Camoni,
B. Suligoi and the Italian STI Laboratory-based
Surveillance Working Group
Remarkable increase of Neisseria
gonorrhoeae with decreased susceptibility
to azithromycin in Japan
M. Yasuda*, K. Nakane, N. Hagiwara,
S. Ishihara, S. Maeda, S. Ito, T. Deguchi
for the Gifu UTI·STI Research Group
P2066
Factors determining serological response
to syphilis treatment
D. Fröhlich Knaute, N. Graf, S. Lautenschlager,
R. Weber, P.P. Bosshard* (Zurich, CH)
P2067
Inflammation on the cervical Papanikolaou
smear: evidence for infection in
asymptomatic women?
S. Baka*, E. Elefteriou, S. Kotsali, A. Panopoulou,
I. Patikas, I. Tsouma, A. Spathi, A. Lykas, D. Makri,
A. Kalantzi, G. Kaparos, E. Kouskouni
(Athens, GR)
12:30 – 13:30
Acute diarrhea
P2068
The prediction of positive stool culture
in patients with acute diarrhoea
S. Cho, J. Chung*, Y. Kwak
(Seoul, Gyeonggi-do, KR)
P2069
Outcomes of and predictors for colectomy in
patients with Clostridium difficile associated
diarrhoea
S. Rushworth*, V. Thomas, F. Miyajima,
N. Beeching, M. Beadsworth (Liverpool, UK)
P2070
Enteroaggregative Escherichia coli in Danish
children attending daycare centres in greater
Copenhagen
B.B. Roldgaard*, A. Munk Petersen,
S. Schjørring, N. Boisen, F. Scheutz, D. Röser,
B. Utoft Andreassen, K.E. Olsen, K. Angeliki
Krogfelt (Copenhagen, Hvidovre, DK)
P2071
Rotavirus G2P[4] and G2P[4]+[6] infections
during norovirus gastroenteritis outbreak
in 2010 summer season in the coastline area
of São Paulo State, Brazil
A. Luchs*, S. Morillo, A. Cilli, S. Calux, C. Ribeiro,
R. Carmona, M. Timenetsky (São Paulo, BR)
12:30 – 13:30
Solid organ transplant infections
P2072
Optimal duration of selective antifungal
prophylaxis in heart transplant recipients
P. Muñoz, M. Valerio*, M. Giannella, J. Palomo,
J. Fernández-Yañez, J. Guinea, A. Eworo,
E. Bouza (Madrid, ES)
P2073
Primary toxoplasmosis after kidney
transplantation: a rare and potentially
fatal complication, with very useful tools
to improve diagnosis and the outcome
B. Denis*, M.-N. Peraldi, J. Menotti, F. Derouin,
J.-M. Molina (Paris, FR)
Final Programme
181
Posters
P2056
Poster Sessions
Tuesday, 10 May
P2074
Histoplasmosis and blastomycosis
in transplant patients in Chicago
F. Lanternier*, M. Angarone, N. Theodoropoulos,
K. Reed, O. Lortholary, M.G. Ison
(Paris, FR; Chicago, US)
P2075
Primary HHV8 infection with systemic
inflammatory syndrome and visceral Kaposi
sarcoma after OLTx, successfully treated
with cidofovir, low-dose of steroids and
liposomal-doxorubicin: case report
V. Lamonaca*, G. Pietrosi, S. Gruttadauria,
A. Provenzani, R. Di Stefano, M. I. Minervini,
P. Grossi, F. Cardinale, A. D'Antoni, B. Gridelli
(Palermo, IT)
P2076
P2077
Parvovirus B19 is a major cause of
opportunistic viral infection in the first year
after kidney transplantation
R. Porignaux, C. Barbe, A. Rauch, D. Talmud,
F. Renois, V. Brodard, T. Tabary, S. Daliphard,
J. Lançon, O. Toupance, S. Lavaud, P. Rieu,
L. Andreoletti, N. Leveque* (Reims, FR)
Monitoring of cell-mediated immune
parameters identifies kidney transplant
recipients at high risk of severe infection
M. Fernández-Ruiz*, F. López-Medrano,
L. Allende, A. García-Reyne, C. Lumbreras,
R. San Juan, M. Lizasoain, A. Andrés,
J.M. Morales, E. Paz, J.M. Aguado (Madrid, ES)
P2078
Identification of patients at high risk for
infections after liver transplantation
S.H. van Olphen*, I.C. Konings, L.H. de Grim,
G. Kazemier, B.E. Hansen, R.A. de Man,
X. Rogiers, C.A. Schurink, H.J. Metselaar
(Rotterdam, NL; Ghent, BE)
P2079
Infections in patients with pancreas
transplantation
G. Sanclemente*, L. Linares, C. Cervera,
I. Hoyo, F. Marco, M. Marcos, R. García,
M. Ricart, A. Moreno (Barcelona, ES)
P2080
Descriptive analysis of infections produced
by respiratory viruses in solid organ transplant
recipients
J. Molina*, O.J. Ben-Marzouk, C. Milara,
A. Martín, C. Martín, V. Cabello, G. Suárez,
M. Sobrino, P. Pérez-Romero, E. Cordero
(Seville, ES)
P2081
Prevalence and clinical characteristics
of mycobacterial infection in a cohort
of solid organ transplant recipients over
a 13-year period
N. Boillat Blanco*, K. Jaton, G. Nseir, P. Yerly,
J.D. Aubert, M. Pascual, O. Manuel
(Lausanne, CH)
Final Programme
P2082
Tuberculosis in solid organ transplant
recipients: risk factors and treatment
outcome
Y.E. Ha*, E.J. Joo, M.K. Joung, S.Y. Park, S.J. Kang,
C.I. Kang, D.R. Chung, J.H. Song,K.R. Peck
(Seoul, KR)
P2083
Validation of a fungal infection prediction
model in 2 European liver transplant centres
I.C. Konings*, S.H. van Olphen, L.H. de Grim,
G. Kazemier, B.E. Hansen, R.A. de Man,
X. Rogiers, C.A. Schurink, H.J. Metselaar
(Rotterdam, NL; Ghent, BE)
12:30 – 13:30
Infections in the immunocompromised host
P2084
Risk factors for development of Pseudomonas
aeruginosa in non-neutropenic cancer
patients with Gram-negative bacteraemia:
a case-control study
C.I. Kang, Y.E. Ha, J. Kim, S.J. Kang, S.Y. Park,
D.R. Chung, K.R. Peck, N. Lee, J.H. Song, E.J. Joo*
(Seoul, KR)
P2085
Vancomicin-resistant enterococci control
measures in a haematologic and bone marrow
transplant unit
A. Giannetti *, M. Vieira, F. Dulley, F. Rossi,
G. Fonseca, T. Alves Lima, J. Nobrega,
T. Guimaraes, S. Costa (Sao Paulo, BR)
P2086
Respiratory viral infections after allogeneic
haematopoietic stem cell transplantation
M. Mikulska*, V. Del Bono, S. Dini, A. Raiola,
A. Dominietto, S. Bregante, M. Van Lint, A. Orsi,
F. Ansaldi, A. Bacigalupo, C. Viscoli (Genoa, IT)
P2087
Severe infection is associated with lower
M-ficolin concentration in patients with
haematological cancer undergoing
chemotherapy
L. Ameye*, M. Paesmans, M. Aoun,
J.C. Jensenius, S. Thiel
(Brussels, BE; Aarhus, DK)
P2088
Limited humoral responses of solid organ
transplant recipients to the AS03-adjuvanted
pandemic influenza vaccine
J. Ambrosioni*, M. Bel, C. Combescure,
K. Hadaya, P.Y. Martin, P. Soccal, T. Berney,
S. Noble, S. Meier, K. Posfay-Barbe, S. Grillet,
L. Kaiser, C.A. Siegrist, C. van Delden
on behalf of the H1N1 study group
P2089
Primary cytomegalovirus infections in
adult liver transplant recipients receiving
I. Lautenschlager*, R. Loginov, K. Höckerstedt
(Helsinki, FI)
Poster Sessions
P2090
Safety and clinical outcomes of high-dose
daptomycin for enterococcal infections
R. Kullar, M. Steed, S. Davis, S. Cosgrove,
B. Potoski, D. Goff, R. Hasbun, C. Crank,
J. Segreti, G. Sakoulas, J. Zhao, D. Levine,
M. Rybak* (Detroit, Baltimore, Pittsburgh,
Columbus, Houston, Chicago, San Diego, US)
P2091
Results from the European Cubicin®
outcomes registry and experience:
daptomycin is effective and safe in patients
with neutropenia and Gram-positive infections
A. Galloway*, N. Kröger, F. Keil, A. Micozzi,
T. Lejko-Zupanc, M. Gutierrez, P. GargalianosKakolyris, R. Parakh, M. Heep, Y. Yin,
R.L. Chaves (Newcastle upon Tyne, UK;
Hamburg, DE; Leoben, AT; Rome, IT; Ljubljana,
SI; Zaragoza, ES; Athens, GR; Gurgaon, IN;
Basel, CH; East Hanover, US)
P2092
P2093
P2094
12:30 – 13:30
P2095
Nosocomial Pneumocystis jirovecii
pneumonia: lessons learned from a case
cluster in kidney transplant recipients
L. Phipps, S.C. Chen*, K. Kable, C. Patterson,
C. Halliday, C. Firacative, W. Meyer,
B. Nankivell (Sydney, AU)
Orthotopic liver transplantation in
HIV-infected patients: experience in
a cohort of 27 patients
M. Montejo, A. Mularoni*, M. Gastaca,
J. Fernandez, A. Valdivieso, M. Testillano,
J. Gonzalez, J. Bustamante, A. Ventoso,
M. Suarez, P. Muñoz, J. Goikoetxea,
E. Bereciartua, J. Ortiz de Urbina
(Barakaldo, ES)
Evaluation of real-time PCR CMV, clinic
correlation, determination and validation
of cut-off point for CMV infection in low-risk
CMV solid organ transplant recipients
C. Martín-Gandul*, M. Sánchez, V. Cabello,
C. Bernal, E. Lage, J. Fijo, M. Aguilar-Guisado,
M.J. Rodríguez-Hernández, E. Cordero
on behalf of the Spanish Network For Research
in Infectious Diseases (REIPI)
Molecular diagnosis of invasive fungal
infections: has the era of empirical
antifungals come to an end?
Clinical validation of a marketed real-time
PCR assay for diagnosis of invasive
aspergillosis in patients without
haematological cancer
J. Guinea*, C. Padilla, S. Recio, P. Escribano,
D. García de Viedma, T. Peláez, P. Muñoz,
B. Padilla, P. Gijón, E. Bouza (Madrid, ES)
P2096
A novel clinical diagnostic assay for the
identification of multiple human fungal
pathogens in a single sample
K. Dempsey*, A. Ricketts, K. Fitchett,
J. Redden, P. White, M. Perry, R. Barnes
(Glasgow, Cardiff, UK)
P2097
Evaluation of a panfungal PCR assay to detect
and identify fungal DNA in up to 7-year-old
formalin-fixed paraffin-embedded tissue
specimens
B. Babouee*, M. Weisser, S. Savic Prince,
L. Bubendorf, M. Battegay, R. Frei,
D. Goldenberger (Basel, CH)
P2098
Rapid identification of yeast species by
the PCR- and microarray-based Prove-it™
sepsis assay
A. Aittakorpi, P. Kuusela, P. Koukila-Kähkölä,
M. Vaara, M. Petrou, V. Gant*, M. Mäki
(Helsinki, FI; London, UK)
P2099
DNA fingerprinting for genotype assignment
and molecular genetic basis of 5-flucytosine
resistance among clinical Candida dubliniensis
isolates in Kuwait
S. Ahmad*, L. Joseph, A. Theyyathel, Z. Khan
(Safat, KW)
P2100
DiversiLab system, automated repetitive
sequence-based PCR, as typing method
for Candida glabrata
R. Kofol*, T. Matos (Ljubljana, SI)
P2101
Comparison of two Aspergillus real-time
PCR methods and clinical significance
of Aspergillus DNA detection in BAL
N. Renaud, L. Delhaes, V. Coiteux, S. Herwegh,
I. Yakoub-Agha, S. Nseir, E. Dei-Cas, E. Fréalle*
(Lille, FR)
P2102
Molecular identification and antifungal
susceptibility of clinical Aspergillus terreus
complex isolates
P. Escribano, T. Peláez, S. Recio, B. Buendía,
E. Bouza, J. Guinea* (Madrid, ES)
P2103
One-step nested-multiplex real-time PCR
for the detection of Aspergillus fumigatus
and Aspergillus lentulus based on a singlelocus target gene
M.J. Buitrago*, I. Cuesta, L. Bernal,
J.L. Rodriguez-Tudela, M. Cuenca-Estrella,
E. Mellado (Majadahonda, Madrid, ES)
Final Programme
183
Posters
Tuesday, 10 May
Poster Sessions
Tuesday, 10 May
12:30 – 13:30
P2104
P2105
P2106
P2113
Efficacy of intravenous itraconazole for the
treatment of invasive candidiasis in surgical
department and acute care medicine –
a multicentre clinical study
Y. Takesue*, S. Oda, N. Aikawa, S. Fujishima,
H. Mikamo (Hyogo, Chiba, Tokyo, Aichi, JP)
P2114
Cytokine profile of patients with invasive
aspergillosis: initial results from the first 100
patients recruited into the Aspergillosis Study
M.M. Ceesay*, S. Kordasti, L. Berry, M. Smith,
J. Wade, G.J. Mufti, A. Pagliuca (London, UK)
Economic evaluation of micafungin versus
liposomal amphotericin B in the treatment
of candidaemia and invasive candidiasis
C.F. Neoh*, D. Liew, M. Slavin, D. Marriott,
S.C. Chen, O. Morrissey, K. Stewart, D. Kong
(Melbourne, Sydney, AU)
P2115
Expression of immune genes by human
macrophages from healthy subjects and CCPA
patients in response to stimulation with
Aspergillus fumigatus
N.L. Smith*, D.W. Denning, A. Simpson, P. Bowyer
(Manchester, UK)
Fungiscope – a global rare fungal infection
registry
M. Vehreschild, W. Heinz, A. Hamprecht,
G. Fischer, S. De Hoog, J. Vehreschild,
O.A. Cornely* on behalf of the Fungiscope
Working Group
P2116
Epidemiology of fungaemia in Spain:
preliminary results of 1,177 episodes from
a multicentre study (FUNGEMYCA) in 2009
J. Pemán*, E. Cantón, C. Pazos, A. García,
S. Algarate, I. Campos, D. Velasco, A. Suárez,
J. Esperalba (Valencia, Caceres, Cádiz,
Zaragoza, Las Palmas, La Coruña, Seville,
Majadahonda, Madrid, ES)
P2117
Hospital contacts with Candida infections
and risk of cancer
M. Nørgaard, D.F. Farkas, M.F. Mogensen,
R.W. Thomsen*, H.T. Sørensen (Aalborg, Aarhus, DK)
P2118
Candidaemia after liver transplantation
in the era of fluconazole prophylaxis:
a prospective survey at one centre over
10 years
C. Camus, J. Letheulle, A. Gacouin, S. Lavoué,
S. Marque, A. Gros, L. Chimot, C. Guiguen,
Y. Le Tulzo, J.-P. Gangneux* (Rennes, FR)
P2119
The value of the Candida Colonisation Index
for predicting Candida infections in a mixed
intensive care unit
B. Ergüt Sezer, M. Dizbay, D. Arman*
(Ankara, TR)
P2120
Candida peritonitis: analysis of 81 episodes
A. Loza*, J. Gonzalez, A. Ubeda, C. Leòn,
C. Castro, P. Saavedra, S. Ruiz
on behalf of the Cava II study group
P2121
Trends in species distribution and antifungal
susceptibility in yeasts isolated from
peritoneal fluid in a general hospital:
an overview of a 16-year period
T. Pelaez*, B. Gama, A. Luis, E. Reigadas,
R. Flores, J. Guinea, P. Muñoz, E. Bouza
(Madrid, ES)
Fungal infections: epidemiology, molecular
bases and management
SNPs associated with a high IL-6, low IL-10
cytokine pattern predispose lung transplant
recipients to pneumonia due to moulds
C. Clancy*, D. Mitsani, A. Zeevi, Y. Toyoda,
M. Nguyen (Pittsburgh, US)
P2107
Fungal pathogens secrete soluble factors
that activate thrombocytes
C. Speth*, G. Rambach, M. Hagleitner,
C. Kupfahl, R. Würzner, C. Lass-Flörl
(Innsbruck, AT; Heidelberg, DE)
P2108
Economic evaluation of voriconazole
versus itraconazole for primary prophylaxis
of invasive fungal infection in allogeneic
H. Schlamm, X. Gao, X. Ji, J. Stephens,
M. Tarallo* (New York, Bethesda, US; Rome, IT)
P2109
Therapeutic drug monitoring of posaconazole
in patients with acute myeloid leukaemia or
myelodysplastic syndrome: a bi-centre study
M. Vaes, M. Hites*, A.M. Bourguignon, M. Csergö,
C. Rasson, F. Cotton, M. Paesmans, L. Ameye,
D. Bron, F. Jacobs, M. Aoun (Brussels, BE)
P2110
Therapeutic drug monitoring among lung
transplant recipients receiving voriconazole
prophylaxis: identification of preventive
breakpoints
D. Mitsani, M. Nguyen, R. Shields, Y. Toyoda,
C. Clancy* (Pittsburgh, US)
P2111
Risk factors for candidaemia-related death
in non-neutropenic critically ill patients
M. Lupse*, M. Flonta, A. Cioara, I. Filipescu,
A. Moisuc, H. Kast, N. Hagau, C. Mitre, C. Bodolea,
I. Vlad, D. Nour, N. Todor (Cluj-Napoca, RO)
P2112
A retrospective trial to evaluate the safety
and efficacy of anidulafungin in individuals
with hepatic dysfunction including liver
M. Barron*, K. Richardson, A. Hilts, M. Levi
(Aurora, US)
Final Programme
Poster Sessions
P2122
Trends of candidaemia in Slovakia –
a comparison of two consecutive,
prospective studies
L. Drgona*, D. Kotulova, J. Trupl, A. Kunova,
M. Lisalova, H. Hupkova, T. Marcek
(Bratislava, SK; Paris, FR)
P2130
Consolidation and nodular infiltrates on
CT scans of patients with invasive pulmonary
aspergillosis correlate with elevated BAL
galactomannan levels
C. Clancy*, J. Wingard, M. Nguyen
(Pittsburgh, Gainesville, US)
P2123
Nosocomial bloodstream infections
due to Candida spp. in the US – species
distribution, clinical features and
susceptibilities
H. Wisplinghoff*, J. Ebbers, L. Geurtz,
D. Stefanik, Y. Major, M.B. Edmond, R.P. Wenzel,
H. Seifert (Cologne, DE; Richmond, US)
P2131
P2124
Epidemiology of candidaemia in two tertiarycare university hospitals in Germany
A. Hamprecht*, S. Göttig, H. Seifert, F. Knapp,
H. Wisplinghoff, G. Plum
(Cologne, Frankfurt, DE)
Are community-acquired invasive
aspergilloses preceded by an increase
of outdoor filamentous fungal load?
M.P. Brenier-Pinchart, B. Lebeau,
J.L. Borel, J.L. Quesada, M.R. Mallaret,
F. Garban, J.-P. Brion, L. Molina, J.L. Bosson,
A. Tiebaut-Bertrand, R. Grillot, H. Pelloux*
(Grenoble, FR)
P2132
Imported AIDS-related histoplasmosis
in metropolitan France: a comparison
of pre-HAART and HAART eras
V. Peigne*, F. Dromer, C. Elie, O. Lidove,
O. Lortholary on behalf of the French Mycosis
Study Group
P2133
Impact of liposomal amphotericin B on renal
function in ICU patients with increased serum
creatinine level
M.C. Soriano*, M. Catalán, A. Llorente, N. Vidart,
M. Garitacelaya, E. Maraví, E. Fernández,
F. Alvarado, M. López, B. Álvarez, D. Granado,
E. Quintana, P. Alvarez-Lerma
(Madrid, Pamplona, Oviedo, Santander,
Alicante, Badajoz, Barcelona, ES)
P2134
Video-assisted thoracoscopic biopsy
is feasible and safe in adult haematooncology patients undergoing stem
cell transplantation or high-dose
chemotherapy
M.M. Ceesay*, L. Berry, S.R. Desai,
M. Marrinan, R. Deshpande, D. Whitaker,
S. Pomplun, A.G. Nicholson, H. Sikondari,
J. Wade, M. Smith, G.J. Mufti, A. Pagliuca
(London, UK)
P2135
Diagnostic value of the 1,3-beta-D-glucan
test for detecting candidaemia
L. Persijn*, A. Piette, S. Blot, K. Vandewoude,
N. Brusselaers, P. Depuydt, D. Benoit,
J. Decruyenaere, D. Vogelaers, G. Claeys
(Ghent, BE)
P2136
Contribution of the mannan antigen
detection for the diagnosis of invasive
candidiasis in neonatal patients
L. Trovato*, P. Betta, M. Romeo, S. Oliveri
(Catania, IT)
P2137
The use of galactomannan detection in urine
samples from haemato-oncology patients at
high risk of invasive aspergillosis
L. Berry*, A. Junor, M.M. Ceesay, H. Sikondari,
A. Pagliuca, J. Wade, M. Smith (London, UK)
P2125
P2126
Phase IV, open-label study of intravenous
anidulafungin followed optionally by oral
voriconazole for treatment of candidaemia/
invasive candidiasis in critically ill patients
M. Nucci*, M. Petti, M. Magana, P. Abreu,
S. Sanchez (Rio de Janeiro, São Paulo, BR;
San Luis Potosi, MX; New York, US)
Invasive aspergillosis in haematologic
patients: description of 127 cases enrolled
in a single-centre prospective surveillance
system, 2004 – 2009
T. Bénet*, M. Nicolle, A. Thiebaut, M. Piens,
N. Voirin, A. Duclos, X. Thomas, F. Nicolini,
F. De Monbrison, M. Perraud, A. Bienvenu,
M. Michallet, P. Vanhems (Lyon, FR)
P2127
The epidemiology of neutropenic patients
with invasive candidiasis using electronic data
E. Kuo, L. Puzniak, R. Reichley, J. Doherty,
B. Camins* (Saint Louis, US)
P2128
Respiratory aspergillosis in non-transplant,
non-neutropenic patients
E. Malmierca, D. Del Castillo, A. Fernandez-Villar,
V. Villena, G. Fernandez, F. Garcia-Perez,
F. Garcia de la Llana, J. Barberan, L. Aguilar,
J.J. Granizo, M.J. Gimenez*
on behalf of the ASP Investigators Group
P2129
Chronic invasive pulmonary aspergillosis:
diagnosis and treatment
Y.V. Borzova, S.N. Khostelidi, M.O. Popova,
R.M. Chernopyatova, T.S. Bogomolova,
S.M. Ignatyeva, O.A. Shurpitskaja, A.S. Kolbin,
I.S. Zjuzgin, N.V. Zubarovskaja, N.V. Vasilyeva*,
N.N. Klimko (Saint Petersburg, RU)
Final Programme
185
Posters
Tuesday, 10 May
Poster Sessions
Tuesday, 10 May
P2138
P2139
12:30 – 13:30
P2140
Study of receptor expression and antiAspergillus functions on phagocytes
from healthy donors before monitoring
transplant patients
D. Aldebert, M. Hypolite, G. Bal,
C. Dumestre-Perard, R. Bertini, C. Rolland,
J. Boutonnat, H. Pelloux, J.-P. Brion*
(La Tronche, Grenoble, FR)
Cost-effectiveness analysis of two
recommendations for antifungal therapy
indication in patients with persistent
febrile neutropenia
A. Martín-Peña*, M.V. Gil Navarro,
M. Aguilar-Guisado, I. Espigado, E. Cordero,
J. Pachón, J.M. Cisneros Herreros
on behalf of the Spanish Network for Research
in Infectious Disease (REIPI)
P2146
In vitro activities of voriconazole,
caspofungin and amphotericin B against
clinical Candida krusei isolates by the
time-kill method
N. Kiraz*, Y. Öz (Istanbul, Eskisehir, TR)
P2147
Efficacy of amphotericin B and caspofungin
in a murine model of disseminated candidiasis
caused by Candida albicans and Candida
glabrata pre-exposed in vitro and in vivo
to fluconazole
R. López-Rojas*, J. Domínguez-Herrera,
F. Docobo-Pérez, M. McConnell, J.M. Cisneros
Herreros, J. Garnacho Montero, J. Pachón
(Seville, ES)
P2148
Antifungal susceptibilities of Aspergillus
fumigatus and sequence of the cyp51A gene
of azole-resistant isolates in Nagasaki, Japan
M. Tashiro*, K. Izumikawa, N. Hosogaya,
T. Takazono, Y. Morinaga, Y. Imamura,
T. Miyazaki, M. Seki, H. Kakeya, Y. Yamamoto,
K. Yanagihara, T. Tashiro, S. Kohno (Nagasaki, JP)
P2149
Genotyping and cyp51A sequencing
of consecutive Aspergillus fumigatus isolates
suggest in vivo as well as ex vivo origin
of azole resistance
R. Jensen*, K. Mortensen, S.J. Howard,
H. Leatherbarrow, E. Mellado, H.K. Johansen,
M. Skov, T. Pressler, M. Cavling Arendrup
(Copenhagen, DK; Manchester, UK; Madrid, ES)
P2150
Posaconazole plasma concentrations
in allogeneic haematopoietic stem cell
J. Winterova*, Z. Racil, L. Malaskova,
M. Toskova, M. Rolencova, J. Mayer (Brno, CZ)
P2151
Chronic Aspergillus fumigatus colonisation
of respiratory tract in cystic fibrosis:
diagnosis, management and antifungal
resistance in a French cohort of cystic
fibrosis patients
L. Delhaes*, A. Jourdain, M. d'Almeida-Fourquet,
E. Fréalle, S. Leroy, C. Pinel, B. Coltey,
L. Favennec, S. Dominique, O. Vagner,
A.-L. Fanton, J.-P. Bouchara, C. Person,
I. Durand-Joly, G. Loeuille, P. Domblides,
I. Accoceberry, A. Farce, P. Chavatte, B. Wallaert
(Lille, Bordeaux, Grenoble, Rouen, Dijon,
Angers, Dunkerque, FR)
P2152
Role of caspofungin in enhancing chronic
haemodialysed and kidney transplant patient
PMN response against Candida glabrata
V. Allizond , G. Banche, F. Giacchino, V. Tullio*,
D. Scalas, C. Merlino, N. Mandras, J. Roana,
G. Garneri, R. Patti, A.M. Cuffini (Turin, Ivrea, IT)
Systemic antifungals: in vitro and in vivo data
Functional characterisation of endogenous
regulators of calcineurin in Candida glabrata
T. Miyazaki*, Y. Nagayoshi, K. Izumikawa,
M. Tashiro, S. Kohno (Nagasaki, JP)
P2141
Functional characterisation of the Slt2regulated transcription factors, Rlm1 and
SBF, in Candida glabrata
Y. Nagayoshi*, T. Miyazaki, K. Izumikawa,
M. Tashiro, S. Kohno (Nagasaki, JP)
P2142
Flow cytometry: a faster method to assess
the in vitro activity of amphotericin B against
Candida spp.
E.M. González Barberá*, L. Cordón, E. Cantón,
A. Sempere, J. Pemán, I. Jarque (Valencia, ES)
P2143
Antifungal activity of echinocandins against
isolates of Candida parapsilosis, Candida
metapsilosis and Candida orthopsilosis
I. Miranda-Zapico*, E. Eraso, J.L. Hernández
Almaraz, A.J. Carrillo Muñoz, J.M. Hernández
Molina, G. Quindós (Bilbao, Barakaldo,
Barcelona, Málaga, ES)
P2144
Echinocandin susceptibility of Candida
blood stream isolates collected during a
one-year period in Sweden
M. Axner-Elings, S. Botero-Kleiven, R. Jensen,
V. Fernandez, M. Cavling Arendrup*
(Solna, SE; Copenhagen, DK)
P2145
Use of proposed species-specific CLSI
breakpoints to interpret anidulafungin
MIC values. Results from three regional
clinical studies of anidulafungin for the
treatment of candidamia/invasive
candidiasis
P. Hogan*, P. Biswas (New York, US)
Final Programme
Poster Sessions
Tuesday, 10 May
12:30 – 13:30
Development of amphotericin B
deoxycholate-induced nephrotoxicity
is associated with induction of a net
pro-inflammatory cytokine profile
L. Chai*, L. Khin, B. Tai, A. Vonk, H. Schlamm,
R. Herbrecht, P. Troke, M. Netea, B. Kullberg
(Nijmegen, NL; Singapore, SG; Rotterdam, NL;
New York, US; Strasbourg, FR; Kent, UK)
VZV glycoprotein E: a novel serological
antigen for the discrimination between VZV
CNS infection and HSV-1 encephalitis
A. Grahn*, E. Thomsson, M. Studahl,
T. Bergström (Gothenburg, SE)
P2163
Occurrence of immunoglobulin M antibodies
against several bacterial and viral pathogens
in acute hantavirus infection
N. Wellinghausen*, A. Goetz, U. Weber
(Ravensburg, DE)
P2164
Evaluation of a rapid detection kit using
immunochromatography for adenovirus
infection
G. Antonaki, M. Matsas*, F. Antonopoulou,
P. Xenos, I. Paraskakis (Athens, GR)
Diagnosis of viral infections
P2154
Time-dependent sensitivity of rapid antigen
test in patients with 2009 H1N1 influenza
C.S. Lee*, J.H. Lee, C.H. Kim, E.S. Kim, B.N. Kim
(JeonJu, Jeonbuk, Goyang, Busan, KR)
P2155
Clinical performance of a rapid antigen
detection test for pandemic influenza A/H1N1
M. Selleri*, S. Meschi, E. Lalle, F. Ferraro, V. Puro,
F.N. Lauria, M.R. Capobianchi (Rome, IT)
P2156
P2162
Evaluation of a new rapid test for influenza
A and B viruses detection and pandemic
A/H1N1 2009 influenza virus subtyping in
respiratory samples
N. Leveque*, D. Talmud, F. Renois, C. Barbe,
L. Andreoletti (Reims, FR)
P2157
Performance evaluation of a new ELISA test
detecting influenza A/H1N1pdm-specific
IgG and IgA
C. Castilletti, D. Lapa*, P. Marsella,
M.R. Capobianchi (Rome, IT)
P2158
Study of norovirus infection from stool
samples in transplant recipients or intensive
care unit patients from a children's hospital
with an antigen detection enzyme
immunoassay test
A.M. Mehlis*, Z. Rentero, S. Garcia-Bujalance
(Madrid, ES)
P2159
Comparison of Epstein-Barr virus tests on
Immulite with Enzygnost/Novagnost tests
I. Verstreken, K. Lagrou* (Louvain, BE)
P2160
Evaluation of new extremely rapid EpsteinBarr virus VCA-IgG, EBNA-1-IgG and VCA-IgM
assays using immunofluorescence as
reference
B. Gaertner*, A. Halfmann, E. Heinzel
(Homburg, DE)
P2161
Analysis of the results of the SEIMC external
quality control programme in the detection
of gastrointestinal viruses
N. Orta*, M.R. Guna, M. Poveda, M. Ovies, E. Ruiz
de Gopegui, J.L. Perez, C. Gimeno (Valencia, ES)
12:30 – 13:30
HIV/AIDS
P2165
HIV-1 is able to infect resting TCD4+ cells
efficiently in a short time of viral exposure
J.T. Maricato*, W. Alkmim, P. Fincatti,
S. Nascimento-Brito, J. Machado Jr., L. Janini
(São Paulo, BR)
P2166
Prevalence of primary resistance mutations
and influence of integrase polymorphism on
virological outcome of Raltegravir-containing
anti-retroviral regimens
V. Guillot*, N. Chueca, M. Alvarez, A. Peña,
M. D. Merida, J. Lopez-Bueno, J. Parra-Ruiz,
J. Pasquau, J. de la Torre, F. Garcia
on behalf of RAL-CoRAO
P2167
Regulation of APOBEC3G as therapeutic
strategy to control HIV-1 infection
L. Ferreira*, A. Ramos, J. Gonçalves, I. Soeiro
(Lisbon, PT)
P2168
Cell entry to nuclear import: HIV cycle may be
influenced by phosphatases and kinases
A. Godinho Santos*, S. Rato, J. Gonçalves
(Lisbon, PT)
P2169
Antiviral drug resistance in HIV-1-infected
individuals. Results from a low-endemicity
area in Germany, comparing patients
with primary HIV infection or antiretroviral
naïve individuals to those with treatment
failures or recurrent blips
T. Grünewald*, S. Weidemann, N. Schmidt,
I. Raila, K. Schreiter, T. Marcello, C. Klein,
H. Müller, A. Pöge, B.R. Ruf
(Leipzig, Hamburg, DE)
Final Programme
187
Posters
P2153
Poster Sessions
Tuesday, 10 May
P2170
K103N minor variants in untreated and
treated patients from southern Spain
M. Alvarez*, V. Guillot, A. Peña, N. Chueca,
J. Lopez-Bueno, M.D. Merida, M. Omar,
V. Gutierrez-Rave, M.A. Martinez-Perez,
F. Garcia on behalf of CoRAO
P2171
Regulation of Vif by phosphorylation
during HIV-1 infection
A. Ramos*, A. Couto, F. Luís, J. Gonçalves,
I. Soeiro (Lisbon, PT)
P2172
P2173
P2174
P2175
P2176
HIV integrase variability and genetic barrier in
antiretroviral naïve and experienced patients
A. Piralla*, S. Paolucci, R. Gulminetti,
F. Baldanti (Pavia, IT)
Determination of drug resistance from
HIV-1 RNA stabilised at room temperature
on solid matrix
M. Rossi de Gasperis*, L. Putignani,
D. Caione, G. Pizzichemi, G. Pontrelli,
S. Bernardi, D. Menichella, F. Callea (Rome, IT)
Prevalence of cognitive impairment
in an Irish HIV-positive clinic population
based on the use of surrogate markers
for cognitive impairment
P.H. McNamara*, C. Doherty, J. Redmond,
C. Bergin (Dublin, IE)
Late presentation of HIV infection
in northern Greece: prevalence and
correlates, 2000 – 2010
S. Metallidis*, D. Pilalas, L. Skoura,
Z.A. Antoniadou, O. Tsachouridou,
A.B. Haidich, T. Chrysanthidis, I. Bakaimi,
E. Magaliou, A. Margariti, I. Nikolaidis,
P. Kollaras, N. Malisiovas, P. Nikolaidis
(Thessaloniki, GR)
Durable outbreak of syphilis in HIV-infected
patients: data from Northern Greece
S. Metallidis*, O. Tsachouridou, P. Kollaras,
E. Sidiropoulou, A.B. Haidich, D. Pilalas,
L. Skoura, T. Chrysanthidis, I. Bakaimi,
A. Margariti, E. Diza, P. Nikolaidis
(Thessaloniki, GR)
P2177
Late diagnosis of HIV infection in Ireland –
a cause for concern
A. Jackson*, M. Brenan, F. Mulcahy,
W. Powderly, M. Codd, S. McConkey
(Dublin, IE)
P2178
Use of risk management as a tool for quality
improvement in a public HIV service
M. Brenan*, A. Jackson, H. Tuite, S. McConkey
(Dublin, IE)
Final Programme
P2179
Leprosy presenting as immune
reconstitution inflammatory syndrome in
patients on highly active anti-retroviral
treatment. A case-series study from
a tertiary care centre in Kerala, South India
T. John*, C. Jacob, M. Sadeep,
K. Shobhanakumary, A. Jacob,
A. George (Kottayam, Trivandrum, IN)
P2180
Susac’s syndrome in a HIV-infected patient
E. Vryonis*, E. Kakalou , A. Baxevanakis,
C. Linardi , K. Papanikolaou,
V. Papastamopoulos, I. Baraboutis,
A. Skoutelis (Athens, GR)
P2181
Adverse effect of influenza A/H1N1
vaccination on endothelial function
of HIV infected patients
H. Sambatakou* (Athens, GR)
P2182
Newly diagnosed HIV-infected patients
in Romania - late presentation
V. Arama, R. Mihailescu*, A. Streinu-Cercel,
A. Hristea, A.M. Tudor, S. Paraschiv, D. Otelea,
M. Radulescu, D. Munteanu, L. Benea,
C. Tiliscan, S.S. Arama (Bucharest, RO)
P2183
High prevalence and incidence of oncogenic
human papillomavirus infection in a cohort of
African HIV-positive women in Belgium
D. Konopnicki*, Y. Manigart, C. Gilles,
J. de Marchin, M. Delforge, F. Feoli, P. Barlow,
S. De Wit, N. Clumeck (Brussels, BE)
P2184
Pulmonary hypertension in HIV-infected
patients: a case-control study
S. Cicalini, P. Chinello, E. Grilli, M. Musso,
R. Bellagamba, C. Castilletti, N. Petrosillo*
(Rome, IT)
P2185
Characteristics of women with a new HIV
diagnosis in Italy, 1985 – 2009
L. Camoni*, V. Regine, M.C. Salfa, M. Raimondo,
S. Boros, B. Suligoi and HIV Surveillance
referents
P2186
Prevalence and persistence of anal infection
by oncogenic human papillomavirus virus
and co-infection with Chlamydia trachomatis
among HIV-infected homosexual males
J. Macías, M. Parra, J. Cabeza, C. Pablos,
N. Sivianes, L. Perez, E. Martín-Mazuelos,
J.C. Palomares* (Seville, ES)
P2187
Human herpesvirus 8 prevalence among
HIV-1 infected patients during 2007 – 2010
F. López-Fabal*, A. Pérez-Rivilla,
J.L. Gómez-Garcés (Madrid, ES)
Poster Sessions
P2188
The influence of HAART on the incidence,
clinical presentation and prognosis of
cryptosporidiosis
M. Korac*, J. Ranin, D. Salemovic, B. Brmbolic,
D. Jevtovic (Belgrade, RS)
P2189
Inflammatory markers and metabolic
syndrome in HIV-positive adults undergoing
highly active anti-retroviral therapy
D. Munteanu*, V. Arama, R. Mihailescu,
A. Streinu Cercel, S.S. Arama, I. Olaru,
A. Hristea, C. Popescu, R. Moroti, D. Ion,
C. Tiliscan, L. Benea, M. Lazar (Bucharest, RO)
P2190
P2191
P2192
P2193
P2194
12:30 – 13:30
Impaired antibody response to pandemic
H1N1 influenza vaccination in HIV-positive
patients
C. Noah*, G. Mohrmann, G. Beckmann,
H. Sahly, H.J. Stellbrink (Hamburg, DE)
Differences in serum levels of soluble Fas
and FasL in patients with human immunodeficiency virus, human herpesvirus type 8
and herpes simplex virus type 2 infections
O. Dakovic Rode*, A. Markotic, M. Kujundzic
Tiljak, S. Zidovec Lepej, J. Begovac (Zagreb, HR)
Disclosure of HIV serostatus and quality
of life among people living with HIV/AIDS in
Thailand
N. Hiransuthikul*, Y. Leelukkanaveera,
P. Sithisarankul, N. Buathong (Bangkok, TH)
Evaluation of experienced patients treated
with raltegravir
R.M. Tavares*, N. Luis, T. Baptista, I. Antunes,
A.C. Miranda, D. Fernandes, F. Borges,
F. Ventura, K. Mansinho (Lisbon, PT)
Underreporting and non-adherence to
post-exposure prophylaxis among healthcare
workers in Iranian university hospitals
S. Shokouhi*, L. Gachkar, P. Youhanaee, M. Sajadi
(Tehran, IR; Baltimore, US)
Virology: non HIV/non hepatitis
P2195
Factors influencing the duration of illness
in pandemic H1N1/2009
J.H. Cho, J.H. Lee*, Y.H. Park (Seoul, KR)
P2196
Secondary bacterial infections in
patients with seasonal influenza A
and pandemic H1N1
K. Liderot*, M. Ahl, V. Özenci (Stockholm, SE)
P2197
Virological diagnosis of paediatric severe
respiratory infections during circulation
of pandemic influenza A/H1N1 in Rome
A. Pierangeli, C. Scagnolari, C. Selvaggi,
K. Monteleone, S. Trombetti, E. Di Biase,
C. Moretti, P. Papoff, F. Midulla, G. Antonelli*
(Rome, IT)
P2198
Seasonal versus pandemic influenza:
differences in severity, course of illness
and treatment
J.C. Rahamat-Langendoen*, A. RiezebosBrilman, E.D. Tutuhatunewa, E.H. Schölvinck,
H.G. Niesters (Groningen, NL)
P2199
Human parechovirus infections in a
hospitalised patient population in Northern
Italy, 2008 – 2010
A. Piralla*, M. Furione, F. Rovida, F. Baldanti
(Pavia, IT)
P2200
Type-specific human papillomavirus infection
in female anal and cervical brushings
A. Pierangeli*, F. Cannella, K. Monteleone,
C. Selvaggi, S. Verzaro, C. Scagnolari,
O. Turriziani, M. Indinnimeo, G. D'ettorre,
A.M. Degener, G. Antonelli (Rome, IT)
P2201
Antiviral effect of siRNA against Langat virus
in cell culture and organotypic hippocampal
rat brain slices
C. Maffioli*, S. Hofer, S. Leib, O. Engler
(Berne, Spiez, CH)
P2202
May oysters favour zoonotic transmission
of norovirus?
M. Pommepuy, H. Maalouf*, J.-C. Le Saux,
N. Ruvoen-Couet, J. Le Pendu, F.S. Le Guyader
(Plouzane, Nantes, FR)
P2203
Cerebrospinal fluid findings in patients
with different clinical features of tick-borne
encephalitis treated with glucocorticoids
I. Vanaga*, I. Reinholde, A. Broduža,
J. Storoženko, B. Rozentale (Riga, LV)
P2204
Lymphocytic choriomeningitis virus
infection within the same geographical area
(southern Spain) during a three-year period
M. Pérez-Ruiz*, J.M. Navarro-Marí,
M.P. Sánchez-Seco, M.I. Gegúndez, G. Fedele,
F. de Ory-Manchón (Granada, Majadahonda,
Madrid, Alcalá de Henares, ES)
P2205
Sporadic detection in children during
a 25-year surveillance in Palermo, Italy,
clarifies the zoonotic potential of G6 rotavirus
strains
F. Bonura, V. Rotolo, M.A. Platia, A. Cascio*,
C. Colomba, G.M. Giammanco, S. De Grazia
(Palermo, Messina, IT)
Final Programme
189
Posters
Tuesday, 10 May
Poster Sessions
Tuesday, 10 May
P2206
Human papillomavirus infection prevalence
in Spain. Preliminary results of a screening
programme in Castilla y León, Spain
M.L. Fernández Rueda, N. Calvo Sánchez,
A.M. Blázquez de Castro, M.N. Gutiérrez
Zufiaurre, S. Muñoz Criado, J.L. Muñoz Bellido*
(Salamanca, ES)
P2207
Rubella susceptibility among women
of childbearing age
N. Terzi, A. Papanagiotou, A. Charalabopoulou*,
A. Bliamou, H. Chrysopoulou, D. Togas,
G. Iliopoulos, K. Tzanetou (Athens, GR)
P2208
Selection of molecules disrupting proteinprotein interactions within the vaccinia
virus replication complex
O. Flusin*, L. Saccucci, P. Colas, J.-M. Crance,
F. Iseni (La Tronche, Grenoble, Roscoff, FR)
P2209
P2210
P2211
P2212
P2213
Systematic control of rubella virus infection
in pregnancy in the childbearing population
in Emila-Romagna region, Italy
P. Billi*, D. Marchetti, S. Semprini, E. Magrini,
M. Della Strada, S. Ghirelli, L. Morotti,
S. Antonelli, C. Rovinetti, R. Dorizzi
(Pievesestina Cesena, Bologna, IT)
Inter-alpha inhibitor proteins exhibit
antiviral activity against influenza virus
strains in vitro
E. Christaki*, J.E. Palardy, N.A. Parejo,
D. Lambrelli, Y.-P. Lim, S. Opal
(Providence, US; Thessaloniki, GR)
In vivo protection against Old World
arenaviruses using phosphorodiamidate
morpholino oligomers with positionally
specific positive molecular charges added
to monomers to backbone
T. Warren, A. Shurtleff, J. Wells, F. Schnell,
D. Mourich, S. Bavari, P. Iversen*
(Fredrick, Bothell, US)
Infection of human intestinal cells and mice
with pepper mild mottle virus, a plant virus
F. Balique, K. Al Moussawi, A. Ferretti, C. Nappez,
H. Lecoq, J.-L. Mège, D. Raoult, P. Colson*
(Marseille, Montfavet, FR)
Kaposi sarcoma-associated herpesvirus
saliva shedding in children and mothers
in Uganda
R. Romano*, F. Tabacchi, G. Russo,
S. Gramolelli, S. Verzaro, F. Marinucci,
G.M. Paganotti, A. Gaeta, M. Coluzzi
(Rome, IT; Baltimore, US)
Final Programme
P2214
Prevalence of anti-hepatitis E virus
antibodies in HCV chronically infected
patients in southeastern France
R. Gérolami*, P. Borentain, A. Motte,
P. Colson (Marseille, FR)
P2215
Increasing CD4+CD25hiFoxP3+ regulatory
T-cells in subjects after repeated booster
doses of rabies vaccination
P. Vejpongsa*, P. Leelasinjaroen, P. Sodsai,
N. Hirankarn, T. Tantawichien (Bangkok, TH)
12:30 – 13:30
Viral hepatitis
P2216
Premature stop codon in HBV S gene among
several patients groups from the Middle East
M. Vaezjalali*, S.M. Alavian, B. Behnava, T.M. Azad
(Tehran, IR)
P2217
Molecular epidemiology of HCV in Morocco
A. Benani*, W. Baha, N. Dersi, M. Ennaji,
F. Lazaar, A. El Malki, M. Hassar
(Casablanca, MA)
P2218
Evaluation of a novel quantitative
HCV Core Ag immunoassay for the study
of chronic hepatitis C
C. Bartzavali*, S. Vamvakopoulou,
E. Jelastopulu, E.D. Anastassiou, M. Christofidou
(Patras, GR)
P2219
The prevalence of HCV infection among
surgical nurses, midwives, their patients and
blood donors: a cross-sectional sero-survey
M. Ganczak* (Szczecin, PL)
P2220
Viral hepatitis B and C among homeless
people living in south-eastern France
P. Colson*, E. Botelho-Nevers, H. Richet,
S. Badiaga, D. Raoult, P. Brouqui (Marseille, FR)
P2221
Hepatitis delta in Marseille, southeastern
France
M. Plumelle, A. Motte, M. Henry, M.-H. Romera,
C. Tourrès, A. Ferretti, C. Tamalet, P. Colson*
(Marseille, FR)
P2222
Frequency and clinico-laboratory features
of mix-infections, caused by CMV and
HSV (1/2) in pregnant women with chronic
HBV- and HCV-infection in Ukraine
V.A. Boyko*, T.A. Achkasova, G.V. Batsyura,
M.T. Gafarova (Simferopol, UA)
P2223
Acute and fulminant hepatitis B in public
hospitals of Marseille, southeastern France
L. Panassié, P. Borentain, C. Nafati, G. Bernardin,
B. Doudier, V. Thibault, R. Gérolami, P. Colson*
(Marseille, Nice, Paris, FR)
Poster Sessions
Tuesday, 10 May
Liver damage in pandemic influenza A/H1N1
N. Papic, A. Pangercic, M. Vargovic, B. Barsic,
A. Vince* (Zagreb, HR)
P2225
Infectivity and pathogenicity of hepatitis
A virus during an outbreak in a communal
living setting
J.H. Cho*, H.J. Hyun, J.H. Lee, Y.H. Park
(Seoul, KR)
P2226
Hepatitis E virus infection in Bulgaria
G. Popov*, M. Baymakova, K. Plochev, I. Dikov
on behalf of the ESCMID Study Group for
Viral Hepatitis (ESGVH)
P2227
Hepatitis A in the area south of Gran Canaria,
Spain
A. De Malet*, A. Hernández-Betancor,
C. Del Rosario-Quintana (Las Palmas, ES)
P2228
Hepatitis E virus in Italy: molecular analysis
of travel-related and autochthonous cases
G. La Rosa*, M. Muscillo, V. Spuri Vennarucci,
A.R. Garbuglia, P. La Scala, M.R. Capobianchi
(Rome, IT)
P2229
Occult hepatitis B infection in couples,
candidates for assisted reproductive
technology
N. Hannachi, M. Khammari, A. Ferjani,
J. Boukadida* (Sousse, TN)
P2230
Thyroid dysfunction related to pegylated
interferon-alpha and ribavirin treatment
for HCV hepatitis
C. Popescu*, V. Arama, R. Moroti, A. Hristea,
V. Molagic, G.A. Popescu, I. Olaru, R. Nastase,
D. Munteanu, M. Radulescu, R. Mihailescu,
M. Ion, I. Niculescu, R. Geanta (Bucharest, RO)
P2231
Hepatitis A and HIV co-infection
A. Infante*, E. Clavijo, A. Gutierrez, I. Viciana,
M. Ortega, M.A. Sanchez (Malaga, ES)
P2232
Quantitative determination of HCV core
antigen: a marker for monitoring hepatitis
C viraemia
K. Ergunay, B. Sener*, A. Alp, J. Karakaya,
G. Hascelik (Ankara, TR)
P2233
Sero-prevalence study of HBsAg among
pregnant women in Albania
M. Goga*, A. Manaj, S. Leli, O. Hoxhaj, N. Pepi,
A. Barbullushi, A. Bulo, M. Dede, E. Shehu,
A. Harxhi (Tirana, AL)
P2234
Multicentre trial of the new Siemens HBsAgII
assays for qualitative detection of HBs
antigen on the ADVIA Centaur systems
E. Saxton, K. Schwarz, S. Froehlich,
S. Patibandla, B. Weissbrich, J. Verheyen*
(Tarrytown, US; Marburg, DE; Würzburg,
Cologne, DE)
P2235
The evaluation of the ELISA kit “DS-EIAanti-HCV- SPECTR-GM” as supplemental
assay for confirmation of anti-HCV
screening positive results
G. Bochkova*, S. Fomina, V. Puzyrev,
A. Obriadina, A. Burkov, T. Ulanova
(Nizhniy Novgorod, RU)
P2236
Assessment of a new Liaison® XL automated
immunoassay for the quantitative and highly
specific detection of HBsAg in human
serum/plasma
F. Capuano*, V. Anrò, M. Petruzziello, S. Enrietti,
L. Pallavicini (Saluggia, IT)
P2237
The serological profile of the samples with
HBsAg concentration below detection limit
of best currently available EIA kits
N. Egorova*, S. Igolkina, I. Pyrenkova,
I. Sharipova, V. Puzyrev, A. Obriadina,
A. Burkov, T. Ulanova (Nizhniy Novgorod, RU)
12:30 – 13:30
Infection in cancer patients
P2238
Human rhinovirus-C: a frequently detected
species in adult haematopoietic stem cell
transplant recipients with lower respiratory
tract infection
P. Ferguson*, N. Gilroy, I. Mackay, T. Sloots,
M. Nissen, T. Sorrell (Blacktown, Sydney,
Brisbane, Westmead, AU)
P2239
Influenza A virus H1N1v in allogeneic
haematopoietic stem cell transplant
recipients: comparison of the antibody
response to monovalent influenza A/H1N1
vaccine versus the response in natural
infection
P. Ribaud*, N. Le Corre, A. Krivine, B. Lioure,
J. Bay, M. Coudert, M. Rubio, P. Agape, A. Garnier,
A. Faugeras, N. Kerbi-Hamimed, A. Bergeron,
J. Le Goff, G. Socié, N. Milpied, B. Autran, N. Dhédin
for the Société Française de Greffe de Moelle
et de Thérapie Cellulaire
P2240
Development of quinolone-resistant
Escherichia coli bacteraemia in neutropenic
cancer patients receiving quinolone
prophylaxis: data from a high-resistance
prevalence setting
P. Zarakolu, S. Etgul, O. Kara, S. Ascioglu,
Y. Buyukasik, M. Akova* (Ankara, TR)
P2241
Enterobacter bacteraemia in adult patients
with solid tumours at a tertiary care cancer
centre in Japan
K. Okinaka*, Y. Hadano, J. Suzuki, I. Kawamura,
H. Kurai, T. Sato, N. Ohmagari
(Shizuoka, Yamagata, JP)
Final Programme
191
Posters
P2224
Poster Sessions
Tuesday, 10 May
P2242
Healthcare-associated infection in
patients during a ten-year period (2001 – 2010)
E. Mendes*, M. Vieira, F. Dulley, M. Basso,
T. Guimaraes, S. Costa (São Paulo, BR)
P2243
18F-fluorodeoxyglucose positron emission
tomography/computerised tomography
(FDG-PET/CT) scanning in persistent febrile
neutropenia: a pilot study
S. Guy*, A. Tramontana, E. Lau, R. Hicks,
J. Seymour, K. Thursky, L. Worth, M. Slavin
(Footscray, Melbourne, AU)
P2244
Bacteraemia due to Enterococcus faecium
in cancer patients: clinical features,
antimicrobial susceptibility, and outcomes
M. Bodro*, J. Ayats, C. Gudiol, C. Garcia-Vidal,
C. Ardanuy, M. Cisnal, M. Cubero, G. Ortí,
M. Antonio, J. Carratalá (Barcelona, ES)
P2245
Description of C. difficile clinical
characteristics in onco-haematological
and stem cell transplant patients
J. Gerhardt *, M. Vieira, F. Spadão, J. Nobrega,
F. Dulley, G. Fonseca, T. Guimaraes, S. Costa
(São Paulo, BR)
P2246
The impact of microbiological factors on
course and outcome of febrile neutropenia in
paediatric cancer patients
H. El-Mahallawy*, A. Abdulall, S. Lotfy,
R. Abdel Hai, L. Shalaby (Cairo, EG)
P2247
Outcome after a long-term intravenous
catheter-related bacterial infection in
oncology: results from a prospective
monocentric study
D. Lebeaux*, V. Zarrouk, B. Larroque,
V. Leflon-Guibout, C. Dreyer, S. Bialek,
A. Froissart, O. Hentic, C. Tessier, B. Fantin
(Clichy, FR)
P2248
Antibacterial prophylaxis for patients
receiving high-dose chemotherapy with
autologous haematopoietic stem cell
transplantation: a randomised-placebo
controlled trial on the efficacy and safety
of moxifloxacin
J. Vehreschild, G. Moritz, M.J. Vehreschild,
D. Arenz, M. Mahne, H. Bredenfeld, J. Chemnitz,
F. Klein, B. Cremer, B. Böll, I. Kaul, M. Hallek,
C. Scheid, G. Wassmer, O.A. Cornely*
(Cologne, DE)
Final Programme
List of Chairpersons
Page
Name
A
E
Abadia-Patino, Lorena
74
Abdullayev, Adalyat
79
Aguado-Garcia, José Maria
78
Akalin, Erdal
48, 87
Akova, Murat
66
Álvarez-Martinez, Miriam J.
44, 85
Amaral, Leonard
47
Ammerlaan, Heidi
69, 73, 89
56
Antonelli, Guido
Antonelli, Massimo
48
Aoun, Mickael
57, 90
Arendrup, Maiken C.
87
Edelstein, Mikhail
Esposito, Silvano
Esposito, Susanna
Evengård, Birgitta
B
Baldanti, Fausto
48, 59, 71, 76
Baquero, Fernando
62, 77
Barchesi, Francesco
85
Barlow, Gavin
73
Bassetti, Matteo
76
Bébéar, Cécile
88
Benzonana, Nur
49
Bertazzoni-Minelli, Elisa
52
Bertoloni, Alessandro
47
Bille, Jacques
51
Bisoffi, Zeno
59
Bonten, Marc
87
Bou, German
88
Bouza, Emilio
45
Brouqui, Philippe
56
Brown, Derek
43, 61
Brunetti, Enrico
78
C
Calandra, Thierry
Cambau, Emanuelle
Cantón, Rafael
Capobianchi, Maria R.
Carmeli, Yehuda
Cauda, Roberto
Cercenado, Emilia
Chiodini, Peter
Cimerman, Sergio
Cirillo, Daniele
Clementi, Massimo
Cohen, Jon
Concia, Ercole
Contini, Carlo
Cornaglia, Giuseppe
Cretu, Carmen
Cuenca-Estrella, Manuel
51
44, 66
70
76
48, 68
74
51
47
83
59
62, 76
64
60
68
50, 62, 77
85
46, 68, 81,
85
D
Dancer, Stephanie
Davidson, Robert N.
Delogu, Giovanni
Desnues, Christelle
Dettenkofer, Markus
Di Perri, Giovanni
Donelli, Gianfranco
Donnelly, Peter
Drancourt, Michel
Drusano, George
Dunning, Jake
86
70
77
60
43
60, 63
62
63
73
51
64
Page
47, 68
78
46, 51
43, 71, 83
G
Garau, Javier
Gavalda, Joan
Geddes, Alasdair
Giamarellos-Bourboulis,
Evangelos J.
Giamarellou, Helen
Giske, Christian
Gniadkowski, Marek
Gould, Ian M.
Graninger, Wolfgang
Greub, Gilbert
Grossi, Paolo
58, 78
84
60
44
70
66
56, 68, 87
43, 45
71
60, 81
66
59
68, 88
46, 74
48
64
53
48, 65
46
I
Inglis, Tom
Irving, William
83
76
J
Jarlier, Vincent
Junghans, Thomas
87
78
K
Kahlmeter, Gunnar
Kaiser, Laurent
Kern, Winfried
Kohno, Shigeru
Kortbeek, Titia
Kostrzewa, Markus
Kozlov, Roman
Kuijper, Ed J.
43
64
78
71, 83
44, 71
81
90
86
54
87
59
54
46, 87
43, 59
76
57
87
76
88
64
89
N
Naber, Kurt
Nagy, Elisabeth
Nathwani, Dilip
Nicoletti, Giuseppe
Nord, Carl Erik
Nordmann, Patrice
Novelli, Andrea
46, 87
56, 81
60, 68
73
54
45, 90
54, 64
O
56
P
Page
Sabin, Caroline
Sagnelli, Evangelista
Salmon, Dominique
Sanguinetta, Maurizio
Sanz, Yolanda
Schrenzel, Jacques
Seifert, Harald
Seme, Katja
Seto, Wing-Hong
Shibl, Atef
Snydman, David R.
Soreng, Katherine
Stange, Eduard
Stefani, Stefania
Struelens, Marc
Sutherland, Colin
89
76
56, 89
51
77
76
66, 88
73
45, 89
52
56
59
62
64
50, 64
63, 84
T
Tenke, Peter
Tenover, Fred
Torres, Antoni
Torres, Carmen
Tortoli, Enrico
Trampuz, Andrej
Trieu-Cout, Patrick
76
45, 81
66
61, 83
87
89
76
U
Pagani, Leonardo
Pagano, Livio
Pan, Angelo
Pantosti, Annalisa
Pappas, Georgios
Peixe, Luisa
Peterson, Lance
Petrikkos, George
Petrosillo, Nicola
Peyron, François
Pfyffer Von Altishofen, Gaby
Picazo, Juan
Poirel, Laurent
Poljak, Mario
Popa, Gabriela Loredana
Popa, Mircea Ioan
Presterl, Elisabeth
64
71
69, 78
63
44, 48
51, 74
64, 81
43
47, 66
71
45, 47
48
63
48
74
65, 77
52
R
Read, Robert
Rex, John
Rodrigo, Carlos
Rodriguez-Baño, Jesus
Rossolini, G.M.
Name
S
Maertens, Johann
Martinez-Martinez, Luis
Masterton, Robert
Mastrantonio, Paola
Matsumoto, Tetsuro
Mazzei, Teresita
Menichetti, Francesco
Metodiew, Krassimir
Meyer, Thomas
Moellering, Robert
Moreillon, Philippe
Moroni, Mauro
Mussini, Cristina
Oosterheert, Jan Jelrik
H
Halligan Eugene
Hegemann, Johannes
Hoepelman, Andy
Hooper, David
Hope, William
Hryniewicz, Waleria
Hsueh, Po-Ren
Hunter, Paul
Page
M
53
60, 83
69
74
F
Fadda, Giovanni
Ferrante, Pasquale
Figueras, Maria José
Finch, Roger
Name
83, 87
63
69
68, 81
71
Ullmann, Andrew
46, 60
V
Van Bambeke, Françoise
52
van Burgel, Nathalie
47
van der Beek, Diederik
84
van der Meer, Jos
66
van der Poll, Tom
51
Van Eldere, Johan
48, 54, 71
Van Zoelen, Marike
77, 84
Vandenech, François
63
Vatcheva-Dobrevska, Rossitza
49
Venditti, Mario
60, 78
Vila, Jordi
48, 77
Viscoli, Claudio
81
Vos, Margreet
50
W
Walsh, Timothy
Wex, Thomas
Widmer, Andreas F.
Woodford, Neil
63
76
44, 62, 89
45
L
Lass-Flörl, Cornelia
Leavis, Helen
Lecuit, Marc
Legnani, Delfino
Leibovici, Leonard
Lortholary, Olivier
43, 71
56, 60
58, 60, 77
79
57
70
Final Programme
193
Chairs & Authors
Name
List of Authors
Name
A
abye, M.G.
Aarestrup, F.M.
Aasnæs, B.
Abbas, M.
Abbas, S.
Abbasi, P.
Abbate, E.
Abd, H.
Abdel Hai, R.
Abdel-Fattah, T.
Abdel-Moneim, J.
Abdelnoor, A.M.
Abdi Ali, A.
Abdissa, A.
Abdukadir, A.
Abdulall, A.
Abdullah, D.
Abel, L.
Abely, M.
Abreu, M.
Abreu, P.
Abu Bakr, F.
Acar, B.
Accetta, G.
Accoceberry, I.
Accogli, M.
Achermann, Y.
Achkasova, T.A.
Achorn, C.
Acicbe, O.
Acikel, C.
Ackerley, D.F.
Acosta, J.
Adam, H.
Adamek, M.
Adamski, P.
Adamson, R.
Adamu, H.
Adamuz, J.
Adas, G.
Adeniyi, B.
Adhikari, B.R.
Adier, C.
Adiloglu, A.
Adizie, T.
Adkin, R.
Adler, B.
Adriaenssens, N.
Adu, F.
Aeppli, G.
Afanas’ev, M.
Afentoglou, P.
Afif, C.
Afonso, A.
Afshar, B.
Agalar, C.
Agape, P.
Agarwal, J.
Agodi, A.
Agouri, S.
Agren, J.
Aguado, J.M.
Agudo, S.
Agüero, J.
Aguilar, D.
Aguilar, L.
Aguilar, M.
Number
O253, P2020
P901
P923, P924
P874
P1768
P621
O255
P1006
P2246
P1158
P823
P1072
P1860
P868, P882
O300
P2246
P1213, P1383
O490
O309
P1378
P2125
P1201
P962
P814
P2151
P1357
P1655
P2222
P1149
P1614
P1927
O389
P1405
O250
P1747
P1779
O43
P868
P1579, P1665
P1413
P1155
P564
P811, P818
O391
P1578
P1177
P1451
P1262, P1271
O409
P1299
P1019
P1492
P1056
P886
O312
P1394
P2239
P991
P1113, P1221,
P1235
P1045
P1513
P1938, P2077
P580
P1833, P1952
P2042
P2128
P878
Name
Aguilar-Guisado, M.
Agut, H.
Ah Tow, L.
Ahl, M.
Ahmad, N.
Ahmad, Safraz
Ahmad, Suhail
Number
P2094, P2139
O32
P625
P2196
P1021
P1397
P1939, P2033,
P2047, P2099
Åhman, J.
P747, P748, P749,
P750, P751, P1832
P863
Ahmed, B.
Ahmed, D.
P1347
Ahmed, M.
P570
Ahmed-Zaid, H.
P745
Ahn, D.
P647
Aikawa, N.
P2113
Aires-de-Sousa, M.
O303
Aísa, M.
P847
Aittakorpi, A.
P2098
Akalin, E.
S183
Akan, H.
P1232
Akashi, K.
P1594
Akawi, N.
P653
Akbulut, A.
P1394
Akcelik, M.
P1906
Aker, F.
P1883
Akgeyik, M.
P1985
Akhalaia, M.
P2036
Akin, O.
P892
Akinci, E.
P1222, P1659
Akinloye, O.M.
O409
Akins, R.
P951
Akira, O.
P1609
Akkoc, N.
P1906
Akksilp, S.
O249
Akova, M.
S185, S453, P672,
P1085, P2240
Akpolat, N.
P1883
Aksaray, S.
O294
Aksoy, F.
O413, P1297
Aksoy, G.
O237
Aksu, N.
P1222, P1659
Aktas, E.
P1394
Akyar, I.
P1412
Al Anazi, A.
P1418
Al Anazi, N.
P1418
Al Aska, A.
P1418
Al Awaji, A.
P850
Al Hedaithy, M.
P1418
Al Johani, S.
P850, P1876
Al Khaldy, S.
P1383
Al Moussawi, K.
P2212
al Naiemi, N.
O102, O354,
P757, P1204
Al Orainey, I.
P1418
Al Sobaie, S.
P1418
Al-Ahmad, A.
P578
Al-hadid, K.
P1633
Al-Haj, M.
O526, P653
Al-Hubail, M.
P711
Al-Mutairi, N.
P2033, P2047
Al-Saigh, R.
P786
Al-Shaikh, A.
P1939
Al-Sweih, N.
P711
Alaca Coskun, F.
P1659
Alaimo, C.
P1446
Alakeel, R.
P1523
Alaoui, S.
P583
Final Programme
Name
Alarcón, T.
Number
O293, P580, P582,
P584, P1153
Alastruey-Izquierdo, A.
O485
Alavian, S.M.
P2216
Albano, C.
P860, P870
Albendin, H.
P1474
Alberte-Castiñeiras, A.
P2029
Albertí, S.
P604, P1749
Alblas, J.
P1302
Albornoz, E.
P773
O48
Albrich, W.C.
Albuquerque, L.
P574
Albuquerque, T.
P1359
Alcala, L.
P1099, P1632
Alcoba-Flórez, J.
P1675
Aldea, I.
P1751
Aldebert, D.
P2138
Alebouyeh, M.
P1704
Aleo, A.
P568
Alepopoulou, E.
P927, P970
Alex, M.
O143
Alexandropoulou, I.
P927
Alexiou, V.
P1638
Alexis, A.
O467
Alfa, M.
O250
Alfaro-Lara, E.R.
P1291
Alffenaar, J.W.
P797
Algarate, S.
P2116
Aliasgari, A.
P1634
Alier, A.
P1934
Alimov, A.
P1042
Aliyu, S.H.
O343
Alkan, A.
P1769
Alkmim, W.
P2165
Allegranzi, B.
S58, O140,
S535, P1380
Allemelou, G.
P1685
Allen, R.C.
P1453
Allende, B.
P878
Allende, L.
P2077
Allerberger, F.
O501, P1208,
P1543, P1729
Alley, M.R.
P796
Allgar, V.
O427
Allison, T.
O427
Allizond, V.
P2152
Allorent, S.
P561
Almansa, R.
P1765
Almeida, C.
P1896
Almeida, S.
P1372
Almela, M.
P1833
Almirante, B.
P1538
Alonso, P.
S207
Alonso-Aguirre, M.A.
P1627
Alp, A.
P2232
Alp, S.
P1085
Alpay, Y.
P1394
Altieri, A.
P1679
Altwegg, M.
P1687, P2052
Alvar, J.
S322
Alvarado, F.
P2133
Álvares, F.
P881
Alvarez, A.
P1942
Álvarez, B.
P2133
Alvarez, M.
O363, P1826,
P2166, P2170
Alvarez, M.E.
P1870
Alvarez, M.I.
P1324
Name
Álvarez, P.
Alvarez-Fernandez, M.
Álvarez-Lerma, F.
Alvarez-Lerma, P.
Álvarez-Martinez, M.J.
Alves, E.
Alves, M.J.
Alves Lima, T.
Alves Matos, A.
Amadeo, B.
Amado, A.
Amador, G.
Amano, H.
Amara, S.
Amaral, L.
Number
P2059
P897
O86, P794
P2133
S530
O41
P893
P2085
P1671
P1282
P1359
P1504
P1433
O43
O255, P723,
P724, P1448
Amaral, S.
P675, P1343
Amari, A.
P1805
Amarti, A.
P583
Ambler, J.
O422
Ambrosi, A.
O248
Ambrosioni, J.
P2088
Ambrozic Avgustin, J.
P1365
Amendola, A.
O245, P1554
Ameye, L.
P2087, P2109
Amhis, W.
P844
Amicosante, G.
P596, P1062
Amiguet, M.
P1783
Amin, D.
O48
Amirsardari, A.
P1634
Ammerlaan, H.
O99, O307
Amor, A.
P883
Amorim, J.
O350
Amoruso, R.
P635
Amrar, N.
P844
Amstutz, C.
P1750
Amyes, S.
P601
An, H.
P999
Anagnostopoulou, M.
P1491
Anastassiou, E.D.
P957, P1760,
P1763,P1880, P2218
Anaya, F.
P1630
Anbalagan, S.
P978
Andaev, E.
P1882
Andaluz, D.
P1765
Anders, A.
P1041, P1173
Andersen, B.
P1318
Andersen, C.Ø.
P922
Andersen, H.S.
P908
Andersen, L.B.
O346
Andersen, M.
P1628
Andersen, P.S.
P1437
Andersen, R.L.
O497
Andersen, S.E.
P1047
Anderson, N.
O33
Andersson, M.
P654
Andersson, P.
O352
Andersson, S.-O.
P949
Andlovic, A.
P571
Andrade, L.N.
P1341
André, C.
O196
Andrén, O.
P949, P1732
Andreoletti, L.
O309, P1865,
P2076, P2156
Andreoni, S.
P1911
Andrés, A.
P2077
Andrés, M.
P1661
Andrés Gualdoni, G.
O243
List of Authors
Number
Andreu, A.
P1942
P733, P1311, P1330
Ang, B.
Angarone, M.
P2074
Angelakis, E.
P882
Angeletti, S.
P1851
Angeliki Krogfelt, K.
P2070
Angkasekwinai, N.
P1003
Anglés, F.
P1629
Anjum, M.
P1812
Anrò, V.
P2236
P2086
Ansaldi, F.
Ansorena-Pool, L.
P964
Ansorge, W.
S284
Antachopoulos, C.
O49
Antal, E.
O470
Anthonisen, I.L.
P752
Antinori, S.
P867
Antón, A.
P1765
Antonacci, C.M.
O415
Antonaki, G.
P1396, P1561, P2164
Antonelli, G.
P2197, P2200
Antonelli, M.
E444, P1285, P1941
Antonelli, S.
P2209
Antoniadou, Z.A.
P2175
Antonio, M.
P2244
Antonioli, F.
P1246
Antonopoulou, A.
P1616
Antonopoulou, F.
P1095, P2164
Antunes, F.
O303
Antunes, I.
P2193
Antunes, P.
O300, P1354
Anunnatsiri, S.
P1547
Aoki, N.
P1604
Aono, A.
P2023
Aouam, A.
P1092, P1546
Aoun, M.
S551, P2087, P2109
Aoyagi, T.
P632
Apfalter, P.
P689
Apirakkan, O.
P1295
Apisarnthanarak, A.
O367
Apostol, I.
O385
Aquilia, S.
P1191
Arai, K.
P632
Arakawa, S.
P1399, P1402
Arakawa, Y.
P1304
Arama, S.S.
P2182, P2189
Arama, V.
P1495, P2182,
P2189, P2230
Arampatzi, S. P1181, P1845, P1846
Arana, C.
P961
Arbeit, R.
P1528
Arcenas, R.
P906
Archer, M.
P1899, P1900
Archontakis, Z.
P822, P2010
Arco, A.
P1475
Ardanuy, C.
P1368, P1374, P2244
Arena, F.
P646, P700
Arenal, N.
O293
Arents, N.L.
P1797, P1802
Arenz, D.
P2248
Areses-Elizalde, P.
P1804
Arezzo, J.
O97
Arfel, V.
P1692
Argentieri, M.
P1239, P1357, P1563
Arghittu, M.
P834, P1314
Argyropoulou, A.
P1147
Arhin, F.F.
P1031, P1529
Arias, A.
P900
Name
Number
Aridogan, B.
O391
P1073
Ariza, J.
Arlet, G.
P1813
Arman, D.
P1394, P2119
Armendarez, V.
P1979
Armstrong, M.
P876, P1007
Arnaiz, A.
O241
Arnold, C.
P1730
Arora, V.
P1544
Arosemena, E.
P2031
P984, P1998
Arosio, M.
Arpi, M.
P658, P660, P922
Arriaga, S.
P1043
Arroyo, D.
P1468
Arslan, H.
P1169, P1602
Arslan, U.
P1707
Arslan Gulen, T.
P1025
Artigot, M.A.
P1821
Arunachalam, A.
P1227
Arunyingmongkol, K.
O36
Arutyunov, G.P.
P1970
Arvidsson, A.
P1261
Arvieux, C.
P998
Asadollahy, E.
P1431
Asaei, S.
P1428, P1429
Asahara, M.
P715
Asano, M.
P1463
Ascioglu, S.
P1643, P2240
Ascione, T.
P1654
Asgeirsson, H.
P1590
Asioglu, S.
P672
Aslaner, H.
P1232
Aspinall, J.
P2016
Aspindzelashvili, R.
P2036
Aspiroz, C.
P901, P937, P939
Astagneau, P.
P1110
Astegiano, S.
O410
Asvametha, K.
P884
Athanasiou, S.
P1439, P1638
Athanazio, D.
O466, P1414
Atkins, B.L.
P1626
Attala, L.
P673
Attanasio, V.
P1460
Attar, H.
O140, P1380
Attili, A.R.
P980, P1727
Aubert, J.D.
P2081
Aucott, J.
O358
Audette, C.
P1677
Autenrieth, I.
P1830
Autran, B.
P2239
Auxilia, F.
P1113
Avanzini, C.
P985
Avci, B.
P1614
Avci, N.
P1222
Aveliodi, K.
P1491
Avolio, M.
P910, P1678, P1806
Awadel-Kariem, F.M.
P1793
Axner-Elings, M.
P2144
Ayats, E.
P2031
Ayats, J.
P2244
Aydillo, T.
O244
Aydin, A.
P1225
Aydin, F.
P1225
Aydin, H.
O413
Aydin, K.
P1297
Ayeni, F.
P1155
Aygun, G.
P1394
Ayling, R.
P1726
Name
Aysin, M.
Azad, T.M.
Azap, A.
Azap, Ö.
Azar, E.
Azevedo, E.C.
Azevedo, N.F.
Azizi, E.
Azizi jalilian, F.
Azmi, I.
Aznar, E.
Aznar, J.
Azza, S.
Azzini, A.M.
B
Number
P1443
P2216
O237, P1232
P1169, P1602
P1056
O466
P769, P1896
P1411
P1201
P1347
P582
P1425, P1722
P720
P1486
ababeik, M.
P1424
Babikir, R.
P1112
Bablishvili, N.
P2036
Babouee, B.
P2097
Bacakoglu, F.
P861
Bacci, S.
O497
Bachvarova-Nedelcheva, A.
P1145
Bacigalupo, A.
P2086
Baculik, T.
P1531
Badal, R.
O524,P556,P565,
P566, P573,P644,P656,
P678,P679,P732, P932,
P946, P1057, P1120,
P1121, P1608
Baddour, L.
P1086
Badiaga, S.
P2220
Badicut, I.
P1495
Badiou, C.
P1502
Baditoiu, L.
P1303
Bae, I.G.
P1197
Bae, I.K.
O527, P655
Báez, R.
P845
Baghaei, P.
P1496, P2032
Bagheri, F.
P1156
Bagid, N.
O237
Baha, W.
P2217
Bahnan, W.
P728
Bahrami, H.
P1662
Baier, M.
P1575
Baietto, L.
P802, P803, P810
Baiget, M.
P1958
Bak, J.
P1210
Baka, S.
P2067
Bakaimi, I.
P2175, P2176
Bakas, A.
P1018
Baker, N.
P913
Baker, S.
P796, P1521
Bakhrouf, A.
P577
Bakir, M.
P1394
Bakir Özbey, S.
P1008
Bakker, L.J.
P1674
Bakkevoll, P.A.
P1306
Bakkiyaraj, D.
P1862
Bal, G.
P2138
Balabanova, Y.
P1999, P2034
Balajee, A.
S170
Balakhonov, S.
P1019, P1882
Balakrishnan, I.
P642
Balayn, D.
P804
Balazsi, G.
O248
Baldan, R.
P832, P1159
Baldanti, F.
P1000, P2172, P2199
Baldassarri, L.
P1851
Name
Number
Baldwin, N.
Balik, I.
Balique, F.
Baljer, G.
Ball, D.
Ball, T.
Ballarini, P.
Ballen, A.
Ballereau, F.
Ballesta, S.
Ballesteros Sanz, M.A.
Balta, F.
Banaei, N.
Bancescu, A.
Bancescu, G.
Banche, G.
Bandeira, M.
Bandera, A.
Bandi, C.
Bandi, M.
Banerjee, D.
Bangura, D.
Banner, D.
Bannister, B.
P1333
P1232
P2212
O528
P1842
O387
P648, P741
P1938
P561
P718
P993, P1471
P887
P772
P1135
P1135
P2152
O466
P1233
P1020
O415
P1011
P1034
P1765
S220, S453,
P1319, P1328
Banu, O.
P1752
Banzola, N.
P1694
Baptista, T.
P2193
Baqer shiroodi, M.
P2015
Baquero, F.
O107, O214, O301,
O355, S395, P620,
P643, P1341, P1928
Baquero, M.
P883, P1409
Baquero, M.R.
P643
Bär, C.
P1447
Baraboutis, I.
P1323, P1327, P2180
Barak, M.
P1406
Baraniak, A.
P743
Barantsevich, E.P.
P709, P1473,
P1929
Barantsevich, N.E.
P709, P1473,
P1929
Barbagiannakos, T.
O299
Barbanti, F.
P1975, P1982
Barbar, S.D.
P1660, P1756
Barbarini, D.
P1919
Barbarousi, V.
O49
Barbe, C.
P2076, P2156
Barbeito, G.
P1723
Barbera, C.
P985
Barberan, J.
P2128
Barbercheck, J.
O469
Barbier, F.
P1195
Barbier, M.
P1749
Barbosa, R.
P1350
Barbuceanu, S-F.
P1135
Barbullushi, A.
P2233
Barbut, F.
P1206, P1338
Barchitta, M.
P1113, P1221, P1235
Bardon, J.
P896
Barford, J.
P936
Bargiggia, G.
P1998
Barguigua, A.
P622
Barkham, T.
O240
Barlow, G.
1, O427
Barlow, P.
P2183
Barnes, R.
P2096
Barnett, A.G.
O147
Final Programme
195
Chairs & Authors
Name
List of Authors
Name
Number
Baron, E.J.
S26, P772
O89
Baron, M.
Barrado, L.
P1405, P1881
Barranco, G.
P1325, P1456
Barreiro, B.
O236
Barreiro, I.
P773
Barricarte, A.
P1077
Barron, M.
P2112
Barros, R.M.
O350
Barsic, B.
P2224
P735
Barsist, A.
Bart, A.
P880
Barthel, C.
P1770
Bartizal, K.
P947
Bartoletti, M-A.
O32
Bartoloni, A.
P673
Bartoszewska-Kornacka, M.
O31
Bartzavali, C.
P2218
Basile-Filho, A.
P1341
Bassetti, M.
S161, S266, P1536
Bassetti, S.
O146
Basso, M.
P2242
Bastide, C.
P1584
Bastug, A.
P833
Basustaoglu, A.
P637
Batard, E.
P1500
Batra, R.
O139, P828
Batsyura, G.V.
P2222
Battegay, M.
P1387, P1467, P2097
Battistel, M.
P1005
Battisti, A.
P635
Battistoni, F.
P798
Baugh, S.
O188
Bauraing, C.
P702
Bavari, S.
O411, P2211
Baxevanakis, A.
P2180
Bay, J.
P2239
Bay, L.
P903, P908
Bayat, A.
O237
Bayindir, Y.
P1394, P1769
Bayir, U.
P1802
Bayirlioglu, S.
P1413
Baylay, A.
P727
Baymakova, M.
P2226
Bayoll-Serradilla, E.
P1247
Bayrak, H.
P1985
Bayrak, M.
O237
Bayram, H.
P1618
Baysallar, M.
P1927
Bazigos, S.
P1997
Bazoche, F.
P1307
Beader, N.
P704
Beadsworth, M.
P2069
Beata, V.G.
P1017
Beato, S.
O495, P886
Bébéar, C.
S528c, P1692, P1693
Bebrone, C.
P611
Becker, A.P.
P839
Becker, K.
P835, P1123, P1186
Beckmann, G.
P2190
Bedenic, B.
P553, P648, P704
Bedford Russell, A.
P1898
Bedir, O.
P637
Beeching, N.
P2069
Beerens, A.
P1695
Begnini, M.
O245
Begovac, J.
P2191
Begovic, T.
P1210
Name
Number
Behnava, B.
P2216
P1480
Behnke, M.
Behrends, H.-B.
P1315
Beiras-Fernandez, A. P1289, P1539
Beitolahi, L.
P1156
Bejon, P.
P1626
Bel, M.
P2088
Belal, S.E.
O526
Belas, A.
P1350
Belausov, N.
P1595
P583
Belghiti, H.
Belhadj, O.
P596
Bell, J.
O352
Bell, S.M.
P1915
Bella, F.
P1661
Belladonna, S.
P1872
Bellagamba, R.
P2184
Bellido, M.
P1346
Bellika, J.G.
P1306
Bellio, P.
P1062
Bellissimo-Rodrigues, F.
P1341
Bello, A.
P2016
Bello, G.
P1941
Beloin, C.
O187
Beltrame, A.
P873
Beltrán Heras, J.
P1200
Ben Abdallah, H.
P659
Ben Brahim, H.
P1092, P1546
Ben Kahla, I.
P2038
Ben Romdhane, F.
P1092, P1546
Ben Saïd, M.
P1569
Ben Sallem, R.
O103
Ben Selma, W.
P2038
Ben Slama, K.
O103, P1249
Ben-David, D.
P652, P735, P1595
Ben-Marzouk, O.J.
P2080
Ben-Moussa, M.
P596
Ben-Smith, A.
O251
Benajah, D.
P583
Benani, A.
P2217
Benbetka, L.
P844
Benea, L.
P2182, P2189
Benet, S.
O236
Bénet, T.
O239, O498, P1192,
P1478, P2126
Bengtsson, S.
P746
Benini, A.
P812, P1501
Benito, D.
P845
Benko, R.
P1220
Benmesbah, S.
P844
Bennani, B.
P583
Benoit, D.
P1953, P2135
Bentley, N.
O343, P1792
Bento, J.
P1896
Benvenuti, M.
P609
Benzaquen, D.
P1789
Benziger, D.
P1519, P1520
Bercelli, F.
P741
Bercot, B.
P1048
Bereciartua, E.
P2093
Berendt, A.
P1626
Berenguer, N.
O86, P794
Beretta, R.
O415
Bergallo, M.
O410
Berger, Ariel
P1281
Berger, A.
P2001
Bergeron, A.
P2239
Bergeron, M.G.
P589
Final Programme
Name
Number
Bergerova, T.
P740, P1172
O423, P2174
Bergin, C.
Bergland, J.N.
P1887
Bergman, M.
P690, P1605
Bergman Jungström, M.
P1832
Bergs, K.
P971
Bergström, T.
P2162
Berhin, C.
P651, P691
Berila, N.
P1863
Berlinger, L.
P1687
P1765
Bermejo-Martin, J.
Bermúdez-Ruiz, M.P.
P1996
Bernabeu, S.
O218, P607
Bernal, C.
P2094
Bernal, L.
P2103
Bernal, S.
P1701
Bernal-Martinez, L.
O151, P1938
Bernaldez, P.
P1557
Bernaola, E.
P1077
Bernard, A.
P1435
Bernardi, A.C.
P1849
Bernardi, S.
P2173
Bernardin, G.
P2223
Bernardini, F.
P1151
Bernaschi, P.
P1239, P1841
Berney, T.
P2088
Bernieri, F.
P1246
Beroual, Y.
P844
Berrouane, Y.
P1317
Berry, L.
O388, P2105,
P2134, P2137
Bertaina, C.
O316, P1553
Bertazzoni Minelli, E.
P812, P1501
Bertiato, G.
P1005
Bertini, R.
P2138
Bertisch, B.
P1385
Bertrand, X.
P994
Bertsch, D.
P638
Bertschy, I.
P615, P936
Bertuccio, T.
P907
Bertz, H.
P1112
Bervini, D.
P1646
Bervoets, L.
O475
Berzina-Cimdina, L.
P1786
Bes, M.
P1052
Besser, S.
P1381
Bethel, C.R.
O386
Bethke, A.
P1028
Betriu, C.
P1925
Betsch, B.
O424
Betta, P.
P2136
Bettamio, V.
P834, P1314
Beuken, E.
P726
Beuret, C.M.
P1015
Beutels, P.
P1265
Beutlich, J.
P1353
Beyersmann, J.
P1109
Bezugla, N.
P1509
Bhattacharjee, A.
P1162, P1165,
P1166
Bialek, S.
P2247
Bian, Q.
P1525
Biancardi, A.
P832
Biard, L.
P1195
Biasin, E.
P810
Biassoni, C.
O190
Biaszczyk, G.
O31
Bicknell, S.
P1856
Name
Number
Bidossi, A.
P976
O142
Biechele, B.
Biedenbach, D.
P1136
Biek, D.
P1171, P1502
Bien, P.
P1516
Bienvenu, A.
P2126
Bierma, M.E.
P1797
Biernat, M.M.
O314, O494
Biernat, P.
O314
Biffi, A.
P959
P1610
Bijlsma, J.J.
Bilir, Y.A.
P1755
Bille, E.
P1217
Bille, J.
E120, O148, P1321
Billi, P.
P2209
Billström, H.
P924
Bilocq, F.
O291
Binazzi, R.
P866
Binwu, Y.
P2019
Biolan, T.
O385
Bird, P.S.
P1105
Birtles, A.
O500
Bischoff, A.L.
P1298
Bisgaard, H.
P1298
Bisgaard, M.
P999
Bishara, J.
P1482
Biswas, P.
O153, P1536, P2145
Bittar, F.
P825
Bittel, P.
P2001
Bittner, S.
P952
Bizzini, A.
P950
Bjarnsholt, T. P1210, P1465, P1931
Bjartling, C.
P1700
Bjelkenbrant, C.
P746
Bjerrum, S.
O490
Bjørnholt, J.V.
O345, P763
Bjørnsdottir, M.
P1465
Bjørnstad, M.
P1739
Bjørslev, N.
P1628
Black, M.T.
P609
Blackburn, R.
P686
Blacky, A.
P1110
Blanc, D.
P1483, P1790
Blanc-Pattin, V.
P1789
Blanchard, E.
O482
Blanchard, J.S.
O386
Blanco, P.
O521
Blandino, G.
P907
Blank, P.R.
O238
Blasi, F.
S340, P1266
Blázquez de Castro, A.M.
P1404,
P2206
Blechova, Z.
P1559
Bleeker-Rovers, C.
P1384, P1617
Bleotu, C.
P1044, P1751
Bliamou, A.
P2060, P2207
Blocher, J.
O362
Bloemberg, G.V.
O213
Blomberg, J.
S168, P1895
Blommaert, A.
P1265
Blondeau, B.J.
P1128
Blondeau, J.M.
P787, P788, P1128
Blondeau, L.D.
P1128
Blot, S.
P1953, P2135
Blumstein, G.
P1406
Blyth, C.
O308
Boan, P.
O306
Boaventura, L.
O350
List of Authors
Number
Bobin, M.
P1787
O94
Bocanegra, R.
Boccafoglio, F.
P2004
Bochkova, G.
P2235
Bodaszewska-Lubas, M.
P1779
Boden, K.
P1575
Bodmer, T.
P2001, P2052
Bodnarova, M.
P2043
Bodolea, C.
P2111
Bodro, M.
P2244
P833, P1222, P1659
Bodur, H.
Body, B.
P1688, P1875
Boehme, C.
S431
Boekhout, T.
P1943
Boel, A.
P982
Boel, E.
O344, P1302, P1674
Boeree, M.
O255
Boesten, R.
P1943
Boga, J.
P1870
Bogaerts, P.
P611, P651, P691,
P702, P1230,
P1669, P1670
Bogdaite, A.
P707
Bogomolova, T.S.
P2129
Boillat Blanco, N.
O254, P2081
Boinett, C.
P1812
Boisen, N.
P2070
Boisset, S.
P1789
Boissinot, M.
P589
Bojarska, A.
P743
Böll, B.
P2248
Bolton, E.
O500
Bombana, E.
P673, P853
Bonde, M.
P1061
Bondulich, C.
P1622
Bonetti, C.
P1911
Bongaerts, M.
P1698
Bongiorno, D.
P776, P907
Bonifácio, E.
P889
Bonini, A.
O154
Bonnafous, P.
O32
Bønnelykke, K.
P1298
Bonnin, A.
P1951
Bonnin, R.
O216, O217
Bonomini, A.
P898
Bonomo, R.A.
O386, P615,
P1669, P1706
Bonten, M.J.
O99, S202, O298,
O307, O344, E444,
P668, P764, P969,
P1010, P1116, P1214, P1215,
P1275, P1276, P1481, P1490,
P1613, P1649, P1673
Bonura, F.
P2205
Boo, T.
P618, P730
Boogen, C.
O347, P758
Bor, O.
P1225
Borel, J.L.
P2131
Borentain, P.
P1959, P2214,
P2223
Borger, R.
O408
Borges, A.
P1848
Borges, F.
P2193
Borghi, E.
O190, P1484
Borgundvaag, B.
P1676
Borisova, T.
P1882
Börjesson, S.
O353
Borlot, F.
P1584
Name
Number
Borman, A.
S77
P1094
Born, R.
Boros, S.
P2185
Borrallo, R.M.
P1661
Borroni, E.
O383, P2013
Borsos, S.D.
P1128
Borte, M.
P2055
Bortolon, E.
O93
Borzova, Y.V.
P2129
Bosch, T.
P1703
O245
Boschini, A.
Bosnjak, Z.
P648, P704
Bossa, M.C.
P1679
Bosshard, P.P.
P2066
Bosson, J.L.
P2131
Bostock, J.
P1454
Botelho-Nevers, E.
P2220
Botero-Kleiven, S.
P2144
Botrugno, R.
P592, P1800
Bou, G.
P718
Bouadma, L.
P1195
Bouchahrouf, W.
P651
Bouchami, O.
O348, P938
Bouchara, J.-P.
P1940, P2151
Bouchillon, S.
O524, P556, P565,
P566, P573, P576,
P644, P656, P678,
P679, P732, P932,
P946, P1057, P1120,
P1121, P1608
Bouckaert, J.
P1924
Boudabous, A.
O103, P1249
Boudreau, D.
P589
Bougault, A.
O304
Boukadida, J.
P2038, P2229
Boukouvala, S.
O49
Boulanger, N.
P1770
Bourbeau, P.
P1799
Bourgarit, A.
O252
Bourgeois-Nicolaos, N.
P605
Bourguignon, A.M.
P2109
Bousnina, S.
P1555
Boutonnat, J.
P2138
Boutrad, Y.
P1068
Bouylout, K.
O85
Bouza, E.
3, S22, O157, S258,
O479, P842, P987,
P1060, P1099, P1468,
P1585, P1621, P1630,
P1631, P1632, P1664, P2072,
P2095, P2102, P2121
Bouzala, G.
P687
Bouzari, M.
P1063
Bowker, K.E.
P729, P795
Bowyer, P.
O480, P2106
Boyart, V.
P1236
Boyce, J.
O141, P1451
Boyd, H.
P774
Boyko, V.A.
P2222
Boyle, F.
O106
Bozdogan, B.
P1053, P1707
Bozkurt, A.
O237
Bozorgmehr, M.
P1430
Bradford, P.
P1065
Bradley, C.B.
P1257
Braeckman, T.
P1076
Bragantini, F.
P873
Braggion, C.
P827
Name
Bragonzi, A.
Bramati, S.
Branco, L.
Brandenburg, A.
Brás, A.
Bratos Pérez, M.A.
Braun, D.L.
Braun, E.
Brazeau, D.
Brazier, J.S.
Bredenfeld, H.
Bregante, S.
Breia, F.
Bréjon, V.
Brenan, M.
Brenes, J.
Brenier-Pinchart, M.P.
Brennan, F.
Brentano, S.
Brenwald, N.P.
Brerra, R.
Bresciani, P.
Breusch, S.
Briales, A.
Briceño, N.
Brienza, N.
Brilakis, E.
Brillo, F.
Brimicombe, R.
Brink, A.A.
Brink-Huis, A.
Brion, J.-P.
Brisdelli, F.
Briska, A.
Brito, M.
Brito, M.J.
Brito-Avô, A.
Britt, H.
Brmbolic, B.
Brocato, R.
Brocchi, M.
Brochet, J.P.
Brockmann, K.
Brodard, V.
Brodt, H.R.
Broduža, A.
Broex, E.
Bromley, M.
Bron, D.
Brouchos, T.
Brouillet, R.
Brouqui, P.
Number
O473, P1151
P1233, P1337
O350
O408
P881
P1416, P1923
P1644
P2030
P779
P1710
P2248
P2086
P1372
P1382
P2177, P2178
P1597
P2131
P1438
P1918
P913
O414
P646
P1736
P599, P1449
P860, P870
P1117
P1635
P873
O149
P1709
P1285, P1384
P2131, P2138
P1062
P1714
S457
O350
P1372
P1983
P2188
O469
P1782
P1794
O362
P2076
P1319, P1328
P2203
P1268, P1270
O480
P2109
P2060
P1686, P1916
S222, P1319,
P1328, P2220
Brown, A.
O423
Brown, A.C.
P1017
Brown, D.
E116, P1300
Brown, J.
O496
Brown, M.
P2016
Brown, N.M.
O343
Brown, T.
P779
Bruce, K.D.
P1936
Bruce, M.
P992
Bruden, D.
P992
Brugnera Muraro, L.
P1005
Bruisten, S.M.
P626
Brum, L.
O384
Brun-Buisson, C. O40, O298, P1490
Bruneau, J.M.
P609
Name
Number
Brunel, P.
P1382
S19, O487, P866
Brunetti, E.
Brunkhorst, F.
P1589
Brunner-Zillikens, S.
P1798
Bruno, F.
P1117, P1494
Brusaferro, S.
P1113, P1335
Brusselaers, N.
P2135
Bruun, B.G.
O497
Bryskier, A.
P1510
Bryssinck, L.
P640
P1779
Brzychczy-Wloch, M.
Bu, W.
P796
Buathong, N.
P2192
Buba, F.
P1418
Bubendorf, L.
P2097
Buchan, B.
O33
Buchard, A.
P797
Bucher, B.
O48
Buckeridge, D.L.
K369
Buckner, L.
P1776
Budding, A.E.
P1672
Budimir, A.
P648, P704
Buechler, J.
P917
Buendía, B.
P2102
Buer, J.
P1127
Buffet-Bataillon, S.
P998
Bühling, A.
P1250
Bühlmann, M.
O146
Buidin, P.
O297, P778
Buising, K.
P1656
Buitenwerf, J.
P1237
Buiting, A.G.
P1481
Buitrago, G.
P1324
Buitrago, M.J.
O151, P1938, P2103
Bulanda, M.
P1935
Bulitta, J.
P784
Bulo, A.
P2233
Bulut, Y.
P1883
Bumrungsri, N.
P1003
Bunsow, E.
P1585, P1664
Burak, E.
P1185
Burckhardt, I.
P766
Burdelski, C.
O191
Bürgel, A.
P1203
Burgmann, H.
O243, O477, P1498,
P1560, P1781
Burillo, A.
P987
Burkov, A.
P2235, P2237
Burl, S.
O251
Burnham, C.
P1059, P1993
Burns, K.
P1294
Busca, A.
O154
Bush, K.
P1293
Buss, A.J.
P1839
Bussolotto, R.
P1682
Busta-Vallina, M.B.
P1627
Bustamante, J.
P2093
Bustinza, A.
O157
But, A.
P1659
Butaye, P.
P1016
Butler, C.
P1266, P1267
Buttazzi, R.
P1263, P1264, P1587
Buyck, J.
P725
Büyük, A.
P710
Buyukasik, Y.
P2240
Buzina, W.
P1827
Bylova, N.A.
P1970
Byren, I.
P1626
Final Programme
197
Chairs & Authors
Name
List of Authors
Name
Byrne, E.
Byrne, H.
Byrne, S.
Number
O47
P1258
P1257
Çabadak, H.
P871, P1064,
P1286, P1541
Caballero, F.
P718
Cabello, V.
P2080, P2094
Cabellos, C.
P1073, P1459
Cabeza, C.
P1958
P2186
Cabeza, J.
Cabibbe, A.M.
P2009, P2013
Cabo, X.
P1073
Cabot, G.
O288, O296, P612
Cabral, A.T.
P889
Cabral, E.
O244
Cachare, M.
P860, P870
Caciagli, P.
P1847
Cadafalch, J.
P1958
Cadeddu, C.
P673, P1118
Cady, A.
P998
Caetano, T.
O105, P661, P1817
Cafferkey, M.
O313, P972
Cafiero, M.A.
P885, P899, P1093
Cafiso, V.
P907
Caiazzo, M.
P885
Caillaux, M.
P1087
Caillon, J.
P561, P1504
Caillot, D.
P1951
Cainarca, M.
P1484
Caione, D.
P2173
Caira, M.
O154, P1941
Çakir, B.
O237
Calado, M.
O495, P886
Calandra, T.
S71, S208, P1483
Calatayud, L.
P1368, P1374
Calbo, E.
O236, P1641,
P1658, P2031
Calderaro, A.
P877, P1892
Calderón, E.
P1212
Calhau, V.
P624, P636
Calisto, F.
P1043
Calistru, P.
O385
Calitri, C.
P1553
Callea, F.
P2173
Cals, J.
P1267
Calux, S.
P2071
Calvo, J.
P1922
Calvo Sanchez, N.
P841, P1404,
P2206
Camacho, R.
P1826
Cambau, E.
S7, S261
Cameo, M.
P847
Cameron, D.
P1050
Camilli, R.
P1371, P1373
Camins, B.
P2127
Camoni, L.
P2064, P2185
Campainha, R.
O350
Campana, S.
P827
Campanile, F.
P776, P907
Campano, E.
P1212
Campillos-Alonso, P.
P1283
Campoli, P.
O484
Camporese, A. P910, P1678, P1806
Campos, I.
P2116
Campos, J.
O300
Campos Damiani, I.A.
P1782
Campos Junior, F.F.
P1849
Name
Number
Camposampiero, D.
P1682
P1909
Camps, M.
Camps, S.M.
O481
Camúñez, F.
P1631
Camus, C.
P2118
Can, F.
P1602
Canales, L.
O236
Candeias, N.
P1082
Candoni, A.
O154
Canducci, F.
O414
P1043
Caneiras, C.
Caniça, M.
P562, P1359, P1366
Cannella, F.
P2200
Cano, M.E.
P1922
Cantón, E.
P1610, P2116, P2142
Cantón, R.
O107, O247, O288,
O296, S341, O355,
P643, P675, P694, P1066,
P1183, P1341, P1343,
P1455, P1725, P1928
Caola, I.
P1805, P1847
Capalbo, F.
P1679
Capatti, C.
P1587
Capdevila, J.A.
P1585
Capobianchi, M.R.
S287, P1499,
P1872, P2155,
P2157, P2228
Capón, P.
P1870
Cappelletti, L.
O190
Caprioli, R.
P1403
Capuano, F.
P1420, P2236
Carannante, A.
P988, P1713
Carannante, N.
P1460
Carattoli, A.
S125, O216,
P559, P1342
Carbis, R.
P1440
Carby, M.
P801
Cardeñoso, L.
P1878
Cardinale, F.
P2075
Cardoso, C.
O41
Cardoso, F.
O41
Cardoso, O.
P574, P1771
Cariani, L.
P959, P1234
Carletti, F.
P872
Carling, P.
P1205
Carlsgart, J.
O486
Carmeli, Y.
O100, O145, E273,
P667, P1148, P1331
Carmona, R.
P2071
Carneiro, F.
P769
Carnevale, L.
P814
Carrascosa, A.V.
P1153
Carrat, F.
O309
Carratalà, J.
P1579, P1665,
P2244
Carrer, A.
P1666
Carrer, D.
O79, P789
Carretto, E.
P1919
Carrillo, N.
P860, P870
Carrillo Muñoz, A.J.
P2143
Carrion, N.
P1622
Carrolo, M.
O189
Carrrascosa, M.
O241
Carryn, S.
P807
Cars, O.
S450, P1450
Carter, I.W.
P1915
Carter Lindsay, J.
P909, P918
Cartman, S.T.
P1744
Final Programme
Name
Cartuyvels, R.
Carugati, M.
Carvalho, M.
Casals, J.B.
Casanova, C.
Cascio, A.
Casella, P.
Caselli, E.
Casey, A.L.
Casini, B.
Cassetta, M.I.
Cassettari, M.
Cassier, P.
Cassir, N.
Cassiri, D.
Cassorla, J.M.
Castanheira, M.
Number
P1004
P1336
O350
P697
P2052
E119, P2205
P834, P1314, P1911
O386
P1209
P700
O82, P800
P677
P1192, P1478
P1472
P1859
P1794, P1796
P613, P614, P616,
P652, P722, P944,
P1161, P1607
Castano, F.
P1685
Castellanos, C.
O470
Castelli, F.
S12
Castiglione, G.
P1235
Castilla, J.
P1077
Castilletti, C.
P872, P1499,
P2157, P2184
Castriciano, S.
P1800
Castro, B.
P900
Castro, C.
P1247, P1950, P2120
Catalán, M.
P2133
Catalano, G.
P1800
Cataldo, M.A.
O46, O145
Cataleta, A.
P899
Caterini, A.
P1284
Catry, B.
O42, P1111,
P1309, P1310
Catsburg, A.
P1002
Cattaneo, C.
O154
Cattaneo, D.
P793
Cattani, G.
P873
Cattolico, V.
P834, P1314
Cauda, R.
O145, P673,
P1118, P1285
Cavaco, L.
P1353
Cavaco Silva, P.
P1082, P1350
Cavaillon, J.M.
S73
Cavaleiro, C.
P862
Cavaliere, N.
P885
Cavallerio, P.
P1234
Cavallo, R.
O410
Cavassin, E.
P760
Cavazza, M.
P581
Cavling Arendrup, M.
S428, O476,
P1768, P1840,
P1954, P2144, P2149
Cavrini, F.
P988
Cavusoglu, C.
P2014, P2027
Cayô, R.
P1922
Cazander, G.
S399
Cazzadori, A.
P2004
Ceausu, E.
O385, P1495
Cecconi, G.
O245
Cecconie, T.
O90
Ceesay, M.M.
O388, P2105,
P2134, P2137
Celenza, G.
P1062
Celik, A.F.
P1755
Celik, F.
P1614
Name
Celik, U.
Cerar, T.
Cercenado, E.
Number
O155
P571, P1365
P842, P987,
P1060, P1066
Ceresola, E.R.
O414
Cerqueira, L.
P769
Cerquetani, F.
P1284
Cerquetti, M.
P1357
Cervantes, E.
P1696
Cervena, D.
P1172
P2079
Cervera, C.
Cesaro, S.
O154
Cetin, C.B.
P1618
Ceuppens, P.
P1438
Cevan, S.
O294
Cevenini, R.
P1694
Cha, S.
P1086
Chaberny, I.F.
P1315
Chabri, S.
P1951
Chacon, J.
O366
Chae, H.
P1356
Chagarjan, A.
P1573
Chagas Jr, A.D.
O466, P1414
Chai, L.
P2153
Chaindamporn, A.
P884
Chaker, W.
P2024
Chakrabarti, A.
E275
Chakroun, M.
P659, P1092, P1546
Champagne, S.
P843
Chan, M.
P838
Chan, Pan
O90
Chan, Paul
P1778
Chan, T.
P2037
Chanard, E.
P1789
Chandler, K.
P909
Chang, E.
O317
Chang, F.-Y.
O305
Chang, H.H.
P1549
Chang, H.M.
P670
Chang, J.
P1356
Chang, K.
P1641
Chang, K.T.
P790, P1969
Chang, R.
P713
Chang, S.C.
O365, P670, P1552
Chang, T.
P2037
Chantratita, W.
O367
Chanzá, M.
P983, P2008
Chaowagul, V.
P1547
Chapelle, S.
O475
Charachousou, E.
P920
Charalabopoulou, A. P2060, P2207
Charalambous, B.M.
P642
Charisiadou, A.
P960
Charitakis, A.
P822, P2010
Charles, P.
P1574
Charles, P.E.
P1660, P1756
Charlett, A.
O144, P1381
Charoenyingwattana, A.
O367
Charos, A.
P1280
Charrel, R.N.
S21, O242
Charrier, M.
O32
Charvalos, E.
P1873
Chassard, D.
P1510
Chastre, J.
S24, S174, S321
Chatsuwan, T.
P956
Chatziandreou, E.
P575, P1125
Chatzidimitriou, D.
P1866
Chatziioannou, S.
P1464
List of Authors
Number
Chatzimichael, A.
P970
P1846
Chatzizisis, Y.
Chaudhry, A.
P1177
Chauhan, A.
O187
Chaussee, M.S.
P978
Chavanet, P.
P1502, P1756
Chavatte, P.
P2151
Chaves, G.M.
P1944
Chaves, R.L.
O85, P1289, P1538,
P1539, P2091
P1298
Chawes, B.
Chayakulkeeree, M.
P1003
Chazan, B.
P1971
Che, Z.Q.
P1224
Cheah, K.
P1583
Chemnitz, J.
P2248
Chen, C.-L.
P1352
Chen, D.
O299
Chen, E.Z.
P1224
Chen, H.
P692
Chen, J.
P1548
Chen, K.T.
P1014
Chen, M.
O469, P1434
Chen, Shili
P1166
Chen, Shudan
P682
Chen, S.C.
P2092, P2114
Chen, V.
O483
Chen, W.C.
P670
Chen, Y.S.
P1548
Chen, Yijian
P1973
Chen, Ying
P1224
Chen, Y.C.
P670
Chen, Y.H.
P1426, P1427
Chen, Z.
P1364
Chenal, L.
P867
Cheng, A.
P1656
Cheng, C.-C.
O305
Cheng, V.
P2005
Cheong, E.
P1202
Cheong, H.J.
P1392, P1598
Cherkaoui, A.
O218, P650
Chernopyatova, R.M.
P2129
Chetchotisakd, P.
P1547
Cheung, J.
P1696
Chevallier, J.
P1408
Chezzi, C.
P877, P1892
Chi, Y.
P1525
Chia, D.Q.
O193, P1176
Chia, J.H.
P1352, P1966
Chiang-Ni, C.
P1014
Chiavaroli, R.
P590
Chichino, G.
P1000
Chierakul, W.
P1547
Chifiriuc, M.C.
P1044, P1751,
P1752
Chikamatsu, K.
P2023
Chimot, L.
P2118
Chin, B.
P1745
Chin, M.Y.
P1174
Chin-Hong, P.
O153
Chinello, P.
P2184
Chinkova, Y.
P2034
Chinniah, T.
P1619
Chiodini, P.
S453, O488
Chiotan, C.
P887
Chiotis, C.
P1251
Chipanin, E.
P1019
Chiu, C.-H.
P713, P1352
Name
Chiueh, T.S.
Chmelizek, G.
Chmelnitsky, I.
Chmielarczyk, A.
Cho, J.
Cho, J.H.
Cho, S.
Cho, S.-H.
Cho, Y.K.
Number
P914, P1377
P1208
O100
P1935
P1601
P2195, P2225
P2068
P684
P1308, P1312,
P1392, P1648
P1290
Choeng, H.
Choi, H.K.
P1976
Choi, H.H.
P1743
Choi, H.J.
P563, P1598, P1648
Choi, J.A.
P1743
Choi, J.Y.
P1598
Choi, W.
P1290
Choi, Y.H.
P1598
Choi, Y.W.
P1869
Chokbumrungsuk, C.
O249
Chomutare, T.
P1306
Chong, Y.
P597
Chonlapan, A.
P1445
Choo, E.J.
P1542
Choong, P.
P1656
Choopanizadeh, M.
P1429
Chopra, I.
P1454, P1854
Chow, A.
P1311, P1330
Chrisochoidou, S.
P1491
Christ-Crain, M.
S235
Christaki, E.
P2210
Christensen, J.
P1969
Christensen, J.J.
P979, P1819
Christerson, L.
P1734
Christiansen, D.B.
P1719
Christiansen, K. O306, P821, P1242
Christner, M.
O191
Christofidou, M.
P2218
Christova, I.
P1024, P2058
Chroma, M.
P633, P681
Chronopoulos, E.
P1635
Chrysagi, A.
P1873
Chrysagi, D.
P1873
Chrysagis, D.
P1018
Chrysanthidis, T.
P2175, P2176
Chrysopoulou, H.
P2060, P2207
Chrysos, G.
P683
Chrysouli, Z.
P1147
Chrzanowska, K.H.
P1462
Chuang, W.J.
P1014
Chudackova, E.
P740, P1172
Chueca, N.
O363, P2166, P2170
Chumachenko, T.
P1088
Chun, B.
P1598
Chung, D.R.
P846, P1391, P1549,
P2082, P2084
Chung, J.
P2068
Chung, M.
P1392
Church, D.L.
P1600
Churchward, C.
P1726
Cicalini, S.
P2184
Cicek Senturk, G.
P1027
Cichero, P.
P832
Cidália, P.
P677
Cigana, C.
O473, P1151
Ciliento, G.
P1239
Cilievici, S.
P887
Cilli, A.
P2071
Name
Number
Cillóniz, C.
P1190
P1222
Cinarbas, I.
Cinque, P.
S532
Cioara, A.
P2111
Ciofi degli Atti, M.
P1239
Cipriani, M.
P1285
Cirasola, D.
O190
Cirillo, D.
O248, O383, O522,
P832, P1159, P1764,
P2009, P2013
P2063
Cisláková, L.
Cisnal, M.
P2244
Cisneros Herreros, J.M. P2139, P2147
Ciullo, I.
P700
Ciusa, M.L.
P976
Civriz-Bozdag, S.
P1232
Claas, E.
S167, P586, P1581,
P1868, P1871
Claeys, G.
P1912, P1953, P2135
Clancy, C.
O152, O155, P2104,
P2110, P2130
Claris, O.
P1569
Clarizia, G.
P959
Clark, C.
P1899, P1900
Clark, C.G.
O491
Clark, K.
O95
Clarke, T.
O313
Claus, H.
P854
Clauss, M.
P1655
Clavijo, E.
P2231
Claxton, A.
P1466
Cleary, T.
P1564
Clément, A.
O521
Clemente, L.
P1359
Clementi, E.
P793
Clementi, M.
O414
Clemons, K.V.
O483
Clerc, M.
P1692, P1693
Clerinx, J.
S13
Cliff, P.
O139
Climaco, E.C.
P1341
Clumeck, N.
P2183
Coates, A.
P936
Cobo, J.
P1279
Cocchi, P.
P827
Codd, M.
P2177
Codina, G.
P1942
Codita, I.
P849
Coen, P.
O500
Coenen, S.
P1262, P1265, P1266,
P1267, P1271
Coenjaerts, F. P1581, P1868, P1871
Cogo, A.
P1289
Cohen Stuart, J.W.
P641, P668,
P688, P759, P764,
P1010, P1668
Coignard, B.
O42, S59, P1111,
P1309, P1310
Coiteux, V.
P2101
Coiz, F.
P1335
Colaizzi, N.
O140
Colakoglu, S.
P1602
Colas, P.
P2208
Coldea, I.L.
P849
Coldham, N.
P628, P1016,
P1345, P1726
Colding, H.
P1905
Cole, A.M.
S17
Name
Number
Coleman, D.
O210, O212, P837
P1770
Collin, E.
Collin, F.
P1166
Collins, C.J.
P666, P1592
Collins, J.
P1936
Colmenarejo, C.
P845, P1949
Cologni, G.
P673
Colomba, C.
P2205
Colombo, A.L.
P1944
Colombo, C.
P1203
P592
Colombo, Roberto
Colombo, Rosaria
P1234
Colosimo, M.
P1234
Colson, P.
P1957, P1959,
P2212, P2214, P2220,
P2221, P2223
Coltella, L.
P1563, P2002
Coltey, B.
P2151
Coluzzi, M.
P2213
Comandatore, F.
P1020
Combadiere, B
S269
Combescure, C.
P1684, P2088
Comesaña-Da-Vila, E.
P897
Conceição, T.
O303
Concia, E.
P1486, P2004
Condon, I.
P618, P730
Conejo, M.C.
P1182
Conesa, G.
P1647
Conneally, E.
P1470
Conrad, A.
P1313
Constantinidis, T.C.
P927
Constenla-Carames, L.
P897
Contag, C.
S543
Conte, M.
P1460, P1654, P1911
Conte, V.
P572, P646
Conter, L.
P592
Conti, M.
P2004
Conti, V.
P1325, P1456
Contreras, C.
P1564
Conway, N.
O308
Cook, I.
P765
Cook, M.
P1209
Cookson, B.
E121, O147, O349,
P829, P1115,
P1335, P1381
Cools, P.
P1912
Coombs, G.
O306, P821, P837
Cooper, B.S.
O147, P1115, P1254
Cooper, D.
O90
Cooper, K.
P912
Cooper, O.
P1406
Cooper, T.
P1335
Coppens, G.
P1004, P1829
Coppolecchia, S.
P1117, P1494
Coque, T.M.
O107, O214, O301,
O355, P619, P620, P675,
P694, P1341, P1343
Corbella, C.
P2031
Corbellino, M.
P867
Corcoran, M.
P618, P730
Cordero, E.
O244, P2080,
P2094, P2139
Cordier, L.
P793
Cordioli, M.
P1486
Córdoba, J.
P1950
Cordón, L.
P2142
Cordonnier, C.
S401
Cordova, E.
P739
Final Programme
199
Chairs & Authors
Name
List of Authors
Name
Number
Corey, L.
Cormican, M.
P1875
O106, S459,
P618, P730
Cornaglia, G.
K178, P648, P741
Cornelis, P.
O291
Cornely, O.A.
O87, S109,
P2115, P2248
Cornet, O.
P1415
Corral, G.
P1191
Corral, J.
P1191
P1324
Corrales, I.F.
Correa, A.
O421
Correa, D.
P856
Correa, N.
P2039
Correia, A.
P639, P1814
Correia, D.
P886
Correia, P.
O350
Correia da Costa, J.M.
P1354
Corso, A.
P773
Cortes, J.A.
P1324
Cortez, J.
P860, P870
Cortez, Joana
P2057
Corti, N.
P799
Cortinas Abrahantes, J.
P1265
Corver, J.
P1012
Corzo-Delgado, J.E.
P1247, P1475
Cosgrove, B.
P823
Cosgrove, S.
P2090
Cosic, G.
P1079
Coskun Alaca, F.
P1222
Costa, A.M.
O350
Costa, Claudio
P1859
Costa, Cristina
O410
Costa, Edson
P1859
Costa, Elena
P834, P1314
Costa, S.
P2085, P2242, P2245
Costantino, S.
O415
Costanzo, C.M.
P2061
Coste, O.
P1977
Cotar, A.
P1044
Cotar, A.I.
P1751, P1752
Cottell, J.L.
P1884
Cotter, M.P.
P1258
Cotter, S.
P972
Cotton, F.
P2109
Coudert, M.
P2239
Couet, W.
P804, P811,
P815, P818
Coulombier, D.
S223
Coutinho, A.
O350
Coutinho, R.
O38
Couto, A.
P2171
Couto, I.
P723, P724
Couto, N.
P598, P1248, P1350
Couwenbergh, N.
P807
Cove, J.
P1854
Cox, G.
P1051
Coyle, E.C
P600
Coyle, P.
O417
Craeghs, J.
P1004
Craig, W.
P1293
Crampin, A.
O251
Crance, J.-M.
P2208
Crandon, J.
P1505
Crank, C.
P2090
Craven, R.
P1059, P1993
Cravioto, A.
P1347
Crawford, C.
P1013
Name
Number
Crawford, T.
P1058
P798
Crea, F.
Cremer, B.
P2248
Crémieux, A.C.
P1068
Cremniter, J.
P605
Crespo Sánchez, M.D.
P1566
Creti, R.
P1851
Crettaz, J.
P848
Cretu, C.M.
S398, P887
Crippa, F.
P1484
P899
Crisetti, E.
Cristea, D.
P1751
Critchley, I.
P968, P1171
Croall, J.
P686
Crobu, M.G.
O415
Croce, F.
P1336
Crocetta, V.
P1150
Croisier, D.
P1756
Croisier-Bertin, D.
P1502
Crokaert, F.
P1924
Cronenberger, S.
O239
Cross, R.
O469, P1434, P1761
Croughs, P.
O149
Crowcroft, N.
P1081
Crowder, C.
O358, O359
Crumley, S.
O411, P1527
Csergö, M.
P2109
Cua, E.
P1287
Cubero, Maria
P2244
Cubero, Meritxell
P1374
Cubero-Ribas, A.
P1416, P1923
Cuchi, E.
O236, P1629,
P1657, P2031
Cuenca-Estrella, M.
O151, 0476,
P1938, P2103
Cuervo, W.
P1923
Cuesta, I.
P2103
Cuevas, O.
P842, P1060
Cuffini, A.M.
P2152
Culebras, E.
P1925
Culebras, M.
P1942
Culha, G.
P875
Cullen, I.M.
P1397
Cullinan, M.P.
P1105
Cunietti, E.
P1118
Cuny, C.
O302
Curiao, T.
O107, O355, P1341
Curova, K.
P1759
Curran, M.
O500
Curti, C.
P853
Curtoni, A.
O410
Cusato, M.
P814
Cusini, M.
P988
Cuteri, V.
P980, P1727
Cutler, S.
P868
Cuzon, G.
P742, P745, P1670
Czarniak, E.
P1736
Czech-Kowalska, J.
O31
D
Ancona, F.
P701
D'Accico, M.
P959
D'Alessandro, A.
P2042
D'Alessandro, D.
P1113
d'Almeida-Fourquet, M.
P2151
D'alteroche, L.
P1961
D'Ambrosio, F.
P1371, P1373
D'Ancona, F.
P1371
D'Andrea, M.M.
P572, P646, P700
Final Programme
Name
Number
D'Angelo, R.
P1403
P2075
D'Antoni, A.
D'Antuono, A.
P988, P1694
d'Arminio Monforte, A.
P1484
D'Avolio, A.
P802, P803, P810
d'Azevedo, P.A.
P839
D'ettorre, G.
P2200
D'Incau, M.
P635
D'Silva, D.
O47
D'Urbano, M.
P1841
O466, P1414
da Silva, C.L.
Da Silva, G.
P624, P636, P1358
Dadvand, H.
P2015
Dagan, R.
S112
Daglia, M.
P1154
Dahl, M.H.
P587
Dahyot-Fizelier, C.
P815
Daikos, G.
P687, P1147
Dailiana, Z.
O85, P1538
Dakovic Rode, O.
P2191
Dal Conte, I.
P988
Dalbøge, C.S.
P797
Dalby, T.
P1080
Dalfino, L.
P1117, P1494
Dalhoff, A.
S540, P785, P792
Dalhoff, K.
P797
Daliphard, S.
P2076
Dalle, F.
P1660, P1951
Dallow, J.
P1065
Dalphin, J.
P1750
Dalsgaard, A.
P999
Dalton, J.
P1166
Damoraki, G.
P789
Dancer, S.J.
P1207
Dangel, M.
P1387, P1467, P1652
Daniel, I.
O350
Daniel, R.
P1646
Daniels, V.
P1603
Danis, A.
P1228
Danziger, L.
P1058
Danzmann, L.
P1241
Dao, A.
P1584
Dao, M.T
P1961
Daoud, Z.
P1056
Daprai, L.
P959
Darbar, A.A.
P1972
Dargis, R.
P979, P1819
Darini, A.L.
P1341
Darling, K.
P1646
Darmoni, S.
P1317
Daryanavard, A.
P1410
Das, A.
P1530
Das, S.
P2022
Dascalu, A.
O385, P1135
Dascalu, L.
P1044, P1751
Daum, L.T.
P1869, P1888
Dautigny, M.
P1415, P1699
Dautzenberg, M.J.
O298, P1490
Davari, B.
P1853
Dave, J.
P1736
Davey, P.G.
P1493
David, K.
O490
David, M.
P934
Davidsen, T.
O470
Davidson, S.
P2030
Davidsson, S.
P949, P1732
Davies, R.H.
P628
Davis, K.
P784
Name
Davis, L.
Davis, S.
Davoodian, P.
Day, N.
De Angelis, D.
De Angelis, G.
De Backer, W.
de Barbeyrac, B.
De Beenhouwer, H.
De Bel, A.
De Brauwer, E.
De Carolis, E.
De Castro, N.
de Cunto, G.
De Filippis, M.
De Francesco, M.
De Gaudio, M.
de Gea-García, J.H.
de Gracia, J.
de Gramont, A.
De Grazia, S.
de Grim, L.H.
de Guchteneire, I.
De Hoog, S.
De Iaco, G.
de Jong, A.
de Kraker, M.E.A.
de la Cámara, R.
De la Horra, C.
de la Torre, J.
De labra, L.
de Ladoucette, A.
De Laere, E.
de Lange, D.W.
De las Cuevas, C.
de Lencastre, H.
Number
P1603
P2090
P1410, P2015
P1547
P1254
O145, P1285
P958
P1692, P1693
P982
P1836
P1400
P1941
O252
P1872
P867
P988
P800
P1279
P1942
P1193
P2205
P2078, P2083
P1384
P2115
P1319
P1100, P1101
P1493
P1878
P1212
P1277, P2166
P1191
P1789
P1033
P1218
O421
S122, O303,
O348, O350, P938,
P940, P1372
de los Reyes-Gavilána, C.
P1155
De Malet, A.
P2227
de Man, R.A.
P2078, P2083
de Marchin, J.
P2183
De Marcos, J.
O236
de Martino, M.
P827
De Martino, S.J.
P1770
de Miguel-Albarreal, A.
P1247
De Monbrison, F.
P2126
de Moraes, M.H.
P1782
de Neeling, A.J.
P764
De Nittis, R.
P988
de Oña, M.
P1870
de Ory-Manchón, F.
P2204
De Pascale, G.
P1941
de Pauw, B.E.
S184
De Ridder, C.
P1788
De Rosa, F.G.
P802, P803, P810
De Rosa, R.
P910, P1678, P1806
de Ruiter, S.C.
P1481
De Ryck, R.
P1236, P1721
de Santiago, V.
P1923
De Schutter, I.
P1924
De Silva, A.
P855
de Silva, J.
P855
De Smet, A.M.
P1214, P1215
De Spirito, M.
P2041
De Sutter, G.
P1829
De Vecchi, E.
P1398
De Vito, D.
P630
List of Authors
Number
De Vos, D.
O291
P626
de Vries, H.J.
De Waard, J.
P1558, P2042
De Waure, C.
O145
de Wit, R.
P1204
De Wit, S.
P2183
De Witte, E.
P1032
De Zoysa, A.
P1898
De-Benito, I.
P965
Deane, J.
O418, P554
P837
Deasy, E.
Debaene, B.
P815
Debets-Ossenkopp, Y.J. O290, O478
Debiaggi, M.
O414
Debruyne, J.
P1924
Debyle, C.
P992
Decante, B.
O187
Decat, E.
P1912
Decker, R.
O191
Decker-Burgard, S.
P808
Decorosi, F.
P976
Decosterd, A.
P874
Decruyenaere, J.
P2135
Dede, M.
P2233
Dediste, A.
P2024
Deeny, S.R.
P1115
Defilippi, G.
P959, P1234
Degener, A.M.
P2200
Degener, J.
P1809, P1831
Deguchi, T.
P2065
Dei-Cas, E.
P2101
Deji-Agboola, M.
O409
Dekhnich, A.
P1376
Dekhnich, N.
P1042
Dekkers, O.M.
O503, P1009
del Arco Jiménez, A.
P1277
Del Bono, V.
P2086
del Campo, R.
O247, O288, O296,
P1378, P1725
Del Castillo, D.
P2128
Del Chierico, F. P1239, P1841, P1948
Del Giudice, G.
P1005
Del Grosso, M.
P1371, P1373
Del Nogal, B.
P1558
Del Nonno, F.
P1872
Del Pin, B.
P873
Del Portillo, P.
P2018
Del Re, S.
P988
del Romero, J.
P1455
Del Rosario-Quintana, C.
P2227
del Toro, M.
O143, P1279
Delaere, B.
P958
Delforge, M.
P2183
Delgado, J.M.
P1416
Delgado, M.
P598
Delhaes, L.
P2101, P2151
Dell’Agostino, C.
P1478
Della Bora, T.
P812, P1501
Della Strada, M.
P2209
Dellamonica, P.
P1287, P1435
Demachy, M.
P742
DeMarco, S.
P1151, P1513
Demarie, V.
P985
DeMarsh, P.
O90, P1508
Demartines, N.
P1650
Dembowsky, K.
P1151, P1513
Demertzi, E.
O312
Demir, E.
P1707
Name
Number
Demir, T.
P1985
P1602
Demirbilek, M.
Demirturk, N.
P1394
Demonchy, E.
P1287
Dempsey, K.
P2096
Deng, Y.
O96
Deniau, M.
P696
Denis, B.
P2073
Denis, O.
O297, P651, P691,
P702, P778, P1236, P1721
P1019
Denisov, A.
Deniz, C.
P1199
Denning, D.W.
P2106
Denys, G.A.
P1143, P1144, P1453
Deplano, A.
P651, P702,
P1236, P1721
Depuydt, P.
P1953, P2135
Derde, L.P.
O298, P1490
Derksen, L.
P1655
Derouin, F.
P2073
Dersi, N.
P2217
Desager, K.
O475
Desai, D.
P1730
Desai, K.
P913
Desai, M.
P1730
Desai, S.
P992
Desai, S.R.
P2134
Deschaght, P.
P1912
Desessard, C.
P1504
Desgrandchamps, D.
P1446
Deshpande, L.
P613, P614,
P616, P652,
P722, P1452
Deshpande, R.
P2134
Deslee, G.
P1865
Desmonet, M.
O32
Desnos-Ollivier, M.
O482
Desnues, C.
K199
Dessau, R.B.
O361
Dettenkofer, M. P1109, P1112, P1313
Dettlaff, S.
P1571
Deutsch, P.
P1303
Deveci, A.
P1614
DeVito, J.
P1162, P1166
DeVivo, M.
P1166
Devlin, C.
O426
Devlin, J.
O417
Devos, P.
P1087
Dhédin, N.
P2239
Dhelia, P.
P1087
Dhole, T.N.
P768, P2000
Di Biase, E.
P2197
Di Bonaventura, G.
P1150, P1851
Di Carlo, A.
P988
Di Caro, A.
P872
Di Francesco, A.
P1694
Di Luca, M.C.
P728
Di Muzio, F.
P1285
Di Nauta, A.
P1159
Di Perri, G.
P802, P803, P810
Di Sarno, R.
P1460
Di Serio, C.
O248
Di Stefano, M.
P1403
Di Stefano, R.
P2075
Di Taranto, A.
P988
Di Traglia, L.
P1679
Di Vincenzo, V.
P1150
Di Yacovo, S.
P1579
Name
Diab-El Schahawi, M.
Diamant, M.
Diana, M.
Dias, C.
Dias, J.
Diatta, G.
Díaz, M.
Diaz, R.
Diaz, S.
Diaz de Alba, P.
Díaz de Heredia, C.
Díaz-Martin, A.
Dicuonzo, G.
Number
P929
S393
P1650
P839
P889
P882
P860, P870
P661, P1817
P1934
P599
P1942
P1425
P798, P1150,
P1373, P1851
Diel, R.
E447
Diene, S.M.
P720
Dierikx, C.M.
P1010
Dietz, U.
P2055
Diez, J.
O253
Díez-Gil, Ó.
P1675
Dijkshoorn, L.
O528, P627, P703
Dikmen, A.
P1226
Dikov, I.
P2226
Dilillo, D.
P1554
Diltoer, M.
O45
Dimarogona, K.
P1491
Dimatatac, F.
O489
Dimitrakopoulos, O.
P1880
Dimitriadi, D.
P1180
Dimitriev, Y.
P1145
Dimitriou, G.
P1760
Dimitrova, A.
P703
Dimiziani, L.
P1948
Dimopoulos, G.
S25, P1616
Dimoulas, C.
P822, P2010
Dinc, B.
P1064
Dinc, G.
P1618
Ding, Y.
P1506
Dingemans, G.
P1943
Dinh, A.
S327, P1068
Dini, S.
P2086
Dinis, A.
P862
Dinis-Ribeiro, M.
P769
Dinleyici, E.C.
P1225
Dinu, S.
P631, P849, P1751
Dionisi, A.
P630
Dixon, R.A.
O89
Diza, E.
P1181, P1845,
P1846, P2176
Dizbay, M.
P734, P1226, P1394,
P1740, P2119
Djekic, J.
P1079
Dmitriev, A.V.
P978
Dobbelaer, I.
P1885, P1886
Dobbeleir, N.
O45
Dobreva, E.
P703, P1711, P1718
Dockrell, H.M.
O251
Docobo-Pérez, F.
O474, P1069,
P2147
Docquier, J.D.
P597, P609
Docx, S.
P2018
Doerge, B.
P761
Doern, C.
P1059
Dogan Ekici, I.
P892
Doherty, C.
P2174
Doherty, J.
P2127
Doherty, T.
P876, P1007
Dohmen, P.
P1538, P1539
Name
Number
Dokoutsidou, E.
P1327
P1639
Dollenz, M.
Domblides, P.
P2151
Doménech-Sánchez, A.
P604
Domingo, M.
P1949
Domingo, P.
P1958
Dominguez, M.A.
P1368
Dominguez, J.
O253
Dominguez-Gil Gonzalez, M. P2029
Domínguez-Herrera, J. O474, P1069,
P2147
Dominietto, A.
P2086
Dominique, S.
P2151
Donabedian, S.
O301
Donatelli, J.
P1141
Donati, V.
P635
Dong, L.
O411
Donlon, S.
P1258
Donnellan, M.R.
P1717
Donnelly, P.J.
S330, O476
Donnio, P.Y.
P994, P998
Doosti, A.
P621
Dopico, E.
P878
Dorca, J.
P1665
Dorizzi, R.
P2209
Dörner, J.C.
P1101
Dorobat, O.
P1495
dos Santos, S.R.
P963
dos Santos Moraes, A.
P1782
Dosch, V.
P929
Doucet-Populaire, F.
P605
Doudier, B.
P2223
Doudoulakakis, A.
P1322
Doudoulakis, A.
P920
Dougan, G.
P558
Douraghi, M.
P1907
Dovgan, E.
P1550
Dowling, C.
O423
Downing, L.
P1974
Dowzicky, M.
O524, P556, P573,
P576, P644, P678, P732,
P932, P946, P1057,
P1120, P1121, P1608
Drago, L.
P1159, P1398
Dragomirescu, L.
P1303
Dragulescu, E.C.
P849
Drake, T.
P712
Drancourt, M.
S27, E120, P1048
Draper, M.
P1074, P1141
Drapier, N.
P1268, P1270
Dreesman, J.
P1307
Drenck, K.
O362
Drese, K.
P1909
Drews, S.
P1370
Dreyer, A.
P1888
Dreyer, C.
P2247
Drgona, L.
P2122
Drieghe, S.
P593
Drieux, L.
P605
Drobniewski, F.
S8, P1999,
P2009, P2034
Drogari-Apiranthitou, M.
P1485
Dromer, F.
O482, P2132
Drougka, E.
P1760
Drugdova, Z.
P676
Drulis-Kawa, Z.
P1152
Drusano, G.
S68
Dryden, M.
S171, S256, P1280
Final Programme
201
Chairs & Authors
Name
List of Authors
Name
Number
Drzewiecki, A.
Duane, T.
Duarte, A.
Duarte Correia, J.
Dubois, V.
Dubouix-Bourandy, A.
Dubus, J.C.
Duckworth, G.
Duclos, A.
Ducoroy, P.
Duffy, E.M.
P1119
P1534
P1043
P598
O196
P1789
P825
P1381
P2126
P1951
O93, P1162,
P1165, P1166
Duffy, L.
O417
Dufour, J.
P1756
Dugernier, T.
P807
Dulley, F.
P2085, P2242, P2245
Dulovic, O.
P1615
Dumartin, C.
P1282
Dumestre-Perard, C.
P2138
Dumitrescu, M.
P1502
Dumitrescu, O.
P1052, P1068
Dumont, E.F.
P1512
Dumyati, G.
O496
Dunne, M.
P1530
Dunne, W.M.
P1059, P1993
Dunning, J.
S336
Dunø, M.
P797
Duo, L.
P2035
DuPont, H.
P1544
Durand, D.
P1564
Durand-Joly, I.
P2151
Durmaz, G.
P1225
Durmaz, R.
O37, P962
Durrant, C.
S69
Durusoy, R.
P1443
Durussel, C.
O148
Dusane, D.
P1864
Dusemund, F.
O48
Duson, G.
P1874, P1926
Dutly, F.
P1002
Duval, X.
S405
Dzajic, E.
P658, P660
Dzieciol, M.
P1904
Dzierzanowska, D.
P1570
Dzierzanowska, D.
O31
DzierZanowska-Fangrat, K. O30, O31,
P1462, P1570, P1762
E
ady, A.
Earnest, A.
Eastaway, A.T.
Ebbers, J.
Eberl, L.
Ebert, S.
Ebrahimzadeh, F.
P1854
P1311
P1305
P2123
O473
P1259
P1423, P1424,
P1907
Ecemis, T.
P2027
Echahidi, F.
P1836
Echenagusia, A.
P1631
Echenagusia, M.
P1631
Echeverría-Ortega, M.
P860, P870
Echols, R.
P1514
Eckburg, P.B.
P968, P1531
Ecker, L.
P1562
Eckmann, C.
S440
Eckmanns, T.
P731, P854, P1307
Eckstein, F.S.
P1652
Economou, E.
P555, P1098
Name
Number
Edelsberg, J.
P1281
P1971
Edelstein, H.
Edelstein, I.
P1573
Edelstein, M.
P740, P1376
Edgeworth, J.
O139, P828, P831
Edmond, M.B.
P2123
Edwards, B.
P765, P823
Edwards, G.
P823, P1717
Edwards, I.
P1676
Edwards, K.
P1898
P1051
Edwards, T.A.
Eerola, E.
P1986
Efstathopoulos, N.
P1635
Efstratiou, A.
O312, P686, P1898
Egervärn, M.
O353
Eggimann, F.
O140
Egli, K.
P1687, P2052
Egorova, N.
P2237
Ehricht, R.
P829, P837, P905,
P917, P1016
Eichhorst, D.
P1417
Eiffert, H.
O362
Eigenmann, K.
P1655
Eigner, U.
P638, P1988
Einsele, H.
S552
Eiroa-De-La-Puente, L.
P897
Eiros, J.
P1765
Eisenhut, C.
P1688
Eisenring, M.C.
P1650
Ejlertsen, T.
P990
Ejrnæs, K.
P1746
Ekkelenkamp, M.B.
P1218, P1481,
P1613
Eklund, R.
P1261
El Abkari, M.
P583
El Aila, N.
P1912
El Chakhtoura, N.
P1194
El Filali, A.
P720
El Garch, F.
P611, P725
El Ghazi, K.
P583
El Helali, N.
P1787
El Malki, A.
P2217
El Otmani, F.
P622
El Sin, M.
S453
El-Mahallawy, H.
P2246
El-Sheikha, S.
O47
Elberts, S.
P1728
Elefante, P.
P1508
Elefanti, A.
P786
Elefteriou, E.
P2067
Elgh, F.
P949, P1732
Elia, F.
P1159
Elie, C.
P2132
Eliopoulos, G.M.
P1050
Ellem, J.
P560, P1811
Ellerbroek, P.M.
P1481
Ellington, M.J.
O343, O349, P1730
Elliott, H.
P729, P795
Elliott, T.S.
P1209
Ellström, K.
P1973
ElShaer, M.
P1158
Elsman, P.
P995
Elston, J.
O427
Elumogo, T.
P1619
Elzi, L.
P1467
Emanuele, A.
P1499
Emini, E.
O425, O426
Emonet, S.
P874
Final Programme
Name
Empel, J.
Enache-Angoulvant, A.
Endimiani, A.
Number
O348
P1946
P615, P936,
P1349, P1669
Endo, S.
P632
Endtz, H.
P1347
Eng, L.C.
P954
Engberg, J.
P990, P1920
Engelmann, E.
P684
Enghild, J.
P1780
O468, P2201
Engler, O.
Englund, S.
O353
Engstrand, L.
S285, P1671
Engstrom, A.
P2018
Ennaji, M.
P2217
Enne, V.I.
P1667, P1810
Enninga, J.
S544
Enrietti, S.
P2236
Entenza, J.M.
P1783
Eom, J.S.
P1308, P1312, P1598
Epis, S.
P1020
Eqbal Eftekhaari, T.
P1410, P2015
Equils, O.
P1535
Eraso, E.
P2143
Erbas, M.
P1228
Erbay, A.
P871, P1008,
P1286, P1541
Erdogan, H.
P1602
Erel, O.
P1025
Eren, S.
P1222
Erensoy, S.
O413
Ergani, A.
P1666
Ergin, I.
P1443
Ergunay, K.
P2232
Ergüt Sezer, B.
P2119
Eriksson, M.
P1261
Ermakova, T.
P826
Ermis, V.Ö.
P1681
Ernst, J.
K175, S453
Ernstson, L.
P1260
Erntell, M.
P1260
Erol, S.
P1090, P1091
Ersozlu Bozkirli, D.
P1457
Ertek, M.
O37, P962
Erzin, Y.
P1755
Esaki, H.
O101
Escada, R.
P619
Escobar, T.
P1826
Escribano, P.
O479, P1099,
P2095, P2102
Escuret, V.
P1192
Esen, B.
P1985
Eshagh Hosseini, M. P1423, P1424,
P1907
Eshoo, M.
O358, O359
Esmaeeli Djavid, G.
P1157
Esmaili, M.
P1423
Espejo, E.
P1661
Esperalba, J.
P2116
Espigado, I.
P2139
Espinal, P.
P1838
Espinel-Ingroff, A.
P1099
Espínola, M.
O293, P584
Espinosa, M.
P1292
Esteban, J.
P1606
Estepa, V.
O103, P1716
Esteves, P.J.
P881
Etgul, S.
P2240
Name
Number
Ethem, E.
Etienne, J.
P1883
O520, P1052, P1068,
P1502, P1569
Eto, M.
O101
Euler, C.
O92
Eustace, A.
O104
Evans, J.T.
P2006, P2044
Evaristo, M.A.
P1341
Eveillard, M.
P664, P1382
Ewig, S.
P1190
P2072
Eworo, A.
Exiara, T.
P888, P1022
Exindari, M.
P1866
Eydmann, M.
P1842
Ezaki, T.
P1933
Ezpeleta Baquedano, C.
P1108
Fabbi, M.
P1020
Fàbrega, A.
P649
Fabry, J.
P1335
Fadda, G.
P1941
Fader, R.
P906
Faella, F.
P1460
Fagan, E.
P1253, P1989
Fagundez Machiain, G.
P1828
Fain, O.
O252
Fairhead, C.
P1946
Fairley, D.
O500
Fajardo, M.
P841
Fakhar, F.
P2015
Fakiri, E.M.
P1180, P1491
Fakiri, H.
P1348
Falagas, M.
E273, P1175,
P1439,P1638
Falcone, M.
O82
Falk, W.
P1772
Falke, S.
P1417
Fallani, S.
O82, P800
Fan, H.
P692, P1364, P1479
Fan, L.
O246
Fan, X.Q.
P796
Fanci, R.
O154
Fang, F.
S432
Fang, H.
P925
Fang, H.Y.
P1014
Fankhauser, C.
P650
Fanning, S.
P1448, P1757
Fantin, B.
P2247
Fanton, A.-L.
P2151
Farajollahi, M.
P1903
Farce, A.
P2151
Faria, N.A.
O348, P940
Faria-Ramos, I.
P767
Farias, A.
P1782
Farina, C.
P834, P1314, P1911
Fariñas, M.C.
O241, P964,
P965, P1627
Fariñas-Alvarez, C.
O241, P964,
P965, P1627
Farjaddoost, A.
P1424
Farkas, D.F.
P2117
Farowski, F.
O87
Farquet, N.
P1388
Farrell, D.
P722, P930, P943,
P944, P945, P1055,P1126,
P1129,P1130,P1131,P1132,
P1134, P1136, P1137, P1138,
P1161, P1179, P1367, P1452
List of Authors
Number
Farshad, S.
P568
P1871
Farzad, N.
Fattorini, L.
O383, P2026
Faugeras, A.
P2239
Faure, K.
P1785
Faustino, A.
O350
Favaro, M.
P1680
Favennec, L.
P2151
Fawley, W.
O499, O500, O502
Fazel, M.
P864
P1911
Fazii, P.
Fazio, C.
P1713
Febra, C.
O350
Feckova, M.
P1096
Fedele, G.
P2204
Fedorin, I.
P2034
Fehr, J.
P799
Feierl, G.
P926, P1827
Feig, M.
P731, P854
Fekri, S.
P1410
Feltrin, F.
P635
Feng, L.
P796
Fennell, J.
P1397
Fenner, I.
P1988
Fenner, J.
P1345
Fenneteau, F.
P1520
Fenoll, A.
P1374
Feoli, F.
P2183
Fereidouni, F.
P1424
Ferguson, P.
P1339, P2238
Ferjani, A.
P2038, P2229
Ferlinz, A.
O39
Fernandes, C.
O88, P931
Fernandes, Daniel
O47
Fernandes, Diana
P2193
Fernandes, L.A.
P931
Fernandes, P.
O95
Fernandes, R.
P769
Fernández, E.
P2133
Fernandez, G.
P2128
Fernández, I.
P1958
Fernandez, J.
P2093
Fernández, P.
P599
Fernandez, V.
P2144
Fernández Guerrero, M.
P1606
Fernandez Jauregui, C.
P1108
Fernández Roblas, R.
P1606
Fernández Rueda, M.L. P1404, P2206
Fernandez Vizan, E.
P1108
Fernández-Alonso, M.
O295
Fernández-Cuenca, F.
P599, P718,
P1879
Fernandez-Mazarrasa, C.
P965,
P993, P1471
Fernández-Natal, I.
P1461
Fernandez-Olmos, A.
P1928
Fernández-Quero, L.
O157
Fernández-Romero, N.
P1712
Fernández-Rufete, A.
P1474
Fernández-Ruiz, M.
P2077
Fernandez-Sampedro, M.
P1627
Fernández-Sánchez, A.
P1996
Fernandez-Villar, A.
P2128
Fernández-Yañez, J.
P2072
Ferrari, A.
P985
Ferrari, R.
P1582
Ferraro, F.
P1284, P1645, P2155
Ferreira, A.
O41
Name
Number
Ferreira, C.
P886
P562, P1359, P1366
Ferreira, E.
Ferreira, G.C.
O350
Ferreira, H.
P716
Ferreira, J.C.
P1341
Ferreira, L.
P2167
Ferreira, P.
P886
Ferreira, R.
P769
Ferreira, S.
P699
Ferrero, M.
P1026
P2212, P2221
Ferretti, A.
Ferro, A.
P1191
Ferroni, A.
P1217
Ferrús, M.A.
P1821
Ferry, T.
O520
Feßler, A.T.
P1101
Festoso, I.
P2013
FeTalento, A.
O210, O212
Fiandaca, M.
P1945
Fiane, A.
P1739
Fidan, I.
P1740
Fielder, M.
P1016, P1726
Fiett, J.
P743
Figols, F.
P1627
Figueiredo, C.
P769
Figuera, A.
P1878
Figueras, C.
P1942
Fijo, J.
P2094
Fila, F.
O415
Filice, C.
O487
Filipescu, I.
P2111
Filipovic, M.
P1937
Filippidou, E.
P888
Filippini, P.
O383, P2026
Filippou, M.
P1636
Fily, F.
P998
Fincatti, P.
P2165
Findik, D.
P1707
Fine, P.
O251, P1875
Fini, M.
P1501
Fink, I.
P1774
Finkelstein, R. P693, P1458, P1663
Finn, M.
O353
Firacative, C.
P2092
Firat, A.K.
P1769
Firsov, A.
S66, O80, P782
Fiscarelli, E.
P1150, P1948
Fischer, Gerald
P1888
Fischer, Guido
P2115
Fischer, G.W.
P1869
Fischer, H.
O150
Fischer, S.
P783, P1510
Fischetti, V.
O92
Fiserova, V.
P2043
Fissette, K.
P2018
Fitchett, J.R.
O251
Fitchett, K.
P2096
Fitting, J.W.
P1572
Fitzgerald, J.
O423
Fitzgerald, M.
P972
Fitzgerald-Hughes, D.
O210, O212
Fitzpatrick, F.
P1258, P1294,
P1329
Flamaing, J.
P958
Flanagan, K.L.
O251
Fleck, M.
P1774
Flonta, M.
P2111
Floré, K.
P1987
Name
Flores, J.
Flores, R.
Fluit, A.C.
Number
P860, P870
P2121
O348, P641, P668,
P688, P759, P764,
P1010, P1668
Flusin, O.
P2208
Flynn, R.
P1397
Fogagnoli, A.
P760
Fognani, G.
P827
Fois, M.
P636
P1760
Foka, A.
Foley, S.
P1294
Folgueira, L.
P1881
Følsgaard, N.
P1298
Fomichev, M.
P2017
Fomicheva, N.
P2017
Fomina, L.
P1019
Fomina, S.
P2235
Fondevilla, E.
P1278
Fonseca, A.
O350
Fonseca, G.
P2085, P2245
Fontana, C.
P1679, P1680
Fontana, R.
P741
Fontanet, A.
P1958
Ford, K.D.
P952
Foresti, S.
P1337
Forey, F.
P1052
Forier, A.-M.
P1004
Forrest, A.
P779, P783, P784
Förster, M.
P1802
Forsthuber, G.
P1639
Forti, F.
O248
Fortineau, N.
P608
Fortun, J.
O247
Foschi, C.
P1694
Fossati, S.
P1557
Foti, G.
P1046, P1233
Fouchard-Hubert, I.
P1961
Foucher, N.
P561
Foulon, I.
O311
Foulon, W.
O311
Fourie, P.B.
P1888
Fournier, P.E.
S406
Fowke, K.
O387
Foyntoylakis, S.
P822, P2010
Fraganza, F.
P1460
Fragou, A.
P1252
Fraher, M.
P1470
Fraile, M.T.
P983, P2008
Franceschi, F.
P1165
Francey, T.
P615
Franchin, T.
P1948
Franchina, C.
P2061
Francia, M.V.
O301
Francis, N.A.
P1267
Francisco, A.P.
O38, P562, P1359
Francisco, S.
O350
Franco, A.
P635
Frangenberg, H.R.
P684
Frank, U.
P1285
Franke, G.
O191
Frans, J.
P1033, P1874, P1926
Fransson, G.
P1488
Frantzidou, F.
P1181
Franzetti, F.
P834, P1314, P1336
Franzin, L.
P985
Frasca, D.
P815
Fraser, L.
P1936
Name
Number
Frasquet Artés, J.
P1828
P2041
Fraziano, M.
Fréalle, E.
P2101, P2151
Freeman, J.
O499
Frei, R.
P1002, P1467, P2097
Freiberger, T.
P904, P1937
Freitag, M.
P2054
Freitas, A.R.
O214, O300,
O301, P619
Freitas, F.
P694, P1343
P1658
Freixas, N.
French, G.
P828, P831, P1254,
P1978, P1992, P1994
Frennet, M.
P1230
Fresson, J.
P1787
Frey, N.
P1387
Freydiere, A.M.
P1789
Frias, M.J.
O189
Friaza, V.
P1212
Frick, J.-S.
P1351
Fridrichova, M.
P896, P1559
Friedland, H.D.
P968, P1531
Friedland, I.
P1519, P1520
Friedman, P.
P1086
Friedrich, A.W.
S57, P835
Frienkel-Krispin, D.
O100
Friis-Møller, A.
P1628, P1920
Frimodt-Møller, N.
P658, P660,
P1293, P1437,
P1746
Fritsche, T.
P1807
Froehlich, S.
P2234
Frohich, K.
P1776
Fröhlich Knaute, D.
P2066
Froissart, A.
P2247
Frydenlund, D.
O470
Frye, S.A.
O470
Fryer, J.
O39
Ftika, L.
P1240
Fuertes, A.
P1405
Fugazza, G.
P755
Fuhr, U.
O87
Fujii, C.M.
P963
Fujimoto, N.
P603, P623
Fujimura, S.
P1855
Fujishima, S.
P2113
Fujita, J.
P967
Fujiwara, Y.
P1433
Fukutsuji, K.
P1054
Fuller, C.
O144, P1381
Fumagalli, R.
P1046, P1233
Fung, T.
P1036, P1037
Furberg, A.-S.
P1734
Furci, L.
O522, P1764
Furione, M.
P2199
Furlan, T.
P571
Furtado, C.
O384
Furustrand, U.
O254, P1857
Fusco, F.M.
P1319, P1328
Fuursted, K.
P658, P660
Fyfe, C.
P1142, P1149
G
abarrus, A.
Gabiano, C.
Gabilondo, G.
Gabriella, D.
Gabriëls, P.
Gachkar, L.
P1190
O316, P1553
O247, O366
O82
P1004
P1545, P1634, P2194
Final Programme
203
Chairs & Authors
Name
List of Authors
Name
Number
Gacouin, A.
Gad El Rab, M.
Gadsby, N.J.
Gaertner, B.
Gaeta, A.
Gafarova, M.T.
Gaga, M.
Gagliardi, M.C.
Gagliotti, C.
P2118
P1418
P1736
P2160
P2213
P2222
O416
P2041
P1263, P1264,
P1300, P1587
O346
Gahrn-Hansen, B.
Galán, J.C.
P643, P1455, P1928
Galani, I.
P736, P1147, P1355
Galani, L.
P1252
Galanopoulou, V.
P1491
Galante, D.
P885, P1093
Galar, A.
P1292
Galeotti, C.
P1982
Galgóczy, L.
P1522, P1947
Galimberti, L.
P867
Galiza, E.
P1898
Galkin, V.
P1550
Gallagher, R.
P1335
Galler, H.
P926
Galli, E.
P1554
Galli, L.
P800
Galloway, A.
P1289, P1538, P2091
Galvez, E.
P1949
Gálvez, R.
P1852
Gama, B.
P842, P1060,
P1099, P2121
Gambarino, S.
O410
Gambillara, V.
P1446
Gámez, M.
P860, P870
Gan, V.
O489, P857, P858
Gan, Y.
P838
Ganczak, M.
P2219
Gandois, J. M.
P1789
Gangneux, J.-P.
S324, P1432,
P1956, P2118
Ganner, M.
O349, P829
Gant, C.M.
P1610
Gant, V.
P2098
Ganteris, G.
P1492
Ganuza, A.
P1108
Gao, Q.
P1724
Gao, X.
P2108
Garau, J.
S162, S186, O236,
P1641, P1658, P2031
Garazzino, S.
O316, P1553
Garba, M.
P895
Garban, F.
P2131
Garbuglia, A.R.
P1872, P2228
García, A.
P2116
Garcia, F.
O363, P1826,
P2166, P2170
García, L.
O143
Garcia, M.S.
P1952
Garcia, M.V.
P961
Garcia, Romina
P1191
García, Raquel
P2079
García Alegría, J.
P1277
García Cabrera, E.
P1425
García de la Fuente, C.
P1833
Garcia de la Llana, F.
P2128
García de Viedma, D.
P2095
Garcia Garcia, F.
P1826
Garcia Irure, J.J.
P1108
Name
García-Bach, M.
Garcia-Bujalance, S.
García-Cabrera, E.
García-Campello, M.
García-Castillo, M.
Number
P1641
P2158
P1291
P2059
O288, O296,
P1183
García-Fernández, A.
P559, P1342
García-García, J.A.
P1247
Garcia-Garcia, L.
P1928
García-Lucas, T.
P1474
P901
Garcia-Migura, L.
Garcia-Noblejas, A.
P1878
García-Palomo, J.D.
O241
Garcia-Perez, F.
P2128
García-Reyne, A.
P1938, P2077
García-Riestra, C.
P1723, P1804
Garcia-Rodriguez, J.
P1938
Garcia-Sureda, L.
P604
García-Vazquez, E.
P1474
Garcia-Vidal, C. P1579, P1665, P2244
García-Zabarte, A.
P1804
Gardiner, S.
P2006, P2044
Garduño, E.
P841
Garea, M.T.
P1723
Garey, K.
P1487, P1544, P1969
Gargalianos-Kakolyris, P.
O85,
P1289, P2091
Garilli, S.
P1246
Garitacelaya, M.
P2133
Garlaschi, M.C.
P959
Garlaschi, M.L.
P959
Garnacho-Montero, C.
P1425
Garnacho-Montero, J. P1425, P2147
Garneri, G.
P2152
Garnier, A.
P2239
Garrido, L.
P1870
Garrigós, C.
P1073
Garrigou, C.
P1408
Garripoli, A.
P985
Garry, C.
O469, P1434
Gartmann, H.
P1316
Gärtner, W.
P1316
Gartzonika, C.
O35
Garvey, E.
O94
Garza, N.
O411
Gasch, A.
O244
Gascón, J.
P649
Gasem, G.
P1213
Gashaw, A.
P868
Gastaca, M.
P2093
Gastmeier, P.
O138, S403,
P1110, P1229, P1241,
P1259, P1301, P1313,
P1320, P1480
Gatermann, S.
P1041, P1173
Gaudenz, R.
P1644
Gaustad, P.
P763
Gautheret-Dejean, A.
O32
Gavaldá, J.
O244
Gayet-Ageron, A.
P1388, P1684
Gaygisiz, U.
P734
Gayoso, J.
O157
Gazawi, A.
O526, P653
Gazin, M.
P640, P667, P1038
Gazzani, G.
P1154
Geanta, R.
P2230
Gebauer, F.
P2055
Geddes, A.
S537
Final Programme
Name
Gefen-Halevi, S.
Geffers, C.
Number
P652
O138, P1110,
P1320, P1480
Gegia, M.
P2036
Gegúndez, M.I.
P2204
Gehrer, M.
P1827
Geiran, O.
P1739
Geller, B.
P1163, P1507
Gemignani, G.
P700
Gemmell, C.
P1067
P1325, P1456
Genduso, G.
Gennari, M.
P1815
Gennaro, M.L.
O248
Gennaro, R.
P1150
Gensichen, J.
P2054
Gentil, K.
O492
Gentner, B.
P1764
George, A.
P1612, P2179
George, J.
P1612
Georgiou, V.
O416
Georgitsi, M.
P1616
Géraudie, B.
O32
Gerber, V.
P615
Gerhardt, J.
P2245
Gérolami, R.
P1957, P1959,
P2214, P2223
Gesualdo, F.
P1245
Getaz, L.
P874
Geurtz, L.
P2123
Geyik, M.F.
P1228
Ghafouryan, S.
P953, P1201
Ghantoji, S.
P1544
Gharbia, S.
P1898
Gharsa, H.
P1249
Gherardi, G.
P1150, P1371,
P1373, P1851
Ghibellini, G.
O95
Ghidini, V.
P1815
Ghigo, J.-M.
O187
Ghirelli, S.
P2209
Ghisetti, V.
P988
Ghorbani-Dalini, S.
P621
Giacchino, F.
P2152
Giacchino, M.
O154
Giakkoupi, P.
P1348
Giamarellos-Bourboulis, E.J.
O79,
O467, P789,
P1616
Giamarellou, H.
S23, S318,
P1147, P1252
Giammanco, A.
P1357
Giammanco, G.M.
P568, P2205
Giani, T.
P572, P646, P700
Giannaki, M.
P1867
Giannakopoulou, K.
P1095, P1561
Giannella, M. P1585, P1664, P2072
Giannetti, A.
P2085
Giannoglou, G.
P1845, P1846
Giannoni, F.
O383, P2026
Giannopoulou, P.
P1565
Giannouli, M.
P1363
Gião, M.
O350
Giaquinta, L.
P1221, P1235
Giardino, R.
P1501
Giavaresi, G.
P1501
Gibson, A.L.
P2006
Gicquel, Q.
P1317
Gidaris, E.
P1022
Name
Number
Giddey, M.
P1783
P1705
Gierczynski, R.
Gijón, D.
O107
Gijon, P.
P1099, P2095
Gil, A.
P1562
Gil, F.J.
P1077
Gil Navarro, M.V.
P1291, P2139
Gilbert, D.
P782
Giles, J.
P1901
Gili, F.
P1579
P1899, P1900
Gilker, J.
Gilles, C.
P2183
Gillespie, S.
O255
Gillini, L.
P590
Gilpin, D.
P1333
Gilroy, N.
P1339, P2238
Giltri, G.
P1046
Gimenez, M.
O357
Gimenez, M.J.
P2128
Gimeno, C.
P983, P2008, P2161
Ginde, S.
P1875
Gion, M.
P1682
Giordani, M.T.
P866
Giordani, S.
P1587
Giordano, A.
P1342
Giormezis, N.
P1760
Gioula, G.
P1866
Giovanakis, M.
P1622
Giovangrandi, Y.
P977, P1787
Giovannini, M.
P1554
Giralt, E.
P1164
Girard, N.
P994
Girardi, E.
P1499
Girardi, W.
P1321
Girvan, E.K.
P1717
Girvan, K.
P823
Giske, C.
S9, P577, P654, P705
Gismondo, M.R.
P867
Gitti, Z.
P1997, P2003
Giufrè, M.
P1357
Giuliani, G.
P867
Giuliani, R.
P1117
Giulieri, S.
P1646
Giwercman, C.
P1298
Gladnishka, T.
P1024, P2058
Glasow, S.
P2055
Glazkova, S.
P826, P1102
Glupczynski, Y.
P611, P651,
P691, P702, P1230,
P1669, P1670
Glushkevich, T.
P1088
Gnanarajah, D.
P1990
Gnanasuntharam, Pirasanya P1036,
P1037
Gnanasuntharam, Piraveina P1036,
P1037, P1676
Gniadkowski, M. P640, P740, P743
Gobernado, M.
P1610
Gobernado Serrano, M.
P1200,
P1828, P1844
Gobin, P.
P804
Godinho, R.
P881
Godinho Santos, A.
P2168
Godino, A.
O415
Goering, R.V.
P1717
Goetz, A.
P2163
Goff, D.
P2090
Goga, M.
P2233
List of Authors
Gogishvili, S.
Goglio, A.
Number
P2040
P853, P872, P984,
P1919, P1998
Gogou, V.
P1363
Goh, M.L.
O240
Gohar, M.
P1158
Goheen, M.P.
P1453
Goic Barisic, I.
P1975
Goik, V.G.
P709
Goikoetxea, J.
P2093
P672
Gokcay Canpolat, A.
Golan, Y.
O504, P1968
Goldenberg, S.
P1978, P1992,
P1994
Goldenberger, D.
P1002, P2097
Goldschmidt, P.
P811
Goldwasser, F.
P1193
Golebiewska, A.
P966, P1075
Gomes, S.
O41
Gomes, T.A.
P1767
Gomes Neves, E.
P1354
Gómez, Lucía
P1629, P1657
Gómez, L.
P860, P870
Gomez, N.
P739
Gomez, V.
P2039
Gómez Luz, R.
P1378
Gómez-Garcés, J.L.
P2187
Gómez-Gil, M.R.
P1712
Gómez-Gómez, J.
P1474
Gómez-Gómez, M.J.
P1291
Gomez-Lopez, A.
O151
Gomez-Mampaso, E.
O247
Gómez-Mateos, J.M.
P1247
Gomez-Roman, J.
P1627
Gómez-Sánchez, M.C.
P718
Gómez-Sanz, E.
P845, P937,
P939,P1249
Gonçalves, D.
P716
Gonçalves, E.
O350
Gonçalves, J.
P2167, P2168, P2171
Gonçalves, M.
O350
Gonçalves, Tânia
P675
Gonçalves, Teresa
P1343
Goncharov, A.
P851
Gondret, R.
P745
Goñi, P.
P1378
Gontier, E.
P1671
González, A.
P1821
González, C.
O143
González, Juan
P900
Gonzalez, Javier
P2093, P2120
Gonzalez, J.L.
O241
Gonzalez, L.
P2018
González, T.
P1950
González, V.
P860, P870
González Barberá, E.M. P1200, P2142
González Cabrero, S.
P1923
Gonzalez Patzan, L.D.
P1533
Gonzalez-Alba, J.M.
P1455
González-Cabrero, S.
P1416
González-Martín, J.
P2025
González-Morán, F.
P1610
González-Ramallo, V.J.
O85
Gonzalez-Ruiz, A.
O85, P1289
Gonzalez-Sagrado, M.
P2029
Gonzalez-Sainz, F.J.
P1455
Gonzalo Giménez, N.
P1283
Goodwin, J.
O485
Name
Goorhuis, A.
Goossens, H.
Number
O503, P1009
O42, O475, P640,
P667, P971, P1038,
P1111, P1262, P1265, P1266,
P1267, P1268, P1269,
P1270, P1271, P1309,
P1310, P1375, P1571,
P1581, P1868, P1909
Goossens, M.
O42, P1111,
P1309, P1310
O504, P1968
Gorbach, S.
Gorbich, Y.
P708
Gorbunov, V.
P826
Gordon, N.
O194, P1626
Gorek Dilektasli, A.
P1457
Gorenko, L.
P1908
Gorgipor, F.
P1903
Görgün, S.
P1412
Gori, A.
P1046, P1233, P1337
Gorovenko, N.
P1908
Gorrini, C.
P877, P1892
Gosbell, I.B.
O299
Gosciniak, G.
O314, O494
Gosiewski, T. P1119, P1779, P1935
Goswami, U.
P1597
Göttig, S.
O215, P744, P2124
Gottleib, A.
O39
Gottlieb, T.
S339, P1202
Gottschalk, R.
P1328
Gottwald, H.-J.
P2055
Goudarzi, H.
P579, P2051
Gough, H.
P1793
Goukos, D.
P687
Gould, I.M.
S546, P765, P823
Goulenok, T.M.
P1217
Gouliouris, T.
O343
Gourbil, M.
P1192
Gourgiotis, D.
O416
Gourguechon, A.
P595
Gousia, P.
P555, P1098
Gouveia, C.
O350
Govorun, V.
P1889
Gowda, R.
P865
Goy, C.
P1408
Gozalan, A.
P962
Gozen, A.G.
P637
Grabein, B.
P921
Grabinska, J.
O314, O494
Grabmeier-Pfistershammer, K. P1498
Grabner, S.
P1827
Grabovskaya, K.
P1441
Grabowska, A.
P743
Grácio, M.A.
O495, P886
Graessel, S.
P1774
Graf, K.
P1243
Graf, N.
P2066
Grafakos, I.
P1565
Grahn, A.
P2162
Grainger, R.
P1397
Grambauer, N.
P1109
Gramegna, M.
P1403
Gramiccia, M.
P873
Grammaticou, M.
P687
Gramolelli, S.
P2213
Granado, D.
P2133
Grandesso, S.
P1682
Grandgirard, D.
O468, P1758
Grandin, A.
P1563
Name
Grandjean, G.
Graninger, W.
Granizo, J.J.
Grantham, K.
Grasman, M.E.
Grassi, B.
Grau, I.
Grau, S.
Graves, N.
Gravet, A.
Gravius, S.
Gravningen, K.
Gray, A.M.
Grayson, L.
Graziani, C.
Greatorex, J.
Green, K.
Green, L.K.
Green, M.
Green, S.
Greenberg, D.
Greenberg, R.
Greenberg, Z.
Grégoire, N.
Gregorek, H.
Gregson, D.B.
Gregson, L.
Greig, J.
Grenouillet, F.
Grenzner, E.
Greub, G.
Number
P561
O150, P929
P2128
O152
P1672
P1420
P1368
O86, P794, P1278
O147
O420
P557
P1734
P1280
P1293, P1574
P1357
O343
P973, P974, P1370
O389
P1702
O500
P1507
O425
P1420
P804, P811
P1462
P1600
O485
P2021
P1946
P878
S371, S278, P1483,
P1572, P1686, P1834
Greve, T.
P975
Gridelli, B.
P2075
Grif, K.
P1344
Griffiths, J.
P1049
Grigis, A.
P984
Grigorova, M.
P703
Grillet, S.
P2088
Grilli, E.
O46, P2184
Grillot, R.
P2131
Grima, P.
P590
Grishechkin, A.
P1818
Griskeviciene, J.
O42, P1111,
P1309, P1310
Griskevicius, L.
P669
Grisold, A.J.
P645, P926, P1827
Groenwold, R.H.
P1649
Gromova, D.
P2034
Grondin, S.
O356
Gros, A.
P2118
Groß, P.
P1772
Groß, U.
O315
Grosini, A.
P1919
Grossi, P.
S134, P2075
Grossman, T.
P762, P1142, P1149
Grosso, S.
P1806
Growcott, J.
P1438
Gruber, W.
O425, O426
Grubhoffer, L.
O359
Grui, E.
O146
Grumezescu, A.
P1044
Grundmann, H.
P1493
Grundy, K.
O313
Grünewald, T. P1028, P2055, P2169
Gruttadauria, S.
P2075
Gryniewicz, O.
P1570
Gu, J.
O246
Name
Number
Guahardo, T.
Gualdoni, G.
Guardabassi, L.
Guardiola, J.
Guarducci, R.
Gudiol, C.
Gudiol, F.
P1565
P1498
P559
P1958
P1499
P2244
P1278, P1459,
P1579, P1665
Gudlaugsson, O.
P1590
Guegueniat, J.
P1671
P1622
Guelfand, L.
Guembe, M.
P1621, P1630,
P1631, P1632
Guerra, B.
P1353
Guerra-Laso, J.M.
P1461
Guerreiro, L.
P1350
Guerrero, L.
P878
Güerri, R.
P1647
Guerriero, L.
P773
Guery, B.
P1785
Gueudet, T.
P1690, P1796
Guglielmetti, L.
P2004
Guglietta, A.
P1140
Guiguen, C.
P1956, P2118
Guillemot, D.
O482
Guillén-Grima, F.
P1292
Guillot, V.
O363, P1826,
P2166, P2170
Guilloteau, V.
P1382
Guimarães, M.
O350
Guimarães, M.A.
O350
Guimaraes, T. P2085, P2242, P2245
Guinand, R.
P1789
Guinea, J.
O479, P1099, P2072,
P2095, P2102, P2121
Guinea Ortega, J.
S76
Guitán Deltell, J.
P1200
Guitard, J.
P1946
Guiu, A.
O421
Gül-Yurtsever, S.
P710
Gulbinovic, J.
P669
Guldemir, D.
P962
Gulen, F.
P861
Gulen, G.
P1027
Guleri, A.
O47, O317, P909, P918,
P1177, P1288, P1379,
P1578, P1633, P1653
Gulesen, R.
P1985
Gulisano, C.
P793
Gulminetti, R.
P2172
Gumba, M.
P1992
Guna, M.R.
P2008, P2161
Gündüz, C.
P861, P875
Guner, R.
P1025, P1643
Guo, L.
P692
Guo, Q.
P634
Guo, X.
P1525
Guo, Y.
P1780
Gupalova, T.
P1441
Gurbuz, Y.
P1027
Gurler, N.
P1556
Gürman, G.
P1232
Gurpinar, T.
P2027
Gurtman, A.
O425, O426
Gurung, M.
P1777
Gustafsson, A.-K.
P1832
Gutierrez, A.
P2231
Gutierrez, M.
P2091
Final Programme
205
Chairs & Authors
Name
List of Authors
Name
Number
Gutiérrez, P.
Gutiérrez Cuadra, M.
Gutiérrez Rodríguez, M.P.
Gutiérrez Zufiaurre, M.N.
P1416
P1471
P1923
P1404,
P2206
Gutierrez-Cuadra, M.
O241
Gutierrez-Rave, V.
P2170
Gutiérrez-Zufiaurre, N.
P841
Gutmann, L.
O356
Guy, S.
P2243
O148
Guyaz, C.
Guzej, J.
P571
Gyssens, I.
P1004, P1293
Ha, Y.E.
P846, P1391,
P2082, P2084
Haag, H.
P1735, P1798
Haapasaari, M.
P1269
Haars, U.
P1589
Haas, D.
P926
Haase, G.
P928, P1791
Habanec, T.
P1567
Habib, M.
P1544
Hackel, M.
O524, P556, P565,
P566, P573, P576, P644,
P656, P678, P679, P732,
P932, P1057, P1120,
P1121, P1184, P1608
Hadad, S.
P693
Hadano, Y.
P2241
Hadaya, K.
P2088
Hadjihanas, L.
P687
Haefner, H.
P928, P1386
Haegelen, C.
P998
Haenni, M.
P595
Hafkin, B.
P1517, P1518
Hafner, D.
P808
Hagau, N.
P2111
Hagège, C.
P1317
Haghighi, A.
P869, P1704
Hagiwara, N.
P2065
Hagleitner, M.
P2107
Haidich, A.B.
P2175, P2176
Haigh, J.
P1991
Haigh, J.D.
P1842
Hainisteanu, T.
O385
Hait, H.
P1528
Hajdu, E.
P1220
Hajikhani, B.
P585
Hajilooi, M.
P1545, P1775
Hajimehdipoor, H.
P1156
Hajjar, M.
P1056
Hak, E.
P969
Hakanen, A.
P690, P1605
Hakeem-Habeeb, A.
O47
Halaby, T.
P757, P1204
Halánová, M.
P2063
Haldorsen, B.
P1361, P1837
Halfmann, A.
P2160
Halim, K.
P1418
Hall, Anthony
P1992
Hall, Anne
P801
Hall, L.M.
P1810
Hallek, M.
O87, P2248
Hällgren, A.
P955
Halliday, C.
P2092
Halligan, E.
O139
Hallin, M.
P778, P1236, P1721
Name
Hamadeh, M.B.
Hamasuna, R.
Number
P653
P603, P623,
P1399, P1402
Hamet, M.
P1660
Hamilton, D.
P996
Hammas, B.
P1700
Hammer, M.
P1819
Hammerschmidt, S.
P1897
Hammerum, A.M. P658, P660, P662,
P923, P1746
P601
Hamouda, A.
Hamprecht, A.
P916, P2115, P2124
Hamzi, W.
P844
Han, C.H.
P1689
Han, S.
P1745
Han, S.B.
P1356, P2053
Hanahoe, B.
O106
Hanaki, H.
P1604
Hanberger, H.
P1488
Hancerli Torun, S.
P1556
Haneef, S.
P2007
Hanley, B.
P1074
Hannachi, N.
P2229
Hannecke, L.
P1819
Hannisdal, A.
P752
Hannon, M.
O210, O212
Hanselle, T.
P1897, P1901
Hansen, B.E.
P2083, P2078
Hansen, D.S.
O497, P658,
P660, P1921
Hansen, F.
P658, P660, P662
Hansen, S.
P1110, P1313
Hansen, S.G.K.
P658
Hansen, W.L.
P1917
Hanses, F.
P1772, P1774
Hanulik, V.
P681, P896
Hao, X.
O246
Harada, S.
O101
Harada, T.
P1054
Harbarth, S.
S60, S262, S281,
P650, P1293
Hardwigsen, J.
P1959
Hardy, D.
P1696
Hardy, K.
O500, P840, P942,
P1710, P1720, P1724
Harizi, H.
P2038
Harmanus, C.
P1962
Harms, M.
P859
Haro, D.
P1629, P1657
Harper, M.
P1451
Harrington, G.
P952
Harrop, C.
O250
Hart, J.
P1242
Härtel, C.
P1223
Hartemann, P.
P1335
Hartl, R.
P689
Hartley, T.
O469
Hartzen, S.H.
P1905
Harxhi, A.
P2233
Hasanoglu, I.
P1025, P1643
Hasbun, R.
P2090
Hascelik, G.
P915, P2232
Hashemi, S.
P1545, P1775
Hashimoto, J.
P1401
Hashmey, R.
P653
Hasman, H.
P559
Hassan, H.
P911
Hassan, I.
O312
Final Programme
Name
Number
Hassan, Z.
P585
P1411
Hassanpour, G.R.
Hassanpour, P.
P1423, P1907
Hassar, M.
P2217
Hassouna, H.
P1194
Hatano, T.
P2023
Hatta, M.
P632
Hatzaki, D.
P1095, P1396
Hatzimiltiadis, S.
P1846
Hausfater, P.
O48
O141
Havill, N.L.
Havlicek, V.
P1940
Hawkey, P.
O104, O500, S534,
P840, P942,P1720,
P1710, P1724,
P2006, P2044
Hawser, S.
O524, P556, P565,
P566, P573, P576,
P644, P656, P678,
P679, P732, P932,
P1120, P1121, P1608
Hawtin, P.
O500
Hay, G.
O297, P778
Hayami, H.
P1399, P1402
Hayes, D.
P1086
Hayez, D.
P1502
Hays, J.
P1347
Hayward, A.
P1381
Hazlett, F.
O492
He, C.
P1364, P1479
He, Q.
O523
Healy, L.
O39
Healy, M.
P2046
Heap, J.T.
P1744
Heath, C.H.
O306
Heath, P.
P1898
Hechler, C.
P1028
Heck, M.E.
P1703
Heczko, P.
P1119, P1779
Heddema, E.
P1698
Hedin, G.
P925
Hedin, K.
P1551
Hedlund, J.
P1580
Heep, M.
O85, P1289, P1538,
P1539, P2091
Heerinckx, F.A.
P1521
Hegemann, J.
S276
Heginbothom, M.
P1255
Hegstad, K.
P923, P924, P1361
Heier, A.
P1438
Heijmans, R.
P1002
Heiling, B.
P1827
Heilmann, F.
P757
Heim, J.
P1823
Heimer, D.
P924
Hein, I.
P1904
Heinz, W.
P2115
Heinzel, E.
P2160
Helali, N.
P1213
Helemejko, I.
O494
Helesic, J.
P1567
Helie, M.C.
P589
Hell, M.
P1208, P1639
Helleberg, M.
O490
Heller, I.
P1344
Hellin, T.
O366
Hellwig, E.
P578
Helmin-Basa, A.
P1762
Name
Number
Helmuth, R.
P1353
P658, P660, P662
Heltberg, O.
Hémery, F.
O40
Hempel, C.
O471
Henderson, K.
P1466
Hendriks, W.
P1237
Heng, N.C.
P1105
Henkhaus, J.
P1714
Henneke, P.
P1758
Hennequin, C.
P1946
P1591
Hennessey, E.
Henriques, I.
P639, P1814
Henry, M.
P720, P2221
Hens, N.
P1265
Hensgens, M.P. O503, P1009, P1962
Hentic, O.
P2247
Heo, S.T.
P1198
Hepnar, D.
P1172
Herbrecht, R.
S329, P1951, P2153
Hercun, M.
P941
Herda, M.
P743
Hermans, P.
P1558
Hérnandez, C.
P1557
Hernandez, E.
P663
Hernández, M.
P1723
Hernandez, V.
P796
Hernández Almaraz, J.L.
P2143
Hernández Molina, J.M.
P2143
Hernandez Sarmiento, J.M.
P2039
Hernández-Betancor, A.
P2227
Hernández-Cáceres, I.
P1675
Hernández-Pando, R.
P2042
Hernández-Quero, J.
O363, P1852
Hernández-Torres, A.
P1474
Heropolitanska-Pliszka, E.
P1462
Herranz, M.
P1077
Herrero, J.A.
P1474
Herrero, M.
P1475
Herrmann, B.
P1734
Herrmann, M. P1122, P1738, P1967
Hershberger, E.
P1519, P1520
Herwegh, S.
P2101
Hesje, C.
P1128
Heslop, H.
S137
Hesselbjerg, A.
P1819
Hetem, D.J.
P1481
Heurer, O.
P1300
Heurté, D.
O32
Heussel, C.P.
S541
Heyligen, J.
P1829
Heyman, I.
P796
Heymans, C.
P1924
Heymans, R.
P626
Hiba, V.
P1196
Hicks, L.
O349
Hicks, R.
P2243
Hidalgo, G.
P860, P870
Hidalgo, R.
P841
Hiemstra, P.
S15
Higgins, P.G.
O192, O215, O525,
P1184, P1706, P1731
Hill, R.
O349, P686, P829
Hilts, A.
P2112
Hilvering, B.
P1613
Himsworth, D.
P586
Hindiyeh, M.
P652
Hindler, J.
P774
Hinrichs, S.
P1714
List of Authors
Hinterholzer, G.
Hira, P.R.
Hirakata, Y.
Hirankarn, N.
Hiransuthikul, N.
Hirmondo, R.
Hirsch, E.B.
Hirsch, H.H.
Hirschl, A.
Hirschl, M.
Hise, A.
Hites, M.
Hitkova, H.
Hitoshi, K.
Hitzenbichler, F.
Hlobil, H.
Ho, P.L.
Hoang, L.
Hoban, D.
Number
P1001
P997
P632
P2215
P2192
P1017
P790
S136
P929
P1737
O492
P2109
P703, P1145
P632
P1772
O315
P838, P2005
O304, P843
O524, P556, P565,
P566, P573, P576,
P644, P656, P678,
P679, P732, P932,
P946, P1057,
P1120, P1121,
P1608
Hocès De La Guardia, A.
O521
Hochman, M.
P1331
Höck, M.
S437
Höckerstedt, K.
P2089
Hocquet, D.
P1750
Hodiamont, C.
P1822
Hoebe, C.J.
P1709
Hoeck, M.
O98, P921
Hoekstra, W.J.
O94
Hoepelman, A.
S257
Hoerauf, A.
P557
Hofer, S.
O472, P2201
Hoffner, S.
P2018, P2034
Hofhuis, A.
O360
Hogan, P.
P2145
Hogea, E.
P1303
Høiby, N.
P797, P1465, P1931
Højbjerg, T.
P658, P660, P662
Hola, V.
P904, P1861
Holban, A.
P1044, P1751, P1752
Holden, P.
P779
Holfelder, M.
P638, P1988
Hollister, A.
P809
Holm, A.
O346
Holmberg, A.
P1858
Holmes, A.
P1717
Holmes, D.
O90
Holt, K.
P558
Holton, J.
P1963, P1964
Homa, M.
P1947
Homans, S.W.
P1051
Homola, L.
P1567
Honda, M.
P603
Hong, H.K.
P1308
Hong, J.
P775
Hong, S.
P770
Honig, V.
O359
Hönigl, M.
P645
Honoré, P.
O45
Hood, K.
P1266, P1267
Hook, E.
P1875
Hooper, D.
S517, P1506
Hoosen, A.A.
P1888
Name
Hoover, J.
Hope, R.
Hope, W.
Number
P1508
P1104, P1177, P1231
S225, S430,
O476, O485
Höpken, M.-E.
P1315
Hopkins, S.
O42, P1111,
P1309, P1310
Hoppe, T.
P557, P1983
Hoque, A.
P1347
Horbach, T.
P819
O86, P794,
Horcajada, J.P.
P1647, P1934
Horch, R.E.
P820
Horhat, F.
P1303
Hornsey, M.
O194, O519, P934
Horrevorts, A.M.
S132
Horsman, G.B.
O304
Horstmann, R.
P2034
Hortal, J.
O157
Horton, R.
P628
Hosgör-Limoncu, M.
P710
Hosmane, S.
P1653
Hosogaya, N.
P2148
Hotzel, H.
P905
Houf, K.
P593
Hovi, T.
O409
Howard, J.
P1081
Howard, S.J.
O485, P2149
Howe, R.
P1603
Hoxhaj, O.
P2233
Hoyo, I.
P2079
Hrabak, J.
P740, P1172
Hricova, K.
P681
Hristea, A.
P1495, P2182,
P2189, P2230
Hruzik, A.
O315
Hryniewicz, W.
O348, P743, P966,
P1075, P1256
Hsiao, R.
P2050
Hsieh, C.
O365, P1960, P2062
Hsieh, P.F.
P1741, P1850
Hsiung, A.
P772
Hsu, C.R.
P1742
Hsu, L.Y.
O193, P1176
Hsueh, P.R.
S545, P1083,
P1469, P1476
Htoutou Sedlakova, M.
P681
Hu, F.
P682
Hu, F.C.
P670
Hu, X.
P2045
Hu, Y.
P569, P1364
Hualde, M.
P1191
Huang, David P1534, P1535, P1536
Huang, Daniel
P1230
Huang, H.
P2037
Huang, M.
P1875
Huang, S.
P2037
Huang, T.D.
P691, P702
Huang, X.
O43, P1281
Huang, Y.
P1083, P1469, P1476
Huang, Y.-C.
O305
Huband, M.
P952, P1161
Hübner, I.
P1589
Hübner, M.
P1650
Hudson, B.
O88
Hughes, C.
P1333
Huguenin, A.
O309
Huh, J.
P1290
Name
Number
Huhulescu, S.
Huicho, L.
Huijts, S.M.
Huisman, A.
Hujer, A.M.
Hujer, K.M.
Huletsky, A.
Hull, M.
Hulscher, M.
Humphrey, B.
Humphrey, G.
Humphreys, H.
P1208, P1729
P1562
P1275, P1276
P1613
P615, P1669, P1706
P615, P1706
P589
P843
P1285, P1384
P1667
P1793
S29, O210, O212,
P666, P972, P1329
Hunfeld, K.P.
O215, P1977, P2054
Hung, C.
O365, P1552,
P1960, P2062
Hunsicker, M.
P1899, P1900
Huntington, P.G.
P931, P1972
Huovinen, P.
P1369, P1605
Hupkova, H.
P1759, P2122
Huq, M.
P1347
Hur, A.C.
P1198
Hur, J.A.
P1198
Hur, M.
P2048
Hurlburt, D.
P992
Hurukawa, T.
P715
Hussain, Y.
P1990
Hussein, K.
P1458, P1663
Hutchinson, J.
S282
Hvolris, J.J.
P1628
Hwang, Y.
P775, P1877
Hyman, J.M.
P1824, P1825
Hypolite, M.
P2138
Hyrossova, P.
P1863
Hyttel, P.
O471
Hyun, H.J.
P2225
Iannece, M.D.
P1654
Ibañez, M.
P1324
Ibrahem, S.
P1733
Ibrahim, M.
O526
Ibrahimagic, A.
P553
Ibrahimi, A.
P583
Ichiyama, S.
P665, P1362
Idelevich, E.A.
P1186
Iebba, V.
P728
Ieven, M.
P971, P1032, P1038,
P1571, P1581,
P1871, P1868
Igimi, S.
O101
Iglesias, N.
P883, P1409
Ignatyeva, O.
P2034
Ignatyeva, S.M.
P2129
Igolkina, S.
P2237
Ihan, A.
P1708
Ijzerman, E.
S28
Ikonomidis, A.
P717
Ikryannikova, L.
P1889
Ilaria, V.
O415
Ilebrekke, L.
P1306
Iliadou, H.
P1565
Ilina, E.
P1889
Iliopoulos, G.
P2207
Ille, T.
P553
Illychysn, A.
P865
Ilmoja, M.
P1568
Imamura, Y.
P2148
Imberti, R.
P814
Name
Number
Imnadze, P.
P891
P2018
Imperiale, B.
Inamatsu, T.
P1433
Inan, A.
O294
Inan, D.
P1394
Indinnimeo, M.
P2200
Infante, A.
P961, P2231
Ingebretsen, A.
O345, P763
Ingemann, T.
P1084
Ingold, A.
P617
O295
Íñigo, M.
Inoue, M.
O240
Ioannou, A.
P1636
Ioannou, S.
P1464
Ion, D.
P2189
Ion, M.
P1495, P2230
Iordanova, R.
P1145
Iosifidis, E.
O49
Iotti, G.
P814
Ip, M.
P840, P837
Ippolito, G.
S221, P872, P1284,
P1319, P1328,P1499, P1645
Ippolito, J.
P1166
Iqbal, J.
P997
Iranzo Tatay, A. P1200, P1828, P1844
Iraqi, F.
S69
Iredell, J.
O88, P560,
P1811, P1930
Isaeva, A.
P2034
Isakov, E.
P1331
Isaksson, B.
P955
Isalska, B.
P1334
Isea Peña, M.C.
P1606
Iseli, P.
P2001
Iseni, F.
P2208
Ishibashi, N.
P632
Ishibashi, T.
P805, P809
Ishihara, S.
P816, P2065
Ishii, Y.
O101, P1390
Ishikawa, K.
P1395, P1399, P1402
Isikoglu, S.
P1025
Iskender, A.
P1228
Islam, M.
P1347
Ismail, N.A.
P1888
Ison, M.G.
P2074
Issa, R.
P1021
Isturiz, R.
S456
Iten, A.
P874
Ito, S.
P2065
Ito, Y.
P665, P1362
Ittah-Desmeulles, H.
P742
Ittycheria, C.
P1612
Itzhaky, D.
P1406
Ivanchik, N.
O419, P1042,
P1576
Ivanov, I.
P703, P1711, P1718
Ivanova, K.
P1718
Ivanova, V.
P1024, P2058
Iversen, A.
P654
Iversen, P.
O411, O469, P1163,
P1507, P1511, P1526,
P1527, P2211
Iwabuchi, H.
P1463
Iwalokun, B.
O409
Iwamoto, A.
P1604
Iwanczak, B.
O314
Iwen, P.
P1714
Iyer, S.
P1974
Final Programme
207
Chairs & Authors
Name
List of Authors
Name
Izadi, M.
Izdebski, R.
Izumikawa, K.
Number
P568, P864
P743
P2140, P2141, P2148
Jabs, W.
P1539
P2177, P2178
O425, O426
P1612, P2179
P1612, P2179
P784
P2109
O45
P1061
P1133
P1504
P1423, P1907
P2051
P1991
P768, P2000
O243
P669
P690, P1369,
P1733, P1986
Jamart, J.
P1230
James, V.
P1300
Jamme, F.
P1500
Jamrozy, D.
P1016
Jamshidi, M.
P2015
Janbakhsh, A.
P1545
Jancura, P.
P1768
Janda, W.
P1058
Jang, I.H.
P777
Janini, L.
P2165
Jankowska, I.
O30
Janlav, M.
P1071
Jannetto, P.
O33
Janoir, C.
O356
Jans, B.
P691, P1268,
P1269, P1270
Jansen, A.
O311
Jansen, K.
O426
Jansen, R.
P1910
Janson, H.
P1700
Janssen van Doorn, K.
O45
Jansz, A.R.
P1802, P1887
Januszkiewicz, A.
P588
Jarcuška, P.
P2063
Jarlier, V.
P605
Jarque, I.
P2142
Jarvis, R.
P686
Jaton, K.
O254, P1572,
P1686, P1834,
P1916, P2081
Jaulhac, B.
P1770
Javad, A.
P653
Jawahara, S.
P1785
Jayawardene, D.
O425, O426
Jeanes, A.
P1381
Jeannin, A.
P1951
Jeannot, K.
O289
Jeffferson, J.
P1205
Jelastopulu, E.
P2218
Jendresen, C.
O471
Jenkins, A.
P752
Jenkins, D.R.
P1115
Jenkins, H.T.
P1051
Jenmalm, M.
S394
Jensen, A.G.
P797
Jackson, A.
Jackson, L.
Jacob, A.
Jacob, C.
Jacob, J.
Jacobs, F.
Jacobs, R.
Jacobsen, K.
Jacobus, N.V.
Jacqueline, C.
Jahangiri, S.
Jahani Sherafat, S.
Jain, A.
Jain, S.
Jaksch, P.
Jakubauskas, A.
Jalava, J.
Name
Jensen, J.S.
Jensen, R.
Number
P623, P1298
P1840, P1954,
P2144, P2149
Jensen, T.G.
O346
Jensen, U.S.
P1914
Jensenius, J.C.
P2087
Jeon, M.H.
P1542
Jeong, S.
P1745
Jeong, S.H.
O527, P597, P655
Jeong, S.Y.
P1308
P1466
Jeppesen, C.
Jeverica, S.
P1708
Jevtovic, D.
P2188
Jeyaratnam, D.
P1254
Jezek, P.
P2043
Ji, X.
P2108
Jian, Z.J.
P1724
Jiang, Z.D.
P1544
Jimenez, A.
P2008
Jiménez, S.
P860, P870
Jiménez-Álvarez, R.
P1425
Jiménez-Mejias, M.E.
P1291
Jin, H.Y.
P1308
Jin, J.S.
P1777
Jin, S.
P1745
Jing, F.
P1224
Jing, H.
O93
Jirawattanapisal, T.
O249
Jo, E.
P1743
Johansen, H.K.
P658, P660, P797,
P903, P2149
Johansen, I.S.
P2020
Johansen, M.E.
O483
Johansson, N.
P1580
John, T.
P1612, P2179
Johnson, A.
P565, P566,
P656, P679
Johnson, B.
O524, P556,
P576, P732, P932,
P1120, P1121
Johnson, J.
O524, P556, P576,
P732, P946, P1057,
P1121, P1608
Johnson, P.D.
P1574
Johnson, S.
S111
Johnston, S.L.
O416
Join-Lambert, O.
P1217
Joly-Guillou, M.
P664, P1382
Jonaidi, N.
P568
Jonaidi Jafari, N.
P864
Jonas, D.
P852
Jonas, V.
P1918
Jones, B.
O91, O480, P1955
Jones, G.
P996
Jones, L.S.
P1512
Jones, M.
P1146
Jones, R.
P613, P614, P616,
P652, P722, P747,
P930, P943, P944,
P945, P1055, P1126,
P1129, P1130, P1131,
P1132, P1134, P1136,
P1137, P1138, P1161, P1179,
P1367, P1452, P1607
Jones, T.
O425
Jones-Dias, D. P562, P1359, P1366
Jonjic, S.
S374
Jönsson, B.
P1260
Final Programme
Name
Joo, E.J.
Jorens, P.
Jørgensen, C.
Jorup-Rönström, C.
Joseph, L.
Joseph, R.
Joshi, R.
Joshi, S.
Jost, M.
Jou, R.
Jou, R.
Jouannet, C.
Jouini, A.
Joung, M.K.
Jourdain, A.
Jové, T.
Juan, C.
Juhas, M.
Juiz, P.M.
Jun, S.
Jun, Y.
Jung, S.
Junghanss, T.
Junor, A.
Jurankova, J.
Jureen, P.
Juškaite, R.
Justesen, U.S.
Justinger, C.
K
aafarany, I.
Kaasch, A.J.
Number
P846, P1391,
P2082, P2084
O45
P1444
P1973
P2099
P1788
P711
P1696
P820
O382
P2037
P696
O103, P1249
P1391, P2082
P2151
P639
O288, P604
O473
P1833
P1777
P563
P1549
E270
P2137
P1803, P1937
P2018
P707
O346, P662,
P753, P1819
P813
O521
P852, P916,
P948, P1589
Kaase, M.
P1041, P1173
Kaatz, G.
P935
Kabir, A.Y.
P895
Kabir, M.
P654
Kable, K.
P2092
Kader, C.
P1008
Kadlec, K.
P933
Kadowaki, M.
P1594
Kadri, Y.
P659
Kafarskaya, L.I.
P1970
Kafetzis, D.A.
O416
Kagkalou, G.
P1018
Kahl, B.
P1186
Kahlert, C.
P1321
Kahlmeter, G.
E116, P746, P747,
P748, P749, P750,
P751, P752, P753
Kahsai, A.
P925
Kairis, D.
P957, P1348
Kaiser, L.
S135, P2088
Kaiser, R.
S169
Kaitsa-Tsiopoulou, E.
P1491
Kaitsa-Tsiopoulou, H.
P1348
Kakalou, E.
P2180
Kakeya, H.
P2148
Kaku, M.
P632, P674
Kal Cakmakliogullari, E.
P1681
Kalandadze, I.
P2040
Kalani, M.
P1428, P1429
Kalantar, E.
P1853
Kalantzi, A.
P2067
Kalaycioglu, A.T.
O37
Kalenic, S.
P648, P704, P1335
Name
Number
Kalicinski, P.
O30
P1580
Kalin, M.
Kalka-Moll, W.
P1035, P1400
Kalkanci, A.
P1740
Kallesøe, B.H.
P658
Kallipolitis, B.
P1061
Kalluinen, M.
P1986
Kalogeras, G.
P1095, P1396
Kalogeropoulou, E.
P1835
Kalpaka, A.
P1022
O354
Kalpoe, J.S.
Kalyasnikova, N.
P1882
Kamaria, F.
P1018
Kambal, A.
P1418
Kamberovic, F.
P553
Kamperogianni, M.
P1492
Kampinga, G.A.
O478
Kampschreur, L.M.
P995
Kanafani, Z.
P1194
Kanaki, S.
P822, P2010
Kanamori, H.
P632
Kandhavelu, J.
P1727
Kaneko, T.
P715
Kanellaki, S.
P1252
Kanerva, M.
P1269
Kang, C.I.
P846, P1391, P1549,
P2082, P2084
Kang, H.J.
P2049
Kang, M.
P692, P1364,
P1479, P2035
Kang, S.J.
P846, P1391,
P2082, P2084
Kania, A.
O494
Kanj, S.
E272, P1194
Kanji, J.N.
O304
Kankawinpong, O.
P1445
Kansouzidou, A.
P1018
Kant, S.
P2000
Kantarci, G.
P892
Kantardjiev, T.
P674, P703,
P1711, P1718
Kantipong, P.
O367
Kantsø, B.
P1444
Kanyilmaz, D.
P1222, P1659
Kanyo, Z.
P1162, P1165, P1166
Kao, C.
P1548
Kapan, S.
O391
Kaparos, G.
P2067
Kapetanakis, J.
P1322
Kaplan, B.
O469, P1434
Kaplan, N.
P1517, P1518
Kappeler, N.
P1299
Kapsali, E.
O35
Kara, A.
P1085
Kara, O.
P2240
Kara-Zaitri, C.
P1326
Karabaxoglou, D.
P1018, P1866
Karabetsos, D.
P1636
Karabinis, A.
P1492
Karabournidis, A.
P1018
Karaferi, A.
P1389, P1393
Karageorgopoulos, D.
P1175
Karagiannis, C.
P1611
Karah, N.
P705, P1837
Karahan, Z.C.
P902
Karaiskos, I.
P1252
Karaiskos, K.
P1238
Karaitianou-Velonaki, A.
P1251
List of Authors
Number
Karakalpakis, D.
P1873
P1769
Karakas, H.M.
Karakaya, J.
P2232
Karaman, K.
P871
Karamanos, N.K.
P1763
Karampogia, P.
P1491
Karan, L.
P1882
Karasahin, O.
P734
Karawajczyk, A.
O481
Karfunkel, D.
O100
P621
Kargar, M.
Karimi, Z.
P1423
Karinaga, R.
P2023
Kariuki, S.
P558
Kärki, T.
P1269
Karlowsky, J.
O250
Karlsson, C.
P751
Karlsson, L.
P1261
Karpanen, T.J.
P1209
Karpinski, T.M.
O390
Karpiskova, R.
P896
Karpov, I.
P708
Karra, C.
P567, P575
Kartali, S.
P970
Kartali-Ktenidou, S.
P957
Karunakaran, A.
P1227
Karutha Pandian, S.
P1862
Kashef, N.
P1157
Kasinathan, V.
P712
Kasper, Y.
P1897
Kassis, I.
P1458, P1663, P2030
Kassner, J.
P1152
Kast, H.
P2111
Kasztelewicz, B.
O30, O31,
P1462, P1762
Katouli, M.
P1063
Katsiari, M.
P1332
Katsifa, H.
P1348
Katz, B.
P1065
Katz, K.C.
P698
Kaufmann, S.
S464
Kaul, I.
P2248
Kavanagh, J.
P600
Kawai, Y.
P989, P1422
Kawakami, S.
P715
Kawamura, I.
P2241
Kawase, M.
P1160
Kawkitinarong, K.
O249
Kaya Kalem, A.
P1025, P1643
Kaya Ozdogan, D.
P1906
Kayaaslan, B.
P833
Kayabas, U.
P1769
Käyhty, H.
P1078
Kazakov, I.
P826
Kazemier, G.
P2078, P2083
Kazila, P.
P1348
Kazma, M.
P667, P1331
Kazuhiro, T.
P1609
Kazura, J.
O492
Kazzi, N.
P1072
Kc, K.
P564
Kean, Y.
O504, P1968
Kearns, A.M.
O349, P829
Keating, D.
P600
Kechrid, A.
P1555
Kee, D.
P1330
Keel, R.
P806, P1505
Kees, F.
P813, P819, P820
Name
Number
Kees, M.G.
P813, P819, P820
P769, P1896
Keevil, C.W.
Kehagia, M.
P1180
Keijser, B.J.F.
P936
Keil, A.
O308
Keil, F.
P2091
Keimel, M.
P1827
Keizo, Y.
P1609
Kelchlin, P.
P779
Kelleher, M.
P1470, P1592
P652, P735, P1595
Keller, N.
Keller, P.M.
O213
Kelley, K.A.
P1446
Kelly, A.F.
P1016
Kelly, M.J.
P1266
Kelly, M.L.
P1744
Kelly, S.
O423
Kelvin, D.
P1765
Kema, G.H.
O481
Kemp, C.L.
P721
Kemp, M.
O346, P979, P1819
Kempf, M.
P882
Kempf, Marie
O420
Kempf, V.A.
P744
Kenesei, É.
P1216
Kennedy, K.
P830
Keramat, F.
P1545
Kerbi-Hamimed, N.
P2239
Keren, L.
P1148
Kergoulay, I.
P1317
Kern, A.
P1770
Kern, J.M.
P1208
Kern, P.
P1589
Kern, W.V.
P852, P1112, P1589
Kerschner, H.
P689
Kesecioglu, J.
P1116
Keshavarz, A.
P869
Keshavarz, H.
P1411
Kesidou, F.
P1348
Kesik-Szeloch, A.
P1152
Keske, S.
P1025, P1643
Kestler, M.
P1468
Keten, D.T.
P1394
Kett, D.
O153, P1536
Keuleyan, E.
P703
Keynan, Y.
O387
Khalid, N.
P997
Khalilzadeh, M.
P1410
Khammari, M.
P2229
Khan, A.
P666
Khan, H.
P1978
Khan, Z.
P1939, P2099
Khanafer, N.
O498, P1489
Khanom, S.
P2006
Khardori, N.
O195
Khetan, A.
P1011
Khin, L.
P2153
Khosravi, A.
P1431
Khostelidi, S.N.
P2129
Khuchua, T.
P891
Ki, H.
P1549
Kiany, S.
P1428, P1429
Kiechle, F.
P906
Kiertiburanakul, S.
O367
Kilic, A.
P637, P1927
Kilic, H.
P1064
Kilic, S.
P1027
Kilpatrick, C.
O140
Name
Kim, B.
Kim, B.N.
Kim, C.
Kim, C.H.
Kim, E.
Kim, E.S.
Number
P1777
P1197, P1198, P2154
P1745
P2154
P1312, P1624
P1197, P1198, P1308,
P1312, P1648, P2154
Kim, H.
P2048
Kim, H.J.
P1743
Kim, H.B.
P1198, P1308, P1648
P2049
Kim, H.S.
Kim, H.Y.
P1198, P1308, P1312,
P1598, P1648
Kim, J.A.
P1440
Kim, Jieun
P1392
Kim, Jungok
P846, P2084
Kim, J.M.
P836
Kim, June Myung
P1598
Kim, J.S.
P2049
Kim, Ji Young
P2048
Kim, Ja-Young
P714
Kim, Jin Yong
P1308, P1312
Kim, K.
P1976
Kim, M.
P1637
Kim, M.K.
P775
Kim, M.J.
P1290, P1598
Kim, M.N.
P647, P1624, P1625
Kim, N.J.
P1198
Kim, S.
P1624, P1625
Kim, S.W.
P1549
Kim, S.I.
P1598
Kim, S.R.
P1308
Kim, S.Y.
P714
Kim, W.
P1290
Kim, Yonggoo
P2053
Kim, Yoonjung
O527, P655
Kim, Y.K.
P1198, P1308,
P1312, P1745
Kim, Yang Soo
P1598
Kim, Yeon-Sook
P890, P1549
Kimani, J.
O387
Kimani, M.
O387
Kingsley, R.
P558
Kipnis, E.
P1785
Kiratisin, P.
P1340
Kiraz, N.
P2146
Kirbs, C.
P817
Kiremitci, A.
P1225
Kirikou, H.
P960
Kirkpatrick, W.
O94, P1955
Kirveskari, J.
P690
Kisac, P.
P1651
Kist, M.
P578
Kitagawa, M.
P632
Kitka, S.
P992
Kitti, G.
P1220
Kitzis, M.D.
P1787
Kiveryte, S.
P669
Kiyota, H.
P1399, P1402
Kizilarslanoglu, M.C.
P1085
Kjær Hansen, S.G.
P660
Kjeldsen, S.
P1588
Klaassen, C.H.
S75, O149,
O481, P1943
Klastersky, J.
E274, S400
Kleefstra, M.
P1801
Kleiboeker, S.
O152
Klein, A.
P1331
Name
Number
Klein, C.
P2055, P2169
P2248
Klein, F.
Klein Gunnewiek, J.
P1617
Kleisarchaki, M.
P822
Kletsas, D.
O416
Klibi, N.
O103, P1249
Klimko, N.N.
P2129
Klimova, E.
P1889
Klingelbiel, B.
P1315
Klingspor, L.
P1913
P1061
Klitgaard, J.K.
Klockars, O.
P1450
Kloft, C.
P806, P817
Kluytmans, J.
O211, P1728, P1481
Kmet, V.
P676
Kmetova, M.
P1759
Knaack, D.
P1223
Knapp, F.
P2124
Knetsch, C.W.
P1012
Knobel, H.
O86, P1647
Knobloch, J.
P941, P1223, P1795,
P1808, P1835
Knoester, M.
P1831
Knudsen, E.
O346
Knudsen, J.
P662, P830, P922,
P1047, P1914
Knudsen, L.S.
P1084
Ko, K.
P1549
Ko, S.Y.
O34
Ko, W.
P1552
Kobayashi, N.
P1378
Kobayashi, T.
P603
Kocagöz, T.
P1412
Koch, A.
P1386
Koch, C.
P615
Kochan, P.
P1119
Köck, R.
P835
Kocnarova, N.
P1559
Koehorst, N.
P757
Koene, M.G.
P1962
Koeth, L.
P1065, P1066
Kofol, R.
P1365, P2100
Koh, T.H.
P1176
Kohda, N.
P1433
Kohl, V.
O87
Köhler, T.
P1750
Kohno, S.
O83, O84, P809, P967,
P2140, P2141, P2148
Kojima, K.E.
P1849
Koksal, I.
O413, P1297, P1394
Kolar, M.
P633, P681, P896
Kolbin, A.S.
P2129
Kõljalg, S.
P1107
Kollaras, P.
P2175, P2176
Kollaritsch, H.
P1560
Koller, W.
P1110
Kollmar, O.
P813
Kolmos, B.
P587
Kolmos, H.
P1061
Kolodzieva, V.
P851
Kolonitsiou, F.
P957, P1760,
P1763
Komitova, R.
P1089
Kommerell, M.
P1798
Komorowski, L.
P1419
Komp Lindgren, P.
P1450
Kon'kova-Reidman, A.
P1818
Kong, D.
P2114
Final Programme
209
Chairs & Authors
Name
List of Authors
Name
Number
Kong, H.
Konings, I.C.
Konkoly-Thege, M.
Konopnicki, D.
Konsil, J.
Konstantinidis, T.
Konstantis, A.
Kontos, F.
Kontsevaya, I.
Koo, S.H.
Kooistra-Smid, A.M.
Koomanachai, P.
Kopinc, R.
Korac, M.
Körber-Irrgang, B.
P912, P1980
P2078, P2083
P919, P1106
P2183
P1295
P927
P888, P1022
P2003, P1997
P1999, P2034
P629
P1932
P1003
P2028
P2188
P754, P808,
P1097, P1123
Korczak, B.
O97, P1168,
P1514, P1515
Kordasti, S.
P2105
Kordossis, T.
O364
Koren, J.
P1759
Kormali, L.
P736
Kornum, J.B.
P1586
Korobova, M.
P2034
Kortbeek, L.M.
O360, P859
Korukluoglu, G.
O37
Korver, J.
P1039
Koskela, S.
P690
Kosmadakis, G.
P2003
Kossivakis, A.
P1867
Kostis, E.
P1238
Kostourou, S.
P1323, P1327
Kostrzewa, M.
O347, S435, P758,
P1839, P1889
Kostykova, E.
P1042
Kostyukova, N.
P1908
Kotadia, R.
P1696
Kothari, N.
P1440
Kothari, S.
P1440
Kotila, S.
P1733
Kotlovsky, T.
O100, P667, P1148
Kotsaki, A.
O467
Kotsali, S.
P2067
Kotsiou, G.
P931, P1972
Kotulova, D.
P2122
Kouatchet, A.
P1217
Koukila-Kähkölä, P.
P2098
Koukou, E.
P1611
Koup, J.R.
P1518
Kouppari, G.
P1251
Kourbeti, I.
P1636
Kouroupi, M.
P888, P1022
Kouskouni, E.
P2067
Koutete, D.
P1611
Koutsia-Carouzou, C.
P957, P1491
Koutsoukou, A.
P567, P575,
P1125
Kovacs, L.
P1759
Kovács, L.
P1522
Kovalev, A.
P2034
Kowalczyk, F.
P664
Kowarik, M.
P1446
Koziel, J.
P1780
Kozlov, R.
O419, P1042, P1376,
P1573, P1576
Kozlova, L.
P1376
Kozlova, N.S.
P709
Krajiw, S.
O36
Name
Kratzer, C.
Number
O150, O477,
P929, P1781
Krause, G.
P731, P854
Krause, K.
P1171
Krause, R.
P645
Krcmery, V.
P1651
Kreder, S.
O528
Kredics, L.
P1947
Kreischitz, N.
O150
Kreiswirth, B.
S507
O525, P754, P808,
Kresken, M.
P1097, P1123
Kretchikova, O.
P1576
Kreuzer, K.-A.
O87
Krevolin, M.
P1696
Krieck, M.
P1307
Kriegel, I.
O187
Kriegeskorte, A.
P1186
Krishnan, P.
P733
Kristiansen, B.-E.
P752
Kristinsson, K.
P1590
Kristjansson, M.
P1590
Kristo, I.
P683, P1170
Kritskyy, A.
P2034
Krivine, A.
P1193, P2239
Krivoy, N.
P693
Krizan Hergouth, V.
P1365
Krizmancic, L.
O415
Krizova, L.
P627
Kröger, N.
P2091
Krogfelt, K.
P1080, P1298,
P1444, P1920
Kroica, J.
P1786
Kronenberg, A.
P657
Krunic, N.
P1894
Kruse, E.B.
P1316
Krutetskaya, I.
P1441
Ksiazyk, J.
P1570
Ku, C.
P784
Ku, N.
P1745
Kubo, R.
P715
Kubota, R.
P805
Kuch, A.
P966, P1075
Kucinskiene, Z.
P669
Kücükercan, M.
O294
Kuehn, B.
P1417
Kuehne, S.A.
P1744
Kühn, F.
O48
Kuijper, E.
S108, O478, O503
P1009, P1012, P1718,
P1831, P1962
Kujath, P.
S257
Kujundzic Tiljak, M.
P2191
Kuleshevich, E.
P981
Kullar, R.
P2090
Kullberg, B.
S179, P1617, P2153
Kulwichit, W.
O36
Kumar, A.R.
P1864
Kumar, G.
P1435
Kumar, S.
P625
Kumarasena, S.
P855
Kummerfeldt, B.
P903, P908
Kummik, T.
P1999
Kunchev, A.
P1089
Kunishima, H.
P632
Kunova, A.
P2122
Kunz, D.
P1349
Kuo, A.J.
P1352, P1966
Final Programme
Name
Number
Kuo, E.
Kuo, H.
Kupfahl, C.
Kupfer, C.
Kupreishvili, L.
Kurai, H.
Kurimura, Y.
Kuroda, M.
Kürschner, A.
Kurt, Ö.
P2127
O501, P1543
P2107
P1897, P1901
P2040
P2241
P1401
O101
P578
P875, P880,
P1412, P1681
Kurtinecz, M.
P1512
Kurtzhals, J.A.
O471
Kurz, S.G.
O386
Kushwaha, R.
P2000
Kusters, J.G.
P1674
Kuti, J.L.
P806
Kütscher, J.
P1589
Kuusela, P.
P2098
Kuusi, M.
P1078
Kuznecova, V.
P1786
Kwa, A.L.
O193, P1176
Kwak, E.
O152
Kwak, Y.
P1197, P1198, P1308,
P1312, P1542, P2068
Kwon, K.
P629
Kwon, K.T.
P1392, P1549
Kwon, S.
P1598
Kypraios, T.
P1254
Kyratsa, A.
P1565
Kyriakou, D.
P1322
Kyryachenko, S.
P1908
La Flamme, A.C.
La Gioia, V.
la Marca, G.
La Rosa, G.
La Salandra, G.
La Scala, P.
La Torre, G.
Laaber, B.
Laakso, S.
Labrou, M.
Labrousse, D.
Labussière, H.
Lackner, E.
Lacomme, S.
Lacroix, C.
Ladhani, S.
Laeuffer, J.
Lafaurie, M.
Laferl, H.
Lafeuille, E.
Laffut, W.
Lage, E.
Lagler, H.
Lagrou, K.
Lahbabi, M.
Lai, H.C.
Laine, M.K.
Laja, A.
Lajara-Marco, F.
Lakdawalla, N.
Laksiri, L.
Lalle, E.
Lallos, S.
Lalor, M.K.
Lam, W.
O389
P1499
P800
P2228
P899
P2228
O145
P1560
P1891
P1503
P1502
P1893
P817
P1671
O156
P1013
P677
O156
P1001, P1540
P607
P1033
P2094
O243, P1498
P2159
P583
P1966
P1369
P1300
P1283
P1963, P1964
P818
P2155
P1635
O251
P1778
Name
Lamarca, K.
Lamarche, I.
Lambert, D.
Lambertsen, L.
Lambrelli, D.
Lameiras, C.
Lammens, C.
Number
P1958
P811
P1274
P979
P2210
O350
O475, P640, P667,
P1038, P1375, P1571,
P1581, P1868
Lamonaca, V.
P2075
P1539
Lampreabe Gaztelu, I.
Lan, L.
P586
Lanata, C.
P1562
Lançon, J.
P2076
Landelle, C.
O40
Landgraf, B.
P1909
Lanfranco, P.
P1337
Lang, S.
P1899, P1900
Lang, S.
P1067
Lange, C.
E447
Langnes, B.
P923
Lanke, S.
P779, P783
Lanlan, W.
P2019
Lansdorp, B.
P1617
Lanskova, A.
P1441
Lanternier, F.
P2074
Lanzafame, P.
P1805
Laosakul, C.
O36
Lapa, D.
P1499, P1872, P2157
Lapanje, A.
P2028
Lapeña, S.
P1461
LaPensee, K.T.
P1281
Lappa, A.
O82
Lappin, D.
P1955
Lara, R.
O244
Laroche, L.
P811
Larrey, D.
P1961
Larroque, B.
P2247
Larry, A.
P1702
Larson, I.
P1451
Lasco, T.
P1487
Lascols, C.
P644, P732
Lass-Flörl, C.
S74, O476,
S550, P2107
Lassnigg, A.
O150
Lastovetska, O.
P680
Laterre, P.F.
S260, P807
Latkóczy, K.
P919, P1106
Latorre, E.
P1026
Latorre, I.
O253
Latour, K.
P1268, P1270
Lau, E.
P2243
Laudano, J.
P1531
Laudat, P.
P696
Launay, O.
P1193
Laupland, K.
P830, P1600
Laurent, F.
O520, P1569, P1789
Lauria, F.N.
P2155
Lautenschlager, I.
P2089
Lautenschlager, S.
P1684, P2066
Lavaud, S.
P2076
Laverdiere, M.
O484
Lavoué, S.
P2118
Lawrence, C.
P605
Lawrence, L.
P1185
Layer, F.
O302
Lazaar, F.
P2217
Lazar, M.
P2189
List of Authors
Number
Lazar, V.
P1044, P1751, P1752
P1635
Lazarettos, J.
Lazzari, R.
P1246
Lazzarotto, T.
S164, S201
Lazzeri, E.
P2009
Le, K.
P1086
Le Cam, S.
P1415
Le Corre, B.
P1195
Le Corre, N.
P2239
Le Falher, G.
P1584
P696
Le floch, V.
Le Fournis, S.
P664
Le Goff, J.
P2239
Le Goffic, A.
P1959
Le Guyader, F.S.
P2202
Le Hen, I.
P1692
Le Mabecque, V.
P1504
Le Pendu, J.
P2202
Le Roy, C.
P1692, P1693
Le Saux, J.-C.
P2202
Le Treut, Y.-P.
P1959
Le Tulzo, Y.
P2118
Le-Nguyen, T.
P1899, P1900
Leahy, R.G.
P1074
Leakey, A.
O422
Leal, A.L.
P1324
Leal, J.R.
P1600
Leandro, C.
P1350
Leatherbarrow, H.
P2149
Leaver, N.
P801
Lebargy, F.
P1865
Lebeau, B.
P2131
Lebeaux, D.
O187, P2247
LeBed, J.
P1875
Lebedev, F.
P826, P1102
Lebessi, E.
P920, P1095, P1322,
P1396, P1561
Leckie, G.
S506
Lecoq, H.
P2212
Lecuyer, H.
P1217
Ledeboer, N.
O33
Ledesma, K.R.
P790
Lee, Christine
P1039
Lee, Chaehoon
P655
Lee, C.S.
P1197, P1198, P2154
Lee, E.H.
P1809
Lee, E.J.
P1542
Lee, G.D.
P2053
Lee, H.
P1392, P1549
Lee, H.C.
P1552
Lee, H.Y.
P713
Lee, Jean
P1446, P1506
Lee, Je Chul
P1777
Lee, Jaehoon
P1601
Lee, Jayoung
P1637
Lee, J.E.
O34
Lee, Jung Hwa
P1777
Lee, Jae-Hoon
P1197
Lee, Ju Hyoung
P2195, P2225
Lee, Ju-Hyung
P1197, P1198,
P2154
Lee, J.S.
P1392
Lee, J.Y.
P1308
Lee, K.
O527, P597, P655
Lee, K.-D.
O305
Lee, K.M.
P2049
Lee, K.S.
P777, P1198
Lee, K.W.
P836
Name
Lee, Miae
Lee, Miyoung
Lee, M.S.
Lee, N.
Lee, N.Y.
Number
P775, P1877
P647
P1308, P1312
P1552
P846, P1624,
P1625, P2084
Lee, R.
P1242
Lee, S.S.J.
P1548
Lee, Seung-Ju
P1689
Lee, Su Jin
P1976
P1976
Lee, S.H.
Lee, S.S.
P1549
Lee, S.-O.
P1308
Lee, S.J.
P1198
Lee, S.R.
P1198
Lee, W.
O193, P1176
Lee, Y.
O527
Lee, Y.K.
P2049
Lee, Y.L.
P914
Lee, Y.S.
P1312
Leegaard, T.M.
P763
Leelaporn, A.
P1003
Leelasinjaroen, P.
P2215
Leelukkanaveera, Y.
P2192
Leenders, A.
P1004
Leerbeck, L.
P1921
Leethong, P.
P884
Leflon-Guibout, V.
P2247
Lefrancq, B.
P1382
Legakis, N.J.
P960
Legout, L.
P1087
Legretto, M.
P630
Legros, N.
O297, P778
Lehmann, T.
P1385
Lehours, P.
O521, P1671
Leib, S.
O472, O468,
P1758, P2201
Leibundgut, T.
P1843
Leighton, A.
P1509
Leihof, R.F.
P660
Leitão, R.
P574, P1771
Leitner, E.
P645, P926, P1827
Leitner, J.
O243, O501, P1001,
P1296, P1498,
P1540, P1543
Leiva, J.
O295, P1292
Leivas, T.P.
P1849
Lejko-Zupanc, T.
P2091
Lelekis, M.
P1251
Leli, S.
P2233
Lemaire, S.
P780, P781, P1139
Lemma, F.
P1726
Lemmen, S.
P928, P1386
Lemmens, A.
P1033
Lemmon, M.M.
P952
Lemos, M.L.
S61
Len, O.
O244
Lensing, C.
P1988
Lentnek, A.
O504, P1968
Lenz, R.
P1600
Leo, Y.S.
O240, O489,
P857, P858
Leòn, C.
P2120
León-Jiménez, E.
P1247
Leonildi, A.
P700
Leónn, L.
P1475
Lepe, J.A.
P1722
Lepore, S.
P1654
Name
Number
Lepoutre, A.
O356, O420
P1331
Lerman, Y.
Leroux-Roels, I.
P1924
Leroy, H.
P998
Leroy, O.
P1087
Leroy, S.
P2151
Lerro, P.
P985
Lespada, M.
P739
Lesprit, P.
O40
Lesseva, M.
P703
P662, P923
Lester, C.
Lestrade, P.J.
P995
Leten, G.
P1375
Letheulle, J.
P2118
Letscher-Bru, V.
P1951
Lettini, A.
P635, P1357
Leung, W.
P1676
Levcovich, A.
S453
Levent, B.
P1985
Leveque, N.
O309, P2076, P2156
Lever, R.
P2016
Leverstein-van Hall, M. P641, P668,
P688, P759, P764,
P1010, P1116, P1214,
P1302, P1668
Levi, M.
P2112
Levidiotou, S.
O35, P555, P1098
Levina, K.
P2017
Levine, D.
P1596, P2090
Levy, S.B.
K198
Levy Hara, G.
S280
Lewington, J.
P1978
Lewinski, M.
P774
Lewis, M.
P1720
Leyder, M.
O311
Leyva, L.
P1895
Lhoste, Y.
O520
Li, D.
P692, P2045
Li, H.-C.
P1352
Li, J.
P784, P1451
Li, Y.
P1525
Lia, A.
P752
Liakopoulos, A.
P920, P957
Liakou, V.
P822, P2010
Liang, H.
P1979
Liao, C.
P1083, P1469, P1476
Licciardi, F.
P1553
Licker, M.
P1303
Liderot, K.
P2196
Lidove, O.
P2132
Lieberman, J.
S512
Liebregts, T.C.
P1797
Liesenfeld, O. P906, P1688, P1696
Liew, D.
P2114
Liga, M.
P1880
Ligozzi, M.
P741
Ligtenberg-Burgman, I.
O354
Liljequist, B.
P924
Lim, S.
P1392
Lim, T.
O193, P733,
P1174, P1176
Lim, Y.
P1743
Lim, Y.-P.
P2210
Lima, C.
O105
Limacher, F.
P1321
Limmathurotsakul, D.
P1547
Lin, C.
P2050
Lin, J.S.
P2050
Name
Number
Lin, T.
P624
P713
Lin, T.Y.
Lin, T.L.
P1741, P1742, P1850
Lin, W.W.
P857, P858
Lin, Y.
P1552
Lin, Y.S.
P1014
Lina, B.
O239
Lina, D.
P2019
Lina, G.
P1052, P1068, P1502
Linardi, C.
P2180
P1066
Linares, F.
Liñares, J.
P1368, P1374
Linares, L.
P2079
Lindebaum, K.
P1897, P1901
Lindemann, P.C.
P1360
Lindholm, L.
O523, P1986
Lindner, M.
P1028
Lindqvist, M.
P955
Ling, L.
P733
Linge, J.
P1307
Linneberg, A.
P1080
Liopeta, K.
P1880
Lioure, B.
P2239
Liousia, M.
P1098
Lipas, K.
P865
Lipka, J.
P1532, P1533
Lipowsky, G.
P1446
Lipson, M.
P1420
Liró, J.
P1722
Lisalova, M.
P2122
Lister, P.
O292
Lite, M.
O357
Lito, L.M.
O350
Litt, D.
P1013
Littauer, P.
P748
Litterio, M.
P1557
Little, P.
P1262, P1266,
P1267, P1871
Liu, C.Y.
P1083, P1469
Liu, C.C.
P1014
Liu, L.
P796, P1521
Liu, W.
O365, P1552,
P1960, P2062
Liu, W.E.
P1724
Liu, X.Y.
P1224
Liu, Yang
P682
Liu, Yidian
O246
Liverman, L.
P1137, P1138
Livermore, D.
S439, E448,
S547, P686, P934,
P1177, S264
Lixandru, B.E.
P849
Lizasoain, M.
P2077
Llácer Luna, M.
P1200
Llaguno, M.
P856
Lleò, M.
S62, P1815
Llop, A.
P1378
Llorca, J.
P964, P965
Llorens, L.
P791, P968
Llorente, A.
P2133
Lloyd-Smith, E.
P843
Lluque, A.
P1754
Lo, P.
P1036, P1037, P1676
Lo, Y.
O365
Lo Cascio, G.
P741, P1486
Lob, S.
P573, P678, P679,
P946, P1057
Locatelli, F.
P1239
Final Programme
211
Chairs & Authors
Name
List of Authors
Name
Number
Locher, F.
Lode, H.
Loens, K.
P1735
S173
P971, P1571, P1581,
P1868
Loeuille, G.
P2151
Loffeier, V.
P1472
Löfgren, S.
P955
Loftus, M.
P1676
Logan, S.
P1299
Logan, S.A.
P876
P2089
Loginov, R.
Logothetidis, S.
P1845, P1846
Loh, C.C.
P1174
Löhr, I.
P1107
Loizaga, G.
P1191
Løken, C.H.
O345
Lollar, R.
P912, P1979, P1980
Lomar, A.
S455
Lombardi, A.
P1002
Lombardi, G.
P1911
Lomtadze, N.
P2036
Lomuto, M.
P885, P1093
Longo, J.M.
P1341
Longshaw, C.
O194
Longtin, Y.
P1388
Lontie, M.
P1030
Loonen, A.J.
P1885, P1887
Lopardo, H.
P1557
Lopata, A.
P1017
Lopes, B.
P601
López, J.
P1630
López, María
P620, P933
López, Marta
P2133
Lopez Hontangas, J.L.
P1844
Lopez Roa, P.
P1099
López-Brea, M.
O293, O421, P580,
P582, P584, P1153
López-Bueno, J.
O363, P2166,
P2170
López-Cerero, L.
O143, P1346,
P1477
Lopez-Coton, C.
P897
López-Fabal, F.
P2187
López-Lozano, J.M.
P1283
López-Medrano, F.
P2077
López-Méndez, J.
O143
López-Prieto, M.
P1475
López-Rojas, R. O474, P1069, P2147
Lora-Tamayo, J.
P1073
Lorè, N.I.
O473
Lorenzato, M.
P1847
Lorenzen, J.
P908, P1465, P1931
Lorenzetti, R.
P635
Lorenzotti, S.
P853
Lortholary, O.
E445, O482, K510,
P2074, P2132
Löschmann, P.-A.
P1123
Lotfy, S.
P2246
Lou, R.
P1166
Loução, F.
P598
Louie, L.
P1036, P1037
Louie, T.
O504, P1968
Louis, K.
O467
Loulergue, P.
P1193
Loupa, C.
P1251
Loupec, T.
P818
Loureiro, A.
P881
Lourenco, J.
P992
212
Name
Louro, D.
Louro, J.
Loussaief, C.
Loutan, L.
Love, J.
Lovgren, M.
Low, D.E.
Loza, A.
Loza, E.
Lozano, A. B.
Lozano, C.
Lozano Serra, J.
Lu, J.J.
Lu, P.
Lu, S.-Y.
Lu, X.
Lu, Y.M.
Lubkina, M.O.
Lucà, G.
Lucasti, C.
Lucero, C.
Lucet, J.
Luchs, A.
Lucien, M.A.
Lucientes, J.
Lucignano, B.
Ludden, C.
Ludwig, C.
Luft, B.
Luft, D.
Luger, C.
Luis, A.
Luís, F.
Luis, N.
Lumbreras, C.
Lundblad, E.W.
Lundgren, B.
Lundgren, J.D.
Lunel-Fabiani, F.
Luño, J.
Lunt, B.
Lunzer, M.
Luong, M.
Lupión, C.
Lupse, M.
Luque, S.
Luraschi, T.
Lurbe, A.
Lutringer, D.
Lutsar, I.
Luzzaro, F.
Luzzi, I.
Lv, X.-J.
Lv, Z.
Ly, T.D.
Lye, D.
Lykas, A.
Lykou, F.
Lynch, M.
Lyons, M.
Lyster, H.
Lyytikainen, O.
M Zali, F.
Maalouf, H.
Final Programme
Number
P1366
P894
P1092, P1546
P874
O425
O304
O304, P973,
P974, P1370
P2120, P1765, P1950
P1725
O363
P845, P901, P937,
P939, P1249
P1566
P914, P1377
P2037
O305
P2035
P1224
P1929
P1499
P1532
P773
P1195
O310, P2071
P589
P1026
P1239, P1841
O106, P618, P730
P1100, P1101
O359
P1109, P1112
P689
P2121
P2171
P2193
P2077
P924
P1746
S335
P1961
P1630
P918
P1639
O152
O143
P2111
O86, P794
P1398
P983
P1192, P1478
P1568
P1118, P1403, P1911
P1357
P1421
P1683
P1415
O489, P733, P857,
P858, P1311, P1330
P2067
P1565
O210, O212
O106
P801
P830, P1269, P1733
O196
P2202
Name
Number
Maass, M.
P1208, P1639
P577
Maatallah, M.
Macarie, C.
P1303
MacAteer, J.
P1381
MacDonald, C.
P685
Macdonald, G.
P1509
Macedo, J.O.
O466
Macedo, K.
P760
Macedo, R.
O384
Macedo-Vinas, M.
P1750
S378, P729, P795
MacGowan, A.
MacGregor, G.
P1856
Machado, D.
P723, P724
Machado, E.
P675, P694, P1343
Machado, M.
P862, P881, P889
Machado Jr., J.
P2165
Macheras, E.
P605
Macia, M.
P612
Macías, J.
P2186
Macioniene, A.
P669
Mack, D.
P1763
Mack, D.J.
P1583
Mackay, I.
P2238
MacKenzie, K.
P787
Macone, A.
P1141, P1074
Macrez, A.
P1195
Madec, J.-Y.
P595
Madsen, H.A.
O351, P1219
Maeda, S.
P2065
Maertens, J.
S209
Maffioli, C.
O468, P2201
Mafura, M.
P1345
Magaliou, E.
P2175
Magana, M.
P2125
Magee, J.
O500
Magerman, K.
P1004
Maggina, P.
O416
Magiorakos, A-P.
S460
Magloire, V.
O472
Magrini, E.
P2209
Maguina, A.
P1332
Maher, K.
P1104, P1140, P1231
Mahjub, H.
P1545
Mahli, G.
P1676
Mahmoud, M.
P583
Mahne, M.
P2248
Mahrouki, S.
P596
Mahvi, A.
P1853
Mai, U.
P1315
Mairal, P.
P1026
Mairos, J.
O350
Major, Y.
P2123
Majtán, V.
P591
Majtánová, L.
P591
Majzoobi, M.
P1545
Mak, E.
P698
Makarona, M.
P736
Makgotlho, E.
P824
Mäki, M.
P1891, P2098
Makri, D.
P2067
Makris, M.
P1439
Makristathis, A.
P1737
Malamou-Lada, E.
P1348, P1492
Malandrin, S.
P1337
Malaskova, L.
P2150
Malawski, A.
P788
Malcolm, W.
O44
Maldonado, J.
O253
Name
Number
Maleki, A.
P1853
P1550
Malev, I.
Malhotra-Kumar, S.
S234, K509,
P640, P667, P1038,
P1375, P1909
Malik, S.
P991
Malisiovas, N.
P1866, P2175
Malithong, A.
P1188
Malizos, K.N.
P1289
Mallaret, M.R.
P2131
P957
Malli, E.
Malmierca, E.
P2128
Malomanova, N.
P2034
Malone, C.
P1793
Maltezou, H.
P1240, P1319, P1328
Mamali, V.
P1485
Mamani, M.
P1545
Mammina, C.
P568
Mamuchishvili, N.
P891
Manageiro, V.
P562, P1359, P1366
Manaj, A.
P2233
Mancinelli, L. P1245, P1948, P2002
Mancini, C.
P1342
Mancini, G.
P1093
Mandal, T.
O90
Manders, M.
P1698
Mandras, N.
P2152
Manecksha, R.P.
P1397
Mangani, S.
P609
Mangoni, P.
P1246
Manhart, L.
S528a
Manickam, K.
O250
Manidaki, A.
P1997, P2003
Manigart, Y.
P2183
Manikandan, P.
P1947
Mank, T.G.
O493, P1910
Mannerquist, K.
P1335
Manosuthi, W.
O249, O367, P1445
Manser, M.
O488
Mansinho, K.
P2193
Manso, E.
P1911
Mansouri, D.
P1496
Mantadakis, E.
P970
Mantegani, P.
O522, P2013
Mantengoli, E.
P673, P1118
Manuel, O.
P2081
Manukian, G.
O469, P1434
Manzano Ramírez, A.
P1539
Manzo, A.
P1191
Manzoor, S.
P1710, P1724
Maor, Y.
P735, P1595
Maples, K.
P796
Mappley, L.
P1726
Marais, C.
P1265
Maraki, S.
P970, P1175, P1636
Marangoni, A.
P1694
Maraví, E.
P1765, P2133
Marcek, T.
P2122
Marcello, T.
P1028, P2169
Marchand, S.
P811, P815, P818
Marchetti, D.
P2209
Marchetti, O.
O148, S226
Marchi, M.
P1263, P1264
Marchi, S.
O466
Marchisio, P.
S114
Marco, F.
P649, P738, P1066,
P1833, P2079
Marco, M.
P847
List of Authors
Number
Marcos, M.
P1190, P1765, P2079
P1559
Maresova, V.
Maresz, K.
P1780
Margari, A.
P1622
Margariti, A.
P2175, P2176
Margaritis, A.
P1355
Margolles, A.
P1155
Maricato, J.T.
P2165
Mariconda, M.
P1654
Marier, J.
P1519, P1520
O252
Mariette, X.
Marimuthu, K.
S453, P733
Marín, A.
P860, P870
Marín, M.
P842, P987,
P1060, P1630
Marina, M.
P1718
Marinescu, C.
P1199
Marinov, K.
P1711
Marinucci, F.
P2213
Marion, A.
O95
Mariotti, S.
P2041
Marjani, M.
P1496, P2032
Markotic, A.
P2191
Markou, F.
P695, P1029
Markowska, M.
P966
Marne, C.
P847
Marone, P.
P1020, P1911,
P1919
Marounek, M.
P1167
Marque, S.
P2118
Marquette, C.
P1435
Marquez, C.
P617
Márquez, I.
O157
Marra, A.
O93
Marra, C.
P802, P803, P810
Marrero, D.
P1378
Marrinan, M.
P2134
Marriott, C.
P1710, P1724
Marriott, D.
P2114
Marschal, M.
P1830
Marsella, P.
P2157
Marsh, P.
P1936
Marshall-Batty, K.
P1507
Marszalek, A.
P1762
Martens, D.
P1983
Martens, K.
P1829
Martens, M.
P1875
Marth, E.
P926, P1827
Marti, S.
O474
Martin, Antonio
P1475
Martin, Anandi
P2018
Martín, Almudena
P2080
Martín, Carmen
P606, P848
Martín, Cecilia
P2080
Martin, E.
P1958
Martin, J.
P1958
Martin, K.
P934
Martin, M.
P1229, P1313
Martin, P.Y.
P2088
Martín, R.
P1368
Martin-Davila, P.
O247
Martín-Gandul, C.
P1291, P2094
Martín-Juan, J.
P1212
Martin-Loeches, I.
P1765
Martín-Mazuelos, E. P1701, P1950,
P2186
Martín-Peña, A.
P2139
Martín-Ponce, M.L.
P1247
Name
Martín-Rabadán, P.
Number
P1621, P1631,
P1632, P1664
Martín-Rodríguez, L.M.
P1247
Martinelli, M.
P1554
Martinez, E.
P617
Martinez, Marife
O483
Martinez, Milton
P2039
Martinez, M.A.
P1475
Martinez, M.B.
P963
Martínez, María José
P582
P580
Martinez, Maria Josefa
Martinez, R.
P1341
Martínez, Santiago
P1716
Martinez, Santos
P1934
Martinez Alarcon, J.
P1585
Martínez de Tejada, G.
O295
Martínez Serrano, M.
P1566
Martinez-Lage, L.
P1474
Martínez-Lirola, M.J.
P1996
Martínez-Martínez, L.
O295, S320,
P594, 612, P718,
P719, P993,P1471,
P1627, P1833,P1902,
P1922, P1952
Martinez-Perez, M.A.
P2170
Martínez-Ramos, I.
P1749
Martinez-Risquez, M.
P1212
Martinez-Rodriguez, A.J.
P1153
Martínez-Yelamos, S.
P1459
Martini, L.
P1284, P1645
Martinovich, A.
P708
Martins, E.
O357
Martins, F.
O350
Martins, M.S.
P1448, P1757
Martins, S.
P1372
Martins da Costa, P.
O303
Martsoukou, M.
P1180
Martynow, J.
P1166
Marwaha, A.
P1989
Marzouk, M.
P2038
Masgala, A.
P1635
Masjedi, M.
P2032
Masoud, L.
P926, P1827
Masterton, R.
S172, S429, S430
Mastouri, M.
P659
Mastrantonio, P. S127, P1713, P1982
Mata, C.
O219
Mata, D.
P2042
Matamala, A.
P1629, P1657
Matar, G.M.
P1072
Matejkova, J.
P1559
Mateos, M.
O366
Mateos-Gómez, A.
P1247
Mathew, J.
P1442
Mathews, H.
O358
Mato, R.
O350
Matos, F.
P1178
Matos, T.
P2100
Matos Silva, C.D.
P1414
Matsas, M.
P1396, P1561, P2164
Matsumoto, M.
P623
Matsumoto, Tetsuro
S377, P603,
P623, P816, P1399,
P1402, P1604
Matsumoto, Tetsuya
P1604
Matsumura, Y.
P665, P1362
Matsunaga, N.
P715
Matsuo, Y.
P805, P809
Name
Matsushima, A.
Matteelli, A.
Matthews, H.
Mattina, R.
Mattner, F.
Mattsson, E.
Matuschek, E.
Number
P665, P1362
P988
O359
P1398
P1229
O478
E116, P747, P748,
P749, P750, P751,
P752, P753
Matuz, M.
P1220
P1282
Maurain, C.
Maurício, I.
P886
Maurya, A.
P768, P2000
Mavridis, A.
O35, P1491
Mavridou, E.
P1768
Mavroidi, A.
P920, P957
Mavromanolakis, D.
P1997, P2003
Mavrommati, A.
P736
Mavros, M.
P1439, P1638
Mayer, J.
P2150
Mayor, D.
P2001
Mazi, W.
P1213, P1383
Mazinska, B.
P1256
Mazurik, V.
P1908
Mazzariol, A.
P648, P741
Mazzotta, V.
S453
Mazzucato, S.
P1682
Mazzulli, T.
P1036, P1037
McAllister, E.
P1515
McBride, A.J.
O466, P1414
McBride, F.W.
O466, P1414
McBride, S.
P1894
McCarthy, K.
P1980
McClean, P.
P1333
McConkey, S.
P2177, P2178
McConnell, M.
P2147
McCormick Smith, I.
O349
McCulloch, Elaine
O480, P1856,
P1955
McCullogh, Eddie
P1397
McCusker, M.P.
P1448, P1757
McDermott, L.A.
P1133
McDermott, T.
P1397
McGeer, A.
P680, P973, P974,
P1036, P1370, P1676
McKendry, R.
P1299
McMurray, C.
P942, P1720
McNamara, P.H.
P2174
McNicholas, S.
O210, O212
Md. Yasin, R.
P1021
Mear, J.B.
P1785
Mearns, G.
O88
Medina, A.
P1562
Medrano, F.J.
P1212
Meece, J.
P1807
Meekelenkamp, J.
P1004
Mégarbane, B.
P804
Mège, J.-L.
P2212
Mégraud, F.
O196, O521, P1671
Megrelishvili, T.
P891
Mehats, V.
P1693
Mehdi, N.
P1789
Mehlis, A.M.
P2158
Mehranzadeh, M.
P1410
Meier, S.
P2088
Meigh, J.
O427
Meigh, R.
O427
Meijering, V.M.
P1218
Name
Number
Meinecke, C.
Meinke, R.
Meis, J.
P1246
P1652
O149, E445,
P1943, P1949
Mejia, G.I.
P2039
Melano, R.
P680, P1370
Melchers, W.
O478, O481, P1768,
Meledandri, M.
P701
Meletiadis, J.
P786, P1768
Melidou, A.
P1866
O154
Melillo, L.
Mélin, P.
P1961
Melkes, A.
P926
Mellado, E.
P2103, P2149
Mellado, P.
P965
Mellmann, A.
P835
Melo, A.S.
P1944
Melo Cristino, J.
O189, O350, O357,
P980, P1043,P1082, P1715
Melón, S.
P1870
Mena, L.
P1875
Menarguez, C.
O157
Mendes, E.
P2242
Mendes, J.J.
P1082
Mendes, R.
P613, P616, P652,
P1130, P1131, P1132,
P1134, P1367, P1452
Mendez, C.
P1925
Mendez Aranibia, M.
P1622
Mendo, S.
O105, P661, P1817
Mendonça, N.
P624, P636, P1358
Mendoza, J.
P860
Mendoza López, P.
P1996
Menegotto, F.
P1416, P1923
Menéndez, B.
P1455
Menendez, R.
P1190
Menichella, D. P1239, P1245, P1841,
P1948P2002, P2173
Menichetti, F.
E443, P700
Menna, P.
P798
Mennesson, E.
P1584
Menotti, J.
P2073
Mensa, J.
P1190
Mentis, A.
P1866, P1867
Mentula, S.
P1733
Mera, R.M.
O351, P1219
Merante, F.
P1894
Mercer, J.
O299
Merelli, M.
P873
Merida, M.D.
O363, P2166, P2170
Merino, P.
P1765
Merkus, P.
O149
Merlani, P.
P874
Merli, S.
P793
Merlin, S.
P1699
Merlino, C.
P2152
Merlino, J.
P617
Mertsola, J.
O523
Meschi, S.
P2155
Meseguer, M.A.
O247
Mestres, C.A.
S407
Metallidis, S.
P2175, P2176
Metselaar, H.J.
P2078, P2083
Metsvaht, T.
P1568
Metzger, M.H.
P1317
Metzger, S.
P1059
Meurman, O.
P1986
Mevius, D.
P1010, P1962
Final Programme
213
Chairs & Authors
Name
List of Authors
Name
Number
Mewada, A.
Mewada, N.
Meyer, C.
Meyer, E.
P1596
P1596
P1589
O138, P1229, P1259,
P1301, P1320
Meyer, S.
O48
Meyer, T.
S511
Meyer, T.F.
S277
Meyer, Wolfgang
P1417, P1419
Meyer, Wieland
P2092
O387
Meyers, A.
Mialdea, I.
O253
Michail, G.
P1070, P1503
Michailellis, E.
P2010
Michalkiewicz, J.
P1762
Michallet, M.
P1478, P2126
Michel, M.
O191
Michel, Y.
P874
Michelet, C.
P998
Michie, S.
O144, P1381
Michl, V.
O501, P1543
Micozzi, A.
P2091
Midulla, F.
P2197
Miegeville, A.F.
P1504
Migdal, M.
P1570
Migliavacca, R.
P755
Miglioranza, C.
P1191
Migliorino, G.
P1046, P1233,P1337
Mignone, F.
O316, P1553
Mihaiescu, D.
P1044
Mihailescu, R. P2182, P2189, P2230
Mihneva, Z.
P1089
Mikamo, H.
S518, P2113
Mikolasek, P.
P1567
Mikulová, J.
P2063
Mikulska, M.
P2086
Milanesi, B.
P898
Milara, C.
P2080
Mildh, M.
P1620
Millar, M.
P1591, P1842
Miller, C.
P828, P831
Miller, L.A.
O351, P1219
Miller, M.
O504, P1968
Milne, K.
P765
Milne, R.
P1521
Milona, A.
P927
Milone, G.
O154
Milosevic, B.
P1615
Milozzi, E.
P1285
Milpied, N.
P2239
Mimoun, M.
P1338
Mimoz, O.
P804, P815, P818
Minarovits, J.
S375
Minervini, M. I.
P2075
Mingeot-Leclercq, M-P.
O78
Mingo, A.
P893
Mingorance, J.
P1712
Minor, D.
O469
Minor, P.
E117
Minotti, G.
P798
Minton, N.P.
P1744
Mintziras, I.
P1180
Miossec, C.
P609
Miotto, P.
O248, O383, O522,
P1764, P2009, P2013
Mir, O.
P1193
Miragaia, M.
O348, O350,
P938, P940
214
Name
Number
Miragliotta, G.
P1117, P1494
P2193
Miranda, A.C.
Miranda-Zapico, I.
P2143
Miriagou, V.
P559
Mironova, S.
P1999, P2034
Mirsamadi, E.
P2051
Mirsepasi, H.
P1920
Misson, P.
P1151
Missorini, S.
P592
Mistry, R.
P1978
P2023
Mitarai, S.
Mitre, C.
P2111
Mitroussia-Ziouva, A.
P1485
Mitrovic, A.
P1615
Mitsani, D.
P2104, P2110
Mitsikostas, P.
P1638
Miyajima, F.
P2069
Miyashita, N.
P989, P1422
Miyazaki, T.
P2140, P2141, P2148
Miyazawa, Y.
P715
Mizuno, K.
P2023
Mlynarczyk, G.
P743
Moazzeni, S.
P1430
Mobasger, M.
P1158
Modiano, D.
S463
Modolo, E.
P1005
Modolo, M.
P910, P1678, P1806
Moeck, G.
P1031, P1529
Moellering, R.
S539, P1050
Moet, G.
P943, P1179
Mogensen, M.F.
P2117
Mohagheghi, M.
P1423, P1424,
P1907
Mohajerani, N.
P1907
Mohammad, F.
P1023
Mohammad Jonaidi, M.
P864
Mohammadi, M.
P1423, P1424,
P1907
Mohammadi, P.
P1860
Mohareb, E.
P1024
Mohd Khalid, K.N.
P1021
Mohebali, M.
P1411
Mohebi, R.
P953
Mohrmann, G.
P2190
Moioli, F.
P1998
Moisuc, A.
P2111
Mokaddas, E. P2007, P2033, P2047
Molagic, V.
P2230
Molas, E.
P1647
Moldovan, O.
O385
Moldovan, R.
P1303
Mølgaard, A.
P1298
Molina, J.
P2080
Molina, J.-M.
O156, P2073
Molina, L.
P2131
Möller, A.V.
P1932
Møller, J.K.
O346, P587, P658,
P660, P975,P1697
Mölling, P.
P671, P949, P1732
Molnar, D.
P1528
Molnar, J.
P1160
Molnar, Z.
P1220
Molstad, D.
O93
Moltoni, I.
P728
Molyneux, D.
K176
Monaco, M.
P898, P1371
Moncalian, G.
P1902
Mondello, P.
P853
Final Programme
Name
Monden, K.
Monecke, S.
Number
P1399
P821, P837, P905,
P917, P1016
Monfort, L.
P1685
Mongelli, G.
P776
Monno, R.
P630
Montagna, M.
P1020
Montagna, M.T.
P1113
Montassier, E.
P1500
Montecchini, S.
P877, P1892
O300
Monteiro, N.
Montejo, M.
P2093
Monteleone, K.
P2197, P2200
Montero, M.
P860, P870
Montero, Milagro
O86, P1647
Montgomery, J.
P1040
Montgomery-Fullerton, M.
P1918
Montin, D.
P1553
Moodley, A.
P559
Moon, C.
P1197, P1549, P1637
Moon, D.C.
P1777
Moon, H.
P2048
Moon, J.
P1653
Moore, W.R.
O94
Moorhouse, L. P1379, P1633, P1653
Mootsikapun, P.
P1547
Morace, G.
O190, S224, P1484
Morad, Z.
O47
Moradi, A.
P1496
Moragas, M.
P1459
Morais, A.
O350, P1372
Moraitou, H.
P736
Morakabati, A.
P1424
Moral-Escudero, E.
P1474
Morales, D.
P1077
Morales, I.
P1110
Morales, J.M.
P2077
Morales, S.
O88
Morán-Barrios, J.
P1279
Moravej, A.
P1428, P1429
Morazzoni, C.
P1911
Morcillo, A.
P900
Morcillo, N.
P2018
Mordechai, E.
P1331
More, R.
P1288
Moreillon, P.
P1783
Moreno, Asunción
P2079
Moreno, Antonio
P1942
Moreno, E.
P1190
Moreno, M.J.
O293
Moreno, Y.
P1821
Moreno Parrado, L.
P1566
Moreno-Flores, A.
P897, P2059
Moreno-Ramos, F.
P1279
Morera, M.A.
P1661
Moretti, C.
P2197
Morfin-Otero, R.
P614
Mörgelin, M.
P1858
Morilla, R.
P1212
Morillo, S.
O310, P2071
Morinaga, Y.
P2148
Morini, F.
P1046
Moritz, G.
P2248
Moro, M.
P832, P834, P1314
Moro, M.L.
E446, P1110, P1263,
P1264, P1587
Morosini, M.
O296, O355,
P1183, P1725
Name
Moroti, R.
Morotti, L.
Morozova, O.
Morré, S.
Number
P1495, P2189, P2230
P2209
P1818
S279, P1002,P1695,
P1698, P1709
Morris, D.
O106, P618, P730
Morris, R.
P1964
Morris, T.
P1288
Morris Downes, M.
P666, P1329
Morrissey, I.
O422, P677, P1140
P2114
Morrissey, O.
Morrow, B.
P625
Mortensen, A.
P903
Mortensen, K.
P2149
Morton, K.
O312
Mosca, A.
P1117, P1494
Mosca, F.
P1234
Moser, C.
P1465, P1931
Moser, M.
P788
Moskorz, K.
P638
Mostafavi, E.
P1907
Motlova, J.
P1559
Motohashi, N.
P1160
Mott, R.
S69
Motta, C.
P1899, P1900
Motta, E.
P1046, P1233, P1337
Motte, A.
P1957, P2214, P2221
Motyl, M.R.
P790
Mouksassi, M.
P1520
Mouktaroudi, M.
O79
Moura, A.
P639, P1814
Mourad-Baars, P.E.
P986
Mourich, D.
O411, O469,
P1527, P2211
Mourvillier, B.
P1195
Mouton, J.
E118, S451, P756,
P807, P1293, P1768
Moutousi, A.
P1866, P1867
Moutsopoulos, H.
O364
Moutte, L.
O309
Moya, B.
P612
Moya, R.
P1475
Mporgi, L.
P888, P1022
Mueller, J.
P1161
Mueller Premru, M.
P1365
Mufti, G.J.
P2105, P2134
Mugasa, J.
P2009
Mühlemann, K.
O424, P657
Muilwijk, J.
P688, P1116
Mularoni, A.
P2093
Mulcahy, F.
P2177
Mullane, K.
O504, P1968
Muller, A.
O42, P1111, P1265,
P1268, P1269, P1270,
P1309, P1310
Muller, A.E.
P807
Müller, B.
O48
Müller, C.
O87
Müller Eckhard
S55
Müller, Elke
P905
Müller, F.
O345, P1739
Müller, H.
P2169
Müller, I.
P1977, P2054
Müller, N.J.
O213
Muller-Pebody, B.
P1466
Müllner, C.
P689
Mun, S.
P1965, P1984
Muniain, M.
O143
List of Authors
Number
Munk Petersen, A.
P2070
P1475
Muñoz, A.
Muñoz, G.
P1629
Muñoz, J.
P1958
Muñoz, K.A.
P1516
Muñoz, L.
P649
Muñoz, P.
O157, S263, P1099,
P1468, P1585, P1630,
P1632, P1664, P2072,
P2093, P2095, P2121
P1404, P2206
Muñoz Bellido, J.L.
Muñoz Criado, S.
P1404, P2206
Muñoz-Gamito, G.
P1657
Munro, S.D.
P772
Muntean, D.
P1303
Munteanu, D. P2182, P2189, P2230
Mura, I.
P1113
Muratani, T.
P603, P1399
Murchan, S.
P972
Murillo, N.
P825
Murillo, O.
P1073
Murk, J.L.
O290
Murphy, M.
P1257
Murphy, P.
P1397
Murray, C.
O91
Murray, M.
P1381
Muscillo, M.
P2228
Mussini, C.
S531
Musso, M.
O46, P2184
Mustazzolu, A.
O383
Musto, P.
O154
Mutters, N.
P1822
Mydlak, K.
P1250
Mylvaganam, H.
P1360
Naaber, P.
P1107
P742, P745, P1666,
P1669, P1670
Naber, K.
S376
Nabi, A.
P1347
Nacinovich, F.
P1538
Naderer, O.J.
P1512
Nadi, E.
P1775
Nadji, S.A.
P1496
Nadkowska, P.
P1570
Naesens, R.
P1004
Naessens, A.
O311
Nafati, C.
P1959, P2223
Nag, V.
P2000
Nagao, M.
P665, P1362
Nagayoshi, Y.
P2140, P2141
Nagibina, O.
P1882
Nagy, E.
S128
Nagy, T.
P919, P1106
Nahvijoo, A.
P1423
Najar Peerayeh, S.
P585
Najem, C.
P1195
Najvar, L.K.
O94
Nakahara, T.
P1463
Nakane, K.
P2065
Nakano, T.
P715
Nakano, Y.
P1855
Nakashima, M.
P1594
Nancharaiah, Y.
P1864
Nanji, K.
P863
Nankivell, B.
P2092
Nappez, C.
P2212
Nar Otgun, S.
P962
Naas, T.
Name
Number
Narciso, A.
P1043
P885, P1093
Nardella La Porta, C.
Nardini, P.
P1694
Narendran, V.
P1947
Narni, F.
P646
Narreddy, S.
P1023
Nascimento-Brito, S.
P2165
Nassar, Nayla
P1685
Nasser, Noah
P912, P1979, P1980
Nassif, X.
P1217
P2230
Nastase, R.
Natalini, G.
P1284
Natera, C.
P1475
Nathwani, D.
O44, S233
Nation, R.
P784, P1451
Navarro, C.
P860, P870
Navarro, Daniel
P1723, P1804
Navarro, Dolores
P1346
Navarro, J.L.
O293
Navarro, M.
P1477
Navarro, R.
P878
Navarro-Marí, J.M.
P2204
Navarro-San Francisco, C.
P1279
Navas, E.
O247
Naveen, S.
P1434
Naveen, S.
O469
Navon-Venezia, S.
O100, P1148,
P1331
Nazemalhosseini-Mojarad, E. P869,
P1704
Nazli, A.
P2014
Ndieyira, J.
P1299
Neagu, A.
P1135
Nebbia, G.
P876
Neerken, S.
P1885, P1886
Nejatizadeh, A.
P2015
Nejentsev, S.
P2034
Nejjari, C.
P583
Nejsum, P.
O486
Nemcova, E.
P904, P1937
Nemec, A.
P627
Nemec, P.
P904
Nenova, R.
P1711
Neoh, C.F.
P2114
Neophytou, C.
P1636
Neou, E.
P1070
Neri, A.
P1713
Neselioglu, S.
P1025
Nesi, F.
P810
Netea, M.
O467, P2153
Netikul, T.
P1340
Neuberger, A.
P1663
Neumüller-Guber, S.
P1498
Neves, J.
P1082
Newham, P.
P1438
Newton, A.
O427
Ng, S.Y.
P954, P1623
Ng, T.
P733
Ng, W.
P1311
Ngamwongwan, S.
P956
Ngo, D.
P783
Nguyen, A.
P761
Nguyen, Catherine
P1899, P1900
Nguyen, Chau
P1910
Nguyen, G.
P1676
Nguyen, M.
O152, O155, P2104,
P2110, P2130
Nguyen, T.
O291
Name
Number
Nguyen Van, J.C.
P977
P1548
Ni, Y.
Nica, M.
O385, P1135, P1495
Nichols, G.
P1434
Nicholson, A.G.
P2134
Nickmans, S.
P982
Nicolau, D.
P1505
Nicoletti, M.
P1062
Nicolini, F.
P2126
Nicolle, M.
P1192, P1478, P2126
O415
Nicosia, A.M.
Niculescu, I.
P2230
Nielsen, A.
P1210
Nielsen, A.G.
P1577
Nielsen, D.
P1840
Nielsen, H.
P990, P1599
Nielsen, H.L.
P990
Nielsen, H.V.
O486, O490, P1719
Nielsen, K.L.
P1437
Nielsen, P.
P1465, P1931
Nielsen, R.B.
P1577, P1586
Nielsen, S.
P1084
Nielsen, X.C,.
P797, P1819
Nieman, A.E.
O211
Niemann, S.
P2009
Niesters, H.G.
O408, O412, P2198
Nieto, B.
P1909
Nightingale, P.
P1209
Nightingale, R.
P784
Nikolaevskyy, V.
P2034
Nikolaidis, I.
P2175
Nikolaidis, P.
P1539, P2175,P2176
Nikolaou, S.
P1491
Nikolayevskyy, V.
P1999, P2009
Nikolic, J.
P1615, P2056
Nikolopoulos, G.
P1635
Nikou, P.
P1252
Niks, M.
P676
Nilsen, S.M.
O345
Nilsson, L.
P955, P1488
Nimitvilai, S.
P1003
Ninet, B.
P1094, P1684
Ning, H.
P692, P2045
Nino-Incani, R.
P860, P870
Nishimaki, K.
P632
Nisii, C.
P872
Nisini, R.
P2041
Nissen, M.
P1339, P2238
Nistor, I.
P1135
Nizzero, P.
P832
Noah, C.
P2190
Noble, M.
P1189
Noble, S.
P2088
Nobre Machado, A.
O297
Nobrega, J.
P2085, P2245
Noel, A.R.
P729, P795
Noel, G.J.
P1528
Noens, L.
P1953
Noh, J.
P1290
Noitung, P.
P1445
Noll, I.
P731, P854
Nollo, G.
P1847
Nolte, O.
P1735, P1798
Nonhoff, C.
O297, P778, P1236
Noomen, S.
P659
Noorland, I.
O345
Nord, C.E.
S129, P1272,
P1273, P1973
Name
Number
Nordgaard-Lassen, I.
P1920
O216, O217, O218,
Nordmann, P.
S380, P607, P608,
P742, P745, P1048,
P1666, P1669, P1670
Nordøy, I.
P1739
Nørgaard, M.
P2117
Normandin, F.
P1692
Norrby, R.S.
S538
Nosari, A.
O154
P2111
Nour, D.
Noureddine López, M.
P1277
Novais, Â.
P675, P694, P1343
Novais, C.
O300, O301, P619
Novak, A.
P1975
Novak, J.
P1937
Novak, P.
P1940
Novak, R.
P1524
Novelli, A.
O82, S319, P800
Novicki, T.
P1807
Novo, M.
P900
Nseir, G.
P2081
Nseir, S.
P2101
Ntetsika, K.
P1125
Nucci, M.
P2125
Nuccio, F.
P630
Nucleo, E.
P755
Nueesch, R.
P1655
Nunes, J.
P2057
Nunes, M.J.
O350
Nunes, S.
P1372
Nuñez-Viejo, M.A.
P964, P965
Nuño, E.
P1475
Nutankalva, L.
P1023
Nuttall, J.
P1266
Nydegger, U.
P1843
Nye, Mindy
P1688
Nye, Melinda
P1875
Nyengaard, J.R.
O471
Nys, S.
P1400
O
' Connell, K.J.
O'Brien, F.G.
O'Brien, W.
O'Connell, B.
O'Connell, N.
O'Connor, J.
O'Dowd, H.
O'Flanagan, D.
O'Gorman, J.
O'Hanley, P.
O313
P821
P1142, P1149
P1470
P618, P730
P774
P1166
P972
O210, O212
P1143, P1144,
P1453
O'Hara, F.P.
O351, P1219
O'Lorcain, P.
P972
O'Neill, A.J.
P1049, P1051,
P1454, P1854
O'Neill, P.
P1254
Öberg, S.
P1261
Obermayr, F.
P1524
Obrecht, D.
P1151, P1513
Obriadina, A.
P2235, P2237
Ocal, A.
O391
Ocampo-Sosa, A. O295, P594, P612
Ocepek, M.
P2028
Ocete, M.D.
P2008
Ochoa, T.
P1562, P1564, P1754
Ochsner, M.
O148
Oda, S.
P2113
Final Programme
215
Chairs & Authors
Name
List of Authors
Name
Number
Odero, V.
P961
P1734
Ödman, K.
Oeconomou, M.
P957
Ofek, I.
S69, P1154
Offidani, M.
O154
Ogan, M.C.
P1740
Ogawa, M.
P632
Ogbadoyi, E.O.
P895
Oggioni, M.R.
P976
Oghalaie, A.
P1423
P1513
Ograbek, A.
Oguchi, K.
P1463
Oh, H.B.
O34
Oh, M.D.
P1198
Oh, W.S.
P1197, P1198
Ohkusu, K.
P1933
Ohlasova, D.
P676
Ohlsson, A.
P925
Ohmagari, N.
P2241
Ohno, A.
P1390
Öhrmalm, C.
P1895
Oikonomidou, D.
P1238
Okamoto, M.
P1463
Okinaka, K.
P2241
Okogun, J.
P895
Oksuz, L.
P1556
Olaiz, A.
P883, P1409
Olalla Sierra, J.
P1277
Olaru, I.
P1495, P2189, P2230
Olearo, F.
S453
Olesen, B.
O497
Oliveira, C.
O310
Oliveira, D.C.
P940
Oliveira, H.
P574
Oliveira, I.
P649
Oliveira, K.
P1945
Oliver, A.
O288, O296, P612
Oliveri, S.
P2136
Ollgren, J.
P1269
Ollivier, F.
P561
Olma, T.
P1930
Olomi, R.
O493
Olsen, K.E.
O497, P1719, P2070
Olsen, S.S.
P662
Olson, B.
P1807
Olsson, J.
P949
Oltolini, C.
P1325
Oluwadun, A.
O409
Omar, M.
P2170
Omar, S.V.
P1888
Omodeo-Zorini, E.
O415
Onal, S.
O391
Onen, A.
P1736
Öner, Y.A.
P1413
Onguru, P.
P1222, P1659
Önnberg, A.
P671
Onni, T.
P899
Ono, Y.
P715
Onori, M.
P1245, P1563, P1948
Onozaki, M.
P715
Ooi, N.
P1854
Oostdijk, E.A.
P1116, P1214, P1215
Oosterheert, J.J.
P995
Opal, S.
S72, P2210
Oppenheim, B.
P913
Oprea, E.
P1044
Orasch, C.E.
O148
Orazi, D.
P1284
216
Name
Number
Orduña, A.
P1416, P1923
O312
Orefici, G.
Oren, I.
P693, P1458, P1663
Oresic, N.
P1981
Orfanidou, M.
P1348, P1492
Oriol, I.
P1579
Oris, E.
P1004, P1829
Orlando, G.
O415, P793
Ørnskov, D.
P587
Orsi, A.
P2086
O190
Orsi, C.F.
Orta, N.
P2161
Ortega, D.
P860, P870
Ortega, M.
P2231
Orth, H.
P824
Orth-Höller, D.
P1344
Ortí, G.
P2244
Ortisi, G.
P834, P1314
Ortiz de Lejarazu, R.
P1765
Ortiz de Urbina, J.
P2093
Ortiz Princz, D.
P581
Ortolani, R.
P2004
Oryasin, E.
P1053, P1707
Osbeck, L.
P1261
Osek, J.
P588
Osiecki, J.
P906
Ossewaarde, J.
P1237
Ossi, C.
P832
Oster, G.
P1281
Österblad, M.
P690
Ostergaard, C.
P830, P1593
Ostyak, A.
P1019
Osztie, H.
P919, P1106
Ota, M.O.
O251
Otelea, D.
P2182
Otero, J.R.
P1881
Otrusina, L.
P1307
Ott, A.
P1417, P1419
Ott, E.
P1315
Ott, T.
P1979
Otte, M.
P1897
Otter, J.
O139, P828
Otter, J.A.
P831, P1206, P1338
Ottersen, O.P.
O470
Otto, M.
S14
Ouanich, J.
P745
Ouburg, S.
P1002
Ouchi, K.
P989, P1422
Overdevest, I.
P1728
Overton, T.W.
P721
Overton-Lewis, C.
P2006
Oviedo, V.
P739
Ovies, M.
P2161
Owlia, P.
P568
Oyama, L.
P1454
Oyur, T.
P1681
Öz, Y.
P2146
Oza, A.
P1274
Ozakin, C.
P1394
Ozbel, Y.
S20, P875
Özbilgin, A.
P875, P1412, P1681
Ozdemir, D.
P1228
Ozdemir, K.
P1226
Özden, I.
P1413
Ozden, K.
P1090, P1091
Özenci, V.
P1620, P1913, P2196
Ozensoy Toz, S.
P861, P875, P880
Ozger, H.S.
P734
Final Programme
Name
Ozinel, M.A.
Oziol, E.
Özkul, A.
Ozkurt, Z.
Ozog, Y.
Oztoprak, N.
Ozturk, R.
Ozyegen Aslan, S.
P
aasch, F.
Pablos, C.
Pace, S.
Pacho, C.
Pachón, J.
Number
P1394
P1584
O37
P1090, P1091
P1943
P1394
P1755
P1740
P2018
P2186
P802, P803, P810
P1958
O244, O474, P1069,
P2139, P2147
Pack, T.
P912, P1979, P1980
Padalko, E.
P1953
Padilla, B.
P2095
Padilla, C.
P2095
Padovan, A.C.
P1944
Pádua, E.
O38
Paesmans, M.
P2087, P2109
Pagani, L.
P755, P1403
Pagano, F.
O415
Pagano, G.
P1284
Pagano, L.
O154, S331, P1941
Paganotti, G.M.
P2213
Page, M.
P1146, P1184
Page, R.
P1508
Pagenstert, G.
P557
Pagliano, P.
P1460, P1654
Pagliuca, A.
O388, P2105,
P2134, P2137
Pagoni, S.
P1611
Pagotto, A.
P873
Pai, H.
P1392
Pai, I.G.
P1198
Pai, S.
O343
Paik, I.-H.
P1166
Paixão, E.
O38
Paixão, P.
O350
Pajoro, M.
P1020
Pakosz, K.
P1119
Pal, T.
O526, P653
Palacian, M.
P847, P1949
Palaiologou, N.
P1095, P1396
Palamara, G.
P988
Palardy, J.E.
P2210
Palermo, C.I.
P2061
Paliogianni, F.
P1880
Pallarés, A.
P2059
Pallarés, R.
P1368
Pallavicini, L.
P1420, P2236
Palmeiro, A.
P883, P1409, P1878
Palmer, H.
P1487
Palmer, R.
P918
Palomar, M.
P1110, P1278
Palomar Pérez, J.J.
P1566
Palomares, J.C.
P1701, P2186
Palomino, J.C.
P2018
Palomo, J.
P2072
Palop-Borrás, B.
P1996
Palumbo, H.
P1794, P1796
Pan, A.
P673, P834, P853,
P1246, P1263, P1264,
P1314, P1587
Pan, Y.J.
P1742
Panagea, T.
P1252
Name
Number
Panagiotopoulos, T.
P1867
P567
Panagopoulou, A.
Panassié, L.
P2223
Panayea, T.
P1147, P1355
Panayotou, G.
P717
Pandrup Duer-Jensen, M.
P697
Pane, J.
P1696
Pangalis, A.
P957, P960
Pangercic, A.
P2224
Paniara, O.
P1323, P1327
P1947
Panneerselvam, K.
Paño-Pardo, J.R.
P1279
Panopoulou, A.
P2067
Panopoulou, M.
P717, P927, P957,
P970, P1491
Pansani, L.
P1239
Pantosti, A.
P898, P1371, P1373
Paolucci, S.
P2172
Papadaki, M.
P1389, P1393
Papadakos, K.
P1866
Papadimitriou, M.
P920, P1095,
P1322
Papadopoulos, C.
P1901
Papadopoulos, N.G.
O416
Papadopoulos, S.
P736
Papadopoulou, C.
P555, P1098
Papadopoulou, D.
P888
Papagiannitsis, C.C.
P1348
Papaioannou, V.
P567, P575,
P1125, P1348
Papamichail, D.
O35
Papanagiotou, A.
P2060, P2207
Papanastasiou, S.
P888, P1022
Papanikolaou, K.
P1323, P2180
Papaparaskevas, J.
P960
Papapetrou, E.
O35
Papastamopoulos, V.
P1323,
P1327, P2180
Papazacharia, I.
P736
Papazoglou, L.
P888, P1022
Papetti, A.
P1154
Papic, N.
P2224
Papineni, P.
P1007, P2016
Papoff, P.
P2197
Papoutsidou, E.
P957
Papoutsidou, H.
P1348
Papp, T.
P1522
Pappa, O.
P1238, P1240,
P1322, P1348
Pappas, G.
S18, E119
Pappas, P.
O153
Paracha, M.
P1578
Paradela, A.
P699
Parakh, R.
P2091
Paraschiv, S.
P2182
Paraskakis, I.
P960, P1561, P2164
Paraskevaidis, S.
P1845
Pardini, M.
O383, P2041
Pardo, F.
P1723
Pardo, J.
P1949
Pardo, T.
P1416
Parejo, N.A.
P2210
Parenti, M.
P1587
Pariani, E.
O245
Parish, T.
P1017
Park, C.W.
O34
Park, D.W.
P1392, P1290, P1598
Park, E.S.
P1308
List of Authors
Park, G.
Park, J.
Park, K.
Park, K.H.
Park, S.
Park, S.J.
Park, S.D.
Park, San Hyuk
Park, Sun Hee
Park, S.W.
Park, S.Y.
Number
P1856
P1743
P1356, P2053
P1197
O476
P890
P777
P647
P1392
P1198
P846, P1391,
P2082, P2084
Park, Y.S.
P1198, P1976
Park, Y.H.
P2195, P2225
Park, Y.J.
P714, P1356, P2053
Parlak, M.
P1090, P1091
Parlato, C.
P1234
Parm, Ü.
P1568
Parneix, P.
P1282
Paroni, M.
P1151
Parra, D.
P1852
Parra, J.A.
O241
Parra, M.
P1701, P2186
Parra-Ruiz, J.
P1852, P2166
Parreira, R.
O495
Parrocchia, S.
P1284
Parry, M.
P1205
Parsons, C.
P1333
Partridge, S.
P560, P1811, P1816
Pascual, A.
O143, P599, P718,
P1182, P1346, P1449,
P1477, P1879
Pascual, M.
P2081
Pascual, V.
O236, P1641,
P1658, P2031
Pasero, D.
P802, P803
Pasini, B.
P984
Pasquarella, C.
P1113
Pasquau, J.
P2166
Passadore, L.F.
P963
Passera, M.
P1911, P1919
Passerini Tosi, C.
P872
Pastagia, M.
O92
Pasteran, F.
P739, P773
Pasxali, A.
P1491
Pataki, M.
P1216
Patel, A.
P1992
Patel, B.
O500
Patel, N.
P1300
Patel, S.
P1370
Paterson, D.L.
O299
Patibandla, S.
P2234
Patikas, I.
P2067
Patroni, A.
P1246
Patterson, C.
P2092
Patterson, T.F.
O94, O153, P1955
Patti, R.
P2152
Patton, A.
O44
Pauksens, K.
O425
Paul, M.
S229, E274,
S402, P1482
Paul, R.
P1023
Paulke-Korinek, M.
P1560
Paulsen, I.
P1811
Pauskar, M.
P1568
Pavan, A.
P959
Pavelka, J.
P1567
Pavlik, I.
P2043
Name
Pavlovic, M.
Pavon, A.
Pawar, V.
Pawlotsky, J.-M.
Pawlowska, J.
Payet, C.
Paz, E.
Pazos, C.
Pazzani, C.
Pea, F.
Peacock, S.
Pearce, D.
Pearlman, E.
Pearson, J.
Peccatori, J.
Pecile, P.
Peck, K.R.
Number
P2056
P1660
P1864
S182
O30
P1192
P2077
P2116
P630
E118
P1547
P1702
O492
O306, P821
O154
P1357
P836, P846,
P1391, P1549, P1598,
P2082, P2084
Pecori, D.
P873
Pecqueur, D.
P1951
Pecsi, I.
P1017
Pedersen, L.
P1298
Pedersen, T.
P923
Pedna, F.
P1587
Pedroni, M.
P898
Peel, T.
P1656
Peetermans, W.
P958
Pefau, M.
P1282
Peigne, V.
P2132
Peixe, L.
O300, O301, S458,
P619, P675, P694,
P1343, P1354
Peláez, T.
O479, P1099, P2095,
P2102, P2121
Peleg, A.Y.
P1050
Pelegrin, I.
P1459
Pellicioni, M.
P1680
Pellin, D.
O248
Pelloux, H.
P2131, P2138
Peltola, V.
O523
Peltroche-Llacsahuanga, H.
P1791
Pemán, J.
P2116, P2142
Pempinello, C.
P1654
Pempinello, R.
P1654
Peña, A.
O363, P1826, P1852,
P2166, P2170
Peña, C.
P612
Peñalver, M.D.
P1723
Peñalver-Barral, D.
P1804
Penasse, C.
O32
Penterman, R.
P1885, P1886
Pepi, N.
P2233
Peppas, G.
P1638
Peradotto, F.
O316
Peral, J.
O157
Peraldi, M.-N.
P2073
Percivalle, E.
P1000
Perdigão, J.
O384
Perdreau-Remington, F.
P906
Pereira, C.
P1814
Pereira, P.
P1358
Pereira, R.
P893
Pereira, S.
P1317
Pereira, S.G.
P574, P1771
Perek, D.
P1570
Perez, J.
O236, P1629, P1661
Perez, J.L.
P2161
Name
Number
Pérez, L.
P1701, P2186
P776
Perez, M.
Perez del Molino Bernal, I.C.
P1952
Perez Saenz, J.L.
P1066
Perez-Blazquez, E.
P1881
Perez-Castro, S.
P897
Pérez-Cortes, S.
P1475
Perez-Lopez, J.A.
P1826
Perez-Ordoñez, A.
O244
Pérez-Pascual, P.
P2029
P2187
Pérez-Rivilla, A.
Perez-Romero, P.
O244, P2080
Pérez-Ruiz, M.
P2204
Perez-Trallero, E.
P1066
Perilli, M.
P596, P1062
Perin, S.
P1911
Perlin, D.S.
O476, O485
Perneger, T.
P1380, P1388, P1684
Perotin, J.
P1865
Perraud, M.
P2126
Perreten, V.
P615, P936, P1349
Perry, M.
P2096
Perry, S.
P1527
Persijn, L.
P1953, P2135
Person, C.
P2151
Persson, K.
P1700
Persson Rova, L.
P1417
Peslova, K.
P1940
Pestova, N.E.
P1473, P1929
Petcu, V.
P1495
Peters, G.
P1186
Peters, R.P.H.
O211
Petersdorf, S.
P557, P1983
Petersen, A.
P747, P1920
Petersen, E.
S10, E270
Petersen, H.
P1988
Peterson, L.
S442
Petinaki, E.
P920, P957
Petit, C.
O142
Petitto, V.
P1062
Peto, Z.
P1220
Petrelli, D.
P728
Petridis, A.
P1491
Petrikkos, G.
E275, P1147, P1252,
P1355, P1539
Petropoulos, A.
P1488
Petrosillo, N.
O46, P1284,
P1645, P2184
Petrou, M.
P2098
Petrovic, M.
P1079
Petruzziello, M.
P2236
Petti, M.
P2125
Peyman-Fard, N.
P1949
Peyron, F.
S396, P1408, P1893
Pfalle, M.
S54
Pfeifer, Y.
O215, P684, P1351
Pfister, W.
P1447
Pham, J.K.
P1899, P1900
Pham, Julien
P1338
Pham, Jeanette
P1915
Phan, T.
P1202
Phee, L.
O194, P1591
Pheng, L.
P1519
Phiboonbanakit, D.
P1188
Philbin, M.
P1274
Phillips, S.-A.
P1736
Piarroux, R.
K200
Phipps, L.
P2092
Name
Number
Piatkowska, E.
Piatti, A.
Piazza, A.
Picaud, J.-C.
Picazo, J.
Piccaro, G.
Piccoli, F.
Piccoli, L.
Piccolin, G.
Piccolo, G.
Pichardo, C.
Pichon, B.
Pickkers, P.
Picón, E.
Piddock, L.J.
Pidone, J.
Piens, M.
Pierangeli, A.
Piérard, D.
Pierce, K.
Pietrosi, G.
Pietrucha, B.
Piette, A.
Pietzka, A.
Pievaroli, L.
Pike, R.
Pilaikul, J.
Pilalas, D.
Pilios, I.
Pillar, C.
O494
P1403
O414, P755
P1569
S160, P663, P1925
O383, P2026
P1847
O487
P1005
P877, P1892
P1069
O349, P829
P1617
P1477
P727, P1884
P1622
P2126
P2200, P2197
P780, P1836, P1924
P1978
P2075
P1462
P1953, P2135
P1729
O140
P934
P1547
P2175, P2176
P1611
O418, P554,
P762, P947, P1143,
P1144, P1185,
Pilmane, M.
P1786
Pilut, C.
P1303
Pimkina, E.
P1999
Pina-Vaz, C.
P767
Pinel, C.
P2151
Pinelli Ortiz, E.
P859
Pinheiro, J.
P1557
Pinho, M.
P980, P1715
Pinholt, M.
P922
Pinilla, B.
O157, P1585
Pinto, A.
P1202
Pinto, Antonio
P886
Pinto, C.
O384
Pinto, F.R.
O189
Pinto, M.
O350
Piphitaporn, S.
P1547
Piralla, A.
P2172, P2199
Pirnay, J.
O291
Piroth, L.
P1502
Pirs, M.
P571, P1365
Pisarev, H.
P1568
Piscoche, N.
P1564
Piselli, P.
P1284, P1645
Piso, R.J.
O146
Pissarra, F.
P2057
Pistella, E.
P1642
Pistone, D.
P1020
Pitart, C.
P649, P738,
P1066, P1833
Pittet, D.
O140, E272, K334,
P1313, P1380, P1388
Pizzichemi, G.
P2173
Pizzolitto, A.C.
P1849
Pizzolitto, E.L.
P1849
Plakias, G.
P1147
Plamondon, L.
P1509
Final Programme
217
Chairs & Authors
Name
List of Authors
Name
Number
Planche, T.
Platia, M.A.
Platsouka, E.
Platt, S.
Platteel, T.N.
P1991, P1995
P2205
P1332, P1348, P1491
P1710
P668, P764,
P1010, P1668
Plaza Garcia, S.
P1627
Pleasiat, P.
P1750
Plésiat, P.
O289
Plevneshi, A.
P973, P974
P2226
Plochev, K.
Plongla, R.
P884, P956
Ploy, M.C.
O420, P639
Pluister, G.N.
P1703
Plum, G.
P916, P2124
Plumelle, M.
P2221
Plummer, F.
O387
Pneumatikos, S.
P1464
Po, J.
P1205
Pochkhua, M.
P2040
Podavalenko, A.
P1088
Pødenphant, L.
P587
Podschun, R.
P1748
Poeppl, W.
O477, P1781
Pöge, A.
P2055, P2169
Poggensee, G.
P2054
Pogka, V.
P1866, P1867
Pogodina, V.
P1882
Poh, B.
P1311
Poirel, L.
O216, O217, O218,
P607, P608, P1048
Polemis, Michael
P1240, P1491
Polemis, Mixalis
P1348
Poletti, R.
O245
Poljak, M.
E117
Polster, K.
P1578
Polverino, E.
P1190
Polykandriotis, E.
P820
Polyzos, K.
P1439
Pomba, C.
P598, P1248, P1350
Pomicino, A.
P1460
Pommepuy, M.
S64, P2202
Pompilio, A.
P1150, P1851, P1948
Pomplun, S.
P2134
Pomponio, S.
P1150, P1851
Pond, M.
P1991
Pong-Porter, S.
P973, P974
Pongratz, P.
P1001, P1540
Pontrelli, G.
P2173
Ponzin, D.
P1682
Poort, L.
P1695
Popa, G.L.
P887
Popa, M.
P1044, P1751, P1752
Pope, C.
P199, P1995
Popescu, C.
P1495, P2189, P2230
Popescu, G.A.
P2230
Popescu, I.
P1532
Popov, G.
P2226
Popova, M.O.
P2129
Popova, O.
P1908
Popovic, N.
P2056
Popow-Kraupp, T.
O243, P1498
Popp, W.
P1335
Poran, H.
P1406
Porignaux, R.
P2076
Porres-Osante, N.
P848
Porter, M.
O427
Porter, V.
P1676
Name
Portillo, M.
Portillo, M.E.
Portnoy, Y.
Portugal, I.
Posch, J.
Posfay-Barbe, K.
Posteraro, B.
Postl, A.
Potel, G.
Potel-Alvarellos, C.
Potempa, J.
Potoski, B.
Poudyal, A.
Poulain, D.
Poulakou, G.
Poulopoulos, K.
Poulou, A.
Number
P1475
P1934
O80, P782
O384
P926
P2088
P1941
P1560
P1500, P1504
P897
P1780
P2090
P784
P1785
P1147
P1491
P683, P695,
P1029, P1170
Poulsen, L.
P999
Pournaras, S.
P683, P695, P737,
P1070, P1170,
P1363, P1503
Pourshafie, M.
P1063
Poutanen, S.M. P1036, P1037, P1676
Poveda, M.
P2161
Povilonis, J.
P706, P707
Powderly, W.
P2177
Pozzi, G.
P976, P2009
Prada, A.
P1754
Prada Pardal, J.
P1277
Pradelle, M.
P1382
Prag, J.
P660
Prager, R.
P1351
Prasad, K.N.
P768
Prata, L.
P1082
Prati, F.
O386
Pratlong, F.
P875
Pratsinis, H.
O416
Prayitno, K.
P1037
Prazakova, S.
P1167
Predazzer, R.
P1805
Preiswerk, B.
P799
Prekates, A.
P1485
Premaratna, R.
P855
Prendergast, B.D.
S405
Prenger-Berninghoff, E.
O528
Prenna, M.
P728
Pressler, T.
P797, P2149
Presterl, E.
O150, P929
Preziuso, S.
P980, P1727
Priavali, E.
O35
Price, N.
P1994
Prieto, M.
P1938
Prifti, H.
P1238, P1240
Prignano, G.
P988
Prin, S.
P1660
Prince, W.
P1524
Princz, G.
P919, P1106
Prisco, V.
O85
Privitera, G.
P700, P1335
Probst, C.
P1419
Prod'hom, G.
P1483, P1834
Proenca, A.
P893
Prokocimer, P.
P1516
Pronicki, M.
O30
Protivinsky, J.
P1803
Protonotariou, E.
P1181, P1845,
P1846
Final Programme
Name
Number
Prouteau, C.
Proux, D.
Provenzani, A.
Prtack, L.
Pruzzo, C.
Przybylo, M.
P664
P1317
P2075
S453
P1154
O47, P909, P1288,
P1379, P1578, P1653
Psarras, S.
O416
Psichogiou, M.
P687, P1147
Puckett, R.
P1696
S373
Puel, A.
Puerta, T.
P1455
Pueyo, I.
P1701
Pugin, J.
P1756
Pugni, L.
P1234
Puig, L.
P794, P1934
Pujol, M.
P1278
Pulcini, C.
P1287, P1293
Pulián, V.
P2059
Puliyel, J.
P1442
Pullukçu, H.
P861, P1443
Pulvirenti, F.R.
P1872
Pumarola, T.
P1765
Punda-Polic, V.
P1975
Punin, A.
P1042, P1573
Punt, N.
P756
Pupillo, A.
P630
Purdell, J.
O499
Puro, V.
P1284, P1319, P1328,
P1645, P2155
Purrello, S.
P907
Puthavathana, P.
P1445
Putignani, L.
P1239, P1841,
P1948, P2173
Puttagunta, S.
P1536
Puy, A.
P1026
Puzniak, L.
P1534, P2127
Puzyrev, V.
P2235, P2237
Pyrenkova, I.
P2237
Q
P1426, P1427
P1221, P1235
P1176
P1660
O196
P994
P2131
P2143
P1161
P952
P1378
P1709
P2133
P1629
O300
R
O354
P1691
P1156
P1331
P1382
P1893
P1351
P1576
P2150
P1843
P941
P1135
iao, H.J.
Quattrocchi, A.
Quayle, A.J.
Quenot, J.P.
Quentin, C.
Quentin, R.
Quesada, J.L.
Quindós, G.
Quinn, J.
Quinn, J.P.
Quiñones Pérez, D.
Quint, W.G.
Quintana, E.
Quintana, S.
Quinteira, S.
aadsen, S.A.
Raaijmakers, L.M.
Rabiei, M.
Rabinowitz, G.
Rabjeau, A.
Rabodonirina, M.
Rabsch, W.
Rachina, S.
Racil, Z.
Radjenovic, D.
Radtke, L.
Radu-Popescu, M.
Name
Number
Radulescu, Matilda
P1303
P2182, P2230
Radulescu, Mihaela
Radulescu, S.
P887
Rafailidis, P.
P1439
Rafalskiy, V.
P1550
Rafeiner, P.
P1655
Raffaldi, I.
O316
Raffoux, E.
O156
Rafila, A.
P1495
Raftari, M.
P1201
P789
Raftogiannis, M.
Raglio, A.
P701, P984, P1357,
P1919, P1998
Rahal, E.A.
P1072
Rahamat-Langendoen, J.C.
O408,
O412, P2198
Rahav, G.
P735, P1595
Rahbar, M.
P1662
Rahimi, F.
P1063
Rahimifard, N.
P1156
Rahmany, G.
P1860
Rai, S.
P768
Raiisi, A.
P1411
Raila, I.
P1028, P2055, P2169
Raimondo, M.
P2064, P2185
Raiola, A.
P2086
Raissouni, F.
P1959
Rajatanavin, N.
O367
Rajendran, Ramaswamy
P1947
Rajendran, Ranjith
O480, P1856,
P1955
Rakhi, A.
P1071
Rakhshani, N.
P1907
Ramage, G.
O91, O480,
P1856, P1955
Ramalheira, E.
O105, P661,
P699, P1817
Ramalho, J.
P1358
Rambach, A.
O101
Rambach, G.
P2107
Ramesh, M.
P1532
Ramírez, E.
O143
Ramirez, M.
O189, O357,
P980, P1715
Ramirez, P.
P1765
Rammer, P.
P1465
Ramos, A.
P2167, P2171
Ramos, B.
P1606
Ramos, J.L.
P983
Rampello, S.
P984
Ramzi, L.
P642
Ran, L.
P1765
Ranalli, T.
P912, P1979, P1980
Randall, C.
P1454
Randall, L.P.
P628, P1726
Ranellou, K.
P695
Ranford-Cartwright, L.
P2009
Ranieri, V.M.
P802, P803
Ranin, J.
P2188
Ranjbar, R.
P568, P864, P953
Rank, D.
P791, P1531
Ranke, C.
P1447
Ranno, S.
P1239, P1841
Rao, A.
P906
Raoult, D.
S133, K177, S205, O242,
P720, P825, P882, P1114,
P1472, P2212, P2220
Raponi, M.
P1239
List of Authors
Number
Rapoport, M.
P773
K197
Rappuoli, R.
Rashid, M.
P1272, P1273, P1973
Rasigade, J.-P.
O520, P1569
Raskin-segal, A.
P1331
Rasmussen, A.K.
P903, P908
Rasmussen, M.
P1858
Rasouli, M.
P1428, P1429
Rasson, C.
P2109
Rastawicki, W.
P588, P1705
P1127
Rath, P.M.
Ratnaraja, N.
P2044
Rato, S.
P2168
Rauch, A.
P2076
Rauch, M.
P1432
Raulin, O.
P1569
Ravaei Sharif-Abadi, G.
P1157
Ravanini, P.
O415
Ravasio, V.
P1998
Raviolo, S.
P802, P803
Ravn, P.
O253, P2020
Raymond, F.
P1382
Raz, R.
P1971
Raz-Pasteur, A.
P1458, P1663
Raza, M.M.
P2046
Read, M.A.
O350
Read, R.
5
Reboldi, M.
P592
Reboli, A.
O153
Recio, S.
O479, P2095, P2102
Redden, J.
P2096
Reddy, S.
P1591
Reddy, Sush
O152
Redelberger-Fritz, M.
O243, P1498
Redmond, J.
P2174
Reed, K.
P2074
Refaat, R.
P1024
Réfrégiers, M.
P1500
Regazzi, M.
P814
Regine, V.
P2064, P2185
Régis, C.
O239
Regnier, B.
P1195
Regueiro, B.J.
P1723
Reich, A.
P2055
Reichley, R.
P2127
Reigadas, E.
P2121
Reijans, M.
P1943
Reijtman, V.
P1557
Reilly, J.
S533
Reina, J.
P1199
Reinhardt, J.
O153
Reinholde, I.
P2203
Reinis, A.
P1786
Reinthaler, F.F.
P926
Reis, M.G.
O466, P1414
Reisman, A.
P1534
Rekeda, L.
P791
Rello, J.
S228
Remy, J.
P1162, P1165, P1166
Renata, B.
P1220
Renaud, N.
P2101
Renders, N.H.
P995
Rendi-Wagner, P.
P1560
Rendina, A.
O250
Rennie, R.
P1189
Renois, F.
O309, P1865,
P2076, P2156
Renteria, M.
P1121
Name
Number
Rentero, Z.
P2158
P1584
Reny, J.
Renzi, G.
P650
Resi, D.
P1263, P1264, P1587
Respaldiza, N.
P1212
Restelli, V.
P1189
Restuccia, G.
P1285
Retamar, P.
P1475, P1477
Reuland, E.A.
O102, O354
Reuthebuch, O.
P1652
P558
Revathi, G.
Revest, M.
P998, P1956
Revillo, M.
P594, P845,
P847, P1949
Revuelto-Rey, J.
P1425
Rex, J.
S180, S259
Rey, E.
P2025
Reynaud-Gaubert, M.
P825
Reynolds, R.
P1104, P1231
Rezaiemanesh, M.R.
P864
Rezende, R.
P651, P1669
Rezo-Vranjes, V.
P704
Rezusta, A.
P594, P845,
P847, P1949
Rhomberg, P.
P930, P945, P1126,
P1137, P1138, P1607
Ribaud, P.
O156, P2239
Ribeiro, C.
P2071
Ribeiro, G.
O350, P624, P636
Ribeiro, Manuela
O350
Ribeiro, Márcia
P894
Ribera, A.
P1459
Ribon, W.
P2018
Ricart, M.
P2079
Ricci, G.
P1036
Ricci, S.
P976
Ricciotti, G.
P1948
Riccobene, T.
P791
Rice, K.
O425
Richardson, G.
O427
Richardson, K.
P2112
Richet, H.
O242, P1114,
P1472, P2220
Richling, B.
P1639
Richmond, P.
O308
Richter-Dahlfors, A.
S542
Ricketts, A.
P2096
Ricotti, E.
P1553
Rieder-Monsch, C.
P1690, P1796
Rieg, S.
P852, P1589
Rieger, A.
P1498
Riem, L.
P894
Riera, E.
O288, O296
Riera, M.
P1658
Rieu, P.
P2076
Riezebos-Brilman, A.
O408,
O412, P2198
Righi, E.
P1113
Rigobello, V.
P853
Rigoni, A.
P1805
Riis, A.H.
P1577, P1588
Rijnders, B.J.
O478
Rijnsburger, M.C.
O102, O354
Rimar, M.
P1096
Rimarova, K.
P1096
Rimmbach, C.
P817
Rio-Maior, H.
P881
Ríos, E.
P1925
Name
Number
Ríos, M.J.
P1879
P728
Ripa, S.
Ripoll, A.
P643
Riquelme Bravo, E.
P1566
Risberg, K.
P1360
Risch, L.
P1843
Risch, M.
P1843
Risggits, A.
P888, P1022
Riss, S.
P1737
Risso, K.
P1435
P1695
Ritmeester, W.
Ritzi-Lehnert, M.
P1909
Riva, E.
P1554
Rivera, F.
P1562
Rivera, M.
P987
Rivera-Olivero, I.A.
P1558
Rivoisy, C.
O252
Rizzi, M.
P872, P1998
Roana, J.
P2152
Robel-Tillich, E.
P2055
Robert, C.
P720
Robert, O.
O239
Robert Nicoud, M.
O289
Robert-Gangneux, F. P1432, P1956
Roberts, D.
P1288
Roberts, J.
P1381
Robertson, C.
P1207
Robinson, J.O.
O306, P1242
Robitaille, R.
O484
Robledo, J.
P2039
Robles, A.
O236
Robles Fonseca, L.
P1566
Robotham, J.V. O147, P1115, P1254
Roc, L.
P1949
Roca, I.
P649, P1838
Rocchetti, A.
P701, P1911
Rocha, R.
P1813
Rocha, S.
P699
Roche, C.
P602
Roche, F.
P1258
Rock, C.
O423
Rockenschaub, S.
O243
Røder, B.
P658, P660
Rödler, S.
O243
Rodloff, A.C.
P1753
Rodolakis, A.
S131
Rodrigo, S.
P1153
Rodrigues, A.G.
P767
Rodrigues, L.
P723, P724
Rodrigues, M.F.
P1859
Rodrigues, V.
P856
Rodríguez, A.
P2042
Rodriguez, Claudia
P739
Rodríguez, Cristina
P612
Rodriguez, C.A.
P1219
Rodriguez, I.
O86
Rodríguez, O.
P581
Rodríguez Rosales, G.
P1631
Rodríguez-Alvarez, C.
P900
Rodríguez-Avial, C.
P663
Rodriguez-Avial, I.
P663, P1925
Rodríguez-Baño, J.
O143, P718,
P1279, P1346, P1475,
P1477, P1879
Rodriguez-Baños, M.
P1725
Rodríguez-Créixems, M.
P1468,
P1621, P1632
Rodriguez-Cundin, P.
O241
Name
Number
Rodriguez-Dominguez, M.
P1455
P841
Rodríguez-Garrido, S.
Rodríguez-Hernández, M.J.
P2094
Rodríguez-Martínez, J.M.
P599,
P1182, P1449
Rodriguez-Morales, A.
P860, P870
Rodriguez-Noriega, E.
P614
Rodríguez-Pintó, I.
P1647
Rodríguez-Pollán, R.H.
P1461
Rodriguez-Tudela, J.L.
O151, O476,
P2103
Rodriguez-Villalobos, H.
P1721
Rodvold, K.
P1058
Roed, C.
P1084
Roeser, T.
P1909
Roger, P.
P1287
Roger, P.M.
P1435
Rogers, G.B.
P1936
Rogers, S.
P1288
Rogers, T.R.
P1592
Rogiers, X.
P2078, P2083
Rogues, A.-M.
P1282
Rohde, H.
O191
Roilides, E.
O49
Roisin, S.
O297, P778, P1236
Roivainen, M.
O409
Roiz, M.P.
P965, P1952
Rojanawiwat, A.
O367
Rojas, L.
P1468, P1630
Rojo, F.
P964
Rojo-Bezares, B.
P606
Rokosz, N.
P1705
Rolain, J.M.
P720, P825
Roldgaard, B.B.
P2070
Rolencova, M.
P2150
Rolland, C.
P2138
Rolo, D.
P1374
Rolo, J.
O348, O350, P938
Román, E.
O295, P594, P612,
P719, P1902
Roman, J.
P1826
Román Paucar, E.
P993
Romani, L.
S549
Romaniszyn, D.
P1935
Romanò, C.
P1159
Romano, R.
P2213
Romanov, A.
P1376
Romanowska, E.
P1570
Romanska-Kita, J.
O31
Romeo, M.
P2136
Romeo, M.A.
P1221, P1235
Romera, M.-H.
P2221
Romero, B.
O366, P1725
Romero-Gómez, M.P.
P1712
Romero-Romero, B.
P1212
Romilowych, M.
P973, P974
Romney, M.
P843
Ronkiewicz, P.
P966
Rönkkö, E.
O409
Ronn, M.
O96
Ronsin, C.
P1699
Roorda, L.
P1237
Ros, J.
P878
Ros, L.
O247
Rosaria, M.
P872
Rosario, P.
P1654
Rosas, R.C.
P1944
Rosati, M.
P1191
Final Programme
219
Chairs & Authors
Name
List of Authors
Name
Number
Roselló, E.
P1942
O486, O490, P2070
Röser, D.
Roset, A.
P1665
Roshak, K.
P774
Rosina, M.
P853
Rosingh, A.W.
P1610
Rosner, M.
P1001
Ross, J.
P1367
Ross, T.
P1600
Rossano, A.
P615
P1691, P1695
Rossen, J.W.
Rossi, F.
P2085
Rossi, Marianna
P1046, P1233,
P1337
Rossi, Marco
P1460
Rossi de Gasperis, M.
P2173
Rossokha, Z.
P1908
Rossolini, G.M.
S328, E448,
P572, P597, P609,
P646, P673,
P700, P1118
Rostami-Nejad, M.
P869
Rostan, O.
P1432
Rostasy, K.
O362
Rostoka, D.
P1786
Rosvoll, T.C.
P923
Rothberg, J.
P774
Rothman, M.
S327
Rotimi, V.
P711
Rotolo, V.
P2205
Rotondo, R.
P1654
Rottier, W.C.
O99
Roudbarmohammadi, S.
P1430
Roudbary, M.
P1430
Rounds, M.
O358, O359
Rousee, J.M.
P1690, P1796
Rousseau, B.
P1193
Rousseau, S.
P1502
Rousson, V.
P1783
Roussou, Z.
P1332, P1348
Routsi, C.
P1616
Routsias, I.
O364
Rouyer, C.
P1785
Rovida, F.
P1000, P2199
Rovinetti, C.
P2209
Roy Chowdhury, P.
P617
Roymans, R.
P1691
Rozemeijer, W.
O211
Rozenberg, O.
P1406
Rozentale, B.
P2203
Ruas-Madiedo, P.
P1155
Rubini, R.
P959
Rubio, C.
P1378
Rubio, J.M.
P1026
Rubio, M.
P2239
Rudiger, A.
P799
Rudnick, W.
P973, P974
Rudolph, K.
P992
Ruef, C.
P1203, P1335, P1644
Ruf, B.R.
P2055, P2169
Ruhnke, M.
S332
Ruhwald, M.
O253, P2020
Ruijs, G.
P1302
Ruiz, E.
P594, P1813
Ruiz, I.
P1942
Ruiz, J.
P1474, P1562,
P1564, P1754
Ruiz, S.
P2120
Name
Number
Ruiz Contreras, J.
Ruiz de Alegria, C.
P1925
P993, P1471,
P1952
Ruiz de Gopegui, E.
P2161
Ruiz Del Castillo, B.
P719, P1902
Ruiz-Garbajosa, P. O107, O301, O355
Ruiz-Perez de Piapaón, M.
P1291
Ruiz-Santana, S.
P1950
Rummukainen, M.-L
P1269
Rumpianesi, F.
P646, P1919
P1369
Ruohola, A.
Rupnik, M.
P1981
Ruppitsch, W.
P1729
Ruscitti, L.E.
P1284, P1645
Rushworth, S.
P2069
Rusiecka-Ziólkowska, J.
O494
Rusman, L.
P586
Russo, Alessandro
O82
Russo, Antonio
P834, P1314
Russo, C.
P1245, P1563,
P1948, P2002
Russo, G.
P2213
Russo, R.
P2061
Rutherford, C.
P1039
Ruvoen-Couet, N.
P2202
Ruxrungtham, K.
O249
Ruzicka, F.
P904, P1861
Rybak, M.
O81, P935, P2090
Rybkina, A.
P2034
Rybkova, N.S.
P1473
Ryu, S.
P1392, P1549
Rzepka, R.
O195
Rzeszutko, M.
O314
Sá-Leão, R.
P1372
P2007
P1078
P1848
P1950, P2120
P1423, P1907
S529
P1532, P1533
P674
P2208
P1447, P1575
O47
P1158
P2179
P568, P953
P1158
P930, P943, P944,
P945, P1055, P1126,
P1129, P1130, P1131,
P1132, P1134, P1136,
P1179, P1367, P1607
Sadlier, C.
O423
Sáenz, Y.
O103, P606,
P848, P1716
Saez, A.
O488
Sáez-Nieto, J.A.
P1461
Safari, R.
P1410
Safarika, A.
O79
Safioleas, P.
P1565
Saga, T.
O101, P674
Sage, B.
P1583
Saglio, F.
P810
Saha, S.
P1011
Sahel, N.
P844
Saad Eldeen, H.
Saarinen, L.
Saavedra, M.J.
Saavedra, P.
Saberi, S.
Sabin, C.
Sable, C.
Sabtcheva, S.
Saccucci, L.
Sachse, S.
Sadasivam, I.
Sadeek, R.
Sadeep, M.
Sadeghifard, N.
Sadeq, R.
Sader, H.
Final Programme
Name
Sahin, N.
Sahin, S.
Sahly, H.
Sahm, D.F.
Number
P1740
P1225
P1748, P2190
O418, P554, P762,
P947, P1143, P1144,
P1185, P1219
Sahuquillo-Arce, J.M.
P1200
Sails, A.
O500
Saiman, L.
E443
Saito, T.
P1433
P2194
Sajadi, M.
Sakagami, E.
P760
Sakarya, M.
P1618
Sakka, V.
P1252
Sakkas, H.
O35, P555, P1098
Sakoulas, G.
P2090
Sala, G.
P1202
Salaam-Dreyer, Z.
P824
Salas, C.
P1833
Salas-Venero, C.
P1627
Salazar, J.
P1958
Salazar, M.
P1487
Salazar-Labori, E.
P860, P870
Salcedo, M.
O157
Saldan, A.
O410
Saleh Mghir, A.
P1068
Salem, E.
P1056
Salemovic, D.
P2188
Sales-Luís, J.
P1248
Salfa, M.C.
P2064, P2185
Salgueiro, L.
P862
Salman, N.
P1556
Salmon Ceron, D.
O252
Salomon, J.
P1331
Saluja, T.
O104
Salvadó, Margarita
P1934
Salvadó, Meritxell
P1658
Salvador, P.
P649
Salvana, E.M.
O492
Salvatorelli, E.
P798
Salvia, A.
P1331
Salvini, F.
P1554
Salzberger, B.
P1772, P1774
Salzer, H.J.
P645
Samadian, M.
P1634
Samaei, A.
P1775
Samarkos, M.
P1323, P1327
Sambatakou, H.
P2181
Sambeat, M.
P1958
Sambri, V.
P988
Samiotaki, M.
P717
Samoilovich, M.
P1441
Samonis, G.
P1175
Sampaio, J.
P760
Sampaio, S.
P760, P1767
Sampaolo, M.
O414
Samson, M.
P1432
Samuel, C.M.
P625
Samuelsen, Ø. P705, P1361, P1837
San Gil, A.
O236, P1641
San Juan, R.
P2077
Sancak, B.
P915
Sánchez, B.
P1155
Sánchez, C.
P1621
Sánchez, M.
P2094
Sanchez, M.A.
P961, P2231
Sanchez, S.
P2125
Sánchez García, M.
S159
Name
Number
Sanchez-Cespedes, J.
P1164
P2204
Sánchez-Seco, M.P.
Sanchini, A.
P898
Sanchis Boix, Y.
P1200
Sancho, L.
O350, P1178
Sanclemente, G.
P2079
Sandell, S.
P1973
Sander, C.
P1035
Sanders, E.A.
P969
Sandoval, N.
P1934
P860, P870
Sandoval, Y.
Sanfiorenzo, C.
P1435
Sangsajja, C.
P1445
Sanguinetti, M.
P1941
Sanjuan, V.
O241
Sanlibaba, P.
P1906
Sanna, S.
P1911
Santangelo, C.
P1235
Santiago, G.
O241, P1912
Santimaleeworagun, W.
P1969
Santinato, S.
P1398
Santini, C.
P1642
Santiwatanakul, S.
P1188
Santori, G.
P862
Santoro, F.
P2009
Santos, Carla
P760
Santos, Cátia
O105, P661, P1817
Santos, C.A.L.
P1849
Santos, C.S.
O466, P1414
Santos, L.M.
P1782
Santos-Antunes, J.
P767
Santos-Morano, J.
P1247
Sanz, E.
P860, P870
Sanz, I.
O366
Sanz, J.
O421, P1606
Sanz, Y.
S204
Sanz-Salanova, J.A.
P964
Saras, E.
P595
Sarasini, A.
P1000
Sardinha, T.
O350, P1178
Sargentini, V.
P2041
Saridou, S.
P888
Sarmiento, I.
P1031, P1529
Sarraz-Bournet, B.
P1087
Sarti, M.
P1587
Sasikala, S.
O193, P1174, P1176
Sato, I.
P1433
Sato, J.
P1604
Sato, T.
P2241
Sauer, P.
P896
Saulnier, P.
P818
Saunkratay, C.
P884, P956
Sauvanet, E.
P977
Savage, J.
P1381
Savarese, M.
P1800
Savelkoul, H.
O493
Savelkoul, P.H.
O102, O211, O354,
P1672, P1695
Saviano, R.
P1284
Savic Prince, S.
P2097
Savicheva, A.
P981
Savio, E.
S454
Saviuc, C.
P1044
Savolainen-Kopra, C.
O409
Savov, E.
P703
Savva, A.
O79, P789, P1616
Sax, H.
O140, P1388
Saxton, E.
P2234
List of Authors
Scaglione, F.
Scagnolari, C.
Scalas, D.
Scalia, G.
Scanu, A.L.
Scarpellini, P.
Scarselli, M.
Scemla, A.
Scerpella, E.
Schaberg, T.
Schack, M.
Schade, R.P.
Schaeftlein, A.
Schaer, M.
Schäfers, H.-J.
Schaffer, K.
Schapendonk, C.M.
Scharnetzki, E.
Scharringa, J.
Number
S67, S441
P2197, P2200
P2152
P2061
P1284
P1325, P1456
P1982
O156
P1536
P1266
P1575
O211
P806
P1823
P1738
P600
P668
P2054
P641, P668,
P688, P759, P764,
P1010, P1668
Scheid, C.
P2248
Scheideman, M.
P1166
Scheithauer, S.
P928, P1386
Schena, E.
O522, P1764
Schenke, K.
P1250
Schepens, M.L.
O290
Scheper, T.
P1417, P1419
Scheutz, F.
P2070
Schewenius, M.
P1261
Schibli, U.
O146
Schiferer, A.
O150
Schiller, R.A.
P684
Schilling, M.K.
P813
Schilling, S.
P1319, P1328
Schipper, M.E.
P1674
Schiroli, C.
P1336
Schjørring, S.
P1298, P2070
Schlamm, H.
P2108, P2153
Schlatterer, K.
P684
Schlegel, M.
P1321, P1385
Schleicher, X.
O525
Schlumberger, W.
P1417, P1419
Schlyakhto, E.V.
P1929
Schmid, D.
O501, P1001,
P1543
Schmidle-Loss, B.
P1560
Schmidt, H.
O362
Schmidt, Karin
P1977
Schmidt, Kristiane
P1885, P1886
Schmidt, N.
P2169
Schmidt, U.
P1524
Schmitt, N.
P1151
Schmitz, F.-J.
P1124
Schmoele-Thoma, B.
O425, O426
Schneider, C.
P852
Schnell, F.
P2211
Schöbi, B.
P1385
Schoevaerdts, D.
P1230
Schölvinck, E.H.
O408, P2198
Schön, G.
P1551
Schonheyder, H.
P830, P1586,
P1588, P1599
Schønning, K.
P658
Schotzinger, R.J.
O94
Schranz, H.
O477, P1781
Schranz, J.
O95
Schreckenberger, P.
P774
Name
Schreiter, K.
Schrenzel, J.
Number
P1028, P2055, P2169
O218, S434,
P650, P1094
Schroeter, A.
P1353
Schubert, Sabine
P785, P792
Schubert, Sören
S326, P758
Schuerch, N.
P1823
Schuetz, P.
O48
Schuhmacher, H.
P1652
Schultheis, N.
P1028
P1316
Schulz-Stübner, S.
Schumacher, H.
P658, P660
Schumacher, M.
P1109
Schumacher, U.
P1830
Schurink, C.A.
P2078, P2083
Schutzer, S.
O358
Schuurman, T.
O412
Schwab, F.
O138, P1112, P1229,
P1250, P1259, P1301,
P1320, P1480
Schwager, S.
O473
Schwartz, M.S.
P790
Schwarz, K.
P2234
Schwarz, S.
P933, P1101
Schwarzwalder, A.
O358
Schweickert, B.
P731, P854
Schweiger, M.
P1326
Schwenkglenks, M.
O238
Schwind, C.
P1909
Scialabba, M.
P1539
Scimè, R.
O154
Scioccati, L.
P988
Sciota, R.
O190
Scocchi, M.
P1150
Scolfaro, C.
O316
Scopes, E.
P1035
Scott, D.
O425, O426
Scott, Rebecca
P1583
Scott, Richard
O97, P1168
Scudeller, L.
P1582, P1642
Scuderi, C.
P776
Seaton, R.A.
O85
Seaton, S.
P1253
Sedigh, M.
P820
Sednaoui, P.
P1685
See, S.
O317
See, T.
P1311
Segatore, B.
P1062
Segond, F.
P1317
Segreti, J.
P2090
Segura, Carmen
O244
Segura, Concha
O86
Seidl-Friedrich, C.
P1560
Seif-Rebiei, M.
P1775
Seifert, H.
O192, O215, O525,
P852, P948, P1123, P1184,
P1450, P1589, P1706,
P1731, P2123, P2124
Seki, M.
P2148
Selleri, M.
P2155
Sellin, M.
P949
Selvaggi, C.
P2197, P2200
Selvarangan, R.
P761
Seme, K.
P571, P1365
Semoun, O.
P811
Sempere, A.
P2142
Semprini, S.
P2209
Sen, S.
P871, P1064,
Name
Number
P1286, P1541
O294
Senbayrak Akcay, S.
Sencan, I.
P1027
Sener, B.
P2232
Sengupta, J.
P1011
Senkyrikova, M.
P681
Senn, G.
P1203
Senn, L.
P1483, P1572, P1790
Senneville, E.
P1087
Senok, A.
P1213, P1383
P1107, P1568
Sepp, E.
Šeputiene, V.
P706, P707
Sergi Sergi, L.
P1764
Serna Ortega, P.
P984, P1919,
P1998
Serra, R.
P1234
Serrander, L.
P1832
Serrano, L.
P1182, P1346
Servino, L.
O415
Sessa, L.
P776
Setacci, D.
P1062
Seto, W.-H.
S203
Sette, P.
P1486
Sexton, H.
P796
Seyed javadi, M.
P2032
Seymour, G.J.
P1105
Seymour, J.
P2243
Seyrek, A.
P1883
Sezai Tasbakan, M.
P861
Sezen, F.
P1027
Sgouras, D.
P1866, P1867
Sguazzini, G.
P1284
Sha, W.
O246
Shabir, S.
O104, P840, P1720
Shachor Meyouhas, Y. P1458, P1663
Shafiq, A.
O47
Shah, D.
P1487, P1544, P1969
Shaked, H.
P1482
Shakhmistova, A.
P2034
Shakib, S.
P1521
Shakler, M.
P1331
Shakya, G.
P564
Shal, E.
P1576
Shalaby, L.
P2246
Shamaei-Tousi, A.
P936
Shamai, M.
P2032
Shamasna, M.
P2057
Shan, A.
P1183
Shang, S.Q.
P1426, P1427
Shao, J.W.
P1224
Sharifi, G.
P1634
Sharifi, Z.
P1903
Sharipova, I.
P2237
Sharma, Manu
P1071
Sharma, Meenaxi
P1016
Sharma, R.
O317, P1177
Sharp, A.
O485
Shashkova, S.
P1780
Shehu, E.
P2233
Shelyakina, O.
P1573
Shemko, M.
O500
Shen, L.
P1776
Sheng, H.Q.
P1224
Sheng, W.
O365
Shenton, D.
P1702
Shepard, J.
P1945
Sheppard, D.
O484
Sheridan, E.
P686, P1466
Name
Number
Sherlock, J.
O39
O91
Sherry, L.
Shestakov, V.
P1019
Shetty, N.
O500
Shewsbury, S.
P1526
Shi, Z.
P1525
Shields, K.
P1446
Shields, M.
P1446
Shields, R.
O152, P2110
Shih, L.
P2050
P809
Shimada, J.
Shimojima, M.
P632
Shimono, N.
P1594
Shin, B.
P1965, P1984
Shin, J.
P1624, P1625, P1637
Shin, K.
P770
Shin, S.
P1601
Shin, S.Y.
P1392
Shinkai, S.
P1433
Sho, T.
P603, P623
Shobana, C.S.
P1947
Shobhanakumary, K.
P2179
Shoeibi, S.
P1156
Shokouhi, S.
P1634, P2194
Shore, A.
O210, O212, P837
Shorman, M.
P911
Shresta, Sujan
P1527
Shrestha, S.
P564
Shrewsbury, S.
P1511
Shrief, R.
P1955
Shubladze, N.
P2036, P2040
Shue, Y.K.
O504
Shukla, S.
P1807
Shurpitskaja, O.A.
P2129
Shurtleff, A.
O411, P2211
Siarakas, S.
P1202
Sias, C.
P1872
Sibunruang, S.
P1497
Sickau, K.
P1208
Sidani, N.
P1194
Sidhu, M.K.
P969
Sidiropoulou, E.
P2176
Sidorova, E.
P1882
Sidoti, F.
O410
Siegfried, L.
P1759
Siegrist, C.A.
P2088
Sierra, A.
P900
Sierra, M.
O357
Siersema, P.D.
P1674
Signorini, L.
P853
Siira, L.
P1369
Sijak, D.
P704
Sikondari, H.
O388, P2134, P2137
Silva, A.F.
O38
Silva, C.
O384
Silva, F.
P1178
Silva, K.
P889
Silva, M.
P856
Silva, R.
O38
Silva, R.
P694
Silva, V.
P856
Silveira, E.
P619
Silveira, F.
O152
Silvestri, A.
P1284
Silvius, M.A.
P772
Sim, J.
P954
Simmel, F.
P817
Simó, G.
P1631
Final Programme
221
Chairs & Authors
Name
List of Authors
Name
Number
Simões, J.
Simões, M.
Simões, R.R.
Simon, A.
Simón, A.
Simon, A.
Simon, A.
Simon, F.
Simon, S.
Simons, A.
Simons, G.
Simonsen, G.S.
P1248
P1848
O303
S325
O479
P801
P1539
P874
O356
P1983
P1943
P923, P1306,
P1361, P1734
Simor, A.
P1036
Simorre, B.
P1584
Simpson, A.
P2106
Simpson, H.
P1736
Singh, K.P.
P991
Singh, M.
P991
Singh, V.
P1969
Singleton, D.
P909, P918
Singley, C.
P1508
Sinha, B.
P824, P1589
Sinishtaj, S.
P1166
Sipsas, N.
O364, P1464
Siriyasatien, P.
O36
Sisco, M.C.
P1558
Sisto, A.
P701
Sithisarankul, P.
P2192
Sitia, S.
P1398
Siu, G.
P2005
Siva Sankar, C.
P1862
Sivagnanam, K.
P1227
Sivaramakrishnan, A.
P1591
Sivaya, O.
O419
Sivec, S.
P553, P704
Sivertsen, A.
P924
Sivianes, N.
P1701, P2186
Sjögren, I.
P924
Sjøveian, A.
P1306
Skaare, D.
P752
Skandami-Epitropaki, V.
P1389,
P1393
Skarmoutsou, N.
P1180
Skenders, G.
S6, P1999, P2018
Skevaki, C.L.
O416
Skinhøj, P.
P1084
Skjøt-Rasmussen, L.
P1746
Skoczynska, A.
P966, P1075
Skoura, L.
P2175, P2176
Skouteli, E.
P1491
Skoutelis, A.
P1323, P1327, P2180
Skov, M.
O346, P2149
Skov, R.
P747, P750, P1065
Skov Jensen, J.
S528b
Skovby, A.L.
P1628
Skripkin, E.
P1165, P1166
Skrivanova, E.
P1167
Skvoretz, R.
P1918
Slack, M.
S115, S268,
P1013, P2043
Slater, J.
O485
Slavin, M.
P2114, P2243
Slickers, P.
P905
Sloots, T.
P1339, P2238
Small, G.
P1676
Smani, Y.
O474
Smaoui, H.
P1555
Name
Smidt, I.
Smirnova, M.
Smismans, A.
Smith, A.
Smith, D.
Smith, E.G.
Smith, M.
Number
P1107
O80
P1874, P1926
P1531
O308
P2006, P2044
O388, P2105,
P2134, P2137
Smith, N.L.
P2106
Smith, S.J.
P1207
O88
Smithyman, A.
Smollan, G.
P652, P735, P1595
Smyth, E.
P1294, P1329
Smyth, R.
P1837
Sneddon, J.
O44
Snelders, E.
O478, O481
Snyder, L.
S286
Snydman, D.R.
S126, P1133
Soares, L.M.
O466
Soares, M.J.
O350
Soavi, L.
P1642
Sobke, A.
P1447
Sobral, A.
P889
Sobrino, M.
P2080
Soccal, P.
P2088
Socias, L.
P1765
Socié, G.
P2239
Söderquist, B.
P671, P949, P1732
Sodsai, P.
P2215
Soeiro, I.
P2167, P2171
Soetens, O.
P1836, P1924
Sofia, T.
P1713
Søgaard, M.
P830, P1586
Sohail, M.
P1086
Sohn, J.
P1290, P1598
Sohr, D.
P1110
Sóki, J.
P919, P1106
Solbach, W.
P1835
Solé, M.M.
P649, P738
Soleimanjahi, H.
P585
Solinas, M.
P1682
Soloaga, R.
P1622
Soloski, M.
O358
Somalo, S.
P1716
Somer, A.
P1556
Sommerfleck, P.
P1557
Somodevilla, A.
O293, P580,
P582, P584, P1878
Son, B.
P770
Son, J.
P1549
Son, N.
P999
Song, C.
P1743
Song, J.H.
P846, P1198, P1391,
P1549, P2082, P2084
Song, J.Y.
P1290
Song, W.
P2049
Song, X.
P2035
Song, Y.G.
P1598, P1745
Sonmez Tamer, G.
P879
Sonmezoglu, M.
P892
Sonnevend, A.
O526 , P653
Soon, R.
P1451
Sooudipour, F.
P774
Soreng, K.
S166
Sørensen, H.T.
P1577, P1586,
P1588, P2117
Sørensen, S.M.
P1599
Soriano, A.
S265, S379
Final Programme
Name
Number
Soriano, M.C.
P2133
P1461
Soriano García, F.
Sorlí, L.
O86, P794, P1647
Sorli, M.L.
P1934
Soroush, J.
P2032
Sorrell, T.
P1339, P2238
Sougakoff, W.
P605
Soulama-Mouze, C.
P783, P1510
Souleimani, A.
P583
Souli, M.
P1147, P1355
P1635
Soultanis, S.
Souod, N.
P621
Sourlas, J.
P1635
Sousa, G.
O350, P1178
Sousa, M.C.
P862, P881, P889
Spada, M.
P1117, P1494
Spadão, F.
P2245
Spadoni, S.
P906
Spalla, M.
P755
Span, M.
P1890
Spang, P.
P1909
Spapen, H.
O45
Sparbier, K.
O347, P758
Spathi, A.
P2067
Specchia, G.
O154
Speck, K.
P1967
Speil, C.
O195
Speth, C.
P2107
Spigaglia, P.
P1975, P1982
Spiliopoulou, A.
P1760, P1763
Spiliopoulou, I.
P957, P1760,
P1763
Spina, D.
P907
Spreafico, E.
P1456
Sprecher, H.
P693, P2030
Sprenger, M.
O48
Sprenger-Haussels, M. P1897, P1901
Springer, C.
P2055
Spuri Vennarucci, V.
P2228
Spyckerelle, I.
P726
Spyridaki, I.S.
O416
Spyridonidis, A.
P1880
Sredkova, M.
P1145
Sreenivas, V.
P1442
Srikanth, P.
P1227
Sriprapun, M.
O36
Srisangchan, P.
P1188
Srisurat, N.
P1188
Srivastava, S.
P991
Staalsø, T.
O471
Stacey, A.
P1974
Staedel, C.
O521
Staff, S.
P918, P1578
Staffolani, M.
P1357
Ståhlsten, A.
P1734
Stamatiou, J.
P1873
Stamatiou, K.
P737
Stamatopoulou, G.
P1491
Stamoulos, K.
P1180, P1348
Stange, E.F.
S392
Stano, P.
P910, P1678, P1806
Stas, G.
P2024
Stastkova, Z.
P896
Stathopoulos, C.
P1503
Stauder, M.
P1154
Stechová, M.
P904, P1937
Steckelberg, J.
P1086
Steed, M.
O81, P935, P2090
Name
Number
Steel, E.
P1953
P1520
Steenbergen, J.
Stefanelli, P.
P988, P1713
Stefani, S.
S65, E271, P776, P907
Stefanik, D.
O525, P948,
P1184, P2123
Stefanou, I.
P1147
Steinberg, D.
P1154
Steinhagen, K.
P1417
Steinlechner, B.
O150
P1127
Steinmann, J.
Stel, H.V.
P1674
Stellbrink, H.J.
P2190
Stender, H.
P903, P1945
Stensvold, C.
O486, O491,
P1681, P1719
Stenzel, T.
P912, P1979, P1980
Stephan, B.
P1100, P1101
Stephens, J.
P2108
Stephens, jr., J.T.
P1143, P1144,
P1453
Stepnell, J.
O352
Stevanovic, G.
P2056
Stevens, D.
P1535
Stevens, D.A.
O483
Stevens, S.
P1945
Stevens, V.
O496
Stewardson, A.
P1380
Stewart, K.
P2114
Stingu, C.S.
P1753
Stobberingh, E. P726, P1400, P1917
Stock, S.
O312
Stoecker, W.
P1417, P1419
Stöger, A.
P1729
Stojakovic, S.
P2056
Stokes, H.
P617
Stokholm, J.
P1298
Stone, S.
E121, O144, P1381
Storey, I.
P1898
Stork, J.
P2043
Storoženko, J.
P2203
Stoyanova, A.
P1145
Straube, E.
P1447, P1575
Straut, M.
P631
Streinu Cercel, A.
P2182, P2189
Streit, J.
O472
Stremler, N.
P825
Strohalm, M.
P1940
Stroobants, R.
P1268, P1270
Struelens, M.
P1721
Strukova, E.
O80
Strus, M.
P1779
Stsepetova, J.
P1107
Stubbings, W.
P1146, P1186
Studahl, M.
P2162
Studentova, V.
P1172
Studer, R.
P874
Stunda, A.
P1786
Styliadis, I.
P1845, P1846
Stylianakis, A.
P567, P575, P1125
Su, J.
P1683
Su, L.
P713, P1352, P1966
Suárez, A.
P2116
Suarez, C.
P612, P1459
Suárez, G.
P2080
Suarez, M.
P1881, P2093
Suaya, J.A.
O351, P1219
Subik, J.
P1863
List of Authors
Number
Subirats, M.
Suborova, T.
Sudre, P.
Suefke, S.
Suetens, C.
P883, P1409
P851
P874
P1539
O42, P1110,
P1111, P1309,
P1310, P1335
Sugamoto, T.
P2023
Sujemecki, A.
P1622
Sulc, M.
P1940
P2064, P2185
Suligoi, B.
Sun, C.
P1142
Sun, C.F.
P1966
Sun, Hsin-Yun
O365, P1960
Sun, Hua
O246
Sun, J.R.
P1377
Sunakawa, K.
P1604
Sundar, S.
S323
Sundqvist, M.
P1551, P1832
Sundsfjord, A.
P705, P923,
P924, P1361,
P1837
Sung, G.
P629
Sungkanuparph, S.
O367
Sunhachawee, A.
P1696
Supattanapong, S.
P1295
Surdeanu, M.
P631
Surmont, F.
P958, P1076
Susaengrat, W.
P1188
Susaenrat, W.
P1547
Sutcliffe, J.
O96, P762, P1142,
P1149, P1509
Suter, F.
P872
Suter-Riniker, F.
P2001
Sutherland, C.
S338
Sutter-Minder, E.
P1687
Suvorov, A.
P981, P1441
Suwanpimolkul, G.
O249
Suybeng, V.
P1893
Sužiedeliene, E.
P706, P707
Suzuki, J.
P2241
Suzuki, S.
P1304
Svennevig, J.
P1739
Swanson, R.
O153
Swine, C.
P1230
Swoboda, S.
P1807
Sy, C.
P1548
Syahidah, N.
P1174
Sycamore, J.
P918
Sypsa, V.
P687
Syriopoulou, V.
P1867
Szabados, F.
P1041, P1173
Szabó, M.
P1216
Szaflarska, A.
P1762
Szegedi, E.
P1160
Szénási, M.
P1216
Szikra, L.
P919, P1106
Szilagyi, E.
P1110
Szkaradkiewicz, A.K.
O390
Szmal, C.
P1751
Szovenyiová, Z.
P2063
Szucs, T.D.
O238
Szych, J.
P588, P1705
Tabacchi, F.
Tabak, T.
Tabarsi, P.
Tabary, T.
P2213
P1681
P1496, P2032
P2076
Name
Taccetti, G.
Tacconelli, E
Number
P827
O46, O145, S283,
S453, S536, P673,
P1118P1285
Tadumadze, N.
P2036
Tafi, M.
P1815
Taghipour, N.
P869
Tagliabue, S.
P635
Tagliaferri, E.
P700
Tähtinen, P.A.
P1369
P2153
Tai, B.
Taira, K.
P1433
Takagi, E.H.
P963
Takahashi, K.
P816
Takahashi, S. P1399, P1401, P1402
Takakura, S.
P665, P1362
Takane, H.
P1855
Takazono, T.
P2148
Takesue, Y.
P2113
Takó, M.
P1522
Tal, I.
P735
Talbot, G.
P1530
Talebkhan, Y. P1423, P1424, P1907
Talento, A.F.
P1329
Talmi, M.
P622
Talmud, D.
O309, P2076, P2156
Talukdar, P.
P1347
Talukder, K.
P1347
Tam, V.
S230, P790, P1969
Tamalet, C.
P1957, P2221
Tamarozzi, F.
O487, P866
Tambic-Andrasevic, A.
2
Tan, H.L.
O306
Tan, L.
P1581
Tan, N.K.
P1995
Tan, Q.
O291
Tan, R.
P1451
Tan, Thean Yen
P733, P954,
P1174, P1176, P1623
Tan, T.T.
O193, P1176
Tanaka, K.
P1399, P1402
Tanaka, S.
P1074, P1141, P1528
Tang, A.
P1288
Tang, S.
O246
Tang, Wen
P912, P1980
Tang, W.Y.
O240
Tang, Y.
P1166
Tanganelli, M.
P827
Tanigawara, Y.
O83
Tanner, H.E.
P1710
Tanner, M.
S206
Tantawichien, T.
P2215
Tantisiriwat, W.
P1188
Tao, C.
P692, P1364,
P1479, P2045
Tao, R.
P1426, P1427
Tarabbo, M.
P1499
Tarallo, M.
P2108
Tardivo, S.
P1113
Tarr, P.E.
O213
Tarragó, C.
P1140
Tas, T.
O391
Tasbakan, M.
P861, P1443
Tascini, C.
P700
Taseva, E.
P1024, P2058
Tashiro, M.
P2140, P2141, P2148
Tashiro, T.
P2148
Tasler, D.
P1993
Name
Number
Tassan din, C.
P1325, P1456
P960
Tassios, P.T.
Tasyaran, M.A.
P1025, P1643
Tateda, K.
O101, P1390, P1463
Tato, M.
O107, O355, P1183
Tattevin, P.
P998, P1956
Tau, C.
P772
Tavares, Alcina
P1354
Tavares, Ana
O348, O350, P1358
Tavares, R.M.
P2193
P1331
Taya, R.
Taylor, S.
P1688, P1875
Teale, C.J.
P628
Teare, L.
P1381
Tebaldi, A.
P872
Tech, R.
P1250
Tedeschi, S.
P1582
Tedim, A.P.
O214, P620
Teh, B.
P1574
Teh, S.
P1623
Teisseyre, J.
O30, P1570
Teitler, N.
P1971
Teja Barbero, J.L.
P993, P1471
Tekeli, A.
P1232
Tekin, N.
P1225
Telcian, A.G.
O416
Teles, C.
P1067
Telford, J.
O312
Téllez, F.
P1475
Telli, G.
P734
Tellini, C.
P1569
Temel, F.
O237
Temmerman, M.
P1912
Templeton, K.E.
P1717, P1736
Tency, I.
P1912
Tenea, C.
P1495
Teng, C.
P733
Tenover, F.
S342
Teo, J.
O193, P1176
Tepeš, B.
P1708
Teramoto, T.
P715
Terçarioli, G.R.
P1944
Terhes, G.
P919, P1106
Terlizzi, M.
O410
Terpstra, P.
O149
Terzi, N.
P2060, P2207
Tesik, P.
O501
Tessari, A.
P1005
Tessarolo, F.
P1847
Tessier, C.
P2247
Testa, F.
P832
Testillano, M.
P2093
Tetik, A.
P861
Tetu, S.
P1811
Teunis, P.
O360
Tezcan, S.
O237
Tezer Tekçe, Y.
P871, P1286, P1541
Tezer-Tekçe, A.
P1064
Thabet, L.
O196
Thaller, F.
P1001
Thamlikitkul, V.
P1188
Thanabalan, R.
P1676
Thanacoody, R.
O255
Thein, T.L.
O489, P857, P858
Themeli-Digalaki, K.
P683, P737,
P1485
Themelidis, D.
P970
Themudo, P.
P1354, P1359
Name
Number
Theodoridou, M.
Theodoropoulos, N.
Theuretzbacher, U.
Theyyathel, A.
Thibault, V.
Thibaut, S.
Thiebaut, A.
Thiel, S.
Thientong, V.
Thijsen, S.
Thinkhamrop, B.
Thiroux, C.
Thoelen, I.
Thogersen, I.
Thomaidis, P.
Thomann, R.
Thomas, K.
Thomas, L.
Thomas, S.
Thomas, T.
Thomas, V.
Thomas, X.
Thompson, C.
Thompson, G.S.
Thomsen, R.W.
P1867
P2074
S449
P2099
P2223
P561
P2126
P2087
P1445
P1302, P1481
P1547
O297, P778
P1004, P1400
P1780
P567, P575
O48
P1353
P1930
P685, P1334
P1329
P2069
P2126
P1534
P1051
P1577, P1586,
P1588, P2117
Thomsen, T.
P908, P1465, P1931
Thomson, G.
P1319
Thomson, N.R.
P1667
Thomsson, E.
P2162
Thønnings, S.
P1593
Thorausch, P.
P1250
Thornhill, C.
P685, P1334
Thornhill, J.A.
P1397
Thorpdal, M.
O497
Threlfall, J.
S461
Thunyaharn, S.
P1188
Thursky, K.
S232, P2243
Thybo, S.
O490
Thye, D.
P791, P968
Thymaki, K.
P2010
Tice, A.
P1535
Tiebaut-Bertrand, A.
P2131
Tiengrim, S.
P1188
Tiesset, H.
P1785
Tigaud, S.
O520, P1569
Tijet, N.
P680
Tiliscan, C.
P2182, P2189
Tillander, I.
O353
Tilley, P.
P1248
Timenetsky, M.
O310, P2071
Timinouni, M.
P622
Timke, M.
P1839
Timurkaynak, F.
P1169
Tinelli, M.
P1118, P1403
Tingi, E.
O47
Tissari, P.
P690
Tissières, P.
P1756
Tissot, F.
P1483
Titov, L.
P826, P1102
Tivoli, N.
P1957
Tjhio, J.
P774
Tkhilaishvili, T.
P891
To, K.
P1778
Toba, M.
P1433
Tobin, E.
O153
Tobudic, S.
O150, O243, O477,
P1498, P1781
Final Programme
223
Chairs & Authors
Name
List of Authors
Name
Number
Tocci, N.
P976
P2111
Todor, N.
Togas, D.
P2060, P2207
Toh, K.P.
O240
Toivonen, L.
O523
Tokuda, K.
P632
Tola, S.
P899
Tolekova, V.
P703
Toleman, M.
O219, P1045, P1146
Tollefsen, T.
P1318
P868
Tolosa, T.
Tomás-Jiménez, C.
P1852
Tomaselli, S.
P729, P795
Tomashefski, F.
P1799
Tomcavage, M.
P1799
Tommaselli, P.
P1499
Toniolo, A.
P921
Tønjum, T.
O470, P1739
Tonkic, M.
P1975
Tonkin-Crine, S.
P1262
Toraman, Z.A.
P1883
Tordato, F.
P1484
Tordoya Titichoca, I.
P1108
Torelli, R.
P1941
Tormo, N.
P983, P2008
Toro, C.
P883, P1409
Toro-Peinado, I.
P1996
Toropainen, M.
P1078
Torre-Cisneros, J.
O244
Torregrossa, V.
P1113
Torrent, A.
P1942
Torres, A.
P1190, P1266
Torres, C.
O103, P594, P606,
P620, P845, P848, P901,
P933, P937, P939,
P1249, P1716, P1813
Torres, E.
P1647
Torres, J.
O236
Torres, Manuel
P1475
Torres, M.
P1664
Torres, M.J.
P1722
Torresani, E.
P959, P1234
Tortajada Goitia, B.
P1277
Tortoli, E.
S505, P2002
Torviso, J.
P1661
Tosas, O.
P828
Tosi, G.
P1357
Toskova, M.
P2150
Tosoni, A.
P867
Toszeghy, M.
P628
Totaro, G.
P1093
Toth, J.
P1017
Totsuka, K.
P1604
Toumi, A.
P659, P1092, P1546
Toupance, O.
P2076
Touratier, S.
O156
Tournigand, C.
P1193
Tourrès, C.
P2221
Toutouza, M. P1389, P1393, P1491
Touzeau-Römer, V.
P1498
Tovar, Y.
P2042
Tovo, P.A.
O316, P1553
Toyoda, Y.
O152, P2104, P2110
Tramontana, A.
P2243
Trampuz, A.
4, O254, P950,
P1646, P1655, P1857
Trape, J.F.
P882
Tredici, S.
P1841
Name
Number
Tremblay, L.W.
O386
P1723, P1804
Trevino, M.
Trevisi, P.
P883, P1409
Trezzi, L.
P1403, P1998
Trienekens, T.
P1400
Trieu-Cuot, P.
S123, P1758
Trifinopoulou, K.
P1491
Trifonova, I.
P1024, P2058
Trigo, M.
P2059
Trigoni, C.
P1873
P1565
Trikka, E.
Trinh, M.
P1519
Tritapepe, L.
O82
Troelstra, A.
P1649
Troillet, N.
P1650
Trojanek, M.
P1559
Troke, P.
P2153
Trombetti, S.
P2197
Tromp, M.
P1384, P1617
Troncoso, G.
P1324
Trostmann, U.
P1538
Troughton, J.
O417
Trouillet, S.
O520
Trovato, L.
P2136
Trsic, T.
P1899, P1900
Trukhina, A.
P1882
Trung, N.
P999
Truntzer, C.
P1951
Trupl, J.
P2122
Trüpschuch, S.
P1351
Truusalu, K.
P1107
Tryfinopoulou, K.
P1238, P1240,
P1322, P1332, P1348
Tsachouridou, O.
P2175, P2176
Tsafaraki, E.
P1348
Tsafnat, G.
P1816
Tsai, Hsih-Yeh
P1476
Tsai, H.
P1548
Tsai, M.
O365
Tsakris, A.
E271, O416, P683,
P695, P737, P1029,
P1070, P1170, P1221,
P1363, P1485,
P1503, P1835
Tsakris, A.Z.
P960
Tsang, R.
P992
Tsao, S.M.
P914
Tschudin Sutter, S.
P1387, P1652
Tseng, Y.
P1960
Tsiakalos, A.
O364
Tsiapara, F.
P1181
Tsiodra, P.
P1611
Tsiodras, S.
P1636
Tsiplakou, S.
P567, P575,
P1125, P1348
Tsiringa, A.
P1389, P1393
Tsiveriotis, K.
P957
Tsorlini, E.
P1491
Tsouma, I.
P2067
Tsouri, A.
P1348
Tsubouchi, M.
P1433
Tsuji, B.
P779, P783, P784
Tsukamoto, T.
P1401
Tsutsui, A.
P1304
Tsvetkova, E.
P1711
Tubach, F.
O252, P1195
Tubau, F.
P612, P1073, P1368
Tucek, G.
P1540
Final Programme
Name
Number
Tucker, D.
Tudó, G.
Tudor, A.M.
Tuite, H.
Tulek, N.
Tulkens, P.
P1994
P2025
P2182
P2178
P1614
O78, O291, S452,
P725, P780, P781,
P807, P1139
Tulli, G.
S328
Tullio, V.
P2152
P1582
Tumietto, F.
Tuna, D.
O350
Tunccan, O.
P1394
Tuncer, I.
P1707
Tunger, O.
P1394, P1618
Tunney, M.
P1333
Tura, G.
P853
Turan, H.
P1602
Turan, M.
P1985
Turcu, E.
O385
Turgay, N.
P861, P880
Turgut, D.
P672
Turlej, A.
O348
Turnbull, L.
P1189
Turner-Gardner, J.
P1334
Turnidge, J.
O352, P756,
P1293
Turrientes, M.C.
P643, P1928
Turriziani, O.
P2200
Turton, J.F.
P934
Turunc, T.
P1457
Tutuhatunewa, E.D.
P2198
Tutuncu, E.
P1027
Tveten, Y.
P752
Tyrrell, G.J.
O304
Tysall, L.
P1736
Tzakis, G.
P1494
Tzanetou, K.
P1238, P1240,
P1491, P2060, P2207
Tzelepi, E.
P1348
Tzioufas, A.
O364
Tzouvelekis, L.S.
P960
Ubeda, A.
Uchida, Y.
Udwadia, Z.
Uehara, A.
Uehara, T.
Uh, Y.
Ulanova, T.
Ullberg, M.
Ulleryd, P.
Ullmann, A.
Ulman, C.
Ulu Kilic, A.
Ulus, A.
Unal, S.
Underwood, A.
Unemo, M.
Unterkoefler, C.
Unver Yolasigmaz, A.
Upadhyay, B.
Urbán, E.
Urbani, A.
Urosevic, A.
Urruzuno, P.
Ursi, D.
P1950, P2120
P1594
O255
P1594
P1401
P777
P2235, P2237
P924, P925,
P1620, P1913
P1261
S56
P1618
P1027
P1614
P902
P1898
P949, P1732
P1639
P861
P564
P919, P1106
P1948
P1615
P580, P584
P1571
Name
Number
Us, E.
P1232
P637, P1927
Uskudar Guclu, A.
Uslan, D.
P1086
Utili, R.
S404, P1538
Utoft Andreassen, B.
P2070
Uyanik, M.H.
P1091
Uyar, Y.
O37
Uysal, H.
P1413
Uzunovic;-Kamberovic, S.
P553
v. Westreenen, M.
O149
P690, P2098
O155
O475
O42, P1111,
P1309, P1310
Vaes, M.
P2109
Vaezjalali, M.
P2216
Vagiakou, E.
P1492
Vagner, O.
P2151
Vágvölgyi, C.
P1522, P1947
Vahdat, H.
P2015
Vaiani, R.
P592
Vailati, F.
P984
Vainio, A.
P1078
Vainio, S.J.
O290
Vakis, A.
P1636
Valadares, I.
O350, P1372
Valdezate-Ramos, S.
P1461
Valdivieso, A.
P2093
Vale, F.
P1671
Valente, C.
P2057
Valente, I.
P2013
Valenti, G.
P1221, P1235
Valentin, T.
P645
Valentin-Domelier, A.-S.
P994
Valentini, D.
P1563
Valentinotti, R.
P2004
Valerio, M.
O157, P2072
Valles, J.
P1278
Vallet, C.
P725
Valverde, A.
O107
Vamvakopoulou, S.
P2218
van 't Klooster, T.
P757
van Achterberg, T.
P1384
Van Bambeke, F.
O291, O297,
P725,P780,
P781, P1139
van Bodegraven, A.A.
P1672
van Bree, J.M.
P1797
Van Broeck, J.
P1982
van Bussel, M.
P586
Van Caeseele, P.
O304
Van Cauwenbergh, M.
P1836
van Cleeff, M.
O426
van Dam, A.P.
P626
Van Damme, P.
P958, P1076
van de Beek, D.
S462
van de Bovenkamp, J. P1691, P1698
van de Pas, M.M.
P1695
van de Sande, N. P688, P764, P1668
van de Sande-Bruinsma, N.
P1302
van de Ven, M.J.
P1797
van de Wiel, P.
P1885, P1886
van Delden, C.
P1750, P2088
Van den Abeele, A.
P593
van den Bergh, M.R.
P969
van den Brande, J.H.
P1674
Vaara, M.
Vadnerkar, A.
Vael, C.
Vaerenberg, S.
List of Authors
van den Broek, P.
van den Brule, A.J.
Number
O528, P703
P1691,
P1885, P1887
van den Munckhof, T.M.
P1010
van den Tempel, S.
P1913
Van den Wijngaert, S.
P2024
van der Donk, C.
P1400, P1917
van der Giessen, J.
P859
van der Heijden, M.
P1610
van der Hoek, W.
S130
P1801
van der Kaap, M.
van der Linden, J.W.
O478
van der Mee-Marquet, N.L.
P994
van der Meer, J.
S453, O467,
P1384
Van Der Pol, B.
P1688, P1875
van der Poll, T.
S70
van der Reijden, T.
O528, P703
van der Reijden, W.A.
P1910
van der Sande, N.
P1010
van der Snoek, E.
S397
van der Zee, A.
P1237
van Deursen, A.M.
P969
van Dommelen, L.
P1709
van Duijn, P.J.
O298, P1490
van Eldere, J.
S113
Van Esbroeck, M.
P1004
van Essen-Zandbergen, A.
P1010,
P1812
van Gool, T.
P880
van Hal, S.J.
O299
Van Heirstraeten, L.
P1375, P1909
Van Herck, K.
P958, P1076
van Herk, C.M.
P1691
Van Hoorenbeeck, K.
O475
Van Horn, K.
P1677
van Ingen, J.
O255
Van Kerkhoven, D.
P1033
van Krugten, H.
P1695
Van Laethem, Y.
P958
van Lieshout, L.
S337
Van Lint, M.
P2086
van Loon, A.
S370, P1581, P1868
van Luit, M.
P1703
van Mansfeld, R.
P1673
Van Meensel, B.
P1030, P1033,
P1874, P1926
van Meerbergen, B.
P1885, P1886
van Mourik, M.S.
P1649
van Nieuwkoop, S.
P1871
van Olphen, S.H.
P2078, P2083
van Pelt, W.
P859
Van Schaeren, J.
P1033
van Soolingen, D.
O255
van Strijen, E.
P703
van Tiel, F.H.
O478, P1709
Van Vaerenbergh, K.
P982
van Wijngaarden, E.
O496
van Zanten, E.
P1932
Vanaga, I.
P2203
Vancheeswaran, R.
P1583
Vancikova, Z.
P1559
Vandamme, A.-M.
S181
Vandecandelaere, P.
P1788
Vandenbroucke-Grauls, C.M.
O102,
O290, O354
Vandenesch, F.
O520, P1052,
P1068, P1502,
Name
Number
P1569
P971, P1571,
P1868
Vandevelde, M.
P1004
Vandewoude, Koen
P1953
Vandewoude, Koenraad
P2135
Vandoorslaer, K.
P1836
Vaneechoutte, M.
P1912, P1943
Vanenti, M.
P1337
Vanhems, P.
O239, O498, P1192,
P1478, P1489, P2126
Vankerckhoven, V.
O42, O475,
P1111, P1268, P1270,
P1309, P1310
Vañó, S.
P1279
Vanstone, G.L.
P642
Varela, J.M.
P1212
Varela, M.
P1641, P2031
Varela Santos, C.
P1335
Varelas, A.
P927
Varga, Z.G.
P1160
Vargovic, M.
P2224
Varolli, F.P.
P1859
Varon, E.
O356, O420
Vasdeki, A.
P957
Vashakidze, E.
P891
Vashakidze, S.
P2040
Vashee, S.
K368
Vashisht, N.
P1442
Vasilaki, O.
P1181
Vasilikos, V.
P1845
Vasilyeva, N.V.
P2129
Vassiliadou, E.
P1018
Vatcheva-Dobrevska, R.
P703,
P1711, P1718
Vatopoulos, A.
P1238, P1240,
P1322, P1332,
P1348, P1491
Vatzeli, K.
P1238, P1240
Vaz, M.T.
O350
Vazquez, J.
O153, P1533
Vázquez-Barbero, F.J.
P1879
Veenemans, J.
O493
Veenhoven, R.H.
P969
Vega Lopez, F.
S11
Vehreschild, Johanne
P2115
Vehreschild, Jörg
O87, P2248
Vehreschild, M.
O87, P2115,
P2248
Veiga, D.
O248
Veillon, P.
P1961
Veini, F.
P1323, P1327
Vejpongsa, P.
P2215
Velakoulis, S.
P1611
Velasco, C.
P1449
Velasco, D.
P2116
Velasco, E.
P1307
Veldenzer, A.
P1988
Veldkamp, K.E.
P986
Veldman, K.
P1353
Veliz, O.
P773
Vella, A.
P2004
Veloo, A.
P1809, P1831
Veloso, T.R.
P1783
Venditti, A.
O154
Venditti, C.
P1342
Venditti, M.
O82, P1342
Vengen, Ø.
P1318
Vanderstraeten, A.
Name
Number
Name
Venier, A.-G.
P1282
P2093
Ventoso, A.
Ventura, F.
P2193
Venturelli, C.
P646, P1587, P1919
Venturiello, S.
O145
Venugopalan, V.
P1864
Verbakel, J.M.
P1691
Verbrugghe, W.
O45
Verdaguer, R.
P1073, P1459,
P1579, P1665
O157, P1468
Verde, E.
Vered, K.
S69
Vergara-López, S.
P1247
Vergison, A.
O297
Verhaar, N.
P880
Verhaegen, J.
P958, P1076
Verheij, T.
P1262, P1266,
P1267, P1871
Verheyen, J.
S165, S200, P2234
Verhoef, H.
O493
Verhoye, E.
P982
Verhulst, C.
P1728
Vermeiren, C.
P698, P1036
Verner-Jeffreys, D.
S63
Verroken, A.
P702, P1230
Versporten, A.
P1271
Verstraelen, H.
P1912
Verstreken, I.
P1874, P1926,
P2159
Vervoort, J.
P640, P667
Verweij, P.
O149, O478, O481,
P1002, P1768
Verzaro, S.
P2200, P2213
Vetouli, E.
P1095, P1396
Vetra, J.
P1786
Vi, M.
P1899, P1900
Viale, P.
S231, P1335, P1582
Vianelli, N.
O154
Viasus, D.
P1579, P1665
Vicari, N.
P1020
Vicente, T.
P987
Vicente Romero, M.R.
P1566
Viciana, I.
P961, P2231
Vickers, A.
O312, P1013, P1898
Vickers, I.
P972
Vidaillac, C.
O81, P935
Vidal-samso, J.
P1331
Vidart, N.
P2133
Viedma, E.
P1405
Vieira, Maria Joao
P769
Vieira, Marjorie
P2085, P2242,
P2245
Vieira, Maria
P1896
Vieira, Pedro
P1358
Viel, E.
P1193
Viganò, E.
P834, P1046,
P1233, P1314,
P1337, P1911
Vighi, G.
P1325, P1456
Vila, J.
O474, P649,
P718, P738,
P1164,P1833,
P1838
Vila-Farres, X.
P1164
Viladot, E.
O236
Viladrich, P.F.
P1459
Vilalta, E.
O157
Vilela, C.
P1082
Villa, G.
Villa, L.
Number
P873
O216, P559,
P1342, P1812
Villalba, G.
P1647
Villamayor, L.
P2008
Villanelli, F.
P800
Villani, A.
P1563
Villani, P.
P814
Villari, P.
P1284
Villegas, E.
P860, P870
P1899, P1900
Villegas, L.
Villena, V.
P2128
Villet, R.
P1506
Villette, S.
P1500
Viñas Castillo, L.
P1766
Vince, A.
P2224
Vindel, A.
P842, P1060
Vinluan, B.
P1899, P1900
Vinué, L.
P1716
Virágh, M.
P1522
Virgincar, N.
P1974
Virolainen, A.
P1078, P1369,
P1733, P1986
Visaggio, D.
P1373, P1851
Viscoli, C.
S227, S430, P2086
Visser, C.
S436, P1801, P1822
Vitali, L.A.
P728
Viti, C.
P976
Vitkauskiene, A.
P706, P707
Vitorino, J.
P889
Vittorakis, S.
O416
Vivas, M.
P1073
Viveen, M.
P1581
Viveiros, M.
O255, P723,
P724, P1448
Vizio, M.
P853
Vizzini, L.
O190
Vlad, I.
P2111
Vlaminckx, B.J.
P1481
Vlek, A.L.
O344
Voets, G.
P688, P759
Voets, G.M.
P641, P668, P764,
P1010, P1668
Vogelaers, D.
S333, P1953,
P2135
Vögeli, N.
P1467
Vogne, C.
P1834
Vogt, M.
P1655
Voirin, N.
O239, P1192, P2126
Volny, M.
P1940
Volonaki, E.
O416
von Eiff, C.
P1123
Von Konell, G.
P760
von Müller, L.
P1122, P1738,
P1967
von Steinbüchel, N.
O362
Vonberg, R.-P.
P1241, P1243
Vonk, A.
P2153
Vorsselmans, A.
O311
Vos, M.
E446
Voskuil, S.
P759
Voss, T.
O469, P1434,
P1527, P1761
Vouillamoz, J.
P1783
Voulgari, E.
P695, P1363
Vouloumanou, E.
P1175
Vourli, S.
P957
Voutsinas, D.
P737
Final Programme
225
Chairs & Authors
Name
List of Authors
Name
Voyatzi, A.
Voyatzoglou, D.
Vranes, J.
Vranic-Ladavac, M.
Vrioni, G.
Vryonis, E.
Vu, C.
Vullo, V.
Vuononvirta, J.
Vuorenoja, K.
Vuotto, F.
Vydyborets, S.
Number
P1565
P1251
P704
P704
P695, P1029,
P1485, P1835
P2180
P1899, P1900
O82
O523
P690, P1369
P1785
P1908
Wach, A.
P1513
P1446
P1288
O388, P2105,
P2134, P2137
Wade, P.
P1994
Wagenaar, J.A.
P1962
Wagner, K.
P1081
Wagner, M.
P1904
Wagner-Eibel, U.
P1827
Wahlberg, T.
P1261
Waidner, B.
P578
Wajda-Drzewiecka, K.
P1119
Wajima, T.
P805, P809
Wake, Z.
O308
Walcher, M.
P1918
Walker, D.
P1667
Walker, K.
P906
Wallaert, B.
P2151
Wallet, F.
P1087
Wallon, M.
P1408, P1893
Walpole, E.
O500
Walsh, J.
P1329
Walsh, J.D.
P1824, P1825
Walsh, Timothy O219, P1045, P1146
Walsh, Thomas
O152
Walsh, T.R.
S124
Walter, D.
P1334
Walters, E.
P1514
Walther, S.
P1488
Walton, C.
P1253, P1300, P1989
Wang, H.
P1525
Wang, Jin
P1776
Wang, Jin-Town
P670, P1083,
P1469, P1741, P1742
Wang, L.
P1364, P1479, P2035
Wang, M.
S548, P634
Wang, T.
P692, P2045
Wang, T.F.
O382
Wang, T.S.
P1224
Wang, W.Y.
P914, P1377
Wang, Yun
P712
Wang, Yung-Hsin
P1548
Wang, K.
P1683
Wangh, L.
P1978
Wangsomboonsiri, W.
O367
Wann, S.
P1548
Ward, D.
P1050
Wareham, D.W.
S163, O194,
O519, P934
Warn, P.
O485, P1955
Warren, R.
P935
Warren, Travis
O411, P2211
Warren, Terry
P1875
Wacker, M.
Waddington, N.
Wade, J.
Name
Number
Warrington, K.
O39
P966, P1075
Wasko, I.
Wasserman, E.
P824
Wassmer, G.
P2248
Watanabe, A.
P1604, P1855
Watson, E.
O44
Watson, M.
P1696
Watt, C.
P1036
Waumans, L.
P1004
Wearing, H.
P628
P1305
Webb, P.
Webber, M.A.
O188, P721, P1884
Weber, C.
P1059
Weber, D.J.
P1281
Weber, R.
P2066
Weber, S.
P819
Weber, U.
P2163
Weber-Dabrowska, B.
P1152
Weeks, J.
O219, P1045, P1146
Weese, J.S.
P1727
Wehkamp, J.
S16
Wei, Y.
P1676
Weidemann, S.
P2169
Weigelt, J.
P1534
Weinstein, M.
P774
Weintraub, A. P1272, P1273, P1973
Weiss, E.I.
P1154
Weiss, K.
O504, P1968
Weiss, R.
O528
Weissbrich, B.
P2234
Weisser, M.
P2097
Weist, K.
O42, P1111, P1309,
P1310, P1335
Weller, U.
O347, P758
Welling, G.W.
P1809
Wellinghausen, N.
P1407, P2163
Wells, J.
O411, P2211
Welte, T.
S158, S267
Wenisch, C.
S442, O501, P1001,
P1540, P1543
Wenzel, R.P.
P2123
Werner, G.
S513
Werngren, W.
P2018
Wessels, E.
P586
Westblade, L.F.
P1993
Westerberg, B.
P1189
Westerman, L.J.
P1674
Westh, H.
S433, P940
Weston, J.
P1487
Wever, P.C.
P995
Wex, T.
S465
Whatmore, A.
P1726
Whitaker, D.
P2134
White, J.
P1081
White, P.
P2096
Whitehead, R.N.
P721
Whitelaw, A.C.
P625
Whitty, C.
P876
Wi, Y.M.
P836
Wiberg, C.
O353
Wicha, W.W.
P1524
Wichelhaus, T.A.
P744
Wick, O.
P1738
Wickramasinghe, N.
O104
Widmann, T.
P1589
Widmer, A.F.
P1112, P1387,
P1467, P1652
Wie, S.
P1392
Final Programme
Name
Wiedemann, B.
Wiederhold, N.P.
Wiefek, J.
Wiegel, P.
Wielders, J.
Wigemyr, M.
Wilbraham, D.
Wilcox, M.
Number
O98, P921
O94
O362
P916
O493
O345
P1513
S110, O499,
O500, O502
Wild, U.
P1988
P1920
Wildt, S.
Wilhelm, A.
O290
Wilks, M.
S438, P1842, P1991
Willems, R.J.
S514, P1673
Willemsen, I.
P1728
Willey, B.M.
P1036, P1037, P1676
William, C.
P1955
Williams, A.
P1899, P1900
Williams, C.
O91, O480, P1856
Williams, D.
P666
Williams, D.N.
P1597
Williams, R.
P1653
Williams, Simon
O308
Williams, Stephanie
P909,
P918, P1177
Wilmer, A.
P843
Wilson, Jennie
O147
Wilson, Julie
P1305
Wilson, Mary
P1980
Wilson, Michael
P936
Wilson, W.
P1086
Wimberly, B.
P1166
Wimmer, M.
P557
Wingard, J.
P2130
Winterfield, P.
P935
Wintermans, R.G.
P1481
Winterova, J.
P2150
Wirtz, D.
P557
Wisell, K.T.
P924
Wisplinghoff, H. O525, P2123, P2124
Wissel, M.
O152
Wistedt, A.
P955
Withey, S.
P771
Witte, W.
O302, P684, P1351
Wittebole, X.
P807
Wittmer, A.
P578
Wittwer, M.
P1823
Witzel, C.L.
P1244
Wiuff, C.
P1305
Woerdeman, P.A.
P1613
Wolff, M.
P1195
Wolff, T.Y.
P908, P1931
Wolffs, P.
P726, P1709,
P1887, P1917
Wong, C.S.
P1810
Wong, K.
P1036, P1037, P1676
Wood, J.
P1266
Woodford, N.
S381, O519, P610,
P686, P934
Woodhead, M.
S516
Woodward, M.
P1345, P1812
Wootton, M.
P1603
Worby, C.
O147, P1254
Worlock, A.
P1899, P1900
Worth, L.
P2243
Worthy, S.A.
P1869
Wotherspoon, R.
O480
Wren, M.
O500
Name
Number
Wright, M.
P1936
P796
Wu, Anne
Wu, An-Bang
P1014
Wu, Chang Teng
P713
Wu, Cheng-Hsin
P1960, P2062
Wu, G.
P628, P1345
Wu, H.
P1552
Wu, J.J.
P1014
Wu, K.
P1548
Wu, M.C.
P1850
P1960, P2062
Wu, P.
Wu, T.L.
P1352, P1966
Wu, U.I.
P670
Wu, Weihong
P682
Wu, Wei
P1426, P1427
Wu, Yuhong
O93
Wu, Yushen
P1166
Wullt, B.
S515
Wunderink, H.F.
P986
Würzner, R.
P2107
Wybo, I.
P1836
Wyganowska-Swiatkowska, M. O390
Wywadis, R.
P1799
Xanthaki, A.
P1389, P1393
P1095, P2164
P1658
O246
O96
P569
P1479
P692, P1364, P1479,
P2035
Xu, Li
O104, P1724
Xu, Luoling
P1765
Xu, W.
P1224
Xu, X.
P634, P682
Xue, R.
O412
Xydaki, Aikaterini
P1332
Xydaki, Anna
P822
Xytsas, S.
P957
Xenos, P.
Xercavins, M.
Xiao, H.
Xiao, X.
Xiao, Y.
Xie, B.
Xie, Y.
Yagci, Serap
Yagci, Server
Yaghoubian, S.
Yagisawa, M.
Yakoub-Agha, I.
Yakushiji, H.
Yalcin, B.
Yam, W.
Yamada, H.
Yamada, M.
Yamada, S.
Yamagishi, T.
Yamaguchi, K.
Yamamoto, M.
Yamamoto, S.
Yamamoto, Y.
Yamane, K.
Yamazhan, M.
Yamazhan, T.
Yamguchi, K.
Yanagihara, K.
Yang, Chia-Jui
Yang, Ching-Shiang
Yang, H.C.
Yang, Yuan-Chieh
Yang, Yi-Jun
P1064
P915
P1895
P1604
P2101
P603
S69
P2005
P2023
P632
P1054
P1304
O101, P1390
P665, P1362
P1399
P2148
P1304
P1443
P1443
P1463
P1604, P2148
P1552
P670
P1850
P2037
P1224
List of Authors
Yang, Z.T.
Yano, H.
Yao, L.
Yapar, D.
Yargic, Z.Y.
Yasmin, M.
Yasuda, M.
Number
P1224
P632
O246
P1025
P1225
P1194
P1399, P1402,
P2065
Yasuma, K.
P665, P1362
Yau, R.
P1487
P1990
Yazdani, F.
Yazdanpanah, Y.
P1087
Ye, X.
P634
Yeom, J.
P1197, P1198, P1549
Yerly, P.
P2081
Yesilkaya, A.
P1169
Yesilyurt, E.
P1740
Yetiser, S.
P1927
Yetkin, F.
P1769
Yetkin, M.A.
P1222, P1659
Yeung, M.K.
P838
Yezli, S.
P1206, P1338
Yildirim, M.
P1228
Yildiz Zeyrek, F.
P875
Yilmaz, Gurdal
O413, P1297
Yilmaz, Gul Ruhsar
P833
Yilmaz, M.
P1755
Yilmaz Celik, G.
P892
Yilmaz-Bozkurt, G.
O237
Yilmaz-Köz, F.F.
P710
Yin, Y.
O85, P1289,
P1538, P1539,
P2091
Ying, B.
P2035,
P2045
Yntema, J.
O149
Yong, D.
P597
Yoon, H.Y.
P2049
Yoon, S.S.
P836
Yoon, Y.K.
P1598
Yoon, K.J.
P777
Yoshida, H.
P1433
Name
Yoshikazu, I.
Yoshizumi, A.
Youhanaee, P.
Youn, Y.
Young, L.
Young, V.
Yovcheva, T.
Yu, Chen Yi
Yu, Heidi
Yu, Jinming
Yu, J.K.
Yuan, J.
Yucel, E.
Yuceyar, H.
Yum, Jong Hwa
Yum, Joon Sup
Yun, Y.
Yuschuk, N.
Yuste, J.R.
Yusuf, U.
Z
aare, S.
Zabicka, D.
Zaccaria, O.
Zacharczuk, K.
Zachariadou, L.
Zacharias, J.
Žagar, Ž.
Zahar, J.-R.
Zakikhany, K.
Zalavras, N.
Zali, M.
Zalila, C.
Zaloudikova, B.
Zamora, E.
Zamorano, L.
Zampeta, E.
Zampoli, M.
Zande, M.
Zander, E.
Number
P1609
O101
P2194
P1290
O39
P1207
P703
O382
P784
O246
P714, P1356,
P2053
P634
P1457
P1618
P597
P1392
P2048
P1889
P1292
P1418
P2015
P743
P1499
P1705
P957
P1288
P553
P1217
P686
P1125
P869, P1704
P950
P904, P1937
O157
P612
P1389, P1393
P625
P1997, P2003
O192, O215,
P1731
Name
Zane, L.T.
Zanetti, A.
Zanetti, E.
Zanetti, G.
Zanini, F.
Zanker, C.
Zapasnik, A.
Zapata, E.M.
Zappa, A.
Zappala, D.
Zar, H.J.
Zarakolu, P.
Zarazaga, M.
Zarb, P.
Zarfel, G.
Zarkadas, P.
Zarkotou, O.
Zarrilli, R.
Zarrouk, V.
Zbinden, A.
Zeevi, A.
Zeidler, A.
Zeitlinger, M.
Zellweger, C.
Zemlickova, H.
Zentz, E.
Zeraati, H.
Zerbi, L.
Zerouali, K.
Zerva, L.
Zervos, M.J.
Zhang, H.
Zhang, L.
Zhang, Q.
Zhang, R.
Number
P796, P1521
O245
P1682
P1483, P1650,
P1790
P1336
P1195
P1462
P2039
P1554
P2061
P625
P672, P902,
P2240
P845, P901,
P937, P939,
P1249, P1813
O42, P1111,
P1309, P1310
P645, P926
P736
P683, P737,
P1170
P1363
P2247
O213
P2104
O390
P817
P1655
P740, P896,
P1172, P1559
P1714
P1411
P1403
P622
P786, P957
O301
P1894, P1895
P1421, P2035
O246
P1364
Name
Number
Zhang, W.
Zhang, Y.
Zhao, J.
Zhao, P.
Zhao, S.Y,
Zhong, M.
Zhou, W.J.
Zhu, C.
Zhu, D.
Zhu, J.Z.
Zhuchenko, E.
Zidaric, V.
Zidovec Lepej, S.
Ziegler, R.
Ziegler, T.
Zimmer, B.
Zimmerli, W.
Zimmermann, S.
Zingg, W.
Zinjarde, S.
Zinkernagel, A.
Zinner, S.
Zjuzgin, I.S.
Zlateva, K.
Zoldowski, A.
Zong, Z.
Zotos, N.
Zou, M.N
Zouari, A.
Zubarovskaja, N.V.
Zuccotti, G.
Zuckerman, T.
Zueva, L.
Zuffardi, O.
Zugravu, R.
Zulz, T.
Zupanets, I.
Zutkis, A.A.
Zweigner, J.
P1142
P682
P2090
P969
P1224
P1224
P1224
P1224
P682
P1512
P1243
P1981
P2191
P1229
O409
P774
P1655, P1857
P766
P1313
P1864
K508
O80, P782
P2129
P1871
P1894
P560, P1811
O35
P2045
P1555
P2129
P1554
P693
P851
S372
P1303
P992
P1509
P978
P1259
Chairs & Authors
Name
Final Programme
227
4HE MOST COMPREHENSIVE AND UPTODATE
PEERREVIEWED JOURNAL IN ANTIMICROBIAL RESEARCH
3.032
4HE /FüCIAL *OURNAL OF THE
)NTERNATIONAL 3OCIETY OF
#HEMOTHERAPY )3# p
)NFECTION AND #ANCER
WWWISCHEMOORG
%DITORIN#HIEF 0ROFESSOR !LASDAIR - 'EDDES
o 2APID PUBLICATION p )DEAL FOR #LINICAL 4RIALS ARTICLES PUBLISHED ONLINE IN
3CIENCE$IRECT FROM AS LITTLE AS WEEKS AFTER ACCEPTANCE
o /VER ARTICLES DOWNLOADED FROM 3CIENCE$IRECT IN o 2EGULAR TOPICAL SUPPLEMENTS ON NEW ANTIMICROBIAL AGENTS
o 3UBMISSION TO FIRST DECISION IS DAYS /NLINE SUBMISSION AVAILABLE FOR SPEEDY PUBLICATION
3UBMIT YOUR PAPER TODAY AT HTTPEESELSEVIERCOMIJAA
&OR MORE INFORMATION OR TO SUBSCRIBE ONLINE VISIT
WWWELSEVIERCOM)*!!
2OUNDED AVERAGE DOWNLOADS FOR )*!! &IGURE BASED ON )*!! FULL TEXT ARTICLES DOWNLOADED IN Editor-in-Chief: Didier Raoult
Latest Impact Factor: 4.014
2009 ISI Journal Citation Reports®
New to CMI
Read the latest Emerging Editorials from CMI on hot
topics including resistant bacteria in New Delhi, the arrival
of indigenous arboviruses in Europe and the risk of new
epidemics of seasonal influenza. All Emerging Editorials
are published rapidly online and freely accessible at
www.cmijournal.com
t When did the doctors become fomites?
E.Tacconelli
t An Animal Farm Called ESBL: Antimicrobial resistance as a zoonosis
G. Pappas
t The Haitian cholera epidemic: is searching for its origin only a matter of
scientific curiosity?
B. Faucher and R. Piarroux
t Measles, a re-emerging disease in France?
F. Freymuth and A. Vabret
t Sometimes they come back—the return of influenza
G. Cornaglia and D. Raoult
t First cases of autochtonous dengue fever and chikungunya fever in
France: from bad dream to reality!
E. A. Gould, P. Gallian, X. De Lamballerie and R. N. Charrel
t New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?
J. M. Rolain, P. Parola and G. Cornaglia
www.cmijournal.com
Industrial Exhibition Overview
201
203
211
111
301
205
307
303
213
313
311
315
215
317
320
319
to/from
Lecture Halls
Secretariat/Registration
221
to/from
Lecture Halls
White 1–3
223
323
321
121
Relax Area
325
225
125
227
129
127
231
131
133
331
123
135
139
141
143
145
149
147
241
245
243
151
Posters
247
161
163
165
Final Programme
341
349
347
361
345
343
363
365
351
401
403
406
407
411
413
410
417
Restaurant
to/from
Lecture Halls
421
521
721
621 622
523
623
624
723
625
525
Relax Area
431
434
626
627
Relax Area
628
435
436
437
438
629
439
725
441
531
444
631 633
533
635
449
535
637
727
729
638
643
451
452
453
454
641
455
539
457
461
463
459
465
645
561
563
565
647
Industrial Exhibition
456
Internet Corner
Final Programme
231
635
Abacus Diagnostica, Turku / FI
721
DRG Instruments GmbH, Marburg / DE
121
Abbott GmbH & Co. KG, Wiesenbaden / DE
133
DSI S.r.l., Saronno / IT
135
Advanced Instruments Inc., Drachten / NL
637
245
AdvanDx, Woburn, MA / US
ECDC – European Center for Disease Prevention
and Control, Stockholm / SE
454
AID GmbH, Strassberg / DE
151
EliTech Group, Puteaux / FR
301
Alere, Morges / CH
723
Elsevier Limited, London / UK
539
Alifax S.p.A., Polverara / IT
561
Eumedica Pharmaceuticals, Brussels / BE
311
Alpha-Tec Systems Inc., Vancouver, WA / US
436
Euprotec Ltd., Manchester / UK
624
American Society for Microbiology,
Washington, DC / US
147
Euroclone S.p.A., Pero / IT
165
Amplex Biosystems GmbH, Giessen / DE
641
Ani Lab Systems Ltd Oy, Vantaa / FI
226
Antimicrobial Copper, Hemel / UK
315
Antimicrobal Therapy Inc., Sperryville, VA / US
435
Applied Maths NV, Sint-Martens-Latem / BE
645
ArcDia International Ltd., Turku / FI
365
Associates of Cape Cod, Liverpool / UK
231
Astellas Pharma Europe Ltd, Staines / UK
403
Astra Diagnostics, Hamburg / DE
521
Balcony
European Committee on Antimicrobial
Susceptibility Testing (EUCAST), Växjö / SE
Balcony
European Society of Clinical Microbiology and
Infectious Diseases (ESCMID), Taufkirchen / DE
241
Focus Diagnostics Inc., Cypress, CA / US
313
Gardhen Bilance SRL, Pomigliano / IT
325
Gen-Probe, San Diego, CA / US
455
Genomica SAU, Madrid / ES
205
Genzyme Virotech / Genzyme Diagnostic,
Rüsselheim / DE
(now Sekisui Virotech / Sekisui Diagnostic)
AstraZeneca, Macclesfield / UK
223
Gilead Sciences Europe Ltd, Uxbridge / UK
411
Autobio Diagnostics Co. Ltd., Zhengzhou / CN
205
Grifols Italia S.p.A., Pisa / IT
321
BD Diagnostics, Heidelberg / DE
141
GSK Biologicals, Rixensart / BE
456
Binding Site, Birmingham / UK
417
Hain Lifescience GmbH, Nehren / DE
525
Bio-Rad, Marnes-La-Coquette / FR
451
Healthcare Infection Society, London / UK
465
Biolife Italiana S.A.R.L., Milano / IT
535
211
bioMérieux SA, Marcy l' Etoile / FR
Health Protection Agency Culture Collections,
Wiltshire / UK
410
Bioquell (UK) Ltd., Andover / UK
317
Human Genetic Signature, Randwick / AU
347
Brahms GmbH, Hennigsdorf / DE
247
Ia2 – SIRscan, Pérols Cedex / FR
323
Bruker Daltonik GmbH, Bremen / DE
563
Idaho Technology Inc., Salt Like City, UT / US
622
Carefusion, Reigate / UK
307
Immuno-Mycologics Inc., Norman, OK / US
421
Cepheid, Maurens-Scopont / FR
638
Infectious Diseases Society of America,
Arlington, VA / US
727
Charles River, L'Arbresle Cedex / FR
243
Innogenenetics, Zwijnaarde / BE
434
Check Points, Wageningen / NL
623
Clonit S.r.l., Milano / IT
441
Copan Italia SpA, Brescia / IT
401
Denka Seiken Co. Ltd., Tokyo / JP
565
Balcony
International Society of Chemotherapy (ISC),
Aberdeen / UK
626
International Society for Infectious Diseases,
Brookline, NY / US
Diagenode S.A., Liège / BE
203
Isentio AS, Bergen / NO
213
Diasorin S.p.A, Saluggia / IT
131
Janssen Cilag, Beerse / BE
625
Ditan Intl. Conference on Infectious Deseases,
Hong Kong / HK
303
John Wiley & Sons Ltd., Chichester / UK
331
Kiestra Lab Automation, Drachten / NE
647
Labquality Group, Helsinki / FI
Final Programme
List of Exhibitors
233
KNOW the diagnosis, KNOW the treatment
At Alere we specialise in advanced RAPID diagnostic tools for the area of Infectious Disease to
deliver timely and accurate information to drive better outcomes.
Alere brings providers, physicians and patients access to the right information at the right time by
offering a broad range of rapid tests.
t
t
t
t
Respiratory (S. pneumoniae, Legionella, Strep A, Influenza and RSV)
Healthcare Associated Infections (MRSA and C. difficile)
HIV Management & Screening
Enteric Disease (Norovirus Test Now Available)
To see our full portfolio of products, please visit www.alere.com
Formerly Inverness Medical
Come and see what else there is to KNOW
by visiting stand No. 301
List of Exhibitors
Life Technologies, Monza / IT
227
Seegene, Seoul / KR
225
Liofilchem, Roseto / IT
205
111
Luminex Europe, Oosterhout / NL
Sekisui Virotech / Sekisui Diagnostic,
Rüsselheim / DE
(former Genzyme Virotech / Genzyme Diagnostic)
431
Mast Group Ltd., Liverpool / UK
539
Serion Immunodiagnostica GmbH, Wuerzburg / DE
163
Medical Wire & Equipment Co. Ltd, Corsham / UK
221
Siemens AG, Erlangen / DE
533
Merck Sharp & Dohme (MSD),
Whitehouse Station, NJ / US
449
SIRS-Lab GmbH, Jena / DE
631
Meridian Biosience Europe Srl., Villa Cortese / IT
143
Statens Serum Institut, Hillerod / DK
453
miacom diagnostics GmbH, Düsseldorf / DE
201
Teleflex Medical GmbH, Atlone/ IE
406
Microsens Medtech Ltd., London / UK
341
The Impact Marketing Group, Glencoe, MD / US
438
Mikrogen GmbH, Neuried / DE
523
Thermo Fisher Scientific, Basingstoke / UK
643
Mobidiag Ltd., Helsinki / FI
145
Tjanjin Era Biology Engineering Co. Ltd.,
Tianjia / China
439
Molzym GmbH & Co. KG, Bremen / DE
343
Trek Diagnostic Systems, Cleveland, OH / US
437
Myconostica Ltd., Manchester / UK
129
TROCAR, Barcelona / ES
363
Nanosphere Inc., Northbrook, IL / US
349
Univercity of Wisconsin, Madison, WI / US
457
Nordiag AB, Hägersten / SW
161
Vircell, Granada / ES
215
Novartis Pharma AG, Basel / CH
407
Wisepress Ltd., London / UK
628
NovaTec Immundiagnostica GmbH,
Dietzenbach / DE
361
World Courier, Zavantem / BE
149
Opgen Inc., Gaithersburg, MD / US
413
Ophardt Hygiene Technik, Issum / DE
461
Oxford Immunotec Ltd., Abingdon / UK
729
Oxford University Press, Oxford / UK
345
PathoFinder B.V., Maastricht / NE
137
Pfizer International Operation, Paris / FR
319
320
725
Pilots Point LLC, Sarasota, FL / US
139
Pocared Diagnostics Ltd, Rehovat / IL
531
Qiagen GmbH, Hilden / DE
627
Quidel Copropation, San Diego, CA / US
629
Quotient Bioresearch, Fordham / UK
444
R-Biopharm AG, Darmstadt / DE
452
Reactifs RAL, Martillac / FR
621
Reagena International Ltd., Toivala / FI
463
Renishaw Diagnostics Ltd., Glasgow / UK
127
River Diagnostics, Rotterdam / NL
125
Roche Molecular Systems, Pleasanton, CA / US
633
Sacace Biotechnologies Srl., Como / IT
351
Sclavo Diagnostics International s.r.l.,
Sovicille / IT
459
Final Programme
235
Exhibitors Guide
ABACUS Diagnostica Oy
Advanced Instruments Inc.
Stand No. 635
ABACUS Diagnostica Oy
Tykistökatu 4D
20520 Turku / Finland
Stand No. 135
Advanced Instruments Inc.
Two Technology Way
02062 Norwood, MA / United States
Contact
Email
Mari Gylling
mari.gylling@abacusdiagnostica.com
Phone
Fax
Website
+358 20 7188 382
+358 20 7188 381
www.abacusdiagnostica.com
Contact
Email
Phone
Website
Abacus Diagnostica Oy develops rapid and simple solutions for IVD
DNA detection. The company's proprietary, fully automated testing
platform GenomEra CDX(TM) takes DNA testing on a new level
of convenience and simplicity. The company’s IVD MRSA product
family makes possible to perform high-performance genetic
testing even outside a specialized laboratory environment and by
personnel without experience in molecular biology.
GenomEra CDX automated system, GenomEra MRSA diagnostic and
screening kits.
Peter Helder
peterh@aicompanies.com
+31 6 515 475 49
www.aicompanies.com
Advanced Instruments, Inc. is a leading supplier of instrumentation
for clinical, pharmaceutical, biotechnology, microbiology and food
laboratories around the world.
Spiral Biotech, Inc. (SBI), an Advanced Instruments Company,
produces automated microbiology systems for research, food,
dairy and environmental sciences laboratories.
Mart Microbiology b.v an Advanced Instruments Company, produces
a system for creating anaerobic, microaerophilic, and capnophilic
environments in jars.
AdvanDx
Abbott
Stand No. 121
Abbott
Max-Planck-Ring 2
65205 Wiesbaden / Germany
Contact
Email
Phone
Fax
Website
Sven Schaffer
sven.schaffer@abbott.com
+49 6122 581 295
+49 6122 582 279
www.abbott.com
Abbott Molecular is a leader in molecular diagnostics. We are committed to exploring new clinical frontiers through the development
and delivery of system and assay solutions that are designed
to provide earlier disease diagnosis, selection of appropriate
therapies and monitoring of disease recurrence. Our expanding
portfolio brings multiples technologies that enable fast, accurate
results.
Stand No. 245
AdvanDx
Bygstubben 11
2950 Vedbaek / Denmark
Contact
Email
Phone
Fax
Website
Steen Hesthaven
info@advandx.com
+45 4516 07 99
+45 4516 07 98
www.advandx.com
AdvanDx develops and markets diagnostic tests based on whole
cell molecular analysis of bacterial pathogens to help prevent,
diagnose, and treat critical infections and sepsis.
PNA FISH® tests rapidly identify bloodstream pathogens and have
been shown in clinical studies to improve antibiotic prescribing,
care and outcomes while controlling hospital costs for patients
with bloodstream infections.
Over 350 products are available in the areas of infectious disease,
oncology, genetics, and automation. Some of the products include
the m2000 system which has an extensive assay menu in infectious disease featuring Abbott RealTime technology. xTAG® RVP
FAST is a diagnostic test developed by Luminex Molecular Diagnostics. Additionally, we have the PLEX-ID system which provides
comprehensive actionable answers, for non-diagnostic use,
to complex microbial identification within hours. Please visit our
booth for more information.
Final Programme
237
Exhibitors Guide
AID GmbH
Alifax S.p.A.
Stand No. 454
AID GmbH
Ebinger Str. 4
72479 Strassberg / Germany
Stand No. 539
Alifax S.p.A.
Via Petrarca 2/1
35020 Polverara / Italy
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Katrin Buck
autoimmun@t-online.de
+49 7434 936 40
+49 7434 936 440
www.aid-diagnostika.com
Tatiana Marchetto
tatiana.marchetto@alifax.com
+39 0490 992 000
+39 0490 992 905
www.alifax.com
Since 1989 AID produces imaging devices and diagnostic assays
within the wide range of autoimmunolgy, immunology, microbiology
and infectious biology.
Alifax is an Italian company leader in the development and production
of automated clinical diagnostic instrumentation for the Bacterial
Culture and determination of the Erythrocite Sedimentation Rate.
Several developments such as reverse hybridisation kits for
detection of TB resistances and the new AID iSpot Spectrum
imaging analyser will be presented.
This FluoroSpot/EliSpot reader for the first time allows to analyse
more than one cytokine and opens new horizons in diagnostics
of tuberculosis infections.
HB&L and Alfred are Alifax latest innovative products in bacteriological culture automation. The patented laser light-scattering technology allows to detect significant bacterial growth in few hours. They
are the first automated bacteriology analyzers capable to perform
bacterial culture and susceptibility test both in urine and Human
Biological Liquids. The susceptibility test is now available also on
positive haemocultures.
Alere
Alpha-Tec Systems, Inc.
Stand No. 301
Alere
Rue des Vignerons 1A
1110 Morges / Switzerland
Stand No. 311
Alpha-Tec Systems, Inc.
PO Box 5435
98668 Vancouver, WA / United States
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Carine Isenegger
carine.isenegger@alere.com
+41 787 390 343
+41 218 020 933
www.alere.com
Laurie Williams
L.Williams@AlphaTecSystems.com
+1 360 2602 779
+1 360 2603 277
www.AlphaTecSystems.com
Alere enables individuals to take charge of improving their health
and quality of life at home by developing new capabilities in nearpatient diagnosis, monitoring and health management.
Alpha-Tec Systems is a scientific leader in the development of
superior, innovative in-vitro diagnostics for clinical microbiology
laboratories.
Focused on cardiology, women’s health, infectious disease, oncology
and drugs of abuse. With professional and consumer offerings
in over 100 disease categories, Alere delivers the widest range of
services and solutions across the widest range of environments–
all around the world.
Alpha-Tec Systems is on the forefront of IVD development with
unique reagents designed for the pre-analytical processing and
diagnostics of patient specimens for infectious diseases. Clinical
laboratories worldwide continue to experience increased sensitivity,
precision and accuracy with Alpha-Tec products.
Final Programme
Exhibitors Guide
American Society for Microbiology
Ani Labsystems Ltd Oy
Stand No. 624
American Society for Microbiology
1752 N Street NW
20036 Washington, DC / United States
Stand No. 641
Ani Labsystems Ltd Oy
Tiilitie 3
01720 Vantaa / Finland
Email
Phone
Website
Contact
Email
Phone
Fax
Website
icaac@asmusa.org
+1 202 737 3600
www.icaac.org
51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17–20, 2011, Chicago, IL
ICAAC, the premier meeting on antimicrobial agents and infectious
diseases, showcases oral and poster presentations containing the
latest-breaking science and lectures from top researchers from
around the globe. ICAAC is designed to facilitate the exchange
of new information among the 10,000 physicians, clinical microbiologists, researchers, pharmacists and trainees in attendance.
Tarja Lahtinen
sales@anilabsystems.com
+358 20 155 7520
+358 20 155 7521
www.anilabsystems.com
Ani Labsystems Ltd Oy develops, manufactures, markets and sells
serologic diagnostic products for various infectious diseases, for
neonatal screening and other disorders.
• EIA kits for C. pneumoniae, M. pneumoniae, B. pertussis and
C. trachomatis antibodies
• Special tests: Quantitative IgD EIA, Toxoplasma IgG, IgM and Avidity
• EIA kits for HIV and hepatitis B
• FEIA and EIA kits for neonatal screening
Amplex BioSystems GmbH
Contact
Email
Phone
Fax
Website
Marcus Faerber
info@amplexbiosystems.de
+49 8073 916 93 50
+49 8073 916 93 55
www.hyplex.de
The Amplex BioSystems GmbH was founded on March 16th 2010 as
a daughter of the Amplex group. The long range of customers starts
from small hospitals over big university institutes, laboratory
consultants and MVZs.
Our system is always up to date not only in terms of the nosocomial
relevant parameters like MRSA, ESBL, MBL, KPC and carbapenem
resistant bacterial strains but also screening tests for the global
relevant resistances like NDM-1, TBC and C. diff 027. Another
product group is the STD line for C. trachomatis, N. gonorrhoeae,
M. hominis, M. genitalium, U. urealyticum / parvum, T. pallidum
and others.
Antimicrobial Copper
Stand No. 226
Antimicrobial Copper
5 Grovelands Business Centre, Boundary Way
Hemel Hempstead HP2 7TE / United Kingdom
Contact
Email
Phone
Fax
Website
Bryony Samuel
helpline@copperdev.co.uk
+44 1442 275705
+44 1442 275716
www.antimicrobialcopper.com
A global network of non-profit organisations, whichdisseminate
information on the use of Antimicrobial Copper touch surfaces
forinfection control.
Antimicrobial Copper has proven, broad-spectrumantimicrobial
efficacy, demonstrated in the laboratory and clinical trials.
Coppercontinuously reduces microbial contamination in clinical
environments,providing an additional infection control measure.
Scientific reports, practical information and typical products will
be available to visitors.
Stand No. 165
Amplex BioSystems GmbH
Kerkrader Str. 11
35394 Giessen / Germany
Final Programme
239
Exhibitors Guide
Antimicrobial Therapy Inc
ArcDia Group
Stand No. 315
Antimicrobial Therapy Inc
PO BOX 276 / 11771 Lee Hwy.
22740 Sperryville, VA / United States
Stand No. 645
ArcDia Group
PO Box 51
20521 Turku / Finland
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Website
Sherry Golden
info@sanfordguide.com
+1 540 987 9480
+1 540 987 9486
www.sanfordguide.com
Antimicrobial Therapy, Inc. is a leading global provider of infectious
diseases treatment information for health care professionals.
Since 1969, its Sanford Guides have provided up-to-date, focused
treatment guidance and related anti-infective drug information
where needed most – at the point of care.
The Sanford Guides are available in a wide array of formats, including the familiar pocket-sized, handy spiral and large library
editions. Our Web Edition is available for individual and institutional
subscription. Coming in 2011: new handheld editions for iPhone and
Android.
Eija Järvinen
eija.jarvinen@arcdia.com
+358 40 565 6699
www.arcdia.com
ArcDia Group is the manufacturer and vendor of the new multianalyte
immunoassay test system mariPOC® for infectious disease nearpatient testing.
mariPOC® multianalyte test system is focused on respiratory tract
infections with 10 analytes. The automated random-access
immunoanalyser is bench-top in size, highly sensitive and easyto-use. Hands-on-time is only few minutes.
mariPOC® is now available for distribution and in-licensing.
www.maripoc.com
Associates of Cape Cod
Applied Maths NV
Stand No. 435
Applied Maths NV
Keistraat 120
9830 Sint-Martens-Latem / Belgium
Email
Phone
Fax
Website
info@applied-maths.com
+32 9 222 21 00
+32 9 222 21 02
www.applied-maths.com
Develops professional bioinformatics applications and services
with emphasis on data integration, platform technology, and
networking.
BioNumerics: universal bioinformatics platform integrating databasing and analysis of all biodata.
GelCompar II: databasing and analysis of electrophoresis gels and
fingerprints.
Kodon: databasing, analysis and comparison of sequences and
chromosomes.
GeneMaths XT: comparative exploration and analysis of microarrays and genechips.
Final Programme
Stand No. 365
Associates of Cape Cod
Deacon Park
Liverpool L33 7RX / United Kingdom
Contact
Email
Phone
Fax
Website
Paul Cross
pcross@acciuk.co.uk
+44 151 547 7444
+44 151 547 7400
www.acciusa.com
Associates of Cape Cod, Inc. (ACC) is a global biopharmaceutical
company specializing in endotoxin and glucan detection. ACC was
the first company licensed by the FDA to manufacture LAL for use
as a quality control test for endotoxin in the pharmaceutical and
medical device markets. ACC also operates a Contract Testing
Service.
The Fungitell® Assay is a rapid, highly sensitive, microplate-based
test that detects (1 3)-ß-D-Glucan in serum. (1 3)-ß-D-Glucan is a
cell wall constituent of most medically important fungi including
Candida and Aspergillus. In at risk patients, serum (1 3)-ßD-Glucan values of at least 80 pg/mL, are highly associated with
invasive fungal infection.
Exhibitors Guide
Astellas Pharma Europe Limited
AstraZeneca
Stand No. 231
Astellas Pharma Europe Limited
Lovett House, Lovett Road
Staines TW18 3AZ / United Kingdom
Stand No. 521
AstraZeneca
Alderley Park
Macclesfield SK10 4TF / United Kingdom
Contact
Email
Contact
Email
Phone
Fax
Phone
Fax
Website
Mindy Dooa
astellas.european.communications@
eu.astellas.com
+44 1784 419 400
+44 1784 419 526
www.astellas.eu
Astellas Pharma Europe Ltd. is a European subsidiary of Tokyobased Astellas Pharma Inc., dedicated to improving the health
of people around the world. In addition to Anti-Infectives, Astellas
focuses on Transplantation, Urology, Dermatology and Pain
Management. Committed to research and development, Astellas
plans to advance the management of serious fungal/bacterial
infections and introduce solutions for this unmet medical need.
Astra Diagnostics
Stand No. 403
Astra Diagnostics
Mörkenstrasse 12
22767 Hamburg / Germany
Email
Phone
Fax
Website
info@astra-diagnostics.com
+49 40 548 06 76 0
+49 40 548 06 76 10
www.astra-diagnostics.com
astra Diagnostics is a Hamburg based company, focused on
the development and commercialisation of real-time PCR based
diagnostic test kits, primarily in the field of infectious disease.
Sandra Brogan
sandra.brogan@astrazeneca.com
+44 1625 515 206
+44 1625 582 912
AstraZeneca is a global, innovation-driven biopharmaceutical company focused on the discovery, development and commercialisation of medicines that bring benefit for patients and add value for
society in important areas of healthcare, including neuroscience,
cancer and heart disease.
Autobio Diagnostics Co. Ltd.
Stand No. 411
Autobio Diagnostics Co. Ltd.
NO.87 Jingbei Yi RD, National Eco&Tech Development
450016 Zhengzhou City / China
Contact
Email
Phone
Fax
Website
Allan Pu
export@autobio.com.cn
+86 371 6798 5313
+86 371 6798 5804
www.autobio-diagnostics.com
Autobio is specializing in production and distribution of in vitro
diagnostic products.
Autobio offers a line of state of art Microbiology Diagnostic
products, such as Mycoplasma IES,Vaginitis Multitest and Blood
culture bottles, the CE certificated products are designed for
performance and reliability.
Our RealStar® Kits are ready to use, IVD-CE marked test systems for
the reliable detection, quantification, and differentiation of
a broad range of viruses, bacteria and parasites. All assays are
developed and validated to be used with most of the established
real-time PCR instruments.
Final Programme
241
Exhibitors Guide
BD Diagnostics
Bio-Rad
Stand No. 321
BD Diagnostics
Tullastrasse 6-12
69126 Heidelberg / Germany
Stand No. 525
Bio-Rad
3 Boulevard Raymond Poincaré
92430 Marnes-La-Coquette / France
Phone
Website
Contact
Email
Phone
Fax
Website
+49 622 130 50
www.bd.com/europe/ds
BD Diagnostics is a leading provider of products for the safe collection and transport of diagnostic specimens and of instrumentation
for quick, accurate analysis across a broad range of infectious
diseases, including the growing problem of healthcare-associated
infections.
BD Diagnostics focuses on improving health outcomes for patients
and economic outcomes for laboratories by providing solutions
that elevate quality, reduce costs, guide medical decisions and
improve the productivity and efficiency of laboratory systems.
Binding Site
Stand No. 456
Binding Site
8 Calthorpe Road
Birmingham B15 1QT / United Kingdom
Phone
Fax
Website
+44 1214 569 500
+44 1214 569 749
www.bindingsite.co.uk
Binding Site is a Specialist Protein company committed to the
research, development and manufacture of immunodiagnostic
assays for laboratories worldwide.
Binding Site is the market leader in the development of products
for the investigation of Primary Immunodeficiency. A wide range
of products are available to assess immune status including IgG
subclasses, specific antibody response to vaccination or infection
and complement.
Guillaume Camard
guillaume.camard@bio-rad.com
+33 147 95 62 61
+33 147 95 81 40
www.bio-rad.com
Bio-Rad Laboratories, Inc is a multinational manufacturer and
distributor of Clinical Diagnostics (Instruments and Kits for Microbiology, Infectious Diseases testing, Molecular diagnostics but
also Diabetes monitoring, Quality Controls, Toxicology, AutoImmune
diseases, Immuno-Hematology) and Life Science research products
(Instruments and Reagents for Electrophoresis, Liquid Chromatography, Amplification, DNA Microarrays, BSE diagnostic ...).
Bio-Rad Laboratories has played a leading role in the advancement
of scientific discovery for over 50 years by providing a broad range
of innovative products and services to the life science research
and clinical diagnostics markets. Founded in 1952, Bio-Rad has
a global team of more than 7,000 employees and serves more than
85,000 clinical and research laboratories, industry customers
worldwide through its global network of operations.
• Molecular Diagnostics
Introducing the new Dx Real-Time System and the Dx CT/NG/MG
Assay.
Built on Bio-Rad's expertise in Infectious Diseases and real-time
PCR, the Dx Assays and Analyzer are easy to use and designed to
provide highly reliable results.
State of the art innovation: The Dx CT/NG/MG assay is the first test
combining the detection of CT, NG and Mycoplasma genitalium in
one tube.
• Microbiology
New ADAGIOTM and Antimicrobial Susceptibility Testing line.
Complete range of products calibrated to EUCAST recommendations,
including the ADAGIOTM, the fully integrated, easy to use and
innovative system for Antimicrobial Susceptibility Testing
SelectTM Chromogenic Culture Media
Direct and rapid identification of MRSA, S.aureus, VRE, GBS, Candida, and Urinary pathogens
• Mycology
Introducing the new BAL Sample claim for Platelia Aspergillus Ag
and new Platelia Candida Ag/Ab plus assays for prevention and
detection of Fungal Infections.
• Serology
Accurate identification of specific EBV IgG and IgM antibodies in
2 minutes with the new single and rapid RDT EBV IgG and IgM Assays.
Introducing the new Platelia C.difficileTox A&B. Qualitative
detection of Clostridium difficile toxins A and B in human stool
specimens.
Final Programme
Exhibitors Guide
Biolife Italiana
Bioquell (UK) Ltd
Stand No. 465
Biolife Italiana
Viale Monza 272
20128 Milano / Italy
Stand No. 410
Bioquell (UK) Ltd
52 Royce Close
SP10 3TS / United Kingdom
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Veronesi Massimo
mktg@biolifeitaliana.it
+39 02 252 091
+39 02 257 6428
www.biolifeitaliana.it
Production and distribution of IvD for platelet aggregation, immunology, rapid tests, clinical chemistry and microbiology.
Dehydrated and ready to use culture media, raw material for
microbiology, selective supplements, immunochromatographic
and ELISA test, reagent for platelet aggregation, clinical chemistry,
ID biochemical test.
James Salkeld
enquiries@bioquell.com
+44 1264 835835
+44 1264 835836
www.bioquell.com
Bioquell provides professional bio-decontamination services using
hydrogen peroxide vapour (HPV) to the healthcare and other
sectors worldwide.
Bioquell’s HPV bio-decontamination services are proven to reduce
environmental contamination and transmission. Services include
emergency call-out to tackle outbreaks and the Proactive Service
to reduce endemic infection rates of pathogens including Clostridium difficile, MRSA, VRE, multidrug-resistant Gram-negative rods
and norovirus.
bioMérieux SA
Phone
Fax
Website
+33 478 872 000
+33 478 872 090
www.biomerieux.com
bioMerieux is a leading international diagnostics company, specializing in in vitro diagnostics for medical analyses and industrial
controls.
Visit Booth N°211 and discover :
Shaping your world together – find out how to empower clinical
decisions by increasing lab performance and flexibility. Shape
your laboratory by changing only what makes sense!
New solutions – ID/AST, Blood Culture, Workflow and starring Myla.
BRAHMS GmbH
Stand No. 347
BRAHMS GmbH
Neuendorfstrasse 25
16761 Hennigsdorf / Germany
Contact
Email
Phone
Fax
Website
Sigrid Riesberg
sigrid.riesberg@thermofisher.com
+49 3302 883825
+49 3302 883850
www.thermoscientific.com/brahms
BRAHMS GmbH, Part of Thermo Fisher Scientific, specialises in
innovative products which facilitate earlier diagnosis of diseases
and better control of therapy, thus enabling doctors to provide
more efficient and economic patient care.
Major fields of activity are diagnosis of infectious and thyroid
diseases, cardiology and pneumology as well as sepsis, tumors,
and Down's syndrome.
Stand No. 211
bioMérieux SA
Chemin de l‘Orme
69280 Marcy l’Etoile / France
Final Programme
243
Exhibitors Guide
Bruker Daltonik GmbH
Cepheid
Stand No. 323
Bruker Daltonik GmbH
Fahrenheitstr. 4
28359 Bremen / Germany
Stand No. 421
Cepheid
Vira Solelh
81470 Maurens Scopont / France
Contact
Email
Phone
Fax
Website
Email
Phone
Fax
Website
Karin Hoffmann
kho@bdal.de
+49 421 2205 2041
+49 421 2205 305
www.bdal.de
Bruker Daltonics Inc. is a leading manufacturer of mass spectrometry (MS) instrumentation for life science, pharmaceutical,
biochemical and chemical research. The Bruker Daltonics MALDI
Biotyper is the leading solution for microbial identification using
MALDI-TOF mass spectrometry, based on Bruker’s advanced
MALDI-TOF technology.
The MALDI Biotyper ia a next generation approach for the identification of microorganisms based on mass spectrometry. While
the MALDI Biotyper is for research use only, the corresponding
IVD MALDI Biotyper has a CE mark according to the EU Directives
98/79/EC.
Carefusion
Stand No. 622
Carefusion
Reigate Place, 43 London Road
Reigate RH2 9PW / United Kingdom
Email
Phone
Fax
Website
enquiries@chloraprep.co.uk
+44 1737 237 942
+44 1737 237 950
www.chloraprep.co.uk
The CareFusion, Infection Prevention mission is to deliver clinically
differentiated evidence-based products and services that support
the global effort to reduce HAIs.
ChloraPrep® – a medicinal product containing a solution of 2%
chlorhexidine gluconate (w/v) in 70% isopropyl alcohol (v/v), is a
single use, sterile, ‘non-touch’ skin antisepsis system. This allows
healthcare practitioners to apply sufficient antiseptic solution with
a gentle back and forth motion whilst remaining compliant with
ANTT. This use of ChloraPrep has been shown to provide greater
skin decontamination, and significant reductions in line related
infections than application with a simple swab and weaker antiseptics.
cepheid@cepheideurope.fr
+33 563 825 300
+33 563 825 301
www.cepheidinternational.com
Cepheid is delivering a better way to realize the benefits of molecular diagnostics. Every day we are transforming healthcare with
our revolutionary approach to molecular testing.
The GeneXpert System is a closed, self-contained, fully-integrated
and automated platform that represents a paradigm shift in the
automation of molecular analysis, producing accurate results in
a timely manner with minimal risk of contamination.
It is the only system to combine sample preparation with real-time
PCR (polymerase chain reaction) amplification and detection for
fully integrated and automated nucleic acid analysis. The system
is designed to purify, concentrate, detect and identify targeted
nucleic acid sequences thereby delivering answers directly from
unprocessed samples.
Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands of any
clinical environment.
Cepheid’s CE-IVD menu of Xpert® tests includes: MRSA Surveillance,
MRSA/SA Skin and Soft Tissue, MRSA/SA Blood Culture, MRSA/SA
presurgical, Clostridium difficile, vanA/vanB, GBS, EV, MTB/RIF, Flu,
BCR-ABL and HemosIL® FII&V.
Cepheid’s product lines also include SmartCycler and affigene.
Charles River
Stand No. 727
Charles River
B.P. 0109
69592 l'Arbresle Cedex / France
Contact
Email
Phone
Fax
Website
Sophie Arsenault
sophie.arsenault@crl.com
+33 474 016 906
+33 474 016531
www.criver.com
Charles River mission is to provide exactly what researchers need
to develop new therapeutics for patients as rapidly as possible
Charles River Endosafe®-PTSTM is a portable handheld endotoxin
testing system with FDA-licensed LAL cartridges, providing quantitative test results in about 15 minutes. Additional rapid testing
products that utilize the PTS for microbiological test are available,
come visit our stand.
Final Programme
Exhibitors Guide
Check-Points
Denka Seiken Co., Ltd.
Stand No. 434
Check-Points
Binnenhaven 5
6709 PD Wageningen / Netherlands
Stand No. 401
Denka Seiken Co., Ltd.
3-4-2 Nihonbashi- Kayabacho, Chuo-ku
103-0025 Tokyo / Japan
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
info@check-points.com
+31 317 453 908
+ 31 317 210 147
www.check-points.com
Denka Seiken is a world renowned company, developing and
manufacturing a wide range of IVD products for the microbiology
markets.
Clonit S.r.l.
Stand No. 623
Clonit S.r.l.
Via Bernardo Quaranta 57
20139 Milano / Italy
Email
Phone
Fax
Website
Bert Kolhorn
b.kolhorn@denka-seiken.co.uk
+81 33669 9421
+81 33669 9390
www.denka-seiken.jp
info@clonit.it
+39 0256 814 413
+39 0256 814 515
www.clonit.it
Offering test kits for the detection of bacterial toxins, viral antigens
and antibodies, a latex agglutination assay for MRSA (PBP2
protein), more than 550 bacterial serotyping antisera and various
lateral flow immuno assays (POCTs) for Influenza and other
viruses.
Diagenode S.A.
Simultaneous detection of virus, bacteria and parasites by Multiplex Fast PCR kits (STD panel, Atypical Bacteria pneumoniae, Fecal
Enterocolitic bacteria, Fecal parasites, HPV screening and high
risk strains, periodontal disease) using the ClonPact System: safe,
reliable, easy and convenient methods.
Copan Italia SpA
Stand No. 441
Copan Italia SpA
via Perotti 10
25125 Brescia / Italy
Contact
Email
Phone
Fax
Website
Lorenzo Fumagalli
lorenzo.fumagalli@copanitalia.com
+39 030 2687 211
+39 030 2687 250
www.copaninnovation.com
Stand No. 565
Diagenode S.A.
Avenue de l'Hôpital, 1
4000 Liege / Belgium
Contact
Email
Phone
Fax
Website
François Dohet
francois.dohet@diagenode.com
+32 4 364 20 50
+32 4 364 20 51
www.diagenodediagnostics.com
Diagenode, Liège, Belgium, develops and markets CE marked
Molecular IVD for Human Infectious Diseases. Q-PCR multiplexed
and LAMP assays.
Diagenode’s portfolio targets: Herpes, Respiratory,Gastric panels,
and more. Diagenode sells directly in Europe and also OEM and
Customized CE marked products for exportation. Diagenode’s R&D
is quick in creating cutting edge multiplexed assays using QPCR
and LAMP technologies. Diagenode is ISO 9001 and 13485.
Research, development and manufacturing for diagnostic systems
in molecular biology. Specialized in Fast PCR reagents for microbiology, virolgy, genetic testing.
Copan is the world leading manufacturer of collection and transport devices for microbiology and automated systems for the
bacteriology laboratory.
WASP is the best selling advanced automation for the bacteriology
laboratory. Copan introduces WASPlab, a fully automated modular
system for the management of streaking of culture plates, gram
preparation, broth inoculation, antibiotic discs application, plates
incubation and evoluted image recording.
Final Programme
245
Exhibitors Guide
DiaSorin S.p.A.
DRG Instruments GmbH
Stand No. 213
DiaSorin S.p.A.
Via Crescentino snc
13040 Saluggia / Italy
Stand No. 721
DRG Instruments GmbH
Frauenbergstr. 18
35039 Marburg / Germany
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Emanuela Lanza
emanuela.lanza@diasorin.it
+39 0161 487 526
+39 0161 487 670
www.diasorin.com
DiaSorin S.p.A., an international player in the in vitro diagnostics
market, develops, produces and markets reagent kits for clinical
laboratory diagnostics. DiaSorin is offering a broad array of high
quality products on fully automated CLIA system (LIAISON®) and
operates in infectious and viral diseases, management of bone and
calcium related diseases, thyroid pathologies, oncology, fertility
testing. For further information: www.diasorin.com
Most efforts in developing LIAISON® menu have been dedicated to
ID serology testing. New assays for Parvo virus B19 diagnosis are
currently available. Complete TORCH and Epstein-Barr virus panel,
Treponema pallidum, Borrelia burgdorferi, VZV and a complete
range of assays for diagnosis of viral hepatitis and retrovirus.
Stefanie Lamers
Lamers@drg-diagnostics.de
+49 6421 1700 0
+49 6421 1700 50
www.drg-diagnostics.de
DRG Instruments GmbH, member of DRG Intl. group, is a diagnostic
manufacturer and distributor, ISO 9001 and ISO 13485 certified.
DRG Instruments GmbH specializes in manufacture and distribution
of enzyme-linked- immunoassays (ELISA’s), chemiluminescenseimmunoassays (CLA’s) and RIA’s for infectious diseases, fertility,
diabetes, and tumor diagnosis for serum and/or saliva samples
and a new analyzer for immunoassays and clinical chemistry.
DSI S.r.l.
Ditan Intl Conference on Infectious Diseases
Stand No. 133
DSI S.r.l.
Via A.Volonterio, 36a
21047 Saronno / Italy
Stand No. 625
Ditan Intl Conference on Infectious Diseases
Cosoman Limited, 9/F., New Hennessy Tower
263 Hennessy Road, Hong Kong / China
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
European manufacturer of high-sensitive ELISA kits (HIV, Hepatitis,
ToRCH, Hormones, Tumor markers) and Quality Control Products.
ISO 13485, CE.
Andrea Lam
andrea.lam@cosoman.com
+86 282 720 91
+86 282 722 20
www.bjditan.org
The DICID serves as a platform for timely communication between
Chinese and international professionals in infectious diseases
management.
The 5th DICID will be held on July 14 – 17, 2011 in Beijing, China
with the theme “Infectious Diseases in the Resistance Era”.
A 3-and-a-half program will bring you the latest updates and an
excellent occasion for scientific exchange.
Final Programme
info@dsitaly.com
+39 02 967 091 11
+39 02 962 018 55
www.dsitaly.com
• High-sensitive screening ELISA kits: HBsAg (0.01 IU/ml), HIV-AgAb
(0.25 IU/ml (p24)), HIV-Ag (0.025 IU/ml). Full range for screening, confirmation and treatment monitoring.
• FAST-ToRCH line (total incubation time is 35min)
• Convenient panel for Thyroids, Fertility and Cancer markers
Exhibitors Guide
ECDC – European Centre for Disease Prevention and Control
Elsevier Limited
Stand No. 637
ECDC European Centre for Disease Prevention and Control
Tomtebodavägen 11a
17183 Stockholm / Sweden
Stand No. 723
Elsevier Limited
32 Jamestown Road
London NW17BY / United Kingdom
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Giovanni Mancarella
giovanni.mancarella@ecdc.europa.eu
+46 8586 010 00
+46 8586 012 94
www.ecdc.europa.eu
The ECDC is an EU agency aimed at strengthening Europe's
defences against infectious diseases.
Valerie Giblin
V.Giblin@elsevier.com
+44 1865 843000
+44 1865 843010
www.elsevierhealth.com
Elsevier Health advances medicine by delivering superior education, reference information and decision support tools to medical
students and medical professionals.
ELITech Group
Stand No. 151
ELITech Group
12-12 bis rue Jean Jaurès
92800 Puteaux / France
Email
Phone
Fax
Website
info@elitechgroup.com
+ 33 1 4145 07 10
+ 33 1 4145 07 19
www.elitechgroup.com
The ELITech Group is a leader in the international medical market.
ELITech has brought together specialized IVD companies to provide
the best offering of innovative, unique and also routine products
to laboratories operating closer to the patient. Through direct sales
in Europe and North America and distribution capabilities in over
100 countries, the ELITech Group offers microbiology, immunology,
molecular biology and clinical chemistry products from its own
facilities as well as complementary products of third-parties.
ELITech, world leader in mycoplasma diagnosis, is proud to announce
the best just got better with the new MYCOFAST® RevolutioN:
EUCAST – The European Committee on Antimicrobial
Susceptibility Testing
Balcony
EUCAST
Central Hospital
351 85 Växjö / Sweden
Contact
Email
Phone
Website
Gunnar Kahlmeter
gunnar.kahlmeter@ltkronoberg.se
+46 470 58 74 77
www.eucast.org
EUCAST, the European Committee on Antimicrobial Susceptibility
Testing, is jointly organized by ESCMID, ECDC and national breakpoint committees in Europe. EUCAST deals with breakpoints and
technical aspects of phenotypic in vitro antimicrobial susceptibility
testing and functions as the breakpoint committee of EMA (The
Europan Medicines Agency) and ECDC (The European Centre for
Disease Prevention and Control).
• New Integrated growth medium
• New Closing system
• New UMMt RevolutioN transport medium
• New highly specific M.h and U.u growth media
Final Programme
247
Exhibitors Guide
Eumedica Pharmaceuticals
Euroclone S.p.A.
Stand No. 561
Eumedica Pharmaceuticals
Winston Churchill Avenue 67
1180 Brussels / Belgium
Stand No. 147
Euroclone S.p.A.
Via Figino 20/22
20016 Pero / Italy
Contact
Email
Phone
Fax
Website
Email
Phone
Fax
Website
Veronique Van Ranst
enquiries@eumedica.com
+32 64 27 17 22
+32 64 27 17 84
www.eumedica.com
Eumedica, a different partnership to the hospital environment,
seeks to ensure development & continuity of vital treatment in
serious indications.
Negaban® temocillin, a narrow spectrum directed towards gramnegative bacteria with a proven stability against most types
of ß-lactamases (ESBLs and AmpCs)
info.euro@euroclone.it
+39 0238 1951
+39 0238 1952 50
www.euroclone.it
EuroClone S.p.A., a research, development and production unit, is a
worldwide supplier of innovative products in Molecular Diagnostics
and Research.
EuroClone Human Diagnostics Unit's mission is to develop,
produce and commercialise the cutting edge molecular biology
products for the diagnosis in the field of: cardio-vascular diseases,
in-vitro fertilisation, respiratory and sexually trasmitted infectious
diseases and oncology.
Euprotec Ltd
Stand No. 436
Euprotec Ltd
48 Grafton Street
Manchester M13 9XX / United Kingdom
Email
Phone
Fax
Website
info@euprotec.com
+44 161 603 7624
+44 161 603 7643
www.euprotec.com
Euprotec is a specialist CRO dedicated to the provision of infectious
disease, respiratory and allergy biology services. With a large and
innovative portfolio of assays and disease models, underpinned
by internationally recognised expertise, we support each stage
of your drug discovery and development programs through to
late stage preclinical investigation and clinical proof-of-concept
studies.
Overview of Services:
• Efficacy models of bacterial/fungal infection and respiratory
diseases, including allergy.
• Hit finding and library/compound collection screening for antimicrobial activity.
• Susceptibility (MIC) testing to identify and quantify antimicrobial activity (to CLSI and EUCAST guidelines).
• ADME and PK assays including sophisticated PK/PD profiling
and mathematical modelling.
Assay and efficacy model development.
Final Programme
ESCMID – European Society of Clinical Microbiology and
Infectious Diseases
Balcony
ESCMID Executive Office
Peter Merian-Strasse 80
P.O. Box
4002 Basel / Switzerland
Email
info@escmid.org
Phone
+41 61 686 77 99
Fax
+41 61 686 77 98
Website
www.escmid.org
ESCMID Membership Office
P.O. Box 1131
82018 Taufkirchen / Germany
Phone
+49 89 612 616 2
Fax
+49 89 612 817 6
Email
membership@escmid.org
The European Society of Clinical Microbiology and Infectious Diseases
is a non-profit organisation whose mission is to improve the
diagnosis, treatment and prevention of infection-related diseases.
This is achieved by promoting and supporting research, education,
training, and good medical practice.
Founded in 1983, ESCMID now has some 4’000 members allover
the world. Combined with its associated and affiliated memberships, ESCMID reaches out to over 33’000 professionals.
The Society is a non-profit organisation registered in Germany, with
membership and administration offices in both Munich and Basel.
ESCMID has been an influential component in the professional lives
of microbiologists and infectious diseases specialists for more
than 25 years and welcomes new colleagues from all nations.
Exhibitors Guide
Focus Diagnostics Inc.
Gen-Probe Deutschland GmbH
Stand No. 241
Focus Diagnostics Inc.
11331 Valley View Street
90630 Cypress, CA / United States
Stand No. 325
Gen-Probe Deutschland GmbH
Otto-von-Guericke-Ring 15
65205 Wiesbaden-Nordenstadt / Germany
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Philip Noone
pnoone@focusdx.com
+1 562 240 6500
+1 562 240 6510
www.focusdx.com
Focus Diagnostics, Inc. manufactures molecular serology diagnostic test products for worldwide distribution. Key brands include:
HerpeSelect®, SimplexaTM, and DxSelectTM .
SimplexaTM molecular products are real-time PCR qualitative and
quantitative assays manufactured by Focus Diagnostics, Inc and
performed on the 3MTM Integrated Cycler. Currently available are
Simplexa H1N1, Flu A/B & RSV, Bordetella, EBV and BKV kits.
John Garland
john.garland@gen-probe.com
+49 6122 707 61 11
+49 6122 707 64
www.gen-probe.com
Gen-Probe is a global leader in molecular diagnostics for infectious
disease, blood screening, oncology and transplant diagnostics.
The company develops, manufactures and markets nucleic acid
tests and fully automated instruments to support women's health
and detect infectious microorganisms, including those causing
sexually transmitted diseases, HIV/HCV, respiratory infectious
diseases, C. diff., tuberculosis, strep throat, pneumonia and
fungal infections.
Gardhen Bilance Srl.
Genomica SAU
Contact
Email
Phone
Fax
Website
Anna Di Leva
anna@gardhenbilance.it
+39 081 8692 160
+39 081 8692 460
www.gardhenbilance.it
Gardhen bilance is presents in most parts of the world thanks to its
exclusive distributors and high quality of products:
• hospital beds with or without scale
• hospital armchairs with or without scale
• weighing systems for healthcare
• multifunctional trolleys
• tilt test table
Stand No. 455
Genomica SAU
Al Carria 7
28823 Madrid / Spain
Phone
Fax
Website
+34 9167 489 90
+34 9167 489 91
www.genomica.es
GENOMICA is a Spanish leading company in molecular disgnostics.
Develops, produces and commercializes applications for different
molecular in vitro diagnosis based on the amplification and detection
of the genetic material on a innovative pltform: CLART® (CLINICAL
ARRAY TECHNOLOGY).
The lines of development include from the diagnosis of viral and
bacterial diseases up to the detection of human genetic regions
associated with the determination of factors of response to therapies.
Stand No. 313
Gardhen Bilance Srl.
Via G. Luraghi c/o Consorzio Il Sole – lt.S
80038 Pomigliano D'Arco / Italy
Final Programme
249
Exhibitors Guide
Gilead Sciences Europe Ltd.
GSK Biologicals
Stand No. 223
Gilead Sciences Europe Ltd.
South Building, 2 Roundwood Avenue, Stockley Park
Uxbridge UB11 1AF / United Kingdom
Stand No. 141
GSK Biologicals
rue de l'institut 89
1330 Rixensart / Belgium
Contact
Email
Fax
Website
Website
Vitor Papao
vitor.papao@gilead.com
+44 2085 872 333
www.gilead.com
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the
care of patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Asia Pacific.
Stand No. 205
Grifols Italia S.p.A.
Via Carducci, 62/d
56010 Ghezzano, Italy
Chiara Contini
italia@grifols.com
+39 05 875 51 11
+39 050 87 98 84
www.grifols.com
Grifols is a group of companies, which serves healthcare professionals
and patients in over 90 countries around the world. The Diagnostic
Division focuses on researching, developing, manufacturing and
marketing diagnostics products for laboratory analysis, including
products for Hospital Blood Banks and Transfusion Centers.
Innovation in diagnostics. The development of diagnostic products
and systems has paralleled the development of new technologies
in fields such as biology. As a result, modern analytical and
diagnostic tests have become ever more effective in determining
a patient‘s clinical state and are essential to the provision of high
quality medical care. From the beginning, Grifols has been a
leader in developing sophisticated instrumentation and methods
for clinical analysis. This is an exciting and fast-moving field and
Grifols‘ activities in this area have led to numerous technological
advances to facilitate the work of diagnosticians in three critical
categories: Immunology,Blood Banking and Hemostasis.
GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline’s
vaccines business, is one of the world’s leading vaccine companies
and a leader in innovation. The company is active in vaccine
research, development and production with over 30 vaccines
approved for marketing and 20 more in development – both in the
prophylactic and therapeutic fields. Headquartered in Belgium, GSK
Biologicals has 14 manufacturing sites strategically positioned
around the globe. In 2010, GSK Biologicals distributed 1.43 billion
doses of vaccines to 179 countries in both the developed and the
developing world.
Through its accomplished and dedicated workforce, GSK Biologicals
applies its expertise to the discovery of innovative vaccines that
contribute to the health and well-being of people of all generations
around the world.
Grifols Italia S.p.A.
Contact
Email
Phone
Fax
Website
www.gsk.com
Final Programme
GlaxoSmithKline – one of the world’s leading research-based
pharmaceutical and healthcare companies – is committed to
improving the quality of human life by enabling people to do more,
feel better and live longer.
Hain Lifescience GmbH
Stand No. 417
Hain Lifescience GmbH
Hardwiesenstr. 1
72147 Nehren / Germany
Contact
Website
info@hain-lifescience.de
www.hain-lifescience.de
Hain Lifescience is an innovative German manufacturer of the
GenoType® and GenoQuick® product series
The GenoType® and GenoQuick® tests are a robust and reliable systems
for routine diagnostics of microbiological species differentiation and
resistance determination. The systems are cost effective, safe, fast,
easy to combine and require minimum equipment costs.
Exhibitors Guide
Healthcare Infection Society
i2a
Stand No. 451
Healthcare Infection Society
612 King's Cross Road
London WC1X 9DH / United Kingdom
Stand No. 247
i2a
Parc de la Méditerranée
34470 Pérols / France
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Sue Hollinshead
sue.hollinshead@his.org.uk
+44 20 7713 0273
+44 20 7713 0255
www.his.org.uk
Christian Curel
export@i2a.info
+33 467 50 48 00
+33 467 17 09 06
www.i2a.info
The Healthcare Infection Society, formerly the Hospital Infection
Society, is a UK based International Society with members in over
60 countries world wide.
Diagnostic and Medical Software Company - Conception, development,
manufacturing and sales of clinical microbiology instruments,
software, reagents and infectiology software.
In 2011 the Hospital Infection Society was renamed the Healthcare
Infection Society. The name change is one of a series of actions
being undertaken to ensure that the Society can adapt to the
changing healthcare environment throughout the world.
SIRscan Automatic: AST incubator-reader,
SIRscan micro: ID-AST reader
VERSATREK: blood culture and mycobacteria
URISED: urine sediment analyzer
Health Protection Agency Culture Collections
ALFRED60: automated system for fast bacterial culture and counting
Stand No. 535
Health Protection Agency Culture Collections
Centre of Emergency Preparedness & Response
Porton Down
Salisbury
Wiltshire SP4 0JG / United Kingdom
Contact
Email
Phone
Website
Annabel Poppe
annabel.hoppe@hpa.org.uk
+44 1980 612 660
www.hpacultures.org.uk
SIRweb: middleware for bacteriology; expert system, traceability,
epidemiology, nosocomial infection and multi-resistant bacteria
monitoring.
SIRweb Maldi-TOF: integration of Maldi-TOF mass spectrometry identification in a clinical laboratory.
Reagents: SIRscanDiscs, ID-strips, ATCC strains, latex, swabs, blood
culture units…
Idaho Technology Inc.
Stand No. 317
Human Genetic Signatures
Virology Research Laboratory
Level 3, Clinical Sciences Building, Prince of Wales Hospital
2031 Randwick / Australia
Contact
Email
Phone
John Melki
john@geneticsignatures.com
+61 02 9870 7116
Stand No. 563
Idaho Technology Inc.
390 Wakara Way
84108 Salt Lake City, UT / United States
Contact
Email
Phone
Fax
Website
Wade Stevenson
wade.stevenson@idahotech.com
+1 800 735 6544
+1 801 588 0507
www.filmarray.com
Idaho Technology develops and manufactures instruments, chemistry, and software for real-time PCR, Hi-Res Melting™, multiplex
PCR, mutation detection, and genotyping.
The FilmArray® is user-friendly multiplex PCR. Our Respiratory Panel
is designed to simultaneously test one sample for 19 viral
and three bacterial pathogens. The FilmArray integrates sample
preparation, amplification, detection, and analysis into one
instrument that processes sample to results in less than 1 hour.
Final Programme
251
Human Genetic Signatures
Exhibitors Guide
Immuno Mycologics Inc.
Int. Society for Infectious Diseases
Stand No. 307
Immuno Mycologics Inc.
2700 Technology Place
73071 Norman, OK / United States
Stand No. 626
Int. Society for Infectious Diseases
9 Babcock street
02446 Brookline, MA / United States
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
JD Sprague
jd-sprague@immy.com
+1 405 360 4669
+1 405 364 1058
www.immy.com
Norman Stein
info@isid.org
+1 617 277 0551
+1 617 278 9113
www.isid.org
ISID is an educational non-profit organization with over 30,000
members worldwide.
Infectious Diseases Society of America
Stand No. 638
Infectious Diseases Society of America
1300 Wilson Boulevard, Suite 300
22209 Arlington, VA / United States
Contact
Email
Phone
Fax
Website
John Buckley
jbuckley@idsociety.org
+1 7032 990 200
+1 7032 990 204
www.idsociety.org
Its objectives are to promote communication among those engaged
in all aspects of infectious diseases. These goals are achieved
through international scientific meetings, exchange fellowships,
grants for infection control programs, a newsletter, and the International Journal of Infectious Diseases.
International Society of Chemotherapy
The Infectious Diseases Society of America (IDSA) represents
physicians, scientists and other health care professionals who
specialize in infectious diseases.
Balcony
Medical Microbiology
Aberdeen Royal Infirmary
Foresterhill
Scotland Aberdeen AB25 2ZN / United Kingdom
IDSA’s purpose is to improve the health of individuals, communities,
and society by promoting excellence in patient care, education,
research, public health, and prevention relating to infectious
diseases.
Contact
Email
Phone
Fax
Innogenetics NV
Stand No. 243
Innogenetics NV
Technologiepark 6
9052 Zwijnaarde / Belgium
Contact
Email
Phone
Fax
Website
Inez Van Hyfte
inez_van_hyfte@innogenetics.com
+32 9329 16 08
+32 9329 17 75
www.innogenetics.com
Final Programme
Fiona M. MacKenzie
isc@abdn.ac.uk
+44 1224 552 127
+44 1224 550 632
The International Society of Chemotherapy (ISC) for Infection and
Cancer established in 1961 is a non-profit organization and is a
registered charity in the UK (No: 1029653).
The general objectives of the Society are to advance the education
and science of chemotherapy. International congresses and
conferences promoting the development of chemotherapy are held
regularly. The ISC encourages, supports and sponsors the formation
of international working groups for special research projects,
commissions, training projects and the use of chemotherapeutics
in the field of antimicrobial and antineoplastic chemotherapy.
It also helps to co-ordinate the activities of these working groups.
The ISC has a worldwide membership composed of national and
regional societies. The Member Societies hold their own congresses
that are supported by the ISC.
Exhibitors Guide
iSentio A.S.
Kiestra Lab Automation BV
Stand No. 203
iSentio A.S.
Thormohlensgate 51
5006 Bergen / Norway
Stand No. 331
Kiestra Lab Automation BV
Marconilaan 6
9207 JC Drachten / Netherlands
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Camilla Huse Bondesson
camilla.huse.bondesson@isentio.com
+46 706 668 209
+47 947 659 36
www.isentio.com
iSentio sells software solutions for analysis and interpretation of
complex sequencing data from mixed clinical samples, with focus
on microbiology.
RipSeq(R) is an online software tool for rapid bacterial identification,
with focus on analyzing mixed clinical samples. This unique
method can reduce the bacterial identification time with up to 90%
and provide answers where other methods fail or are inadequate.
Anneke Dalstra
sales@kiestra.nl
+31 512 510 710
+31512 524 585
www.kiestra.nl
KIESTRA Lab Automation provides the best fit solutions for large,
mid sized and small laboratories
Our concepts for Total Lab Automation, Work Cell Automation and
Bench Top Automation will ensure a match between your laboratory
and KIESTRA. We know your laboratory is different, therefore our
products are developed in close collaboration with our customers.
Labquality Group
Janssen
Stand No. 131
Janssen
Turnhoutseweg 30
2340 Beerse / Belgium
Contact
Email
Website
Pygmalion Anastasopoulos
panastas@its.jnj.com
www.janssen-emea.com
Janssen is the new common identity for all pharmaceutical
companies of Johnson & Johnson worldwide
DORIBAX® is a potent carbapenem, which rapidly kills bacteria
(bactericidal) and is active against a wide range of pathogens,
including serious Gram-negative bacteria resistant to many
therapies available today.
John Wiley & Sons Ltd.
Stand No. 647
Labquality Group
Ratamestarinkatu 11 A
00520 Helsinki / Finland
Email
Phone
Fax
Website
info@labquality.fi
+358 9 8566 8200
+358 9 8566 8280
www.labquality.fi
Labquality organizes External Quality Assessment Services among
4000 laboratories in 40 countries.
Internal Quality Controls by Bioclin.
EQA Schemes in
• Andrology
• Clinical Chemistry
• Haematology
• Laboratory Instrumentation
• Bacterial serology
• Parasitology
• Pathology
• Cardiac physiology
• Genetics
• Immunology
• Microbiology
• Bacteriology, mycology
• Virology
• Point-of-care tests
Contact
Email
Phone
Fax
Website
Stand No. 303
John Wiley & Sons Ltd.
The Atrium
Chichester PO19 8SQ / United Kingdom
Starr Chiang
schiang@wiley.com
+44 65 6511 8071
+44 65 6511 8288
www.wiley.com
Final Programme
253
Exhibitors Guide
Life Technologies
Luminex Europe
Stand No. 459
Life Technologies
via Tiepolo, 18
20900 Monza / Italy
Stand No. 111
Luminex Europe
Krombraak 13-15
4906CR Oosterhout / Netherlands
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Silvana Biraghi
silvana.biraghi@lifetech.com
+39 039 83891
+39 039 8389493
www.lifetechnologies.com
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition.
Our instrument systems, consumables and services enable
researchers to accelerate their work across the biological spectrum,
working to advance personalized medicine, regenerative science,
molecular diagnostics, agricultural and environmental research. For
more information, visit our website: www.lifetechnologies.com.
Life Technologies portfolio of instrument systems, consumables
and services are provided under these leading brands: Applied
Biosystems, Invitrogen, Ion Torrent and Ambion. Sequencing
instrument systems include 3500 and 3500 Dx Genetic Analyzers,
Ion Torrent™ PGM and 5500 Series SOLiD™ Sequencers for next
generation sequencing. PCR thermal cyclers and real-time PCR
instrument systems include ViiA™ 7 Real-Time PCR System, Open
Array® Real-Time PCR System and 7500Fast Dx Real-Time PCR
System. Featured consumables kits include the TrueScience™
RespiFinder® Pathogen and Viral Identification Panels.
Britt Franken
bfranken@luminexcorp.com
+31 162 408 333
+31 162 408 337
www.luminexcorp.com
Luminex Corporation develops manufactures and markets proprietary biological testing technologies with applications throughout
the diagnostics and life sciences industries.
The Company’s xMAP® multiplex solutions include an open architecture, multi-analyte technology platform that delivers fast,
accurate and cost-effective bioassay results to markets as diverse
as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets.
The Company’s xMAP technology is sold worldwide and is already
is use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.
Mast Group
Stand No. 431
Mast Group
Mast House, Derby Road
Liverpool L20 1EA / United Kingdom
Liofilchem Srl.
Stand No. 225
Liofilchem Srl.
Via Scozia Z.I.
64026 Roseto degli Abruzzi / Italy
Contact
Email
Phone
Fax
Website
Fabio Brocco
fabiobrocco@liofilchem.net
+39 0858 939 745
+39 0858 930 330
www.liofilchem.net
Liofilchem manufactures microbiology products for clinical and
industrial use. Liofilchem produces MIC Test Strip and antibiotic/
antifungal discs for Antimicrobial Susceptibility Testing, systems
for microbial identification and antibiogram, systems for chemical/
microbial screening in food, sterilization process control systems,
dehydrated and ready-to-use culture media, supplements,
dip-slide. Liofilchem is ISO 9001 and ISO 13485 certified.
Final Programme
Contact
Email
Phone
Fax
Website
Anne Kilpatrick
akilpatrick@mastgrp.com
+44 151 933 7277
+44 151 944 1332
www.mastgrp.com
Mast Group is an independent world class manufacturer and supplier
of diagnostic products for clinical and veterinary microbiology
With hospital acquired infections and antibiotic resistance representing two globally significant healthcare issues, Mast offers a
range of products for the detection, identification and management
of predominant and emerging pathogens, including MRSA and ESBL
producing bacteria.
Exhibitors Guide
Medical Wire & Equipment Co. Ltd.
Meridian Bioscience Europe Srl
Stand No. 163
Medical Wire & Equipment Co. Ltd.
Potley Lane
Corsham SN13 9RT / United Kingdom
Stand No. 631
Meridian Bioscience Europe Srl
Via dell'Industria 7
20020 Villa Cortese / Italy
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Richard Seuke
sales@mwe.co.uk
+44 1225 810 361
+44 1225 810 153
www.mwe.co.uk
Cristiano Burinato
info@mdeur.com
+39 0331 433 636
+39 0331 433 616
www.mdeur.com
UK manufacturer and pioneers of specimen collection and transport devices for Microbiology and Virology including the Sigma
liquid swab.
Meridian Bioscience is a leader in innovative gastrointestinal and
respiratory infectious diseases rapid detection and molecular
biology assays.
Whether you require liquid or gel based swabs for Microbiology or
Virology we are global leaders of M40 compliant swabs. In addition
to Transwab and Virocult the company will discuss your swab
requirements for automatic plate streaking machines.
Clostridium difficile toxigenic strains can now be accurately
detected with the ILLUMIGENE molecular biology system, based
on LAMP amplification. Up to 10 specimens can be tested in less
than one hour, with 2 minutes hands-on time, using a compact
equipment.
New for 2011 is Sigma VCM for Virus, Chlamydia and Mycoplasma.
miacom diagnostics GmbH
Merck Sharp & Dohme (MSD)
Phone
Fax
Website
+1 908 423 1000
+1 908 423 1513
www.merck.com
Today's MSD is a global healthcare leader working to help the world
be well. MSD is known as Merck in the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies,
and consumer care and animal health products, we work with
customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment
to increasing access to healthcare through far-reaching policies,
programs and partnerships. MSD. Be well. For more information,
visit www.msd.com
Stand No. 453
miacom diagnostics GmbH
Merowingerplatz 1a
40225 Düsseldorf / Germany
Contact
Email
Phone
Fax
Website
Eve Blömeke
e.bloemeke@miacom- diagnostics.com
+49 211 3015 5795
+49 211 2989 143
www.miacom-diagnostics.com
miacom is a German/United States diagnostic company offering
unique and innovative solutions for the rapid identification and
characterization of microorganisms for a variety of infectious
diseases.
miacom currently offers molecular diagnostic tests for pneumonia
and sepsis. Our affordable multiplex panels enable 30min identification of clinically relevant pathogens directly from respiratory
secretions or positive blood cultures. All tests are CE-marked and
designed to perfectly work in today’s laboratory routine as timeconsuming culture or amplification steps have been omitted and
no expensive new hardware is needed.
Final Programme
255
Stand No. 533
Merck Sharp & Dohme (MSD)
One Merck Drive
08889 Whitehouse Station, NJ / United States
Exhibitors Guide
Microsens Medtech Ltd
Mobidiag Ltd
Stand No. 406
Microsens Medtech Ltd
Royal College Street
London NW1 0NH / United Kingdom
Stand No. 643
Mobidiag Ltd
Biomedicum 2U, Tukholmankatu 8
00290 Helsinki / Finland
Contact
Email
Phone
Fax
Website
Email
Phone
Fax
Website
Roger Rosedale
roger.rosedale@microsens.co.uk
+44 207 691 2147
+44 709 200 7393
www.microsens.co.uk
Founded in 2000 and headquarted in London, UK – Microsens Medtech develops novel technology solutions to diagnostic problems.
TB-Beads – concentration of Tuberculosis without the need for
centrifugation and electricity. Microsens Lumin – compact LED
flourescence adaptor, cost effectively converts almost any microscope to fluorescence.
LiMA – Rapid and ultra sensitive detection of bacterial infection/
contamination.
info@mobidiag.com
+3589 1912 5021
+358919125020
www.mobidiag.com
Mobidiag Ltd is a Finnish biotechnology company engaged in
developing PCR-microarray based diagnostic assays for infectious
diseases.
Mobidiag provides unique and innovative Prove-it™ technology
for early and accurate diagnosis of life-threatening pathogenic
microbes. The technology combines DNA amplification and microarray detection with software analysis.
Products:
Prove-it™ Sepsis (CE-IVD)
Prove-it™ Herpes (CE-IVD)
Prove-it™ Bone and Joint (RUO)
Mikrogen GmbH
Stand No. 438
Mikrogen GmbH
Floriansbogen 2-4
82061 Neuried / Germany
Contact
Email
Phone
Fax
Website
Molzym GmbH & Co. KG
Thorsten Zacher
zacher@mikrogen.de
+49 89 54801135
+49 89 54801100
www.mikrogen.de
Mikrogen GmbH focuses on the development, production and
distribution of IVD test systems for infectious diseases and
autoimmunity.
Mikrogen GmbH uses its own recombinant antigen technology
for manufacturing 5 different product lines: recomBlot (classical
Western Blot test systems), recomLine (qualitative strip assays),
recomWell (Elisa test systems), recomBead (Luminex Multiplex
Technology) and PCR products.
Final Programme
Stand No. 439
Molzym GmbH & Co. KG
Mary-Astell-Str.10
28359 Bremen / Germany
Contact
Email
Phone
Fax
Website
Michael Lustig
lustig@molzym.com
+49 421 696 162 0
+49 421 696 162 11
www.molzym.com
Molzym is committed producing innovative solutions for the
molecular analysis of pathogens direct from tissue, blood or other
body fluids.
Molzym produces products for highly sensitive molecular pathogen
analysis. MolYsis allows selective DNA isolation of bacteria plus
human DNA background removal. DNA-free PCR reagents ensure
sensitive PCR. The SepsiTest™ and UMD diagnostic tests detect and
identify more than 345 pathogens.
Exhibitors Guide
Myconostica Ltd
Nordiag AB
Stand No. 437
Myconostica Ltd
South Court, Sharston Road
Manchester M22 4SN / United Kingdom
Stand No. 457
Nordiag AB
Instrumentvägen 19
12653 Hägersten / Sweden
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Heidi Wahlefeld-Moghimi
heidi.wahlefeld@myconostica.co.uk
+44 161 998 7239
+44 161 902 2496
www.myconostica.co.uk
Myconostica Ltd, a UK-based medical diagnostic company, develops
and commercialises a portfolio of rapid and highly specific real-time
molecular diagnostic tests for the presence of fungi responsible
for life-threatening infections including aspergillosis, fungal pneumonia and candidiasis.
Our family of MycAssay™ and MycArray™ products, as well as our
fungal free DNA extraction kit, MycXtra®, represent an integrated
solution to rapidly identify Aspergillus, Pneumocystis and Candida
spp. from range of clinical sample types.
NorDiag is a company that is specialized in nucleic acid extraction.
NorDiag supply the instruments Arrow and Bullet for extraction of
nucleic acids from a broad variety of samples types. The reagent
kits are Bugsń Beads, Viral NA, Stool, Blood, DNA, RNA and the new
CellSep.
Novartis Pharma AG
Stand No. 215
Novartis Pharma AG
Forum 1, Novartis Campus
4056 Basel / Switzerland
Nanosphere
Stand No. 363
Nanospehre
4088 Commercial Ave
60062 Northbrook, IL / United States
Contact
Email
Phone
Fax
Website
Jan Wikstén
jan.wiksten@nordiag.com
+46 8440 0485
+46 8411 1850
www.nordiag.com
Bill Athenson
bathenson@nanosphere.us
+1 888 837 4436
+1 847 400 9199
www.nanosphere.us
Nanosphere, Inc. is a leader in the development and commercialization of advanced moleculardiagnostics systems for simple,
on-demand, detection of broad infectiousdisease panels.
Website
www.novartis.com
Novartis provides healthcare solutions that address the evolving
needs of patients and societies. Focused solely on healthcare,
Novartis offers a diversified portfolio to best meet these needs:
innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products.
Cubicin® (daptomycin) is a cyclic lipopeptide that is indicated for
the treatment of complicated skin and soft-tissue infections
(cSSTI), right-sided infective endocarditis (RIE) due to Staphylococcus aureus and Staphylococcus aureus bacteraemia (SAB)
when associated with RIE or with cSSTI.
Nanospheres implifies molecular testing by providing fully automated sample-to-result,simultaneous detection of Influenza A
subtypes, Influenza B, RSV andOseltamivir resistance. Later this
year will release assays that identify the~30 most commonly
isolated gram-positive, gram-negative, and fungal pathogensand
critical resistance markers from positive blood cultures.
Final Programme
257
Exhibitors Guide
NovaTec Immundiagnostica GmbH
Ophardt Hygiene-Technik
Stand No. 628
NovaTec Immundiagnostica GmbH
Waldstrasse 23 A6
63128 Dietzenbach / Germany
Stand No. 413
Ophardt Hygiene-Technik
Lindenau 27
47661 Issum / Germany
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Rodrigo Berlie
marketing@novatec-id.com
+49 6074 4876 0
+49 6074 4876 29
www.novatec-id.com
Manufacturer, Research and Development Company located in
Germany. ISO 13485 and CE Certified as well as register with the
FDA (USA) as a Manufacturer.
Focused on the development and production of diagnostic test kits
for human and veterinarian markets. Expertise includes areas of
Infectious Diseases, Hormones, Tumor Markers and Auto Immune
Diseases. Product range includes ELISA, Chemiluminescence and
Western Blots. Private labeling (OEM) is available upon request.
Thomas Fröhling
info@ophardt.com
+49 2835180
+49 2835 18 189
www.ophardt.com
OPHARDT hygiene develops, produces and sells innovative dispensing systems and hygiene solutions to improve hand hygiene
compliance in hospitals, thus preventing healthcare-associated
infections.
ingo-man dispensing systems are for more than 40 years the
measure stick for hygiene, practical use and longevity in the
medical realm. The upcoming ingo-man Wi eco will offer integrated
counter function, wireless data transfer and fully automatic monitoring of dispenser functionality.
OpGen
Oxford Immunotec Ltd
Stand No. 149
OpGen
708 Quince Orchard Road
20878 Gaithersburg, MD / United States
Phone
Fax
Website
+1 301 869 9683
+1 301 869 9684
www.opgen.com
OpGen, Inc. provides the Argus™ Optical Mapping System for generating high-resolution, ordered, whole-genome restriction maps
from single DNA molecules. Independent of sequence information,
Optical Maps enable a comprehensive view of genomic architecture. Use Optical Maps for comparative genomics, strain typing and
sequence assembly.
Stand No. 461
Oxford Immunotec Ltd
94C Milton Park
Abingdon OX14 4RY / United Kingdom
Email
Phone
Fax
Website
info@oxfordimmunotec.com
+44 1235 442 780
+44 1235 442 781
www.oxfordimmunotec.com
For more information, please contact Oxford Immunotec:
Tel: +44 1235 442780
Fax: +44 1235 442781
E-mail: info@oxfordimmunotec.com
Website: www.oxfordimmunotec.com
Medical Eduction: www.learntb.com
On stand 461, Oxford Immunotec will present the in-vitro T-SPOT.TB
test for the detection of active and latent tuberculosis. It is extremely sensitive and specific making it suitable for all patient groups,
including immunosuppressed populations and extrapulmonary TB.
Final Programme
Exhibitors Guide
Oxford University Press
Pfizer International Operations
Stand No. 729
Oxford University Press
Great Clarendon Street
Oxford OX2 6DP / United Kingdom
Stands No. 137, 319, 320
Pfizer International Operations
23/25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / France
Contact
Email
Contact
Email
Phone
Fax
Website
Phone
Fax
Website
Oxford University Press publishes some of most respected medical
books and journals in the world.
Clinical Infectious Diseases, the Journal of Infectious Diseases and
the Journal of Antimicrobial Chemotherapy are leading global
publications. To discover more about these journals, browse our
books or to pick up free copies of the journals, please visit our
stand.
PathoFinder B.V.
Stand No. 345
PathoFinder B.V.
Oxfordlaan 70
6229EV Maastricht / Netherlands
Contact
Email
Phone
Website
Rob Janssen
rob.janssen@pathofinder.com
+31 433 885 852
www.pathofinder.com
Next Generation Molecular Diagnostics
RespiFinder SMART 22 is a multiplex PCR test which can detect
and differentiate 22 respiratory pathogens (18 viruses as well as
4 bacteria) in a single RealTime PCR based, CE-IVD marked assay.
Fast, sensitive and comprehensive!
Rhym Abdennbi
Rhym.abdennbi@pfizer.com
+33 1 58 07 30 00
+33 1 58 07 30 01
www.pfizer.com
PFIZER is a pharmaceutical group which strives to improve health
and well-being at every stage of like. Pfizer is working to meet
unmet health needs head on, bringing together the best scientific
minds to challenge the most feared diseases of our time.
Zyvox® (linezolid) is a synthetic antibiotic that is active against
important Gram positive bacteria. It makes part of the oxazolidinones and has a unique mechanism of action. Its indicated for
the treatment of nosocomial pneumonia, community-acquired
pneumonia and documented complicated-skin and soft tissue
infections.
Tygacil® (tygecycline) is indicated in adults for the treatment of
the following infections:
• Complicated skin and soft tissue infections, excluding diabetic
foot infections,
• Complicated intra-abdominal infections.
Tygacil® should be used only in situations where it is known or
suspected that other alternatives are not suitable. Consideration
should be given to official guidance on the appropriate use of
antibacterial agents.
Ecalta® (anidulafungin) is an intravenous antifungal agent of the
echinocandin class, a class of antifungal drugs that inhibits the
synthesis of 1,3-ss-D-glucan, and is indicated for the treatment of
invasive candidiasis in adult non neutropenic patient.
Vfend® (voriconazole) is a triazole antifungal agent which is indicated for the treatment of invasive aspergillosis, of candidemia in
non-neutropenic, of fluconazole-resistant serious invasive Candida
infections (including C. krusei) and treatment of serious fungal
infections caused by Scedosporium spp. and Fusarium spp. Vfend®
is available as 50mg and 200 mg film-coated tablets, 200 mg
powder for solution for infusion and 40 mg/ml powder for oral
suspension.
Prevenar 13® is indicated for active immunisation for the prevention
of invasive disease, pneumonia and acute otitis media caused by
Streptococcus pneumoniae in infants and children from 6 weeks to
5 years of age. The use of Prevenar 13® should be determined on
the basis of official recommendations taking into consideration the
impact of invasive disease in different age groups as well as the
variability of serotype epidemiology in different geographical
areas.
Final Programme
259
Sophie Morris
jnls.mkt@oup.com
medicine.books.uk@oup.com
+44 1865 556767
+44 1865 556646
www.oup.com
Exhibitors Guide
Pocared Diagnostics Ltd.
Qiagen GmbH
Stand No. 139
Pocared Diagnostics Ltd.
3 Haim Pekeris St, Park Rabin
76705 Rehovot / Israel
Stand No. 531
Qiagen GmbH
Qiagenstrasse. 1
40724 Hilden / Germany
Contact
Email
Phone
Fax
Website
Email
Phone
Fax
Website
Jonathan Gurfinkel
jonathan.gurfinkel@pocared.com
+972 545 662 106
+972 577 948 956
www.pocared.com
qiagen@qiagen.com
+49 2103 89 2269
+49 2103 29 2177
www.qiagen.com
QIAGEN is the leading provider of sample and assay technologies.
POCARED is an IVD systems developer and manufacturer developing the next generation reagent free, real-time and fully automated
diagnostics systems.
POCARED's P-1000 system is a reagents free, real-time and fully
automated diagnostics systems enabling evidence based medicine,
hence optimizing infectious disease treatment. The P-1000 system
analyzes fresh specimens and eliminates the need for growth or
multiplication cycles.
We have developed and market more than 500 consumable
products and automated solutions. The company provides these
products to molecular diagnostics laboratories, academic
researchers, pharmaceutical and biotechnology companies, and
applied testing customers for purposes such as forensics, animal
or food testing and pharmaceutical process control.
QIAGEN's assay technologies include one of the broadest panels
of molecular diagnostic tests available worldwide. This panel
includes the digene HPV Test as well as a broad suite of solutions
for infectious disease testing and companion diagnostics.
Quidel Corporation
Stand No. 627
Quidel Corporation
10165 McKellar Court
92121 San Diego, CA / United States
Contact
Email
Phone
Fax
Website
Drew Hoffman
dhoffman@quidel.com
+1 8585 521 100
+1 8002 278 855
www.quidel.com
Quidel® Corporation enhances people’s health and well being
through research and diagnostic solutions that can lead to improved
patient healthcare.
Quidel’s products aid in the detection and diagnosis of critical
diseases and conditions, e.g., respiratory viruses, Strep A, herpes,
C. Difficile, thyroid, Chlamydia, and H. pylori. Quidel’s broad platform technologies include RT-PCR, Isothermal-HDA, rapid immunoassays, ELISA, DFA and engineered cells.
Final Programme
Quotient Bioresearch
Stand No. 629
Quotient Bioresearch
Newmarket Road, Fordham
Cambridgeshire CB7 5WW / United Kingdom
Email
Phone
Fax
Website
info@quotientbioresearch.com
+44 1638 720 500
+44 1638 724 200
www.quotientbioresearch.com
Quotient Bioresearch is a world-class provider of global drug development services with special expertise in anti-infectives.
Quotient Bioresearch provides comprehensive anti-infective drug
development services including lead compound selection, preclinical evaluation, molecular biology, central laboratory and phase
I/IIa clinical trial support. We are also experts in resistance
surveillance studies with laboratories world-wide.
Exhibitors Guide
R-Biopharm AG
Reagena International Ltd.
Stand No. 444
R-Biopharm AG
An der neuen Bergstrasse 17
64297 Darmstadt / Germany
Stand No. 621
Reagena International Ltd.
Takojantie 18
70900 Toivala / Finland
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Martina Scheidenberger
m.scheidenberger@r-biopharm.de
+49 6151 810252
+49 6151 8102688
www.r-biopharm.com
Fabrizio Galbiati
info@reagena.fi
+358 17 368 8500
+358 17 368 8530
www.reagena.fi
R-Biopharm AG is sucessful in various diagnostic fields: Infections
of gastrointestinal tract, infectious serology, gastroenterology,
allergy and food and feed analysis.
Reagena develops and manufactures IVD products such as immunoassay tests (including EIA and lateral flow), reagents, and readyto-use biological stains.
Emerging diseases outbreaks have a significant impact on
morbidity and mortality and costs in health care settings.
R-Biopharm AG is providing ELISA, PCR and rapid tests for infection
control to initialize interventions: Norovirus, C. difficile, Verotoxin,
Campylobacter, Giardia and many more.
Reagena’s leading product is ReaScan® diagnostic system, a
proprietary lateral flow immunoassay technology combined with
a pocket-sized reader producing accurate results in 10-15 minutes.
Our expanding test portfolio includes Strep-A, Influenza A/B/H1N1,
different Hantaviruses and the oncoming TBE-virus test.
Reactifs RAL
Renishaw Diagnostics Ltd.
Stand No. 452
Reactifs RAL
2 rue Jacques Monod
33650 Martillac / France
Stand No. 463
Renishaw Diagnostics Ltd.
Nova Technology Park, 5 Robroyston Oval
Glasgow G33 1AP / United Kingdom
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Matthieu Dibon
mdibon@reactifs-ral.fr
+33 05 57 96 04 04
+33 05 57 96 04 05
mdibon@reactifs-ral.fr
Jim Greaves
jim.greaves@renishawdiagnostics.com
+44 141 5577 900
+44 141 5577 949
www.renishawdiagnostics.com
Renishaw Diagnostics, formerly D3 Technologies, is focused on
developing and commercialising its first in vitro diagnostic and
clinical research products.
RAL will be presenting its latest products: the RAL Stainer: a simple,
compact and efficient automated staining device equipped with
RFID, for a constant, reliable and traceable protocol performance,
and the Fluo-RAL module: a LED Illuminator, turn your standard
fluorescence microscope into a LED microscope, highly reliable,
sensitive, timesaving and economical.
Renishaw Diagnostics uses patented RenDxTM technology, based
on surface enhanced resonance Raman scattering (SERRS), in
molecular diagnostic tests for infectious disease and for research
applications. Key advantages of this technology are high sensitivity
and multiplex detection (10 targets per reaction) .
RAL Diagnostics manufactures and sells a complete range of clinical
stains worldwide: we are your partner in a reliable biological
diagnostic.
Final Programme
261
Exhibitors Guide
River Diagnostics B.V.
Sacace Biotechnologies Srl
Stand No. 127
River Diagnostics B.V.
Marconistraat 16
3029 AK Rotterdam / Netherlands
Stand No. 633
Sacace Biotechnologies Srl
via Scalabrini 44
22100 Como / Italy
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Bas Dirkson
info@riverd.com
+31 102 210 720
+31 102 210 721
www.riverd.com
River Diagnostics brings to market innovative solutions for cell and
in vivo tissue analysis, based on non-invasive and non-destructive
Raman spectroscopy.
SpectraCell RA® Bacterial Strain Analyzer for simple and reproducible
real-time molecular typing of gram+/gram- bacteria, directly from
culture. Minimal hands-on time. Automated analysis and easy matching to previously analyzed pathogens. Valuable epidemiological
information for infection prevention.
Alexander Safoian
info@sacace.com
+39 0314 892 927
+39 0314 892 926
www.sacace.com
Sacace is a molecular biology Italian company that manufactures
molecular diagnostic kits for human, veterinary and food analysis.
Sacace offers more than 100 different kits for the detection of STD,
Herpes viruses, respiratory, neurological and intestinal infections
as well as an innovative line of kits for tuberculosis detection,
differentiation and resistance.
Sclavo Diagnostics International s.r.l
Roche Molecular Systems, Inc.
Stand No. 125
Roche Molecular Systems, Inc.
4300 Hacienda Drive
94588 Pleasanton, CA / United States
Contact
Email
Phone
Fax
Website
April Falcone
april.falcone@roche.com
+1 925 730 8793
+1 925 225 0875
molecular.roche.com
As the world leader in in-vitro diagnostics, Roche offers a broad
portfolio of instruments and assays for the screening, diagnosis,
and prevention of infectious diseases.
Roche Diagnostics will be featuring the LightCycler® MRSA Advanced
Test, designed to provide accurate and reliable MRSA screening
results for improved patient management, the cobas® 4800
System and Assays for HPV and CT/NG testing, and the cobas e 411
analyzer and its infectious diseases immunoassay portfolio for
patient oriented decision making.
Final Programme
Stand No. 351
Sclavo Diagnostics International s.r.l
Località Pian dei Mori, via Po 28
53018 Sovicille / Italy
Contact
Email
Phone
Fax
Website
Emanuele Rossi
sclavoexport@dgroup.it
+39 0293 991 569
+39 0293 991 393
www.sclavodiagnostics.com
Sclavo Diagnostics International is an Italian Company active in
research, development, production and marketing of in-vitro clinical
diagnostic reagent kits and is also the ideal partner for supplying
OEM products, Private Label products and IVD reagents’ certification
services
Sclavo is experienced and leading manufacturer of Prepared Media
for Bacteriology in Plates and Tubes, Serology, Bacterial Identification, Clinical Chemistry, Specific Plasma Proteins, Specific Urinary
Proteins, and Coagulation IVD kits. Sclavo’s manufacturing processes
are fully managed and controlled in-house and the whole production
cycle is based on Sclavo’s modern know-how and experience on
state-of-the-art manufacturing technologies.
Exhibitors Guide
Seegene Inc.
Serion Immundiagnostica GmbH
Stand No. 227
Seegene Inc.
8,9F Taewon Bldg 65-5 Bangyi-Dong Songpa-Gu
138-050 Seoul / Korea
Stand No. 539
Serion Immundiagnostica GmbH
Friedrich-Bergius-Ring 19
97076 Wuerzburg / Germany
Contact
Email
Phone
Fax
Website
Contact
Email
Phone
Fax
Website
Joanna Ahn
ahn@seegene.com
+82 2 2240 4022
+82 2 2240 4040
www.seegene.com
Seegene, Inc. is a leading developer of multiplex molecular
diagnostics (MDx) products.
Seegene tests can be used to diagnose a wide range of disease,
including respiratory infections, STDs, TB, sepsis, HPV, meningitis,
diarrhea, H1N1, and many drug resistant pathogens. Seegene also
provides personalized genetic tests for diagnosing thyroid cancer
and leukemia.
Frederic Paquet
dialog@virion-serion.de
+49 931 3045 580
+49 931 3045 590
www.virion-serion.de
German in-vitro diagnostic company with 30 years of experience.
Extensive high-quality product portfolio for the diagnosis of infectious diseases.
SERION ELISA classic: quantified antibody detection in human
serum, plasma and cerebrospinal fluid against viral, bacterial,
fungal and parasitic infections; SERION ELISA antigen: direct antigen detection; Immunomat: automated ELISA processor; SERION
Multianalyt particle-based Immunoassays for Flow Cytometry:
allow simultaneous antibody detection against multiple antigens;
Complement Fixation Tests
Sekisui Virotech GmbH
Contact
Email
Phone
Fax
Website
Michael Becker / Denise Dimmick
info@sekisuivirotech.com;
ukdiagcustomerservice@sekisuidiagnostics.com
+49 6142 6909 16
+49 6142 9666 13
www.sekisuivirotech.com;
www.sekisuidiagnostics.com
Sekisui Virotech and Sekisui Diagnostics develop, manufacture and
market a wide range of products for the detection of Infectious
Diseases.
Sekisui Virotech offers ELISAs and Line Immunoassays. Its microbiology panel is based on a microplate system for bacterial identification and susceptibility testing. In addition a panel of enterodiagnostic antigen detection ELISAs is offered.
Sekisui Diagnostics offers point-of-care rapid assays.
Siemens AG, Healthcare Division
Stand No. 221
Siemens AG, Healthcare Division
Henkestrasse 127
91052 Erlangen / Germany
Website
www.siemens.com/diagnostics
Siemens Healthcare Diagnostics is the leading clinical diagnostics
company in the world. We are committed to providing clinicians
with the vital information they need for the accurate diagnosis,
treatment and monitoring of patients.
Our comprehensive portfolio of performance-driven systems,
unmatched menu offering and IT solutions, in conjunction with
highly responsive service, is designed to streamline workflow,
enhance operational efficiency and support improved patient care.
The depth and breadth of our diagnostic solutions-chemistry,
immunoassay, automation, hematology, hemostasis, microbiology,
diabetes, urinalysis, blood gas and molecular testing are designed
to meet the growing demands of our customers, today and tomorrow.
Final Programme
263
Stand No. 205
Sekisui Virotech GmbH
Löwenplatz 5
65428 Rüsselsheim / Germany
Exhibitors Guide
SIRS-Lab GmbH
Teleflex Medical Europe Ltd
Stand No. 449
SIRS-Lab GmbH
Otto-Schott-Str. 15
07745 Jena / Germany
Stand No. 201
Teleflex Medical Europe Ltd
IDA Business and Technology Park, Dublin Road
- Athlone, Co Westmeath / Ireland
Contact
Email
Phone
Fax
Website
Email
Phone
Fax
Website
Daniela Adler
adler@sirslab.com
+49 3641 3103 100
+49 3641 3103 102
www.sirslab.com
SIRS-Lab produces molecular diagnostics to identify life-threatening
infections to enable early and targeted antibiotic therapy of sepsis.
VYOO sepsis test:
Within 7 hours, the multiplex PCR test VYOO detects 99% of all sepsisrelevant bacteria and fungi as well as important resistances. VYOO
carries significant potential to guide antibiotic therapy in the
pivotal therapeutic window.
orders.intl@teleflexmedical.com
+353 90 64 60 800
+353 90 64 65 938
www.teleflex.com
Teleflex, with its numerous trusted brands Arrow, Rüsch, Gibeck
and Hudson, is a global provider of healthcare products designed
to help protect against infections and enhance patient outcomes.
We focus on clinically proven infection control technologies.
Our portfolio stretches from Arrow’s antimicrobial-impregnated
CVCs, via Gibeck’s advanced bacterial/viral HMEFs, to the first
convertible endotracheal tube which facilitates post-operative
subglottic suctioning and thereby helps protect against VAP. Plus,
we can offer the world’s only anti-infection Foley catheter indicated
for the reduction of CAUTI.
Statens Serum Institut
The Impact Marketing Group
Stand No. 143
Statens Serum Institut
Herredsvejen 2
3400 Hillerød / Denmark
Contact
Email
Phone
Fax
Website
Aase Meyer
aam@ssi.dk
+45 4829 9135
+45 4829 9179
www.ssi.dk
SSI Diagnostica manafactures and sells in vitro diagnostic products
for clinical microbiology, veterinary diagnostics,food analysis and
environmental control.
SSI's product range:
Antisera for serotyping of bacteria
Bacterial test strains
Biological indicators
Culture media
Elisa for Pseudomonas
Legionella Blood strip test
PCR kits for DEC and Dermatophytes
Pneumococcal antigens
Various monoclonal antibodies
Final Programme
Stand No. 341
The Impact Marketing Group
P.O. Box 307
21152 Glencoe, MD / United States
Contact
Email
Phone
Fax
Website
Scott Piercy
scott.piercy@theimpactmarketinggroup.com
410 584 1221
410 584 8279
www.theimpactmarketinggroup.com
A full service marketing research group conducting tradeshow
surveys and interviews for the marketing of medical diagnostic
products.
Exhibitors Guide
Thermo Fisher Scientific
TROCAR
Stand No. 523
Thermo Fisher Scientific
Wade Road RG24 8PW / United Kingdom
Stand No. 129
TROCAR
University of Barcelona
School of Medicine
170 Villarroel
08036 Barcelona / Spain
Contact
Email
Phone
Fax
Website
Fiona Macrae
fiona.macrae@thermofisher.com
+44 1256 6943 18
+44 1256 3297 28
www.oxoid.com
Oxoid, with Remel, part of Thermo Fisher Scientific, continue to
offer ever better products for detection and diagnosis of resistant
organisms.
Come to stand 523 to see how we are evolving for the future.
Contact
Email
Jordi Vila Estape
jvila@ub.edu
The driving concept of TROCAR is to investigate the fundamentals
of the epidemiology of new highly virulent multiresistant strains.
The project focuses on three major strategic aims: Definition of
the major high-risk resistant clones; Genomic and proteomic
approaches to investigate specific traits in comparison with nonepidemic clones; and the development of bioinformatics tools to
fully exploit genomic data.
Tianjin Era Biology Engineering Co., Ltd
Stand No. 145
Tianjin Era Biology Engineering Co., Ltd
C8-3, Tianda Science Park, No.80, 4th Avenue,Teda
300457 Tianjin / China
Contact
Email
Phone
Fax
Website
Jeff Wang
marketing@era-bio.com
+86 022 65378483
+86 022 65378484
www.era-bio.com
The consortium of researchers includes many internationally
recognized experts whose expertise spans diverse fields, including
medical microbiology, genomics and proteomics, molecular typing
and population genetics, antimicrobial resistance, bacterial
pathogenicity and computational analysis. The project is coordinated
by Professor Dr. Jordi Vila, Head of the Department of Clinical
Bacteriology, Hospital Clínic, Barcelona, Spain. Moreover, the
project is conducted under the patronage of the European Society
of Clinical Microbiology and Infectious Diseases (ESCMID), the
leading scientific society in the field of human infection in Europe.
*TROCAR is a project in the LifeSciHealth Priority of the European
Commission Seventh Framework Programme.
Specializing in developing Fungus (1,3) Beta-D glucan and gram
negative bacterial endotoxin detection.
TREK Diagnostic Systems: a Magellan Biosciences Brand
Stand No. 343
TREK Diagnostic Systems: a Magellan Biosciences Brand
17-19 The Birches Industrial Estate
East Grinstead RH19 1XZ / United Kingdom
Contact
Email
Phone
Fax
Website
Paul Daga
sales@trekds.co.uk
+44 1342 318 777
+44 1342 318 666
www.trekds.com
TREK Diagnostic Systems, a Magellan Biosciences brand, is a
global manufacturer and distributor of automated systems and
consumable products for microbiology diagnostic testing.
TREK’s signature product lines, the VersaTREK® Automated Microbial
Detection System and the Sensititre® Automated Susceptibility and
Identification Testing System, are designed to provide cost-effective
improvements in workflow efficiencies, ergonomics and test result
performance.
Final Programme
265
Fungus (1,3) Beta-D Glucan Detection Reagents; Gram negative
bacterial endotoxin detection reagents; Pneumocystis Staining
Fluid; Microbiology Kinetic Rapid Reader.
Exhibitors Guide
University of Wisconsin School of Medicine and Public Health –
Office of Continuing Professional Development
Stand No. 349
University of Wisconsin School of Medicine and Public Health –
Office of Continuing Professional Development
2701 International Lane, #208
53704 Madison, WI / United States
Contact
Email
Phone
Fax
Website
Danielle Hepting
drhepting@ocpd.wisc.edu
+1 608 240 2147
+1 608 240 6040
www.ocpd.wisc.edu
The University of Wisconsin School of Medicine and Public Health
aims to achieve preeminence in continuing medical education
(CME) through state, national and international educational activities
that are built on a platform of evidence based medicine and adult
learning principles.
The University of Wisconsin School of Medicine and Public Health is
an accredited provider of CME. Visit our booth to receive information
on a CME activity developed specifically for clinicians and other
healthcare professionals who manage patients with invasive
fungal infections (IFIs). View this activity and other CME-certified
activities at www.ocpd.wisc.edu.
Vircell S.L.
Stand No. 161
Vircell S.L.
Pol. Ind. Dos de Octubre; Plz. Dominguez Ortiz, 1
18320 Granada / Spain
Contact
Email
Phone
Fax
Website
Laura Altuzarra
marketing@vircell.com
+34 958 44 12 64
+34 958 51 07 12
www.vircell.com
Vircell develops and produces diagnostic kits for human infectious
diseases by different techniques. ISO standards. CE marked
products.
Vircell offers more than 300 references for the diagnosis of respiratory
infections, STD, TORCH panel, MMR, tick borne diseases and other
zoonosis, by different techniques: ELISA, IFA, Cell culture, Immunocapture, PCR, Rapid Tests and Oligochromatography.
Final Programme
Wisepress Ltd.
Stand No. 407
Wisepress Ltd
25 High Path
London SW19 2JL / United Kingdom
Contact
Email
Phone
Fax
Website
Michelle Coogan
bookshop@wisepress.com
+44 208 715 1812
+44 208 715 1722
www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a
complete range of books and journals relevant to the meeting.
Books can be purchased at the stand or posted to you – Wisepress
will deliver worldwide. In addition to attending 250 conferences
per year, Wisepress has a comprehensive medical and scientific
bookshop online with great offers.
World Courier Belgium n.v.
Stand No. 361
World Courier Belgium n.v.
Minervastraat 18
1930 Zaventem / Belgium
Contact
Email
Phone
Fax
Website
Noël Foucart
nfoucart@worldcourier.be
+32 2 712 50 80
+32 2 712 50 89
www.worldcourier.com
A pioneer in global biopharmaceutical transport, storage and
distribution, World Courier is the market leader in state-of-the-art
clinical trial logistics. With over 140 offices in more than 50 countries
and 12 strategically located investigational drug storage facilities,
only World Courier offers global GxP compliance from origin to
destination.
World Courier’s sophisticated and industry-compliant VIP thermal
packaging system has proven to be exceptionally stable over time
in even the harshest environments and delivers a high degree
of protection for high value shipments or those with little or no
tolerance for temperature excursions.
General Information (in alphabetical order)
Cameras and Recordings
Any kind of electronic recording as well as taking photographs is
prohibited in all lecture halls during all sessions.
Certificates
From Monday, 9 May 2011, afternoon onwards, certificates of
attendance can be printed at self-service stations in the preregistration area, using the barcode on your name badge.
€ 10 will be charged for certificate changes due to incorrect
submission of names and/or addresses.
Cloakroom / Left Luggage
A cloakroom is available on the ground level within the main
entrance foyer to keep your coats and bags free of charge.
CME Accreditation – now online
The CME accreditation is valid for the main congress programme
including Educational Workshops and Meet-the-Expert Sessions
and neither covers the company-sponsored integrated symposia
nor the posters. A maximum of 24 CME credit points can be claimed
and printed via the congress website (www.eccmid-icc2011.org)
after electronic evaluation.
ESCMID and ISC sought accreditation by the European Accreditation
Council for Continuing Medical Education (EACCME) to provide CME
credits for medical specialists. The EACCME is an institution of the
European Union of Medical Specialists (UEMS, www.uems.net).
EACCME credits are recognised as Physician’s Recognition Awards
(PRA) by the American Medical Association. To convert EACCME
credits to AMA PRA, please contact the AMA (www.ama-assn.org).
Italian delegates will receive their CME certificates after the
congress after having evaluated the congress online.
Non-Italian delegates: To claim CME credits please log in on the
congress website (www.eccmid-icc2011.org), link CME. After
completing the questionnaire print the certificate which indicates
the CME credits you have achieved. For instructions please refer
to page 37.
Italian ECM Credits
I crediti formativi ECM saranno certificati dal Provider Scientific
Press srl (n. 245) secondo la nuova regolamentazione approvata dalla Commissione Nazionale per la Formazione Continua il
13 gennaio 2010.
I crediti attribuiti sono 5 e sono rivolti a Medici specialisti in
malattie infettive, oncologia, medicina generale, anestesia e
rianimazione, microbiologia e virologia, farmacologia, ematologia.
Avranno diritto ai crediti ECM solo coloro che saranno presenti
almeno all’80% del programma scientifico del congresso ed
avranno compilato l’apposito questionario disponibile esclusivamente on-line sul sito www.eccmid-icc2011.org alla pagina
ITALIAN ECM CREDITS a partire dal 13 Maggio 2011 e fino al
30 Giugno 2011.
Per l’accesso al questionario sarà indispensabile inserire il
codice di registrazione che verrà inviato via e-mail a tutti i
partecipanti Italiani. Si ricorda, inoltre, la determinazione assunta
dalla Commissione Nazionale Formazione Continua del 18 gennaio
u.s. alla luce della quale ogni partecipante potrà maturare 1/3 dei
crediti formativi ricondotti al triennio di riferimento (150
totali per il triennio 2011–2013) mediante reclutamento diretto
da parte dello sponsor e dovrà consegnare al provider dell’evento
una copia dell’invito o una dichiarazione sottoscritta attestante
l’invito, con firma autografa e leggibile, unitamente ai propri
dati anagrafici. A tal fine è stata predisposta un’apposita sezione
nel questionario on-line. Un desk ITALIAN ECM CREDITS è attivo
on-site per informazioni e chiarimenti.
Currency
All official congress prices are indicated in Euro (€), which is also
the official currency in Italy. All major credit cards are accepted in
most hotels, restaurants and shops.
Electricity
The electrical power supply in Italy is 230 volts.
ESCMID World
During the congress, ESCMID staff will welcome you and be happy
to answer your questions at their booth located on the balcony
after the main entrance foyer.
ESCMID’s Online Job Board
As part of the ESCMID World after the main entrance foyer, computers
are available to access ESCMID’s online job board. On this website, job
seekers and employers can post their profiles or open positions
letting employers and potential candidates know that they are at
ECCMID / ICC 2011 in Milan. You can also search for profiles or open
positions and identify others attending the ECCMID / ICC in Milan.
This interactive website is free of charge and names and addresses
of individuals are not published. Visit the ESCMID website for more
information at www.escmid.org/career.
Exhibition
Companies from all over the world will display their latest products,
services and technical innovations in the industrial exhibition area
(see p. 233 – 235 for a list of exhibitors), located on level 0.
The opening hours are as follows:
Saturday, 7 May 12.00–18.45
Sunday, 8 May 10.00–18.30
Monday, 9 May 10.00–18.30
Tuesday, 10 May 10.00–13.30
Contact on-site:
Phone: +39 024 34 23 640
Fax:
+39 024 34 23 642
Flights
Congrex Travel Ltd., the official ECCMID / ICC travel agency, offers
its services at the “Flights” desk in the entrance hall next to the
secretariat on all congress days.
Contact on-site:
Phone: +39 024 34 23 643
Fax:
+39 024 34 23 644
Final Programme
267
General Information
Badges
Only your personal badge allows you to access all scientific sessions
and the exhibition. Thus, please wear your name badge throughout
the congress. € 30 will be charged for replacement of a lost badge.
On-site changes of name badges due to incorrect submission of
names and/or addresses will be charged € 10.
GLAXOSMITHKLINE INTEGRATED SYMPOSIUM
21 ST EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES (ECCMID) &
27 TH INTERNATIONAL CONGRESS OF CHEMOTHERAPY (ICC)
Milan, Italy
Bacterial invasive and non-invasive diseases:
aetiology, epidemiology,
treatment implications, prevention
and surveillance
S a turda y 7 t h Ma y 2 0 1 1
16. 30 - 1 8 . 3 0
Chair
University of Florence, Italy
M ila n C o ng re s s Centre,
Le c ture H a ll A m ber 4
Co-chair
16.30
18.30
(Italy)
Are dual infections myth or reality? The example of otitis media
Prof. Ron Dagan
(Israel)
Evolving resistance in respiratory pathogens and its implications
Prof.
Johan Van Eldere
(Belgium)
Potential benefit of integrating vaccination in clinical guidelines to
optimize antibiotic use
Prof. Paola Marchisio
(Italy)
The need for improved surveillance of invasive bacterial disease
Dr Mary Slack
(United Kingdom)
All faculty
Symposium close
Graphic Design: visible.be (7303) BIO/SYN/0013/11 Production March 2011, Wavre, Belgium
Prof. Johan Van Eldere
UZ Leuven, Laboratory Medicine,
Leuven, Belgium
Hotel Accommodation
Congrex Travel Ltd., the official ECCMID / ICC travel agency, offers
its services at the “Hotel” desk in the entrance hall next to the
secretariat on all congress days.
Contact on-site:
Phone: +39 024 34 23 643
Fax:
+39 024 34 23 644
Insurance
The congress organisers cannot accept liability for personal
injuries sustained, or for loss or damage of property belonging
to congress participants (or their accompanying persons), either
during, or as a result of the congress. Please check the validity of
your own insurance.
Photography
Taking photographs is prohibited in all lecture halls during all
sessions.
Press
Journalists are asked to bring their press card/ID and register
for the congress at the Press Centre located on level 2. A press
agenda, press releases and other information is available at
www.escmid.org/press.
Publication – Online Library
All accepted abstracts are published in an online library to Clinical
Microbiology and Infection (CMI), the official journal of ESCMID.
There is no printed abstract book.
Scan this tag to access the online library or visit the congress
website.
Internet Corner and Wi-Fi
Internet terminals for all delegates, sponsored by Gen-Probe, are
located in the exhibition hall and available during exhibition hours.
In addition, several hotspots in the congress centre offer free Wi-Fi.
Language
The congress language is English. Simultaneous translation
will not be provided. Italian is the official language in Milan and is
spoken as a first language by the entire population.
Message Centre
A message centre to leave or collect messages is available next
to the congress secretariat in the main entrance foyer. Numerous
display terminals throughout the congress centre announce
the names of persons for whom messages have been received. If
your name appears on the screen, please proceed to the message
centre to collect your message.
Mobile Phones
Please be aware that mobile telephones must be switched off
during all sessions.
Network Corner
The Network Corner is located within the poster exhibition (hall B).
ESCMID Study Groups, ISC Working Groups, ESCMID Collaborative
Centres, EUCAST and related organisations provide information on
posters about their various initiatives.
The authors of the posters will be present to answer questions
during the following presentation times:
Sunday, 8 May 13.00 – 14.00
Monday, 9 May 13.00 – 14.00
Learn more about these initiatives and meet individuals involved
in these groups.
The opening hours are as follow:
Saturday, 7 May 09.00 – 19.00
Sunday, 8 May 09.00 – 18.00
Monday, 9 May 09.00 – 18.00
Tuesday, 10 May 09.00 – 15.00
http://gettag.mobi
Registration
Name badges and congress bags including the Final Programme,
vouchers, etc., can be picked up at the registration desk by all
registered participants during the following opening hours:
Saturday, 7 May 07.45–19.00 Monday, 9 May 07.30–18.15
Sunday, 8 May 07.15–18.15 Tuesday, 10 May 07.30–16.00
The same opening hours apply for new registrations. Please note
that we cannot guarantee availability of all congress documents
for all on-site registrations.
Registration Fees (on site)
ESCMID / ISC Member *
€ 550
Non-member
€ 680
Physician / scientist in training (<_ 35 years) ** € 420
Student ***
€ 110
Accompanying person
€ 50
* Members of ISC member societies: only valid with proofof-membership
** Colleagues in training, born after 1 January 1976 (copy of
passport obligatory)
*** Students will need to provide proof (written certification by
head of department)
The registration fee for participants includes a congress bag, Final
Programme, admission to all ECCMID/ICC congress activities,
Opening Ceremony and Welcome Reception. (Please note that
some activities require additional separate registration.)
The registration fee for accompanying persons includes admission
to the Opening Ceremony, Welcome Reception and access to the
industrial exhibition.
Final Programme
269
General Information
ISC Booth
During the congress, ISC staff will welcome you and are happy to
answer your questions at their booth located on the balcony after
the main entrance foyer.
Responsibility
The participant acknowledges that he/she has no right to lodge
damage claims against the organisers should the holding of the
congress be hindered or prevented by unexpected political or
economic events or by force majeure, or should the non-appearance of speakers or other reasons necessitate programme
changes. With registration, the participant accepts this proviso.
Restaurants
Milan is one of the world’s trendiest cities, not only in terms of
clothing and accessories. The original blend of various national
traditions makes it an important part of the global culinary scene.
However, Milan remains one of the strongest bastions of traditional
Italian cooking, where authentic national elements are still very
much praised and appreciated.
The first course, consisting of pasta or rice, is the most important
part of the meal. In the days before industrialisation, dry pasta
made from durum wheat, water, and a pinch of salt (spaghetti,
rigatoni etc.) was easier to make, and therefore more popular in
the South where warmer temperatures and increased sunlight
hastened the drying of the pasta. And indeed, though there are now
dry pasta factories everywhere, modern Italians generally feel that
southerners still make the best dry pasta. Northern Italy (especially Lombardy, Emilia Romagna, Piemonte) are instead known
for fresh pasta made with eggs, flour and salt (e.g. tagliatelle or
pappardelle). Central and Northern Italy are also known for
stuffed pasta (e.g. ravioli or tortellini). But Lombardy is definitely
famous for a very particular dish: Polenta or corn meal mush, a
staple food of the poor, and risotto; most of the world's best shortgrained strains of rice, including Arborio, Carnaroli, and Vialone
Nano are produced in Northern Italy. Another important ingredient
of Lombardy’s cuisine is the world famous Parmesan cheese.
Milanese restaurants serve lunch at more or less standard Italian
times, which is between 1 pm and 3 pm. Dinners, as everywhere
else in Italy, are served late – around 9 pm – and are usually very
light.
Shopping
Milan is without doubt one of the main centres for shopping
in Italy, and the numerous districts in Milan provide a shopper’s
paradise. Whether you are looking for high fashion, antiques,
furniture or home accessories, rest assured that shopping in Milan
will provide you with a huge choice.
Milan was the birthplace for a number of labels that evoke the
utmost respect in anyone familiar with the basics of fashion
design. Versace, Prada, Dolce & Gabbana and Armani all set up their
original boutiques here. For those looking for something more
affordable, Milan offers a multitude of shopping options for both
new and second-hand fashion. Here is our recommended itinerary:
Quadrilatero d'Oro is the collective name for the streets holding
the greatest concentration of top designer studios, such as Montenapoleone, Della Spiga, Borgospesso, Sant' Andrea, Manzoni and
Santo Spirito. Even if you are not planning to shop for high fashion,
take a stroll down these boulevards to experience their unique chic
atmosphere. Navigli is home to several noteworthy second-hand
shopping venues. For the best bargains, browse at Eliogabaldo, Biffi
and Floretta Coen Musil. Corso Buenos Aires is a street with some
excellent male vintage fashion shops. You will find rock-bottom
prices at Darsena, Calzaturifico di Parabiago and Il Drug Store.
Galleria Vittorio Emanuele, located between the Duomo and
La Scala, is an original 19th century shopping mall that continues
to impress as one of the city's most elegant landmarks.
Final Programme
Speakers' Service Centre (SSC)
The Speakers' Service Centre (SSC) is centrally located on the
mezzanine level providing remote connection to all the lecture
halls. All speakers will be asked to hand in their PowerPoint
presentations at least 1 hour before their lecture at the SSC.
Smoking Policy
There is a strict non-smoking policy in the entire Milano Convention Centre.
ESCMID Survey on Parity in CM & ID
ESCMID is conducting an online survey on discrimination regarding gender, minorities and geographic areas among CM and ID
specialists in their employment and roles within universities and
hospitals in Europe. We encourage you to take part in this online
survey and visit the ESCMID Parity Commission booth in the main
entrance foyer. Computers are available to access the survey.
For more information please go to www.escmid.org/parity.
Travel within Milan
Milan is a conveniently compact city, so it is easy to get around on
foot. Participants of the 21st ECCMID / 27th ICC can receive a free
ticket for the use of the entire Milan public transportation system,
consisting of trams, trains, busses and the metro, valid during
the four days of the congress. Participants receive a voucher with
the congress documents that must be submitted to receive a
public transportation ticket at the secretariat and/or pre-registration
area.
From downtown Milan, it is a 10 to 15 minute ride by underground
(red line, M1) to the Milano Convention Centre, stop Amendola
Fiera. From the metro station to the main entrance it is a 5-minute
walk.
On Friday, 6 May, Saturday, 7 May, and Tuesday, 10 May, a free
shuttle bus, running every 40 minutes, connecting Malpensa
airport and the congress centre (city centre Piazzale Lotto on
Friday) is offered.
The bus schedule is as follows:
Friday,
6 May 15.00 – 24.00 (to Piazzale Lotto)
Saturday, 7 May 08.00 – 20.00
Tuesday, 10 May 11.00 – 16.00
Social / Cultural Events
Daily Tours
Opening Ceremony
The traditional Opening Ceremony will be held on Saturday, 7 May
2011 at 19.00 in the Auditorium (Lecture Hall Gold) of the Milano
Convention Centre. All participants, registered accompanying
persons and exhibitors are invited to attend.
An attractive choice of guided tours has been prepared for all delegates and accompanying persons. Below you will find the respective schedule and short descriptions. Please note that during all
tours you will be accompanied by knowledgeable, English-speaking
guides. The organiser reserves the right to cancel any tour in case
of less than 25 registered persons. Full refunds will be made if an
activity is cancelled due to lack of participants. On-site requests for
tours are welcome but cannot be guaranteed. If you require further
information on any of the tours below, please contact the tours and
travel desk in the entrance hall.
Welcome Reception
After the Opening Ceremony all participants, registered accompanying persons and exhibitors are invited to attend the Welcome
Reception, giving you a taste of the culinary specialities of the
Italian cuisine. The reception will be held in hall 4 of the Milano
Convention Centre. The Opening Ceremony as well as the Welcome
Reception is included in the registration fee.
Philharmonic Italian Orchestra
Concert in Sala Puccini at the Conservatory of Milan
Date/Time: Sunday, 8 May 2011, 20.00
Length: approx. 2 hours
Price: € 78 per person
The Milan Conservatory is a college of music which was established by a royal decree in 1807 in Milan, capital of the Napoleonic
Kingdom of Italy. Today it is the largest institute of musical education in Italy. During the past two centuries, many of the most important Italian musicians have studied there: Giacomo Puccini,
Arrigo Boito, Giovanni Bottesini, Alfredo Catalani, Riccardo Chailly,
Vittorio Giannini and Pietro Mascagni.
Tour 1: Milan City Tour
Length: approx. 3.5 hours
Meeting point and departure in front of Castello Sforzesco –
main entrance
(incl. guide, entrance fee to Duomo, Musei Civici Castello
Sforzesco, Teatro alla Scala)
The walking tour starts at the Sforza Castel, Castello Sforzesco,
leads through the pedestrian area of Via Dante, a large street full of
shops and restaurants, and reaches Milan’s cathedral, “Duomo”,
that is, with its 134 steeples and 3’400 statues, the most important
Italian Gothic monument. Through Vittorio Emanuele II Gallery it
stretches to the Scala Square – Piazza della Scala. A visit to the
lyrical theatre is possible.
Programme
Director: Stefano Miceli
Soprano: Mimma Briganti
Tenor:
Nicola Pisaniello
G. Rossini – Il Barbiere di Siviglia (sinfonia)
G. Verdi
– Il Trovatore – Di quella pira
G. Puccini – La Bohème – Si, mi chiamano Mimì
G. Puccini – La Bohème – O soave fanciulla
P. Mascagni – Cavalleria rusticana – Intermezzo
G. Puccini – Madama Butterfly – Un bel di vedremo
G. Puccini – Turandot – Nessun dorma
G. Puccini – Turandot – Tu che di gel sei cinta
G. Puccini – Tosca – E lucean le stelle
G. Verdi
– La Traviata – Brindisi
Teatro della Scala
Final Programme
271
General Information
The order of the pieces may be changed.
solutions
for infectious disease research
Visit Lif
Life
fe Technologies
Technologies at tthe ECCMID Congr
Congress
ess 2011
Discover the
Discover
th
he latest
latest ttechnologies
echnologies in path
pathogen
hogen det
detection
ection and identific
identification
cation at our booth (#459)
at the ECCM
ECCMID
MID Congr
Congress.
ess. Learn about our
o ne
newest
west pr
products
oducts and app
applications,
plications, and see e
exactly
xactly
ho
w our innovations
inn
novations ccan
an bring br
eakthrroughs tto
o yyour
our rresearch.
esearch.
how
breakthroughs
Go
o tto
o www.appliedbiosystems.org.uk/ECCMID2011
www.appliedbiosys
appliedbiosystems.or
ems org.uk/ECCMID2011
e
g uk/ECCMID2011
Do
Download
ownload the free
free mobil
mobile
e app at http://gett
http://gettag.mobi
tag.mobi
Scan
access
more
information
Sc
an the barcode
barcode tto
o instantly
instantly ac
cess mor
e inf
ormation about RNA
Life
L
ife T
Technologies
echnologies o
offers
ffers a breadth
breadth o
off p
products
roducts
D
DNA
NA | RNA
RNA | P
PROTEIN
ROTEIN | C
CELL CULTURE
ELL CULTURE | IINSTRUMENTS
NSTRUMENTS
FOR RESEARCH USE
FOR
USE ONL
ONLY.
Y. NO
NOT
T INTENDED FOR
FOR ANY ANIMAL OR
R HUMAN THERAPEUTIC OR DIAGNOSTIC
DIAGNOSTIC USE..
Life
Technologies
herein
Life
Technologies
owners.
© 2011 Lif
eT
echno
ologies Corporation.
Corporation. All rights rreserved.
eserved. The trademarks
trademarks
a
mentioned her
ein are
are the property
property of Lif
eT
echnologies Corporation
Corporation or their respective
respectiv
ive o
wners. TaqMan
TaqMan is a registered
registered
trademark
Molecular
tr
ademark of Roche
Roch
he Mol
ecular Systems,
Systems, Inc. CO22683 0311
Daily Tours
In this tour of one of the most characteristic areas in Milan, you
experience both past and present. A visit in the surrounding area
of Naviglio Grande reveals its characteristic lanes and yards, the
Darsena and the nearly unknown Conca di Varenna through which
at the end of XIV century the marble used to the build the Duomo
got to town. During the tour there will be a visit to the Columns of San
Lorenzo, the Church of San Lorenzo and the Sacello of San Aquilino.
Naviglio Grande
Tour 3: Verona, Borghetto and Sigurtà Park
Date/Time: Monday, 9 May 2011, 09.00
Meeting point and departure in front of Castello Sforzesco
(incl. guide, coach, lunch, entrance fee to monuments and garden)
Begins with a guided walking tour in the historical centre starting
from Piazza Brà and the Arena. The tour will go all through the
Piazza delle Erbe and Piazza dei Signori. The programme also
includes on-foot sightseeing of many historical monuments,
ancient yards, hidden building beauties as well as Giulietta’s House
with its famous balcony. Lunch will be served in the centre of town.
In the afternoon the tour leads to Borghetto by bus. Borghetto is
an ancient medieval village with original still-functioning water
mills. The tour ends with the visit of Sigurtà Botanical Park.
Tour 4: The Da Vinci Last Supper, the Church of Santa Maria
delle Grazie and Sant’ Ambrogio
Date/Time: Wednesday, 11 May 2011, 15.30
Length: approx. 3.5 hours
Meeting point and departure at Piazza Santa Maria delle Grazie,
at the entrance of the church
(incl. guide, entrance fee to church of Santa Maria delle Grazie,
the Last Supper and S. Ambrogio)
A guided walking tour to the church of Santa Maria delle Grazie and
viewing of the Last Supper by Leonardo da Vinci. Afterwards there
is a visit to the church of Sant’ Ambrogio. The church of Santa Maria
delle Grazie’s construction started in the second half of the XV century and was ordered by the Black Friars. In 1492, Ludovico il Moro,
Lord of Milan, entitled Donato Bramante as master of the works.
Leonardo painted “The Last Supper” from 1494 to 1497 in the
dining hall of the monastery of Santa Maria delle Grazie as ordered
by Ludovico il Moro. Sant’ Ambrogio Church, founded by Bishop
Ambrogio between 379 and 386 in the area of “Church yard of
Martyrs” outside Porta Vercellina, the ancient Basilica Martyrum
called “Ambrosiana” is universally considered the most important
example of Romanesque Lombardy architecture.
Tour 5: Brera
Date/Time: Tuesday, 10 May 2011, 14.30
Meeting point and departure in front of Pinacoteca di Brera –
Via Brera, 28
(incl. guide, entrance fee to Pinacoteca di Brera and Basilica di
San Simpliciano)
A wonderful collection of fine art from Caravaggio to Bramante,
often considered Lombardy's finest art collection. The Pinacoteca
was first a collection of paintings for students of the Accademia di
Belle Arti in the same building; the paintings were harvested from
churches and monasteries suppressed by the Napoleonic regime.
Although it cannot compete with the Louvre or London's National
Gallery, the Pinacoteca is of a size that makes for an easy visit. The
collection is modest in breadth, but exquisite in quality, and
covers works by major Italian artists from the 13th to the 20th
century. From Brera the tour leads on foot to the Basilica of
San Simpliciano. The site of the present church was occupied in the
3rd century AD by a Pagan cemetery. Here Saint Ambrogio began
the construction of the Basilica Virginum “Basilica of the Virgins”,
which was finished by his successor Simplicianus Soresini who
was buried here.
Final Programme
273
General Information
Tour 2: Naviglio Grande
Meeting point in front of Porta Genova metro Station
(incl. guide, entrance fee to Church of San Lorenzo)
Post-Congress Tour
Post-Congress Tour to Turin
Departure: Wednesday, 11 May 2011, 11.00
Return: Thursday, 12 May 2011, 19.00
Meeting point in front of Castello Sforzesco – main entrance
For availability and price information please contact the tours
and travel desk.
Post-Congress Tour to Mantua
and travel desk.
11.00: Departure by private coach from Milan and direct transfer
to Turin. The coach will arrive in Turin at approximately 13.00. Meet
the guide and walk through the historical centre with a visit to the
following monuments:
• Piazza San Carlo with its Baroque style representing the heart of
the town
• Piazza Carignano with its palace, a masterpiece carried out by
Guarino Guarini. It has been the house of the First Italian Parliament and the place where the first king of Italy was born.
• Piazza Carlo Alberto with its refined style
• Piazza Castello overlooking Palazzo Reale and the Church of
San Lorenzo
• Palazzo Madama, house of the first Italian Senate
In the afternoon, a visit to the National Movie Museum, one of the
most important of its kind in the world because of the great variety
of scientific and communication activities which are carried out
there. The museum is situated inside Mole Antoneliana, a bizarre
and fascinating monument, symbol of the town. François Cofino,
the famous Swiss art director, created with fantasy and a sophisticated style many different paths offering the visitors spectacular environments with strong continuous and creative unexpected
urges, both visual and auditory, as experienced while watching an
emotional and involving movie. The tour ends at the hotel for checkin and individual dinner out.
10.30: Departure by private coach from Milan and direct transfer to
Mantua. The coach will arrive in Mantua at approximately 13.00.
Meet the guide and walk through the historical centre.
Mantua, or Mantova, is a beautiful, historic city in northern Italy
surrounded on three sides by lakes. It was one of the greatest
Renaissance Courts in Europe and home of the wealthy Gonzaga
family. The town's centre is three spacious and lively piazzas that
join together. In 2008 Mantova became a UNESCO World Heritage
Site based on its Renaissance planning and architecture.
Thursday, 12 May 2011
After breakfast and check out at 09.00, the guide will meet you at
Stazione Sassi. Visit of Basilica of Superga situated on an overlook
with an amazing view. The basilica, masterpiece of Filippo Juvarra,
was built in the 18th century to celebrate the victory of ItalianAustro-Hungarian troops against Louis XIV’ armada together with
the liberation of the town after a very hard siege. Visit to the crypt
where the Savoia Kings are buried. In the afternoon, visit to the
Egyptian Museum, the second important of its kind after Cairo,
which is exclusively dedicated to art and culture of ancient Egypt.
Many world famous scientists and hieroglyphic experts like
Jean-François Champollion, while in town in 1824, dedicated their
studies to this museum collection. It now houses many ancient
pieces as well as more recent archeological finds brought to light
by the Archeological Italian Mission in Egypt from 1900 to 1930.
The price includes
• 1 night accommodation in twin/double or single room with
breakfast buffet at a 4* hotel
• Meals and tours as per the above-mentioned programme
• Admission fees for National Movie Museum, Basilica of
Superga, Egyptian Museum
• English-speaking guide
• Private coach for the whole tour, i.e. transfer from Milan to
Turin, sightseeing in Turin and return to Milan
Final Programme
After breakfast and check out at 09.00, the guide will meet you and
take you on a boat tour on the river Mincio to visit the lakes and
parks. In the afternoon the tour continues with a visit to the Palazzo
Ducale. The Palazzo Ducale di Mantova is a group of buildings built
between the 14th and the 17th century mainly by the noble family
of Gonzaga as their royal residence in the capital of their Duchy. The
buildings are connected by corridors and galleries and are enriched
by inner courts and wide gardens. The complex includes some 500
rooms and occupies an area of 34’000 m². Although most famous for
Mantegna's frescos in the Camera degli Sposi (Wedding Room), they
have many other very significant architectural and painted
elements. Afterwards you will visit the Palazzo Te, the acknowledged
masterpiece of the Italian architect Giulio Romano. In the beginning
Mantua was divided by the channel “Rio” into two big islands surrounded by lakes and a third small island called Tejeto which name
was shortened in “TE” and has been chosen for the construction of
Te Palace.
The price includes
• Meals and tour as per the above mentioned programme
• Admission fees for Palazzo Ducale, Saint George Castle and
Palazzo Te
• English-speaking guide
Mantua, sightseeing in Mantua and return to Milan
All prices include VAT.
Post-Congress Tour
Post-Congress Tour to Florence
and travel desk.
Post-Congress Tour to Rome
and travel desk.
07.30: Departure by private coach from Milan and direct transfer to
Florence. The coach will arrive in Florence at approximately 13.00.
Free-time for lunch and meeting with the guide. Walking tour
through the historical centre with visit to the following sites: Piazza
Duomo and Cathedral with the famous cupola by Brunelleschi,
Giotto’s bell tower and the Baptistery with its bronze doors; Piazza
della Signoria with the famous Uffizi museum (only external visit),
Palazzo Vecchio and the copy of Michelangelo’s David. Walk on
the “Ponte Vecchio” with its famous gold shops to Palazzo Pitti.
to Rome. The coach will arrive in Rome at approximately 13.00.
Free-time for lunch and meeting with the guide. Walking tour
through the historical centre with visit to the following monuments: “Fori Imperiali” area with the famous Colosseum and the
Costantinum arch, Piazza Venezia, Fontana di Trevi, Quirinale (residence of the President of Italian Republic) and Piazza Navona.
The price includes
• Visits and admission fees as per the above-mentioned
programme
• English-speaking guide where mentioned
Florence, sightseeing in Florence and return to Milan
The price includes
programme
• Private coach for the whole tour
Post-Congress Tour to Naples and Capri
Return: Friday, 13 May 2011, 20.00
and travel desk.
to Naples. The coach will arrive at approximately 14.30. Meet the
guide and walk through the historical centre with external visit to
the main monuments: Duomo church, Royal Palace, Market Square,
Plebiscito Square, Castel dell’Ovo and the harbour.
After breakfast at 8.00, full day excursion to Capri (return boat trip,
island tour and lunch).
Friday, 13 May 2011
After breakfast and check out at 9.30, departure to Milan. Arrival in
the evening.
The price includes
• 2 nights accommodation in twin/double or single room with
programme
• Private coach for the whole tour
Final Programme
275
General Information
After breakfast and check out at 09.00, visit of the Galleria degli
Uffizi Museum, one of the most famous museums in the world for
paintings and sculpture. Its collection of Primitive and Renaissance
paintings comprises several universally acclaimed all-time
masterpieces including works by Giotto, Simone Martini, Piero della
Francesca, Fra Angelico, Filippo Lippi, Botticelli, Mantegna, Correggio, Leonardo da Vinci, Raphael, Michelangelo and Caravaggio.
After the visit, free-time for lunch and transfer to Santa Croce
basilica, one of the oldest Franciscan basilicas.
Everything in the church is of the very highest quality such as
the frescoes executed through the contributions of Giotto. At midafternoon, return trip to Milan with arrival in the evening.
After breakfast and check out at 09.00, the guide will meet you
at Vatican City. Visit of the famous St. Peter basilica, the Vatican
Museum and the Sistine chapel with ceiling paintings by Michelangelo. Walk through St. Angelo bridge and arrival to Castel
St. Angelo. Early afternoon departure to Milan and return in late
evening.
Milan City Map
18
7
24
25
12
4
33
20
23
19
14
8
Entrance
5
1
21st
27th
ICC
35
3
3
37
37
17
Final Programme
Milan City Map
Hotel Legend
10
16
5-star Hotels *****
38
28
1 Melia Milano
2 Westin
4-star Hotels ****
11
3 Antares Rubens
30
4 AC Milano
6
34
5 ATA Fiera Milano
6 ATA Executive
7 Antares Accademia
8 Admiral
9 Cristoforo Colombo
13
10 Crowne Plaza
11 Doria Grand
2
12 Enterprise
36
29
22
13 Galles
14 Hermitage
15 Hilton
9
16 Holiday Inn Garibaldi
17 Marriott
18 Mirage
26
19 Mozart
20 Nasco
21 NH President
22 NH Touring
23 Poliziano Fiera
24 Radisson Blu
25 Regency
1
26 Sheraton Diana
27 Starhotel Rosa Grand
28 Starhotel Anderson
29 Starhotel Ritz
30 Una Century
31 Una Cusani
21
32 Una Mediterraneo
33 Una Scandinavia
34 Una Tocq
3-star Hotels ***
35 Domenicchino
36 Ibis Centro
37 Palazzo delle Stelline
38 Soperga
32
Final Programme
277
General Information
27
22nd ECCMID 2012
• 31 March – 3 April 2012
• London, United Kingdom
• ExCel London
• www.escmid.org/eccmid2012
22nd
London, United Kingdom
31 March – 3 April 2012
ECCMID
Future Congresses
23rd ECCMID 2013
• 27 – 30 April 2013
• Berlin, Germany
• ICC Berlin
• www.escmid.org/eccmid2013
23rd
Berlin, Germany
27 – 30 April 2013
ECCMID
www.escmid.org/eccmid2012
www.escmid.org/eccmid2013
28th ICC 2013
• 6 – 9 June 2013
• Yokohama, Japan
• Yokohama Congress Centre
• www2.convention.co.jp/icc2013
3.032
URL : http://www2.convention.co.jp/icc2013
*OURNAL OF THE
AL 3OCIETY OF
APY )3# p
ND #ANCER
MOORG
IN#HIEF 0ROFESSOR !LASDAIR - 'EDDES
D PUBLICATION p )DEAL FOR #LINICAL 4RIALS ARTICLES PUBLISHED ONLINE IN
NCE$IRECT FROM AS LITTLE AS WEEKS AFTER ACCEPTANCE
ARTICLES DOWNLOADED FROM 3CIENCE$IRECT IN ULAR TOPICAL SUPPLEMENTS ON NEW ANTIMICROBIAL AGENTS
MISSION TO FIRST DECISION IS DAYS SUBMISSION AVAILABLE FOR SPEEDY PUBLICATION
T YOUR PAPER TODAY AT HTTPEESELSEVIERCOMIJAA
ORE INFORMATION OR TO SUBSCRIBE ONLINE VISIT
WELSEVIERCOM)*!!
AVERAGE DOWNLOADS FOR )*!! &IGURE BASED ON )*!! FULL TEXT ARTICLES DOWNLOADED IN Incorporating the 14th Asia-Pacific Congress of Clinical Microbiology and Infection
President
Congress Secretariat
28th International Congress of Chemotherapy and Infection (ICC2013)
c/o Japan Convention Services, Inc.
E-mail: icc2013@convention.co.jp
・International
・In
nter
ern
rnational
tional
al Society
Society
cieety of
of Chemothera
C
Chemotherapy
he
hemothera
emothera
othera
hera
era
raapy
・Japanese
・JJaappanese
esee Society
Society
ciety
iety
ety
ty of
of Chemothera
Chemotherapy
Che
hemothera
emothera
othera
herapy
he
・Asia-Pacific
Asia-Pacific
ia-Pacific
a-Pacific
Pacific
cific
ific
fic Society
ociety
ciiety
ty of
of Clinical
Clinical
inical
nical
ical
caal Micr
Microbiology
Micr
icro
crrobiolog
iolog
olog
logy
oggy and
and In
Infection
Inf
nffection
ection
ction
ion
on
Final Programme
Final Programme
279
General Information
Notes
Notes
Final Programme
The clues are there
but can you see the answer?
Recurrent, persistent or unusual infections?
It could be PID; should you raise the alarm?
Early diagnosis of Primary Immunodeficiency (PID) is crucial to
prevent further infections, permanent complications and life-threatening
illness.
Binding Site offer a range of products for the investigation of PID
including laboratory tests to measure specific antibody response*,
immunoglobulins and complement activity.
For more information - www.bindingsite.com
Come and see us at ECCMID to find out more.
(Stand 456)
*Please enquire regarding FDA status
The Binding Site Group Ltd
Tel: +44 (0)121 456 9500 • info@bindingsite.co.uk • www.bindingsite.com
The Specialist Protein Company
WORKING TO FILL LIVES
WITH MORE YEARS AND
YEARS WITH MORE LIFE.
As one of the most diversified
companies in health care, Pfizer
is committed to improving
health and well-being at every
stage of life.
Today’s Pfizer is a leader in
human and animal health,
primary and specialty care,
biologics and pharmaceuticals,
with a robust portfolio of
vaccines, nutritionals and
consumer products.
Most importantly, we’re
bringing together the world’s
best scientific minds to take on
the world’s most feared diseases,
with a renewed focus on areas
that represent significant unmet
health needs, such as Alzheimer’s,
diabetes, inflammation and
immunology, cancer and pain.
By working together, we can
change the lives of more people
in more powerful and effective
ways than ever before. Learn
about how we’re doing things
differently at pfizer.com
Copyright ©2011 Pfizer Inc. All rights reserved. Wyeth is now part of Pfizer. The merger of local Wyeth and Pfizer entities may be pending in various
jurisdictions and integration is subject to completion of various local legal and regulatory obligations, including works council and/or union consultations.
WORKING TOGETHER FOR A HEALTHIER WORLD.

Scientific Programme

Transcription

Similar documents

ENG - Riccardo Arena

Motosikal dan Enjin Nasional Sdn Bhd (354613-V)

Here - Designboom

milan glorie

INDIAN COLLEGE OF CARDIOLOGY

le “rose” delle squadre del 1902

Palazzo Mezzanotte Palazzo Affari ai Giureconsulti Bulgari

Infezioni nelle strutture strutture assistenziali

david chipperfield architects valentino flagship

SHIPPING LIST No. : 102261730030